"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04372602","Duvelisib to Combat COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Duvelisib|Procedure: Peripheral blood draw","Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0","Washington University School of Medicine|Verastem, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-28-20-DiPersio","June 30, 2020","July 31, 2021","December 31, 2021","May 4, 2020",,"May 4, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04372602"
2,"NCT04388436","Post Covid-19 Cardiopulmonary and Immunological Changes","covid-19","Active, not recruiting","No Results Available","COVID",,"measurement of pulmonary function changes either obstructive or restrictive also lung diffusion and if there is remaining interstitial fibrosis|measurement for cardiac function and ejection fraction changes and if there is changes in pulmonary artery pressure|assessment of IGM and IGG level and if there is immunological changes","Mansoura University","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20.05.67","May 11, 2020","July 10, 2021","October 10, 2021","May 14, 2020",,"May 19, 2020","Mansoura faculty of medicine, Mansoura, Dakahlia, Egypt",,"https://ClinicalTrials.gov/show/NCT04388436"
3,"NCT04364698","Observational Cohort of COVID-19 Patients at Raymond-Poincare","COVID-RPC","Recruiting","No Results Available","COVID-19",,"clinical, biological and radiological characteristics|patients' journey description|Treatments effects","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20SBS-COVID-RPC","May 7, 2020","June 2020","June 2020","April 28, 2020",,"May 14, 2020","Department of Infectiology, Raymond Poincaré Hospital, APHP, Garches, France",,"https://ClinicalTrials.gov/show/NCT04364698"
4,"NCT04374838","Effect of COVID-19 Pandemic on Pediatric Cancer Care",,"Not yet recruiting","No Results Available","Covid19",,"pediatric cancer care pattern during COVID 19 pandemic","South Egypt Cancer Institute","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","COVID-19 and Pediatric Cancer","May 15, 2020","December 15, 2020","May 15, 2021","May 5, 2020",,"May 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04374838"
5,"NCT04346446","Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients",,"Recruiting","No Results Available","COVID","Drug: Convalescent Plasma Transfusion|Other: Supportive Care|Drug: Random Donor Plasma","Proportion of patients remaining free of mechanical ventilation in both groups|Mortality in both groups|Improvement in Pa02/Fi02 ratio in both groups|Improvement in SOFA score in both groups|Duration of hospital Stay in both group.|Duration of Intensive Care Unit stay in both groups.|Requirements of Vasopressor in both groups.|Days free of dialysis in both groups.","Institute of Liver and Biliary Sciences, India","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ILBS-COVID-02","April 21, 2020","June 30, 2020","June 30, 2020","April 15, 2020",,"May 12, 2020","Maulana Azad medical College, New Delhi, Delhi, India|Institute of Liver and Biliary Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04346446"
6,"NCT04343183","Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection",,"Not yet recruiting","No Results Available","COVID-19","Device: Hyperbaric Oxygen Therapy","Decrease incidence of intubation by 30% or greater|Decrease renal injury","Ochsner Health System","All","18 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY00001051","April 2020","June 2020","June 2020","April 13, 2020",,"April 13, 2020","Ochsner Medical Center, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04343183"
7,"NCT04374513","Community Pharmacists Behaviour During Covid-19",,"Recruiting","No Results Available","Covid19",,"community pharmacists facing covid-19","Damanhour University","All","Child, Adult, Older Adult",,"50","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Pharmacists and covid-19","May 2, 2020","October 1, 2020","April 2021","May 5, 2020",,"May 19, 2020","Damanhour university, Beheira, Damanhour, Egypt|Damanhour universty, Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT04374513"
8,"NCT04333550","Application of Desferal to Treat COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Deferoxamine","Mortality rate|change in patients clinical manifestation|change in patients PaO2|Length of hospitalization|C-reactive protein|lymphocyte count|length of intensive care unit stay","Kermanshah University of Medical Sciences","All","3 Years to 99 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1398.1224","April 2020","September 2020","March 2021","April 3, 2020",,"May 4, 2020","Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04333550"
9,"NCT04349371","Saved From COVID-19",,"Recruiting","No Results Available","COVID","Drug: Chloroquine|Drug: Placebo oral tablet","Number of symptomatic illness in at risk healthcare workers|Number of healthcare workers with symptomatic COVID infections|Number of severe illness in at risk healthcare workers|Number of sero-conversions in at risk healthcare workers|Percentage of patients with adverse events Grade 3 or higher|Percentage of patients with GI intolerance","Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AAAS9992","April 2020","April 2021","April 2021","April 16, 2020",,"April 21, 2020","Columbia University Irving Medical Center/NYP, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04349371"
10,"NCT04336904","Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19",,"Active, not recruiting","No Results Available","COVID-19","Drug: Favipiravir|Other: Placebo","Time from randomization to clinical recovery|Time from randomization to negativity in RT-PCR nucleic acid test|Incidence of deterioration/aggravation of pneumonia|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy|ICU admission rate|Mortality","Giuliano Rizzardini|ASST Fatebenefratelli Sacco","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","HS216C17-PHASE III","March 25, 2020","July 2020","July 2020","April 7, 2020",,"April 8, 2020","Asst Fatebenefratelli Sacco, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04336904"
11,"NCT04359095","Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment","Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection","Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","76968","May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",,"April 24, 2020","Hospital Universitario de Neiva, Neiva, Huila, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia",,"https://ClinicalTrials.gov/show/NCT04359095"
12,"NCT04354831","A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Biological: anti-SARS-CoV-2 convalescent plasma","Overall Mortality within 60 days|Length of ICU stay during current admission for COVID","Medical College of Wisconsin|Froedtert Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","131","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00037712","May 11, 2020","May 1, 2022","May 1, 2023","April 21, 2020",,"May 13, 2020","Froedtert Hospital, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04354831"
13,"NCT04351802","CORonavirus (COVID-19) Diagnostic Lung UltraSound Study","COR-DLUS","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: Lung ultrasound","Diagnosis of COVID-19 on lung ultrasound|Difference in diagnosis of COVID-19 on lung ultrasound vs. chest x-ray|Diagnosis of alternative condition to COVID-19 on lung ultrasound vs. chest x-ray|Ability of surveillance lung ultrasound to predict clinical trajectory / outcome in patients with COVID-19|Consistency of lung ultrasound interpretation in patients presenting with suspected COVID-19","University Hospital Plymouth NHS Trust","All","18 Years and older   (Adult, Older Adult)",,"180","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282661","April 20, 2020","January 20, 2021","January 20, 2021","April 17, 2020",,"April 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04351802"
14,"NCT04345445","Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression",,"Not yet recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Drug: Methylprednisolone","The proportion of patients requiring mechanical ventilation|Mean days of ventilation|The proportion of patients requiring ICU admission|Overall 28-day survival|Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline|Duration of hospital and ICU stay","University of Malaya","All","18 Years and older   (Adult, Older Adult)","Phase 3","310","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TVCS-COVID19","April 15, 2020","October 31, 2020","October 31, 2020","April 14, 2020",,"April 14, 2020","University Malaya Medical Centre, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT04345445"
15,"NCT04366271","Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19","MESCEL-COVID19","Recruiting","No Results Available","COVID","Biological: Mesenchymal cells|Drug: Standard of care","Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment|Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment|Mortality from any cause at 28 days|Days without mechanical respirator and without vasopressor treatment for 28 days|Patients alive without mechanical ventilation and without vasopressors on day 28|Patients alive and without mechanical ventilation on day 14|Patients alive and without mechanical ventilation on day 28|Patients alive and without vasopressors on day 28|Days without vasopressors for 28 days|Patients cured at 15 days|Incidence of Treatment-Emergent Adverse Events","Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Apices Soluciones S.L.","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","106","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MESCEL-COVID19|2020-001450-22","May 7, 2020","July 31, 2020","May 31, 2021","April 28, 2020",,"May 11, 2020","Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Complejo Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04366271"
16,"NCT04359303","Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID19) in Non-intubated Patients","OzonoCOVID19","Not yet recruiting","No Results Available","COVID","Other: Systemic indirect endovenous ozone therapy","COVID19 clinical scale|Number of died patients|Oro/nasopharynx virus|Thorax imaging (0=none; 1=unilateral; 2=bilateral; 3=ground-glass opacification; 4=consolidation)|Days in hospital|Venous gas blood analysis","Javier Hidalgo Tallón|Sociedad Española de Ozonoterapia|Universidad Católica San Antonio de Murcia","All","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","P.Inv. Ozono-COVID19 Ver.1.2","June 2020","November 2020","December 2020","April 24, 2020",,"May 19, 2020","SEOT, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04359303"
17,"NCT04366739","Repurposing of Chlorpromazine in Covid-19 Treatment","reCoVery","Not yet recruiting","No Results Available","COVID-19","Drug: CHLORPROMAZINE (CPZ)|Combination Product: Standard of Care (SOC)","Time To Response (TTR)|Objective Response Rate (ORR)|All-cause mortality|Duration in days required for hospital discharge|Duration in days required for National Early Warning Score ≤ 2 maintained 24 hours|Number of days without oxygen therapy|Incidence of oxygen use, NIV or high flow oxygen therapy|Duration in days of oxygen prescription, NIV or high flow oxygen therapy|Biochemical response: rate of patients positive for SARS-CoV-2 PCR on a nasopharyngeal sample|Biochemical response: viral load of SARS-CoV-2 on a nasopharyngeal sample|Biochemical response: serum viral load of SARS-CoV-2|Biochemical response: C-reactive protein (CRP)|Biochemical response: blood test for lymphocytes (lymphopenia)|Parenchymal involvement (chest CT)|Define the optimal dose of CPZ and its tolerance: rates of serious adverse events|Define the optimal dose of CPZ and its tolerance: rates of non-serious side effects|Define the optimal dose of CPZ and its tolerance: anxiety assessment on Global Anxiety - Visual Analog Scale (GA-VAS)|Define the optimal dose of CPZ and its tolerance: Rates of drug discontinuation|Define the optimal dose of CPZ and its tolerance: biological anomalies|Define the optimal dose of CPZ and its tolerance: ECG abnormalities|Define the optimal dose of CPZ and its tolerance: plasma CPK assessment|Define the optimal dose of CPZ and its tolerance:plasma CPZ assessment|Define the optimal dose of CPZ and its tolerance: CPZ dose administered","Centre Hospitalier St Anne|Hôpital Cochin","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","D20-P016","April 29, 2020","August 30, 2020","September 30, 2020","April 29, 2020",,"April 29, 2020","Centre Hospitalier Sainte-Anne, Paris, France",,"https://ClinicalTrials.gov/show/NCT04366739"
18,"NCT04366960","Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients","X-Covid 19","Recruiting","No Results Available","Covid19","Drug: Enoxaparin","Incidence of venous thromboembolism detected by imaging|In hospital major complications|Number of deep venous thrombosis events|Sequential organ failure assessment|C-reactive protein|Interleukin‐6|D-dimer|hs-troponin levels|Acute Respiratory Distress Syndrome|Hospital stay|Right ventricular function|Number of pulmonary embolism events","Niguarda Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","2712","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001708-41","May 14, 2020","August 2020","November 2020","April 29, 2020",,"May 15, 2020","Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04366960"
19,"NCT04355741","Gut Microbiota, ""Spark and Flame"" of COVID-19 Disease",,"Not yet recruiting","No Results Available","COVID-19","Other: Exposure","Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.|Differences in gut microbiota composition between COVID-19 patients in relation to mortality.|Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.|Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation.","Universidade Nova de Lisboa|NOVA Medical School of Universidade NOVA de Lisboa|Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental|Centro Hospitalar Universitário São João|CUF Academic and Research Medical Center|Hospital CUF Infante Santo, S.A.|Centro de Medicina Laboratorial Germano de Sousa, S.A.|CINTESIS - Center for Health Technology and Services Research","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COVID19_Microbiota","April 2020","July 2020","December 2020","April 21, 2020",,"April 21, 2020","Hospital CUF Infante Santo, S.A., Lisbon, Portugal|Hospital de São Francisco Xavier, Lisbon, Portugal|Centro Hospitalar Universitário São João, Oporto, Portugal",,"https://ClinicalTrials.gov/show/NCT04355741"
20,"NCT04361422","Isotretinoin in Treatment of COVID-19","Randomized","Not yet recruiting","No Results Available","COVID-19","Drug: Isotretinoin Only Product in Oral Dose Form","Clinical clearance","Tanta University","All","18 Years to 40 Years   (Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9469305c","April 21, 2020","June 2020","September 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04361422"
21,"NCT04388683","Inhaled Nitric Oxide for Preventing Progression in COVID-19","NO-COVID-19","Recruiting","No Results Available","COVID-19","Drug: Nitric Oxide","Prevention of progressive systemic de-oxygenation, with escalation to higher levels of oxygen and ventilatory support or death, assessed using a 7-point severity scale.|Prevention of progression assessed by an alternate severity scale|Time to reaching maximal severity score|Proportion of patients in each stage at maximum severity|PaO2/FIO2 or SaO2/FIO2 ratio, measured daily|Length of hospital Stay (death assigned as worst case)|Frequency of Intubation, ECMO, or need to intubate with ""Do Not Resuscitate"" order|Mortality|IL6 level|TNF-alpha level|Fibrinogen level|CRP level|Ferritin Level|D-dimer level","Tufts Medical Center|Bellerophon","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","42","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000554","May 12, 2020","April 30, 2021","July 31, 2021","May 14, 2020",,"May 18, 2020","Tufts Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04388683"
22,"NCT04328272","Effectiveness of Hydroxychloroquine in Covid-19 Patients","Covid","Not yet recruiting","No Results Available","COVID19","Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets","National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers","Prof. Dr. Umar Farooq|Ayub Medical College, Abbottabad","All","18 Years to 50 Years   (Adult)","Phase 3","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Ath/ct101/22/3","March 28, 2020","May 28, 2020","June 28, 2020","March 31, 2020",,"April 2, 2020","Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan",,"https://ClinicalTrials.gov/show/NCT04328272"
23,"NCT04377763","Developement and Evaluation of Serological Assays for COVID-19","SEROCOV","Not yet recruiting","No Results Available","COVID-19",,"Sensibility and specificity|Delay between the first symptoms and the positive serological result","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20MWI-SEROCOV","May 2020","October 2020","October 2020","May 6, 2020",,"May 8, 2020","Laboratory of microbiology of hospital hygiene, Ambroise Paré Hospital, APHP, Boulogne-Billancourt, France",,"https://ClinicalTrials.gov/show/NCT04377763"
24,"NCT04347915","The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Clevudine|Drug: Hydroxychloroquine","The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)|The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) in consecutive two days of Real-Time RT-PCR tests|The rate of subjects indicated by the improvement of lung invasive|The change of viral load","Bukwang Pharmaceutical","All","19 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BK-CLV-201","May 6, 2020","September 30, 2020","December 31, 2020","April 15, 2020",,"May 11, 2020","Korea University Guro Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04347915"
25,"NCT04345679","Anti COVID-19 Convalescent Plasma Therapy",,"Not yet recruiting","No Results Available","COVID 19","Biological: anti-SARS-CoV-2 convalescent plasma","Changing of viral load of SARS-CoV2|Changes in immunglobulin G COVID-19 antibody titer|Changes at the cytokine pattern|Intensive Care Unit Admission|Length of hospital stay|Duration of mechanical ventilation|Clinical Status|Mortality","Orthosera Kft.|Semmelweis University|University of Pécs|Hungarian National Blood Service|Humán Bioplazma Kft - Kedrion","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AntiCOVID19ORT","April 14, 2020","June 1, 2020","April 1, 2021","April 14, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04345679"
26,"NCT04333407","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","C-19-ACS","Recruiting","No Results Available","COVID-19","Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg","All-cause mortality at 30 days after admission|Absolute change in serum troponin from admission to peak value|Discharge Rate|Intubation Rate","Imperial College London","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","3170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20HH5868","April 3, 2020","March 30, 2021","March 30, 2021","April 3, 2020",,"April 9, 2020","Charing Cross Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04333407"
27,"NCT04321421","Hyperimmune Plasma for Critical Patients With COVID-19","COV19-PLASMA","Recruiting","No Results Available","COVID-19","Other: hyperimmune plasma","death|time to extubation|length of intensive care unit stay|time to CPAP weaning|viral load|immune response","Foundation IRCCS San Matteo Hospital|OSPEDALE CARLO POMA ASST MANTOVA","All","18 Years and older   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRCCSSanMatteoH","March 17, 2020","May 31, 2020","May 31, 2020","March 25, 2020",,"April 27, 2020","Catherine Klersy, Pavia, PV, Italy|Ospedale Asst Carlo Poma Mantova, Mantova, Italy",,"https://ClinicalTrials.gov/show/NCT04321421"
28,"NCT04370288","Clinical Application of Methylene Blue for Treatment of Covid-19 Patients","Covid-19","Recruiting","No Results Available","Covid-19","Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)","Proportion of patients remaining free of need for mechanical ventilation in both groups|Mortality rate in both groups|Improvement in Pa02/Fi02 ratio in both groups|Duration of hospital stay in both group.|Duration of Intensive Care Unit stay in both groups|Days free of dialysis in both groups|C-reactive proteins|WBC Count","Mashhad University of Medical Sciences","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IR.MUMS.REC.1399.122","April 19, 2020","September 20, 2020","September 21, 2020","April 30, 2020",,"May 4, 2020","Imam Reza Hospital, Mashhad, Razavi Khorasan, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04370288"
29,"NCT04347460","Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH","COVIDHLH","Recruiting","No Results Available","COVID",,"Presence of sHLH as determined by expert chart review by two independent reviewers|Determine the incidence of patients fulfilling HLH criteria in Covid 19 viral infection|Determine the incidence of patients fulfilling modified 2004 HLH diagnostic criteria (Ferritin > 10000 μg/L) in Covid 19 viral infection|Characterization and incidence of the hyper-inflammatory state in COVID-19|all cause mortality assesed on day 15|all cause mortality assesed on day 29|immunophenotpye","Technische Universität München","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","161/20 S","March 27, 2020","July 1, 2020","August 31, 2020","April 15, 2020",,"April 15, 2020","Department of nephrology, Klinikum rechts der Isar, München, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT04347460"
30,"NCT04377685","Prediction of Clinical Course in COVID19 Patients","COVID-CTPRED","Recruiting","No Results Available","COVID 19","Other: CT-Scan","diagnostic of COVID disease composite","Centre Hospitalier Universitaire de Saint Etienne|Institut National des Sciences Appliquées (INSA)|Institut National de la Santé Et de la Recherche Médicale, France|Centre National pour le Recherche Scientifique (CNRS)|Université de Lyon|Université Jean Monnet","All","18 Years and older   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20CH109|IRBN652020/CHUSTE","March 1, 2020","September 30, 2020","September 30, 2020","May 6, 2020",,"May 18, 2020","Chu Saint-Etienne, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT04377685"
31,"NCT04375046","Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2","Bacterial ACE2","Not yet recruiting","No Results Available","COVID-19","Drug: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)","Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events","Kafrelsheikh University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","proposed by Mahmoud kazazzaz","August 2020","September 2020","October 2020","May 5, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04375046"
32,"NCT04379297","COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE)","CON-VINCE","Active, not recruiting","No Results Available","COVID19",,"Prevalence and dynamics of the SARS-COV 2 infection in Luxemburg|Collection of samples for research|Psycho-social evaluation","Luxembourg Institute of Health|Luxembourg National Research Funds|University of Luxembourg/ Luxembourg Centre for Systems Biomedicine|Centre Hospitalier du Luxembourg|TNS-Ilres|Laboratoires Réunis|BioneXt Lab|Ketterthill|Laboratoire National de santé","All","18 Years and older   (Adult, Older Adult)",,"1800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CNER 202004/01|831x6ce0d|FNR/CON-VINCE","April 10, 2020","May 28, 2021","December 31, 2021","May 7, 2020",,"May 7, 2020","Luxembourg Institute of Health, Strassen, Luxembourg",,"https://ClinicalTrials.gov/show/NCT04379297"
33,"NCT04291053","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Huaier Granule","Mortality rate|Clinical status assessed according to the official guideline|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|Length of hospital stay (days)|Length of ICU stay (days)|Pulmonary function","Tongji Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJ-IRB20200205","April 1, 2020","August 1, 2020","September 1, 2020","March 2, 2020",,"March 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04291053"
34,"NCT04365725","Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections","REMDECO-19","Recruiting","No Results Available","COVID-19","Drug: Remdesivir","Clinical course on Day 15.|Clinical course on Day 3.|Clinical course on Day 8|Clinical course on Day 11.|Clinical course on Day 29.|Duration of treatment|Sepsis-related Organ Failure Assessment score|Duration without mechanical ventilation|Mortality|cumulative incidence of grade 3 and 4 adverse events (AEs).","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","APHP200522","May 5, 2020","June 2020","June 2020","April 28, 2020",,"May 13, 2020","Hôpital Cochin, Paris, France",,"https://ClinicalTrials.gov/show/NCT04365725"
35,"NCT04342637","COVID-19 Endoscopy Survey","COVID-19 Endo","Completed","No Results Available","COVID-19","Other: Practice details","Effect of GI societies recommendations on prevention of SARS-CoV-2 infection|To measure the percentage change in performed endoscopic procedure in response to COVID-19|Effect of COVID-19 precautions on procedure time|Effect of COVID-19 precautions on time of disinfection|Effect of COVID-19 precautions on procedure success|Effect of COVID-19 precautions on complications|Effect of COVID-19 precautions on working time|Effect of COVID-19 precautions on staff number","Al-Azhar University","All","30 Years to 70 Years   (Adult, Older Adult)",,"163","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","WES-2","April 10, 2020","April 25, 2020","May 1, 2020","April 13, 2020",,"May 20, 2020","Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt|Al-Azhar Univerisity, Cairo, Egypt|Ahvaz Imam hospital, Ahvaz, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04342637"
36,"NCT04331509","COVID-19 Symptom Tracker",,"Recruiting","No Results Available","COVID-19","Other: No Intervention","Physical health symptoms|Lack of physical health symptoms|Fever","King's College London|Zoe Global Limited|Massachusetts General Hospital|Harvard School of Public Health|Stanford University","All","18 Years and older   (Adult, Older Adult)",,"10000000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 Symptom tracker","March 23, 2020","March 23, 2022","March 23, 2022","April 2, 2020",,"April 7, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|King's College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04331509"
37,"NCT04343976","Pegylated Interferon Lambda Treatment for COVID-19",,"Not yet recruiting","No Results Available","COVID-19|COVID","Drug: Pegylated interferon lambda","Undetectable COVID PCR at day 7|Undetectable COVID PCR at day 3, 10 and 14|Percentage of subjects on Lambda vs standard of care with symptomatic improvement|Percentage of subjects on Lambda vs standard of care with improved clinical outcomes","Raymond Chung|Eiger BioPharmaceuticals|Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020P001083","May 15, 2020","October 1, 2020","December 31, 2021","April 14, 2020",,"April 24, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04343976"
38,"NCT04386668","Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic","LIO-C","Not yet recruiting","No Results Available","COVID19","Other: Let It Out (LIO)-C|Other: Neutral writing control","Kessler Psychological Distress Scale (K10)|Perceived Stress Scale (PSS-10)|Pittsburgh Sleep Quality Index (PSQI)|Self-compassion scale (SCS)|UCLA Loneliness Scale (UCLA LS)|Uptake of existing mental health services (MHS)|Mood and meaning|Acceptability","University College, London","All","18 Years and older   (Adult, Older Adult)","Not Applicable","286","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","15281/003","May 2020","September 2020","November 2020","May 13, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04386668"
39,"NCT04347993","A Prospective ""Universal"" Observational Database for COVID-19",,"Recruiting","No Results Available","COVID-19",,"Need for hospitalization|Duration of hospitalization|Need for ICU/Ventilator Support|Duration of ICU/Ventilator Support|Overall Survival","Hackensack Meridian Health","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Pro2020-0342","March 27, 2020","April 2021","April 2021","April 15, 2020",,"April 24, 2020","Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04347993"
40,"NCT04396067","Combination With Alvelestat and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated Vaccines","Antibodies","Not yet recruiting","No Results Available","COVID -19","Drug: Alvelestat (MPH996) Plus Aerosolized 13 cis retinoic acid|Other: Placebo","Within-individual % change in plasma desmosine/isodesmosine|Numbers and % of subjects who experience at least 1 treatment-emergent adverse event|lung injury score|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|d-dimers|Absolute lymphocyte counts|The immune correlates of protection against future exposure to SARS-CoV-2|Immunological profile|Total duration of mechanical ventilation, ventilatory weaning and curarisation|Occurrence of adverse event related to immunoglobulins|IgG, IgA and IgM against COVID-19|ACE2 expression in patients with COVID-19 infection|All cause mortality rate [|Ventilation free days|ICU free days","Kafrelsheikh University|Damietta University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19","June 2020","September 2020","November 2020","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04396067"
41,"NCT04345991","Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort","CORIPLASM","Recruiting","No Results Available","Covid19","Drug: Transfusion of COVID-19 convalescent plasma","Survival without needs of ventilator utilization or use of immunomodulatory drugs|WHO progression scale ≥6|Severe adverse events|WHO progression scale|Overall survival|Time from randomization to discharge|Time to oxygen supply independency|Survival without needs of ventilator utilization|Survival without use of immunomodulatory drugs","Assistance Publique - Hôpitaux de Paris|Etablissement Français du Sang","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-10|2020-001246-18","April 15, 2020","May 15, 2020","June 1, 2020","April 15, 2020",,"May 20, 2020","SMIT, Saint Antoine hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT04345991"
42,"NCT04355871","Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain","COVID19@Spain","Completed","No Results Available","Covid19",,"Overall mortality|Mechanical ventilation","Fundacion SEIMC-GESIDA","All","Child, Adult, Older Adult",,"4035","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COVID-19/SEIMC-FSG","March 18, 2020","April 15, 2020","April 17, 2020","April 21, 2020",,"May 11, 2020","Comp. Hosp. Univ. A Coruña, A Coruña, Spain|H. Quiron A Coruña, A Coruña, Spain|H. de Alcaniz, Alcañiz, Spain|H. Gral Univ. de Alicante, Alicante, Spain|H. Univ. San Juan de Alicante, Alicante, Spain|H. Univ. de la Ribera, Alzira, Spain|H. Santos Reyes, Aranda De Duero, Spain|H. Dr. Jose Molina Orosa, Arrecife, Spain|Consorcio Sanitari Integral (CAIDM), Barcelona, Spain|H. Clinic, Barcelona, Spain|H. del Mar, Barcelona, Spain|H. Parc Sanitari Sant Joan de Deu, Barcelona, Spain|H. Santa Creu y Sant Pau, Barcelona, Spain|H. Univ. de Bellvitge, Barcelona, Spain|H. Vall d'Hebron, Barcelona, Spain|Hospital CIMA-Sanitas, Barcelona, Spain|SCIAS H. de Barcelona, Barcelona, Spain|H. Clinica de Benidorm, Benidorm, Spain|H. de Cruces, Bilbao, Spain|H. San Eloy_Barakaldo, Bilbao, Spain|H. Univ. de Basurto, Bilbao, Spain|H. Urduliz-Alfredo Espinosa, Bilbao, Spain|H. Gral de La Palma, Breña Alta, Spain|H. de Puerto Real, Cadiz, Spain|H. de Calahorra, Calahorra, Spain|H. Sant Jaume de Calella, Calella, Spain|H. Univ Santa Lucia, Cartagena, Spain|H. Univ de Henares, Coslada, Spain|Hospital Marina Salud de Dénia, Denia, Spain|Hospital Don Benito-Villanueva de la Serena, Don Benito, Spain|H. Gral Univ. de Elche, Elche, Spain|H. Univ. del Vinalopo, Elche, Spain|Comp. Hospt. Univ. de Ferrol, Ferrol, Spain|H. Francesc de Borja, Gandia, Spain|H. de Figueres, Gerona, Spain|H. Comarcal de Blanes, Girona, Spain|H. Josep Trueta, Girona, Spain|H. Clinico San Cecilio, Granada, Spain|Hospital HLA Inmaculada, Granada, Spain|H. de Guadalajara, Guadalajara, Spain|H. de Guadarrama, Guadarrama, Spain|H. Juan Ramón Jiménez, Huelva, Spain|H. Riotinto, Huelva, Spain|H. Can Misses, Ibiza, Spain|H. Universitario de Jaén, Jaén, Spain|H. Univ. de Jerez de la Frontera, Jerez De La Frontera, Spain|H. Univ Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain|H. Universitario de Gran Canaria Dr. Negrin, Las Palmas De Gran Canaria, Spain|H. Univ. Severo Ochoa, Leganés, Spain|H. San Pedro, Logroño, Spain|H. Univ. Menez Rafael Mendez, Lorca, Spain|H. Lucus Augusti, Lugo, Spain|H. 12 de Octubre, Madrid, Spain|H. Clinica Univ. de Navarra_ Campus Madrid, Madrid, Spain|H. Clinico San Carlos, Madrid, Spain|H. Fundacion Jiménez Díaz, Madrid, Spain|H. Gral de la Defensa Gomez Ulla, Madrid, Spain|H. HLA Univ. Moncloa, Madrid, Spain|H. HM Sanchinarro, Madrid, Spain|H. Puerta de Hierro, Madrid, Spain|H. Univ HM Madrid, Madrid, Spain|H. Univ Principe de Asturias, Madrid, Spain|H. Univ. de Alcorcón, Madrid, Spain|H. Univ. de Getafe, Madrid, Spain|H. Univ. de Móstoles, Madrid, Spain|H. Univ. Gregorio Marañon, Madrid, Spain|H. Univ. HM Monteprincipe, Madrid, Spain|H. UNiv. HM Puerta del Sur, Madrid, Spain|H. Univ. Infanta Leonor, Madrid, Spain|H. Univ. La Paz, Madrid, Spain|H. Univ. La Princesa, Madrid, Spain|H. Univ. Ramón y Cajal, Madrid, Spain|H. Univ. Rey Juan Carlos, Madrid, Spain|H. Costa del Sol, Marbella, Spain|H. de Mataro, Mataró, Spain|H. de Melilla, Melilla, Spain|H. de Mendaro, Mendaro, Spain|Hospital Alto Deba, Mondragón, Spain|H. Virgen de la Arrixaca, Murcia, Spain|H. Marbella Internacional, Málaga, Spain|H. Virgen de la Victoria, Málaga, Spain|H. Vega Baja, Orihuela, Spain|H. Univ. Central de Asturias, Oviedo, Spain|H. de Palamos, Palamós, Spain|H. Son Espases, Palma De Mallorca, Spain|H. Son Llatzer, Palma De Mallorca, Spain|H. Clinica Univ. Navarra, Pamplona, Spain|H. Virgen del Puerto, Plasencia, Spain|H. El Bierzo, Ponferrada, Spain|H. Do Salnes, Pontevedra, Spain|H. UNiv. Los Arcos del Mar Menor, Pozo Aledo, Spain|H. Santa Barbara, Puertollano, Spain|H. Parc Tauli, Sabadell, Spain|Complejo Asist. Univ. de Salamanca, Salamanca, Spain|H. Infanta Sofia, San Sebastián De Los Reyes, Spain|H. de Donostia, San Sebastián, Spain|H. de l'Esperit Sant, Santa Coloma De Gramenet, Spain|H. Univ. Marques de Valdecilla, Santander, Spain|H. Clinico Univ. Santiago de Compostela, Santiago De Compostela, Spain|H. Univ de Valme, Sevilla, Spain|H. Univ. Virgen del Rocio, Sevilla, Spain|H. Univ. Virgen Macarena, Sevilla, Spain|H. Virgen Macarena, Sevilla, Spain|H. Univ Joan XXIII, Tarragona, Spain|H. U. de Canarias, Tenerife, Spain|H. Univ. Nuestra Sra. de la Candelaria, Tenerife, Spain|H. Mutua de Terrasa, Terrassa, Spain|Complejo Hospitalario Virgen de la Salud, Toledo, Spain|H. Univ. HM Torrelodones, Torrelodones, Spain|H. Quiron Salud Torrevieja, Torrevieja, Spain|H. Virgen de la Cinta, Tortosa, Spain|H. Reina Sofia de Tudela, Tudela, Spain|H. Arnau de Vilanova-Lliria, Valencia, Spain|H. Clinico Univ. de Valencia, Valencia, Spain|H. de Sagunto, Valencia, Spain|H. Univ. y Polit. La Fe, Valencia, Spain|H. Clin. Univ. de Valladolid, Valladolid, Spain|H. Rio Hortega, Valladolid, Spain|H. Alvaro Cunqueiro, Vigo, Spain|H. de Viladecans, Viladecans, Spain|H. de la Marina Baixa, Villajoyosa, Spain|Hospital de la Plana, Villareal, Spain|H. Univ de Alava, Vitoria, Spain|H. Virgen de la Concha, Zamora, Spain|H. Lozano Blesa, Zaragoza, Spain|H. Miguel Servet, Zaragoza, Spain|H. Ntra. Sra. de Gracia, Zaragoza, Spain|Complejo Asistencial de Avila, Ávila, Spain",,"https://ClinicalTrials.gov/show/NCT04355871"
43,"NCT04321993","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients",,"Recruiting","No Results Available","COVID-19","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate|Drug: Baricitinib (janus kinase inhibitor)","Clinical status of subject at day 15 (on a 7 point ordinal scale).|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.|Length of time to clinical improvement|Number of participants with normal pulmonary function and normal O2 saturation on days 11, 15 and 29|Number of participants that developed Acute Respiratory Distress Syndrome (ARDS) after treatment|Length of time to clinical progression|Cause of death (if applicable)|Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized and on days 15 and 29. (Initial, highest, deltas and mean)|Length of time to normalization of fever|Length of time to normalization of oxygen saturation|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Duration of hospitalization|Adverse events","Lisa Barrett|Nova Scotia Health Authority|Dalhousie University","All","18 Years and older   (Adult, Older Adult)","Phase 2","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAIL-004","April 17, 2020","February 2022","March 2022","March 26, 2020",,"May 19, 2020","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT04321993"
44,"NCT04336462","Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19","COVID-19","Recruiting","No Results Available","COVID-19","Device: oxyhydrogen|Device: Oxygen","Recovery time|Clinical Symptom Remission time|fever duration|Leicester cough questionaire (LCQ)|minimum oxygen|Negative conversion rate|white blood cell(WBC)|Red blood cells(RBC)|Hemoglobin(Hb )|Platelets(PLT)|Lymphocyte count|The percentage of lymphocyte|neutrophils|C-reactive protein (CRP)|Myocardial enzyme|liver function|Renal function|Muscle enzyme","Shanghai Asclepius Meditec Inc.|Shanghai Public Health Clinical Center|Henan Provincial People's Hospital|Shenzhen Third People's Hospital|The First People's Hospital of Yunnan|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai 6th People's Hospital|Guangdong Provincial Hospital of Traditional Chinese Medicine","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JT202002LZ","February 15, 2020","February 21, 2020","August 1, 2020","April 7, 2020",,"April 7, 2020","First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04336462"
45,"NCT04389658","Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION)","CONDITION","Recruiting","No Results Available","COVID-19",,"Prevalence of contagiousness in asymptomatic individuals by PCR|Ratio of asymptomatic immunized (IgA/IgM and IgG) population|Description of demographic characteristics","Igenomix","All","Child, Adult, Older Adult",,"1000","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","IGX1-COV-XS-20-01","May 7, 2020","June 2020","August 2020","May 15, 2020",,"May 18, 2020","Igenomix, Paterna, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04389658"
46,"NCT04393038","ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19","Mir-Age","Recruiting","No Results Available","COVID-19","Drug: ABX464|Drug: Placebo","Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive|Rate of patients hospitalized|Percentage of patients reporting each severity rating on a 7-point ordinal scale|Change from enrolment in inflammatory markers in plasma and in immune phenotype and assessment of cell-activation markers in PBMCs|Rate of patients requiring oxygen supplementation|Time to hospitalization|Time to assisted ventilation and oxygen supplementation|Change from baseline in microRNA-124 levels|Change from baseline in CRP, Troponin I & T and D-dimer|SARS-CoV-2 viral load|Number and rates of participants with Treatment Emergent Adverse Event","Abivax S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1034","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ABX464-401","May 1, 2020","December 30, 2020","April 30, 2021","May 19, 2020",,"May 19, 2020","Centre Hospitalier Universitaire de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT04393038"
47,"NCT04381052","Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID-19","Drug: Clazakizumab|Other: Placebo","Cumulative incidence of serious adverse events associated with clazakizumab or placebo|Cumulative Incidence of Intubation|Time to Extubation|Length of Intensive Care Unit (ICU) stay|Number of Patients who Present a Decrease in C-reactive protein (CRP)|Number of Patients with Acute Kidney Injury (AKI)|Number of Patients with a Need for Renal Replacement Therapy (RRT)|Duration of Renal Replacement Therapy (RRT)|Patient Survival|Number of Patients with Hemodialysis|Number of Patients with Continuous Renal Replacement Therapies (CRRT)|Number of Patients with Peritoneal Dialysis","Columbia University|NYU Langone Health|Vitaeris INC","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AAAT0142","May 2020","August 1, 2020","August 1, 2020","May 8, 2020",,"May 8, 2020","Columbia University Medical Center / New York Presbyerian Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04381052"
48,"NCT04368390","Neuroradiolological Analysis of COVID-19 Patients","COVID-19BRAIN","Recruiting","No Results Available","Covid-19",,"Neuroradiological analysis of patients brain MRI","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7759","April 3, 2020","April 2021","April 2021","April 29, 2020",,"April 29, 2020","Service d'Imagerie 2 - Neuroradiologie, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04368390"
49,"NCT04363346","Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia",,"Recruiting","No Results Available","COVID-19","Drug: FT516","Number of participants with Dose Limiting Toxicity Events|The time in days from the 1st FT516 infusion to the elimination of viral shedding in nasal pharyngeal and stool samples|The time in days from the 1st FT516 infusion to discontinued need for supplemental oxygen|The time in days from the 1st FT516 infusion to hospital discharge","Masonic Cancer Center, University of Minnesota","All","18 Years to 76 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDIM-2020-28708|2020LS083","May 14, 2020","January 2022","January 2022","April 27, 2020",,"May 18, 2020","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04363346"
50,"NCT04338906","Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19","CLOCC","Not yet recruiting","No Results Available","COVID","Drug: Camostat Mesilate|Drug: Placebo|Drug: Hydroxychloroquine","Not hospitalized|Time to improvement of 2 categories from admission on a 7-point ordinal scale|Proportion of participants in each group with normalization of fever|Proportion of participants in each group with oxygen saturation > 94% on room air for >24h|Time to fever normalization (if febrile at baseline)|Time to first negative SARS-CoV-2 PCR in NP swap (if pos. at baseline)|Time to first negative SARS-CoV-2 PCR in lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) (if positive at baseline)|Duration of oxygen therapy|Proportion of participants in each group with need for mechanical ventilation|Duration of hospitalization|All cause mortality","Heinrich-Heine University, Duesseldorf|Universitätsklinikum Hamburg-Eppendorf|University Hospital, Frankfurt|St. Georg Hospital Leipzig, Germany|Hospital Schwabing Munich, Germany|Missioklinik, Wuerzburg, Germany","All","18 Years and older   (Adult, Older Adult)","Phase 4","334","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLOCC-2020","June 1, 2020","June 1, 2021","December 31, 2021","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04338906"
51,"NCT04372979","Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.","PLASCOSSA","Not yet recruiting","No Results Available","COVID-19","Drug: Transfusion of SARS-CoV-2 Convalescent Plasma.|Drug: Transfusion of standard Plasma.","Survival time without needs of a ventilator.|Morbidity|Mortality|Length of stay|Effect on viral pharyngeal specimen clearance|Effect on viral blood specimen clearance|Effect on hemostasis disorders|Kinetics of appearance of neutralizing antibodies|Transfusion endotheliopathy effect|Transfusion biological Inflammation effect|Transfusion hemovigilance|Decrease in the consumption of antibiotics","Direction Centrale du Service de Santé des Armées|University Hospital, Grenoble","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-A01166-33","May 2020","October 2020","May 2021","May 4, 2020",,"May 15, 2020","HIA Percy, Clamart, France|HIA Laveran, Marseille, France|HIA Bégin, Saint-Mandé, France|HIA Sainte Anne, Toulon, France",,"https://ClinicalTrials.gov/show/NCT04372979"
52,"NCT04383626","Fear Among Dentists During COVID-19 Pandemic",,"Completed","No Results Available","COVID",,"fear among dentist during COVID 19 epidemic|practice modification among dentist during COVID 19 epidemic","Cairo University","All","20 Years and older   (Adult, Older Adult)",,"216","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","COVID-19 pandemic","March 2, 2020","April 5, 2020","May 5, 2020","May 12, 2020",,"May 12, 2020","Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04383626"
53,"NCT04333420","Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","PANAMO","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Best supportive Care (BSC) + IFX-1|Drug: Best supportive care only","Change in PaO2/FiO2|Patients achieving early response","InflaRx GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IFX-1-P2.9","March 31, 2020","October 31, 2020","December 31, 2020","April 3, 2020",,"April 16, 2020","University Amsterdam, Amsterdam, Netherlands|University Amsterdam, Amsterdam, Netherlands|University Maastricht, Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04333420"
54,"NCT04342689","The Role of Resistant Starch in COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID-19","Drug: Dietary Supplement containing resistant starch|Dietary Supplement: Placebo Starch","Rates of hospitalization for a COVID-19 related complication|Time to clinical recovery (TTCR)|Symptom Severity Score","Yale University|University of Michigan|University of Minnesota","All","19 Years and older   (Adult, Older Adult)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2000027887","June 1, 2020","June 1, 2021","June 1, 2021","April 13, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04342689"
55,"NCT04382794","Sitagliptin Treatment in Diabetic COVID-19 Positive Patients","SIDIACO-RETRO'","Recruiting","No Results Available","Covid19","Drug: Retrospective case-control analysis","Clinical parameter of acute lung disease|Death|Biochemical parameter of acute lung disease","University of Milan|Papa Giovanni XXIII Hospital|IRCCS Policlinico S. Matteo|Humanitas Hospital, Italy|Ospedale dell'Angelo, Venezia-Mestre|University of Pavia","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","5/2020","May 14, 2020","June 15, 2020","August 15, 2020","May 11, 2020",,"May 18, 2020","ASST FBF-Sacco P.O. Sacco, Milan, MI, Italy|Papa Giovanni XXIII Hospital, Bergamo, Italy|Ospedale dell'Angelo, Venezia-Mestre, Mestre, Italy|Humanitas Hospital, Milan, Italy|University of Pavia, Pavia, Italy|IRCCS Policlinico S. Matteo, Pavia, Italy",,"https://ClinicalTrials.gov/show/NCT04382794"
56,"NCT04366206","Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est",,"Recruiting","No Results Available","COVID|SARS-CoV 2",,"Composite of death and mechanical ventilation|Need for mechanical ventilation|Death|Acute kidney injury|Acute respiratory distress syndrome|Cardiac arrhythmia and conduction disorder|60-days mortality|60-days mechanical ventilation","Centre Hospitalier Intercommunal Robert Ballanger|Groupe Hospitalier Pitie-Salpetriere","All","Child, Adult, Older Adult",,"143","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GHTRB-2020-01","March 14, 2020","July 31, 2020","July 31, 2020","April 28, 2020",,"April 28, 2020","Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Groupe Hospitalier Pitie Salpetriere, Paris, France",,"https://ClinicalTrials.gov/show/NCT04366206"
57,"NCT04341506","Non-contact ECG Sensor System for COVID19",,"Not yet recruiting","No Results Available","COVID-19","Device: Non-contact ECG","ECG changes associated with COVID-19","Northwestern Medicine","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-0407","April 15, 2020","July 15, 2020","September 15, 2020","April 10, 2020",,"April 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04341506"
58,"NCT04343755","Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma","For patients hospitalized for COVID-19 but not intubated|Primary objective for patients with COVID-19 already intubated|Duration of hospitalization|Duration of mechanical ventilation|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at day 10|Impact of donor titers level on efficacy|Impact of donor titers level on safety|Recipient Anti-SARS-CoV2 titer assessment on days 0 (pre-infusion),3,10,30, 60","Hackensack Meridian Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro2020-0375","April 9, 2020","April 2021","April 2021","April 13, 2020",,"April 17, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04343755"
59,"NCT04369820","C5a Receptor Expression - COVID-19 (C5-COV)","C5-COV","Recruiting","No Results Available","COVID-19","Other: draw blood","Show an overexpression of C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers).","Assistance Publique Hopitaux De Marseille|Innate Pharma","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2020-14|IDRCB","March 31, 2020","September 2020","November 2020","April 30, 2020",,"May 4, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT04369820"
60,"NCT04324489","DAS181 for Severe COVID-19: Compassionate Use",,"Completed","No Results Available","COVID-19","Drug: DAS181","Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death","Renmin Hospital of Wuhan University|Ansun Biopharma, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","4","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAS181-SARS-CoV-2","March 6, 2020","April 16, 2020","April 30, 2020","March 27, 2020",,"May 5, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04324489"
61,"NCT04391712","Cold Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease",,"Recruiting","No Results Available","COVID-19","Device: MLS Laser|Other: Regular Inpatient Medical Care","Patient Disposition Post treatment|oxygenation|IL-6 levels|Chest Xray radiographic results|Brescia-COVID Respiratory Severity Scale|SMART-COP Score|PSI Score|CRP levels","Lowell General Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020.01","April 30, 2020","May 30, 2020","June 30, 2020","May 18, 2020",,"May 18, 2020","Lowell General Hospital, Lowell, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04391712"
62,"NCT04392141","Colchicine Plus Phenolic Monoterpenes to Treat COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Standard Treatment|Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions","Mortality rate|Change in patients clinical manifestation|Length of hospitalization|C-reactive protein|lymphocyte count|serum lactate dehydrogenase|serum Interleukin-6|erythrocyte sedimentation rate","Kermanshah University of Medical Sciences","All","10 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1399.062","April 1, 2020","June 1, 2020","October 1, 2020","May 18, 2020",,"May 18, 2020","Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04392141"
63,"NCT04379284","Risks of COVID19 in the Pregnant Population",,"Not yet recruiting","No Results Available","COVID19","Other: Biospecimen collection","Determine the prevalence of maternal fetal transmission of COVID19|Describe the outcomes of COVID19 positive pregnancies|Understand the placental impact of COVID19 in pregnancy at various gestational ages","Mayo Clinic","Female","18 Years to 45 Years   (Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20-003251","May 5, 2020","April 30, 2021","July 31, 2021","May 7, 2020",,"May 11, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04379284"
64,"NCT04365582","OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome","OUTCOV","Not yet recruiting","No Results Available","COVID","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab","Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events","Groupe Hospitalier Paris Saint Joseph","All","50 Years and older   (Adult, Older Adult)","Phase 3","640","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OUTCOV","April 28, 2020","July 28, 2020","January 28, 2021","April 28, 2020",,"April 28, 2020","Hôpital Privé d'Antony, Antony, France|Hôpital Avicenne, Bobigny, France|Centre Hospitalier Intercommunal de Créteil, Créteil, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|Institut Mutualiste Montsouris, Paris, France",,"https://ClinicalTrials.gov/show/NCT04365582"
65,"NCT04329611","ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","Composite of hospitalization, invasive mechanical ventilation or death within 30 days|mortality|Symptom duration|Disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased (categorical)","Dr. Michael Hill|Alberta Health Services|University of Alberta|University of Calgary|Calgary Health Trust|Alberta Innovates Health Solutions|Government of Alberta","All","18 Years and older   (Adult, Older Adult)","Phase 3","1660","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ABCOV-01 version 1.5","April 13, 2020","August 31, 2020","September 30, 2020","April 1, 2020",,"May 18, 2020","University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04329611"
66,"NCT04335123","Study of Open Label Losartan in COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Losartan","Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg","University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00145514","March 25, 2020","September 2020","October 2020","April 6, 2020",,"April 24, 2020","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04335123"
67,"NCT04351659","Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19",,"Recruiting","No Results Available","COVID-19","Other: Blood donation from convalescent donor","Success rate in production of SARS-CoV-2 specific T cells from convalescent donor","KK Women's and Children's Hospital|Singapore General Hospital|National University Hospital, Singapore","All","21 Years to 65 Years   (Adult, Older Adult)",,"8","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-T 1.0","April 2020","August 2020","August 2020","April 17, 2020",,"April 17, 2020","National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04351659"
68,"NCT04386759","COVID-19 Infection in Healthcare Workers","HOP-COVID","Not yet recruiting","No Results Available","COVID-19","Other: Cohort","SARS-COV-2 infection|Individual factors|Hospital ward level","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","APHP200483","May 2020","October 2020","October 2020","May 13, 2020",,"May 13, 2020","Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France",,"https://ClinicalTrials.gov/show/NCT04386759"
69,"NCT04382586","Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants",,"Not yet recruiting","No Results Available","COVID-19 Pulmonary Complications|COVID-19","Drug: Zanubrutinib|Drug: Supportive Care|Drug: Placebo","Respiratory failure-free survival rate at day 28|Median reduction in days spent on supplemental oxygen|All-cause mortality|Proportion of participants experiencing respiratory failure or death|Mechanical ventilation-free survival|Days on mechanical ventilation|Duration of hospitalization|Time to discharge|PaO2:FiO2 and/or oxygenation index|Change from Baseline to Day 14 in WHO - 8 Point Ordinal Scale","BeiGene","All","18 Years and older   (Adult, Older Adult)","Phase 2","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BGB-3111-219","May 2020","July 2020","September 2020","May 11, 2020",,"May 11, 2020","Loyola University Medical Center, Maywood, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham And Women's Hospital, Boston, Massachusetts, United States|Atlantic Health System Inc. / Morristown Medical Center, Morristown, New Jersey, United States|Rutgers University Hospital, Newark, New Jersey, United States|Atlantic Health System Inc. / Overlook Hospital, Summit, New Jersey, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04382586"
70,"NCT04323228","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19","ONSCOVID19","Not yet recruiting","No Results Available","COVID-19","Dietary Supplement: oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants|Dietary Supplement: isocaloric/isonutrigenous ONS","Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial|Change from baseline Serum ferritin level at end of the trial|Change from baseline serum Interleukin-6 concentration at end of the trial|Change from baseline serum C-reactive protein concentration at end of the trial|Change from baseline serum Tumor necrosis factor-α concentration at end of the trial|Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial|Change from baseline Weight at end of the trial|Height|Change from baseline BMI at end of the trial|Change from baseline mid arm circumference at end of the trial|Change from baseline triceps skin-fold thickness at end of the trial|Change from baseline MAMA at end of the trial|Change from baseline percentage of peripheral O2 saturation at end of the trial|Change from baseline degree of body temperature at end of the trial|Change from baseline count the total leukocyte at end of the trial|Change from baseline differential lymphocytic count at end of the trial|Change from baseline Neutrophil count at end of the trial|Change from baseline neutrophil to lymphocyte ratio at end of the trial","King Saud University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","ONS_COVID-19","May 1, 2020","October 1, 2020","October 30, 2020","March 26, 2020",,"April 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04323228"
71,"NCT04341168","Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults",,"Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Other: this study is non- interventional","Clinical course of COVID-19|Analysis of development of antibodies to SARS-CoV-2|Estimation of viral load|Detection of viral coinfections|Measurement of cytokine and chemokine response|Characterisation of virus-host-interaction|Identification of disease patterns in proteome|Analysis of change in lymphocyte subtypes|Analysis of histological changes in severe lung disease|Detection of bacterial coinfections","University Hospital of Cologne|Clinic for Internal Medicine I, University Hospital Cologne, Germany|Institute of Virology, University Hospital Cologne, Germany|Center for Molecular Medicine Cologne (CMMC) Cologne, Germany","All","Child, Adult, Older Adult",,"160","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KICC19","April 2020","October 2020","October 2020","April 10, 2020",,"April 14, 2020","University Hospital Cologne, Cologne, NRW, Germany",,"https://ClinicalTrials.gov/show/NCT04341168"
72,"NCT04376788","Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19","COVID-19","Not yet recruiting","No Results Available","COVID-19","Biological: exchange blood transfusion from normal donor|Biological: plasma from convalescent patients with COVID-19|Drug: Methylene Blue 5 MG/ML","improvement of condition|change in organs function with PFS and OS","Ain Shams University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FMASU P22/2020","May 5, 2020","June 1, 2020","June 1, 2020","May 6, 2020",,"May 6, 2020","Ain Shams University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04376788"
73,"NCT04366882","Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients","MIA-COVID-19","Recruiting","No Results Available","COVID-19","Procedure: CT-scan with minimal invasive autopsy","Determination of cause of death and contributing factors based on clinical, radiological, microbiological and histopathological data of the deceased patient|Detailed description of the postmortem radiological changes induced by COVID-19|Detailed description of the postmortem histopathological changes induced by COVID-19|Postmortem quantity of viral RNA|Postmortem disease mechanisms at cellular level","Jessa Hospital|Hasselt University|University Hospital, Antwerp","All","Child, Adult, Older Adult","Not Applicable","45","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","JessaH_COVID-19_MIA","April 14, 2020","December 2020","December 2020","April 29, 2020",,"April 29, 2020","Jessa Hospital, Hasselt, Belgium",,"https://ClinicalTrials.gov/show/NCT04366882"
74,"NCT04360356","Ivermectin and Nitazoxanide Combination Therapy for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Combination Product: Ivermectin plus Nitazoxanide|Other: Standard Care","Number of Patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNFα|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio ""INR"" for prothrombin time|Number of patients with normalized complete blood count ""CBC""|The Mortality rate among treated patients","Tanta University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IVR/NTZ","May 2020","October 2020","December 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04360356"
75,"NCT04370262","Multi-site Adaptive Trials Using Hydroxycholoroquine for COVID-19","MATCH","Recruiting","No Results Available","COVID-19","Drug: HCQ + Intravenous Famotidine|Drug: HCQ + Placebo","Mortality|Virologic response to study treatment detected in blood|Virologic clearance in nasal swab and/or lower respiratory secretions|Clinical Severity","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Phase 3","1170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20-0268","April 7, 2020","September 7, 2020","April 7, 2021","April 30, 2020",,"May 13, 2020","Southside Hospital, Bay Shore, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States|Staten Island University Hospital, Staten Island, New York, United States",,"https://ClinicalTrials.gov/show/NCT04370262"
76,"NCT04366180","Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers",,"Recruiting","No Results Available","Covid-19","Dietary Supplement: Probiotic|Dietary Supplement: Control","Incidence of SARS CoV-2 infection in healthcare workers|Incidence of hospital admissions caused by SARS-CoV-2 infection|Incidence of ICU admissions caused by SARS-CoV-2 infection|Incidence of pneumonia caused by SARS-CoV-2 infection|Incidence of oxygen support requirement caused by SARS-CoV-2 infection|Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection|Days with body's temperature > 37.5 ºC|Days with cough|Days with fatigue|Medical treatment","Biosearch S.A.","All","20 Years and older   (Adult, Older Adult)","Not Applicable","314","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","P054","April 24, 2020","June 2020","October 2020","April 28, 2020",,"April 30, 2020","Raquel Rodriguez Blanque, Granada, Spain",,"https://ClinicalTrials.gov/show/NCT04366180"
77,"NCT04382235","Non-invasive Ventilatory Support of Patients Affected by COVID-19","WARd-COVID","Active, not recruiting","No Results Available","Covid-19","Device: Non-invasive ventilatory support","The number of patients treated with non-invasive ventilation devices.|Incidence of patients requiring mechanical ventilation|Incidence of organ failure|Duration of hospitalization|Clinical outcome at hospital discharge","University of Milano Bicocca","All","18 Years and older   (Adult, Older Adult)",,"900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","WARd-COVID","March 26, 2020","May 31, 2020","June 30, 2020","May 11, 2020",,"May 11, 2020","Policlinico San Marco - Ospedale Zingonia, Zingonia, BG, Italy|ASST Papa Giovanni XXIII - Bergamo, Bergamo, Italy|Azienda Ospedaliera - Universitaria di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy|ASST Spedali Civili - Brescia, Brescia, Italy|ASST Valle Olona - Ospedale di Busto Arsizio, Busto Arsizio, Italy|ASST Lariana - Ospedale Sant'Anna, Como, Italy|ASST Crema - Ospedale Maggiore di Crema, Crema, Italy|ASST Cremona - Ospedale di Cremona, Cremona, Italy|Istituto Clinico Humanitas Gavazzeni, Cremona, Italy|ASST Garda - Presidio di Desenzano del Garda, Desenzano Del Garda, Italy|ASST Monza - Desio, Desio, Italy|ASST Spedali Civili -Ospedale di Gardone Val Trompia, Gardone Val Trompia, Italy|ASST Lecco - Ospedale ""A. Manzoni"", Lecco, Italy|ASST Ovest milanese - Ospedale di Legnano, Legnano, Italy|ASST Lodi - Ospedale Maggiore di Lodi, Lodi, Italy|ASST OVEST Milanese - Ospedale di Magenta, Magenta, Italy|ASST Garda - Ospedale di Manerbio, Manerbio, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|ASST Melegnano e della Martesana - Presidio di Melzo-Gorgonzola, Melzo, Italy|ASST Fatebenefratelli - Presidi Fatebenefratelli & M. Melloni, Milano, Italy|ASST Fatebenefratelli - Sacco, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Ospedale San Giuseppe, Milano, Italy|ASST Spedali Civili -Presidio Ospedaliero di Montichiari, Montichiari, Italy|ASST Monza - Ospedale San Gerardo, Monza, Italy|Fondazione IRCCS Policlinico San Matteo - Pavia, Pavia, Italy|Policlinico San Pietro, Ponte San Pietro, Italy|Istituto Clinico Humanitas Rozzano, Rozzano, Italy|ASST Valle Olona - Ospedale di Saronno, Saronno, Italy|ASST Bergamo OVEST - Ospedale ""Treviglio-Caravaggio"" di Treviglio, Treviglio, Italy|Ospedale di Circolo e Fondazione Macchi - Varese, Varese, Italy|ASST Vimercate - Ospedale di Vimercate, Vimercate, Italy|ASST Melegnano e della Martesana - Ospedale di Vizzolo Predabissi, Vizzolo Predabissi, Italy",,"https://ClinicalTrials.gov/show/NCT04382235"
78,"NCT04350593","Dapagliflozin in Respiratory Failure in Patients With COVID-19","DARE-19","Recruiting","No Results Available","COVID-19","Drug: Dapagliflozin 10 MG|Drug: Placebo","Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up, defined as at least one of the following:|Hierarchical composite outcome measures:|Time to hospital discharge|Total number of days alive, out of hospital, and/or free from mechanical ventilation|Total number of days alive, not in the ICU, and free from mechanical ventilation (as defined in the primary outcome measure)|Time to death from any cause|Time to new/worsened organ dysfunction|Time to acute kidney injury (defined as doubling of s-Creatinine compared to baseline)","Saint Luke's Health System|AstraZeneca|George Clinical Pty Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 3","900","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1690C00081|ESR-20-20653","April 15, 2020","October 2020","December 2020","April 17, 2020",,"April 17, 2020","Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04350593"
79,"NCT04370223","Ozone Auto-hemotherapy for COVID-19 Pneumonia","COVID-OZO","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Biological: Ozone auto-hemotherapy","Rate of patients achieving improvement in clinical condition at day 14 after recruitment|Mortality at day 28|Rate of patients achieving improvement in clinical condition at day 28 after recruitment|Rate of patients achieving improvement in clinical condition at day 7 after recruitment|Time to clinical improvement or hospital discharge|Number of ventilator-free days at 28 days|Hospital length of stay|Time to a 2-fold decrease in ferritin|Time to a 2-fold decrease in C-protein reactive|Time to a 2-fold decrease in Dimer-D|Time to a 2-fold decrease in Lactate Dehydrogenase|Time to a 2-fold decrease in Neutrophils to Lymphocytes ratio","Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta|Clinica Nuestra Senora del Rosario|Sociedad Española de Ozonoterapia","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","208","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19 Networking group","May 4, 2020","October 25, 2020","December 25, 2020","April 30, 2020",,"May 5, 2020","Hospital Universitari Dr Josep Trueta, Girona, Spain|Clinica Nuestra Señora del Rosario, Ibiza, Spain|Hospital Quirón Rey Juan Carlos I, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Príncipe de Asturias de Alcalá de Henares, Madrid, Spain|Fundació Althaia de Manresa, Manresa, Spain|Spanish Society of Ozone therapy, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04370223"
80,"NCT04344171","CovidDB: The Covid-19 Inpatient Database",,"Recruiting","No Results Available","COVID-19",,"Outcome comparison between different antiviral therapies|Outcome comparisons between ventilation types|Identification of risk factors|Number of days in hospital vs. clinical classification","ClarData","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CovidDB","March 30, 2020","December 31, 2022","June 30, 2023","April 14, 2020",,"April 21, 2020","RoMed - Klinikum Bad Aibling, Bad Aibling, Germany|DONAUISAR Klinikum Deggendorf, Deggendorf, Germany|DONAUISAR Klinikum Dingolfing, Dingolfing, Germany|RoMed - Klinikum Prien am Chiemsee, Prien, Germany|RoMed - Klinikum Rosenheim, Rosenheim, Germany|Universitätsklinikum Ulm, Ulm, Germany|RoMed - Klinikum Wasserburg Am Inn, Wasserburg Am Inn, Germany|Klinikum Altmühlfranken, Weißenburg, Germany|Timiş County Emergency Clinical Hospital, Timisoara, Romania",,"https://ClinicalTrials.gov/show/NCT04344171"
81,"NCT04363489","The CEDiD Study (COVID-19 Early Diagnosis in Doctors)","CEDiD","Not yet recruiting","No Results Available","Covid19","Device: Wearable Medical Device (Empatica E4)","COVID-19","King's College London|Empatica, Inc.","All","18 Years and older   (Adult, Older Adult)",,"30","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEDiD Study STH","April 27, 2020","May 27, 2020","May 27, 2020","April 27, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04363489"
82,"NCT04361318","Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Combination Product: Hydroxychloroquine plus Nitazoxanide|Other: Standard care","Number of patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNFα|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio ""INR"" for prothrombin time|Number of patients with normalized complete blood count ""CBC""|The Mortality rate among treated patients","Tanta University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","HCQ/NTZ","May 2020","October 2020","December 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04361318"
83,"NCT04287686","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19",,"Withdrawn","No Results Available","COVID-19","Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)","Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events","The First Affiliated Hospital of Guangzhou Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIRH-APN01","February 2020","April 2020","April 2020","February 27, 2020",,"March 17, 2020","GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04287686"
84,"NCT04354857","Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection","Anosmie-COVID","Recruiting","No Results Available","COVID-19","Other: olfactory and gustatory tests","SARS-CoV-2 infection status|Olfactory and gustatory loss|Ability to detect odor|Ability to detect salty taste|Ability to detect sweet taste|Severity of infection according to hospitalization rate","Centre Hospitalier Universitaire de Nīmes","All","18 Years and older   (Adult, Older Adult)",,"454","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB: 20.04.09","March 27, 2020","July 2020","November 2020","April 21, 2020",,"April 21, 2020","CHU de Nimes, Nîmes, France",,"https://ClinicalTrials.gov/show/NCT04354857"
85,"NCT04400448","Acceptance of Telemedicine During the COVID-19 Pandemic",,"Not yet recruiting","No Results Available","Covid-19",,"Acceptance of telemedicine|Patient satisfaction","Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","TELECOVID","June 1, 2020","August 31, 2020","October 31, 2020","May 25, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04400448"
86,"NCT04352933","PROLIFIC ChemoprophylaxisTrial (COVID-19)",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine - Daily dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Matched Placebo Hydroxychloroquine","Time to positive COVID-19 disease|Number of COVID-19 test positive cases|Number of COVID-19 serological test positive cases|Severity of COVID-19 disease between each arm|Number of common COVID-19 complications between each arm","Cambridge University Hospitals NHS Foundation Trust","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PROLIFIC2020 (A095583)","May 11, 2020","October 31, 2020","April 2021","April 20, 2020",,"May 13, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04352933"
87,"NCT04347889","Preventing COVID-19 in Healthcare Workers With HCQ: A RCT",,"Not yet recruiting","No Results Available","Covid-19","Drug: Hydroxychloroquine|Other: Vitamin C","COVID-19 Seroconversion rate|Admission for Covid-19","Stony Brook University","All","18 Years and older   (Adult, Older Adult)","Phase 2","1212","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","IRB2020-00222","April 20, 2020","December 30, 2020","December 30, 2020","April 15, 2020",,"April 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04347889"
88,"NCT04347850","A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19)","COVIDothèque","Recruiting","No Results Available","SARS-CoV-2|COVID-19","Other: blood sample","Number of confirmed COVID-19|Number of severe COVID-19","University Hospital, Montpellier","All","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0185","February 1, 2020","December 1, 2022","December 30, 2022","April 15, 2020",,"April 16, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04347850"
89,"NCT04364022","Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland","COPEP","Recruiting","No Results Available","Prevention of COVID-19","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Lopinavir/ritonavir","21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline (intent-to-treat (ITT) analysis).|21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)|21-day incidence of SARS-CoV-2 infection in individuals exposed to SARS-CoV-2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)|Severity of clinical COVID-19 on a 7-point ordinal scale","Calmy Alexandra|University Hospital, Geneva","All","18 Years and older   (Adult, Older Adult)","Phase 3","420","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CCER 2020-00864","April 2020","October 2020","October 2020","April 27, 2020",,"April 27, 2020","Universitätsspital Basel and SwissTPH, Basel, Switzerland|Hôpitaux Universitaires de Genève, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT04364022"
90,"NCT04379310","Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019)","Covid-19","Recruiting","No Results Available","Covid-19","Drug: ACE Inhibitors and Calcium Channel Blockers","extend of lung involvement|oxygen saturation on admission","Nisantasi University","All","18 Years to 99 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20200504441","May 1, 2020","May 5, 2020","May 8, 2020","May 7, 2020",,"May 7, 2020","Vital Hospital, Bahcelievler, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04379310"
91,"NCT04325633","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","ENACOVID","Not yet recruiting","No Results Available","COVID-19","Drug: 1: Naproxen|Drug: 2: Standard of care","Mortality all causes at day30|Number of days alive free of mechanical ventilation|Number of days alive outside|Number of days alive outside hospital|Maximal changes in Sofa score|Time to negativation of virus titer in the nasopharyngeal aspirate (NPA)","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 3","584","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200387","April 13, 2020","May 13, 2021","July 13, 2021","March 27, 2020",,"April 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04325633"
92,"NCT04368884","Observational Study to Assess the Seroconversion Status of Health Care Workers and Suspected or Confirmed Cases of COVID-19 Patients",,"Recruiting","No Results Available","Covid-19",,"Development of antibodies","Max Healthcare Insititute Limited","All","18 Years to 80 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Covid-19/MHC-2/2020","April 22, 2020","June 30, 2020","July 30, 2020","April 30, 2020",,"April 30, 2020","Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04368884"
93,"NCT04382066","Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19","APLICOV-PC","Recruiting","No Results Available","COVID-19","Drug: Plitidepsin 1.5 mg/day|Drug: Plitidepsin 2.0 mg/day|Drug: Plitidepsin 2.5 mg/day","Frequency of occurrence of Neutropenia ≥ grade 3|Frequency of occurrence of Thrombocytopenia ≥ grade 3|Frequency of occurrence of Anemia ≥ grade 3|Frequency of occurrence of Lymphopenia ≥ grade 3|Frequency of occurrence of CPK increase ≥ grade 3|Frequency of occurrence of Increase ALT and / or AST ≥ grade 3|Frequency of occurrence of Increase total bilirubin or direct bilirubin ≥ grade 3|Frequency of occurrence of Neurotoxicity ≥ grade 3|Frequency of occurrence of QT-QTc interval extension ≥ grade 3|Frequency of occurrence of Other adverse events ≥ grade 3|Percentage of patients in whom treatment cannot be completed.|Percentage of patients with adverse events.|Percentage of patients with serious adverse events.|Percentage of patients with ECG abnormalities.|Change in the viral load of SARS-CoV-2|Time to negative PCR test for COVID-19|Mortality|Percentage of patients requiring invasive mechanical ventilation and / or ICU admission|Percentage of patients requiring non-invasive mechanical ventilation|Percentage of patients requiring oxygen therapy","PharmaMar|Apices Soluciones S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APL-D-002-20|2020-001993-31","May 12, 2020","November 2020","November 2020","May 11, 2020",,"May 15, 2020","Hospital Universitario Hm Montepríncipe, Boadilla Del Monte, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04382066"
94,"NCT04387929","Detection of Anti-COVID-19 Antibody Levels in an Hospital Population",,"Recruiting","No Results Available","COVID-19","Diagnostic Test: Detection of anti-COVID-19 antibody level","SARS-CoV-2 levels of IgG antibodies|SARS-CoV-2 viral load in nasopharyngeal swab of IgG positive subjects|Epidemiology correlations","Istituto Clinico Humanitas","All","18 Years to 90 Years   (Adult, Older Adult)",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1374 IgG COVID-19 HUMANITAS","May 4, 2020","May 30, 2021","May 30, 2021","May 14, 2020",,"May 15, 2020","Humanitas Rozzano/San Pio X, Rozzano, Lombardia, Italy",,"https://ClinicalTrials.gov/show/NCT04387929"
95,"NCT04375202","Colchicine in COVID-19: a Pilot Study","COLVID-19","Recruiting","No Results Available","COVID-19","Drug: Colchicine 1 MG Oral Tablet","Rate of entering the critical stage|Trend of White blood cell count|Change of the ""Sequential Organ failure Assessment"" (SOFA)|Rate of biochemical criterion (CK, ALT, ferritin) recovery|Rate of disease remission|Toxicity of Colchicine","University Of Perugia","All","18 Years and older   (Adult, Older Adult)","Phase 2","308","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001475-33","April 18, 2020","June 30, 2020","October 31, 2020","May 5, 2020",,"May 5, 2020","Associazione Italiana Pneumologi Ospedalieri, Milan, Italy|Società Italiana di Reumatologia, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT04375202"
96,"NCT04390178","Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)",,"Active, not recruiting","No Results Available","COVID-19","Biological: SARS-CoV-2 convalescent plasma","Disease progression|Adverse events (AE)|Time ro resolution of fever and symptoms|Clearance of viraemia|Inflammatory parameters|Antibody response to SARS-CoV-2","Joakim Dillner|Danderyd Hospital|Karolinska Institutet|Karolinska University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CP1","April 10, 2020","June 2020","December 2020","May 15, 2020",,"May 15, 2020","Danderyd Hospital, Danderyd, Sweden",,"https://ClinicalTrials.gov/show/NCT04390178"
97,"NCT04380532","Tableted COVID-19 Therapeutic Vaccine","COVID-19","Recruiting","No Results Available","Covid19","Biological: V-SARS","Effect on CBC as per CTCAE v4.0|Effect on biochemistry parameters as per CTCAE v4.0|Lack of adverse events as per CTCAE v4.0","Immunitor LLC|Immunitor Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Imm24","June 15, 2020","May 15, 2021","June 15, 2021","May 8, 2020",,"May 8, 2020","Immunitor Inc, Vancouver, BC - British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT04380532"
98,"NCT04385043","Hyperimmune Plasma in Patients With COVID-19 Severe Infection","COV2-CP","Recruiting","No Results Available","COVID-19","Other: plasma hyperimmune|Drug: standard therapy","decrease in mortality|lymphocytes|PCR levels vs control|PCR levels vs before treatment|AB levels and clinical improvement|Inflammatory cytokines vs controls|Inflammatory cytokines vs before treatment","University of Catanzaro|Azienda Ospedaliera Policlinico ""Mater Domini""|Azienda Sanitaria Provinciale Di Catanzaro|Annunziata Hospital, Cosenza, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Covid-19 convalescent plasma","May 1, 2020","October 15, 2020","May 15, 2021","May 12, 2020",,"May 12, 2020","Azienda Ospedaliera Policlinico Mater Domini, Catanzaro, Italy|Azienda Ospedaliera Pugliese Ciaccio Catanzaro, Catanzaro, Italy|Azienda Ospedaliera Annunziata, Cosenza, Italy|Azienda Sanitaria Provinciale, Crotone, Italy|Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy|Azienda Sanitaria Provinciale, Vibo Valentia, Italy",,"https://ClinicalTrials.gov/show/NCT04385043"
99,"NCT04352348","Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being","COVIDeF","Recruiting","No Results Available","COVID-19","Other: blood samples","Identification of prognostic factors for progression to a severe form of COVID-19 infection|Clinical aggravation of the infection|Discharge of hospitalization|Death|Description of clinical manifestations|Description of biological manifestations|Description of radiological manifestations|Description of physiological manifestations|Patient-related prognostic factors|Virus-related risk factors|Comparison of the results of different diagnosis tests","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","APHP200382|2020-A00754-35","March 31, 2020","May 31, 2021","March 31, 2022","April 20, 2020",,"May 12, 2020","GH Pitié-Salpêtrière / Service d'Accueil des Urgences, Paris, Ile-de-France, France",,"https://ClinicalTrials.gov/show/NCT04352348"
100,"NCT04323332","Traditional Chinese Medicine for Severe COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Traditional Chinese Medicine Prescription","Length of hospital stay (days)|Duration (days) of supplemental oxygenation|CT imaging changes|Mortality rate|Time to Clinical Improvement (TTCI)|The pneumonia severity index scores|Time to COVID-19 nucleic acid testing negativity in throat swab|Blood immune cell count|Serum inflammatory markers|Erythrocyte sedimentation rate|Platelet and D-dimer changes|Creatinine changes|Muscle enzymes changes|Usage of antibiotics|Usage of glucocorticoids|Frequency of adverse events","Xiyuan Hospital of China Academy of Chinese Medical Sciences","All","up to 85 Years   (Child, Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020XLA015-1","March 2020","March 2020","April 2020","March 26, 2020",,"March 26, 2020","Hao Li, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04323332"
101,"NCT04362813","Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia","CAN-COVID","Recruiting","No Results Available","COVID-19","Drug: Canakinumab|Drug: Placebo","Number of patients with clinical response|COVID-19-related death rate during the 4-week period after study treatment|Ratio to baseline in the C-reactive protein (CRP)|Ratio to baseline in the serum ferritin|Ratio to baseline in the D-dimer|Number of participants with Adverse Event (AE), serious adverse events (SAE), clinically significant changes in laboratory measures, and vital signs","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CACZ885D2310|2020-001370-30","April 30, 2020","July 10, 2020","October 16, 2020","April 27, 2020",,"May 21, 2020","Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Barnet, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04362813"
102,"NCT04336956","Covid-19 Pediatric Observatory","PANDOR","Recruiting","No Results Available","COVID-19","Other: hospitalized children with Covid19","Percentage of children with severe or critical form.|Percentage of children requiring intensive care support|Clinical symptoms of children|Biological results of children|CT chest of children|Pulmonary echography|nasopharynx SARScov2 PCR|nasopharynx sarscov2 load|nasopharynx multiplex PCR|number of hospital days","Centre Hospitalier Intercommunal Creteil|ACTIV|GPIP|Société Française de Pédiatrie|GFRUP","All","up to 18 Years   (Child, Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Other","PANDOR","April 7, 2020","June 30, 2021","June 30, 2021","April 7, 2020",,"May 25, 2020","Chu Felix Guyon, Saint Denis, La Réunion, France|Ch St Esprit, Agen, France|Ch General Aix En Provence -, Aix-en-Provence, France|CHU Angers, Angers, France|CH d'ANGOULEME, Angoulème, France|Pringy - Ch D'Annecy, Annecy, France|CH Argenteuil, Argenteuil, France|Ch Armentieres, Armentières, France|CH Arpajon, Arpajon, France|Ch Auxerre, Auxerre, France|CH GENERAL Henri Duffaut, Avignon, France|CHU de BESANCON, Besançon, France|Hopital Femme Enfant, Caen, France|Ch de Pontoise, Cergy-Pontoise, France|Ch W. Morey, Chalon-sur-Saône, France|CH de CHAMBERY, Chambéry, France|Ch Hotel Dieu, Chartres, France|Centre Hospitalier intercommunal de Creteil, Creteil, France|Ch de Dax, Dax, France|Hopital D'Enfants Chu Dijon, Dijon, France|CH Louviers Val de Reuil, Elbeuf, France|CH Gonesse, Gonesse, France|CH d'HYERES, Hyères, France|Ch de Marne La Vallee, Jossigny, France|Chru de Grenoble, La Tronche, France|CHGénéral du HAVRE, Le Havre, France|Hopital Roger Salengro - Lille, Lille, France|Hopital Saint Vincent de Paul, Lille, France|Ch de Longjumeau, Longjumeau, France|Lorient - Ch de Bretagne Sud, Lorient, France|Hopital Femme Mere Enfant-Bron, Lyon, France|Hopital Nord Enfants, Marseille, France|Hopital de Meaux, Meaux, France|CH de Montargis, Montargis, France|CH de MONTBRISON, Montbrison, France|CHRU de Nancy, Nancy, France|Nantes - Hopital Mere Enfant, Nantes, France|Ch de Neuilly Sur Seine, Neuilly-sur-Seine, France|Hopital Lenval, Nice, France|CHU Nimes Caremeau, Nîmes, France|Assistance Publique Hôpitaux de Paris, Paris, France|POISSY - CH de POISSY, Poissy, France|QUIMPER - CH de Cornouaille, Quimper, France|RANG du FLIERS - C.H.A.M., RANG du FLIERS, France|Hopital Américain CHU REIMS, Reims, France|CH RODEZ, Rodez, France|Chu Rouen, Rouen, France|Hopital Charles-Nicolle, Rouen, France|Chu St Etienne, Saint Etienne, France|Ch de Saint Denis, Saint-Denis, France|Ch de Saint Malo, Saint-Malo, France|Ch Du Pays Du Mont Blanc, Sallanches, France|Chg Salon de Provence, Salon de Provence, France|CH Tarbes, Tarbes, France|CH Bel Air, Thionville, France|Hopital Sainte Musse, Toulon, France|CHU Toulouse-hôpital des Enfants, Toulouse, France|CH de TROYES, Troyes, France|Ch Bretagne Atlantique, Vannes, France|Ch Le Chesnay, Versailles, France|Hopital de Villeneuve Saint Georges, Villeneuve-Saint-Georges, France",,"https://ClinicalTrials.gov/show/NCT04336956"
103,"NCT04317092","Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)","TOCIVID-19","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab Injection","One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples","All","Child, Adult, Older Adult","Phase 2","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOCIVID-19|2020-001110-38","March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",,"April 7, 2020","Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy|ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy|Azienda Ospedaliero-Universitaria di Modena, Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy|National Cancer Institute, Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy|Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy|ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy|A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy|Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy",,"https://ClinicalTrials.gov/show/NCT04317092"
104,"NCT04356534","Convalescent Plasma Trial in COVID -19 Patients",,"Recruiting","No Results Available","SARS-CoV 2|COVID-19","Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2|Other: Routine care for COVID-19 patients","Requirement for invasive ventilation|Change in viral clearance|Radiological change|Change in white cell count|C reactive protein measurement|lactate dehydrogenase measurement|Procalcitonin measurement|D Dimer measurement|Ferritin measurement|Troponin T measurement|Brain naturetic peptide measurement|Mortality rate","Royal College of Surgeons in Ireland - Medical University of Bahrain|Salmaniya Medical Complex|Bahrain Defence Force Royal Medical Services, Military Hospital|Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali","All","21 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BDF/R&REC/2020-423","April 19, 2020","May 30, 2020","June 30, 2020","April 22, 2020",,"May 14, 2020","Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain",,"https://ClinicalTrials.gov/show/NCT04356534"
105,"NCT04339660","Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID-19","Biological: UC-MSCs|Other: Placebo","The immune function (TNF-α 、IL-1β、IL-6、TGF-β、IL-8、PCT、CRP)|Blood oxygen saturation|Rate of mortality within 28-days|Size of lesion area by chest imaging|CD4+ and CD8+ T cells count|Peripheral blood count recovery time|Duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.)|COVID-19 nucleic acid negative time","Puren Hospital Affiliated to Wuhan University of Science and Technology|Shanghai University|Qingdao Co-orient Watson Biotechnology group co. LTD|Basic Medical Sciences, Chinese Academy of Medical Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Pr20200402","February 1, 2020","June 30, 2020","June 30, 2020","April 9, 2020",,"April 9, 2020","Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04339660"
106,"NCT04363099","Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.","COVID AMBU 60","Recruiting","No Results Available","Covid-19","Other: observational","clinical description of covid 19 ambulatory cases.|Biological and radiological description of ambulatory cases|Prevalence of positive cases (PCR and/or serological positive)","Maison de Sante Pluridisciplinaire de Creil","All","up to 99 Years   (Child, Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2020-A01059-30","March 1, 2020","June 30, 2020","December 31, 2020","April 27, 2020",,"April 27, 2020","Msp de Creil, Creil, France",,"https://ClinicalTrials.gov/show/NCT04363099"
107,"NCT04348071","Safety and Efficacy of Ruxolitinib for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ruxolitinib","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)","University of Colorado, Denver","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-0869","June 2020","August 2020","October 2020","April 15, 2020",,"May 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04348071"
108,"NCT04306497","Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.","CTOROTSADTOC","Recruiting","No Results Available","COVID-19","Drug: TCM prescriptions","The relief / disappearance rate of main symptoms|Chest CT absorption|Virus antigen negative conversion rate|Clinical effective time: the average effective time|The number of severe and critical conversion cases|Incidence of complications|Traditional Chinese Medicine Syndrome Score","Jiangsu Famous Medical Technology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)",,"340","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","JSZYJ202001","March 2, 2020","May 2020","May 2020","March 13, 2020",,"March 17, 2020","Huai'an fourth people's Hospital, Huaian, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04306497"
109,"NCT04340232","Safety and Efficacy of Baricitinib for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Baricitinib","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)","University of Colorado, Denver","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-0738","June 2020","August 2020","October 2020","April 9, 2020",,"May 6, 2020","University of Colorado, Denver, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04340232"
110,"NCT04357444","Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19","LILIADE-COVID","Not yet recruiting","No Results Available","COVID 19","Drug: 1: ILT101|Drug: 2: Placebo Comparator","The PaO2/FiO2 ratio at D7|Changes in Tregs between Baseline and Day 7 (expressed in %)|Number of days alive with oxygen therapy within 28 days|Maximal oxygen rate within 28 days|Number of days alive free of invasive or non-invasive ventilation within 28 days|Number of days alive outside ICU within 28 days|Number of days alive outside hospital within 28 days|Time (in days) from randomization to death|Mortality rate at D28|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Use of antibiotics for respiratory (proved or suspected) infection within 28 days|Number of prone positioning sessions|Changes in Tregs during the different visits between baseline and day 28|Cytokines analysis on plasma samples at Day 0, 7 and 14|Tregs numbers during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Tregs percentages during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.|Deep Immunophenotyping of Cellular components in blood samples at Day 0, 7, and 14|T cell repertoire on Treg, after sorting from blood at Day 7 and Day 14 and compared to baseline|T cell repertoire on Teff (CD4 and CD8) after sorting from blood at Day 7 and Day 14 and compared to baseline|Single cells sequencing will be performed in BAL at Day 7 and Day 14 and compared to baseline.","Assistance Publique - Hôpitaux de Paris|Iltoo Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APHP200406|2020-001571-32","April 2020","May 2020","July 2020","April 22, 2020",,"April 22, 2020","Service Anesthésie Réanimation - Groupe Hospitalier Pitié-Salpêtrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04357444"
111,"NCT04382092","Co-infection Management in COVID-19 Critically Ill",,"Completed","No Results Available","COVID-19","Diagnostic Test: FilmArray Pneumonia","% of COVID-19 co-infections|% of antibiotic switches following FA results","Cliniques universitaires Saint-Luc- Université Catholique de Louvain|BioMérieux","All","18 Years and older   (Adult, Older Adult)","Not Applicable","32","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2019/14MAR/124","March 23, 2020","April 24, 2020","April 24, 2020","May 11, 2020",,"May 11, 2020","Cliniques Universitaires Saint-Luc, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04382092"
112,"NCT04355338","Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA)","AVISA","Not yet recruiting","No Results Available","COVID-19",,"Incidence of SARS-CoV-2 infection|Incidence of COVID-19|Incidence of hospitalization due to COVID-19|Level of neutralizing antibodies|Previous SARS-CoV-2 infection","Butantan Institute","All","Child, Adult, Older Adult",,"4100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COV-01-IB","May 15, 2020","November 30, 2020","May 15, 2022","April 21, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04355338"
113,"NCT04385108","Predictive Immune Biomarkers for COVID-19 Pathogenesis","COVIDBioToul","Not yet recruiting","No Results Available","COVID-19","Biological: Blood collection on admission and longitudinally|Biological: Blood collection on their first consultation and 10 to 14 days later","Immune signature|Dosage of cytokines and chemokines in plasma samples|Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity","University Hospital, Toulouse","All","18 Years and older   (Adult, Older Adult)","Not Applicable","170","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RC31/20/0162","May 12, 2020","December 31, 2021","December 31, 2021","May 12, 2020",,"May 12, 2020","Purpan University Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04385108"
114,"NCT04355793","Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection",,"Available","No Results Available","COVID-19","Drug: Ruxolitinib",,"Incyte Corporation","All","12 Years and older   (Child, Adult, Older Adult)",,,"Industry","Expanded Access:Treatment IND/Protocol",,"INCB 18424-MA-COVID-19-301",,,,"April 21, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04355793"
115,"NCT04329832","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19","HAHPS","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score","Intermountain Health Care, Inc.|University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1051355","March 30, 2020","December 31, 2020","December 31, 2021","April 1, 2020",,"April 9, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04329832"
116,"NCT04346602","A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019",,"Recruiting","No Results Available","COVID-2019","Other: all treatment about COVID-2019","fever|cough|diarrhea|anxiety|insomnia|depression","Jilin University","All","1 Year to 80 Years   (Child, Adult, Older Adult)",,"132","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","130004","February 1, 2020","June 1, 2020","December 1, 2020","April 15, 2020",,"April 15, 2020","the First Hospital of Jilin University, Chang chun, Jilin, China",,"https://ClinicalTrials.gov/show/NCT04346602"
117,"NCT04388410","Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19","EPCOvid-1","Not yet recruiting","No Results Available","COVID-19","Biological: convalescent plasma","Severity and death|Adverse events that require study treatment interruption|Time to clinical improvement|Antibodies against SARS-CoV-2|Disease progression 1|Disease progression 2|Time on mechanical ventilation|Number of days with fever|Adverse events attributed to the study intervention","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Hospital San Jose Tec de Monterrey|Instituto Nacional de Enfermedades Respiratorias|Instituto Nacional de Cardiologia Ignacio Chavez|Hospital General Dr. Manuel Gea González|Instituto Nacional de Cancerologia, Columbia|Hospital Regional de Alta Especialidad del Bajio","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3380","June 1, 2020","October 31, 2020","December 31, 2020","May 14, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04388410"
118,"NCT04362137","Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)","RUXCOVID","Recruiting","No Results Available","COVID-19","Drug: Ruxolitinib|Drug: Placebo","Proportion of patients who die, develop respiratory failure [require mechanical ventilation] or require intensive care unit (ICU) care|Clinical status|Percentage of patients with at least two-point improvement from baseline in clinical status|Percentage of patients with at least one-point improvement from baseline in clinical status|Percentage of patients with at least one-point deterioration from baseline in clinical status|Time to improvement in clinical status|Mean change from baseline in the clinical status|Mortality rate|Proportion of patients requiring mechanical ventilation|Duration of hospitalization|Time to discharge or to a NEWS2 score of ≤2|Change from baseline in NEWS2 score|Change from baseline in SpO2/FiO2 ratio.|Proportion of patients with no oxygen therapy","Novartis Pharmaceuticals|Incyte Corporation|Novartis","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","402","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CINC424J12301|INCB 18424-368|2020-001662-11","May 1, 2020","July 10, 2020","July 13, 2020","April 24, 2020",,"May 21, 2020","Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04362137"
119,"NCT04361916","Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino)","Mon-Covid","Recruiting","No Results Available","COVID-19","Other: home care monitoring","SpO2|in-hospital mortality|need of intubation|feasibility of active monitoring","Mario Negri Institute for Pharmacological Research","All","18 Years and older   (Adult, Older Adult)","Not Applicable","425","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Mon-Covid","April 21, 2020","October 31, 2020","December 31, 2020","April 24, 2020",,"April 24, 2020","Asl Alessandria, Casale Monferrato, Alessandria, Italy",,"https://ClinicalTrials.gov/show/NCT04361916"
120,"NCT04344145","Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population",,"Recruiting","No Results Available","COVID-19",,"Burnout|Emotional Distress|Insomnia|Needs and difficulties in work situations","Université Libre de Bruxelles","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","PSY-ENCOVID19","April 16, 2020","June 15, 2020","July 15, 2020","April 14, 2020",,"April 20, 2020","Erasme Hospital CUB, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04344145"
121,"NCT04362865","Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection",,"Recruiting","No Results Available","COVID-19",,"Characterize immune response|B- and T-cell arm immune response|Immune response and outcome","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"150","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200103|20-C-0103","April 27, 2020","December 1, 2023","December 1, 2024","April 27, 2020",,"May 12, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04362865"
122,"NCT04372368","Convalescent Plasma for the Treatment of Patients With COVID-19",,"Available","No Results Available","COVID-19|SARS-CoV 2","Biological: COVID-19 Convalescent Plasma",,"University of Colorado, Denver","All","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Treatment IND/Protocol",,"20-0990",,,,"May 4, 2020",,"May 4, 2020","Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04372368"
123,"NCT04397796","Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation",,"Not yet recruiting","No Results Available","COVID","Biological: BM-Allo.MSC|Biological: Placebo","Incidence of AEs|Mortality|Death|Number of ventilator-free days|Improvement of one category|7-point ordinal scale|NEWS|NEWS of ≤ 2|Sequential Organ Failure Assessment (SOFA)|Oxygen|Hospitalization|Incidence of SAEs","NantKwest, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","QUILT-COVID-19-MSC","June 2020","June 2021","June 2021","May 21, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04397796"
124,"NCT04370808","VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection","VITACOV","Not yet recruiting","No Results Available","COVID-19","Other: Exposure","Differences in vitamin D blood levels between COVID-19 patients with different degrees of disease severity.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients with different degrees of disease severity.|Differences in vitamin D blood levels between COVID-19 patients in relation to mortality.|Differences in vitamin D blood levels between COVID-19 patients in relation to length of stay in hospitals.|Differences in vitamin D blood levels between COVID-19 patients in relation to duration of mechanical ventilation.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to mortality.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to length of stay in hospitals.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to duration of mechanical ventilation.","University of Lisbon|Cardiovascular Centre of Universidade de Lisboa (CCUL)|Faculty of Medicine of Universidade de Lisboa (FMUL)|Centro Hospitalar Universitário Lisboa Norte (CHULN)|Centro Hospitalar Universitário São João (CHUSJ)|CINTESIS - Center for Health Technology and Services Research|NOVA Medical School of Universidade NOVA de Lisboa|HeartGenetics, Genetics and Biotechnology SA|Instituto Gulbenkian de Ciência (IGC)","All","18 Years and older   (Adult, Older Adult)",,"500","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","VITACOV","June 2020","October 2020","March 2021","May 1, 2020",,"May 19, 2020","Cardiovascular Center at Universidade de Lisboa, Lisbon, Lisboa, Portugal|Centro Hospitalar Universitário Lisboa Norte, Lisbon, Lisboa, Portugal|Centro Hospitalar de São João, Oporto, Portugal",,"https://ClinicalTrials.gov/show/NCT04370808"
125,"NCT04354389","DAS181 for STOP COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: DAS181|Drug: Placebo","COVID-19 Clinical Classification (CCC)|Return to room air (RTRA)|Improved COVID-19 Clinical Classification|Return To Room Air (RTRA)|Death (all cause)|SARS-CoV-2 RNA undetectable|Percent of subjects discharged|Clinical Deterioration","Ansun Biopharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DAS181-3-02-EU|2020-001874-30","May 25, 2020","June 30, 2020","October 31, 2020","April 21, 2020",,"May 11, 2020","Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy|A.O.U Policlinico Di Modena, Modena, Italy",,"https://ClinicalTrials.gov/show/NCT04354389"
126,"NCT04361786","Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection",,"Recruiting","No Results Available","COVID 19",,"Biological acquired thrombophilia|Overexpression of interferon type I","University Hospital, Montpellier|Lyon Civil Hospitals - Lyon Sud Hospital Center|Marseille University Hospital - Assistance-Publique Hôpitaux de Marseille.","All","Child, Adult, Older Adult",,"10","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RECHMPL20_0211","April 1, 2020","June 30, 2020","October 30, 2020","April 24, 2020",,"April 24, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04361786"
127,"NCT04384497","Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study",,"Recruiting","No Results Available","COVID-19","Biological: SARS-CoV-2 convalescent plasma","Number and proportion of patients with progression to ventilation or sustained requirement of supplementary oxygen therapy|Adverse events|Dose of plasma needed to clear viremia|Clearance of viremia|Fever and symptoms|Inflammatory parameters|Antibody response to SARS-CoV-2","Joakim Dillner|Danderyd Hospital|Karolinska University Hospital|Karolinska Institutet","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CP2","May 7, 2020","June 2020","December 2020","May 12, 2020",,"May 12, 2020","Danderyd Hospital, Danderyd, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04384497"
128,"NCT04324996","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells","Clinical response|Side effects in the treatment group","Chongqing Public Health Medical Center|Chongqing Sidemu Biotechnology Technology Co.,Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ChongqingPublicHMC","March 21, 2020","May 31, 2020","September 30, 2020","March 27, 2020",,"March 27, 2020","Chongqing Public Health Medical Center, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04324996"
129,"NCT04354597","Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients","MOPHYDA","Not yet recruiting","No Results Available","COVID-19","Drug: HCQ & AZ","Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients|Safety of HCQ and AZ|Oxygen requirement|ICU admission|Mortality rate","King Hussein Cancer Center","All","25 Years to 70 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20 KHCC 67","May 1, 2020","August 15, 2020","October 15, 2020","April 21, 2020",,"May 5, 2020","King Hussein Cancer Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04354597"
130,"NCT04363008","COVID 19 Biomarkers",,"Recruiting","No Results Available","COVID 19","Diagnostic Test: serum inflammatory biomarkers","Inflammation|Oxygenation|Chronic Pulmonary outcomes|Pulmonary artery pressure using transthoracic echocardiography|Exertion|Quality of life assessment","University of British Columbia","All","Child, Adult, Older Adult",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H20-00971","March 30, 2020","April 30, 2020","September 30, 2021","April 27, 2020",,"May 8, 2020","Vancouver General Hospital, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT04363008"
131,"NCT04382781","Immunosupressive Treatment in COVID-19 Patients","SAM-COVID","Recruiting","No Results Available","COVID-19 Infection","Drug: NO-Immunosuppressive|Drug: Immunosuppressive|Drug: Immunoglubulins","Invasive ventilation or death|Ventilation|Death|Secondary infections|Digestive tract hemorrhage|Change in 7 points scale","Spanish Network for Research in Infectious Diseases|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","FIS-INM-2020-03","May 2020","May 2020","May 2020","May 11, 2020",,"May 12, 2020","Hospital Virgen Macarena, Sevilla, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04382781/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04382781"
132,"NCT04348396","Clinical and Biological Predictors of COVID-19 Disease in Older Patients",,"Not yet recruiting","No Results Available","COVID-19",,"Descriptive-epidemiological analysis of health conditions|Evaluation of frailty condition|Identification of biomarkers of inflammation|Assessment of functional capacity|Evaluation of drug consumption|Evaluation of inflamma-miRs","Istituto Nazionale di Ricovero e Cura per Anziani","All","65 Years and older   (Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","INRCA_01_2020","April 2020","December 2020","December 2020","April 16, 2020",,"April 16, 2020","IRCCS INRCA Hospital, Ancona, Italy",,"https://ClinicalTrials.gov/show/NCT04348396"
133,"NCT04352582","COVID-19 and Vaccination Attitudes","VACAT","Recruiting","No Results Available","COVID-19","Other: Survey","How vaccination and other attitudes are affected by COVID","University Hospital, Geneva|University of Zurich|University of Lausanne","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","VACAT","April 14, 2020","April 30, 2020","April 30, 2020","April 20, 2020",,"April 20, 2020","Survey, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04352582"
134,"NCT04380688","Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.","CALAVI US","Not yet recruiting","No Results Available","COVID-19","Drug: Acalabrutinib","Occurrence of Adverse Events and Serious Adverse Events|Subject alive and free of respiratory failure|Proportion of subjects alive and free of respiratory failure|Percent change from baseline in CRP|Change from baseline in ferritin|Change from baseline in absolute lymphocyte counts|All cause mortality|Proportion of subjects alive and discharged from ICU|Time from randomization to first occurrence of respiratory failure or death on study due to any cause|Number of days alive and free of respiratory failure|Number of days with respiratory failure|Number of days hospitalized|Number of days in ICU (length of stay)|Number of days alive outside of hospital|Relative change from baseline in oxygenation index (PaO2/FiO2)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Cmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Tmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (AUC)","AstraZeneca|Acerta Pharma B.V.","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 2","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D822FC00003","May 12, 2020","September 30, 2020","September 30, 2020","May 8, 2020",,"May 8, 2020","Research Site, Washington, District of Columbia, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT04380688"
135,"NCT04397822","COVID-19: Study of INFLAmmasome and PLAtelets Functions","CO-QUETTES","Recruiting","No Results Available","COVID-19","Biological: Blood samples","Activation of platelet NLRP3 inflammasome","University Hospital, Toulouse","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC31/20/0142","April 16, 2020","October 2020","April 2021","May 21, 2020",,"May 21, 2020","CHU Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04397822"
136,"NCT04346199","Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.","CALAVI","Not yet recruiting","No Results Available","COVID-19","Drug: Acalabrutinib","Subject alive and free of respiratory failure|Proportion of subjects alive and free of respiratory failure|Percent change from baseline in CRP|Change from baseline in ferritin|Chnage from baseline in absolute lymphocyte counts|All cause mortality|Proportion of subjects alive and discharged from ICU|Time from randomization to first occurrence of respiratory failure or death on study due to any cause|Number of days alive and free of respiratory failure|Number of days with respiratory failure|Number of days hospitalized|Number of days in ICU (length of stay)|Number of days alive outside of hospital|Relative change from baseline in oxygenation index (PaO2/FiO2)|Occurrence of Adverse Events and Serious Adverse Events|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Cmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Tmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (AUC)","AstraZeneca|Acerta Pharma B.V.","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 2","140","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D822FC00001","May 11, 2020","November 30, 2020","November 30, 2020","April 15, 2020",,"May 11, 2020","Research Site, Bobigny, France|Research Site, Villejuif Cedex, France|Research Site, Bologna, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Fuenlabrada, Spain|Research Site, Madrid, Spain|Research Site, Mérida, Spain|Research Site, Pozuelo de Alarcón, Spain",,"https://ClinicalTrials.gov/show/NCT04346199"
137,"NCT04357808","Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)","SARCOVID","Recruiting","No Results Available","Covid-19","Drug: Sarilumab|Other: Standar of care","Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation|Duration of hospitalisation (days)|Death|Time to become afebrile (days)|Time to non-invasive mechanical ventilation (days)|Time to invasive mechanical ventilation (days)|Time to independence from supplementary oxygen therapy (days)|Mean change in clinical status assessment using the 7-point ordinal scale at day 14 after randomisation","Maria del Rosario Garcia de Vicuña Pinedo|Instituto de Investigación Sanitaria Hospital Universitario de la Princesa|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SARCOVID|2020-001634-36","April 13, 2020","June 2020","June 2020","April 22, 2020",,"April 22, 2020","Hospital Universitario de la Princesa, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04357808"
138,"NCT04371406","Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients","MG-COVID","Not yet recruiting","No Results Available","Covid-19","Drug: Hydroxychloroquine and Azithromycin|Dietary Supplement: Azinc","Rate of patients with occurrence of an unfavorable outcome between randomization and day 14|Primary outcome of ancillary virological study : evolution of viral load between day 0 and day 14|The all-cause mortality rate at day 14|The all-cause mortality rate at day 28|Rate of patients with occurrence of an unfavorable outcome between randomization and day 28|The rate of use of mechanical ventilation at day 14|The rate of use of mechanical ventilation at day 28|The Intensive Care Unit admission rate at day 14|The Intensive Care Unit admission rate at day 28|Number of days of hospitalization for any cause between day 0 and day 14|Number of days of hospitalization for any cause between day 0 and day 28|The time to resolution of all COVID symptoms at day 14|The time to resolution of all COVID symptoms atday 28|The rate of use of oxygen therapy at day 14|The rate of use of oxygen therapy at day 28|The rate of use of secondary antibiotic therapy (after day 2) at day 14|The rate of use of secondary antibiotic therapy (after day 2) at day 28|Clinical status at day 14|Clinical status at day 28|number of serious adverse events at day 14|number serious adverse events at day 28|number of adverse events at day 14|number of adverse events at day 28|The rate of patients with treatment withdrawal|Ancillary virological study : rate of patients with negative viral load at day 8|Ancillary virological study : rate of patients with negative viral load at day 14","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","2770","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200447|2020-001702-35","May 2, 2020","August 2, 2020","September 2, 2020","May 1, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04371406"
139,"NCT04335188","COVID-19 Registry Rhineland-Palatinate (Germany)",,"Recruiting","No Results Available","COVID","Other: Prospective oberservational registry","Chest x-ray|Chest CT|Supportive care - ICU|Supportive care - oxygen therapy|Supportive care - ventilation|Medication|Therapeutic strategies|Lab parameters|Intra-hospital complications|Vital status at discharge","IHF GmbH - Institut für Herzinfarktforschung|Ministerium für Soziales, Arbeit, Gesundheit und Demografie des Landes Rheinland-Pfalz","All","Child, Adult, Older Adult",,"4000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","COVID-19 Registry","April 6, 2020","July 31, 2021","September 30, 2021","April 6, 2020",,"April 8, 2020","Klinikum der Stadt Ludwigshafen am Rhein GmbH, Klinik für Herzchirurgie, Ludwigshafen, RLP, Germany",,"https://ClinicalTrials.gov/show/NCT04335188"
140,"NCT04362345","Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia",,"Recruiting","No Results Available","Covid-19",,"Identification of risk factors for severity (death or transfer to resuscitation) of Covid-19 infection","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7773","April 9, 2020","May 17, 2020","May 17, 2020","April 24, 2020",,"April 30, 2020","Service des Maladies Infectieuses et Tropicales, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04362345"
141,"NCT04381884","Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19",,"Recruiting","No Results Available","COVID-19 Drug Treatment","Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.","Reduction in SARS-CoV-2 viral load|Number of patients with partial or complete response in COVID-19 clinical symptoms|Number of patients with worsening in the clinical condition|Number of patients with adverse events as a measure of safety and tolerability|Ivermectin concentrations measured in plasma|Evaluation of reactivity of the antibodies against SARS-CoV-2","Laboratorio Elea Phoenix S.A.|Universidad Nacional de Salta|Centro de Investigación Veterinaria Tandil CIVETAN|Hospital de Pediatría Prof Dr. Juan P. Garrahan|Universidad Nacional de Quilmes","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 2","45","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IVM-AR-1","May 11, 2020","June 30, 2020","June 30, 2020","May 11, 2020",,"May 19, 2020","Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT04381884"
142,"NCT04334291","International COVID19 Clinical Evaluation Registry,","HOPE COVID 19","Recruiting","No Results Available","COVID 19","Combination Product: Observational (registry)","Death|In hospital stay.|Heart failure|Renal failure|Respiratory Insufficiency.|Upper respiratory tract involvement|Pneumonia|Sepsis|Systemic inflammatory response Syndrome.|Clinically relevant bleeding|Other complications.","IVAN J NUÑEZ GIL|St Carlos Hospital, Madrid, Spain","All","Child, Adult, Older Adult",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","20/241-E|EUPAS34399","March 23, 2020","May 1, 2020","May 5, 2020","April 6, 2020",,"April 28, 2020","Hospital Lclinico San Carlos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04334291"
143,"NCT04344015","COVID-19 Plasma Collection",,"Recruiting","No Results Available","COVID-19","Other: Plasma Donation","Number of patients who screen eligible for donation|Number of patients who consent to plasma donation|Number of plasma donations received|Safety of donation procedures","Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20D.346","April 13, 2020","April 12, 2021","April 12, 2021","April 14, 2020",,"May 11, 2020","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04344015"
144,"NCT04367896","COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY",,"Completed","No Results Available","COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION","Other: Survey Group","Management of Solid Organ Transplant during COVID-19 pandemic|Equity of resource distribution|Equity rank of resource distribution","Fondazione Policlinico Universitario Agostino Gemelli IRCCS",,"Child, Adult, Older Adult",,"1819","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Covid-19_V1","March 24, 2020","April 17, 2020","April 17, 2020","April 29, 2020",,"April 29, 2020","Fondazione Policlinico Universitario ""Agostino Gemelli"", Rome, Italy",,"https://ClinicalTrials.gov/show/NCT04367896"
145,"NCT04359615","Favipiravir in Hospitalized COVID-19 Patients","FIC","Not yet recruiting","No Results Available","COVID-19","Drug: Favipiravir|Drug: Hydroxychloroquine","Time to clinical improvement|Mortality|oxygen saturation by pulse oximetry (SpO2) Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Favipiravir in COVID-19","April 20, 2020","May 3, 2020","May 5, 2020","April 24, 2020",,"April 28, 2020","Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04359615"
146,"NCT04351646","Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak)",,"Not yet recruiting","No Results Available","COVID-19",,"Antibody titres to SARS-CoV-2","St George's, University of London","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020.0075","April 15, 2020","April 15, 2022","April 15, 2022","April 17, 2020",,"April 17, 2020","St. Georges Hospital Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04351646"
147,"NCT04352400","Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)","RACONA","Not yet recruiting","No Results Available","COVID19","Drug: Nafamostat Mesilate|Drug: Placebo","Time-to-clinical improvement|Responders|Critical or dead patients|pO2/FiO2 ratio|SOFA score over time|Hospitalization|Mechanical ventilation|Mechanical ventilation duration|Cardiovascular disease","University Hospital Padova|Yokohama City University|University of Zurich","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","256","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RACONA Nafamostat","April 2020","December 2021","December 2021","April 20, 2020",,"April 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04352400"
148,"NCT04364828","NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression","COVID-19 NGS","Not yet recruiting","No Results Available","COVID-19","Genetic: Whole Genome Analysis|Genetic: T-cell receptor (TCR) repertoire|Genetic: SARS-CoV-2 viral composition","Viral evolution|Immune response|Disease severity","University Hospital Tuebingen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","COVID-19 NGS","April 2020","April 2021","August 2021","April 28, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04364828"
149,"NCT04364815","The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine plus standard preventive measures|Drug: Placebo plus standard preventive measures","Efficacy of HCQ Prophylaxis in Preventing COVID-19 infection|Efficacy of study drug as post-exposure prophylaxis in preventing COVID-19 related symptoms (to be reported as absolute number and frequency of events)|Time to COVID-19 infection in patients receiving study drug (in days)|Safety and tolerability of study drug (to be reported as absolute number and frequency of events)","University of the Philippines","All","18 Years to 59 Years   (Adult)","Phase 3","960","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","RGAO-2020-0339","May 2020","May 2021","May 2021","April 28, 2020",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04364815"
150,"NCT04359316","Azithromycin in Hospitalized COVID-19 Patients","AIC","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Azithromycin in COVID-19","April 20, 2020","May 3, 2020","May 5, 2020","April 24, 2020",,"April 24, 2020","Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04359316"
151,"NCT04374123","COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit",,"Recruiting","No Results Available","COVID","Diagnostic Test: Serological screening for IgG and IgM antibodies against COVID-19","Rate of COVID-19 nosocomial infection among the endoscopy staff at the end of the 30-days study.|Numbers of patients evaluated and treated during the COVID-19 outbreak in the endoscopy unit at the end of the 30-days study.|Technical success rate of endoscopic procedures during the 30-days study period.|IgG and IgM against COVID-19 in the endoscopy staff measured at the end of the study.|Adverse events rate of endoscopic procedures during the 30-days","Instituto Ecuatoriano de Enfermedades Digestivas","All","18 Years to 80 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IECED-04-15-covid","April 20, 2020","May 20, 2020","June 1, 2020","May 5, 2020",,"May 5, 2020","Ecuadorian Institute of Digestive Diseases, Guayaquil, Guayas, Ecuador",,"https://ClinicalTrials.gov/show/NCT04374123"
152,"NCT04333355","Safety in Convalescent Plasma Transfusion to COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma","Side effects|Heart Failure|Pulmonary Edema|Allergic Reaction|Viral load of SARS-CoV-2","Hospital San Jose Tec de Monterrey|Tecnologico de Monterrey","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PC-TecSalud Fase I","May 25, 2020","December 20, 2020","April 30, 2021","April 3, 2020",,"May 8, 2020","Hospital San José, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT04333355"
153,"NCT04361942","Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)","COVID_MSV","Recruiting","No Results Available","COVID-19 Pneumonia","Biological: Mesenchymal Stromal Cells|Other: Placebo","Proportion of patients who have achieved withdrawal of invasive mechanical ventilation|Rate of mortality|Proportion of patients who have achieved clinical response|Proportion of patients who have achieved radiological responses","Red de Terapia Celular|Citospin|University of Valladolid|Castilla-León Health Service|Hospital del Río Hortega|Instituto de Salud Carlos III","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TerCel_007|2020-001682-36","April 2020","November 30, 2020","December 31, 2020","April 24, 2020",,"April 29, 2020","Hospital Universitario Rio Hortega, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04361942"
154,"NCT04355936","Telmisartan for Treatment of COVID-19 Patients",,"Not yet recruiting","No Results Available","COVID-19 Drug Treatment","Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.","C reactive protein|Number of opacified quadrants on lung Rx|Occurrence of mechanical ventilation|Intensive care unit admission|Death|LDH|Troponin|Time to mechanical ventilation","Laboratorio Elea Phoenix S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001","May 15, 2020","October 1, 2020","October 1, 2020","April 21, 2020",,"May 14, 2020","Hospital de Clínicas 'José de San Martín', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Ciudad De Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT04355936"
155,"NCT04343768","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","COVIFERON","Completed","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon Beta-1A|Drug: Interferon Beta-1B","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Different Interferons in COVID","April 9, 2020","April 27, 2020","April 27, 2020","April 13, 2020",,"May 5, 2020","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04343768"
156,"NCT04392713","Efficacy of Ivermectin in COVID-19",,"Recruiting","No Results Available","COVID","Drug: Ivermectin 6 MG Oral Tablet (2 tablets)","Negative PCR|Need for mechanical ventilation","Combined Military Hospital, Pakistan","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IVE-COV","April 15, 2020","July 2020","July 2020","May 19, 2020",,"May 19, 2020","Combined Military Hospital Lahore, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04392713"
157,"NCT04349592","Qatar Prospective RCT Of Therapy Eliminating Covid Transmission","Q-PROTECT","Not yet recruiting","No Results Available","Covid19","Drug: Hydroxychloroquine + Azithromycin|Drug: Hydroxychloroquine + Placebo|Other: Placebo + Placebo","Proportion of virologically cured (no virus detected) cases at day 6|The dichotomous virologic shedding endpoint as assessed at two weeks after study entry|Quantitative viral load (assessed with each virology testing set)","Hamad Medical Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","456","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MRC-05-001","April 14, 2020","May 14, 2020","May 30, 2020","April 16, 2020",,"April 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04349592"
158,"NCT04357431","COVID-19 Among Egyptian Health Care Providers",,"Recruiting","No Results Available","COVID","Other: self-administered questionnaire","The percentage of knowledge regarding COVID-19 information","Assiut University","All","Child, Adult, Older Adult",,"600","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","COVIDQ","April 22, 2020","May 5, 2020","May 30, 2020","April 22, 2020",,"May 13, 2020","Ahmed Abbas, Assiut, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04357431"
159,"NCT04365231","Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial","HASCOPT","Not yet recruiting","No Results Available","COVID19","Drug: Hydroxychloroquine and azithromycin treatment|Other: conventional management of patients","Percentage of patients with a negative RT-PCR test result to COVID-19|Maternal outcomes: Percentage of severe forms of the disease|Newborn outcomes: Rate of newborns hospitalized in intensive care or transferred to resuscitation unit","Hospital St. Joseph, Marseille, France","Female","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HASCOPT2020","April 2020","June 2020","January 2021","April 28, 2020",,"April 28, 2020","Hopital Saint Joseph, Marseille, Paca, France",,"https://ClinicalTrials.gov/show/NCT04365231"
160,"NCT04358536","Classification of COVID-19 Infection in Posteroanterior Chest X-rays",,"Completed","No Results Available","COVID-19","Device: CovX","Identification of COVID-19","Dascena","All","18 Years and older   (Adult, Older Adult)",,"230","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","04202002","April 1, 2020","April 17, 2020","April 17, 2020","April 24, 2020",,"April 24, 2020","Dascena, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT04358536"
161,"NCT04392245","Proctologic Practice and Covid-19","PROCTOLOCK","Completed","No Results Available","Proctologic Practice During COVID-19",,"Predictive power of respondents' and hospitals' demographics on the change of status of proctologic surgical and outpatient activities","Societa Italiana di Chirurgia ColoRettale|Gaetano Gallo|Alessandro Sturiale|Veronica De Simone|Gian Luca Di Tanna|Iacopo Giani|Ugo Grossi","All","Child, Adult, Older Adult",,"1050","Other","Observational","Observational Model: Other|Time Perspective: Prospective","1.0","April 15, 2020","April 26, 2020","April 26, 2020","May 18, 2020",,"May 18, 2020","Gallo Gallo, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04392245"
162,"NCT04358835","Keto-diet for Intubated Critical Care COVID-19","KICC-COVID19","Not yet recruiting","No Results Available","COVID-19","Dietary Supplement: Ketogenic diet|Other: standard of care","Change in the partial pressure of carbon dioxide (PaCO2)|Change in minute ventilation|Change in respiratory system compliance|Change in driving pressure|Change in ventilator synchrony|Change in mean arterial pressure|Change in the fraction of inspired oxygen percentage of oxygen (FiO2)|Change in the partial pressure of carbon dioxide (PaO2) to the fraction of inspired oxygen percentage of oxygen (FiO2) ratio|Change in hydrogen ion activity (pH)|Change in Bicarbonate (HCO3)|Change in red blood cell count|Change in white blood cell count|Change in white cell differential|Change in hemoglobin levels|Change in hematocrit|Change in mean cell volume|Change in mean cell hemoglobin|Change in mean cell hemoglobin concentration|Change in platelet count|Change in red cell distribution width|Change in blood albumin level|Change in serum alkaline phosphatase level|Change in serum aspartate transaminase level|Change in serum alanine aminotransferase level|Change in blood urea nitrogen levels|Change in serum calcium level|Change in serum chloride level|Change in serum potassium level|Change in serum creatinine level|Date patient is re-intubated or need mechanical ventilation for a second time|Length of intensive care unit stay|The total hospital stay|Disposition at discharge|Change in heart rate|Change in the dosage of vasopressor medication","Johns Hopkins University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00247383","April 20, 2020","August 1, 2020","August 1, 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04358835"
163,"NCT04252118","Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: MSCs","Size of lesion area by chest radiograph or CT|Side effects in the MSCs treatment group|Improvement of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|Rate of mortality within 28-days|CD4+ and CD8+ T celll count|Alanine aminotransferase|C-reactive protein|Creatine kinase","Beijing 302 Hospital|Innovative Precision Medicine Group (IPM), Hangzhou, China.|Huoshenshan Hospital|Tianjin Haihe Hospital|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China|Shenzhen Third People's Hospital|Fifth Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020003D","January 27, 2020","December 2020","December 2021","February 5, 2020",,"April 15, 2020","Beijing 302 Military Hospital of China, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04252118"
164,"NCT04280705","Adaptive COVID-19 Treatment Trial (ACTT)",,"Recruiting","No Results Available","COVID-19","Other: Placebo|Drug: Remdesivir","Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of investigational therapeutics|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","800","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-0006","February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",,"May 7, 2020","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany|Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece|Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom|John Radcliffe Hospital, Headington, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04280705"
165,"NCT04348656","CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)","CONCOR-1","Recruiting","No Results Available","COVID-19","Other: Convalescent plasma","Intubation or death in hospital|Need for Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Development of myocarditis|Adverse events and serious adverse events|CCP transfusion-associated adverse events (AE)","Hamilton Health Sciences Corporation|Canadian Blood Services|Héma-Québec|University of Toronto|Université de Montréal|McMaster University","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CONCOR-1","May 11, 2020","October 31, 2020","December 31, 2020","April 16, 2020",,"May 21, 2020","University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|St. Jospeh's Healthcare Hamtilon, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Thunder Bay Regional Health Sciences Centre - Cancer Centre, Thunder Bay, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Unity Health Toronto, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Hôpital de la Cité-de-la-Santé, Laval, Quebec, Canada|Hotel Dieu Hospital of Lévis, Lévis, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hôpital du Sacré-Coeur de Montreal, Montréal, Quebec, Canada|Centre hospitalier universitaire de Québec, Quebec City, Quebec, Canada|Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Centre hospitalier affilié universitaire régional de Trois-Rivières, Trois-Rivières, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04348656"
166,"NCT04359953","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19","COVID-Aging","Not yet recruiting","No Results Available","COVID-19 Infection","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Telmisartan","Two-weeks survival rate|Rate of undetectable RT-PCR of SARS-CoV-2|Rate of death|Hypotension|Hypothermia and hyperthermia|Pneumonia severity according to WHO|Pneumonia severity according to PSI (Hung et al 2017)|Rate of no cough|Rate of no dyspnea|Rate of no fever|Rate of no requiring supplemental oxygen|Rate of SARS-Cov-2 undetectable|Recovery time|Critical admission rate|Mechanical ventilation rate|Changes in Activity of Daily Living (ADL) Activity of Daily Living)|Changes in Activity of Daily Living IADL (Instrumental Activity of Daily Living)|The number and dose of added corticosteroids, immonumodulators or immunosuppressants","University Hospital, Strasbourg, France","All","60 Years and older   (Adult, Older Adult)","Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7747","April 24, 2020","June 1, 2021","June 1, 2021","April 24, 2020",,"April 24, 2020","CHU de Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04359953"
167,"NCT04380662","Risk Factors Worsening COVID19 for Out-patient With Home Monitoring","COVIDADOMEVA","Not yet recruiting","No Results Available","Covid19","Other: Risk factors","Identify the factors associated with the worsening of the COVID19|Describe the clinical care pathway of patients from Day 0 to Day 14|Describe the health status at Day 30|Describe the quality of life during the disease","University Hospital, Grenoble","All","Child, Adult, Older Adult",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","38RC20.135|2020-A01040-39","May 20, 2020","September 30, 2020","December 30, 2020","May 8, 2020",,"May 19, 2020","Grenoble University Hospital, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT04380662"
168,"NCT04367792","Cardiac Injury in COVID-19: a Pathology Study",,"Recruiting","No Results Available","COVID-19",,"Cardiac pathological findings from series of >= 50 patients dying from COVID-19 disease|viral load in cardiac tissues and the extent of damage|Co-localize the SARS-CoV-2 using RNAscope in situ hybridization, with its entry receptor ACE2 and serine protease TMPRSS2 in different cell types found in the heart","A.O. Ospedale Papa Giovanni XXIII|CVPath Institute Inc. Renu Virmani, Aloke Finn|A.O. Ospedale Papa Giovanni XXIII, Anatomia Patologica, Dr Andrea Gianatti, co-PI","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","56/20","April 2020","October 2020","March 2021","April 29, 2020",,"May 1, 2020","ASST Ospedale Papa Giovanni XXIII, Bergamo, Italy",,"https://ClinicalTrials.gov/show/NCT04367792"
169,"NCT04389294","HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists",,"Recruiting","No Results Available","COVID","Diagnostic Test: SARS-CoV2 serum antibody testing","Correlation between serology testing and clinical suspicion of COVID-19|Prevalence of SARS-CoV2 exposure|Correlation of pre-existing risk factors with results of serology testing|Number of asymptomatic participants with positive antibody serology|Proportion of antibody- positive participants who subsequently develop COVID-19|Proportion of participants who are eligible for in plasma donation","Hospital for Special Surgery, New York","All","21 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2020-0850","May 5, 2020","September 30, 2020","October 30, 2020","May 15, 2020",,"May 15, 2020","Hospital for Special Surgery, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04389294"
170,"NCT04330586","A Trial of Ciclesonide in Adults With Mild COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ciclesonide Metered Dose Inhaler [Alvesco]|Drug: Hydroxychloroquine","Rate of SARS-CoV-2 eradication at day 14 from study enrollment|Rate of SARS-CoV-2 eradication at day 7 from study enrollment|Time to SARS-CoV-2 eradication (days)|Viral load area-under-the-curve (AUC) reduction versus control|Time to clinical improvement (days)|Proportion of clinical failure","Korea University Guro Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","141","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KUMC-COVID-19","April 1, 2020","June 30, 2020","September 30, 2020","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330586"
171,"NCT04331171","Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage","COVID CALL 15","Recruiting","No Results Available","COVID-19","Device: Web application users","To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess the evolution over time of the COVID 19 epidemic|To assess the evolution over space of the COVID 19 epidemic|To assess symptoms|To assess the users population","Weprom|Institut Pasteur|Assistance Publique - Hôpitaux de Paris|DOCAPOST|Direction Générale de l'Offre de Soins","All","18 Years and older   (Adult, Older Adult)",,"3000000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","WP-2020-02","March 17, 2020","March 31, 2020","July 31, 2020","April 2, 2020",,"April 17, 2020","All French Emergency services, Le Mans, France",,"https://ClinicalTrials.gov/show/NCT04331171"
172,"NCT04387760","Favipiravir vs Hydroxychloroquine in COVID -19",,"Not yet recruiting","No Results Available","SARS-CoV 2|COVID-19","Drug: Hydroxychloroquine|Drug: Favipiravir|Other: Routine care for COVID-19 patients","Primary outcome measure will be time to viral clearance|Requirement of Escalation of Respiratory Support|Time until resolution of presenting symptoms|Adverse effects|Requirement of ICU Admission|Mortality rate|Serum lactate measurement|Serum Ferritin measurement|Serum D Dimer measurement|Serum procalcitonin measurement|Serum brain naturetic peptide measurement|Ratio of Lymphocyte to Neutrophil, measurement","Royal College of Surgeons in Ireland - Medical University of Bahrain|Bahrain Defence Force Royal Medical Services, Military Hospital|Ebrahim Khalil Kanoo Community Medical Center","All","21 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","40 / 07-May-2020","May 14, 2020","July 14, 2020","August 14, 2020","May 14, 2020",,"May 14, 2020","Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain",,"https://ClinicalTrials.gov/show/NCT04387760"
173,"NCT04353154","The RAPID COVID TRIAGE Algorithm",,"Not yet recruiting","No Results Available","COVID","Diagnostic Test: Spartan Cube Point-of Care Covid-19 test","Sensitivity","Ottawa Heart Institute Research Corporation","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20200228-01H","April 15, 2020","August 31, 2020","February 28, 2021","April 20, 2020",,"April 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04353154"
174,"NCT04397328","COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo","Incidence of symptomatic fever >37.8, dry cough, or shortness of breath (resident/patient report or nurse observation) respiratory infection with confirmed PCR+ result for SARS-CoV-2.|Requirement for admission to acute care hospital and/or ICU admission or death|Asymptomatic PCR+ SARS-CoV-2 test result|Time to clinical recovery (TTCR).","Lawson Health Research Institute","All","40 Years and older   (Adult, Older Adult)","Phase 3","336","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","9881","May 19, 2020","April 30, 2021","April 30, 2021","May 21, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04397328"
175,"NCT04383652","Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales","COSiN","Recruiting","No Results Available","COVID","Other: Biological sample and clinical data collection","Coronavirus sequencing|Coronavirus culturing","Kirby Institute","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VISP2005","May 6, 2020","June 30, 2021","June 30, 2021","May 12, 2020",,"May 12, 2020","NSW Health Pathology, Randwick, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Sydney Children's Hospital, Randwick, New South Wales, Australia|Blacktown Hospital, Blacktown, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|St Vincent's Hospital, Darlinghurst, Australia|Northern Beaches Hospital, Frenchs Forest, Australia|Royal North Shore Hospital, Saint Leonards, Australia|Westmead Hospital, Westmead, Australia",,"https://ClinicalTrials.gov/show/NCT04383652"
176,"NCT04359329","Estrogen Patch for COVID-19 Symptoms",,"Recruiting","No Results Available","COVID","Drug: Estradiol patch","Rate of Hospitalization|Rate of Transfer to Intensive Care Unit|Rate of Intubation|Rate of Death","Sharon Nachman|Stony Brook University","All","18 Years and older   (Adult, Older Adult)","Phase 2","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SBU-EstrogenPatch-COVID19","April 20, 2020","November 15, 2020","November 15, 2020","April 24, 2020",,"April 24, 2020","Stony Brook University Hospital, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT04359329"
177,"NCT04351295","Efficacy of Faviprevir in COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID","Drug: Favipiravir|Drug: Placebos","Number of patients with viral cure","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","faviprevir covid","April 17, 2020","December 1, 2030","December 1, 2030","April 17, 2020",,"April 17, 2020","Tanta University, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04351295"
178,"NCT04299724","Safety and Immunity of Covid-19 aAPC Vaccine",,"Recruiting","No Results Available","Treat and Prevent Covid-19 Infection","Biological: Pathogen-specific aAPC","Frequency of vaccine events|Frequency of serious vaccine events|Proportion of subjects with positive T cell response|28-day mortality|Duration of mechanical ventilation if applicable|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Clinical improvement based on the 7-point scale if applicable|Lower Murray lung injury score if applicable","Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital","All","6 Months to 80 Years   (Child, Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-20002","February 15, 2020","July 31, 2023","December 31, 2024","March 9, 2020",,"March 9, 2020","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04299724"
179,"NCT04386850","Oral 25-hydroxyvitamin D3 and COVID-19",,"Recruiting","No Results Available","COVID 19","Drug: Oral 25-Hydroxyvitamin D3","COVID-19 (SARA-Cov-2) infection|Severity of COVID-19 (SARA-Cov-2) infection|Hospitalization|Disease duration|Death|Oxygen support|Type of oxygen support|Symptoms of COVID-19|Serum Levels of 25-hydroxyvitamin D3|Biochemical measurements","Tehran University of Medical Sciences|Boston University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRCT2020-0401046909N2|IRCT20200401046909N1","April 14, 2020","November 15, 2020","March 15, 2021","May 13, 2020",,"May 13, 2020","Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04386850"
180,"NCT04345523","Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients","ConPlas-19","Recruiting","No Results Available","COVID-19","Other: Blood and derivatives.|Drug: Standard of Care","Category Changes in Ordinal Scale|Time to category 5, 6 or 7 of the ordinal scale|Mortality of any cause at 15 days|Mortality of any cause at 29 days|Oxygenation free days|Ventilator free days|Incidence of Treatment-Emergent Adverse Events|Antibodies levels in CP donors recovered from COVID-19|Viral load","Cristina Avendaño Solá|Puerta de Hierro University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","278","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ConPlas-19","April 3, 2020","July 2020","July 2020","April 14, 2020",,"April 15, 2020","Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Príncipe de Asturias, Meco, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04345523"
181,"NCT04366232","Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)","JAKINKOV","Not yet recruiting","No Results Available","Covid-19","Drug: Anakinra alone (stages 2b/3)|Drug: Anakinra and Ruxolitinib (overcome stage 3)|Other: Standard of care","Biological criteria|Duration of oxygen therapy (days)|Number of intensive care units admissions|Number of days in intensive care units|Mortality rate|Total number of days in hospital|Organ failure score modification (Sepsis-related Organ Failure Assessment (SOFA) score)|Number of bacterial and/or fungal sepsis","Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|Hopital d'instruction des Armees Sainte-Anne|Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-CHITS-003|2020-001963-10","May 15, 2020","August 31, 2020","August 31, 2020","April 28, 2020",,"May 25, 2020","AP-HM, Hôpital de la Conception, Marseille, Bouches-du-Rhône, France|Hôpital Sainte-Musse, Toulon, VAR, France|Sainte Anne Teaching Military Hospital, Toulon, Var, France",,"https://ClinicalTrials.gov/show/NCT04366232"
182,"NCT04394884","Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)",,"Recruiting","No Results Available","COVID-19",,"To characterize the immunologic mechanisms by which BTK inhibition may ameliorate hyper- inflammatory responses in patients with COVID-19.|1. Characterization of TLR3 and TLR7/8-dependent immunologic phenotypes in COVID-19 patients before and after BTK inhibition.|2. Evaluation of mechanisms of immune cell-specific activation, cytokine production, exhaustion and apoptosis in COVID-19 patients before and after BTK inhibition.|3. Transcriptional, chromatin, and epigenetic profiling of immune cells at the single cell level in COVID-19 patients before and after BTK inhibition.|4. Longitudinal evaluation of TCR and BCR repertoire development in COVID-19 patients before and after BTK inhibition.|5. Characterization of SARS- CoV-2 serological responses in COVID-19 patients with and without BTK inhibition.|6. Characterization of genetic variants that correlate with disease severity and/or response to BTK inhibition treatment.|7. Evaluation of soluble biomarkers as surrogate markers of hyper- inflammation/prognosis and of response to BTK inhibition therapy in COVID-19 patients","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"160","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999920114|20-I-N114","May 28, 2020","April 30, 2023","April 30, 2023","May 20, 2020",,"May 25, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States|Walter Reed National Medical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04394884"
183,"NCT04359121","COVID-19 and the Developement of Phobic Fears of Disease",,"Recruiting","No Results Available","COVID19","Other: Questionnaires for specific phobia","Development of phobias","Medical University of Graz","All","18 Years to 90 Years   (Adult, Older Adult)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","32-354 ex 19/20","April 15, 2020","April 15, 2023","April 15, 2024","April 24, 2020",,"May 6, 2020","Medical University of Graz, Graz, Styria, Austria",,"https://ClinicalTrials.gov/show/NCT04359121"
184,"NCT04362969","COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador",,"Not yet recruiting","No Results Available","COVID",,"Clinical characteristics of patients with COVID-19|Prognosis of patients, in terms of need for admission to intensive care, use of mechanical ventilation or death|Clinical characteristics of the patients with the worst prognosis|Relationship between the different treatments and the prognosis","Hospital San Carlos, Madrid|Universidad Catolica Santiago de Guayaquil","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","001","May 2020","May 2020","May 2020","April 27, 2020",,"May 7, 2020","GastroMuñoz, Guayaquil, Guayas, Ecuador",,"https://ClinicalTrials.gov/show/NCT04362969"
185,"NCT04350671","Interferon Beta 1a in Hospitalized COVID-19 Patients","IB1aIC","Enrolling by invitation","No Results Available","COVID-19","Drug: Interferon Beta-1A|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Shahid Beheshti University of Medical Sciences","All","50 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Interferon Beta 1a in COVID-19","April 15, 2020","April 20, 2020","April 24, 2020","April 17, 2020",,"April 20, 2020","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04350671"
186,"NCT04365257","Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)","PREVENT","Recruiting","No Results Available","COVID-19","Drug: Prazosin|Other: Standard of care","Death|Hospitalized, requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO|Hospitalized, requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2)|Cumulative incidence of grade 3 and 4 adverse events|Number of participants with serious adverse events|Incidence of symptomatic hypotension or hypotension requiring cessation of prazosin|Number of participants with laboratory abnormalities in peripheral blood|Duration of laboratory abnormalities in peripheral blood|Number of participants with laboratory abnormalities in plasma|Duration of laboratory abnormalities in plasma","Johns Hopkins University|Fast Grants","All","45 Years to 85 Years   (Adult, Older Adult)","Phase 2","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00246659|COV2001","May 13, 2020","December 2020","December 2020","April 28, 2020",,"May 15, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04365257"
187,"NCT04345406","Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19",,"Not yet recruiting","No Results Available","COVID","Drug: ACEIs|Drug: Conventional treatment","number of patients with virological cure","Tanta University","All","Child, Adult, Older Adult","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACEIS COVID 19","April 15, 2020","December 1, 2029","December 1, 2029","April 14, 2020",,"April 14, 2020","Tanta University, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04345406"
188,"NCT04374695","Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19","COVHYP","Not yet recruiting","No Results Available","COVID-19",,"Prior treatment by ACEi|Prior treatment by ARB|Baseline characteristics and comorbidities|Major Clinical Adverse Events","Versailles Hospital|Bernard LIVAREK, MD, Cardiology department, Versailles Hospital|Jean-Paul BERESSI, MD, Department of diabetology, Versailles Hospital|Mehrsa KOUKABI FRADELIZZI, MD, Emergency department, Versailles Hospital|Floriane GILLES, MD, Cardiology department, Versailles Hospital|Alisson BERTRAND, Cardiology department, Versailles Hospital|Marie DE TOURNEMIRE, Cardiology department, Versailles Hospital|Victorien MONGUILLON, Cardiology department, Versailles Hospital|Maeva PASQUALINI, Cardiology department, Versailles Hospital|Alix PREVOT, Cardiology department, Versailles Hospital|Guillaume ROGER, Cardiology department, Versailles Hospital|Joseph SABA, Cardiology department, Versailles Hospital|Joséphine SOLTANI, Cardiology department, Versailles Hospital|Jean-François PROST, Cardiology department, Versailles Hospital|Cécile LAUREANA, Department of medical information, Versailles Hospital","All","18 Years and older   (Adult, Older Adult)",,"700","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","P20/11_COVHYP","May 1, 2020","June 1, 2020","July 1, 2020","May 5, 2020",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04374695"
189,"NCT04374279","Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy","RECOVER","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Ivermectin 3Mg Tab","Number of participants who have clinical improvement at day 7 after randomization|All-cause mortality|Duration of hospitalization|Percentage of patients needing upgrade to the intermediate care unit (IMC)|Duration of IMC stay|Percentage of patients needing upgrade to the intensive care unit (ICU)|Duration of ICU stay|Number of participants requiring mechanical ventilation|Duration of mechanical ventilation|Number of participants experiencing adverse events","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COV2003|IRB00249425","June 2020","June 2021","June 2021","May 5, 2020",,"May 5, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04374279"
190,"NCT04345419","A Real-life Experience on Treatment of Patients With COVID 19",,"Not yet recruiting","No Results Available","COVID","Drug: Chloroquine|Drug: Favipiravir|Drug: Nitazoxanide|Drug: Ivermectin|Drug: Niclosamide|Drug: Other drugs","Number of patients with decreased viral load","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","COVID 19 treatment","April 30, 2020","December 2029","December 2029","April 14, 2020",,"April 29, 2020","Tanta university hospital, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04345419"
191,"NCT04393402","Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19)","LUS-COVID19","Recruiting","No Results Available","COVID","Procedure: lung ultrasound (LUS)","LUS applicability with COVID 19|Radiographic correlation (chest Xray and tomodensitometry)|LUS Mortality prediction|Prediction of Prone position response","Centre Hospitalier Universitaire de Nice","All","18 Years to 95 Years   (Adult, Older Adult)",,"14","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20reamedcovid03","March 20, 2020","December 31, 2020","December 31, 2020","May 19, 2020",,"May 19, 2020","CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT04393402"
192,"NCT04350073","Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)",,"Recruiting","No Results Available","COVID-19","Device: Q-NRG Metobolic Cart Device|Device: MuscleSound Ultrasound|Device: Multifrequency Bioimpedance Spectroscopy","Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure(REE) over time, as measured by the indirect calorimetry Q-NRG device|Metabolic and Nutritional Needs of COVID-19 Patients:Changes of the Respiratory Exchange Ratio (RER) as measured by the indirect calorimetry Q-NRG device|Cardiac Output and Cardiac Measures (non-invasive) in COVID-19 patients|Muscle Mass and Quality Changes from COVID-19: Measured via Changes of Intramuscular Adipose Tissue (IMAT) Content From CT Scans of the Psoas at the Level of L3/Th3|Muscle Mass, Quality, Glycogen Changes in COVID-19: Via Metabolic/Muscle Imaging Derived From Muscle-Specific Ultrasound of Leg/Intercostal/Head Muscles|Body Composition in COVID-19 Patients: Measured via Multifrequency Bioimpedance Spectroscopy|Phase Angle in COVID-19 Patients: Measured via Multifrequency","Duke University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00105221","April 20, 2020","October 1, 2020","December 1, 2020","April 16, 2020",,"April 22, 2020","Duke University Medial Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04350073"
193,"NCT04390503","Convalescent Plasma for COVID-19 Close Contacts",,"Recruiting","No Results Available","SARS-CoV 2|COVID-19","Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Control (albumin 5%)","Rate of Severe Disease|Rate of measurable anti-SARS-CoV-2 titers|Rate of SARS-CoV-2 PCR Positivity|Duration of SARS-CoV-2 PCR Positivity|Levels of SARS-CoV-2 RNA","Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","AAAT0052","May 2020","April 2021","April 2021","May 15, 2020",,"May 15, 2020","Columbia University Irving Medical Center/NYP, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04390503"
194,"NCT04353180","Assessment the Activity Value of 13- Cis-Retinoic Acid (Isotretinoin) in the Treatment of COVID-19 (Randomized)","Isotretinoin","Not yet recruiting","No Results Available","COVID19","Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|Drug: Standard treatment","lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap","Kafrelsheikh University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Proposed by Mahmoud Elkazzaz","May 2020","June 2020","July 2020","April 20, 2020",,"May 15, 2020","Faculty of Medicine, Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt|Faculty of Medicine, Kafr El-sheikh University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04353180"
195,"NCT04354753","AiM COVID for Covid 19 Tracking and Prediction",,"Completed","No Results Available","COVID 19","Other: No Intervention","Physical symptoms|Contact History|Travel History|Fever|Headache|Soar Throat|Runny nose|Cough|Shortness of breath|Nausea|Vomiting|Muscle pain|Joint pain|Diarrhoea|Other|Hospitalisation history|Co-morbid conditions","Aarogyam UK|University of Warwick|Igor Sikorsky Kyiv Polytechnic Institute|ClickMedix LLC","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","AU12","March 28, 2020","April 14, 2020","April 17, 2020","April 21, 2020",,"April 21, 2020","Aarogyam (UK), Leicester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04354753"
196,"NCT04362943","Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults","COVID-AGE","Recruiting","No Results Available","COVID-19","Drug: Baricitinib or Anakinra","Mortality|X-ray changes|Disability changes|Ambulation changes|lymphocyte count changes|C-Reactive Protein changes|Ferritin changes|D-Dimer changes","Complejo Hospitalario Universitario de Albacete","All","70 Years and older   (Older Adult)",,"576","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","PAS-BAR-2020-04","April 20, 2020","May 15, 2020","July 31, 2020","April 27, 2020",,"April 27, 2020","Complejo Hospitalario Universitario de Albacete, Albacete, Spain",,"https://ClinicalTrials.gov/show/NCT04362943"
197,"NCT04328285","Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers","COVIDAXIS","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets","Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)|Evaluation of the occurrence of adverse events in each arm,|Evaluation of the discontinuation rates of the investigational drug in each arm,|Evaluation of the adherence of participants to study drug,|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.|corrected QT interval (ms)","Centre Hospitalier Universitaire de Saint Etienne|Institut Pasteur","All","18 Years and older   (Adult, Older Adult)","Phase 3","1200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20PH061|2020-001188-96","April 14, 2020","November 30, 2020","November 30, 2020","March 31, 2020",,"April 29, 2020","CHU d'Angers, Angers, France|CHU de Bordeaux, Bordeaux, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|AP-HP - Hôpital Bichat, Paris, France|CHU de Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT04328285"
198,"NCT04390594","Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal","SEN-CoV-Fadj","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + Azithromycin","SARS-CoV-2 viral load level|Vital status|Proportion of patients with serious adverse events reported during the clinical trial.|Length of hospitalization|Length of hospitalization in a resuscitation unit|Duration of oxygen therapy|Maximum quick SOFA (qSOFA) score during hospitalisation","Institut Pasteur de Dakar|Fann Hospital, Senegal|Ministry of Health, Senegal|Diamniadio Children Hospital, Senegal|Dalal Jamm Hospital, Senegal|Epicentre, Paris, France.","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","258","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-002","June 1, 2020","December 1, 2020","June 1, 2021","May 15, 2020",,"May 15, 2020","Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal|Diamniadio Children Hospital, Diamniadio, Senegal|Dalal Jamm Hospital, Guédiawaye, Senegal",,"https://ClinicalTrials.gov/show/NCT04390594"
199,"NCT04376853","CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch","CoronaWatch","Recruiting","No Results Available","COVID-19","Device: Apple Watch Series 5","Biomarker|Protective factors|SmartWatch compliance|Arrhythmias|QT time changes|Longitudinal risk models","University Hospital Heidelberg|The German Heart Foundation|Klaus Tschira Stiftung|Freunde und Förderer der Kardiologie Heidelberg","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CoronaWatch","April 15, 2020","June 2020","July 2020","May 6, 2020",,"May 6, 2020","Department III of Internal Medicine, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT04376853"
200,"NCT04359901","Sarilumab for Patients With Moderate COVID-19 Disease",,"Suspended","No Results Available","COVID","Biological: SARILUMAB","Intubation or death","Westyn Branch-Elliman|VA Boston Healthcare System","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB 3305","April 10, 2020","April 2022","April 2023","April 24, 2020",,"May 14, 2020","VA Boston Healthcare System, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT04359901/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT04359901/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04359901"
201,"NCT04379479","Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T)","FUTURE-T","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection","Drug: Dialyzable Leukocyte Extract|Drug: Placebo oral","Change in the score of the ""Contingency scale to assess the severity of acute respiratory disease in cases suspected/confirmed by COVID-19""|Clinical deterioration|Duration of the clinical status","National Polytechnic Institute, Mexico","All","18 Years and older   (Adult, Older Adult)","Phase 2","562","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IC-20-001|SH-001-2020","May 2020","August 2020","December 2020","May 7, 2020",,"May 7, 2020","Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04379479"
202,"NCT04338945","Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy",,"Completed","No Results Available","COVID","Behavioral: COVID-surgRES questionaire","Measure of the impact of COVID Emergency on surgical specialist training programs|Measure of impact of COVID Emergency on wellness of residents","Ospedale Policlinico San Martino","All","18 Years and older   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-ItaliansurgRES-SPIGC","March 15, 2020","April 15, 2020","May 1, 2020","April 8, 2020",,"May 20, 2020","U.O.C. Chirurgia Generale Universitaria ""V. Bonomo"", Bari, Italy|Ospedale Perrino Asl Brindisi, Brindisi, Italy|Dipartimento di scienze mediche e chirurgiche, Università di Catanzaro, Catanzaro, Italy|Ospedale Policlinico San Martino, Genova, Italy|Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy|IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Ospedale Cristo re, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04338945"
203,"NCT04339608","Max COVID19- Study",,"Recruiting","No Results Available","COVID-19",,"COVID-19 positive case","Max Healthcare Insititute Limited","All","18 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Covid-19/MHC/2020","April 2, 2020","May 30, 2020","June 30, 2020","April 9, 2020",,"April 9, 2020","Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04339608"
204,"NCT04313322","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells",,"Recruiting","No Results Available","Use of Stem Cells for COVID-19 Treatment","Biological: WJ-MSCs","Clinical outcome|CT Scan|RT-PCR results","Stem Cells Arabia","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19","March 16, 2020","June 30, 2020","September 30, 2020","March 18, 2020",,"March 18, 2020","Stem Cells Arabia, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04313322"
205,"NCT04355897","CoVID-19 Plasma in Treatment of COVID-19 Patients",,"Recruiting","No Results Available","COVID 19","Biological: Convalescent COVID 19 Plasma","Reduce mortality|Reduce requirement for mechanical ventilation.|Reduce the duration of mechanical ventilation.|Review of treatment related adverse events.","The Christ Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-23","April 28, 2020","July 2020","August 2020","April 21, 2020",,"May 20, 2020","The Christ Hospital, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04355897"
206,"NCT04351347","The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID","Drug: Chloroquine|Drug: Nitazoxanide|Drug: Ivermectin","Number of patients with virological cure","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ivermecin covid","April 17, 2020","December 1, 2030","December 1, 2030","April 17, 2020",,"April 17, 2020","Tanta University, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04351347"
207,"NCT04315298","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Sarilumab|Drug: Placebo","Percent change in C-reactive protein (CRP) levels|Time to improvement (2 points) in clinical status assessment using the 7-point ordinal scale in patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels|Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|Time to resolution of fever for at least 48 hours without antipyretics by clinical severity|Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels|Time to improvement in oxygenation for at least 48 hours|Time to improvement in oxygenation for at least 48 hours by clinical severity|Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels|Time to resolution of fever and improvement in oxygenation for at least 48 hours|Mean change in the 7-point ordinal scale|Percentage of patients in each clinical status category using the 7-point ordinal scale|Time to discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours|Change from baseline in NEWS2 scoring system|Number of days with fever|Proportion of patients alive, off oxygen|Number of days of resting respiratory rate >24 breaths/min|Number of days with hypoxemia|Number of days of supplemental oxygen use|Time to saturation ≥94% on room air|Number of ventilator free days in the first 28 days|Number of patients requiring initiation of mechanical ventilation|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients admitted into an intensive care unit (ICU)|Number of days of hospitalization among survivors|Number of deaths due to any cause|Change in serum CRP levels|Incidence of serious adverse events|Incidence of Grade 4 neutropenia (ANC <500/mm3)|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia|Incidence of hypersensitivity reactions|Incidence of infusion reactions|Incidence of gastrointestinal perforation|White blood cell count|Hemoglobin levels|Platelet count|Creatinine levels|Total bilirubin level|Alanine aminotransferase (ALT) level|Aspartate aminotransferase (AST) level","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6R88-COV-2040","March 18, 2020","March 9, 2021","April 1, 2021","March 19, 2020",,"April 6, 2020","Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Coral Gables, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Detroit, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Facility 2, Manhasset, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04315298"
208,"NCT04346186","COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff",,"Not yet recruiting","No Results Available","COVID","Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2","Positive IgM/IgG tests|Comparison of the point of care test and Elisa|Re-infection rate|IgM/IgG positive participants on follow-up test","Herlev Hospital|Nordsjaellands Hospital|Hvidovre University Hospital|Rigshospitalet, Denmark|Mental Health Services in the Capital Region, Denmark|University Hospital Bispebjerg and Frederiksberg","All","Child, Adult, Older Adult",,"30000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RegHCOVIDScreening","April 15, 2020","October 1, 2020","August 1, 2021","April 15, 2020",,"April 15, 2020","Herlev Hospital, Herlev, Region Hovedstaden, Denmark|Bispebjerg Hospital, København NV, Region Hovedstaden, Denmark|Psykiatrisk Center Ballerup, Ballerup, Denmark|Psykiatrisk Center København, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Psykiatrisk Center Amager, Copenhagen, Denmark|Psykiatrisk Center Stolpegaard, Gentofte, Denmark|Børne- og Ungdomspsykiatrisk Center, Glostrup, Denmark|Psykiatrisk Center Glostrup, Glostrup, Denmark|Nordsjaellands Hospital, Hillerød, Denmark|Psykiatrisk Center Nordsjælland, Hillerød, Denmark|Psykiatrisk Center Sankt Hans, Roskilde, Denmark|Bornholms Hospital, Rønne, Denmark|Psykiatrisk Center Bornholm, Rønne, Denmark",,"https://ClinicalTrials.gov/show/NCT04346186"
209,"NCT04350684","Umifenovir in Hospitalized COVID-19 Patients","UAIIC","Enrolling by invitation","No Results Available","COVID-19","Drug: Umifenovir|Drug: Interferon-β 1a|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine|Drug: Standards of Care","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Umifenovir in COVID-19","April 15, 2020","April 22, 2020","April 24, 2020","April 17, 2020",,"April 20, 2020","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04350684"
210,"NCT04351581","Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19","RASCOVID-19","Recruiting","No Results Available","Covid-19","Other: Discontinuation of ACEi/ARB|Other: Continuation of ACEi/ARB","Days alive and out of hospital within 14 days after recruitment|Key-secondary composite endpoint: Occurrence of worsening of COVID-19|Occurrence and time to occurrence of each of the components of the key-secondary composite endpoint|Kidney function assessed by plasma creatinine|Duration of index hospitalisation|30-day mortality|Number of days alive during the intervention period|Number of participants not yet discharged at day 30|Number of readmissions after 30 days.|Kidney function as assessed by eGFR","University Hospital, Gentofte, Copenhagen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","215","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H-20026484|2020-001544-26","May 8, 2020","December 2020","December 2020","April 17, 2020",,"May 7, 2020","Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Capital Region Of Denmark, Denmark|Department of Medicine, Herlev Hospital, University of Copenhagen, Herlev, Capital Region Of Denmark, Denmark",,"https://ClinicalTrials.gov/show/NCT04351581"
211,"NCT04394390","Do Vitamin D Levels Really Correlated With Disease Severity in COVID-19 Patients?","COVIDVIT","Enrolling by invitation","No Results Available","COVID","Dietary Supplement: vitamin d","laboratory measured vitamin D levels","Bursa City Hospital","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1","May 1, 2020","June 15, 2020","June 30, 2020","May 19, 2020",,"May 19, 2020","Bursa City Hospital, Bursa, Dogankoy, Turkey",,"https://ClinicalTrials.gov/show/NCT04394390"
212,"NCT04389359","PROphylaxis for paTiEnts at Risk of COVID-19 infecTion","PROTECT","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate 200 MG","Time to confirmed diagnosis of COVID-19|All-cause mortality|Severity of COVID-19 disease|Incidence of COVID-19 complications","Cambridge University Hospitals NHS Foundation Trust|University of Cambridge","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","A095590","May 2020","August 2021","August 2025","May 15, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04389359"
213,"NCT04363372","A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: MRx-4DP0004|Drug: Placebo","Change in mean clinical status score in each treatment arm|Number of adverse events in each treatment arm|Number of patients with an improvement in clinical status score in each treatment arm|Number of patients with a deterioration in clinical status score in each treatment arm|Number of patients with at least 95% oxygen saturation on room air in each treatment arm|Time to patients with at least 95% oxygen saturation on room air in each treatment arm|Number of patients with an improvement in the National Early Warning Score (NEWS) 2 in each treatment arm|Number of patients with an deterioration in the National Early Warning Score (NEWS) 2 in each treatment arm|Number of patients requiring Continuous Positive Airway Pressure in each treatment arm|Number of patients requiring Intermittent Positive Pressure Ventilation in each treatment arm|Time to patients requiring Continuous Positive Airway Pressure in each treatment arm|Time to patients requiring Intermittent Positive Pressure Ventilation in each treatment arm|Time to discharge in each treatment arm|Number of deaths in each treatment arm","4D pharma plc","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MRx-4DP0004-II-001","May 2020","August 2020","September 2020","April 27, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04363372"
214,"NCT04379466","Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19","CovRep","Not yet recruiting","No Results Available","COVID-19",,"A list of COVID-19 specific TCR sequences|One or more measures from peripheral blood immunophenotyping that is/are associated with COVID-19 outcome|Group of COVID-19 specific TCR sequences that is associated with COVID-19 outcome","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP200544|2020-A01245-34","May 2020","July 2020","November 2020","May 7, 2020",,"May 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04379466"
215,"NCT04376593","PET/CT Imaging in COVID-19 Patients",,"Enrolling by invitation","No Results Available","COVID-19|SARS-CoV-2 Infection","Drug: 18F-αvβ6-BP","Administration of 18F-αvβ6-BP|Determine whether 18F-αvβ6-BP demonstrates accumulation in lung damage","University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1592298","May 2020","May 2021","May 2022","May 6, 2020",,"May 6, 2020","University of California Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT04376593"
216,"NCT04354714","Ruxolitinib to Combat COVID-19",,"Withdrawn","No Results Available","COVID-19","Drug: Ruxolitinib|Procedure: Peripheral blood draw","Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0|Proportion of participants with detectable virus","Washington University School of Medicine|Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-13-20-DiPersio","June 30, 2020","July 31, 2021","December 31, 2021","April 21, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04354714"
217,"NCT04399746","Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19","IvAzCol","Recruiting","No Results Available","COVID","Drug: Ivermectin|Drug: Azithromycin|Drug: Cholecalciferol","Viral clearance|Symptoms duration|SpO2|SpO2/FiO2","Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IvAzCol","March 15, 2020","May 20, 2020","June 10, 2020","May 25, 2020",,"May 25, 2020","Outpatient treatment, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04399746"
218,"NCT04377620","Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)",,"Recruiting","No Results Available","COVID-19","Drug: Placebo|Drug: Ruxolitinib","Proportion of participants who have died due to any cause|Number of Ventilator free days|Number of ICU free days|Oxygen free days|Vasopressor free days|Hospital free days|Improvement in the COVID-19 ordinal scale|Change in SOFA Score|Number of treatment-related adverse events","Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","INCB 18424-369","May 8, 2020","July 29, 2020","July 29, 2020","May 6, 2020",,"May 8, 2020","West Penn Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04377620"
219,"NCT04275947","The COVID-19 Mobile Health Study (CMHS)","CMHS","Recruiting","No Results Available","COVID-19","Other: nCapp, a cell phone-based auto-diagnosis system","Accuracy of nCapp COVID-19 risk diagnostic model","Chinese Alliance Against Lung Cancer|Shanghai Respiratory Research Institution","All","18 Years to 90 Years   (Adult, Older Adult)",,"450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CAALC-008-CMHS","February 14, 2020","April 30, 2020","May 31, 2020","February 19, 2020",,"February 19, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04275947"
220,"NCT04377750","The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation",,"Recruiting","No Results Available","Covid19 Pneumonia","Drug: Tocilizumab","Survival","Hadassah Medical Organization|Sheba Medical Center|Wolfson Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0224-20-HMO-CTIL","April 8, 2020","April 29, 2020","May 8, 2021","May 6, 2020",,"May 6, 2020","Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel|Barzilai Medical Center, Ashkelon, Israel|Wolfson Medical Center, H̱olon, Israel|Sheba Medical Center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT04377750"
221,"NCT04347954","PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)",,"Not yet recruiting","No Results Available","COVID-19","Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%","Mean change in viral titers of SARS-CoV-2|Frequency of adverse effects of interest after nasal sprays|Frequency of symptoms related to SARS-CoV-2","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB-56134","June 2020","July 2020","August 2020","April 15, 2020",,"May 19, 2020","Stanford Health Care, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04347954"
222,"NCT04381962","A Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2)","ATOMIC2","Not yet recruiting","No Results Available","COVID-19","Drug: Azithromycin Capsule","Proportion progressing to respiratory failure or death (all clinically-diagnosed participants)|Proportion progressing to respiratory failure or death (SARS-CoV-2 PCR positive)|All cause mortality|Proportion progressing to pneumonia.|Proportion progressing to severe pneumonia|Peak severity of illness|Safety and tolerability","University of Oxford|Pfizer","All","19 Years and older   (Adult, Older Adult)","Phase 3","800","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATOMIC2|2020-001740-26|282892|20/HRA/2105","May 13, 2020","September 13, 2020","October 13, 2020","May 11, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04381962"
223,"NCT04368923","Management of Covid-19 Patients During Home Isolation",,"Active, not recruiting","No Results Available","Covid 19","Device: Oxygen Therapy|Procedure: Physical Therapy","Arterial Blood Gases (ABG): Partial Pressure of Oxygen and Carbon Dioxide|Arterial Blood Gases (ABG): Acidity Potential Hydrogen (pH)|Vital Signs (Temprature)|Vital Signs (Respiratory Rate)|Vital Signs (Oxygen Saturation)|Vital Signs (Heart Rate)|Vital Signs (Blood Pressure)","Cairo University","All","21 Years to 40 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2318087","March 15, 2020","May 15, 2020","May 20, 2020","April 30, 2020",,"April 30, 2020","M. Sedky, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04368923"
224,"NCT04395768","International ALLIANCE Study of Therapies to Prevent Progression of COVID-19",,"Not yet recruiting","No Results Available","COVID19","Dietary Supplement: Vitamin C|Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Zinc Citrate|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin B12","Symptoms|Length of hospital stay|invasive mechanical ventilation or mortality|Mortality|mechanical ventilation|oxygen|ICU|days in hospital|days in ICU|renal replacement therapy|Extracorporeal support","National Institute of Integrative Medicine, Australia|Catholic Health Initiatives","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alliance-COVID19","May 25, 2020","May 31, 2021","December 31, 2021","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04395768"
225,"NCT04346628","Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19",,"Not yet recruiting","No Results Available","COVID","Drug: Favipiravir|Other: Standard of care treatment","Time until cessation of oral shedding of SARS-CoV-2 virus|Count of participants with clinical worsening of COVID-19 disease|Sars-CoV-2 viral load|Count of participants with development of SARS-CoV-2 antibodies|Time until cessation of symptoms|Cmax of favipiravir|Cmin of favipiravir","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","56032","June 2020","April 2021","April 2021","April 15, 2020",,"May 15, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04346628"
226,"NCT04330638","Treatment of COVID-19 Patients With Anti-interleukin Drugs","COV-AID","Recruiting","No Results Available","COVID-19","Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab","Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre","All","18 Years and older   (Adult, Older Adult)","Phase 3","342","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COV-AID","April 2020","September 2020","December 2020","April 1, 2020",,"April 24, 2020","AZ Sint-Jan Brugge, Brugge, Belgium|University Hospital Saint-Pierre, Brussels, Belgium|Erasmus University Hospital, Brussels, Belgium|University Hospital Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Ziekenhuis Oost-Limurg, Genk, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jessa ZH, Hasselt, Belgium|University Hospital Brussels, Jette, Belgium|CHU Tivoli, La Louvière, Belgium|CHR de la Citadelle, Liège, Belgium|University Hospital Liège, Liège, Belgium|Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium|AZ Delta, Roeselare, Belgium",,"https://ClinicalTrials.gov/show/NCT04330638"
227,"NCT04342884","COVID-19 Community Research Partnership",,"Active, not recruiting","No Results Available","Coronavirus|COVID",,"Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina|Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina|Cumulative incidence of SARS-CoV-2 infection|Monthly incidence of SARS-CoV-2 infection|Stratified incidence of SARS-CoV-2 infection by age group|Stratified incidence of SARS-CoV-2 infection by sex|Stratified incidence of SARS-CoV-2 by season|Stratified incidence of SARS-CoV-2 infection by geographic area (zip code)|Stratified incidence of SARS-CoV-2 infection by preexisting comorbidities|Stratified incidence of SARS-CoV-2 infection by COVID-2 contacts|Stratified incidence of SARS-CoV-2 infection by use of personal protective equipment (PPE) by health workers|Relative risk of SARS-CoV-2 infection by age group|Relative risk of SARS-CoV-2 infection by sex|Relative risk of SARS-CoV-2 infection by season|Relative risk of SARS-CoV-2 infection by geographic area (zip code)|Relative risk of SARS-CoV-2 infection by preexisting comorbidities|Relative risk of SARS-CoV-2 infection by COVID-2 contacts|Relative risk of SARS-CoV-2 infection by use of PPE by health workers|Incidence of sequelae","Wake Forest University Health Sciences","All","Child, Adult, Older Adult",,"150000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00064912","April 8, 2020","December 2021","December 2021","April 13, 2020",,"April 28, 2020","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04342884"
228,"NCT04371965","Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19","KILLER","Not yet recruiting","No Results Available","COVID-19","Drug: Povidone-Iodine","Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day7|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal carriage|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal cell cultures|Thyroid tests at Day0 and Day7|Patient satisfaction at Day7 using a numerical comfort scale, graduated from 0 (any discomfort) to 10 (maximum possible discomfort)|Daily presence of clinical signs in favour of COVID-19, including respiratory distress using NYHA scale, chest pain, anosmia, agueusia, tiredness, cough, stiffness, nasal congestion, dysphagia and diarrhea|Need for ward or intensive care hospitalization","Poitiers University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KILLER","May 1, 2020","July 1, 2020","August 1, 2020","May 1, 2020",,"May 1, 2020","University Hospital of Poitiers, Poitiers, France",,"https://ClinicalTrials.gov/show/NCT04371965"
229,"NCT04344431","Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)","OHB10cov","Recruiting","No Results Available","Covid-19","Combination Product: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)","Time to normalize the oxygen requirement (oxygeno-dependence)|Days of hospitalization between the HBO group and the control group.|Oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% values between the HBO group and the control group.|Days on invasive mechanical ventilation|Mortality","Direction Centrale du Service de Santé des Armées","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020PPRC03","April 14, 2020","April 2021","May 2021","April 14, 2020",,"April 21, 2020","Sainte Anne Military Teaching Hospital, Toulon, France",,"https://ClinicalTrials.gov/show/NCT04344431"
230,"NCT04368871","Radiographic Findings and Their Temporal Changes in COVID-19 Positive Changes Patients: A Prospective Study",,"Not yet recruiting","No Results Available","COVID",,"Radiographic findings and their temporal changes in COVID-19 positive patient: A Prospective study","Max Healthcare Insititute Limited","All","18 Years to 75 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Covid-19/RFTC/MHC/2020","April 28, 2020","June 30, 2020","May 30, 2021","April 30, 2020",,"May 4, 2020","Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT04368871"
231,"NCT04385940","Vitamin D and COVID-19 Management",,"Not yet recruiting","No Results Available","COVID-19","Dietary Supplement: Ergocalciferol|Dietary Supplement: Vitamin D3","Symptoms recovery|Hospitalization|Blood white blood cell count (WBC)|Duration of mechanical ventilation|Duration of hospitalization|Intensive care unit (ICU) admission|Duration of ICU stay|Blood C-reactive protein (CRP)|Blood Lymphocyte count|Blood Ferritin|Blood platelet count|Blood interleukin-6 (IL-6)|Blood Tumor Necrosis Factor alpha (TNF)","University of Alberta","All","17 Years and older   (Child, Adult, Older Adult)","Phase 3","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00100606","May 2020","August 2020","December 2020","May 13, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04385940"
232,"NCT04347824","Predict Adverse Events by Covid-19 Nephritis",,"Recruiting","No Results Available","Covid-19",,"Disease-Aggrevation|Complications","University Hospital Goettingen|Universitätsklinikum Hamburg-Eppendorf|University Hospital, Aachen|Transplantationszentrum Köln-Merheim","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","UMG_Co19-Nephritis","April 27, 2020","December 31, 2020","December 31, 2021","April 15, 2020",,"May 12, 2020","University Medical Center Goettingen, Göttingen, Germany",,"https://ClinicalTrials.gov/show/NCT04347824"
233,"NCT04371367","Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )","FORCE","Recruiting","No Results Available","COVID","Biological: avdoralimab|Other: Placebo","Number of patients alive and no longer hospitalized at D14|Number of ventilator-free days at Day 28 (VFD28)|Number of participants with treatment-related adverse events","Assistance Publique Hopitaux De Marseille|Innate Pharma","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","108","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2020-21","April 27, 2020","June 27, 2020","October 27, 2020","May 1, 2020",,"May 1, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT04371367"
234,"NCT04344535","Convalescent Plasma vs. Standard Plasma for COVID-19",,"Enrolling by invitation","No Results Available","COVID","Biological: Convalescent Plasma|Biological: Standard Donor Plasma","28 day ventilator free days|90 day all-cause mortality","Stony Brook University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SBU-COVID19-ConvalescentPlasma","April 8, 2020","April 30, 2021","August 31, 2021","April 14, 2020",,"April 17, 2020","Stony Brook University Hospital, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT04344535"
235,"NCT04337996","Dynamic Evaluation of COVID-19 Diagnostic Tests","TRODVID-19","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: COVID-19 diagnostic test","Positive or negative character of the three tests|sensitivity and specificity of the tests according to the time elapsed since the first symptoms","Tourcoing Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","176","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RIPH_2020_6","April 2020","July 2020","October 2020","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04337996"
236,"NCT04398303","ACT-20 in Patients With Severe COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19 Pneumonia","Biological: ACT-20-MSC|Biological: ACT-20-CM|Biological: Placebo","Mortality at day 30|Ventilated Subjects - Ventilator Free Days|Ventilated Subjects - Improvement in Ventilator Settings|High-Flow O2 Support Subjects - Step-Down O2 Therapy|High Flow O2 Support Subjects - Respiration Rate|Both Ventilated and High-Flow O2 Support Subjects - ICU-Free Days|Both Ventilated and High-Flow O2 Support Subjects - Pulmonary Function Improvement|Both Ventilated and High-Flow O2 Support Subjects - Increased Berlin Score","Aspire Health Science","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AHS 20-03","May 2020","October 2020","October 2020","May 21, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04398303"
237,"NCT04341688","A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients","GARGLES","Not yet recruiting","No Results Available","Covid-19","Drug: Gargle/Mouthwash","Intraoral viral load|Salivary cytokine profile","Aga Khan University|University of Karachi","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","2020-Sur-ERC-20","July 1, 2020","December 31, 2020","March 31, 2021","April 10, 2020",,"May 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04341688"
238,"NCT04394442","Hydroxychloroquine in COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","time to viral clearance|% of mortality|Length of stay|time to be afebrile|need for mechanical ventilation","Samah Lutfy|Zagazig University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNH1352020","March 21, 2020","August 2020","August 2020","May 19, 2020",,"May 19, 2020","SNH, Mecca, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04394442"
239,"NCT04363866","A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Hydroxychloroquine|Drug: Placebo","Clinical Status at Day 5 Assessed by a 6-Point Ordinal Scale|Number of Participants with Detectable SARS-CoV-2 Virus from Day 0 to Day 28 and at Day 5|Toxicity of Study Drug Assessed by Incidence of Adverse Events","Oregon Health and Science University|OHSU Knight Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STUDY00021303","May 2020","December 2020","June 2021","April 27, 2020",,"April 27, 2020","Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04363866"
240,"NCT04353206","Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure",,"Recruiting","No Results Available","Covid-19|Sars-CoV2","Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma","Proportion of subjects who consent to the study and receive at least one dose of convalescent plasma.|Overall survival of patients in the ICU receiving at least once dose of convalescent plasma for Covid-19-induced respiratory failure.","Noah Merin|Johns Hopkins University|Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Acute Care CP Consortium Trial","May 2020","May 2021","May 2021","April 20, 2020",,"May 14, 2020","8700 Beverly Blvd., Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04353206"
241,"NCT04369742","Treating COVID-19 With Hydroxychloroquine (TEACH)",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine (HCQ)|Other: Pacebo: Calcium citrate","Cumulative incidence of SAEs through day 30|Cumulative incidence of grade 3 or 4 AEs through day 30|Incidence of discontinuation of therapy (for any reason)|Severe disease progression composite outcome|Cumulative incidence of events|Hospital length of stay|Days of fever|Days of non-invasive ventilator use|Days of non-rebreather mask oxygen supplementation|Score on Cytokine Release Syndrome (CRS) Grading Scale|Percentage of subjects reporting each severity score on 8 point ordinal scale Day 1 and EOT (End of Treatment - Day 6)|Percentage of subjects with qTC prolongation at EOT|Cumulative Incidence of mortality|Cumulative Incidence of ICU admission|Cumulative Incidence of Invasive mechanical ventilation|Cumulative Incidence of ECMO|Cumulative Incidence of hypotension requiring vasopressor support|SARS-CoV-2 viral eradication from nasopharyngeal specimens at EOT|Change in Alanine Aminotransferase (ALT) levels|Change in Aspartate Aminotransferase (AST) levels|Change in Creatinine levels|Change in Glucose levels|Change in White Blood Cell (WBC) count|Change in Hemoglobin levels|Change in Platelet count|Change in total bilirubin levels|Change in Lactate Dehydrogenase (LDH) levels|Change in C-Reactive Protein (CRP) levels|Change in Interleukin 6 (IL-6) levels","NYU Langone Health|State University of New York - Downstate Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","626","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","20-00463","April 15, 2020","June 2020","June 2020","April 30, 2020",,"May 1, 2020","State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York, United States|NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04369742"
242,"NCT04368234","Duke COVID-19 Shared Data and Specimen Repository",,"Recruiting","No Results Available","COVID-19",,"Development of data repository to provide a secure, centralized storage location for COVID-19 related specimens","Duke University","All","Child, Adult, Older Adult",,"100000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00105316","May 5, 2020","April 30, 2025","April 30, 2025","April 29, 2020",,"April 29, 2020","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04368234"
243,"NCT04382625","Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial",,"Not yet recruiting","No Results Available","SARS-CoV-2 Pneumonia|COVID-19","Drug: Hydroxychloroquine","Change from Baseline Oxygenation on Day 1 to Day 5|Change from Baseline Oxygenation at Day 5|Intensive Care length of stay|Required Mechanical Ventilation|Required Oxygen supplementation|Hospitalization length of Stay|Mortality|Cardiac Arrhythmia - Polymorphic Ventricular Tachycardia|Cardiac Arrhythmia - Ventricular Tachycardia|Cardiac Arrhythmia - Lengthening QTc","Kootenai Health|Washington State University","All","18 Years and older   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18244","May 2020","January 1, 2022","June 1, 2022","May 11, 2020",,"May 11, 2020","Kootenai Health, Coeur d'Alene, Idaho, United States",,"https://ClinicalTrials.gov/show/NCT04382625"
244,"NCT04348942","A COVID-19 Symptom, Exposure and Immune Response Registry",,"Not yet recruiting","No Results Available","COVID-19",,"Registry Data","ObvioHealth","All","18 Years and older   (Adult, Older Adult)",,"10000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","OBVIO-OBV-001","April 20, 2020","May 1, 2021","May 1, 2021","April 16, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04348942"
245,"NCT04359797","COVID-19 Patient Positioning Pragmatic Trial",,"Enrolling by invitation","No Results Available","COVID-19","Other: Prone|Other: Usual Care","Modified WHO Ordinal Scale|Mean FIO2","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","200727","April 27, 2020","April 2021","June 2021","April 24, 2020",,"April 28, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04359797"
246,"NCT04363502","Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection",,"Recruiting","No Results Available","COVID","Drug: Clazakizumab|Drug: Placebo","Change in C-reactive protein (CRP) level","Johns Hopkins University","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00247932","May 7, 2020","August 2020","August 2020","April 27, 2020",,"May 19, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04363502"
247,"NCT04343690","COPING With COVID-19( CWC-19)",,"Not yet recruiting","No Results Available","COVID-19","Behavioral: Crisis management coaching","Change in stress level as measured by survey|Change wellness as measured by survey","Duke University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00105319","April 13, 2020","June 30, 2020","June 30, 2020","April 13, 2020",,"April 13, 2020","Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04343690"
248,"NCT04389567","Famotidine Outpatient COVID-19 Treatment Study",,"Active, not recruiting","No Results Available","COVID-19","Drug: Famotidine","Symptomatic improvement|Peripheral blood oxygen saturation","Northwell Health|Cold Spring Harbor Laboratory","All","18 Years and older   (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","1605914-1","May 12, 2020","May 20, 2020","May 20, 2020","May 15, 2020",,"May 15, 2020","Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States",,"https://ClinicalTrials.gov/show/NCT04389567"
249,"NCT04380519","Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)",,"Recruiting","No Results Available","COVID-19","Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo","Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2|Phase 3","372","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CL04041078","April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",,"May 8, 2020","Federal State Budget Institution ""National Medical Surgery Center named after N.I. Pirogov"" of Ministry of Health of Russian Federation, Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital № 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation|Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation|Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation|State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation|Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital #40"", Moscow City Healthcare Department, ""Communarca"" Division, Moscow, Russian Federation|АО ""State Company ""Medsi"" based on Clinical Hospital №1"", Moscow, Russian Federation|Saint Petersburg State Budget Institution of Healthcare ""Clinical infectious diseases hospital named after S.P. Botkin"", Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Institution of Healthcare ""City Hospital №40"", Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04380519"
250,"NCT04387214","COVID-19 Pandemic and Academic Performance of Veterinary Students",,"Enrolling by invitation","No Results Available","COVID-19","Other: survey","Measure the effect of COVID-19 pandemic on the academic performance of veterinary medical students|Measure the average studying time|Evaluate on-line education during COVID-19 pandemic lockdown|Evaluate on-line education in practical lessons during COVID-19 pandemic lockdown","South Valley University","All","17 Years to 60 Years   (Child, Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","1-2020","April 13, 2020","May 13, 2020","May 15, 2020","May 13, 2020",,"May 15, 2020","South Valley University, Qinā, Egypt",,"https://ClinicalTrials.gov/show/NCT04387214"
251,"NCT04361214","Leflunomide in Mild COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Drug: Leflunomide","Tolerability of high dose leflunomide as measured by leflunomide dose modifications|Tolerability of high dose leflunomide as measured by discontinuation of leflunomide|Tolerability of high dose leflunomide as measured by Adverse Events|Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0622","May 5, 2020","July 2020","July 2020","April 24, 2020",,"May 20, 2020","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04361214"
252,"NCT04308317","Tetrandrine Tablets Used in the Treatment of COVID-19","TT-NPC","Enrolling by invitation","No Results Available","Corona Virus Disease 2019,COVID-19","Drug: Tetrandrine","Survival rate|body temperature","Henan Provincial People's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TT-NPC","March 5, 2020","March 1, 2021","May 1, 2021","March 16, 2020",,"March 16, 2020","Tetrandrine Tablets, Jinhua, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04308317"
253,"NCT04371562","Predicting Death and ICU Admission in COVID-19 Patients in ED",,"Completed","No Results Available","COVID",,"7-day death|7-day ICU","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","0017055/20","March 1, 2020","March 31, 2020","April 15, 2020","May 1, 2020",,"May 5, 2020","Marcello Covino, Roma, RM, Italy",,"https://ClinicalTrials.gov/show/NCT04371562"
254,"NCT04337762","Beat COVID-19 - Observational Trial","JUPITER","Recruiting","No Results Available","COVID-19",,"Health Outcomes","Beat COVID LLC","All","18 Years to 110 Years   (Adult, Older Adult)",,"100000","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20200835","April 6, 2020","December 2020","July 2021","April 8, 2020",,"April 9, 2020","Beat COIVD, LLC, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04337762"
255,"NCT04382924","Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed COVID-19 Infected Hospitalized Patients",,"Not yet recruiting","No Results Available","COVID","Drug: NP-120 (Ifenprodil)","Patient clinical status (on the WHO 7-point ordinal scale) at day 15 in IP versus SOC control group patients:|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 28 in IP versus control group patients|NEWS assessed days 3, 5, 8 ,11 daily while hospitalized and on days 15 and 29 in IP versus control group patients|Rate of mechanical ventilation in IP versus control group patients|Duration of mechanical ventilation (if applicable) in IP versus control group patients|Duration of supplemental oxygen in IP versus control group patients|Time to return to room pressure (SpO2 > 94%) on room air|Duration in ICU (if applicable) in IP versus control group patients|Rate of Mortality in IP versus control group patients|Duration of hospitalization in IP versus control group patients|Time to discharge in IP versus control group patients|Effect on the rate of change of partial pressure of oxygen (PaO2) and PaO2/FiO2 ratio taken at baseline and measured once daily up to 2 weeks of treatment in IP versus control group patients","Algernon Pharmaceuticals|Novotech (Australia)","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","462","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGN120-3","July 2020","January 2022","February 2022","May 11, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04382924"
256,"NCT04367064","To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare (SCOPe Study)","SCOPe","Recruiting","No Results Available","COVID",,"we will compare the clinical outcome of the COVID 19 patients with their age and gender|we will compare the effect of different treatments given to the COVID 19 patients at Max Hospital","Max Healthcare Insititute Limited","All","18 Years to 75 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SCOPe/MHC/Covid-19/2020","April 25, 2020","June 25, 2020","July 25, 2020","April 29, 2020",,"April 29, 2020","Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04367064"
257,"NCT04389411","The COvid-19 Symptom MOntelukast Trial","COSMO","Not yet recruiting","No Results Available","COVID-19","Drug: Montelukast 10mg","Emergency Room Visits and Hospitalizations|Emergency room visit count|Hospitalization admission count|Time to ER Visit|Time to hospitalization|All-cause mortality|Inpatient Length of stay|Time to ICU admission|Time to intubation|Time to other serious COVID-19 complications","McGill University|Lady Davis Institute","All","40 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","443807","July 2020","February 2021","June 2021","May 15, 2020",,"May 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04389411"
258,"NCT04399109","Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER)","ReCOVER","Recruiting","No Results Available","COVID","Device: TCC-COVID mHealth solution","Rate of avoidable Emergency Department presentations per diagnosed COVID-19 case|All cause mortality per diagnosed COVID-19 case All-cause mortality rate at 30 days per diagnosed COVID-19 case|Rate of hospital admission per diagnosed COVID case|Rate of MBS claims for un-referred visits to general practitioners and analogous COVID-19 MBS telehealth items per diagnosed COVID case|Average length of stay (LOS) for admitted patients per diagnosed COVID case|Rate of admission to Intensive Care Unit (ICU) for admitted patients per diagnosed COVID case|Time from presentation to admission to ICU for patients admitted to ICU per diagnosed COVID case|Rate of intubation in admitted patients per diagnosed COVID case|Rate of readmission within 30 days of discharge in admitted patients per diagnosed COVID case|All-cause mortality at 90 days per diagnosed COVID case|Rate of avoidable Emergency Department presentations with COVID-19 diagnosis per 100,000 population, during trial period|Rate of hospital admission with COVID-19 diagnosis per 100,000 population, during trial period|Rate of admission to ICU with COVID-19 diagnosis per 100,000 population during trial period|Rate of mortality with COVID-19 cause of death per 100,000 population, during trial period|Qualitative assessment of TCC-COVID app usability via a subjective feedback questionnaire provided to all patients enrolled in the study.|Cost-effectiveness of TCC-COVID by measuring the incremental cost per death averted, per ICU admission averted and per length of stay in ICU|Rate of hospital bed days with COVID-19 diagnosis per 100,000 population, during trial period|Rate of ICU bed days with COVID-19 diagnosis per 100,000 population, during trial period|Qualitative assessment of KIOLA physician portal usability via a subjective feedback questionnaire","Dr Sze-Yuan Ooi|The University of New South Wales|The George Institute|South Eastern Sydney Local Health District|Prince of Wales Hospital, Sydney","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PID00770","May 20, 2020","May 19, 2021","May 19, 2021","May 25, 2020",,"May 25, 2020","The Sutherland Hospital, Caringbah, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT04399109"
259,"NCT04326920","Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)","SARPAC","Recruiting","No Results Available","COVID-19","Drug: Sargramostim|Other: Control","Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure|Incidence of AE (Adverse Event)|Incidence of SAEs (Serious Adverse Event)|Clinical Status using 6-point ordinal scale|Clinical Status using Clincal sign score|Clinical Status using SOFA score (Sequential Organ Failure Assessment score),|Clinical Status using NEWS2 score (National Early Warning Score)|incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection|number of patients requiring initiation of mechanical ventilation|Number of deaths due to any cause at 4 weeks|Number of deaths due to any cause at 20 weeks|number of patients developing features of secondary haemophagocytic lymphohistiocytosis|long term Clinical status defined by 6-point ordinal scale|long term Clinical status defined by chest X-ray|long term Clinical status defined lung function","University Hospital, Ghent|Flanders Institute of Biotechnology","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SARPAC","March 24, 2020","October 31, 2020","December 31, 2020","March 30, 2020",,"April 24, 2020","AZ Sint Jan Brugge, Brugge, Belgium|University Hospital Ghent, Gent, Belgium|UZ Brussel, Jette, Belgium|AZ Delta Roeselare, Roeselare, Belgium",,"https://ClinicalTrials.gov/show/NCT04326920"
260,"NCT04369300","Anxiety And Depression During COVID-19 IN INDIA",,"Not yet recruiting","No Results Available","COVID-19","Behavioral: Registery Data Collection","Prevalence (magnitude) of anxiety of general adult population during COVID-19|prevalence (magnitude) of depression and anxiety of general adult population during COVID 19","Max Healthcare Insititute Limited","All","18 Years to 90 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","Covid-19/MHC/PSYCH/20-10","April 24, 2020","November 24, 2020","February 24, 2021","April 30, 2020",,"April 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04369300"
261,"NCT04394117","Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease","CLARITY","Not yet recruiting","No Results Available","SARS-Cov-2|COVID-19","Drug: Angiotensin Receptor Blockers","7-Point National Institute of Health Clinical Health Score|Mortality|Intensive Care Unit Admission|Respiratory Failure|Dialysis Requirement|Hospitalisation Days|Ventilator-Free Days|Dialysis Days|Acute Kidney Injury|Hypotension Requiring Vasopressors","The George Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","605","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","11052020","May 20, 2020","January 30, 2021","April 30, 2021","May 19, 2020",,"May 19, 2020","Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Canterbury Hospital, Campsie, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT04394117"
262,"NCT04344548","Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia",,"Not yet recruiting","No Results Available","COVID","Biological: Allogeneic NK transfer","Adverse effects and Safety|NK transfer Immunogenicity","Universidad Nacional de Colombia|Fundación Salud de los Andes","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UNAL FSA COVID","April 13, 2020","June 10, 2020","November 10, 2020","April 14, 2020",,"April 14, 2020","Fundacion Salud De Los Andes, Bogotá, Bogotá Distrito Capital, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT04344548"
263,"NCT04377477","COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19)","COLOR-19","Recruiting","No Results Available","COVID-19","Radiation: Single fraction whole lung radiotherapy","Lenght of hospital stay (days)|Number of Intensive Care Unit admissions|Variation of the Brescia COVID-19 Respiratory Severity Scale after treatment|Occurence of CTCAE 5.0 adverse events|Variation of the chest X-ray radiological findings according to Brixia scoring system","Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","All","50 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NP 4097","May 10, 2020","May 10, 2021","July 23, 2022","May 6, 2020",,"May 8, 2020","Radiation Oncology Department, ASST SpedaliCivili, Brescia, Brescia, Italy",,"https://ClinicalTrials.gov/show/NCT04377477"
264,"NCT04304313","A Pilot Study of Sildenafil in COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Sildenafil citrate tablets","Rate of disease remission|Rate of entering the critical stage|Time of entering the critical stage|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of C-reactive protein (CRP) recovery|Rate of Biochemical criterion (CK, ALT, Mb) recovery|Rate of undetectable viral RNA (continuous twice)|Time for hospitalization|Rate of adverse event","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GST-G1","February 9, 2020","March 1, 2020","November 9, 2020","March 11, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04304313"
265,"NCT04365530","Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City","COVIDGHPSJCite","Recruiting","No Results Available","COVID",,"Clinical consequences of a Covid-19 infection in the care population|Risk factors at M6|Risk factors at year 1|Risk factors at year 2|Impact of hospital reorganization on medical care at M6|Impact of hospital reorganization on medical care at Year 1|Impact of hospital reorganization on medical care at Year 2","Groupe Hospitalier Paris Saint Joseph","All","Child, Adult, Older Adult",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","Cohorte COVID GHPSJ CiteH","April 1, 2020","April 1, 2022","December 31, 2022","April 28, 2020",,"April 29, 2020","Hôpital Marie Lannelongue, Le Plessis-Robinson, France|AURA Paris Plaisance, Paris, France|Fondation Sainte-Marie, Paris, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|Hôpital Bellan, Paris, France",,"https://ClinicalTrials.gov/show/NCT04365530"
266,"NCT04363034","Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program",,"Available","No Results Available","COVID-19","Biological: Convalescent Plasma",,"University of Arkansas","All","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Intermediate-size Population",,"260944",,,,"April 27, 2020",,"April 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04363034"
267,"NCT04332081","Hyperbaric Oxygen for COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Device: hyperbaric oxygen therapy (HBOT)","Mortality|Need for mechanical ventilation|Days on invasive mechanical ventilation","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00399","April 6, 2020","July 2020","July 2020","April 2, 2020",,"May 5, 2020","NYU Winthrop Hospital, Mineola, New York, United States",,"https://ClinicalTrials.gov/show/NCT04332081"
268,"NCT04382755","Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure","ZILU-COV","Not yet recruiting","No Results Available","COVID-19","Drug: Zilucoplan®|Drug: Placebo","Mean change in oxygenation|Median change in oxygenation|number of AE's (Adverse Events)|number of SAE's (Serious Adverse Events)|mean change in 6-point ordinal scale change|Time since randomization until improvement in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence of fever (defined as 37.1°C or more) for more than 48h without antipyretic|Number of days with fever|Time to halving of CRP levels to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AE's|Incidence of SAE's|Incidence of SUSAR's (Suspected Unexpected Serious Adverse Reaction)|Incidence of SAR's (Serious Adverse Reaction)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 6|Mean change in clinical sign score between day 1and day 15 (or on discharge, whichever is first)|Mean change in clinical sign score between day 1 and day 28 (or on discharge, whichever is first)|Mean change of SOFA score between day 1 and day 6 (or on discharge, whichever is first)|Mean change of SOFA score between day 1 and day 15 or on discharge, whichever is first)|Mean change NEWS2 (National Early Warning) score between day 1 and day 6|Mean change NEWS2 (National Early Warning) score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale at randomization, day 6 and 15 (or discharge, whichever comes first) and day 28 (phone call)|6-point Ordinal Scale at 6 and 15 days (or discharge whichever comes first) and day 28 (phone call), in relation to serum D-dimers and complement C5a levels at randomization|Incidence of nosocomial bacterial or invasive fungal infection for 28 days (phone call) after enrolment in trial|incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum D-dimers and complement C5a at randomization|Time since randomization until first use of high-flow oxygen devices in non-ventilated patients|Time since randomization until first use of non-invasive mechanical ventilation in non-ventilated patients|Time since randomization until first use of invasive mechanical ventilation in non-ventilated patients|Time since to first use of salvage systemic steroids in ventilated patients|Number of ventilator-free days|Duration of invasive and non-invasive mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial on invasive or non-invasive mechanical ventilation for less than 24h prior to or after randomization|Time since randomization to progression to ARDS (Acute Respiratory Distress Syndrome) in ventilated patients|Time to progression to ARDS in ventilated patients according to D-dimers at randomization|Time to progression to ARDS in ventilated patients according to complement C5a at randomization|All-cause mortality rate (excluding group that entered during ventilation)|All-cause mortality rate (including group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Mean change in clinical sign score between day 1 and follow up 12-22 weeks|Incidence of lung function abnormalities at follow|Incidence of lung fibrosis on chest CT scan|All cause mortality for the entire study population","University Hospital, Ghent|UCB Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","81","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZILU-COV","May 2020","May 2021","September 2021","May 11, 2020",,"May 11, 2020","OLVZ Aalst, Aalst, Belgium|AZ Sint Jan Brugge, Brugge, Belgium|Erasmus University Hospital, Brussels, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jan Yperman Ziekenhuis Ieper, Ieper, Belgium|University Hospital Liège, Liège, Belgium|AZ Delta, Roeselare, Belgium|AZ Vesalius, Tongeren, Belgium",,"https://ClinicalTrials.gov/show/NCT04382755"
269,"NCT04344587","Awake Prone Position for Early Hypoxemia in COVID-19","APPEX-19","Enrolling by invitation","No Results Available","COVID-19","Other: Self-prone position recommendation|Other: Usual care","Change in respiratory status|Length of time participant spends in the prone position|Length of time participant spends in the supine position|Length of time participant spends lying on side|Length of time participant spends sitting up|Length of time participant spends standing or walking|Dyspnea or difficult/labored breathing|Discomfort with proning|Length of hospital stay|Invasive mechanical ventilation|Loss of IV access as a consequence of turning in bed|Acute respiratory distress syndrome (ARDS) diagnosis|Hospital mortality","Boston University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","560","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H-40070","April 23, 2020","December 2020","December 2020","April 14, 2020",,"May 13, 2020","MedStar Georgetown University Hospital, Washington, District of Columbia, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Boston Medical Center, Boston, Massachusetts, United States|Creighton University, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT04344587"
270,"NCT04376580","Use of the Nasal Cannula During COVID-19",,"Enrolling by invitation","No Results Available","COVID 19",,"Number of physician using los flow nasal cannula during COVID 19 pandemia|Number of physician getting sick during Covid 19 pandemic","Tiva Group","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","Nasal cannulas flow rate","April 30, 2020","July 31, 2020","September 30, 2020","May 6, 2020",,"May 21, 2020","Carolina Frederico, Buenos Aires, Caba, Argentina",,"https://ClinicalTrials.gov/show/NCT04376580"
271,"NCT04355247","Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm",,"Recruiting","No Results Available","Covid-19","Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension","Clinical complete response criteria|Clinical Partial Response criteria|Secondary response criteria","Auxilio Mutuo Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CCAM 20-01","April 14, 2020","July 31, 2020","April 30, 2021","April 21, 2020",,"April 21, 2020","San Juan City Hospital / Puerto Rico Medical Center, San Juan, Puerto Rico|Hospital Auxilio Mutuo Cancer Center, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04355247"
272,"NCT04353596","Stopping ACE-inhibitors in COVID-19","ACEI-COVID","Recruiting","No Results Available","SARS-CoV-2|COVID-19","Drug: ACE inhibitor, angiotensin receptor blocker","Combination of maximum Sequential Organ Failure Assessment (SOFA) Score and death|Composite of admission to an intensive care unit (ICU), the use of mechanical ventilation, or all-cause death|Maximum and median maximum Sequential Organ Failure Assessment (SOFA) Score|Rates of non-invasive ventilation|Rates of renal replacement therapies|Change of viral burden|Change of C-reactive protein (CRP), interleukin 6 (IL-6), D-Dimer, IL-6, hochsensitives Troponin (hsTN), NT-pro-brain natriuretic peptide (NT-pro BNP)|Number of patients with systolic/diastolic blood pressure > 180/120 mmHg|Hospitalisation due to cardiac decompensation|Rates of mechanical ventilation|Rates of clonal hematopoiesis of indeterminate potential (CHIP)","Medical University Innsbruck|Ludwig-Maximilians - University of Munich","All","18 Years and older   (Adult, Older Adult)","Phase 4","208","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","EudraCT 2020-001206-35","April 15, 2020","May 15, 2021","May 15, 2022","April 20, 2020",,"April 24, 2020","Medical University Innsbruck, University Hospital of Internal Medicine III, Innsbruck, Tyrol, Austria|Landeskrankenhaus Hall, Hall In Tirol, Austria|Medical University Innsbruck, Intensive Care and Emergency Medicine Department, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine II, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine IV, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine I, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine V, Innsbruck, Austria|Klinikum Klagenfurt, Klagenfurt, Austria|Bezirkskrankenhaus Kufstein, Kufstein, Austria|Bezirkskrankenhaus St. Johann, Sankt Johann In Tirol, Austria|Bezirkskrankenhaus Schwaz, Schwaz, Austria|Krankenhaus St. Vinzenz Zams, Zams, Austria|LMU Klinikum, Medizinische Klinik I, Munich, Bavaria, Germany|Asklepios Stadtklinik Bad Tölz, Bad Tölz, Germany|Klinikum Landkreis Erding, Erding, Germany|Klinikum Memmingen, Memmingen, Germany|Deutsches Herzzentrum München, Munich, Germany|Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Munich, Germany|LMU Klinikum, Medizinische Klinik III, Munich, Germany|LMU Klinikum, Medizinische Klinik II, Munich, Germany|LMU Klinikum, Medizinische Klinik IV, Munich, Germany|München Klinik Bogenhausen und Schwabing, Munich, Germany|Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nürnberg, Germany|Klinikum Starnberg, Starnberg, Germany|Klinik für Innere Medizin Weilheim, Weilheim, Germany",,"https://ClinicalTrials.gov/show/NCT04353596"
273,"NCT04337541","Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System",,"Recruiting","No Results Available","COVID-19","Other: Surgical facial mask","Reduction in COVID-19 infection frequency|Antibody-screening","Rigshospitalet, Denmark|Nordsjaellands Hospital|Hvidovre University Hospital|Herlev Hospital|Technical University of Denmark","All","18 Years and older   (Adult, Older Adult)","Not Applicable","6000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020-04-02","April 2, 2020","July 1, 2020","July 1, 2020","April 7, 2020",,"April 7, 2020","Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04337541"
274,"NCT04389710","Convalescent Plasma for the Treatment of COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Convalescent Plasma","Number of patients who receive COVID-19 convalescent plasma transfusions in acute care facilities infected with SARS-CoV-2|Number and type of adverse events associated with COVID-19 convalescent plasma in patients with COVID-19|Length of hospital stay|Length of Intensive Care Unit stay|Length of intubation|Survival to discharge|Changes in complete blood count in patients after receiving convalescent plasma|Abnormal changes in Basic Metabolic Panel (BMP) measures in patients after receiving convalescent plasma|Changes in C-Reactive Protein (CRP) in patients after receiving convalescent plasma|Changes in d-dimer in patients after receiving convalescent plasma|Changes in fibrinogen in patients after receiving convalescent plasma|Changes in prothrombin time (PT) in patients after receiving convalescent plasma|Changes in partial thromboplastin time (PTT) in patients after receiving convalescent plasma","Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20D.379","April 15, 2020","April 14, 2021","April 14, 2021","May 15, 2020",,"May 15, 2020","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04389710"
275,"NCT04379440","Geriatric Population COVID-19 Observational Study (GEROCOVIDobs)","GEROCOVIDobs","Recruiting","No Results Available","COVID-19",,"Health status (WHO classification)|Incidence of Serious Adverse Events|COVID-19 prevalent symptoms at onset|COVID-19 Prognostic Factors|Incidence of COVID-19 in the RSA cohort|Affective/mood state change from baseline in the "" At home "" cohort|Cognitive function in the ""Dementia"" and ""At home "" cohorts|Daily Life Function in the ""Dementia"" and ""At home "" cohorts|Instrumental Daily Life function in the ""Dementia"" and ""At home "" cohorts|Residual signs and symptoms in the "" Outcomes "" cohort|Incidence of outcomes in the "" Outcomes "" cohort per Frailty Status|Incidence of outcomes in the "" Outcomes "" cohort per Comorbidity burden at baseline","Raffaele Antonelli Incalzi|Italian Society of Gerontology and Geriatrics|BLUECOMPANION FRANCE|BLUECOMPANION LTD|Campus Bio-Medico University","All","60 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","GC01-Obs","April 25, 2020","September 30, 2020","November 30, 2020","May 7, 2020",,"May 7, 2020","RSA La Quiete, Castiglione Cosentino, Calabria, Italy|ASP Catanzaro, Catanzaro Lido, Calabria, Italy|AOU Ferrara, Ferrara, Emilia Romagna, Italy|Policlinico Campus Bio-Medico, Rome, Roma, Italy|AOU Careggi, Firenze, Toscana, Italy|AOU Pisana Geriatria, Pisa, Toscana, Italy|Ospedale di Comunita' ULSS 6 Euganea- COVID Center, Camposampiero, Veneto, Italy",,"https://ClinicalTrials.gov/show/NCT04379440"
276,"NCT04395664","Arrhythmias in Patients With COVID-19","ACOVID","Recruiting","No Results Available","COVID-19","Device: C3+ Holter Monitor","In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis|Incident intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis|Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis|Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis|Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis","Herlev and Gentofte Hospital","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-20021500","April 16, 2020","August 2020","April 1, 2021","May 20, 2020",,"May 20, 2020","Department of Cardiology, Herlev & Gentofte Hospital, Copenhagen, Hellerup, Denmark",,"https://ClinicalTrials.gov/show/NCT04395664"
277,"NCT04365699","Cardiovascular Effects of COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: AT-001","Proportion of subjects with decreased left ventricular ejection fraction ≥10% from baseline at time of hospitalization|Incidence of Adverse Events for patients receiving AT-001|Change in left ventricular ejection fraction|Change in left ventricular end-diastolic diameter|Change in left ventricular end-systolic diameter|Change in biomarkers of cardiac injury|Frequency of atrial fibrillation|Frequency of heart block|Frequency of non-sustained ventricular tachycardia|Frequency of sustained ventricular tachycardia|Frequency of ventricular fibrillation|Proportion of subjects requiring mechanical ventilation|Proportion of subjects with decrease in left ventricular ejection fraction ≥10% from baseline at time of hospitalization","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-00416","April 8, 2020","December 31, 2020","December 31, 2020","April 28, 2020",,"April 28, 2020","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04365699"
278,"NCT04338347","CAP-1002 in Severe COVID-19 Disease",,"Available","No Results Available","COVID-19","Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells",,"Capricor Inc.","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"CAP-1002-COVID-19",,,,"April 8, 2020",,"May 5, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04338347"
279,"NCT04359277","A Randomized Trial of Anticoagulation Strategies in COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Enoxaparin Higher Dose|Drug: Lower-dose prophylactic anticoagulation","All-cause mortality|Incidence of Cardiac Arrest|Incidence of symptomatic Deep Venous Thrombosis|Incidence of Pulmonary Embolism|Incidence of Arterial thromboembolism|Incidence of myocardial infarction|Incidence of hemodynamic shock|Incidence of Renal failure|Days of hypoxemia|Cardiac injury (e.g. troponin, NTproBNP)|Hypercoagulability (e.g. D-dimer, fibrinogen)|DIC score|Incidence of major bleeding|Time to change in NEWS2 from baseline|Requirement of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Requirement of non-invasive ventilation or high flow oxygen devices|Requirement of supplemental oxygen","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00479","April 16, 2020","April 16, 2021","April 16, 2021","April 24, 2020",,"May 1, 2020","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04359277"
280,"NCT04386239","Study on the Use of Sarilumab in Patients With COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID19","Drug: Sarilumab Prefilled Syringe","Proportion of patients who show an improvement of the respiratory function|Evaluation of the time to resolution of fever|Evaluation of the viral load on blood and sputum for COVID-19|Evaluation of the plasma concentration of GM-CSF|Evaluation of the plasma concentration of Il-6|Evaluation of the plasma concentration of TNF-α|Evaluation of the rate of progression of White Blood Cell (WBC) fraction","ASST Fatebenefratelli Sacco","All","18 Years to 84 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-SARI-001","May 2020","December 2020","December 2020","May 13, 2020",,"May 13, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT04386239/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04386239"
281,"NCT04351763","Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms","ReCOVery-SIRIO","Recruiting","No Results Available","COVID-19","Drug: Amiodarone|Drug: Verapamil","Clinical improvement|Mean change in the 7-point ordinal scale|Mortality|Time to resolution of fever|Clinical improvement or fever resolution|Tachyarrhythmias|Mortality or tachyarrhythmias|Time to clinical improvement from admission using the 7-point ordinal scale|Change in NEWS2 score|Duration of hospitalization|PO2/FIO2","Nicolaus Copernicus University","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2|Phase 3","804","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NCU-COVID19","April 27, 2020","March 2, 2021","April 10, 2021","April 17, 2020",,"April 17, 2020","Nicolaus Copernicus University, Bydgoszcz, Poland",,"https://ClinicalTrials.gov/show/NCT04351763"
282,"NCT04353284","Camostat Mesylate in COVID-19 Outpatients",,"Not yet recruiting","No Results Available","COVID-19","Drug: Camostat Mesilate|Other: Placebo","Change in SARS-COV-2 viral load|Change in positive COVID-19 status|Change in COVID-19 symptom severity|Change in COVID-19 symptom frequency|Change in body temperature","Yale University","All","18 Years and older   (Adult, Older Adult)","Phase 2","114","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2000027971","May 31, 2020","May 31, 2021","May 31, 2021","April 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04353284"
283,"NCT04354805","Administration of Chloropromazine as a Treatment for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Chlorpromazine Injection","Lactate dehydrogenase (LDH)","Cairo University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical","May 2020","August 2020","September 2020","April 21, 2020",,"April 21, 2020","Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04354805"
284,"NCT04380402","Atorvastatin as Adjunctive Therapy in COVID-19","STATCO19","Not yet recruiting","No Results Available","COVID-19","Drug: Atorvastatin","Proportion of patients that progress to severe or critical requiring ICU admission and/or emergency salvage therapy, or death|Overall score of patients in each arm on Day 7 based on WHO Ordinal Scale for Clinical Improvement|Overall score of patients in each arm on Day 30 based on WHO Ordinal Scale for Clinical Improvement|Proportions of patients in each arm who test negative for SARS-CoV-2 on Day 7","Mount Auburn Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MountAuburn","May 20, 2020","December 31, 2021","May 8, 2022","May 8, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04380402"
285,"NCT04388527","COVID-19 Convalescent Plasma for Mechanically Ventilated Population",,"Recruiting","No Results Available","Covid-19","Biological: COVID-19 Convalescent Plasma","Participants with serious adverse events.|Time to clinical improvement.|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new oxygen use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Oxygen-free days of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Ventilator/ECMO free days to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of hospitalization of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Mortality of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in WBC with differential through day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in platelets measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in creatinine measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in glucose measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in bilirubin measurement through Day 29 of convalescent plasma administration as compared to matched participants form the control arm of DMID Protocol No. 20-0006..|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in AST measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","842996 (PennCCP-01)","April 30, 2020","August 30, 2020","September 30, 2020","May 14, 2020",,"May 14, 2020","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04388527"
286,"NCT04340544","Hydroxychloroquine for the Treatment of Mild COVID-19 Disease","COMIHY","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo","Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment|Difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until Day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered)|All-cause mortality within 28 days","University Hospital Tuebingen|Robert Bosch Medical Center|Universitätsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","2700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COMIHY","April 22, 2020","November 30, 2021","September 30, 2022","April 9, 2020",,"May 11, 2020","Institute for Tropical Medicine, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT04340544"
287,"NCT04382950","Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2",,"Not yet recruiting","No Results Available","COVID","Combination Product: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid","Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Interleukin 6 (IL-6) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Frequency of adverse events and severe adverse events","Kafrelsheikh University","All","18 Years to 60 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COV-2019 Treatment This is","May 2020","July 2020","September 2020","May 11, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04382950"
288,"NCT04377035","The Role of Ultrasound in COVID-19",,"Recruiting","No Results Available","COVID-19",,"In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis|Incident ARDS (Adult Respiratory Distress Syndrome) and intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis|Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis|Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis|Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis|Death from any cause after hospital admission with a confirmed COVID-19 diagnosis at follow-up|Incident stroke after hospital admission with a confirmed COVID-19 diagnosis at follow-up|Incident heart failure after hospital admission with a confirmed COVID-19 diagnosis at follow-up|Incident myocardial infarction after hospital admission with a confirmed COVID-19 diagnosis at follow-up","University Hospital, Gentofte, Copenhagen","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-20021500","March 31, 2020","May 1, 2020","March 1, 2021","May 6, 2020",,"May 8, 2020","Cardiovascular Non-Invasive Imaging Research Laboratory, department of Cardiology, Herlev & Gentofte Hospital, Hellerup, Denmark",,"https://ClinicalTrials.gov/show/NCT04377035"
289,"NCT04355715","Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia","COVID-Scan","Active, not recruiting","No Results Available","COVID 19|SARS-Cov-2",,"Confirmed diagnosis of COVID-19 infection|Incidence of unexpected COVID-19 positive patients admitted to the hospital|Number of contaminating events avoided by the early detection of COVID-19 patients|Incidence of SARS-Cov-2 seroconversion","University Hospital, Montpellier","All","18 Years to 99 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0223","April 1, 2019","October 1, 2020","October 20, 2020","April 21, 2020",,"April 27, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04355715"
290,"NCT04348422","Evaluating the Immune Response for COVID-19","COVIDIMMUNE","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: COVID-19 RT-PCR|Diagnostic Test: COVID-19 Serology|Other: Symptoms questionnare","Proportion of symptomatic patients with immune response (IgM/IgG/IgA)|Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA)|Time to IgM|Time to IgG|Time to IgA|Serology kits inter-observer agreement","Assaf-Harofeh Medical Center","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","105-20-ASF","April 20, 2020","December 1, 2020","December 31, 2020","April 16, 2020",,"April 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04348422"
291,"NCT04338828","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED","NO COV-ED","Recruiting","No Results Available","COVID19","Drug: Nitric Oxide Gas|Other: Inhaled Supplemental Oxygen","Rates of return visits to the ED|Inpatient hospitalizations required|Rates of intubation|Rates of mortality","Massachusetts General Hospital|Department of Anesthesia, MGH","All","18 Years and older   (Adult, Older Adult)","Phase 2","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2019P00XXXX","April 18, 2020","April 2021","April 2022","April 8, 2020",,"May 20, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04338828"
292,"NCT04338958","Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation","RuxCoFlam","Recruiting","No Results Available","Covid-19","Drug: Ruxolitinib","overall response rate in reversal of hyperinflammation","University of Jena","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RuxCoFlam","April 22, 2020","January 31, 2021","August 31, 2021","April 8, 2020",,"May 1, 2020","Universitätsmedizin Göttingen - Klinik für Hämatologie und Onkologie, Göttingen, Germany|University Hospital Jena, Jena, Germany|Klinikum der Landeshauptstadt Stuttgart gKöR, Stuttgart, Germany|Universitätsklinikum Ulm, Ulm, Germany|Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Villingen-Schwenningen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT04338958"
293,"NCT04384900","Accelerated Prone Position Ventilation of Patients With COVID-19","PROVENT-COVID","Recruiting","No Results Available","COVID-19","Procedure: Prone position ventilation","Days alive without respiratory life support (invasive mechanical ventilation) at day 28.|Days alive and out of hospital on day 28 after randomisation.|Days alive at day 28 without life support (vasopressor/inotropic support, invasive mechanical ventilation or renal replacement therapy).|Number of participants with one or more SARs as described in section 6.1 plus incidence of new persistent nerve injury or grade 3 or 4 (full-thickness skin loss or worse) pressure wounds.|28-days all-cause mortality.","Nordsjaellands Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H-20027361","May 11, 2020","November 2020","December 2020","May 12, 2020",,"May 14, 2020","Nordsjællands Hospital, Hillerød, Region Hovedstanden, Denmark",,"https://ClinicalTrials.gov/show/NCT04384900"
294,"NCT04369807","Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection","COVERSCAN","Recruiting","No Results Available","COVID-19","Diagnostic Test: Outpatient MRI","Characterise prevalence and severity of organ volume change and damage (heart, kidneys and liver)|Characterise prevalence and severity of organ volume change and damage (lung, pancreas and spleen)|Change from Baseline in liver-specific biomarkers: volume, iron corrected T1(cT1), fat content and T2star|Change from Baseline in organ-specific biomarkers characterising organ volume change in the heart and spleen along with organ volume and damage in the kidney, liver and pancreas assessed by volume, iron corrected T1 (cT1) and fat infiltration|Change in patient reported outcome measured by the Dyspnea-12 questionnaire|Change in patient reported outcome measured by the St. George's Respiratory questionnaire (SGRQ)|Change in patient reported outcome measured by the EQ-5D-5L questionnaire|Degree of change in liver MR-derived biomarkers","Perspectum Diagnostics Ltd","All","18 Years and older   (Adult, Older Adult)",,"507","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20/SC/0185","April 21, 2020","May 31, 2023","May 31, 2023","April 30, 2020",,"April 30, 2020","Mayo Clinic Healthcare, London, United Kingdom|Gemini, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04369807"
295,"NCT04375124","Treatment of Angiotensin Peptide (1-7) for COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma","mortality","Kanuni Sultan Suleyman Training and Research Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSSEAH--0059","April 25, 2020","August 31, 2020","September 30, 2020","May 5, 2020",,"May 15, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04375124"
296,"NCT04373486","Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels","COVID-APE","Recruiting","No Results Available","Covid-19 With Positive RT-PCR",,"Rate of positivity for Acute Pulmonary Embolism","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"160","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7840","March 3, 2020","April 30, 2020","May 1, 2020","May 4, 2020",,"May 4, 2020","Service de Radiologie B - NHC, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04373486"
297,"NCT04371952","DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19)","DYNAMIC","Not yet recruiting","No Results Available","COVID19","Drug: Doxycycline|Drug: Placebo","Percentage of Patients with Clinical Respiratory Aggravation|Percentage of patients hospitalized|Percentage of patients requiring ventilatory assistance|Positive SARS-CoV-2 PCR Test|Duration of symptoms|Duration of hospitalization|Hospitalization intensive care or reanimation|Duration of mechanical ventilatory assistance|Percentage of deaths related to SARS-CoV-2|AE / SAE in both arms","Nantes University Hospital","All","46 Years and older   (Adult, Older Adult)","Phase 3","330","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RC20_0191","June 1, 2020","December 1, 2020","December 1, 2020","May 1, 2020",,"May 18, 2020","CHU Avicenne - APHP, Bobigny, France|CHU Bordeaux, Bordeaux, France|CHU Caen, Caen, France|CHU Dijon, Dijon, France|CHU Grenoble, Grenoble, France|CHU Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT04371952"
298,"NCT04381351","Noncoding RNAs in COVID-19 and COVID-19 Related Kidney Dysfunction","MiRCOVID","Recruiting","No Results Available","COVID-19",,"predicitive value of noncoding RNAs in COVID-19 associated organ dysfunction","Heinrich-Heine University, Duesseldorf","All","18 Years to 90 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1","April 16, 2020","March 1, 2021","July 31, 2021","May 8, 2020",,"May 8, 2020","Klinik für Anästhesiologie, Düsseldorf, Germany",,"https://ClinicalTrials.gov/show/NCT04381351"
299,"NCT04377789","Effect of Quercetin on Prophylaxis and Treatment of COVID-19",,"Recruiting","No Results Available","COVID-19","Dietary Supplement: Quercetin Prophylaxis|Dietary Supplement: Quercetin Treatment","Prevalence of COVID-19 calculated using a questionnaire|Standardized Mortality rate|Morbidity rate","Kanuni Sultan Suleyman Training and Research Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","KSSEAH--0058","March 20, 2020","July 31, 2020","August 31, 2020","May 6, 2020",,"May 15, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04377789"
300,"NCT04374903","Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients","COVID19-HOPE","Not yet recruiting","No Results Available","COVID-19 Patients","Drug: HCQ & AZ vs HCQ+SIR","Time to Clinical improvement (TTCI)|Clinical failure defined as death or need for Intubation and mechanical ventilation|Adverse effects|QT interval prolongation|Failure to continue assigned therapy|Time to viral clearance","King Hussein Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20 KHCC 74","May 1, 2020","August 1, 2020","September 1, 2020","May 5, 2020",,"May 5, 2020","King Hussein Cancer Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04374903"
301,"NCT04356690","Etoposide in Patients With COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Etoposide","Change in pulmonary status|Change in ferritin levels|Change in C-reactive protein levels|Change in d-dimer levels|Change in white blood cell count|Incidence of serious adverse events|Overall survival|Length of hospitalization|Duration of ventilation|Ventilator free days|Improvement in arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2)","Boston Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H-40102","May 8, 2020","December 2020","December 2021","April 22, 2020",,"May 11, 2020","Boston Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04356690"
302,"NCT04366115","Evaluating AVM0703 for Treatment of COVID-19","AVM0703","Not yet recruiting","No Results Available","COVID-19","Drug: AVM0703|Drug: Placebo|Drug: hydrocortisone","Dose-Limiting Toxicities|28 day all-cause mortality will be a primary end point for Phase 1 and 2","AVM Biotechnology LLC|Medpace, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVM0703-101","June 2020","June 2022","June 2023","April 28, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04366115"
303,"NCT04383002","High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients)",,"Not yet recruiting","No Results Available","COVID-19","Drug: Nitric Oxide","COVID-19 PCR status at completion of treatment (day 3) from tracheal aspirate","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-5449","May 2020","December 2020","December 2020","May 11, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04383002"
304,"NCT04395976","Ayurveda as Prophylaxis for Suspected COVID-19 Patients",,"Not yet recruiting","No Results Available","Covid-19","Other: Ayurveda","Clinical confirmation of Covid-19","British Ayurvedic Medical Council|All Party Parliamentary Group - Indian Traditional Sciences|University of Warwick","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BAMC01","June 10, 2020","September 10, 2020","October 1, 2020","May 20, 2020",,"May 20, 2020","British Ayurvedic Medical Council, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04395976"
305,"NCT04376398","Survey: COVID-19 Patients Managed in the Operating Theatre of Belgian Hospitals","COVID","Recruiting","No Results Available","COVID-19",,"Global evaluation of the implication of the Belgian anesthesiologists during COVID-19 pandemic|If any compare our results with other countries","Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Society for Anesthesia and Resuscitation of Belgium","All","up to 100 Years   (Child, Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COVID-ANESTHESIO","April 6, 2020","June 30, 2020","September 30, 2020","May 6, 2020",,"May 6, 2020","Cliniques Universitaires Saint Luc, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04376398"
306,"NCT04371822","Efficacy of Sn-protoporphyrin IX (SnPPIX) and Sulfonatoporphyrin(TPPS)Against Covid-19","SnPPIX","Not yet recruiting","No Results Available","COVID-19","Drug: SnPP Protoporphyrin|Drug: Sulfonatoporphyrin(TPPS)","lung injury score|Serum ferritin|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap","Kafrelsheikh University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","56","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Proposed by Mahmoud Elkazz","May 2020","June 2020","August 2020","May 1, 2020",,"May 13, 2020","Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt",,"https://ClinicalTrials.gov/show/NCT04371822"
307,"NCT04399317","Flow Controlled Ventilation in ARDS Associated With COVID-19",,"Not yet recruiting","No Results Available","ARDS Associated With COVID-19","Device: Flow controlled ventilation (Evone-ventilator)","arterial oxygen partial pressure (PaO2)","Hamad Medical Corporation","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","MRC-05-018","May 2020","July 2020","August 2020","May 25, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04399317"
308,"NCT04327674","The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19",,"Recruiting","No Results Available","COVID-19",,"FLUS findings and respiratory failure|FLUS findings and chest x-ray.|FLUS findings and admission to intensive care.|FLUS findings and SAR-CoV-2 PCR-test result.","University of Aarhus","All","18 Years and older   (Adult, Older Adult)",,"375","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-FLUS","March 14, 2020","May 15, 2020","May 15, 2020","March 31, 2020",,"March 31, 2020","Lungemedicinsk Forskningsafdeling. Aarhus University Hospital, Aarhus, Denmark|Regionshospitalet Horsens., Horsens, Denmark",,"https://ClinicalTrials.gov/show/NCT04327674"
309,"NCT04347070","Implementation of Physiotherapy on COVID-19 Patients in ICU","PHYSIO-COVID","Recruiting","No Results Available","Sars-CoV2|COVID-19","Other: Phsyiotherapy","Time of physiotherapy|Type of physiotherapy implemented","University Hospital, Montpellier|Société espagnole de pneumologie (SEPAR)|Societe française de kinésithérapie en réanimation (SKR)","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL20_0175","April 1, 2017","September 1, 2020","December 1, 2022","April 15, 2020",,"April 16, 2020","Uhmontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04347070"
310,"NCT04361981","Influence of COVID-19 Infection in Thromboembolic Venous Disease: National Cohort Study","TVP-COVID-RIV","Not yet recruiting","No Results Available","COVID-19","Other: Deep Venous Disease Diagnostic","Deep Venous Disease Incidence|30-days mortality|ICU admission|Anticoagulant treatment","Sociedad Espanola de Angiologia y Cirugia Vascular","All","Child, Adult, Older Adult",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RIV-R3","April 2020","August 31, 2020","December 31, 2020","April 24, 2020",,"April 27, 2020","Red de Investigacion Vascular (SEACV), Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04361981"
311,"NCT04338074","TXA and Corona Virus 2019 (COVID19) in Outpatients","TCOutpatient","Not yet recruiting","No Results Available","COVID-19","Drug: Tranexamic acid tablets|Drug: Placebo oral tablet","Hospitalization","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TXACOVID1","May 25, 2020","October 15, 2020","October 30, 2020","April 8, 2020",,"May 25, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04338074"
312,"NCT04373824","Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study",,"Recruiting","No Results Available","COVID","Drug: Ivermectin","effect of Ivermectin on eradication of virus.","Max Healthcare Insititute Limited","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MHC-COVID-19- INV- ACT-BHR","April 25, 2020","July 25, 2020","July 25, 2020","May 4, 2020",,"May 4, 2020","Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04373824"
313,"NCT04387643","Protecting Health Care Workers During the COVID-19 Outbreak",,"Completed","No Results Available","Covid-19","Dietary Supplement: Ayurvedic Kadha","Physical Health|Psychological Health|Coping with distress|Self-Help","Aarogyam UK|Samta Ayurveda Prakoshtha, India","All","18 Years to 60 Years   (Adult)",,"52","Other","Observational","Observational Model: Other|Time Perspective: Prospective","AU/SA/01","March 1, 2020","April 2, 2020","April 2, 2020","May 14, 2020",,"May 14, 2020","Samta Ayurveda Prakoshtha, Jaipur, Rajasthan, India",,"https://ClinicalTrials.gov/show/NCT04387643"
314,"NCT04368065","Registry to Study Factors That May Impact COVID-19 Occurrence and Severity",,"Recruiting","No Results Available","COVID-19",,"COVID-19 symptom occurrence and severity|COVID-19 treatments|Hospitalization","Iqvia Pty Ltd","All","18 Years and older   (Adult, Older Adult)",,"100000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IQVIA_COVIDREGISTRY_2020","April 2, 2020","December 31, 2021","June 1, 2022","April 29, 2020",,"April 29, 2020","IQVIA, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04368065"
315,"NCT04347538","Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19",,"Recruiting","No Results Available","COVID 19","Other: Saline Nasal Irrigation|Other: Saline with Baby Shampoo Nasal Irrigation","Change in SARS-CoV-2 mucosal immune response in the nasopharynx|Change in microbial load in the nasopharynx|Change in Viral Load in the nasopharynx over the course of COVID-19 infection|Symptom assessment|Temperature assessment","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200693","May 1, 2020","June 2021","June 2022","April 15, 2020",,"May 14, 2020","Vanderblt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04347538"
316,"NCT04338360","Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19",,"Available","No Results Available","COVID19","Biological: COVID-19 convalescent plasma",,"Mayo Clinic","All","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Intermediate-size Population",,"20-003312",,,,"April 8, 2020",,"April 8, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States|Mayo Clinic Health System in Austin, Austin, Minnesota, United States|Mayo Clinic Health System in Cannon Falls, Cannon Falls, Minnesota, United States|Mayo Clinic Health System in Lake City, Lake City, Minnesota, United States|Mayo Clinic Health System in Mankato, Mankato, Minnesota, United States|Mayo Clinic Health System in Owatonna, Owatonna, Minnesota, United States|Mayo Clinic Health System in Red Wing, Red Wing, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Mayo Clinic Health System - Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System - Franciscan Healthcare, La Crosse, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04338360"
317,"NCT04369365","A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",,"Recruiting","No Results Available","COVID","Drug: Azithromycin 500 milligram (mg) oral Tablet|Drug: Placebo","Cumulative number of severe acute respiratory syndrome corona virus 2 (SARS-COV-2) infections|Number of severe COVID-19 cases|Severity of COVID-19 cases|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Number of viral and bacterial infections|Number of participants with azithromycin-resistant bacterial strains in nasal swabs test","Prof. Dr. Matthias Preusser|Medical University of Vienna","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","OnCoVID-19 Trial","April 27, 2020","August 27, 2020","December 27, 2020","April 30, 2020",,"May 1, 2020","AKH Vienna, Department for Internal Medicine I, Oncology, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04369365"
318,"NCT04338126","Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients","TCInpatient","Not yet recruiting","No Results Available","COVID19","Drug: Tranexamic acid|Drug: Placebo oral tablet","Admission to Intensive Care Unit","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TXACOVID2","June 30, 2020","October 15, 2020","December 15, 2020","April 8, 2020",,"May 25, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04338126"
319,"NCT04355026","Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia",,"Recruiting","No Results Available","Covid-19","Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet","Duration of hospitalization|Duration of disease|Hospital-aquired pneumonia|ICU stay duration|Oxygene therapy duration|Mechanical ventilatory support duration","General and Teaching Hospital Celje","All","19 Years and older   (Adult, Older Adult)","Phase 4","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SBCebromhexinCovid-19","April 10, 2020","June 30, 2020","July 31, 2020","April 21, 2020",,"April 21, 2020","SB Celje, Celje, Slovenia",,"https://ClinicalTrials.gov/show/NCT04355026"
320,"NCT04341675","Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia","SCOPE","Recruiting","No Results Available","COVID-19","Drug: Sirolimus|Drug: Placebo","Proportion of patients who are alive and free from advanced respiratory support measures at day 28.|Proportion of patients who require escalation in care|Change over time in study-specific biomarkers (LDH, Ferritin, D-dimer, lymphocyte count)|Proportion of patients surviving to hospital discharge|Drug safety profile|Duration of advanced respiratory support|Duration of hospital stay|Time from treatment initiation to death|Time to resolution of fever|Proportion of patients who require initiation of off-label therapies","University of Cincinnati","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-0337","April 24, 2020","July 2020","September 2020","April 10, 2020",,"May 20, 2020","Loyola University Medical Center, Chicago, Illinois, United States|University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04341675"
321,"NCT04336774","CAPTION AI to Minimize Risk of COVID Exposure","CAPTION AI","Recruiting","No Results Available","COVID-19","Device: Caption AI","Percent of patient echos that are not interpretable|Percent of patient echos that provide an automated (AI) LVEF (left ventricular ejection fraction)|Time to acquire images as measured by time stamps|Percent of agreement between AI calculate LVEF and LVEF read by physician","Duke University|Caption Health, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","pro00105212","May 2020","November 1, 2020","November 9, 2020","April 7, 2020",,"May 8, 2020","Duke Health, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04336774"
322,"NCT04366050","Ramipril for the Treatment of COVID-19","RAMIC","Not yet recruiting","No Results Available","COVID-19","Drug: Ramipril 2.5 MG Oral Capsule|Drug: Placebo oral capsule","Composite of mortality or need for ICU admission or ventilator use","University of California, San Diego|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","560","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RAMIC Trial","April 2020","April 2021","April 2021","April 28, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04366050"
323,"NCT04400058","OCTAGAM 10% THERAPY IN COVID-19 PATIENTS WITH SEVERE DISEASE PROGRESSION",,"Not yet recruiting","No Results Available","Covid-19","Biological: Octagam 10%|Other: Placebo","Stabilization or Improvement in Clinical Status|Oxygen saturation|Modified Borg Dyspnea scale|Quality of Life (McGill Quality of Life Single-Item Scale)|Time to intubation|Time to extubation|Time to mechanical ventilation|Time to cessation of mechanical ventilation|Time to change of modality for oxygenation|Time to death|Imaging findings (chest CT/chest X-ray)|Blood glucose|Blood calcium|Sodium|Potassium|Carbon dioxide|Chloride|Albumin|Total protein|Alkaline phosphatase|Alanine transaminase|Aspartate aminotransferase|Bilirubin|Blood urea nitrogen|D-dimer|Fibrinogen|PT|PTT|INR|hsCRP|Ferritin|LDH|IgG|IgM|IgA|IFE|Troponin|Red blood cell count|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|White blood cell count|White blood cell differential|Platelet count|Mean platelet volume|Platelet distribution width|Frequency of adverse events|Frequency of serious adverse events","Octapharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","GAM10-10","June 1, 2020","September 30, 2020","September 30, 2020","May 25, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04400058"
324,"NCT04329923","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","PATCH","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate 400 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg once a day|Drug: Placebo oral tablet","Median release from quarantine time|Rate of hospital discharge|Rate of infection|Rate of housemate infection|Rate of hospitalization|Cohort 1 adverse event rate|Time to condition appropriate for discharge|Rate of ICU admission|Time to PCR negativity|Cohort 2 adverse events|Scheduled shifts missed|Cohort 3 adverse events","Ravi Amaravadi, MD|University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","842838","April 9, 2020","April 1, 2021","December 1, 2021","April 1, 2020",,"April 28, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04329923"
325,"NCT04394416","Trial of Imatinib for Hospitalized Adults With COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Imatinib|Drug: Placebo oral tablet","The proportion of patients with a two-point change using the 8-category ordinal scale|All-Cause mortality|Time to a 2-point clinical change|Hospitalization|Duration of ECMO or invasive mechanical ventilation|Duration of ICU stay|SARS-CoV-2 negative|Negative oropharyngeal or nasopharyngeal swab|Serious adverse events (SAEs)|Discontinuation due to adverse events","University of Maryland, Baltimore","All","18 Years and older   (Adult, Older Adult)","Phase 3","204","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2038GCCC","May 20, 2020","June 1, 2022","June 1, 2023","May 19, 2020",,"May 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04394416"
326,"NCT04374461","A Study of N-acetylcysteine in Patients With COVID-19 Infection",,"Recruiting","No Results Available","Covid-19","Drug: N-acetylcysteine","Arm A: number of patients who are successfully extubated and/or transferred out of critical care due to clinical improvement|Arm B: number of patients who are discharged from the hospital due to clinical improvement","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","86","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-168","May 1, 2020","May 2021","May 2021","May 5, 2020",,"May 25, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04374461"
327,"NCT04341142","Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER","COVID-SER","Recruiting","No Results Available","Covid19","Diagnostic Test: Serological tests will be applied on patients blood sampling","The positivity (Yes/No) of the serological test.","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","69HCL20_0329","April 9, 2020","September 9, 2020","September 9, 2020","April 10, 2020",,"April 20, 2020","Hôpital Lyon Sud,Sainte Eugénie bat 4M,5, Chemin du Grand Revoyet, Pierre-Bénite cedex, France",,"https://ClinicalTrials.gov/show/NCT04341142"
328,"NCT04397757","COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.",,"Recruiting","No Results Available","COVID-19","Biological: COVID-19 Convalescent Plasma","Participants with serious adverse events.|Comparison of clinical severity score between patients on the experimental versus control arms;|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration by comparing treatment vs control arms|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration by comparing treatment vs control arms|Oxygen-free days of convalescent plasma administration by comparing treatment vs control arms|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of new oxygen use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Ventilator/ECMO free days to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of hospitalization of convalescent plasma administration by comparing treatment vs control arms|Mortality of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in WBC with differential through day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in platelets measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in creatinine measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in glucose measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in bilirubin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in AST measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","843003 (PennCCP-02)","May 13, 2020","September 13, 2020","November 13, 2020","May 21, 2020",,"May 21, 2020","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04397757"
329,"NCT04377802","Safe Return to Regular Clinical Operation After COVID-19 Pandemic",,"Not yet recruiting","No Results Available","COVID 19","Diagnostic Test: molecular testing for virus RNA using RT-PCR","Health care provider safe return to work","King Fahad Specialist Hospital Dammam","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","KFSH-ONC-02","May 17, 2020","November 16, 2020","December 30, 2020","May 6, 2020",,"May 6, 2020","king Fahad specialist hospital, Dammam, Eastern Province, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04377802"
330,"NCT04361643","Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial","GETAFE","Not yet recruiting","No Results Available","COVID-19","Drug: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.|Drug: Placebo","Clinical improvement|Immune-inflammatory improvement|Mortality","Hospital Universitario Getafe","All","60 Years and older   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVID19-EC01","April 27, 2020","August 31, 2020","December 31, 2020","April 24, 2020",,"April 29, 2020","Hospital Universitario de Getafe, Getafe, Spain",,"https://ClinicalTrials.gov/show/NCT04361643"
331,"NCT04318418","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","CODIV-ACE","Not yet recruiting","No Results Available","COVID-19",,"Severe COVID-19|Death","Neuromed IRCCS","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","DEP_012020","March 23, 2020","April 10, 2020","April 30, 2020","March 24, 2020",,"March 24, 2020","IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy",,"https://ClinicalTrials.gov/show/NCT04318418"
332,"NCT04285801","Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study",,"Completed","No Results Available","COVID-19",,"28 day mortality|vasopressor days|days on mechanical ventilation|sequential organ function assessment score|ECMO use|percentage nitric oxide use|percentage free from oxygen supplement","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"8","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","2020.059","February 14, 2020","February 25, 2020","February 25, 2020","February 26, 2020",,"March 10, 2020","Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04285801"
333,"NCT04333628","Chloroquine for Mild Symptomatic and Asymptomatic COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: chloroquine|Other: standard care","change in virus duration (viral shedding)|change in the number of patients going from asymptomatic to moderately disease","HaEmek Medical Center, Israel|T MAY BIOPHARMA LTD.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EMC 0045-20","April 2020","April 2021","December 2021","April 3, 2020",,"April 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04333628"
334,"NCT04330599","Longitudinal Population-based Observational Study of COVID-19 in the UK Population","COVIDENCE UK","Not yet recruiting","No Results Available","COVID-19",,"Incidence of confirmed COVID-19|Incidence of probable or suspected COVID-19|Incidence of COVID-19 requiring hospitalisation|Incidence of COVID-19 requiring ventilatory support|Incidence of fatal COVID-19|Symptom duration per COVID-19 episode|Symptom severity per COVID-19 episode|Incidence of seroconversion to SARS-CoV-2|Incidence of recurrent COVID-19|EQ-5D-3L health-related quality of life score|Health care costs associated with incident COVID-19|Impact of the COVID-19 pandemic and the societal response on participants' financial status|Incidence of COVID-19 on participant's physical health|Impact of COVID-19 on participants' mental health|Impact of COVID-19 on physical health of offspring born to participants during follow-up","Queen Mary University of London|King's College London|London School of Hygiene and Tropical Medicine|University of Edinburgh|Swansea University|Queen's University, Belfast|Barts Charity","All","16 Years and older   (Child, Adult, Older Adult)",,"12000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIDENCE UK","May 5, 2020","April 1, 2025","April 1, 2025","April 1, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04330599"
335,"NCT04365738","Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection",,"Completed","No Results Available","COVID-19","Other: Rehabilitation","Dyspnea|Chest expansion|Fatigue severity|Visual Analog Scale for pain|Hospital anxiety and depression scale","Istanbul Bilgi University","All","28 Years to 45 Years   (Adult)","Not Applicable","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","PR COVID-19","March 11, 2020","April 10, 2020","April 26, 2020","April 28, 2020",,"April 28, 2020","Istanbul Bilgi University, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04365738"
336,"NCT04372628","Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19","TREAT NOW","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Lopinavir/ritonavir 400 mg/100 mg|Other: Placebo","Modified COVID Ordinal Outcomes Scale: Study Day 15|Modified COVID Ordinal Outcome Scale: Study Day 8|Modified COVID Ordinal Outcome Scale: Study Day 29|Proportion of patients hospitalized: Day 1 to 29|Time to hospitalization Day 1 to Day 29|Time to symptom resolution: Day 1 to Day 29|All-cause, all-location mortality: Day 1 to Day 29|Oxygen-free days: Day 1 to Day 29|Fever-free days: Day 1 to Day 29|Ventilator-free days: Day 1 to Day 29|ICU-free days: Day 1 to Day 29|Hospital-free days: Day 1 to Day 29","Vanderbilt University Medical Center|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","900","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","200827","May 31, 2020","December 1, 2020","May 1, 2021","May 4, 2020",,"May 19, 2020","University of Colorado School of Medicine, Aurora, Colorado, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04372628"
337,"NCT04372472","SQuISH-COVID: A Pilot Study",,"Active, not recruiting","No Results Available","Sepsis|COVID-19",,"To demonstrate the performance of the SeptiScan System as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection.","Cytovale, Inc.|Biomedical Advanced Research and Development Authority","All","18 Years and older   (Adult, Older Adult)",,"300","Industry|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","CV-CLN-003","April 7, 2020","May 29, 2020","May 29, 2020","May 4, 2020",,"May 4, 2020","Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04372472"
338,"NCT04304053","Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention","HCQ4COV19","Recruiting","No Results Available","COVID-19","Drug: Treatment and prophylaxis|Other: Standard Public Health measures","Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3|The mortality rate of subjects at weeks 2|Proportion of participants that drop out of study|Proportion of participants that show non-compliance with study drug","Fundacio Lluita Contra la SIDA|Germans Trias i Pujol Hospital|Department of Health, Generalitat de Catalunya|FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA|Laboratorios Gebro Pharma SA|Laboratorios Rubió|Institut Catala de Salut","All","18 Years and older   (Adult, Older Adult)","Phase 3","3040","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HCQ4COV19|2020-001031-27","March 18, 2020","June 15, 2020","June 15, 2020","March 11, 2020",,"April 16, 2020","Departament de Salut, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04304053"
339,"NCT04380792","Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital","SCREENING","Recruiting","No Results Available","COVID-19",,"VTE events and complications","Manuel Monreal|Foundation for the study of VTE diseases. (FUENTE)","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","SCREENING042020","April 13, 2020","April 13, 2025","June 30, 2025","May 8, 2020",,"May 8, 2020","Manuel Monreal, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04380792"
340,"NCT04376879","Predicting the Need for Intubation in Hospitalised COVID-19 Patients (PRED ICU COVID19)",,"Not yet recruiting","No Results Available","COVID-19","Other: Data monitoring for 48h within the first 12 hours of admission for COVID-19","the number of intubations in COVID-19 patients initially hospitalised in wards|the number of intubations in COVID-19 patients initially hospitalised in wards.","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)",,"384","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A01076-33","May 2020","November 2020","November 2020","May 6, 2020",,"May 8, 2020","Louis Mourier hospital (AP-HP), Colombes, France|Brabois Hospital (CHRU de Nancy), Vandœuvre-lès-Nancy, France",,"https://ClinicalTrials.gov/show/NCT04376879"
341,"NCT04361500","Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter","COSA","Recruiting","No Results Available","COVID-19","Device: Seraph 100","Survival|Length of ICU stay|Length of Hospital stay|Length of ventilator therapy|Adverse events","Hannover Medical School|Medical Clinic V Nephrology, Academic Teaching Hospital Brunswick","All","18 Years to 99 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COSA-8998","April 15, 2020","October 1, 2020","October 1, 2021","April 24, 2020",,"April 24, 2020","Academic Teaching Hospital Brunswick, Brunswick, Lower Saxony, Germany|Hannover Medical School, Hannover, Germany",,"https://ClinicalTrials.gov/show/NCT04361500"
342,"NCT04355143","Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)","COLHEART-19","Recruiting","No Results Available","COVID-19","Drug: Colchicine Tablets|Other: Current care per UCLA treating physicians","Composite of all-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)|Delta (peak minus baseline) troponin level|Delta (baseline to peak) brain natriuretic peptide (BNP) level|Change in left ventricular ejection fraction (LVEF) on echocardiography|Delta (peak minus baseline) C-Reactive protein (CRP) inflammatory biomarker level|Delta (peak minus baseline) D-Dimer inflammatory biomarker level|Time (days) to primary endpoint|Number of participants requiring mechanical ventilation|Number of participants requiring mechanical circulatory support (MCS)|Re-hospitalization at 90 days|All-cause mortality","University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-000685","May 1, 2020","April 25, 2021","April 25, 2021","April 21, 2020",,"May 21, 2020","UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|UCLA Santa Monica Hospital, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT04355143"
343,"NCT04363385","Collection of Biological Samples With Clinical Characterization of Covid-19 Patients",,"Not yet recruiting","No Results Available","Covid-19","Biological: Biological test","Phenotype/genotype correlation research modulating the severity of Covid-19 disease|Phenotype/transcriptomic correlation research modulating the severity of Covid-19 disease|Phenotype/biomarker correlation research modulating the severity of Covid-19 disease|Development of clinical-biological scores in the severity of Covid-19 disease|Development of predictive imaging scores in the severity of Covid-19 disease|Identification of pathophysiological pathways to susceptibility to Covid-19 disease|Identification of genetic markers for treatment response|Identification of transcriptomic markers for treatment response|Identification of proteomic for treatment response","Centre Hospitalier Intercommunal Creteil","All","Child, Adult, Older Adult","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","COVIGENET","May 15, 2020","December 15, 2020","December 15, 2020","April 27, 2020",,"May 14, 2020","Centre hospitalier intercommunal de Créteil, Créteil, France",,"https://ClinicalTrials.gov/show/NCT04363385"
344,"NCT04359459","Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study","CIPOLLINI","Not yet recruiting","No Results Available","COVID-19",,"Nasal epithelial transcriptional response to SARS-CoV2|ACE2-AngII system","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIPOLLINI","June 2020","June 2022","June 2022","April 24, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04359459"
345,"NCT04362085","Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care",,"Recruiting","No Results Available","COVID-19","Drug: Therapeutic Anticoagulation","Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.|All-cause death|Composite outcome of ICU admission or all-cause death|Major bleeding|Number of participants who received red blood cell transfusion|Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate.|Number of hospital-free days alive up to day 28|Number of ICU-free days alive up to day 28|Number of ventilator-free days alive up to day 28|Number of participants with venous thromboembolism|Number of participants with arterial thromboembolism|Number of participants with heparin induced thrombocytopenia|Changes in D-dimer up to day 3","St. Michael's Hospital, Toronto|University of Vermont Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","462","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RAPID COVID-COAG","May 11, 2020","November 2020","December 2020","April 24, 2020",,"May 15, 2020","St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04362085"
346,"NCT04351620","High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","Tolerability of high dose HCQ as measured by HCQ dose modification|Tolerability of high dose HCQ as measured by discontinuation of HCQ|Tolerability of High Dose HCQ as measured by Adverse Events|Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0572","April 2020","June 2020","June 2020","April 17, 2020",,"April 17, 2020","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04351620"
347,"NCT04372004","Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19)","CATCH COVID-19","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: diagnostic tests for COVID-19 infection","Compare the efficacy of detection of viral infection using serology and viral-RNA detection kits|Define the temporal trend of antibodies in blood","Texas Cardiac Arrhythmia Research Foundation","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TCAI_CATCH COVID-19","May 2020","May 2021","June 2021","May 1, 2020",,"May 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04372004"
348,"NCT04319315","Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak",,"Recruiting","No Results Available","COVID-19","Other: survey","Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice","Assiut University","All","25 Years to 65 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Prospective","AssiutU-3-2020","March 11, 2020","April 1, 2020","April 16, 2020","March 24, 2020",,"April 7, 2020","Assiut University Hospitals, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04319315"
349,"NCT04343742","Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19",,"Recruiting","No Results Available","COVID-19","Drug: chlorine dioxide 3000 ppm","negative testing of covid19","Genesis Foundation","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Genesis AKCOVID- FG-1","April 1, 2020","April 7, 2020","June 1, 2020","April 13, 2020",,"April 13, 2020","San Carlos Hospital, Bogota, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT04343742"
350,"NCT04390464","mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)","TACTIC-R","Recruiting","No Results Available","COVID19","Drug: Ravulizumab|Drug: Baricitinib|Other: Standard of care","Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure|Change in clinical status as assessed on 7-point ordinal scale compared to baseline|Proportion of patients with adverse events of special interest in each treatment arm|Time to Sp02 >94% on room air|Time to first negative SARS-CoV2 PCR|Duration of oxygen therapy|Duration of hospitalisation|All cause mortality at day 28|Time to clinical improvement","Cambridge University Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Phase 4","1167","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TACTIC-R","May 8, 2020","May 7, 2021","May 1, 2022","May 15, 2020",,"May 18, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04390464"
351,"NCT04334252","Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia",,"Recruiting","No Results Available","COVID 19","Other: Questionnaire","Prevalence of symptoms|Prevalence of positive Sars CoV-2 PCR|Prevalence of positive radiological findings|Prediction of symptoms","Jessa Hospital","All","18 Years and older   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","JessaH_COVID19_prescreening","April 17, 2020","December 20, 2020","December 20, 2020","April 6, 2020",,"May 19, 2020","Jessa hospital, Hasselt, Belgium",,"https://ClinicalTrials.gov/show/NCT04334252"
352,"NCT04360278","Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19",,"Recruiting","No Results Available","COVID-19",,"Collection of convalescent plasma","National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"1500","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200092|20-CC-0092","April 21, 2020","April 14, 2030","April 14, 2030","April 24, 2020",,"May 4, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04360278"
353,"NCT04363216","Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ascorbic Acid","Clinical Improvement|Patient status upgraded to ICU level [Clinical decline]|Oxygen supplementation|Days with fever|Days to discharge|SAEs","Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JT#15681","May 2020","May 2021","May 2021","April 27, 2020",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04363216"
354,"NCT04370236","XPro1595 for the Treatment of Pulmonary Complications From COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: XPro1595","Proportion of participants with treatment failure|Proportion of participants with an increase in the World Health Organization (WHO) Ordinal Scale of Clinical Improvement|Time to treatment failure|Proportion of patients with all-cause mortality|Time to death|Length of index-hospital stay|Length of ICU level of care","Inmune Bio, Inc.","All","50 Years to 100 Years   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XPro1595-COVID-19","June 2020","January 2021","January 2021","April 30, 2020",,"April 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04370236"
355,"NCT04339426","Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection",,"Recruiting","No Results Available","Covid19","Drug: Atovaquone/Azithromycin","Virology Cure Rate|Incidence of GI adverse events|Cardiac Toxicity","HonorHealth Research Institute","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HRI-COVID-19-Anti-Malarial-001","April 20, 2020","October 2020","April 2021","April 9, 2020",,"April 21, 2020","HonorHealth, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04339426"
356,"NCT04354766","COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2","ANTI-COV-2","Recruiting","No Results Available","COVID","Other: Blood sample","Production of several human monoclonal antibodies capable of neutralizing the infection of a target cell by SARS-COV-2.","Hospices Civils de Lyon|Eurobio Scientific","All","18 Years and older   (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL20_0340|2020-A01038-31","April 29, 2020","July 2020","July 2020","April 21, 2020",,"May 4, 2020","Hôpital de la Croix-Rousse, Lyon, France",,"https://ClinicalTrials.gov/show/NCT04354766"
357,"NCT04368156","Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms","SAVIOR","Recruiting","No Results Available","Covid-19","Device: gammaCore® (Vagus nerve stimulation)","Need for mechanical ventilation|Supplemental oxygen requirements|Mortality|Delay onset of ventilation|Cytokine levels","Carlos Tornero|Hospital Clínico Universitario de Valencia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAVIOR","April 20, 2020","July 31, 2020","July 31, 2020","April 29, 2020",,"April 29, 2020","Hospital Clínico Universitario de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04368156"
358,"NCT04334382","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19","HyAzOUT","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days","Intermountain Health Care, Inc.|University of Utah|Utah Department of Health","All","45 Years and older   (Adult, Older Adult)","Phase 3","1550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1051360","April 2, 2020","December 31, 2020","December 31, 2021","April 6, 2020",,"April 9, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04334382"
359,"NCT04345536","Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital","CovidRegOUH","Recruiting","No Results Available","COVID-19",,"Mortality|Severe disease","Oslo University Hospital","All","Child, Adult, Older Adult",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CovidRegOUH","March 15, 2020","January 1, 2021","May 1, 2021","April 14, 2020",,"April 14, 2020","Oslo University Hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT04345536"
360,"NCT04380987","Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis","Predi-COVID","Recruiting","No Results Available","Covid19","Biological: Biological sampling","Description of clinical manifestations|Clinical aggravation of the infection|Discharge of hospitalization|Death|Description of biological manifestations|Patient-related prognostic factors|Virus-related prognostic factors|Vocal biomarker of Covid-19 related respiratory complications","Luxembourg Institute of Health|Centre Hospitalier du Luxembourg|Hopitaux Robert Schuman (Luxembourg)|Laboratoire National de Santé (Luxembourg)|University of Luxembourg","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Predi-Covid","May 4, 2020","July 31, 2021","December 31, 2021","May 8, 2020",,"May 8, 2020","Luxembourg Institute of Health, Luxembourg, Luxembourg",,"https://ClinicalTrials.gov/show/NCT04380987"
361,"NCT04350320","Trial to Study the Benefit of Colchicine in Patients With COVID-19","COL-COVID","Recruiting","No Results Available","COVID19","Drug: Colchicine Tablets|Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.","Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group|Changes in IL-6 concentrations|Improvement in the clinical status|Changes in the score for the Sequential Organ Failure Assessment (SOFA score)|Changes in the punctuation in the National Early Warning Score|Number of days with invasive mechanical ventilation|Number of days with high flow oxygen therapy|Changes in other inflammatory markers|Changes in severity markers|Changes in myocardial damage|Time until reaching a virus negative status|Length of hospital stay|Number of days in the intensive care unit.|Mortality","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","All","18 Years and older   (Adult, Older Adult)","Phase 3","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMIB-COLVID-2020-03","April 30, 2020","October 20, 2020","November 20, 2020","April 17, 2020",,"May 5, 2020","Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT04350320"
362,"NCT04342182","Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)","ConCoVid-19","Recruiting","No Results Available","COVID-19","Biological: Convalescent plasma","Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first|Impact of 300ml convP therapy on hospital days|Impact of 300ml convP on weaning from oxygen therapy|Impact of 300ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission|Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population|Impact of 300ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission|Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways|Impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer|Safety of convP therapy|Change of the 8-point WHO COVID19 disease severity scale on day 15|Change of the 8-point WHO COVID19 disease severity scale on day 30|Change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (PRNT50) <80.|Impact of plasma therapy on risk of long-term structural lung damage and lung function","Erasmus Medical Center|Sanquin Plasma Products BV","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","426","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL73489.078.20","April 8, 2020","July 1, 2020","July 1, 2020","April 10, 2020",,"May 18, 2020","Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|NoordWest Ziekenhuisgroep, Alkmaar, Netherlands|Onze Lieve Vrouwen Gasthuis, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Haaglanden Medisch Centrum, Den Haag, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Martini Hospital, Groningen, Netherlands|Spaarna Gasthuis, Haarlem, Netherlands|Alrijne Ziekenhuis, Leiderdorp, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius-Wilhelmina Hospital, Nijmegen, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|ZorgSaam Hospital, Terneuzen, Netherlands|Bernhoven Hospital, Uden, Netherlands|VieCuri, Venlo, Netherlands",,"https://ClinicalTrials.gov/show/NCT04342182"
363,"NCT04343001","Coronavirus Response - Active Support for Hospitalised Covid-19 Patients","CRASH-19","Not yet recruiting","No Results Available","Covid-19","Drug: Aspirin|Drug: Losartan|Drug: Simvastatin","Death|Myocardial infarction|Congestive cardiac failure|Severe cardiac arrythmia|Myocarditis|Respiratory failure including ARDS|Viral pneumonitis|Acute renal failure|Sepsis|Stroke|Gastrointestinal bleeding|Receipt of non invasive or mechanical ventilation|Ability to self care at hospital discharge","London School of Hygiene and Tropical Medicine","All","40 Years and older   (Adult, Older Adult)","Phase 3","10000","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-KEP-420","April 2020","April 2021","August 2021","April 13, 2020",,"April 20, 2020","University College Hospital, Ibadan, Oyo, Nigeria|Shifa Tameer-e-Millat University, Rawalpindi, Pakistan",,"https://ClinicalTrials.gov/show/NCT04343001"
364,"NCT04367662","Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19","COVID'HEMOS","Recruiting","No Results Available","COVID-19","Procedure: blood sampling","Clinical worsening (yes/no) of the patient during hospitalization|D-DIMERS plasma levels in blood|Fibrin monomers plasma levels in blood|Antithrombin plasma levels in blood|Prothrombin Fragment 1 plasma levels in blood|Prothrombin Fragment 2 plasma levels in blood|Thrombin generation test plasma levels in blood|Microvesicles of platelet plasma levels in blood|Cross-linked platelets plasma levels in blood|Willebrand Factor plasma levels in blood|Factor VIII plasma levels in blood","University Hospital, Rouen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2020/0104/OB","April 9, 2020","July 2020","July 2020","April 29, 2020",,"April 29, 2020","Rouen University Hospital, Rouen, France",,"https://ClinicalTrials.gov/show/NCT04367662"
365,"NCT04343794","Using Biovitals® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19",,"Recruiting","No Results Available","COVID19","Device: BIOVITALS","Time to diagnosis of COVID-19 by RT-PCR in subjects|Compliance to complete the study|Sensitivity and specificity of Biovitals® Sentinel|Cross infection rate within the family cluster|Length of hospital stay of positive subjects|Length of ICU stay of positive patients|National Early Warning Score 2 rating of positive patients|Viral load of positive patients|Worsening of comorbidities|Mortality","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","COVID19_Biovitals_Protocol_1","April 1, 2020","December 31, 2021","January 31, 2022","April 13, 2020",,"April 15, 2020","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04343794"
366,"NCT04347174","A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients",,"Recruiting","No Results Available","COVID-19","Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Drug: Standard therapy of COVID-19","Sequential Organ Failure Assessment (SOFA) scores|7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)|All-cause mortality|Incidence of AE / SAE or event of clinical significance|SARS-CoV-2 detectable in nasal or oropharyngeal (OP) sample|ICU length of stay|Duration of mechanical ventilation|Duration of hospitalization|Clinical improvement|Time (in days) from treatment initiation to death","Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRSC20004","April 30, 2020","June 30, 2020","July 30, 2020","April 15, 2020",,"May 12, 2020","All India Institute of Medical Sciences, Bhopal, Bhopal, Madhya Pradesh, India|Postgraduate Institute of Medical Education and Research, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT04347174"
367,"NCT04357990","Kerecis Oral and Nasal Spray for Treating the Symptoms of COVID-19","KONS-COVID-19","Recruiting","No Results Available","COVID-19","Device: Kerecis Oral and Nasal Spray|Other: Placebo","Number of days until complete resolution of symptoms per group|Number of hospital admissions per group|Number of days until a reduction in symptoms per group|Number of adverse events per group","Kerecis Ltd.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KS-0470","May 1, 2020","July 2020","July 2020","April 22, 2020",,"May 6, 2020","National Hospital of Iceland (Landspítali), Reykjavík, Iceland",,"https://ClinicalTrials.gov/show/NCT04357990"
368,"NCT04368013","Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial","CoVUm","Not yet recruiting","No Results Available","COVID-19","Procedure: Extended sampling and procedures","Mortality","Johan Normark|Umeå University|Västerbotten County Council","All","15 Years to 100 Years   (Child, Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CoVUm","April 28, 2020","April 14, 2026","April 14, 2026","April 29, 2020",,"April 29, 2020","Incectious Diseases Clinic, Umeå, Västerbotten, Sweden",,"https://ClinicalTrials.gov/show/NCT04368013"
369,"NCT04368221","Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU","MY-CO-VID","Not yet recruiting","No Results Available","Covid-19",,"Opportunistic fungal co-infections.|Median time|Time between diagnosis and targeted treatment|Preventive strategies","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Other","35RC20_8885_MY_CO_VID","May 2020","May 2021","May 2021","April 29, 2020",,"May 13, 2020","CHU Angers, Angers, France|CHU de Brest, Brest, France|CHU de Dijon, Dijon, France|CHU Grenoble, Grenoble, France|CHU Lille, Lille, France|CHU Lyon, Lyon, France|CHU Marseille, Marseille, France|CHU Nantes, Nantes, France|CHU de Nice, Nice, France|CHU Paris - Avicenne, Paris, France|CHU Paris - Bichat, Paris, France|CHU Paris - HEGP, Paris, France|CHU Paris - Mondor, Paris, France|CHU Paris - Tenon, Paris, France|Hôpital Lariboisière/ St Louis, Paris, France|Hôpital Necker-Enfants Malades, Paris, France|Hôpital Pitié-Salpêtrière, Paris, France|CHU Poitiers, Poitiers, France|CHU Rennes, Rennes, France|CHU Strasbourg, Strasbourg, France|CHU Toulouse, Toulouse, France|CHU Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT04368221"
370,"NCT04393311","Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ulinastatin|Drug: Placebo","Time to recovery|COVID-19 disease severity scale score on Day 8|COVID-19 disease severity scale score on Day 15|COVID-19 disease severity scale score on Day 22|COVID-19 disease severity scale score on Day 29|Incidence of mortality at Day 29|Incidence of in-hospital mortality|Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose|Number of patients with resolution of symptoms defined as score of 8 on the 8-point ordinal scale at Day 29|Number of patients alive and free of respiratory failure defined as score of 4, 5, 6, 7, or 8 on the 8-point ordinal scale at Day 29|Duration of mechanical ventilation|Duration of ECMO|Duration of noninvasive ventilation|Duration of ICU stay|Duration of hospital stay|Change in oxygen saturation","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","56639","June 2020","December 2020","December 2020","May 19, 2020",,"May 19, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04393311"
371,"NCT04392414","Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease",,"Recruiting","No Results Available","COVID-19","Biological: COVID-19 convalescent hyperimmune plasma|Biological: Non-convalescent fresh frozen plasma (Standard plasma)","The number and proportion of patients with the normal body temperature (≤37.2 C) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy|Days before mechanical ventilation|Days of need for oxygen therapy|Days of stay in the ICU|Days of hospitalization|Changes of the titer of the SARS-CoV-2 antibodies in the blood plasma of patients|Dynamics of the cytokine profile|Dynamics of the level of C-reactive protein|30-day mortality rate","Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CovPlas-Covid19","May 1, 2020","August 1, 2020","September 15, 2020","May 18, 2020",,"May 18, 2020","Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04392414"
372,"NCT04348500","Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease",,"Not yet recruiting","No Results Available","COVID19","Drug: Clazakizumab","Evaluate the safety and efficacy of clazakizumab for the treatment of patients with COVID-19 disease and signs of pulmonary involvement|Patient survival at 28 days|Patient survival at 60 days|Number of patients requiring the dose of open-label clazakizumab|Reduced duration of intensive care unit stay|Reduced duration of hospital stay","Cedars-Sinai Medical Center","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00000644","April 21, 2020","December 31, 2020","March 31, 2021","April 16, 2020",,"April 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04348500"
373,"NCT04368260","Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic",,"Recruiting","No Results Available","COVID19","Device: Control swab|Device: Prototype swab","Number of subjects for which the prototype swab and the control swab provide the same COVID-19 PCR result","University of Virginia","All","up to 99 Years   (Child, Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","HSR200127","April 24, 2020","July 31, 2020","July 31, 2020","April 29, 2020",,"April 29, 2020","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04368260"
374,"NCT04276896","Immunity and Safety of Covid-19 Synthetic Minigene Vaccine",,"Recruiting","No Results Available","Pathogen Infection Covid-19 Infection","Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs","Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of vaccine/CTL Events|Frequency of Serious vaccine/CTL Events","Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital","All","6 Months to 80 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-20001","March 24, 2020","July 31, 2023","December 31, 2024","February 19, 2020",,"March 19, 2020","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, China|Shenzhen Third People's Hospital, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04276896"
375,"NCT04358211","Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19",,"Available","No Results Available","COVID-19","Biological: Biological: COVID-19 convalescent plasma",,"Nakhle Saba, MD|Tulane University","All","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"2020-595",,,,"April 24, 2020",,"April 24, 2020","Tulane Medical Center, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04358211"
376,"NCT04373096","Enhanced Hood PPE to Minimize COVID-19 Transmission to Front-line Health Care Workers",,"Not yet recruiting","No Results Available","Covid19","Device: current IPAC-UHN PPE|Device: modified IPAC-UHN PPE","Incidence of contamination of any part of the base clothing or exposed skin of the upper body|1) Number of body areas contaminated|2) Number of discrete areas of contamination of <1 cm2 and >1 cm2|3) Visibility during the simulated procedure|4) Ease of intubation procedures when wearing PPE|5) Ease of breathing while wearing PPE|6) Thermal comfort while wearing the PPE|7) Incidence of breaching of doffing procedures","University Health Network, Toronto","All","20 Years to 75 Years   (Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","20-5448","June 1, 2020","August 31, 2020","August 31, 2020","May 4, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04373096"
377,"NCT04360980","The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Colchicine Tablets","CRPxN/R ratio change|Clinical deterioration by the WHO definition|PCR Viral Load|CT severity involvement index|LDH change","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SBMU.IR.REC.165423","March 20, 2020","May 20, 2020","May 30, 2020","April 24, 2020",,"April 27, 2020","SBMU, Tehran, Iran, Islamic Republic of|Nooshin Dalili, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04360980"
378,"NCT04335136","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","APN01-COVID-19","Recruiting","No Results Available","COVID-19","Drug: RhACE2 APN01|Drug: Physiological saline solution","Cause of death or invasive mechanical ventilation|LDH level|Mortality|VFD|Time to death","Apeiron Biologics","All","35 Years to 80 Years   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","APN01-01-COVID19","April 30, 2020","September 2020","November 2020","April 6, 2020",,"May 5, 2020","Medizinische Universität Innsbruck, Innsbruck, Austria|Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria|Medizinische Universität Wien, Wien, Austria|The National University Hospital, Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum rechts der Isar, Technische Universität München, München, Germany",,"https://ClinicalTrials.gov/show/NCT04335136"
379,"NCT04331366","Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","GO2 PEEP","Recruiting","No Results Available","COVID-19","Device: GO2 PEEP MOUTHPIECE","Change in Oxygen Saturation by Pulse Oximetry|Change in Respiratory Rate|Change in Heart Rate|Change in Blood Pressure|Change in Subjective Work of Breathing|Change in Partial Pressure of Oxygen (PaO2)|Change in Partial Pressure of Carbon Dioxide (PaCO2)|Change in pH|Change in Bicarbonate (HCO3)|Change in Oxygen Saturation (O2Sat) by Arterial Blood Gas Test","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","STUDY00000381","April 8, 2020","May 2020","May 2020","April 2, 2020",,"April 14, 2020","Emory University Hospital, Atlanta, Georgia, United States|Emory St. Joseph's Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04331366"
380,"NCT04391127","Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo","Mean days of hospital stay|Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead|Mean of oxygenation index delta|Mean time to viral PCR negativization","Centenario Hospital Miguel Hidalgo","All","16 Years to 90 Years   (Child, Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2020-A-09","May 4, 2020","August 30, 2020","September 30, 2020","May 18, 2020",,"May 18, 2020","Jose Manuel Arreola Guerra, Aguascalientes, Mexico",,"https://ClinicalTrials.gov/show/NCT04391127"
381,"NCT04389645","Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients",,"Completed","No Results Available","COVID-19","Diagnostic Test: IP-10 in CDS protocol","IP-10 levels","MeMed Diagnostics Ltd.","All","18 Years and older   (Adult, Older Adult)",,"52","Industry","Observational",,"MM-5000-BV","April 7, 2020","May 12, 2020","May 12, 2020","May 15, 2020",,"May 15, 2020","Rabin Medical Center, Petach Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT04389645"
382,"NCT04371679","Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients","COVID-HO","Recruiting","No Results Available","Covid-19","Other: No interventions planned","Death (all-cause mortality) or discharge from ICU (limit of 4 months)","Hasselt University","All","Child, Adult, Older Adult",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Covid-HO","April 1, 2020","October 1, 2020","December 1, 2020","May 1, 2020",,"May 1, 2020","Jessa Hospital, Hasselt, Belgium",,"https://ClinicalTrials.gov/show/NCT04371679"
383,"NCT04359537","Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19","CHEER","Recruiting","No Results Available","COVID 19","Drug: Hydroxychloroquine Sulfate 200 MG|Other: Placebo","COVID-19-free survival in experimental arms compared to placebo|Incidence of confirmed SARS-COV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related adverse events","Shaheed Zulfiqar Ali Bhutto Medical University","All","18 Years to 60 Years   (Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","F.1-1/2015/ERB/SZABMU/549","May 1, 2020","August 25, 2020","September 25, 2020","April 24, 2020",,"May 19, 2020","Shaheed Zulfiaqar Ali Bhutto Medical University, Islamabad, Federal Capital, Pakistan",,"https://ClinicalTrials.gov/show/NCT04359537"
384,"NCT04355884","Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Coronavirus Disease 2019 (COVID19) Survivors",,"Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: Standard 12-lead ECG, NT-proBNP, echocardiography","New-onset cardiac arrhythmia|Elevation of NT-proBNP|Left ventricular dysfunction","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID_LVD_SCREEN","April 20, 2020","May 1, 2020","May 1, 2020","April 21, 2020",,"April 24, 2020","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04355884"
385,"NCT04362189","Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: HB-adMSC|Drug: Placebo","D-dimer|Interleukin-6|C Reactive protein|Oxygenation|PCR test SARS-CoV-2|EKG qt interval|Leukocyte differential|TNF alpha|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|NK cell surface antigen (CD3-CD54+)|CD4+/CD8+ ratio|IL-10|VEGF|Myoglobin|Troponin|Creatinine kinase|Serum ferritin|Adverse events|7-point ordinal scale","Hope Biosciences|Advanced Diagnostics Healthcare|Hope Biosciences Stem Cell Research Foundation","All","Child, Adult, Older Adult","Phase 2","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allogeneic Treatment COVID-19","May 15, 2020","October 31, 2020","October 31, 2020","April 24, 2020",,"May 25, 2020","River Oaks Hospital and Clinics, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04362189"
386,"NCT04330690","Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","CATCO","Recruiting","No Results Available","COVID-19","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: remdesivir","Efficacy of Interventions as assessed by all-cause mortality|Time to improvement of one category from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)","Sunnybrook Health Sciences Centre|AbbVie|Apotex Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","440","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2114","March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",,"May 5, 2020","University of Alberta Hopsital, Edmonton, Alberty, Canada|Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|Island Health - Royal Jubilee Hospital, Victoria, British Columbia, Canada|Island Health - Victoria General Hospital, Victoria, British Columbia, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada|McGill University Health Centre-Glen Site Royal Victoria Hospital, Montréal, Quebec, Canada|CHU de Québec - Université Laval, Québec, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval, Québec, Quebec, Canada|Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04330690"
387,"NCT04343092","Ivermectin Adjuvant to Hydroxychloroquin and Azithromycine in COVID19 Patients",,"Recruiting","No Results Available","COVID 19","Drug: Ivermectine|Drug: Hydroxychloroquine Sulfate|Drug: Placebos|Drug: Azithromycin 500 mg","Number of cured patients|Number of participants with treatment-related adverse events","University of Baghdad","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRO20040001","April 18, 2020","August 1, 2020","August 1, 2020","April 13, 2020",,"April 24, 2020","General Directorate of Medical City, Bagdad, Baghdad, Iraq",,"https://ClinicalTrials.gov/show/NCT04343092"
388,"NCT04352491","An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease",,"Recruiting","No Results Available","COVID 19","Other: No intervention","Assessment of the fear levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Assessment of the anxiety levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Assessment of the stress levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)|Association between presence of Liver disease and fear levels|Association between presence of Liver disease and anxiety levels|Association between presence of Liver disease and stress levels|Correlation between Fear and Child-Turcotte-Pugh Score|Correlation between anxiety and Child-Turcotte-Pugh Score|Correlation between stress and Child-Turcotte-Pugh Score|Correlation between fear and Model for End Stage Liver Disease Score|Correlation between anxiety and Model for End Stage Liver Disease Score|Correlation between stress and Model for End Stage Liver Disease Score","Institute of Liver and Biliary Sciences, India","All","18 Years to 75 Years   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","ILBS-COVID-03","April 22, 2020","April 30, 2020","April 30, 2020","April 20, 2020",,"April 22, 2020","Institute of Liver and Biliary Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04352491"
389,"NCT04359511","Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia","CORTICOVIDHUGO","Not yet recruiting","No Results Available","COVID-19","Drug: Prednisone|Drug: Hydrocortisone","Clinical improvement defined by the improvement of 2 points on a 7-category ordinal scale, at 14 days.|Proportion of patients free of oxygen at day 14 and 28|Proportion of patients discharged alive from hospital at day 14 and 28|Time to discharge for patients alive|Proportion of patients that were hospitalized to ICU or who died at day 14 and 28|14 and 28 day mortality rate|The time until weaning from oxygen therapy|The proportion of patients with clinical degradation of at least 1 point on the ordinal scale to 7 categories on D14 and D28","University Hospital, Tours","All","18 Years and older   (Adult, Older Adult)","Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CORTI-COVID-19-HUGO|DR200136","May 2020","November 2020","November 2020","April 24, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04359511"
390,"NCT04331795","Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis","COVIDOSE","Recruiting","No Results Available","COVID-19","Drug: Tocilizumab","Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days|Duration of Increased Supplemental Oxygen Requirement from Baseline","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0515","April 4, 2020","July 2020","December 2020","April 2, 2020",,"May 1, 2020","University of Chicago Medicine, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04331795"
391,"NCT04396106","Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19","Drug: AT-527|Other: Placebo","Proportions (active vs. placebo) of subjects who progress to respiratory failure|Proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events|Time to clinical recovery","Atea Pharmaceuticals, Inc.","All","45 Years to 80 Years   (Adult, Older Adult)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AT-03A-001","May 2020","July 2020","August 2020","May 20, 2020",,"May 20, 2020","Atea Study Site, Sacramento, California, United States|Atea Study Site, San Diego, California, United States|Atea Study Site, Chicago, Illinois, United States|Atea Study Site, Baltimore, Maryland, United States|Atea Study Site, Boston, Massachusetts, United States|Atea Study Site, Saint Louis, Missouri, United States|Atea Study Site, Cincinnati, Ohio, United States|Atea Study Site, Cleveland, Ohio, United States|Atea Study Site, Columbus, Ohio, United States|Atea Study Site, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04396106"
392,"NCT04333225","Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers",,"Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","Rate of COVID-19 positive conversion|Time-to-first clinical event","Baylor Research Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","228","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","020-132","April 3, 2020","July 30, 2020","July 30, 2020","April 3, 2020",,"May 5, 2020","Baylor University Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04333225"
393,"NCT04335097","Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation","HSC19","Recruiting","No Results Available","COVID 19","Device: Biosensors","Stop home isolation|NEWS score|Clinic at hospitalization|Symptoms developed|Relative/peers evaluation of the patient|Serious of symptoms at admittance hospital","Lars Wik|University of Stavanger|Oslo University Hospital|Norwegian Telemedicine|University of Basque Country (UPV/EHU)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","214","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","127157","April 22, 2020","April 8, 2021","December 20, 2025","April 6, 2020",,"May 13, 2020","Lillestrom legevakt, Lillestrom, Norway",,"https://ClinicalTrials.gov/show/NCT04335097"
394,"NCT04351724","Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","ACOVACT","Recruiting","No Results Available","COVID-19","Drug: Chloroquine or Hydroxychloroquine|Drug: Lopinavir/Ritonavir|Other: Best standard of care|Drug: Rivaroxaban|Drug: Thromboprophylaxis|Drug: Candesartan|Drug: non-RAS blocking antihypertensives|Drug: Clazakizumab|Drug: placebo for clazakizumab","sustained improvement (>48h) of one point on the WHO Scale|Time to improvement on WHO Scale|Mean change in the ranking on an ordinal scale from baseline|time to discharge or a National Early Warning Score (NEWS) ≤2 (maintained for 24h), whichever occurs first|change from baseline in National Early Warning Score (NEWS)|Oxygenation free days|Incidence of new oxygen use during the trial|duration of oxygen use during the trial|Ventilator free days until day 29|Incidence of new mechanical ventilation use during the trial|duration of mechanical ventilation use during the trial|Viral load/viral clearance|Duration of Hospitalization|Mortality|Obesity - mortality|Obesity - duration of hospitalization|Obesity - ICU admission|Obesity - new oxygen use|Drug-drug interactions with lopinavir/ritonavir|Renin Angiotensin System (RAS) fingerprint","Medical University of Vienna|Kaiser Franz Josef Hospital|SMZ-Ost Donauspital|Otto Wagner Hospital|Hospital Hietzing|Wilhelminenspital Vienna|Medical University Innsbruck","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2|Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACOVACT","April 16, 2020","December 1, 2020","December 31, 2020","April 17, 2020",,"April 24, 2020","Medical University of Innsbruck, Innsbruck, Tirol, Austria|Medical University of Vienna, Vienna, Austria|Wilhelminenspital, Vienna, Austria|SMZ Süd Kaiser Franz Josef Spital, Vienna, Austria|KH Hietzing, Vienna, Austria|SMZ Baumgartner Höhe Otto Wagner Spital, Vienna, Austria|SMZ Ost Donauspital, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04351724"
395,"NCT04344444","Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease","RCT","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Most severe outcome","LCMC Health","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID 2020-001","April 10, 2020","April 10, 2021","December 10, 2021","April 14, 2020",,"April 14, 2020","University Medical Center New Orleans, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04344444"
396,"NCT04373889","COVID-19 Among Healthcare Workers in Belgian Hospitals","COVHECBEHO","Recruiting","No Results Available","SARS-CoV-2|COVID-19",,"Change of prevalence of COVID-19 infection among Belgian active hospital healthcare workers (HCW)|Change of seroprevalence of SARS-CoV-2 among Belgian active hospital HCW|Change in new cases (incidence) of COVID-19 among Belgian hospital HCW|Change in SARS-CoV-2 seroconversion among Belgian hospital HCW|Sensitivity and specificity of serological tests|Sensitivity and specificity of saliva sampling method (sampling with Oracol or equivalent)|Validate the nasal swab against the standard|Potential risk factors for the infection|The proportion of asymptomatic cases among new cases that develop during a period of 5 months|The presence of virus shedding in urine, feces and sperm as well as cellular immune response","Sciensano|Institute of Tropical Medicine Antwerp","All","18 Years and older   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Sciensano","April 22, 2020","September 27, 2020","September 27, 2020","May 5, 2020",,"May 5, 2020","Sciensano, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04373889"
397,"NCT04359264","Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial","DISTANSE COVID","Not yet recruiting","No Results Available","COVID-19","Other: Cash transfer","Symptoms consisent with COVID-19|Number of close contacts|Number of participants with positive test for COVID-19|Self-reported health based on the single question: ""In general, would you say your health is..""|Ability to make ends meet based on the single question: ""At the end of the month, are you able to make ends meet?""","St. Michael's Hospital, Toronto","All","18 Years and older   (Adult, Older Adult)","Not Applicable","392","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20-081","April 20, 2020","December 31, 2020","June 30, 2021","April 24, 2020",,"April 24, 2020","Municipality of Assiginack Family Health Team, Assiginack, Ontario, Canada|St Michael's Hospital Academic Family Health Team, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04359264"
398,"NCT04344080","Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19","CYTOCOV-19","Recruiting","No Results Available","COVID-19","Device: CytoSorb-Therapy","Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours|Change in organ dysfunction|Lactate clearance|Renal replacement therapy|Extracorporeal Membrane Oxygenation|ICU length of stay|Time on mechanical ventilation|Cumulative catecholamine dose|Overall and ICU mortality|Change of plasma Interleukin-6 (IL6) level|Change of plasma Interleukin-10 (IL10) level|Change of plasma Procalcitonin (PCT) level|Change of HLA-DR level|Change of TNF alpha level after ex-vivo stimulation","Universitätsklinikum Hamburg-Eppendorf","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CYTOCOV-19|U1111-1250-2078|DRKS00021199","April 1, 2020","December 2020","February 2021","April 14, 2020",,"April 14, 2020","University Medical Center Hamburg-Eppendorf, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT04344080"
399,"NCT04377659","Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Tocilizumab","Progression of respiratory failure or death","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-185","May 1, 2020","May 1, 2021","May 1, 2021","May 6, 2020",,"May 6, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04377659"
400,"NCT04352465","Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients",,"Not yet recruiting","No Results Available","COVID-19","Drug: Methotrexate","Change in clinical conditions|Change of Clinical symptoms - respiratory rate|Hypoxia|Changes of blood oxygen|Inflammatory parameters|Evolution of Acute Respiratory Syndrome|Hospital discharge|ICU discharge|Rate of mortality","Azidus Brasil|InCor Heart Institute|Hospital Santa Marcelina|PREVENT SENIOR PRIVATE OPERADORA DE SAÚDE LTDA","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","42","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LDE-MTX_COVID19","May 1, 2020","June 30, 2020","November 30, 2020","April 20, 2020",,"April 29, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04352465"
401,"NCT04380779","Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses","BLEEDING","Recruiting","No Results Available","COVID-19",,"Bleeding events and complications","Manuel Monreal|Foundation for the study of VTE diseases. (FUENTE)","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","BLEEDING042020","April 13, 2020","April 13, 2025","June 13, 2025","May 8, 2020",,"May 8, 2020","Manuel Monreal, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04380779"
402,"NCT04381871","Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients","GA&COVID19","Not yet recruiting","No Results Available","COVID 19","Dietary Supplement: Acacia Senegal|Dietary Supplement: Pectin","Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks )|Mortality rate|Determine viral load in each patient","Al-Neelain University|University of Khartoum","All","5 Years to 90 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GA& COVID19","June 1, 2020","August 1, 2020","September 1, 2020","May 11, 2020",,"May 12, 2020","Omdurman Teaching Hospital, Khartoum, Omdurman, Sudan|Jabra Hospital,, Khartoum, Sudan",,"https://ClinicalTrials.gov/show/NCT04381871"
403,"NCT04352751","Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020",,"Recruiting","No Results Available","Covid-19","Other: convalescent plasma","Change in COVID-19 severity status","Hilton Pharma","All","18 Years to 55 Years   (Adult)","Not Applicable","2000","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PIPK- 0000 /NIBD-0000/2020","May 1, 2020","April 2021","April 2021","April 20, 2020",,"May 15, 2020","National Institute of Blood Diseases and Bone Marrow Transplantation (NIBD), Karachi, Sindh, Pakistan",,"https://ClinicalTrials.gov/show/NCT04352751"
404,"NCT04389801","Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection",,"Not yet recruiting","No Results Available","Covid 19","Drug: Desferal 500 MG Injection","Mortality rate|Duration of severe symptoms","Hesham Al-Inany|Cairo University","All","Child, Adult, Older Adult","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","0012","June 1, 2020","September 30, 2020","December 31, 2020","May 15, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04389801"
405,"NCT04348448","Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19","Drug: Canakinumab 150 MG/ML [Ilaris]","intensive care treatment|ICU stay times|% died after 1 month after treatment|hospitalization|adverse event","AUSL Romagna Rimini","All","18 Years to 100 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CANASCOV","April 2020","July 2020","September 2020","April 16, 2020",,"April 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04348448"
406,"NCT04365816","NutriCovid30 : Nutritional Evaluation for Covid-19 Infection at D30",,"Not yet recruiting","No Results Available","COVID-19","Other: Interview","Evaluation of food intake at 1 month after discharge from hospital for COVID|Weight variation during the infection|Clinical signs limiting food intake|Factors limiting food intake|Implemented nutritional strategy|Pre-existing chronic disorders|Covid-19 repercussions","University Hospital, Grenoble|University Grenoble Alps","All","18 Years and older   (Adult, Older Adult)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A01120-39","May 2020","July 2020","November 2020","April 28, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04365816"
407,"NCT04393246","mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)",,"Not yet recruiting","No Results Available","COVID-19","Drug: EDP1815|Drug: Dapagliflozin|Drug: Ambrisentan|Other: Standard of care","Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure|Change in biomarkers known to be associated with progression of COVID-19 compared to baseline|Change in therapy-specific markers of pharmacodynamic response in patients receiving EDP1815 or Dapagliflozin+Ambrisentan compared to baseline|Change in clinical status as assessed on 7-point ordinal scale compared to baseline|Time to each of the individual endpoints of the composite primary outcome measure|Proportion of patients with adverse events of special interest in each treatment arm|Time to Sp02 >94% on room air|Time to first negative SARS-CoV2 PCR|Duration of oxygen therapy|Duration of hospitalisation|All-cause mortality at day 28|Time to clinical improvement","Cambridge University Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1407","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TACTIC-E","May 20, 2020","January 20, 2021","May 20, 2021","May 19, 2020",,"May 19, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04393246"
408,"NCT04344925","Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19",,"Not yet recruiting","No Results Available","COVID-19","Device: Aerosol-reducing Mask|Device: Standard Mask","Total Leak Volume of Non Invasive Ventilation Mask|Glasgow Coma Scale(GCS)|Respiratory Rate|Heart Rate|Metabolic Data: Blood Gas Measurements|Metabolic Data: Bicarbonate (HC03)|Metabolic Data: Partial Pressure of Carbon Dioxide (PaC02)|Metabolic Data: Partial Pressure of Oxygen (Pa02)","Lawson Health Research Institute","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","137654","April 2020","June 2020","August 2020","April 14, 2020",,"April 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04344925"
409,"NCT04375761","COVID-19: Human Epidemiology and Response to SARS-CoV-2","HEROS","Enrolling by invitation","No Results Available","Coronavirus Disease 2019 (COVID-19)|SARS-CoV-2","Procedure: Collection of Biological Samples|Procedure: Symptom and Exposure Surveys","Cumulative Incidence of SARS-CoV-2 RNA Detection in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period|Percent of Index Participants and Their Household Contacts with Detectable SARS-CoV-2-Specific Antibodies in Serum Over the Study/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants with Asthma and Other Atopic Disease Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period|Percent of Index Participants with Asthma and Other Atopic Disease with Detectable SARS-CoV-2-Specific Antibodies in Serum Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period|Changes in the Nasal Transcriptome Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period|Changes in the Nasal Transcriptome Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants with Asthma and Other Atopic Disease Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period|Symptoms Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants using Topical Steroids Compared to Index Participants that are Not Using Topical Steroids Over the Study/Surveillance Period|Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants Using Topical, Oral, or Inhaled Steroids Compared to Index Participants that are Not Using Topical, Oral, or Inhaled Steroids During the Study/Surveillance Period|Analysis of Factors, Baseline and Prior History, for Possible Association with the Cumulative Incidence of SARS-COV-2 Detection in Nasal Samples: Index Participants and Their Household Contacts Over the Study/Surveillance Period","National Institute of Allergy and Infectious Diseases (NIAID)|Rho, Inc.","All","Child, Adult, Older Adult",,"8000","NIH|Industry","Observational","Observational Model: Family-Based|Time Perspective: Prospective","DAIT-COVID-19-001","May 1, 2020","December 2020","December 2020","May 5, 2020",,"May 18, 2020","Children's Hospital Colorado: Inner City Asthma Consortium (ICAC) Site, Aurora, Colorado, United States|Children's Hospital Colorado: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) Site, Aurora, Colorado, United States|Children's National Medical Center: Inner City Asthma Consortium (ICAC) Site, Washington, District of Columbia, United States|Massachusetts General Hospital:Childhood Microbiome (CHIME) and Wheezing Index (WIND) Site, Boston, Massachusetts, United States|Boston Children's Hospital: School Inner-City Asthma Study (SICAS-2), Environmental Assessment of Sleep in Youth (EASY), Severe Asthma Research Program (SARP) and Preventing Asthma in High Risk Kids (PARK) Site, Boston, Massachusetts, United States|Boston Medical Center: Inner City Asthma Consortium (ICAC) Site, Boston, Massachusetts, United States|Henry Ford Health System: Inner City Asthma Consortium (ICAC) Site, Detroit, Michigan, United States|Henry Ford Health System: Microbes, Asthma, Allergy and Pets (MAAP) and Wayne County Health, Environment, Allergy, and Asthma Longitudinal Study (WHEALS) Site, Detroit, Michigan, United States|St. Louis Children's Hospital: Inner City Asthma Consortium (ICAC) Site, Saint Louis, Missouri, United States|Columbia University Medical Center: Inner City Asthma Consortium (ICAC) Site, New York, New York, United States|Cincinnati Children's Hospital Medical Center: Greater Cincinnati Pediatric Clinic Repository (GCPCR) and Mechanisms of Progression of Atopic Dermatitis to Asthma in Children (MPAACH) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center: Inner City Asthma Consortium (ICAC) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center:Cincinnati Childhood Allergy & Air Pollution Study (CCAAPS) Site, Cincinnati, Ohio, United States|Vanderbilt University Medical Center: Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE) Site, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center: Inner City Asthma Consortium (ICAC) Site, Dallas, Texas, United States|University of Wisconsin Hospital and Clinics: Childhood Origins of Asthma (COAST) Site, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics: Wisconsin Infant Study Cohort (WISC) Site, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04375761"
410,"NCT04387292","Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic","SOCOVID","Recruiting","No Results Available","COVID19|Ophthalmopathy","Procedure: Ophthalmologic exam","Description of the ophthalmological problems observed","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","MMT_2020_12","June 2020","February 2021","February 2021","May 13, 2020",,"May 13, 2020","Fondation A de Rothschild, Paris, France",,"https://ClinicalTrials.gov/show/NCT04387292"
411,"NCT04397718","Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization","HITCH","Not yet recruiting","No Results Available","CoVID19","Drug: Degarelix|Other: Saline","A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.|Time to clinical improvement|Inpatient mortality|Duration of hospitalization|Duration of intubation for mechanical ventilation.|Time to normalization of temperature.|Maximum severity of COVID19 illness.","VA Office of Research and Development","Male","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","198","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","COVID19-8900-15","June 1, 2020","October 1, 2020","October 1, 2020","May 21, 2020",,"May 21, 2020","VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Brooklyn Campus of the VA NY Harbor Healthcare System, Brooklyn, NY, Brooklyn, New York, United States|Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04397718"
412,"NCT04367402","COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)","COST ACTION","Recruiting","No Results Available","COVID-19","Other: BioMedomics COVID-19 IgM-IgG Rapid Test","Retrospective study on individuals with or without symptoms to verify the reliability of a prognostic/diagnostic test based on IgM/IgG analysis.|ACE2 expression in patients with COVID-19 infection","Azienda Ospedaliera San Paolo","All","18 Years and older   (Adult, Older Adult)",,"600","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","2020/ST/057","March 30, 2020","April 24, 2020","September 2020","April 29, 2020",,"April 30, 2020","AO San Paolo, Milan, IT, Italy",,"https://ClinicalTrials.gov/show/NCT04367402"
413,"NCT04328441","Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine","BCG-CORONA","Recruiting","No Results Available","COVID-19","Drug: BCG Vaccine|Drug: Placebo","Health Care Workers absenteeism|the cumulative incidence of documented COVID-19|the cumulative incidence of Hospital Admission due to documented COVID-19|the number of days of unplanned absenteeism, because of documented COVID-19|the cumulative incidence of self-reported acute respiratory symptoms or fever|the cumulative incidence of death due to documented COVID-19|the cumulative incidence of Intensive Care Admission due to documented COVID-19|the number of days of absenteeism, because of imposed quarantine as a result of exposure to COVID-19|the number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented COVID-19|the number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|the number of days of self-reported fever (≥38 gr C)|the cumulative incidence of self-reported fever (≥38 gr C)|the number of days of self-reported acute respiratory symptoms|the cumulative incidence of self-reported acute respiratory symptoms|the cumulative incidence of death for any reason|the cumulative incidence of Intensive Care Admission for any reason|the cumulative incidence of Hospital Admission for any reason|• the cumulative incidence and magnitude of plasma/serum antibodies (IgA,M,G) and SARS-CoV-2-specific antibodies at 12 weeks after vaccination and at the end of the study period","UMC Utrecht|Radboud University","All","18 Years and older   (Adult, Older Adult)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NL73249.041.20","March 25, 2020","October 25, 2020","December 25, 2020","March 31, 2020",,"April 29, 2020","Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Radboud UMC, Nijmegen, Gelderland, Netherlands|Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands|Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands|Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04328441"
414,"NCT04391920","Registry of CytoSorb Therapy in COVID-19 ICU Patients","CTC REGISTRY","Not yet recruiting","No Results Available","COVID-19","Device: CytoSorb 300 mL device","ICU mortality|Duration of ECMO after start of CytoSorb|Duration of mechanical ventilatory support after start of CytoSorb|Duration of pharmacologic hemodynamic support after start of CytoSorb|Change in serum concentrations of inflammatory biomarkers after start of CytoSorb","CytoSorbents, Inc","All","18 Years and older   (Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-001|FDA EUA","May 2020","May 2021","August 2021","May 18, 2020",,"May 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04391920"
415,"NCT04365634","A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.",,"Completed","No Results Available","COVID-19",,"Find the prediction factors associated with hospitalized death of patients with COVID-19 by univariate and multivariate analysis|Demographics and clinical characteristics|Laboratory parameters and radiography image features|Treatment, complications and clinical outcomes","Tongji Hospital","All","Child, Adult, Older Adult",,"306","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","TJ20200202","February 2, 2020","March 15, 2020","April 1, 2020","April 28, 2020",,"April 28, 2020","Tongji Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04365634"
416,"NCT04354610","Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection","Nancy-CovH-AKI","Recruiting","No Results Available","COVID 19","Procedure: Biological samples specific to research|Procedure: Clinical examination|Procedure: Telephone follow-up","Worsening of renal function by at least KDIGO grade 1 during hospitalization for Covid-19 infection|Troponin greater than 99th percentile during hospitalization for Covid-19 infection|AKI KDIGO grade 1 or higher in hospitalisation (approach with AND without a priori)|Elevation of troponin> 99th percentile in hospitalisation (approach with AND without a priori)|AKI KDIGO grade 1 or higher|Association with troponin elevation >99th|Association with elevation of serum creatinine >30%|With the onset of chronic renal failure (eDFG <60 ml / min / 1.73m2)|The occurrence of cardiovascular events (stroke, myocardial infarction, hospitalisation for heart failure, cardiovascular death) during hospitalisation and three months after discharge from hospital|The occurrence of death from any cause during hospitalisation and three months after discharge from hospital","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","57","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2020PI072","April 27, 2020","July 18, 2020","October 18, 2020","April 21, 2020",,"May 6, 2020","CHRU de Nancy, Nancy, France|CHRU de Nancy, Vandœuvre-lès-Nancy, France",,"https://ClinicalTrials.gov/show/NCT04354610"
417,"NCT04385849","Study of the Safety of Therapeutic Treatment With an Immunomodulary Agent (N-803 in Adults With COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Biological: N-803|Other: Saline","Preliminary safety and efficacy evaluation of N-803 by adverse event (AE) incidence|Preliminary safety and efficacy evaluation of N-803 by subject clinical status using a the 7-point ordinal scale.|Preliminary safety and efficacy evaluation of N-803 by changes in lymphocyte counts|Further evaluate efficacy of N-803 using changes to the National Early Warning Score (NEWS)|Further evaluate the safety of N-803 using change from baseline in hemoglobin|Further evaluate the safety of N-803 using change from baseline in platelets|Further evaluate the safety of N-803 using change from baseline in white blood cell count","ImmunityBio, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","QUILT-COVID-19","May 11, 2020","July 11, 2020","July 11, 2020","May 13, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04385849"
418,"NCT04307693","Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)",,"Terminated","No Results Available","COVID-19","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate","Viral load|Viral load change|Time to clinical improvement (TTCI)|Percentage of progression to supplemental oxygen requirement by day 7|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7|adverse effects|Concentration of Lopinavir/ritonavir and hydroxychloroquine","Asan Medical Center","All","16 Years to 99 Years   (Child, Adult, Older Adult)","Phase 2","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S2020-0472-0001","March 11, 2020","April 30, 2020","April 30, 2020","March 13, 2020",,"May 25, 2020","Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04307693"
419,"NCT04329650","Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID-19","Drug: Siltuximab|Drug: Methylprednisolone","Proportion of patients requiring ICU admission at any time within the study period.|Days of stay in the ICU during the study period.|Days until resolution of fever defined as body temperature (axillary ≤ 36.6 ° C, oral ≤ 37.2 ° C, or rectal or tympanic ≤ 37.8 ° C) for at least 48 hours, without administration of antipyretics or until hospital discharge.|Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.|Days with hypoxemia (SpO2 <93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.|Proportion of patients using mechanical ventilation at 29 days.|Days with use of mechanical ventilation at 29 days.|Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.|Days of hospitalization among survivors at 29 days.|Mortality rate from any cause at 29 days.|Proportion of patients with serious adverse events at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute <500 / mm3) at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.|Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.|Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.|Proportion of patients with gastrointestinal perforation at 29 days.|Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.|Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.|Proportion of patients with ALT≥ 3 times ULN (for patients with initial values normal) or> 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9.|Changes from baseline in chest Rx at days 1, 3 and 5.","Judit Pich Martínez|Fundacion Clinic per a la Recerca Biomédica","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SILCOR-COVID-19","April 15, 2020","May 20, 2020","May 20, 2020","April 1, 2020",,"April 17, 2020","Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitari Mútua de Terrassa, Terrassa, Spain",,"https://ClinicalTrials.gov/show/NCT04329650"
420,"NCT04344236","Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Saline oral/nasal rinse|Drug: 0.5% Povidone/Iodine oral/nasal rinse|Drug: 0.12% Chlorhexidine oral/nasal rinse","Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx|Oxygen requirement of the patient|Oxygen saturation of the patient","NYU Langone Health","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00444","April 9, 2020","May 1, 2020","May 9, 2020","April 14, 2020",,"April 14, 2020","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04344236"
421,"NCT04400461","Short-term Physical Function Outcomes in Severe COVID-19 Patients Admitted to ICU for Invasive Mechanical Ventilation",,"Recruiting","No Results Available","COVID-19","Other: Data collection and clinical testing of subjects","Medical Research Council sum score (MRC- SS).|The Functional Status Score for the ICU (FSS-ICU)|Age|Sex|Body Mass Index|Baseline mobility|APACHE II score|Length of stay in ICU|Number of days on mechanical ventilation|Polyneuropathy diagnosis|Number of days on Neuromuscular Blockers|Episodes of prone positioning|Length of stay in hospital|Continuation of care","Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","All","18 Years to 80 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","165/20","May 15, 2020","September 30, 2020","November 15, 2020","May 25, 2020",,"May 25, 2020","Medical ICU. Hospital Universitario Ramón y Cajal, Madrid, Spain|Surgical ICU. Hospital Universitario Ramón y Cajal, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04400461"
422,"NCT04363814","Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID-19","Biological: Bactek-R","Clinical recovery|Clinical worsening|Clinical severity|Time to symptoms remission|Medication Use|Hospitalization time|Blood routine test|Heart rate|Blood pressure|Cardiac auscultation|Oxygen saturation|Adverse events","Inmunotek S.L.|BioClever 2005 S.L.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MV130-SLG-35","June 10, 2020","July 1, 2020","July 31, 2020","April 27, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04363814"
423,"NCT04345692","A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","OAHU-COVID19","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","i. Clinical status|Oxygenation|Mechanical Ventilation|Hospitalization|Mortality","Queen's Medical Centre","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 3","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RA-2020-018","March 26, 2020","December 31, 2021","December 31, 2021","April 14, 2020",,"April 14, 2020","Queen's Medical Center, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT04345692"
424,"NCT04397562","A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19","CORONA","Recruiting","No Results Available","COVID-19","Drug: Levilimab|Drug: Placebo","Mortality rate","Biocad","All","18 Years and older   (Adult, Older Adult)","Phase 3","204","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BCD-089-4","April 29, 2020","April 2021","April 2021","May 21, 2020",,"May 21, 2020","City Clinical Hospital № 15 named. O.M. Filatov, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04397562"
425,"NCT04331899","Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19","COVID-Lambda","Recruiting","No Results Available","COVID-19","Drug: Peginterferon Lambda-1a|Other: Placebo","Duration of Viral shedding of SARS-CoV-2 by qRT-PCR","Stanford University","All","18 Years to 64 Years   (Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","55619","April 24, 2020","May 31, 2021","May 31, 2022","April 2, 2020",,"April 27, 2020","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04331899"
426,"NCT04362332","Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19","ARCHAIC","Recruiting","No Results Available","COVID-19","Drug: Chloroquine Sulfate|Drug: Hydroxychloroquine|Other: Standard supportive care","Composite endpoint with disease progression defined as a NEWS2score ≥ 7 within 14 days or resulting in admission to Intensive/Medium Care unit or resulting in death within 14 days.|Side effects","UMC Utrecht|ZonMw: The Netherlands Organisation for Health Research and Development","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 4","950","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL73529.041.20 versie 3","April 14, 2020","April 14, 2021","May 14, 2021","April 24, 2020",,"April 24, 2020","UMCU, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04362332"
427,"NCT04323631","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Other: The control group will not receive hydroxychloroquine","Number patients developing severe infection or death","Rambam Health Care Campus|Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1116","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0154-20-RMB","March 2020","December 2020","December 2020","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04323631"
428,"NCT04331834","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic","PrEP_COVID","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebos","Confirmed cases of a COVID-19|SARS-CoV-2 seroconversion|Occurrence of any adverse event related with hydroxychloroquine treatment|Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers|Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19|COVID-19 Biobank","Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Laboratorios Rubió","All","18 Years and older   (Adult, Older Adult)","Phase 3","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PrEP_COVID","April 3, 2020","October 3, 2020","October 30, 2020","April 2, 2020",,"April 7, 2020","ISGlobal, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04331834"
429,"NCT04331470","Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine","Clear chest CT-scan|PCR test|Physical statues of patient","Fasa University of Medical Sciences","All","15 Years to 100 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","97548","April 4, 2020","April 20, 2020","May 20, 2020","April 2, 2020",,"April 13, 2020","Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04331470"
430,"NCT04371926","Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk","PREVENT","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate","Time to reach normal body temperature|Development of COVID-19 symptoms during HCQ preventive therapy in staff|COVID-19 test result at follow-up in patients|Worsening of symptoms in COVID-19 patients","Texas Cardiac Arrhythmia Research Foundation","All","18 Months to 85 Years   (Child, Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","TCAI_PREVENT","June 2020","June 2021","July 2021","May 1, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04371926"
431,"NCT04348383","Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.","DEFACOVID","Recruiting","No Results Available","COVID19","Drug: Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|Drug: Placebo 250 cc 24 hours continuous infusion for 15 days","1. Mortality rate|Clinical improvement by WHO|Clinical improvement by NEWS2 scales|Biologic response|Radiological response|Collection and storage of biological samples","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IMIB-DFC-2020-02","April 8, 2020","July 8, 2020","August 8, 2020","April 16, 2020",,"April 17, 2020","Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT04348383"
432,"NCT04356677","Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19",,"Not yet recruiting","No Results Available","COVID19","Drug: 50 mg/mL Virazole|Drug: 100 mg/mL Virazole","Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment|Time to recover gas exchange to a PaO2/FiO2 ≥300 for at least 24 hours.|Time to reach peripheral capillary oxygen saturation (Sp02) >94% for at least 24 hours.","Bausch Health Americas, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BHC-RIB-5401-HC","April 2020","April 2021","April 2021","April 22, 2020",,"April 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04356677"
433,"NCT04313023","The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2",,"Not yet recruiting","No Results Available","COVID-19","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Severity of COVID-19|Incidence of SARS-CoV-2 infection|ICU admission|Mechanical ventilation|Mortality","Pulmotect, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PUL-042-501","May 2020","September 2020","October 2020","March 18, 2020",,"May 6, 2020","Ascension St. John, Tulsa, Oklahoma, United States|Texas Center for Drug Development, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04313023"
434,"NCT04364763","The Effect of RBT-9 [Stannous Protoporphyrin (SnPP)] on Progression of COVID-19 Infection in High-Risk Individuals (The PREVENT Study)",,"Not yet recruiting","No Results Available","COVID-19","Drug: Stannous Protoporphyrin (90 mg)|Drug: 0.9% sodium chloride (normal saline)","Evaluate the effect of RBT-9 (Stannous Protoporphyrin) versus placebo on clinical status of COVID-19 patients as measured using the 8-point World Health Organization (WHO) Ordinal Clinical Scale|Time to first occurrence of death from any cause or new/worsened organ dysfunction|All-cause survival|Respiratory distress rate|Fever incidence|Acute kidney injury (AKI) incidence|New or worsening congestive heart failure (HF)|Hospitalization status|Ventricular tachycardia or fibrillation lasting at least 30 seconds and/or associated with hemodynamic instability or pulseless electrical activity, or resuscitated cardiac arrest|Oxygen-free days|Intensive care unit (ICU) status|Days on ventilator|Time to and duration of vasopressor or inotrope utilization|Dialysis status","Renibus Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","252","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REN-005","June 1, 2020","June 30, 2021","December 31, 2021","April 28, 2020",,"May 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04364763"
435,"NCT04336254","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Other: Intravenous saline injection (Placebo)","TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein (mg/L)","Renmin Hospital of Wuhan University|Beijing SH Bio-Tech Corporation, Beijing (CN)|Utooth Biological Technology Co., Ltd. Hubei (CN)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020K-G005|hDPSC-CoVID-2019-02-2020","April 6, 2020","December 31, 2020","March 31, 2021","April 7, 2020",,"April 7, 2020","Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04336254"
436,"NCT04292899","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)",,"Recruiting","No Results Available","COVID-19","Drug: Remdesivir|Drug: Standard of Care","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events","Gilead Sciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","6000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-540-5773|2020-000841-15","March 6, 2020","May 2020","May 2020","March 3, 2020",,"May 13, 2020","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente-Oakland, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, 270-05 76th Ave, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04292899"
437,"NCT04332094","Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","TOCOVID","Recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin","In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III","All","18 Years and older   (Adult, Older Adult)","Phase 2","276","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIBSP-COV-2020-23","April 2, 2020","September 2020","October 2020","April 2, 2020",,"April 7, 2020","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04332094"
438,"NCT04312997","The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection",,"Recruiting","No Results Available","COVID-19","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Severity of COVID-19|SARS-CoV-2 infection|Severity of COVID-19 over 14 days|Severity of COVID-19 symptoms|ICU admission|Mechanical Ventilation|Mortality","Pulmotect, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PUL-042-502","May 2020","September 2020","October 2020","March 18, 2020",,"May 12, 2020","St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Ascension St. John, Tulsa, Oklahoma, United States|Texas Center for Drug Development, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04312997"
439,"NCT04385264","#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19","#StayHome","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Mannitol","Proportion of poor outcomes (in index cases)|Secondary household attack rate (in household contacts)|Subjective disease severity (in index cases)|Rate of acute respiratory distress syndrome (in index cases)|Severity of radiological lung pathology (in index cases)|Objective disease severity (in index cases)|Safety: Unintended toxic HCQ accumulation (in index cases)|Safety: Adverse events (in index cases)|Social distancing knowledge, attitudes and practices amongst index cases and household contacts","Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Unisante","May 12, 2020","August 2020","October 2020","May 12, 2020",,"May 12, 2020","Unisanté, Lausanne, Vaud, Switzerland",,"https://ClinicalTrials.gov/show/NCT04385264"
440,"NCT04370782","Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline","Time to Resolution of Symptoms relative to baseline (day 1 of trial)|Number of participants hospitalized and/or requiring repeat ER visits|ICU Length of Stay|Ventilator|Severity of symptoms|Number of participants with adverse events due to drug regimen|Number of participants with QTc prolongation >500ms","St. Francis Hospital, New York","All","30 Years and older   (Adult, Older Adult)","Phase 4","750","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-21","April 28, 2020","September 30, 2020","December 31, 2020","May 1, 2020",,"May 18, 2020","St Francis Hospital, Roslyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT04370782"
441,"NCT04334980","Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Biological: bacTRL-Spike|Other: Placebo","Frequency of Adverse Events|SARS-CoV-2 antibodies|Incidence of COVID-19 infection|bacTRL-Spike in stool post-vaccination|Seroconversion of circulating anti-Spike IgG antibodies & stability of serum IgG titers|Effectiveness of intestinal colonization of the probiotic-based bacTRL-Spike oral vaccine","Symvivo Corporation","All","19 Years to 45 Years   (Adult)","Phase 1","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","bacTRL-Spike-1","April 30, 2020","August 31, 2021","December 31, 2021","April 6, 2020",,"April 22, 2020","Vaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia., Vancouver, British Columbia, Canada|Canadian Center for Vaccinology Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT04334980"
442,"NCT04352764","ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings",,"Recruiting","No Results Available","Covid19","Diagnostic Test: CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test","prevalence of COVID-19 exposure|correlation between the test results with the presence or lack of COVID-19 symptoms or illness|correlate pre-existing risk factors with test results and baseline symptoms|correlate subsequent healthcare utilization with test results and baseline symptoms","Texas Cardiac Arrhythmia Research Foundation","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","TCAI_COVID-19","March 27, 2020","December 31, 2020","January 31, 2021","April 20, 2020",,"April 27, 2020","St. David's Medical Center, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04352764"
443,"NCT04374487","A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications",,"Not yet recruiting","No Results Available","COVID 19","Drug: Convalescent Plasma|Other: Standard Care Therapy","The primary outcome is a composite measure of the avoidance of - 1. Progression to severe ARDS (P/F ratio 100) and 2. All-cause Mortality at 28 days|Time to symptom resolution-Fever,Shortness of Breath,Fatigue|Hospital length of stay|Change in SOFA pre and post transfusion|Duration of respiratory support required a. Duration of Invasive Mechanical Ventilation b. Duration of Non-Invasive|Radiological improvement|Adverse events (AE) associated with transfusion|To measure the change in RNA levels (Ct values) of SARS-CoV-2 from RT-PCR [Time Frame: Days 0, 1, 3, and 7 after transfusion]|Levels of bio-markers pre and post transfusion|Need of Vasopressor use","Max Healthcare Insititute Limited","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MHC-COVID-19-CP","May 9, 2020","May 9, 2021","May 9, 2021","May 5, 2020",,"May 5, 2020","Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04374487"
444,"NCT04345510","Testing for COVID-19 Infection in Asymptomatic Persons",,"Not yet recruiting","No Results Available","COVID-19 Infection",,"COVID-19 infection","German Cancer Research Center","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19-1.0-DKFZ","April 20, 2020","May 31, 2020","December 31, 2020","April 14, 2020",,"April 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04345510"
445,"NCT04348409","Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Nitazoxanide Tablets|Drug: Placebo","Viral load|Evolution of acute respiratory syndrome|Change in Clinical Condition|Hospital discharge|Rate of mortality within 21-days|Need of mechanical ventilation","Azidus Brasil|Farmoquimica S.A.|Hospital Vera Cruz|Hospital Casa de Saúde - Vera Cruz - Campinas - SP - Brazil|Centro de Genomas - UNIFESP|Emilio Ribas Institute of Infectious Diseases","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NITFQM0320OR","April 12, 2020","May 31, 2020","June 30, 2020","April 16, 2020",,"April 22, 2020","Hospital Vera Cruz, Campinas, São Paulo, Brazil|Centro de Genomas, São Paulo, Brazil|Hospital Emílio Ribas, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04348409"
446,"NCT04377711","A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ciclesonide|Drug: Placebo","Percentage of patients hospital admission or death by day 30|All-cause mortality by day 30|COVID-19-related mortality by day 30|Percentage of patients with subsequent emergency department visit or hospital admission for reasons attributable to COVID 19 by day 30|Time to hospital admission or death|Time to alleviation of COVID-19-related symptoms of cough, dyspnea, chills, and feeling feverish, defined as symptom-free for a continuous period of more than 24 hours (ie, > 3 AM/PM assessments)|Change from baseline in oxygen saturation levels|Change from baseline in COVID-19 viral load in nasopharyngel sample nasal secretions at day 30|Safety will be assessed based on adverse events.","Covis Pharma S.à.r.l.","All","12 Years to 100 Years   (Child, Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALV-020-001","May 26, 2020","September 1, 2020","December 1, 2020","May 6, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04377711"
447,"NCT04382729","Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia",,"Recruiting","No Results Available","COVID-19 Pneumonia","Other: Neuromuscular Electrical Stimulation|Other: Physical Therapy Exercise","Short Physical Performance Battery (SPPB) Score|Functional Independence Measure (FIM) Scale Score|Fatigue Severity Scale Score|Muscle Strength|Two Step Test Length|Six Minutes Walking Test Distance|Muscle Thickness","University of Turin, Italy|San Luigi Gonzaga Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","ESC270320","April 17, 2020","July 2020","July 2020","May 11, 2020",,"May 11, 2020","San Luigi Gonzaga Hospital, Orbassano, TO, Italy",,"https://ClinicalTrials.gov/show/NCT04382729"
448,"NCT04353518","Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Other: Placebo","Number of subject acquiring COVID-19 infection|Incidence of Adverse Event and Serious Adverse Event (safety and tolerability)|Number of subject developing Upper Respiratory Tract Infection (URTI) symptoms|Number of subject developing severe COVID-19 infection based on ordinal scale","Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India","All","18 Years and older   (Adult, Older Adult)","Phase 3","4000","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CRSC20005","April 30, 2020","March 30, 2021","May 30, 2021","April 20, 2020",,"April 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04353518"
449,"NCT04349540","Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19","(COVID19_BMT)","Active, not recruiting","No Results Available","COVID19","Other: no intervention","Comparison of inflammatory/immunological biomarkers <72 hours after development of oxygen requirement|Overall survival at 30 and 100 days after development of oxygen requirement|Comparison of 30 and 100 day survival in SCT patients who are vs are not ongoing immunosuppression|Proportion of patients requiring mechanical ventilation|Incidence of secondary HLH (as defined by HS score)","Great Ormond Street Hospital for Children NHS Foundation Trust","All","3 Months and older   (Child, Adult, Older Adult)",,"40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20BO08","April 15, 2020","October 15, 2020","January 15, 2021","April 16, 2020",,"April 16, 2020","Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04349540"
450,"NCT04371744","QT-Logs : Artificial Intelligence for QT Interval Analysis of ECG From Smartwatches in Patient Receiving Treatment for Covid-19","QT-Logs","Recruiting","No Results Available","COVID-19",,"Corrected QT (QTc) interval measurement","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIL 2020-52","April 17, 2020","May 4, 2020","May 11, 2020","May 1, 2020",,"May 1, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT04371744"
451,"NCT04360551","Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients",,"Not yet recruiting","No Results Available","COVID-19","Drug: Telmisartan 40mg|Drug: Placebo","Maximum clinical severity of disease|Incidence of treatment emergent adverse events|Renin angiotensin system peptides|Plasma biomarkers","University of Hawaii","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","H051","July 1, 2020","June 30, 2021","June 30, 2021","April 24, 2020",,"April 24, 2020","University of Hawaii - Manoa, John A Burns School of Medicine UH Clinics at Kakaako, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT04360551"
452,"NCT04384614","Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study","CONNAITRE","Not yet recruiting","No Results Available","Covid 19|BCG Vaccination","Diagnostic Test: Test PCR|Genetic: TDR|Other: Clinical Examination","Differences related to epidemiological demographic characteristics","Direction des Soins de Santé de Base|Eshmoun Clinical Research Centre|Dacima Consulting","All","18 Years to 80 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","ECC2020-07","May 15, 2020","July 15, 2020","July 15, 2020","May 12, 2020",,"May 13, 2020","Eshmoun Clinical Research Centre, Tunis, Tunisia",,"https://ClinicalTrials.gov/show/NCT04384614"
453,"NCT04343989","A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Clazakizumab 25 mg|Drug: Clazakizumab 12.5 mg|Other: Placebo","Cumulative incidence of serious adverse events associated with clazakizumab or placebo|Cumulative incidence of intubation|Time to extubation|Length of ICU stay|Number of patients who present a decrease in C-reactive protein|Patient Survival","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","s20-00392","March 31, 2020","July 1, 2020","July 1, 2020","April 14, 2020",,"May 6, 2020","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04343989"
454,"NCT04348474","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19",,"Suspended","No Results Available","Covid-19","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Change in Clinical Condition|Hospitalization|Rate of mortality within 28-days|Change in Clinical Condition related to comorbidity","Azidus Brasil","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","200","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIAPRE0420OR","April 20, 2020","June 30, 2020","July 31, 2020","April 16, 2020",,"April 22, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04348474"
455,"NCT04358809","Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill",,"Not yet recruiting","No Results Available","COVID-19","Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Other: Placebo","Number of patients with increased disease severity|Incidence of adverse events and serious adverse events (Safety)|Number of COVID-19 patients discharged from hospital|Number of COVID-19 patients transfer to ICU|Number of COVID-19 patients with reduction in disease severity by 1 ordinal scale|Number of of symptom free patients","Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India","All","18 Years and older   (Adult, Older Adult)","Phase 3","480","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRSC20006","April 30, 2020","February 28, 2021","April 30, 2021","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04358809"
456,"NCT04312464","Myocardial Damage in COVID-19",,"Enrolling by invitation","No Results Available","COVID-19|Cardiovascular Diseases","Other: non","The myocardial injury incidence|The risk factors analysis for the death|Clinical characteristics|Clinical course|Cardiovascular comorbidity|Analysis of causes of death","Wuhan Union Hospital, China","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","MD-COVID-19","January 1, 2020","March 15, 2020","March 18, 2020","March 18, 2020",,"March 18, 2020","Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04312464"
457,"NCT04329507","Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)",,"Not yet recruiting","No Results Available","COVID-19|Respiratory Disease","Diagnostic Test: Breath test","To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.|Detection of markers of Covid-19 pneumonia in non-invasive breath samples.|Relationship of this biomarker signature to the presence of SARS-CoV-2 in nasal and throat swabs.|Subsequently, the signature's relationship to other biomarkers of SARS-CoV-2 infection which are currently being explored|In a smaller group of participants, ideally daily non-invasive breath samples will be collected to determine if there are changes between SARS-CoV-2 positive patients and those that are negative until hospital discharge or undue participant burden .","NHS Lothian","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282014","March 25, 2020","March 25, 2020","March 25, 2020","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04329507"
458,"NCT04348435","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",,"Enrolling by invitation","No Results Available","COVID-19","Drug: HB-adMSCs|Drug: Placebos","Incidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9","Hope Biosciences|Hope Biosciences Stem Cell Research Foundation","All","Child, Adult, Older Adult","Phase 2","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allogeneic COVID-19 Protection","April 23, 2020","December 31, 2020","April 30, 2021","April 16, 2020",,"April 30, 2020","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04348435"
459,"NCT04329572","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19",,"Suspended","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days","Azidus Brasil","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","400","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIAPRE0320OR","April 23, 2020","May 31, 2020","June 30, 2020","April 1, 2020",,"April 22, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04329572"
460,"NCT04374591","Inhalable Sodium Bicarbonate: A Possible Adjuvant Treatment of Patients With Novel COVID-19",,"Active, not recruiting","No Results Available","Pneumonia|Covid19","Drug: Sodium Bicarbonate","Time to clinical recovery|Pulmonary recovery status","Mansoura University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sodium Bicarbonate COVID-19","April 1, 2020","June 1, 2020","June 1, 2020","May 5, 2020",,"May 5, 2020","Gomhoria Street, Mansoura, Outside U.S./Canada, Egypt",,"https://ClinicalTrials.gov/show/NCT04374591"
461,"NCT04292730","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",,"Recruiting","No Results Available","COVID-19","Drug: Remdesivir|Drug: Standard of Care","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events","Gilead Sciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","1600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-540-5774|2020-000842-32","March 15, 2020","May 2020","May 2020","March 3, 2020",,"May 20, 2020","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente-Oakland/San Francisco, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente-Oakland/San Francisco, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente-Oakland/San Francisco, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente-Oakland/San Francisco, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente-Oakland/San Francisco, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente-Oakland/San Francisco, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale University, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Cook County General Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UTSW Medical Center, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College NHS Trust, London, Greater London, United Kingdom|NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04292730"
462,"NCT04358549","Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Favipiravir + Standard of Care|Drug: Standard of Care","Time to viral clearance|Status of clinical recovery as measured by the study-specific 6-point ordinal scale on Day 15|Clinical effect of favipiravir + SOC compared to SOC measured by the National Early Warning Score 2 (NEWS2)|Characterize the pharmacokinetics (PK) of favipiravir in plasma: Cmax)|Characterized the pharmacokinetics (PK) of favipiravir in plasma: Cmin|Characterized the pharmacokinetics (PK) of favipiravir in plasma: AUC","Fujifilm Pharmaceuticals U.S.A., Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FAVI-COV-US201","April 17, 2020","August 2020","December 2020","April 24, 2020",,"April 28, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Memorial Health Care, Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04358549"
463,"NCT04347278","Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry","RegCOVID19","Not yet recruiting","No Results Available","SARS-CoV-2","Drug: Patients with the treatment agains COVID19","Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice|Risk factors or modifiers of pharmacological effect such as demographic characteristics, comorbidity or underlying pathology, concomitant medication.|Information on the patterns of use of these drugs (dose, duration of treatment,|Adverse events|Time of hospital admission and/or stay in ICU and maximum severity reached.|Treatments for SARS-CoV-2 positive patients not described in the protocol|healthy survey for patients after their recovery/discharge from hospital.","Instituto de Investigación Marqués de Valdecilla","All","1 Year to 100 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Other","IDI-REM-2020-1","April 15, 2020","October 15, 2020","January 1, 2021","April 15, 2020",,"April 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04347278"
464,"NCT04346615","Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen",,"Recruiting","No Results Available","COVID-19 Infection","Drug: Vazegepant (BHV-3500)|Drug: Placebo","To evaluate efficacy of vazegepant (BHV-3500) compared with placebo in subjects hospitalized with COVID-19 infection requiring supplemental oxygen, using a 6-point ordinal scale.|The number of unique subjects alive and off of oxygen. These are subjects in categories 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.|A subject requiring initiation of invasive mechanical ventilation, non-invasive ventilation, or a high flow nasal cannula is a subject that has any eCRF showing the use of any such device on any day.|The number of unique subjects admitted to an ICU verse those not admitted.|Subjects are alive and respiratory-failure free if they are categorized as being in categories 3, 4, 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.|Subjects are alive and free of either invasive mechanical ventilation or non-invasive ventilation if they are categorized as being in categories 4, 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.|Efficacy on Day 29 will be evaluated using the same 6-point severity scales that is used at Day 15.|Time to improvement of one category on the 6-point severity scale will be determined as the number of days from baseline to the first day that an eCRF indicates a one category improvement in the scale.|A 48-hour improvement in SpO2/FiO2 ratio consists of two consecutive days where the case report forms show a clinically meaningful increase from baseline.|The time to improvement in the in the NEWS2 scale will be determined as the number of days from baseline to the first eCRF that shows an improvement.|A score < 2 for 24 hours on the NEWS2 scale consists of a day where all of the reported NEWS2 scores are < 2.|The change in NEWS2 scores will be determined as the change from baseline at Day 15 and at Day 29.|The number of unique subjects alive and off of oxygen.|The percentage of subjects discharged to home on supplemental oxygen will determined from the unique number of subjects have eCRF pages indicating they were discharged to home while still on supplemental oxygen.|A day with a resting respiratory rate > 24 is a day in which all eCRFs collected for a subject indicate observed respiratory rates > 24 breaths per minute.|A day with supplemental oxygen is one in which any case report form collected on that day indicates the use of any amount of supplemental oxygen.|Time to saturation greater than or equal to 90% on room air is measured by the number of days from baseline to the first day on which an eCRF indicates saturation greater than or equal to 90% without any supplemental oxygenation.|A ventilator free day is a day in which all of the eCRFs collected indicate that the subject was not using a ventilator.|SOFA scores will be determined from eCRFs. Values will be determined for subjects at admission to an ICU and for all subjects still in an ICU at the end of the study (Day 29).|The number of days of hospitalization will be determined from eCRFs. A hospitalization day is any day that it is shown that a subject spent at least spent part of the day in a hospital.|Time to fever resolution, without antipyretics, during two contiguous days .|The number of deaths, SAEs, severe AEs and Grade 3 or 4 laboratory abnormalities will be tabulated as the number of unique subjects meeting those criteria.|The incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infections will be tabulated as the number of unique subjects, reported in eCRFs, as having these conditions at any point in the study|The incidence of intranasal administration reactions will be tabulated, from eCRFs, as the number of unique subjects having such a condition at any point in the study.|The percentage of subjects who develop significant renal disease.","Biohaven Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BHV3500-203","April 25, 2020","July 2020","September 2020","April 15, 2020",,"May 20, 2020","Georgetown University Medical Center, Washington, District of Columbia, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04346615"
465,"NCT04371471","Covid-19 Pandemic Triage Score","STC-19","Active, not recruiting","No Results Available","Sars-CoV2|Covid19","Diagnostic Test: STC-19 score","STC-19 score","Groupe Hospitalier de la Rochelle Ré Aunis|Numa Health International","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020/P04/288","March 1, 2020","April 30, 2020","April 30, 2020","May 1, 2020",,"May 1, 2020","Groupe Hospitalier de la Rochelle Ré Aunis, La Rochelle, France",,"https://ClinicalTrials.gov/show/NCT04371471"
466,"NCT04367714","Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19","COVCKD","Recruiting","No Results Available","COVID|Terminal Renal Insufficiency",,"AAntibody response","Region MidtJylland Denmark|Aarhus University Hospital|Central Jutland Regional Hospital|Aalborg University Hospital","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FHM-1-2020","March 15, 2020","December 1, 2020","December 1, 2021","April 29, 2020",,"April 29, 2020","Godstrup Hospital, Herning, Denmark",,"https://ClinicalTrials.gov/show/NCT04367714"
467,"NCT04359992","Study of Hemostasis in Case of Severe COVID-19","THROMBOVID","Not yet recruiting","No Results Available","COVID-19 Infection","Other: Extra blood sample","Platelet activation intensity with the occurrence of clinical thrombotic complications","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","7774","April 17, 2020","April 17, 2021","May 1, 2021","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04359992"
468,"NCT04328493","The Vietnam Chloroquine Treatment on COVID-19","VICO","Recruiting","No Results Available","SARS-CoV-2 Infection|COVID-19","Drug: Chloroquine phosphate","Viral clearance time|Lengh of hospital stay|Ventilator free days|Oxygene free days|Time to death|Adverse events|Time to viral PCR negative from rectal swab|fever clearance time|Ordinal outcome scale|Development of ARDS","Oxford University Clinical Research Unit, Vietnam|Ministry of Health, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Vietnam|Can Gio COVID Hospital, Vietnam|Cho Ray Hospital, Vietnam|National Hospital for Tropical Diseases, Hanoi, Vietnam|Department of Health, Ho Chi Minh city","All","18 Years and older   (Adult, Older Adult)","Phase 2","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID","April 7, 2020","April 1, 2021","April 1, 2022","March 31, 2020",,"May 5, 2020","National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT04328493"
469,"NCT04383548","Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients",,"Not yet recruiting","No Results Available","COVID19","Other: hyper immunoglobulins containing anti-Corona VS2 immunoglobulin","Efficacy of COVID19 hyper immunoglobulins for patients|Efficacy of COVID19 hyper immunoglobulins for high risk groups|Safety of anti-SARS-CoV-2 hyper immunoglobulins assessed by percentage of adverse events","Assiut University","All","21 Years to 50 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Mini-pooled IVIG in COVID19","June 1, 2020","December 1, 2020","January 1, 2021","May 12, 2020",,"May 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04383548"
470,"NCT04358029","Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)",,"Recruiting","No Results Available","COVID 19 Cardiac|COVID 16 Arrhythmia|COVID 19 Death",,"Frequency of cardiac arrhythmias|Mode of death","Vivek Reddy|Icahn School of Medicine at Mount Sinai","All","Child, Adult, Older Adult",,"10000","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","GCO 20-0931","April 9, 2020","May 2021","December 2021","April 22, 2020",,"May 13, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04358029"
471,"NCT04360824","Covid-19 Associated Coagulopathy",,"Not yet recruiting","No Results Available","COVID 19 Associated Coagulopathy","Drug: Intermediate dose thromboprophylaxis|Drug: Standard of Care thromboprophylaxis","Mortality|Major Bleeding|Arterial Thrombosis|Venous Thromboembolism|ICU admission, intubation/ventilation|Packed Red Blood Cell Transfusions|Platelet Transfusions|Fresh Frozen Plasma Transfusions|Cryoprecipitate Transfusions|Prothrombin Complex Concentrate Transfusions","University of Iowa","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202004235","May 6, 2020","April 16, 2021","April 16, 2021","April 24, 2020",,"May 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04360824"
472,"NCT04373759","Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs","ACICOVID","Recruiting","No Results Available","Sars-CoV2|Covid-19","Other: Cardiopulmonary resuscitation|Other: Modified Rankin score","Incidence of unexpected cardiac arrest|Charlson score|Organ failure score at ICU admission and/or before unexpected in-ICU cardiac arrest|Etiology retained to explain cardiac arrest occurrence|Modified Rankin score (mRS) at ICU discharge, at hospital discharge and at 3 months","Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-CHITS-004","May 2020","September 2020","December 2020","May 4, 2020",,"May 21, 2020","CHU Felix Guyon, Saint-Denis, La Reunion, France|CH Angoulème, Angoulême, France|CH Argenteuil, Argenteuil, France|CH Bethune, Beuvry, France|CHU Ambroise Paré AP-HP, Boulogne-Billancourt, France|CH Brive, Brive-la-Gaillarde, France|CHU Caen, Caen, France|Hôpital Privé St Martin, Caen, France|CH Cahors, Cahors, France|CHU Antoine Béclère AP-HP, Clamart, France|CH Louis Mourier AP-HP, Colombes, France|CHU Henri Mondor AP-HP, Créteil, France|CHU Dijon, Dijon, France|CH de la Dracénie, Draguignan, France|CHI Frejus St Raphael, Fréjus, France|Grand Hôpital de l'Est Francilien, Jossigny, France|CH La Rochelle, La Rochelle, France|CHU Grenoble-Alpes, La Tronche, France|CH Versailles, Le Chesnay, France|CHU Kremlin Bicêtre, Le Kremlin-Bicêtre, France|CH Lens, Lens, France|CHRU Roger Salengro, Lille, France|CH Sambre Avesnois, Maubeuge, France|CHU Meaux, Meaux, France|Groupe Hospitalier Sud Ile de France, Melun, France|CHU Montpellier, Montpellier, France|CHR Orléans, Orléans, France|CHU Lariboisière AP-HP, Paris, France|CHU Saint Louis AP-HP, Paris, France|CHU St Antoine, Paris, France|Groupe Hospitalier Saint Joseph, Paris, France|CHU Necker Enfants Malades, Paris, France|Groupe Hospitalier Diaconesse Croix Saint-Simon, Paris, France|Hôpital Privé Claude Galien, Quincy-sous-Sénart, France|CHU Rouen, Rouen, France|Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, Toulon, France|Hôpital Nord Franche Comté, Trévenans, France|Institut Gustave Roussy, Villejuif, France|CH Etampes, Étampes, France",,"https://ClinicalTrials.gov/show/NCT04373759"
473,"NCT04349410","The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","FMTVDM","Enrolling by invitation","No Results Available","CoVid 19 Positive","Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum","Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status","The Camelot Foundation","All","Child, Adult, Older Adult","Phase 2|Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","FMTVDM2020","April 11, 2020","October 11, 2020","November 11, 2020","April 16, 2020",,"April 17, 2020","FHHI-OI-Camelot; QME, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04349410"
474,"NCT04368728","Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults",,"Recruiting","No Results Available","SARS-CoV-2 Infection|COVID-19","Biological: BNT162a1|Biological: BNT162b1|Biological: BNT162b2|Biological: BNT162c2|Other: Placebo","Percentage of participants reporting local reactions|Percentage of participants reporting systemic events|Percentage of participants reporting adverse events|Percentage of participants reporting serious adverse events|Percentage of sentinel cohort participants with abnormal hematology and chemistry laboratory values|Percentage of sentinel cohort participants with grading shifts in hematology and chemistry laboratory assessments|SARS-CoV-2-specific WT serum neutralizing antibody levels, expressed as GMTs|GMFR in SARS-CoV-2-specific WT serum neutralizing titers from before vaccination to each subsequent time point|Proportion of participants achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2-specific WT serum neutralizing antibody levels|SARS-CoV-2--spike protein-specific binding antibody levels and RBD-specific binding antibody levels, expressed as GMCs|Proportion of participants achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2--spike protein-specific binding antibody levels and RBD-specific binding antibody levels|GMFR in SARS-CoV-2-spike protein-specific binding antibody levels and RBD-specific binding antibody levels from before vaccination to each subsequent time point|GMR of the geometric mean of SARS-CoV-2-specific WT serum neutralizing titers to the geometric mean of SARS CoV 2 (spike protein and RBD) specific binding antibody levels|Confirmed COVID-19 incidence","Biontech SE|Pfizer","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","7600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","C4591001","April 29, 2020","August 11, 2021","March 8, 2023","April 30, 2020",,"May 14, 2020","University of Maryland General Clinical Research Center, Baltimore, Maryland, United States|University of Maryland Medical Center Investigational Drug Service Pharmacy, Baltimore, Maryland, United States|University of Maryland, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States|NYU Langone Health, New York, New York, United States|Rochester Regional Health/Rochester General Hospital, Rochester, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04368728"
475,"NCT04345848","Preventing COVID-19 Complications With Low- and High-dose Anticoagulation","COVID-HEP","Recruiting","No Results Available","COVID|Sars-CoV2","Drug: Enoxaparin","Composite outcome of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality|Arterial thrombosis|Venous thromboembolism|Disseminated intravascular coagulation|All-cause mortality|Sepsis-induced coagulopathy|Acute respiratory distress syndrome|Durations of hospital stay, ICU stay, ventilation|Sequential organ failure assessment score|Clinical deterioration","University Hospital, Geneva","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020-00794","April 28, 2020","November 30, 2020","November 30, 2020","April 15, 2020",,"April 30, 2020","Geneva University Hospitals, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT04345848"
476,"NCT04376996","Slovenian National COVID-19 Prevalence Study","SLO-COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Diagnostic Test: NO intervention planned due to the observational study design - only a diagnostic testing","Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples|Prevalence of anti-SARS-CoV-2 antibodies in blood samples","University of Ljubljana","All","Child, Adult, Older Adult",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ULMF2020-COVID-19","April 20, 2020","October 2020","December 2020","May 6, 2020",,"May 7, 2020","University of Ljubljana, Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT04376996"
477,"NCT04399603","Mechanisms of Multi-organ Failure in COVID-19",,"Not yet recruiting","No Results Available","COVID","Other: no intervention-mechanistic study","Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19|Correlation of inflammatory mediators in the bronchoalveolar lavage fluid with extent of lung injury (e.g. based upon oxygen requirement)|Correlation of circulating inflammatory mediators with renal and cardiovascular markers|Assess the role of inflammatory mediators obtained from patients in the development of renal injury using in vitro models (i.e. applying these inflammatory mediators isolated from these clinical samples on kidneys cells in a petri dish)","Imperial College London","All","18 Years to 90 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Other|Time Perspective: Prospective","283783","May 18, 2020","November 17, 2021","November 17, 2021","May 25, 2020",,"May 25, 2020","Imperial College NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04399603"
478,"NCT04375709","Quality of Life and Physical Performance After Novel Coronavirus Infection (COVID-19);",,"Recruiting","No Results Available","Covid-19 (New Coronavirus) Infection","Other: Physical exercise|Behavioral: Education sessions","Health-related quality of life; EuroQoL (EQ-5D-5L)|6-minute walk test|Jamar dynamometer|Hospital Anxiety and Depression Scale (HADS)|revised Impact of Event Scale (IES-R)|Mini-Nutritional Assessment (MNA)|Spirometry (bed-side)|Post-Covid Functional Scale (PCFS)|modified Medical Research Council Dyspnoea Scale (mMRC Dyspnoea)","Kantonsspital Winterthur KSW","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_00899 / COV19_2020","March 15, 2020","June 30, 2021","August 31, 2021","May 5, 2020",,"May 12, 2020","Kantonsspital Winterthur, Winterthur, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04375709"
479,"NCT04323514","Use of Ascorbic Acid in Patients With COVID 19",,"Recruiting","No Results Available","Hospitalized Patients With Covid-19 Pneumonia","Dietary Supplement: Vitamin C","In-hospital mortality|PCR levels|Lactate clearance|Hospital stay|Symptoms|Positive swab|Tomography imaging","University of Palermo","All","Child, Adult, Older Adult","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3143","March 13, 2020","March 13, 2021","March 13, 2021","March 26, 2020",,"March 26, 2020","A.R.N.A.S. Civico - Di Cristina - Benfratelli, Palermo, Italy","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04323514/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04323514"
480,"NCT04358614","Baricitinib Therapy in COVID-19",,"Completed","No Results Available","COVID|Pneumonia","Drug: Baricitinib 4 MG Oral Tablet","To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate.|To evaluate the impact of baricitinib in terms of clinical, laboratory, respiratory parameters.|ICU admission rate|Discharge rate.","Fabrizio Cantini|Hospital of Prato","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HPrato-4","March 16, 2020","April 5, 2020","April 7, 2020","April 24, 2020",,"April 24, 2020","Fabrizio Cantini, Prato, Tuscany, Italy",,"https://ClinicalTrials.gov/show/NCT04358614"
481,"NCT04377464","COVID-19 - Quality of Life After Infection",,"Not yet recruiting","No Results Available","COVID-19|Quality of Life","Other: SF12, EQ-5D-5L and work status standardized quantitative assessments","Six-month SF-12v2(HK) Scores|Six-month EQ-5D-5L Scores|One-month SF-12v2(HK)|One-month EQ-5D-5L Scores|Three-month SF-12v2(HK) Scores|Three-month EQ-5D-5L Scores|One, Three and Six-month Return to Work Status","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NTEC-2020-0227","May 5, 2020","April 30, 2021","April 30, 2022","May 6, 2020",,"May 6, 2020",,"""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04377464/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04377464/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04377464"
482,"NCT04327531","Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study",,"Active, not recruiting","No Results Available","COVID-19|Physician-Patient Relations","Behavioral: turkish physicians","Evaluation of covid-19 knowledge level of turkish physicians|what they think about the future","Kanuni Sultan Suleyman Training and Research Hospital","All","25 Years to 55 Years   (Adult)",,"200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","turkishcovid19","March 26, 2020","May 22, 2020","May 28, 2020","March 31, 2020",,"May 20, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04327531"
483,"NCT04355533","Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19","PED-COVID","Not yet recruiting","No Results Available","COVID-19 Infection","Biological: serology test|Diagnostic Test: NG Biotech|Biological: nasopharyngeal swab|Biological: rectal swab|Biological: saliva sample","Seroconversion against SARS-CoV2 in children of the Parisian area|Protective immunity|Measure of Ab antiN and Ab anti-S1|Neutralization activity|Positive qPCR|correlation between different Ab and qPCR and neutralization activity|correlation of the NGBiotech rapid test with the classical serological result|correlation of the NGBiotech rapid test with qPCR results|duration of viral carriage in stool, saliva and or nasopharynx|correlation between antibody profile and viral clearance|Ab profile and memory of immunity|saliva biofluid characteristics of COVID-19 infected|correlation of LIPS, the NGBiotech rapid test with the classical serological result|Presence of COVID-19 Symptom|seroconversion against SARS-CoV2 in parents of the Parisian area|Intra-family correlation of serological results|Measure of Ab antiN and Ab anti-S1 and neutralization activity|correlation between different Ab and qPCR","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|NG Biotech|Commissariat a l’energie atomique et aux energies alternatives|Institut Pasteur","All","up to 17 Years   (Child)","Not Applicable","1920","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","APHP200467|2020-A00999-30","June 2020","June 2020","September 2021","April 21, 2020",,"May 20, 2020","Hôpital necker Enfants-Malades, ¨Paris, France",,"https://ClinicalTrials.gov/show/NCT04355533"
484,"NCT04325061","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","DEXA-COVID19","Recruiting","No Results Available","Acute Respiratory Distress Syndrome Caused by COVID-19","Drug: Dexamethasone","60-day mortality|Ventilator-free days","Dr. Negrin University Hospital|Li Ka Shing Knowledge Institute|Consorcio Centro de Investigación Biomédica en Red, M.P.","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001278-31","April 3, 2020","October 30, 2020","October 30, 2020","March 27, 2020",,"April 17, 2020","ICU, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Las Palmas, Spain|Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|AVI, Hospital Clinic, Barcelona, Spain|Cardiac ICU, Hospital Clinic, Barcelona, Spain|Department of Anesthesia, Hospital Clinic, Barcelona, Spain|Hepatic ICU, Hospital Clínic, Barcelona, Spain|UVIR, Hospital Clinic, Barcelona, Spain|Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain|Department of Anesthesia, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Department of Anesthesia, Hospital Universitario La Paz, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain|Department of Anesthesia, Hospital Universitario Virgen de Arrixaca, Murcia, Spain|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Department of Anesthesia, Hospital Unversitario Montecelo, Pontevedra, Spain|Anesthesia, Hospital General Universitario de Valencia, Valencia, Spain|Department of Anesthesia, Hospital Clinico Universitario, Valencia, Spain|Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain|Department of Anesthesia, Hospital Clínico Universitario, Valladolid, Spain|Anesthesia, Hospital Universitario Río Hortega, Valladolid, Spain|Intensive Care Unit, Hospital Universitario Río Hortega, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04325061"
485,"NCT04391309","IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19)",,"Not yet recruiting","No Results Available","Sars-CoV2","Biological: IC14|Other: Placebo","Acute respiratory failure|Time to clinical improvement|Invasive mechanical ventilation|Hospitalization|Sequential Organ Failure Assessment|Ordinal Scale|Time to clinical improvment|Time to recovery|Change in C-reactive protein|Adverse events|Serious adverse events","Implicit Bioscience|University of Washington","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","300","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COV04","July 2020","July 2021","September 2021","May 18, 2020",,"May 25, 2020","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04391309"
486,"NCT04364802","COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients","PIIPPI","Recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Povidone-Iodine Nasal Spray and Gargle","Percent of healthcare workers testing positive for COVID-19.|Percent of patients testing positive for COVID-9.|PVP-I Ease of Use|PVP-I Comfort","Alexandra Kejner|University of Kentucky","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","58748","April 29, 2020","May 2021","May 2021","April 28, 2020",,"May 14, 2020","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04364802"
487,"NCT04347369","A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease",,"Recruiting","No Results Available","COVID-19 Disease","Other: other","discrimination|Calibration|Net benefit","Xinqiao Hospital of Chongqing","All","18 Years to 80 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","XQonc-015","January 17, 2020","April 30, 2020","May 31, 2020","April 15, 2020",,"April 15, 2020","Xinqiao Hospital of Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04347369"
488,"NCT04381858","Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Plasma from COVID-19 convalescent patient|Drug: Human immunoglobulin","Mean hospitalization time|Mean Oxigenation index evolution|Rate of severe ARDS|Rate and time to dead|Mean time with invasive mechanical ventilation|Time to Viral PCR Negativization","Centenario Hospital Miguel Hidalgo","All","16 Years to 90 Years   (Child, Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2020-A-10","May 6, 2020","August 30, 2020","September 30, 2020","May 11, 2020",,"May 12, 2020","Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico",,"https://ClinicalTrials.gov/show/NCT04381858"
489,"NCT04381312","Direct and Indirect Impact of COVID-19 In Older Populations","COVID-OLD","Recruiting","No Results Available","Risk Factors for COVID-19 Outcomes in Elderly Populations",,"mortality|Risk factors for death|Describe clinical symptoms specific to old population|describe specific and non-specific treatments used for COVID 19|describe all acute complications|functional decline|Rehospitalisation|medical complications|Admission in nursing home|risk factors for 3-month functional decline, acute complication and admission to nursing home","University Hospital, Grenoble","All","70 Years and older   (Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","38RC20.118|2020-A00846-33","April 9, 2020","July 9, 2021","October 9, 2021","May 8, 2020",,"May 8, 2020","Chu Grenoble Alpes, Grenoble Cedex 9, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT04381312"
490,"NCT04346355","Efficacy of Early Administration of Tocilizumab in COVID-19 Patients",,"Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab","Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count","Azienda Unità Sanitaria Locale Reggio Emilia","All","18 Years and older   (Adult, Older Adult)","Phase 2","398","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RCT-TCZ-COVID-19|2020-001386-37","March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",,"April 15, 2020","Ospedale di Guastalla, Guastalla, RE, Italy|Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|ASST Cremona, Cremona, Italy|Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Ospedale Evangelico Internazionale di Genova, Genova, Italy|Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy|Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|IRCCS Istituto Auxologico Italiano Milano, Milano, Italy|Azienda Ospedaliero-Universitaria ""Maggiore della Carità"" di Novara, Novara, Italy|Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy|Azienda Ospedaliero-Universitaria Parma, Parma, Italy|Azienda Unità Sanitaria Locale di Piacenza, Piacenza, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|AO Ordine Mauriziano di Torino, Torino, Italy|ASST Bergamo Ovest -Treviglio, Treviglio, Italy|AULSS 2 Marca Trevigiana, Treviso, Italy|AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy|AULSS 3 Serenissima Ospedale ""Dell'Angelo"", Venezia, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|IRCCS Sacro Cuore Don Calabria, Verona, Italy",,"https://ClinicalTrials.gov/show/NCT04346355"
491,"NCT04376710","Surgical Telemedicine in the COVID-19 Pandemic Era",,"Not yet recruiting","No Results Available","COVID|Surgery","Other: Completion of pre-pandemic survey|Other: Completion of survey after peak of pandemic|Other: Completion of post telemedicine encounter survey","Evaluate surgeon perceptions to telemedicine and perceived barriers to implementation|Evaluate patient perceptions to telemedicine and perceived barriers to implementation","University of Colorado, Denver","All","31 Days to 18 Years   (Child, Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","20-1177","June 1, 2020","December 31, 2020","December 31, 2020","May 6, 2020",,"May 6, 2020","Children's Hospital Colorado, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04376710"
492,"NCT04360954","Evaluation of Antibody Tests for COVID-19",,"Recruiting","No Results Available","COVID|Coronavirus","Diagnostic Test: Diagnostic test","Test Sensitivity|Test Specificity","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","202004088","April 27, 2020","October 27, 2020","October 27, 2020","April 24, 2020",,"April 28, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04360954"
493,"NCT04323878","Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.","EC-COVID-PCS","Not yet recruiting","No Results Available","Early CPAP Ventilation in COVID-19 Patients",,"Death or need of intubation|30-day mortality","Mario Negri Institute for Pharmacological Research","All","18 Years and older   (Adult, Older Adult)",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EC-COVID-PCS-Fenice","April 6, 2020","October 5, 2020","November 9, 2020","March 27, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04323878"
494,"NCT04273646","Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19",,"Not yet recruiting","No Results Available","2019 Novel Coronavirus Pneumonia|COVID-19","Biological: UC-MSCs|Drug: Placebo","Pneumonia severity index|Oxygenation index (PaO2/FiO2)|Side effects in the UC-MSCs treatment group|28-days survival|Sequential organ failure assessment|C-reactive protein|Procalcitonin|Lymphocyte count|CD3+, CD4+ and CD8+ T celll count|CD4+/CD8+ratio","Wuhan Union Hospital, China|Wuhan Hamilton Bio-technology Co., Ltd, China.","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202001","April 20, 2020","June 30, 2020","February 15, 2022","February 18, 2020",,"April 14, 2020","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04273646"
495,"NCT04374019","Novel Agents for Treatment of High-risk COVID-19 Positive Patients",,"Recruiting","No Results Available","COVID|Sars-CoV2","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine and Azithromycin|Drug: Hydroxychloroquine and Ivermectin|Drug: Camostat Mesilate","Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Change in Clinical Status|Mortality|Rate of severe adverse events|Oxygen-free days|Ventilator-free days|Vasopressor-free days|ICU-free days|Hospital-free days|Patients meeting Hy's Law criteria|Liver Function|Heart Function","Susanne Arnold|University of Kentucky","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-20-COVID-01-PMC","May 1, 2020","May 2021","May 2021","May 5, 2020",,"May 7, 2020","University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04374019"
496,"NCT04365959","The Prone Position in Covid-19 Affected Patients","PRON-COVID","Active, not recruiting","No Results Available","Sars-CoV2","Procedure: Prone position","Number of patients in whom the prone position caused an increase in oxygenation|The feasibility of prone position","University of Milano Bicocca","All","18 Years to 75 Years   (Adult, Older Adult)",,"56","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PRON-COVID","March 20, 2020","April 9, 2020","May 31, 2020","April 28, 2020",,"April 28, 2020","ASST Monza, Monza, MB, Italy",,"https://ClinicalTrials.gov/show/NCT04365959"
497,"NCT04359602","COVID-19 Recovered Volunteer Research Participant Pool Registry",,"Recruiting","No Results Available","Recovered From COVID-19",,"Serological testing of COVID patients|Immune response","University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20-000625","April 8, 2020","April 20, 2022","April 20, 2042","April 24, 2020",,"May 4, 2020","Ronald Reagan UCLA Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04359602"
498,"NCT04333862","Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy","Covid-19","Recruiting","No Results Available","SARS-CoV-2",,"Fraction of healthcare workers infected with SARS-CoV-2|Fraction of healthcare workers with COVID-19|Number of patients infected in the hospital|Development of SARS-CoV2 specific antibody repertoire","University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00563","March 19, 2020","June 30, 2020","December 31, 2021","April 3, 2020",,"April 3, 2020","Guido Beldi, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04333862"
499,"NCT04305106","Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT","BEST-RCT","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Bevacizumab","The time from randomization to clinical improvement","Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Ialy Moriggia Pelascini Gravedona Hospital S.p.A|Wuhan University|Jiangbei Union Hospital of Huazhong University of science and technology|Shandong Provincial Chest Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","QLEmer","March 17, 2020","June 30, 2020","July 31, 2020","March 12, 2020",,"March 26, 2020","Qilu Hospital of Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04305106"
500,"NCT04384250","Genetic Basis of COVID-19 Infection",,"Recruiting","No Results Available","Genetic Basis of COVID-19 Infection","Diagnostic Test: Whole Exome Sequencing","Mutations leading to increase susceptibility to SARS-COV-2 infection","Mansoura University","All","up to 50 Years   (Child, Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RP:20.05.70","May 10, 2020","August 31, 2020","May 1, 2021","May 12, 2020",,"May 12, 2020","Mansoura University, Mansoura, Dakahlyia, Egypt",,"https://ClinicalTrials.gov/show/NCT04384250"
501,"NCT04315987","NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","HOPE","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Biological: NestCell®","Change in Clinical Condition|Rate of mortality within 10-days|Change of Clinical symptoms - respiratory rate|Hypoxia|PaO2 / FiO2 ratio|CD4+ and CD8+ T cell count|Changes of blood oxygen|Side effects in the treatment group|Complete blood count, cardiac, hepatic and renal profiles;","Azidus Brasil|Cellavita Pesquisa Científica Ltda|Hospital Vera Cruz","All","18 Years and older   (Adult, Older Adult)","Phase 1","66","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOPE","April 2020","May 2020","June 2020","March 20, 2020",,"April 15, 2020","Hospital Vera Cruz, Campina Grande, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04315987"
502,"NCT04315896","Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)","HYDRA","Recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","All-cause hospital mortality|Length of hospital stay|Need of mechanical ventilation|Ventilator free days|Grade 3-4 adverse reaction","National Institute of Respiratory Diseases, Mexico|Sanofi","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HidroxycloroquinaCOVID19","April 14, 2020","October 31, 2020","March 22, 2021","March 20, 2020",,"April 17, 2020","Instituto Nacional de Enfermedades Respiratorias, ""Ismael Cosío Villegas"", Mexico, City, Mexico",,"https://ClinicalTrials.gov/show/NCT04315896"
503,"NCT04353323","COVID 19-Caregivers IGg Seroconversion","CoSigS","Not yet recruiting","No Results Available","Infection, COVID-19","Other: Blood sampling","Seroconversion","University Hospital, Limoges","All","18 Years and older   (Adult, Older Adult)",,"130","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","87RI20_0016/CoSigS","May 25, 2020","June 25, 2020","December 25, 2020","April 20, 2020",,"May 11, 2020","CHU de Limoges, Limoges, France",,"https://ClinicalTrials.gov/show/NCT04353323"
504,"NCT04244591","Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure",,"Completed","No Results Available","COVID-19 Infections","Drug: methylprednisolone therapy|Other: Standard care","Lower Murray lung injury score|The difference of PaO2/FiO2 between two groups|Lower Sequential Organ Failure Assessment (SOFA) score|Mechanical ventilation support|Clearance of noval coronavirus|All-cause mortality","Peking Union Medical College Hospital|Zhongda Hospital|Zhongnan Hospital|Renmin Hospital of Wuhan University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Glucocorticoid COVID-19","January 26, 2020","April 13, 2020","April 13, 2020","January 28, 2020",,"April 15, 2020","Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04244591"
505,"NCT04346329","Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19","Chloroquine UN","Not yet recruiting","No Results Available","COVID","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Adverse effects|Immune-score|COVID-19 prevention|Clinical response","Universidad Nacional de Colombia|Fundación Salud de los Andes","All","18 Years and older   (Adult, Older Adult)","Phase 3","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","UNAL-COVID-CP","April 20, 2020","June 1, 2020","October 1, 2020","April 15, 2020",,"April 15, 2020","Facultad de Medicina - Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT04346329"
506,"NCT04354870","COVID-19 PrEP HCW HCQ Study",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine (HCQ)","Frequency of seroconversion to SARS-CoV-2|Incidence of COVID-19 symptoms in the 4 weeks preceding seroconversion|Hospital admission rate|ICU admission rate|Mortality rate|Incidents of AEs or SAEs related to HCQ upon study termination time","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","350","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00390","April 3, 2020","August 1, 2020","September 1, 2020","April 21, 2020",,"April 22, 2020","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04354870"
507,"NCT04344756","Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","CORIMMUNO-COAG","Not yet recruiting","No Results Available","COVID19 Pneumonia","Drug: Tinzaparin or unfractionated heparin","Survival without ventilation (VNI or mechanical ventilation)|ventilator free survival|World Health Organisation(WHO) progression scale ≤5|World Health Organisation(WHO) progression scale|overall survival|Length of hospital stay|Length of ICU stay|time to oxygenation supply independency|time to ventilator (non invasive or invasive)|rate of acute kidney injury|time to Renal Replacement Therapy (RRT) initiation|rate of clinically overt pulmonary embolism or proximal deep vein thrombosis|Rate of clinically overt arterial thrombosis|Rate of unscheduled central venous catheter replacement for catheter dysfunction|Rate of central venous catheter-related deep vein thrombosis (CVC-DVT)|Rate of unscheduled indwelling arterial catheter replacement for catheter dysfunction|Rate of acute clotting leading to the replacement the renal replacement therapy circuit stratified by regional citrate anticoagulation or not|Time to acute clot formation within the oxygenator (acute oxygenator thrombosis, AOT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Time to acute clot formation within the pump head (pump head thrombosis, PHT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Incidence of adverse events","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","808","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200389-6","April 20, 2020","July 31, 2020","September 30, 2020","April 14, 2020",,"April 15, 2020","Réanimation hôpital Louis Mourier, Colombes, Hauts De Seine, France|réanimation hôpital Cochin, Paris, France|Médecine vasculaire, Hôpital Européen Georges Pompidou, Paris, France",,"https://ClinicalTrials.gov/show/NCT04344756"
508,"NCT04320615","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","COVACTA","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab (TCZ)|Drug: Placebo","Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WA42380|2020-001154-22","April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",,"April 27, 2020","University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Denver Health Medical Center, Denver, Colorado, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Baystate Health System, Springfield, Massachusetts, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States|James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States|New York University Langone Medical Center, New York, New York, United States|NYU-Langone Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Smith Clinic-Harris County Hospital, Houston, Texas, United States|Intermountain Medical Group, Saint George, Utah, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|Evergreen Health Infectious Disease, Kirkland, Washington, United States|Swedish Hospital Medical Center, Seattle, Washington, United States|McMaster University Medical Centre, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Clinical Research Institute of Montreal, Montreal, Quebec, Canada|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier et Universitaire de Limoges, Limoges, France|Hôpital de La Croix Rousse, Lyon, France|Hotel Dieu - Nantes, Nantes, France|Hopital de la Pitie Salpetriere, Paris, France|HOPITAL COCHIN university hospital, Paris, France|CHRU de Tours, Pharmacie, Tours, France|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany|Uniklinik Köln, Köln, Germany|LMU Klinikum der Universitat Munchen, Munchen, Germany|Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy|ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy|Amphia Ziekenhuis, Breda, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain|Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Royal Free Hospital, London, United Kingdom|Imperial College London, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Salford Royal Hospital, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04320615"
509,"NCT04395482","Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury","TAC-COVID19","Recruiting","No Results Available","covid19","Other: Lung CT scan analysis in COVID-19 patients","A qualitative analysis of parenchymal lung damage induced by COVID-19|A quantitative analysis of parenchymal lung damage induced by COVID-19|The potential impact of parenchymal morphological CT scans in patients with severe moderate respiratory failure.|Automated segmentation of lung scans of patients with COVID-19 and ARDS.|Knowledge of chest CT features in COVID-19 patients and their detail through the use of machine learning and other quantitative techniques.|The ability within which the analysis of artificial intelligence that uses deep learning models can be used to predict clinical outcomes","University of Milano Bicocca","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","TAC-COVID19","April 15, 2020","June 15, 2020","October 15, 2020","May 20, 2020",,"May 20, 2020","Ospedale Papa Giovanni XXIII, Bergamo, Italy|Policlinico San Marco-San Donato group, Bergamo, Italy|Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy|ASST di Lecco Ospedale Alessandro Manzoni, Lecco, Italy|ASST Melegnano-Martesana, Ospedale Santa Maria delle Stelle, Melzo, Italy|ASST Monza, Monza, Italy|AUSL Romagna-Ospedale Infermi di Rimini, Rimini, Italy|Istituto per la Sicurezza Sociale-Ospedale della Repubblica di San Marino, San Marino, San Marino",,"https://ClinicalTrials.gov/show/NCT04395482"
510,"NCT04383444","Surveillance of Individuals Following SARS-CoV-2 Exposure",,"Recruiting","No Results Available","COVID-19",,"SARS-CoV-2 RT-PCR test result|SARS-CoV-2 antibody assay result|Symptom checklist","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"1050","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200117|20-I-0117","May 28, 2020","June 16, 2023","June 16, 2023","May 12, 2020",,"May 25, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04383444"
511,"NCT04368000","Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization","PAPR","Recruiting","No Results Available","Respiratory Failure|COVID-19","Behavioral: Intermittent prone positioning instructions|Behavioral: Usual care positioning with no instructions","Change in imputed partial pressure of oxygen over fraction of inspired oxygen (PaO2/FiO2) from peripheral capillary oxygen saturation over fraction of inspired oxygen (SpO2/FiO2)|Change in imputed PaO2/FiO2 from SpO2/FiO2|Proportion of participants requiring endotracheal intubation|Proportion of participants requiring mechanical ventilation|Proportion of participants transferred to intensive care for worsening respiratory failure|Proportion of participants who had escalated oxygen delivery needs|Average number of days hospitalized|Average number of ventilator-free days|Proportion of participants discharged from hospital on hospice|Proportion of participants with all-cause inpatient mortality","University of Utah","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB_00132123","April 29, 2020","December 2020","January 2021","April 29, 2020",,"May 20, 2020","University of Utah Health Sciences Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04368000"
512,"NCT04392531","Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19",,"Recruiting","No Results Available","COVID19 Infection","Drug: Cyclosporine|Drug: Standard treatment","Severity Category|Mortality Rate|Number of Days in hospital|Number of days in ICU beds|Fio2 Needs|Adverse events rate|Change in CRP|Change in ferritin|Change in LDH|Change in CPK|Change in D Dimer|Change in IL-6|Change in KL-6|Change in Viral Load|Change specific antibodies","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FJD-COVID19-20-01","April 16, 2020","July 2020","July 2020","May 19, 2020",,"May 19, 2020","Complejo Hospitalario Universitario La Coruña, La Coruña, Galicia, Spain|Hospital Quiron La Coruña, La Coruña, Galicia, Spain|Hospital Rey Juan Carlos, Mostoles, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital General de Villalba, Villalba, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Clinica Universitaria de Navarra, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04392531"
513,"NCT04372186","A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19 Pneumonia","Drug: Placebo|Drug: Tocilizumab","Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","379","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ML42528","May 8, 2020","August 5, 2020","October 5, 2020","May 1, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04372186"
514,"NCT04378777","Immunophenotyping Assessment in a COVID-19 Cohort","IMPACC","Enrolling by invitation","No Results Available","Coronavirus Disease 2019 (COVID-19)|SARS-CoV-2","Procedure: Biological sample collection|Procedure: Data Collection: Clinical Care Assessments","Mortality Rate Among COVID-19 Patients|Proportion of Patients with COVID-19 who Require Intensive Care Unit (ICU)-Level Care, Mechanical Ventilatory Support (MV), and/or Extracorporeal Membrane Oxygenation (ECMO) Over Time to Day 28|Proportion of Patients with COVID-19 who Develop Shock, Secondary Organ Failure, or Secondary Infection Over Time to Day 28|Mechanistic: Longitudinal Assessment of Viral Load by Semi-Quantitative Polymerase Chain Reaction (PCR) Over Time to Day 28|Mechanistic: Antibody Isotype/Subclass Classification and Functionality Over Time through Day 28 and at follow-up through month 12|Mechanistic: Longitudinal Assessment of Inflammatory Mediators as Collected Over Time to Day 28|Mechanistic: Longitudinal Assessment of Markers of Myocardial Injury Over Time to Day 28|Duration of Mechanical Ventilation in Patients with COVID-19 Over Time to Day 28|Proportion of Patients with COVID-19 with Requirement for New (Or Increased from Baseline if on Home Oxygen) Supplemental Oxygen Over Time to Day 28|Requirement for Extracorporeal Membrane Oxygenation (ECMO) in COVID-19 Patients with COVID-19 Over Time to Day 28|Mechanistic: Immune Cell Frequencies and Activation Status (CyTOF) in Blood and Endotracheal Aspirate over time Through Day 28 and In blood at Select Study Visits Through Month 12|Mechanistic: Gene Expression (Transcriptomics) in Blood|Mechanistic: Gene Expression (Transcriptomics) in Respiratory Epithelium|Mechanistic: Gene Expression (Transcriptomics) in Plasma Protein|Mechanistic: Gene expression (Transcriptomics) in Metabolic Profiling|Mechanistic: Circulating Immune Mediators Assessed by OLINK Methodology","National Institute of Allergy and Infectious Diseases (NIAID)|Benaroya Research Institute|Boston Children’s Hospital","All","18 Years and older   (Adult, Older Adult)",,"2000","NIH|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DAIT-COVID-19-002","May 1, 2020","December 2020","December 2021","May 7, 2020",,"May 14, 2020","University of California, Los Angeles: Department of Medicine, Los Angeles, California, United States|University of California San Francisco School of Medicine, San Francisco, California, United States|Stanford Medicine: Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, United States|Yale School of Medicine, New Haven, Connecticut, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04378777"
515,"NCT04344782","Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","CORIMMUNO-BEVA","Not yet recruiting","No Results Available","COVID19 Pneumonia","Drug: Bevacizumab Injection","Proportion of surviving patients without need for intubation for respiratory support|Saturation of Oxygen in the blood (SaO2)|Arterial oxygen partial pressure (paO2)|Ratio of arterial oxygen partial pressure to fractional inspired oxygen (paO2/FiO2)|CT-scan score|dyspnea|overall survival|admissionn to the intensive care unit (ICU)|incidence of mechanical ventilation|hospital length of stay|incidence of adverse event|VEGF plasma concentration","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200389-7","April 15, 2020","September 30, 2020","November 30, 2020","April 14, 2020",,"April 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04344782"
516,"NCT04335201","Defibrotide in COVID-19 Pneumonia","DEFI-VID19","Not yet recruiting","No Results Available","Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure","Drug: Defibrotide Injection","to able to reduce the progression of acute respiratory failure|Adverse events|duration of hospitalization|systemic inflammation|overall survival","IRCCS San Raffaele","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DEFI-VID19","April 6, 2020","September 30, 2020","December 31, 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335201"
517,"NCT04386616","A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia","COVASTIL","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: MSTT1041A|Drug: MSTT1041A-matched Placebo|Drug: UTTR1147A|Drug: UTTR1147A-matched Placebo","Clinical Status, Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) of ≤2 Maintained for 24 hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First)|Mortality Rate at Days 7, 14, 21, 28, and 60|Time to Hospital Discharge or ""Ready for Discharge""|Duration of Supplemental Oxygen|Duration of Hypoxemia|Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)|Change from Baseline in Respiratory Rate|Change from Baseline in Pulse Rate|Change from Baseline in Systolic Blood Pressure|Change from Baseline in Diastolic Blood Pressure|Change from Baseline in Body Temperature|Change from Baseline in Oxygen Saturation|Change from Baseline in RR, QRS, PR, QT, and QTcF Intervals, as Measured by Electrocardiogram (ECG)|Change from Baseline in Heart Rate, as Measured by Electrocardiogram (ECG)|Number of Participants with Clinical Laboratory Test Abnormalities in Hematology Parameters|Number of Participants with Clinical Laboratory Test Abnormalities in Blood Chemistry Parameters|Serum Concentration of UTTR1147A at Specified Timepoints|Serum Concentration of MSTT1041A at Specified Timepoints","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GA42469","May 22, 2020","September 24, 2020","October 27, 2020","May 13, 2020",,"May 21, 2020","eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|eStudySite, La Mesa, California, United States|Torrance Memorial Medcal Center, Torrance, California, United States|Westchester General Hospital, Miami, Florida, United States|MedPharmics, Metairie, Louisiana, United States|Southeast Louisiana Veterans Health Care System - NAVREF, New Orleans, Louisiana, United States|Henry Ford Health System, Detroit, Michigan, United States|WR-CRCN LLC/North Vista Hospital, North Las Vegas, Nevada, United States|St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center; Lewis M. Fraad Department of Pediatrics, Bronx, New York, United States|University of Rochester, Rochester, New York, United States|Staten Island University Hospital; Department of Pharmacy, Staten Island, New York, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Temple Uni Medical Center; Pulmonary & Critical Care Medicine, Philadelphia, Pennsylvania, United States|Parkland Health & Hospital System, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|MultiCare Institute for Research and Innovation; Clinic/Outpatient Facility, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04386616"
518,"NCT04342663","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","STOP COVID","Recruiting","No Results Available","COVID 19|Coronavirus","Drug: Fluvoxamine|Drug: Placebo","Time to clinical worsening|clinical deterioration on a Likert-type scale (1-6)|clinical deterioration measured by number of days|Symptomatic severity on a likert scale (0-10 where 0= none and 10=very severe)","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","202004023","April 10, 2020","August 1, 2020","September 1, 2020","April 13, 2020",,"May 19, 2020","BJC, Belleville, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04342663"
519,"NCT04332107","Azithromycin for COVID-19 Treatment in Outpatients Nationwide","ACTION","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Azithromycin|Drug: Placebos","Hospitalization|Viral load|Mortality|Adverse events|Positive SARS-CoV-2 test - nasal swab|Positive SARS-CoV-2 test - saliva swab|Positive SARS-CoV-2 test - rectal swab|Genetic macrolide resistance determinants|COVID-19 symptoms|Number of emergency room visits|Number of household members with COVID-19 (confirmed or symptomatic)|Death","Thomas M. Lietman|Bill and Melinda Gates Foundation|Pfizer|Stanford University|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 3","2271","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20-30504","May 22, 2020","September 30, 2020","September 30, 2021","April 2, 2020",,"May 25, 2020","University of California San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04332107"
520,"NCT04363736","A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia","MARIPOSA","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tociliuzumab","Concentration of C-Reactive Protein (CRP)|Serum Concentration of Interleukin-6 (IL-6)|Serum Concentration of Soluble Interleukin Receptor (sIL-6R)|Serum Concentration of Ferritin|Serum Concentration of TCZ Following Administration of 8 mg/kg IV TCZ|Serum Concentration of TCZ Following Administration of 4 mg/kg IV TCZ|Clinical Status, as Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) of </=2 Maintained for 24 Hours|Time to Improvement in at Least Two Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Duration of Supplemental Oxygen Use|Incidence of Intensive Care Unit (ICU) Stays|Incidence of Mechanical Ventilation|Duration of ICU Stay|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate|Time to Hospital Discharge or ""Ready for Discharge""|Frequency of Addition of a Second Dose of TCZ|Pecentage of Participants with Adverse Events|SARS-CoV-2 (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA42481","May 4, 2020","June 11, 2020","August 3, 2020","April 27, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04363736"
521,"NCT04370821","COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers","CHAMPS","Recruiting","No Results Available","Occupational Exposure to SARS-CoV-2|COVID-19",,"Sample Size of enrolled CHAMPS Study participants by demographic characteristics during the first two years of the study|Exposure to SARS-CoV-2 based on models computed from participant baseline data and community variables, if available.|Infectious disease and chronic disease incidence rates by demographic characteristics|Completeness of data by demographic characteristics.|Participation rates in ancillary and sub-studies within the CHAMPS registry.|Number of participants enrolled in randomized trials based on the CHAMPS registry","Villanova University","All","18 Years and older   (Adult, Older Adult)",,"20000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB FY2020-215","May 9, 2020","April 27, 2040","April 27, 2040","May 1, 2020",,"May 12, 2020","Villanova University, Villanova, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04370821"
522,"NCT04382053","Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID 19 Pneumonia, Impaired Respiratory Function","Drug: DFV890|Drug: Standard of Care (SoC)","APACHE II severity of disease score on Day 15 or on the day of discharge (whichever is earlier)|Serum C-reactive protein (CRP) levels|Clinical status over time|Proportion of participants not requiring mechanical ventilation for survival.|Proportion of participants with at least one-point improvement from baseline in clinical status","Novartis Pharmaceuticals|Novartis","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDFV890D12201|2020-001870-32","May 15, 2020","July 29, 2020","July 29, 2020","May 11, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04382053"
523,"NCT04356560","COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department",,"Enrolling by invitation","No Results Available","COVID-19","Diagnostic Test: COVID-19 test, polymerase chain reaction for SARS-CoV-2","Incidence of healthcare workers with SARS-CoV-2|Incidence of ENT patients with SARS-CoV-2|Development of SARS-CoV-2 antibodies among healthcare workers|Sensitivity and specificity of a COVID-19 screening symptom questionnaire among healthcare workers|SARS CoV-2 and bacterial super infections in upper respiratory airways","Rigshospitalet, Denmark","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DT P-2020-353","March 23, 2020","September 30, 2020","December 31, 2020","April 22, 2020",,"April 24, 2020","Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04356560"
524,"NCT04344730","Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia","COVIDICUS","Recruiting","No Results Available","Acute Hypoxemic Respiratory Failure|COVID-19","Drug: Dexamethasone injection|Drug: placebo|Procedure: conventional oxygen|Procedure: CPAP|Procedure: HFNO|Procedure: mechanical ventilation","The time-to-death from all causes|The time to need for mechanical ventilation (MV)|The viral load in the respiratory tract|Number of patient with at least one episode of healthcare-associated infections|Number of days alive without mechanical ventilation|Measure of SOFA score|Number of days alive without renal replacement therapy|Lengths of ICU-stay|Lengths of hospital-stay|Number of patients with severe hypoxemia,|Number of patients with cardiac arrest within 1 hour after intubation","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","550","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APHP200388|2020-001457-43","April 10, 2020","December 31, 2020","December 31, 2020","April 14, 2020",,"April 14, 2020","Hopital Bichat - Aphp, Paris, France",,"https://ClinicalTrials.gov/show/NCT04344730"
525,"NCT04363060","Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit","AziA","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Combination Product: Azithromycin with amoxicillin/clavulanate|Drug: amoxicillin/clavulanate","Rate of positive SARS-CoV-2 RT-PCR|Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19|Total duration of antibiotic treatment during the 30 days following inclusion|Number of all-cause mortality during the 30 days following inclusion|Number of in-hospital mortality during the 30 days following inclusion|Number of patients transferred to intensive care unit during the 30-day follow-up|Number of days without mechanical ventilation during the 30 days following inclusion|adverse events attributable to antibiotic treatment during the 30 days following inclusion|Hospital length of stay during the 30 days following inclusion","Nantes University Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RC20_0168","April 30, 2020","July 30, 2020","July 30, 2020","April 27, 2020",,"April 29, 2020","Chu Angers, Angers, France|CHD Vendée, La Roche-sur-Yon, France|CHU Poitiers, Poitiers, France",,"https://ClinicalTrials.gov/show/NCT04363060"
526,"NCT04390412","Low Dose Radiotherapy in COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID|SARS (Severe Acute Respiratory Syndrome)","Radiation: Low Dose Radiotherapy","Change from baseline blood oxygenation|Number of Hospital stay days|Number of ICU stay days|Number of intubation events|WBC|Platelets|ESR|CRP|IL-6|Chest CT scan","Shahid Beheshti University of Medical Sciences","All","60 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","23568|IRCT20200509047366N1","May 4, 2020","August 2020","December 2020","May 15, 2020",,"May 15, 2020","Imam Hossein Hospital, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04390412"
527,"NCT04351516","Test and Treat COVID 65plus+","COVID65plus","Recruiting","No Results Available","SARS-CoV 2|COVID-19","Drug: Hydroxychloroquine|Other: Placebo","● Rate of hospitalization or death at day 7 after study inclusion","University Hospital Tuebingen","All","65 Years and older   (Older Adult)","Phase 2|Phase 3","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVID65plus","April 21, 2020","December 31, 2020","May 1, 2021","April 17, 2020",,"May 1, 2020","Uniklinikum Tuebingen, Tuebingen, Germany|Uniklinikum Ulm, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT04351516"
528,"NCT04346056","Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19","Explore","Recruiting","No Results Available","Coronavirus Disease (COVID-19)|COVID-19",,"Exploring the presence of COVID-19","Ain Shams University","All","1 Year to 80 Years   (Child, Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","FMASU P17a/ 2020","April 14, 2020","October 1, 2020","December 1, 2020","April 15, 2020",,"April 20, 2020","Faculty of Medicine Ain Shams University, Cairo, Non-US, Egypt|Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,"https://ClinicalTrials.gov/show/NCT04346056"
529,"NCT04273529","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia",,"Not yet recruiting","No Results Available","COVID-19 Thalidomide","Drug: thalidomide|Drug: placebo","Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence","First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20200214-COVID-19-M-T","February 20, 2020","May 30, 2020","June 30, 2020","February 18, 2020",,"February 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04273529"
530,"NCT04273581","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19",,"Not yet recruiting","No Results Available","COVID-19 Thalidomide","Drug: placebo|Drug: Thalidomide","Time to Clinical Improvement (TTCI)|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events|Serum TNF-α, IL-1β, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1α and other cytokine expression levels before and after treatment","First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20200214-COVID-19-S-T","February 18, 2020","April 30, 2020","May 30, 2020","February 18, 2020",,"February 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04273581"
531,"NCT04337359","Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness",,"Available","No Results Available","Severe/Very Severe COVID-19 Illness","Drug: Ruxolitinib",,"Novartis Pharmaceuticals|Novartis","All","6 Years and older   (Child, Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population",,"CINC424A2001M",,,,"April 7, 2020",,"May 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04337359"
532,"NCT04371640","Sirolimus in COVID-19 Phase 1","SirCO-1","Recruiting","No Results Available","SARS-CoV-2|Covid-19","Drug: Sirolimus 1 MG/ML|Drug: Placebo","Change in SARS-CoV-2 viral burden from baseline to day 7 of treatment|Change in SARS-CoV-2 viral burden at days 1-6|Rate of treatment emergent adverse events","Walter K. Kraft|Thomas Jefferson University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15680","May 2020","July 2020","August 2020","May 1, 2020",,"May 7, 2020","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04371640"
533,"NCT04382469","Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT",,"Completed","No Results Available","COVID",,"Radiological pattern of initial presentation, disease progress, healing and recovery|Survey of co-morbid lung diseases","Alexandria University","All","Child, Adult, Older Adult",,"48","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Retrospective","IRB (00012098), FWA (00018699)","February 1, 2020","April 30, 2020","May 1, 2020","May 11, 2020",,"May 12, 2020","Faculty of Medicine, University of Alexandria, Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT04382469"
534,"NCT04386109","Neonatal Complications of Coronavirus Disease (COVID-19)",,"Recruiting","No Results Available","Neonatal COVID-19 Disease","Other: No intervention - exposure is to COVID-19","Incidence of neonatal COVID-19|Incidence of vertically transmitted COVID-19|Presentation and natural history of neonatal COVID-19|Presentation of neonates with COVID-19 positive mothers|Outcomes for neonates with COVID-19|Clinical treatment of neonatal COVID-19|Neonatal secondary impacts of maternal COVID-19","University of Oxford|Imperial College London|University of Leicester|University of Nottingham|University of Glasgow|University Hospital of Wales|Public Health England|St George's, University of London","All","up to 29 Days   (Child)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","14905","April 1, 2020","March 31, 2021","September 30, 2021","May 13, 2020",,"May 13, 2020","Imperial College, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04386109"
535,"NCT04374032","Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection",,"Recruiting","No Results Available","COVID-19 Infection","Drug: metenkefalin + tridecactide|Drug: The standard of care","Time to onset of change in the patient's clinical condition|Safety and tolerability evaluation - treatment-related adverse events will be assessed by CTCAE|Length of in-hospital stay|Survival rate|Intubation rate|Proinflammatory markers levels","Bosnalijek D.D","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EN-COVCS-01","May 1, 2020","August 31, 2020","October 31, 2020","May 5, 2020",,"May 7, 2020","Clinical Center University of Sarajevo, Sarajevo, Sarajevo Canton, Bosnia and Herzegovina",,"https://ClinicalTrials.gov/show/NCT04374032"
536,"NCT04342221","Hydroxychloroquine for COVID-19","COV-HCQ","Recruiting","No Results Available","COVID-19, Hydroxychloroquine Sulfate","Drug: Hydroxychloroquine Sulfate|Drug: Placebo","Effect of HCQ on in vivo viral clearance","University Hospital Tuebingen|Robert Bosch Medical Center|Universitätsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COV-HCQ|2020-001224-33","March 29, 2020","March 2021","February 2022","April 10, 2020",,"April 10, 2020","Institute for Tropical Medicine, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT04342221"
537,"NCT04399356","Niclosamide for Mild to Moderate COVID-19",,"Not yet recruiting","No Results Available","COVID (SARS-CoV-2)","Drug: Niclosamide|Drug: Placebo|Other: Telehealth monitoring","Change in respiratory viral clearance (by PCR)|Fecal viral clearance (by PCR)|Reduction (change) in viral shedding (by PCR)","Tufts Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","STUDY00000605","June 1, 2020","October 1, 2020","November 30, 2020","May 25, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04399356"
538,"NCT04334044","Treatment of SARS Caused by COVID-19 With Ruxolitinib",,"Recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2","Drug: Ruxolitinib Oral Tablet","Recovery of Pneumonia|Response of C-reactive protein|Response of Ferritin|Response of D-dimer|Rate of ICU admission|Rate of mechanical ventilation|Overall Survival|Toxicity Rate","Grupo Cooperativo de Hemopatías Malignas","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HAL 345/2020","April 15, 2020","June 1, 2020","June 1, 2020","April 3, 2020",,"April 17, 2020","Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, Estado De México, Mexico",,"https://ClinicalTrials.gov/show/NCT04334044"
539,"NCT04392427","New Antiviral Drugs for Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID|Drug Effect","Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :","negative test result for COVID-19","Mansoura University","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","20.05.69","May 2020","May 2022","May 2022","May 18, 2020",,"May 18, 2020","Mansoura University, Mansoura, Select A State Or Province, Egypt",,"https://ClinicalTrials.gov/show/NCT04392427"
540,"NCT04379336","BCG Vaccination for Healthcare Workers in COVID-19 Pandemic",,"Recruiting","No Results Available","COVID-19|Sars-CoV2","Biological: Bacille Calmette-Guérin (BCG)|Other: Placebo Comparator","Incidence of HCWs hospitalized due to COVID-19 per arm|Incidence of SARS-CoV-2 infection per arm|Incidence of upper respiratory tract infections per arm|Days of unplanned absenteeism due to COVID-19 or any reason per arm|Incidence of hospitalization for any reason per arm|Incidence of intensive care unit admission per arm|Incidence of death per arm|Prevalence of latent TB infection|Incidence of active TB per arm|Compare the effect of latent TB on morbidity and mortality due to COVID-19 per arm|Incidence of treatment related adverse events","TASK Applied Science","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TASK-008 BCG-CORONA","May 4, 2020","April 28, 2021","April 28, 2021","May 7, 2020",,"May 7, 2020","TASK Foundation, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04379336"
541,"NCT04397666","RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19","P20/09","Recruiting","No Results Available","Covid 19 , Conjunctivitus","Diagnostic Test: conjunctival RT PCR","the SARS-Cov-2 positivity rate in patients with Covid-19 with or without signs of conjunctivitis","Versailles Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","P20/09_COVEYES","May 15, 2020","September 15, 2020","November 15, 2020","May 21, 2020",,"May 21, 2020","Centre Hospitalier de versailles, Le Chesnay, France",,"https://ClinicalTrials.gov/show/NCT04397666"
542,"NCT04365127","Progesterone for the Treatment of COVID-19 in Hospitalized Men",,"Recruiting","No Results Available","COVID-19|Sars-CoV2","Drug: Progesterone 100 MG","Change in clinical status of subjects at Day 15 based on the following 7-point ordinal scale|Change in clinical status of subjects assessed daily while hospitalized and on Day 29|Duration of supplemental oxygen, mechanical ventilation (if applicable), and hospitalization","Sara Ghandehari|IBSA Institut Biochimique SA|Cedars-Sinai Medical Center","Male","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000611","April 27, 2020","September 1, 2020","April 17, 2021","April 28, 2020",,"April 28, 2020","Cedars Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04365127"
543,"NCT04385810","Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19","DOCOV","Recruiting","No Results Available","Covid19|Sars-CoV2","Procedure: Ophthalmologic exam","Describe ophthalmologic damage to the cornea with direct exam at day 0|Describe ophthalmologic damage to the cornea with direct exam at day 7|Describe ophthalmologic damage to the cornea with direct exam at day 14|Describe ophthalmologic damage to the cornea with direct exam at discharge of hospital|Describe ophthalmologic damage to the cornea with slit lamp exam at day 0|Describe ophthalmologic damage to the cornea with slit lamp exam at day 7|Describe ophthalmologic damage to the cornea with slit lamp exam at day 14|Describe ophthalmologic damage to the cornea with slit lamp exam at discharge of hospital|Describe tear film anomalies at day 0|Describe tear film anomalies at day 7|Describe tear film anomalies at day 14|Describe tear film anomalies at discharge of hospital|Describe ophthalmologic damage to the retina at day 0|Describe ophthalmologic damage to the retina at day 7|Describe ophthalmologic damage to the retina at day 14|Describe ophthalmologic damage to the retina at discharge of hospital|Describe ophthalmologic damage to the optic nerve at day 0|Describe ophthalmologic damage to the optic nerve at day 7|Describe ophthalmologic damage to the optic nerve at day 14|Describe ophthalmologic damage to the optic nerve at discharge of hospital","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","JDS_2020_13","April 27, 2020","October 2020","October 2020","May 13, 2020",,"May 13, 2020","Fondation Adolphe de Rothschild, Paris, France",,"https://ClinicalTrials.gov/show/NCT04385810"
544,"NCT04382651","Study of Efficacy and Safety of MAS825 in Patients With COVID-19","MAS-COVID","Not yet recruiting","No Results Available","COVID-19 Pneumonia, Impaired Respiratory Function","Drug: MAS825|Drug: Matching placebo","APACHE II severity of disease score on Day 15 or on day of discharge (whichever is earlier)|Serum C-reactive protein (CRP levels)|Ferritin levels|Proportion of participants without the need for invasive mechanical ventilation|Proportion of participants with at least one level improvement in clinical status|Clinical status over time","Novartis Pharmaceuticals|Novartis","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CMAS825F12201","May 15, 2020","July 29, 2020","November 5, 2020","May 11, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04382651"
545,"NCT04341207","Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients","ONCOVID","Recruiting","No Results Available","Cancer & COVID 19","Drug: Hydroxychloroquine|Drug: Azithromycin","Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001250-21|2020/3078","April 3, 2020","April 2022","April 2022","April 10, 2020",,"April 10, 2020","Gustave Roussy, Villejuif, Val De Marne, France",,"https://ClinicalTrials.gov/show/NCT04341207"
546,"NCT04351711","Immunological Profiling of Patients With COVID-19 in Respiratory Distress","ACTICOV-2","Not yet recruiting","No Results Available","SARS-CoV-2|Covid-19","Other: Immunological profiling","Membrane expression of Human Leukocyte Antigen -DR isotype compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 38 compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of Programmed cell death 1 protein compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 45RA compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 27 (naïve/central memory/effector memory) compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of CD57 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 27 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 28 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of Human Leukocyte Antigen -DR isotype on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 69 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 56 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 57 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 14 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Membrane expression of cluster of differentiation 16 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)|Number of regulatory T cells (CD4+CD25hiCD127loFoxP3+).|Percentage of regulatory T cells (CD4+CD25hiCD127loFoxP3+).|Rate of circulating Immunoglobulin A compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Immunoglobulin G compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Immunoglobulin M compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Soluble cluster of differentiation 14 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Soluble cluster of differentiation 163 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Ultrasensitive C-Reactive Protein compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Soluble tumor necrosis factor alpha receptor type I compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating E-selectin (cluster of differentiation 62E) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Granulocyte Macrophage Colony-Stimulating Factor compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating InterCellular Adhesion Molecule-1 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interferon alpha compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interferon beta compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interferon gamma compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-1 alpha compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-1 beta compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-4 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-6 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-8 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-10 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-12p70 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-13 compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Interleukin-17A compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Induced Protein 10 (C-X-C motif chemokine 10) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Monocyte Chemoattractant Protein-1 (C-C Motif Chemokine Ligand 2) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Macrophage inflammatory protein-1 alpha (C-C Motif Chemokine Ligand 3) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating Macrophage inflammatory protein-1 beta (C-C Motif Chemokine Ligand 4) compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of circulating P-selectin compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of tumor necrosis factor alpha compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of tissue plasminogen activator compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of soluble form of endothelial protein C receptor compared to normal values (based on 150 healthy volunteers previously sampled)|Rate of D-Dimers compared to normal values (based on 150 healthy volunteers previously sampled)|Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 before any respiratory distress against that of 150 volunteers from the general population (data already existing).|Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 with respiratory failure against versus those without respiratory failure|Mortality rate|Comparison of E-selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Granulocyte Macrophage Colony-Stimulating Factor levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of InterCellular Adhesion Molecule levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interferon alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interferon gamma levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-4 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-6 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-8 (C-X-C motif ligand 8) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-10 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-12p70 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-13 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Interleukin-17A levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Induced Protein -10 (C-X-C motif chemokine 10) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Monocyte Chemoattractant Protein-1 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Macrophage Inflammatory Protein-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Macrophage Inflammatory Protein -1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of P-Selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Comparison of Tumor necrosis factor alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects|Identify inflammatory mediators over-produced by the PBMC of patients with COVID-19 before respiratory distress|Compare the inflammatory mediators over-produced by the peripheral blood mononuclear cells of patients with COVID-19 with versus without respiratory failure|Comparison of transcriptome from peripheral blood mononuclear cells from 12 patients with respiratory failure (from intensive care ward) and 10 without (normal hospitalization)","Centre Hospitalier Universitaire de Nīmes|Institute of Human Genetics, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NIMAO/2020-01/PC-01","April 2020","October 2020","October 2020","April 17, 2020",,"April 17, 2020","CHU de Nimes, Nîmes, France",,"https://ClinicalTrials.gov/show/NCT04351711"
547,"NCT04350476","COVID-19 Remote Monitoring",,"Not yet recruiting","No Results Available","COVID-19|Cardiac Arrhythmias","Diagnostic Test: VitalConnect Vital Sign Patch","Number of different arrhythmias|Temperature|Oxygen Saturation","Vivek Reddy|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","GCO 20-0932","July 2020","April 2021","April 2021","April 17, 2020",,"May 13, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04350476"
548,"NCT04372017","Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection",,"Recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin D","Cohort A: Percentage of COVID-19 exposed healthcare workers treated with hydroxychloroquine with a positive COVID-19 test.|Cohort B: Percentage of COVID-19 exposed high-risk individuals treated with hydroxychloroquine with a positive COVID-19 test.","Sanford Health","All","18 Years and older   (Adult, Older Adult)","Phase 3","1739","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PEPCOH","May 14, 2020","April 20, 2022","April 20, 2023","May 1, 2020",,"May 18, 2020","Sanford Health, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT04372017"
549,"NCT04283461","Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)",,"Recruiting","No Results Available","COVID-19|COVID-19 Immunisation","Biological: mRNA-1273","Frequency of solicited local reactogenicity adverse events (AEs)|Frequency of any medically-attended adverse events (MAAEs)|Frequency of any new-onset chronic medical conditions (NOCMCs)|Frequency of any serious adverse events (SAEs)|Frequency of any unsolicited adverse events (AEs)|Frequency of solicited systemic reactogenicity adverse events (AEs)|Grade of any unsolicited adverse events (AEs)|Grade of solicited local reactogenicity adverse events (AEs)|Grade of solicited systemic reactogenicity adverse events (AEs)|Geometric mean fold rise (GMFR) in IgG titer from baseline|Geometric mean titer (GMT) of antibody|Percentage of subjects who seroconverted","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","105","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20-0003|1UM1AI148373-01","March 16, 2020","September 20, 2021","September 20, 2021","February 25, 2020",,"May 4, 2020","Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, United States|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04283461"
550,"NCT04384471","Covid-19 Pandemic: Patients' Experience in T1D",,"Enrolling by invitation","No Results Available","Type1diabetes|Covid19","Other: Online survey","Self-reported acute diabetes complication|Self-reported hypoglycemia|Ability to get diabetes supplies and to access diabetes care|Concern about not having access to diabetes supplies and to access diabetes care|Impact of the pandemic situation on daily life activities|Impact on stress, anxiety and depression for adults participants|Impact on stress, anxiety and depression for children and adolescents","McGill University|Juvenile Diabetes Research Foundation|Canadian Institutes of Health Research (CIHR)","All","1 Year and older   (Child, Adult, Older Adult)",,"384","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2021-1079","April 29, 2020","July 1, 2020","January 1, 2021","May 12, 2020",,"May 12, 2020","Institut de Recherches Cliniques de Montréal, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04384471"
551,"NCT04359680","Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- or Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers",,"Not yet recruiting","No Results Available","COVID-19|Viral Respiratory Illnesses","Drug: Nitazoxanide|Drug: Placebo","The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.|The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.","Romark Laboratories L.C.","All","18 Years to 64 Years   (Adult)","Phase 3","800","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","RM08-3007","April 30, 2020","August 31, 2020","August 31, 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04359680"
552,"NCT04363203","VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)","VA-REACH","Active, not recruiting","No Results Available","SARS-CoV-2|COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Placebo oral tablet","Days to resolution of cough, fever and shortness of breath|Days to resolution of all COVID-19 symptoms|All cause hospitalization|All cause mortality|COVID-19 specific mortality|COVID-19 specific hospitalization","Salomeh Keyhani MD|San Francisco VA Health Care System","All","216 Months and older   (Adult, Older Adult)","Phase 3","300","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20-30517","April 30, 2020","March 2021","August 2021","April 27, 2020",,"May 11, 2020","San Francisco VA, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04363203"
553,"NCT04343781","National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19","COVID19PUGG2","Completed","No Results Available","SARS-CoV-2|COVID-19","Other: observation","symptoms of COVID-19 in older patients","University Hospital, Angers","All","70 Years and older   (Older Adult)",,"353","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","ar20-0031v1","March 22, 2020","April 5, 2020","April 5, 2020","April 13, 2020",,"April 14, 2020","Angers University Hospital, Angers, France",,"https://ClinicalTrials.gov/show/NCT04343781"
554,"NCT04394793","Low Dose Radiation Therapy for Covid-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19|Pneumonia","Radiation: Low dose radiation therapy","Symptomatic improvement by National Early warning score (NEWS)|Length of hospital stay|Number of ICU admissions or deaths","All India Institute of Medical Sciences, New Delhi","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-AIIMS","June 2020","January 2021","June 2021","May 19, 2020",,"May 19, 2020","All India Institute of Medical Sciences, New Delhi, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04394793"
555,"NCT04393558","Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms",,"Recruiting","No Results Available","COVID-19|Healthy Control","Device: ADAM Sensor","Body temperature|Cough Frequency|Respiratory frequency|Heart Rate Instantaneous heart rate every 15 minutes.","Shirley Ryan AbilityLab","All","18 Years to 95 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STU00212522","April 20, 2020","December 31, 2022","December 31, 2022","May 19, 2020",,"May 21, 2020","Shirley Ryan AbilityLab, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04393558"
556,"NCT04344002","LunG canceR pAtients coVId19 Disease (GRAVID)","GRAVID","Recruiting","No Results Available","Covid-19|Lung Cancer",,"Clinical data of lung cancer patients with COVID-19 diagnoses|Diagnosis data|Treatments received|Prognostic factors","Spanish Lung Cancer Group","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Other","GECP 20/02_GRAVID","April 21, 2020","September 15, 2020","December 15, 2020","April 14, 2020",,"May 14, 2020","Complejo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain|H. Clínica Benidorm, Benidorm, Alicante, Spain|Hospital de Elche, Elche, Alicante, Spain|Hospital General Universitario de Elda, Elda, Alicante, Spain|Hospital de Torrevieja, Torrevieja, Alicante, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Cetir Centre Mèdic, Esplugues De Llobregat, Barcelona, Spain|Hospital General de Granollers, Granollers, Barcelona, Spain|Hospital Universitario de Galdakao, Galdakao, Bizkaia, Spain|Complejo Hospitalario de la Coruña, La Coruña, Coruña, Spain|H. Insular de Gran Canarias, Las Palmas De Gran Canaria, Gran Canarias, Spain|Hospital San Pedro, Logroño, La Rioja, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital Universitario de Móstoles, Móstoles, Madrid, Spain|Hospital de Manacor, Manacor, Mallorca, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Instituto Onkologikoa, San Sebastián, País Vasco, Spain|Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Verge de la Cinta, Tortosa, Tarragona, Spain|H. Universitario de Canarias, La Laguna, Tenerife, Spain|Hospital Universitario de La Ribera, Alzira, Valencia, Spain|Hospital de Manises, Manises, Valencia, Spain|Hospital de Cruces, Baracaldo, Vizcaya, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|H. Gen. Universitario Alicante, Alicante, Spain|H. Universitario Quirón Dexeus, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|H. Duran i Reynals-ICO, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital La Mancha Centro, Ciudad Real, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Universitario de Puerto Real, Cádiz, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Guadalajara, Guadalajara, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital San Millan Y San Pedro, Logroño, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|MD Anderson, Madrid, Spain|H.U. Puerta de Hierro, Madrid, Spain|Fundación Jimenez Diaz, Madrid, Spain|Hospital Universitario Infanta Sofía, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital de Sanchinarro, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario del Henares, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Santa María Naí, Ourense, Spain|Hospital Son Espases, Palma de Mallorca, Spain|H. Son Llàtzer, Palma de Mallorca, Spain|Hospital Clinico de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Sant Pau i Santa Tecla, Tarragona, Spain|Hospital universitario Nuestra Señora Candelaria, Tenerife, Spain|H. General U. de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital Politècnic i Universitari La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|H. Miguel Servet, Zaragoza, Spain|Hospital Ntra. Sra. Sónsoles, Ávila, Spain|Hospital Universitario de Áraba, Vitoria, Áraba, Spain",,"https://ClinicalTrials.gov/show/NCT04344002"
557,"NCT04362124","Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection",,"Not yet recruiting","No Results Available","COVID-19","Biological: vaccine BCG|Other: Placebo","Primary outcome|Secondary outcome","Universidad de Antioquia","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","PEC03_2020","April 2020","June 2021","November 2021","April 24, 2020",,"April 28, 2020","Program for Research and Control in Tropical Diseases - PECET, Medellín, Antioquia, Colombia",,"https://ClinicalTrials.gov/show/NCT04362124"
558,"NCT04353271","Trial of Hydroxychloroquine In Covid-19 Kinetics","THICK","Active, not recruiting","No Results Available","Covid 19|Corona Virus Infection","Drug: Hydroxychloroquine|Other: Placebo","Percentage of virus free subjects|Disease severity|Incidence of hospitalization|Incidence of Death|Incidence of confirmed SARS-CoV-2 Detection|Incidence of all-cause study medication discontinuation or withdrawal|Immunity to Covid-19","University of South Alabama","All","19 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","[1582736-1]","April 17, 2020","July 1, 2020","December 1, 2020","April 20, 2020",,"April 28, 2020","University of South Alabama, Mobile, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04353271"
559,"NCT04379089","Neurologic Manifestations of COVID 19 in Children",,"Recruiting","No Results Available","COVID|Neurologic Manifestations","Other: Observational study only","Frequency of neurologic manifestations of COVID 19 among pediatric patients requiring hospital admission for confirmed or presumed COVID 19|Associations between prescription of empiric COVID-19 directed therapies and patient characteristics and outcomes among children with or without neurologic manifestations and confirmed or presumed COVID-19","University of Pittsburgh|University of Utah|Johns Hopkins University","All","up to 17 Years   (Child)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STUDY20040154","April 29, 2020","December 31, 2021","December 31, 2022","May 7, 2020",,"May 7, 2020","UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04379089"
560,"NCT04385017","Role of Inflammasomes in COVID-19 Disease","CoVInnate","Recruiting","No Results Available","COVID-19 by SARS-CoV-2 Infection","Other: COVID-19 patients","Level of activation of inflammasomes in monocytes and polymorphonuclear neutrophils during COVID-19|Genes nucleoside polymorphism analysis","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20-PP-07","May 11, 2020","June 12, 2021","June 12, 2021","May 12, 2020",,"May 12, 2020","Ch Cannes, Réanimation, Cannes, Alpes Maritimes, France|CHU de nice, Nice, Alpes-Maritimes, France",,"https://ClinicalTrials.gov/show/NCT04385017"
561,"NCT04389554","D-dimer Levels in Pregnant With COVID-19",,"Enrolling by invitation","No Results Available","COVID-19|D-dimer","Other: Blood D-dimer assay","Compare D-dimer values of COVID-19 patients and healthy pregnant women","Kanuni Sultan Suleyman Training and Research Hospital","Female","18 Years to 45 Years   (Adult)",,"400","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","MTalmac","May 14, 2020","July 1, 2020","July 3, 2020","May 15, 2020",,"May 18, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turgut Ozal, Turkey",,"https://ClinicalTrials.gov/show/NCT04389554"
562,"NCT04367805","COVID-19 Infection in Patients With Hepatocellular Carcinoma","COVID19-CHIEF","Recruiting","No Results Available","Hepatocellular Carcinoma|COVID-19","Diagnostic Test: nasopharyngeal Covid 19 RT-PCR","Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France","Centre Hospitalier Universitaire, Amiens|Centre Hospitalier-Universitaire Bondy|University Hospital, Bordeaux|Centre Hospitalier-Universitaire CLICHY|Centre Hospitalier Général CORBEIL-ESSONNE|CHU CRETEIL|University Hospital, Grenoble|University Hospital, Lille|CHU LYON|Poitiers University Hospital|Rennes University Hospital|University Hospital, Rouen|University Hospital, Toulouse|CHU VILLEJUIF|Central Hospital, Nancy, France|Centre Hospitalier Universitaire de Nice|University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PI2020_843_0042","April 27, 2020","October 2020","October 2020","April 29, 2020",,"April 29, 2020","CHU Amiens, Amiens, France",,"https://ClinicalTrials.gov/show/NCT04367805"
563,"NCT04386512","Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1)","LymphoCov1","Not yet recruiting","No Results Available","COVID|Lymphoma",,"mortality|transfer to ICU","Versailles Hospital","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","P20/12_LymphoCov","May 15, 2020","June 1, 2020","July 15, 2020","May 13, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04386512"
564,"NCT04343248","Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)",,"Not yet recruiting","No Results Available","COVID-19|Viral Respiratory Illnesses","Drug: Nitazoxanide|Drug: Placebo","Symptomatic laboratory-confirmed COVID-19|Symptomatic laboratory-confirmed VRI","Romark Laboratories L.C.","All","65 Years to 120 Years   (Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","RM08-3006","April 30, 2020","August 31, 2020","August 31, 2020","April 13, 2020",,"April 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04343248"
565,"NCT04366167","Patient Recovery From Heart Surgery During the Covid-19 Pandemic","CardiacCovid","Recruiting","No Results Available","Cardiac Surgery|COVID","Other: Cardiac surgery","Change in Impact of Events scores|Survival|Morbidity|Change in Health-related quality of life scores|Change in Depression scores","Barts & The London NHS Trust|Queen Mary University of London","All","18 Years to 120 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","132127","April 18, 2020","April 19, 2021","December 31, 2021","April 28, 2020",,"April 28, 2020","St Bartholomew's Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04366167"
566,"NCT04252664","A Trial of Remdesivir in Adults With Mild and Moderate COVID-19",,"Suspended","No Results Available","COVID-19|SARS-CoV-2","Drug: Remdesivir|Drug: Remdesivir placebo","Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events","Capital Medical University|Chinese Academy of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 3","308","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAP-China remdesivir 1","February 12, 2020","April 10, 2020","April 27, 2020","February 5, 2020",,"April 15, 2020","Jin Yin-tan hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04252664"
567,"NCT04397614","Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients",,"Not yet recruiting","No Results Available","Sars-CoV2|Covid-19","Other: mHealth Assessments","Percentage of ecological momentary assessments completed|Percentage of satisfied mHealth app users|Proportion of manifestation of severe disease|Proportion of treatment-related toxicity|Proportion of hospitalization|Proportion of COVID-19 related mortality","University of Oklahoma","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 Mobile Health","June 2020","December 2021","December 2021","May 21, 2020",,"May 21, 2020","Stephenson Cancer Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT04397614"
568,"NCT04391881","Oral Manifestation of COVID 19 Patient: A Cross Sectional Study on Egyptian Population",,"Not yet recruiting","No Results Available","Oral Health and COVID 19",,"Oral manifestation","Cairo University","All","18 Years to 60 Years   (Adult)",,"500","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","54678","May 30, 2020","June 30, 2020","June 30, 2020","May 18, 2020",,"May 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04391881"
569,"NCT04395391","Home Usability Study of the SARS-CoV-2 Test",,"Recruiting","No Results Available","COVID-19","Diagnostic Test: SARS-CoV-2","Valid SARS-CoV-2 Test","Exact Sciences Corporation","All","18 Years and older   (Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-06","May 18, 2020","May 21, 2020","June 2020","May 20, 2020",,"May 20, 2020","Exact Sciences, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04395391"
570,"NCT04357535","Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives",,"Terminated","No Results Available","COVID-19","Drug: Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)","Assess the rate of requirement of invasive mechanical ventilation|Mortality|Septic shock as defined by sepsis-3 criteria|Degree of severity of respiratory disease","Hakeam Abdulaziz Hakeam|Buraidah Central Hospital|King Khalid University Hospital|King Faisal Specialist Hospital & Research Center","All","18 Years and older   (Adult, Older Adult)",,"17","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2210061","April 12, 2020","May 3, 2020","May 3, 2020","April 22, 2020",,"May 8, 2020","King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04357535"
571,"NCT04329559","COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study",,"Recruiting","No Results Available","COVID-19|Liver Cirrhosis",,"All-cause mortality of COVID-19 patients with liver cirrhosis|Liver-related mortality of COVID-19 patients with liver cirrhosis|Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis|Baseline characteristics of COVID-19 patients with liver cirrhosis","Hepatopancreatobiliary Surgery Institute of Gansu Province|Renmin Hospital of Wuhan University|LanZhou University|Minda Hospital Affiliated to Hubei University for Nationalities|Wuhan Union Hospital, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture|Tianjin Second People's Hospital|Sixth People’s Hospital of Shenyang|Guangxi Zhuang Autonomous Region|Shenzhen Third People's Hospital|Ankang Central Hospital|Xingtai People's Hospital|Dalian Sixth People’s Hospital|The Central Hospital of Lishui City|The Affiliated Third Hospital of Jiangsu University|Suizhou Hospital, Hubei University of Medicine","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","CHESS2002","March 30, 2020","June 29, 2020","June 29, 2021","April 1, 2020",,"April 1, 2020","Dalian Sixth People's Hospital, Dalian, China|Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China|The First Hospital of Lanzhou University, Lanzhou, China|The Central Hospital of Lishui City, Lishui, China|Guangxi Zhuang Autonomous Region, Nanning, China|The Sixth Peoples Hospital of Shenyang, Shenyang, China|Shenzhen Third People's Hospital, Shenzhen, China|Suizhou Hospital, Hubei University of Medicine, Suizhou, China|Tianjin Second People's Hospital, Tianjin, China|Ankang Central Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|Wuhan Union Hospital, Wuhan, China|Xingtai People's Hospital, Xingtai, China|The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China",,"https://ClinicalTrials.gov/show/NCT04329559"
572,"NCT04373161","Home Pulse Oximeter Use in Patients With COVID-19",,"Completed","No Results Available","Sars-CoV2|COVID-19|COVID","Device: Home Pulse Oximetry Monitoring","Hospitalization in COVID-19 patients with low home SpO2|Trend in resting home pulse oximetry readings|Timing of SpO2 <92%|Home pulse oximeter use effect on subsequent ED visits|Reason for return to the Emergency Department|Hospitalization outcome - morbidity|Hospitalization outcome - mortality|Median Length of Stay","Swedish Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","209","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2020032301","March 20, 2020","April 22, 2020","April 22, 2020","May 4, 2020",,"May 6, 2020","Swedish Hospital, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04373161"
573,"NCT04318431","Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children","COVILLE","Recruiting","No Results Available","Covid19","Diagnostic Test: Data collection and rhinopharyngeal swab","Proportion of asymptomatic children or children with mild respiratory symptoms|Confirmed Cov2-SARS cases by age|Confirmed Cov2-SARS cases by symptoms|Viral load|Other respiratory viruses|Sars-Cov2 IgM|Sars-Cov2 IgG","Centre Hospitalier Intercommunal Creteil|ACTIV","All","6 Months to 15 Years   (Child)","Not Applicable","600","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","COVILLE|2020-A00724-35","April 14, 2020","June 2020","June 2020","March 24, 2020",,"April 24, 2020","Cabinet du Dr Belaroussi, Boulogne, France|Cabinet du Dr Derkx, Champigny-sur-Marne, France|Cabinet du Dr Coicadan, Chennevières-sur-Marne, France|14 Av rené Samuel, Clamart, France|Cabinet du Dr Corrard, Combs-la-Ville, France|10 rue Delambre, Lagny-sur-Marne, France|157 Avenue du Général Leclerc, Maisons-Alfort, France|21 Grande Rue Charles de Gaulle, Nogent-sur-Marne, France|Cabinet du Dr Deberdt, Nogent-sur-Marne, France|Cabinet du Dr Wollner, Nogent-sur-Marne, France|4 allée des Norottes, Noisy-le-Grand, France|Cabinet du Dr D'acremont, Paris, France|146 Avenue Ledru Rollin, Paris, France|132 Boulevard du Montparnasse, Paris, France|Cabinet du Dr Romain, Paris, France|Cabinet du Dr Turberg-Romain, Paris, France|15 Quai Louis Blériot, Paris, France|Cabinet du Dr Michot, Paris, France|24 rue Volta, Puteaux, France|Cabinet du Dr Cohen, Saint-Maur-des-Fossés, France|Cabinet de Pédiatrie des Docteurs Ravilly et Bessa, Villejuif, France|13 Villa Beauséjour, Vincennes, France",,"https://ClinicalTrials.gov/show/NCT04318431"
574,"NCT04280588","Fingolimod in COVID-19",,"Recruiting","No Results Available","Coronavirus Disease (COVID-19)","Drug: Fingolimod 0.5 mg","The change of pneumonia severity on X-ray images","First Affiliated Hospital of Fujian Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRCTA, ECFAH of FMU [2020]027","February 22, 2020","July 1, 2020","July 1, 2020","February 21, 2020",,"February 21, 2020","Wan-Jin Chen, Fuzhou, China",,"https://ClinicalTrials.gov/show/NCT04280588"
575,"NCT04355767","Convalescent Plasma vs. Placebo in Emergency Room Patients With COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma|Biological: Standard Plasma","Time to disease progression|Change in symptom severity over time","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 2","206","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","56249","May 2020","December 2022","December 2022","April 21, 2020",,"April 21, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04355767"
576,"NCT04377646","A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers","COVID-Milit","Not yet recruiting","No Results Available","Sars-CoV2|COVID19","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine (placebo)|Drug: Zinc|Drug: Zinc (Placebo)","SARS CoV2 infection|COVID-19 symptoms description|Adverse Events","Military Hospital of Tunis|UR17DN02 : Autoimmune Diseases Research Unit|Dacima Consulting","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","660","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","UR17DN02-001|TN2020-NAT-INS-38","May 4, 2020","May 24, 2020","July 31, 2020","May 6, 2020",,"May 6, 2020","Military Hospital of Tunis, Tunis, Tunisia",,"https://ClinicalTrials.gov/show/NCT04377646"
577,"NCT04343261","Convalescent Plasma in the Treatment of COVID 19",,"Enrolling by invitation","No Results Available","SARS-CoV-2|COVID|Coronavirus","Biological: Convalescent Plasma","Mortality|Viral Load|Serum Antibody Titers","Saint Francis Care","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SFH-20-23","April 10, 2020","December 1, 2020","April 1, 2021","April 13, 2020",,"May 13, 2020","Trinity Health Of New England, Hartford, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04343261"
578,"NCT04318301","Hypertension in Patients Hospitalized With COVID-19","HT-COVID19","Completed","No Results Available","COVID-19|Hypertension",,"Rate of Death|the severity of pneumonia","Zhenhua Zen|Nanfang Hospital of Southern Medical University","All","18 Years to 100 Years   (Adult, Older Adult)",,"275","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","HT-COVID19","March 21, 2020","March 28, 2020","March 30, 2020","March 23, 2020",,"April 29, 2020","Hankou Hospital, Hankou, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04318301"
579,"NCT04358068","Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19",,"Recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin","Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset","National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD","All","18 Years and older   (Adult, Older Adult)","Phase 2","2000","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACTG A5395|38720","May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",,"May 18, 2020","Alabama CRS, Birmingham, Alabama, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Ucsf Hiv/Aids Crs, San Francisco, California, United States|Harbor-UCLA CRS, Torrance, California, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|Rush University CRS, Chicago, Illinois, United States|Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Weill Cornell Chelsea CRS, New York, New York, United States|Weill Cornell Uptown CRS, New York, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Greensboro CRS, Greensboro, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|Ohio State University CRS, Columbus, Ohio, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|University of Washington AIDS CRS, Seattle, Washington, United States|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04358068"
580,"NCT04377815","Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste","FORECAST","Recruiting","No Results Available","COVID-19|Anosmia","Other: General Public cohort","Percentage of people reporting changes in smell/taste|mortality rate|Percentage of people with change in smell/taste before other symptoms|proportion of other COVID-19 linked symptoms in people with smell and/or taste change|Percentage of people with persistent changes in smell and/or taste|Percentage of hospitalisation|co-morbidities association|prevalence of changes in smell/taste|clinical outcomes","University College, London","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","132311|20/HRA/1879","April 23, 2020","August 30, 2020","December 23, 2020","May 6, 2020",,"May 6, 2020","University College London Hospital, London, United Kingdom|GP Practices, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04377815"
581,"NCT04374084","Moxibustion Plus Cupping in Convalescent Patients With COVID-19",,"Not yet recruiting","No Results Available","COVID-19|Convalescence","Other: Moxibustion plus Cupping","The change of the average VAS score from baseline to week 4|The change of the average VAS score from baseline to week 2, week 4 and week 8|The change of the severity VAS score from baseline to week 2, week 4 and week 8|The change of the average insomnia VAS score from baseline to week 2, week 4 and week 8|The change of the average VAS score of sweating, mental fatigue, anorexia and nervousness from baseline to week 2, week 4 and week 8|The change of the average times of diarrhea and complete spontaneous bowel movement to week 2, week 4 and week 8|The proportion of patients with improved clinical symptoms to week 2, week 4 and week 8|The change of the walking distance of six-minute-walking test from baseline to week 2, week 4 and week 8|The change of the lowest oxygen saturation of six-minute-walking test from baseline to week 2, week 4 and week 8|The proportion of patients in recovery of pulmonary function on week 2 and week 4|The proportion of patients whose lung CT return to normal on week 4|The change of the WHO QOL-BREF score from baseline to week 4 and week 8|The change of the SAS score from baseline to week 4 and week 8|The change of the SDS score from baseline to week 4 and week 8|The change of the blood CRP value from baseline to week 4|The change of the blood LYMPH# value from baseline to week 4|The change of the blood NEUT% value from baseline to week 4|The change of the average VAS score from baseline to week 4 in different age groups.|The change of the average VAS score from baseline to week 4 in different gender groups.|The change of the average VAS score from baseline to week 4 in different clinical classification of COVID-19.","Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Hubei Hospital of Traditional Chinese Medicine|Hubei Provincial Hospital of Integrated Chinese & Western Medicine|Wuhan Hospital of Traditional Chinese Medicine|The Third Hospital of Wuhan|Huangshi Hospital of Traditional Chinese Medicine|Yichang Hospital of Traditional Chinese Medicine|Ezhou Hospital of Traditional Chinese Medicine|The First Hospital of Hunan University of Chinese Medicine|The Hospital of Jiangxi University of Traditional Chinese Medicine|Shenzhen Bao'an Traditional Chinese Medicine Hospital Group","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020YFC0845000","May 2020","December 2021","December 2021","May 5, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04374084"
582,"NCT04351919","Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)","COVID+PA","Not yet recruiting","No Results Available","Patients With COVID19","Drug: Hydroxychloroquine|Drug: Azithromycin","improvment or healing of clinical signs|Evolution of clinical signs","Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Dacima Consulting","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECC2020-04","May 5, 2020","July 15, 2020","July 15, 2020","April 17, 2020",,"May 5, 2020","Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia",,"https://ClinicalTrials.gov/show/NCT04351919"
583,"NCT04354259","Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19","ILIAD","Recruiting","No Results Available","Sars-CoV2|Covid-19","Drug: Peginterferon Lambda-1A|Other: placebo","Cohort A (Ambulatory) - Proportion swab negative at day 7 (Primary efficacy endpoint)|Cohort A (Ambulatory) - Treatment-emergent and treatment related serious adverse events (Primary Safety Endpoint)|Cohort B (Hospitalized) - Time to viral negativity (Primary Efficacy Endpoint)|Cohort B (Hospitalized) - treatment-emergent and treatment-related serious adverse events (Primary Safety Endpoint)|Cohort A (Ambulatory) - Symptom Resolution (Clinical Outcome #1)|Cohort A (Ambulatory) - Symptom severity scores (Clinical Outcome #2)|Cohort A (Ambulatory) - Hospitalization (Clinical Outcome #3)|Cohort A (Ambulatory) - Adverse and serious adverse events (Clinical Outcome #4)|Cohort A (Ambulatory) - Swab negative at day 3 (Virologic/Immunological Outcome #1)|Cohort A (Ambulatory) - Time RNA negativity (Virologic/Immunological Outcome #2)|Cohort A (Ambulatory) - Proportion viremic (Virologic/Immunological Outcome #3)|Cohort A (Ambulatory) - Proportion with antibodies (Virologic/Immunological Outcome #4)|Cohort A (Ambulatory) - Correlation with interferon lambda 4 genotype (Virologic/Immunological Outcome #5)|Cohort A (Ambulatory) - Symptoms in household contacts (Transmission Outcome #1)|Cohort A (Ambulatory) - COVID-19 in household contacts (Transmission Outcome #2)|Cohort B (Hospitalized) - ICU admission (Clinical Outcome #1)|Cohort B (Hospitalized) - Need for intubation (Clinical Outcome #2)|Cohort B (Hospitalized) - Length of hospital stay (Clinical Outcome #3)|Cohort B (Hospitalized) - Change in respiratory symptom score (Clinical Outcome #4)|Cohort B (Hospitalized) - Readmission to hospital (Clinical Outcome #5)|Cohort B (Hospitalized) - All-cause mortality (Clinical Outcome #6)|Cohort B (Hospitalized) - COVID-19-related mortality (Clinical Outcome #7)|Cohort B (Hospitalized) - Adverse (AEs) and Serious Adverse Events (SAEs) (Clinical Outcome #8)|Cohort B (Hospitalized) - Dose reduction or dose omission (Clinical Outcome #9)|Cohort B (Hospitalized) - Proportion negative swab. (Virologic/Immunological Outcome #1)|Cohort B (Hospitalized) - Proportion negative by day 14 (Virologic/Immunological Outcome) #2)|Cohort B (Hospitalized) - Time to negativity by rectal swab (Virologic/Immunological Outcome #3)|Cohort B (Hospitalized) - Correlation with interferon lambda 4 (IFNL4) genotype (Virologic/Immunological Outcome #4)|Cohort B (Hospitalized) - Proportion with Antibody (Virologic/Immunological Outcome #6)|Cohort B (Hospitalized) - Proportion with viremia (Virologic/Immunological Outcome #7)","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Phase 2","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JF-4-2020","May 13, 2020","August 1, 2020","November 30, 2020","April 21, 2020",,"May 18, 2020","Toronto General Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04354259"
584,"NCT04352608","Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)",,"Recruiting","No Results Available","COVID-19","Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of placebo at the emergency vaccination schedule|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of placebo at the routine vaccination schedule","Safety indexes of adverse reactions|Immunogenicity indexes of neutralizing-antibody seroconversion rates for the emergency vaccination schedule （day 0,14）|Immunogenicity indexes of neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28)|Occurrence of abnormal changes of laboratory safety examinations (hemoglobin,WBCs, platelets, ALT, AST, total bilirubin, creatinine, creatine phosphokinase, urine protein, urine sugar, urinary erythrocyte)|Safety indexes of serious adverse events (SAEs）|Immunogenicity indexes of neutralizing-antibody seroconversion rates|Immunogenicity indexes of IgG antibody seropositivity rates|Immunogenicity indexes IgM antibody seropositivity rates|Immunogenicity indexes of GMT of neutralizing-antibody|Immunogenicity indexes of GMR of neutralizing-antibody","Sinovac Research and Development Co., Ltd.|Sinovac Biotech Co., Ltd","All","18 Years to 59 Years   (Adult)","Phase 1|Phase 2","744","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PRO-nCOV-1001","April 16, 2020","August 13, 2020","December 13, 2020","April 20, 2020",,"April 28, 2020","Suining County Center for Disease Control and Prevention, Xuzhou, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04352608"
585,"NCT04383574","Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)",,"Not yet recruiting","No Results Available","COVID-19","Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Other: Two doses of placebo at the schedule of day 0,28","Safety index-incidence of adverse reactions|Immunogenicity index-seroconversion rates of neutralizing antibody|Safety index-incidence of serious adverse events|Immunogenicity index-seropositive rates of neutralizing antibody|Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody|Immunogenicity index-geometric mean ratio (GMR) of neutralizing antibody","Sinovac Research and Development Co., Ltd.|Sinovac Biotech Co., Ltd","All","60 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","422","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PRO-nCOV-1002","May 20, 2020","July 20, 2020","July 20, 2020","May 12, 2020",,"May 12, 2020","Renqiu City Center for Disease Control and Prevention, Renqiu, Hebei, China",,"https://ClinicalTrials.gov/show/NCT04383574"
586,"NCT04379154","Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-CoV-2 (COVID-19)","VOC-COVID","Recruiting","No Results Available","COVID-19","Device: Volatile Organic Compounds analysis","Profiles of volatile organic compounds (VOCs) in exhaled air between 2 health conditions|Profiles of volatil organic compounds (VOCs) in exhaled air on 1 health condition|Profiles of volatil organic compounds (VOCs) in exhaled air between 2 periods","Hopital Foch","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2020_0060","April 14, 2020","June 28, 2020","November 16, 2020","May 7, 2020",,"May 7, 2020","Hôpital Foch, Suresnes, France",,"https://ClinicalTrials.gov/show/NCT04379154"
587,"NCT04370275","Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia","POCUSars-CoV-2","Recruiting","No Results Available","COVID-19|Pneumonia, Viral",,"Negative Predictive Value of Lung Ultrasound in the diagnosis of COVID-19|Positive Predictive Value of Lung Ultrasound in the diagnosis of COVID-19|Sensitivity and Specificity of Lung Ultrasound in the diagnosis of COVID-19","Ospedale di Latisana","All","18 Years and older   (Adult, Older Adult)",,"235","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEUR-2020-Os-086","April 23, 2020","May 23, 2020","May 31, 2020","April 30, 2020",,"April 30, 2020","SC Pronto Soccorso e Medicina d'Urgenza, Latisana, Udine, Italy",,"https://ClinicalTrials.gov/show/NCT04370275"
588,"NCT04371432","Genetics of COVID-19 Susceptibility and Manifestations",,"Recruiting","No Results Available","COVID-19|Coronavirus 2019",,"Molecular etiology of host susceptibility to severe COVID-19|Mechanisms of disease","National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","3 Years to 60 Years   (Child, Adult)",,"2500","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","200090|20-HG-0090","May 28, 2020","June 1, 2025","June 1, 2025","May 1, 2020",,"May 25, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04371432"
589,"NCT04363749","COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities","CRC-COVID","Not yet recruiting","No Results Available","Covid19|Neurological Complication","Other: hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint","Intensity of the emotional response to hypoxic exposure (14.3 et 12.7% FIO2)|Perception of a hypoxic stimulus induced dyspnea (14.3 et 12.7% FIO2)|Perception of a hypercapnic stimulus induced dyspnea (7% CO2)|Perception of a inspiratory mechanical constraint induced dyspnea|brain MRI","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","APHP200476","April 27, 2020","April 27, 2021","November 27, 2021","April 27, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04363749"
590,"NCT04345315","Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.","CORSA","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Other: serological test|Other: Rapid molecular test|Genetic: Next generation Sequencing (NGS) analysis|Other: serum chemistry analysis","epidemiology|Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies evaluation|methods comparison|correlation between biochemical and coagulative factors with SARS-CoV-2 positivity.|phylogenetic map|interactions between the virus and host cells","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|AUSL Romagna","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","IRSTB113","March 27, 2020","March 2021","March 2022","April 14, 2020",,"April 15, 2020","UO Microbiologia,Centro Servizi Pievesestina, AUSL Romagna, Cesena, FC, Italy|Irst Irccs, Meldola, FC, Italy",,"https://ClinicalTrials.gov/show/NCT04345315"
591,"NCT04348240","Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions",,"Recruiting","No Results Available","COVID-19",,"To determine SARS-CoV-2 viral load and infectivity in saliva that may contribute to asymptomatic transmission","National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"60","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200094|20-D-0094","April 16, 2020","July 1, 2020","July 1, 2020","April 16, 2020",,"May 21, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04348240"
592,"NCT04389944","Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19",,"Recruiting","No Results Available","Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection)","Other: convalescent plasma application to SARS-CoV-2 infected patients","Serious adverse events in convalescent plasma treated patients|Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients|Transfer to ICU|in-hospital death|Virologic clearance in plasma of convalescent plasma treated patients|Time to discharge from hospital after enrolment|Humoral immune response","University Hospital, Basel, Switzerland","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Req-2020-00508; me20khanna2","March 31, 2020","June 30, 2020","June 30, 2020","May 15, 2020",,"May 15, 2020","Blutspendezentrum SRK beider Basel, University Hospital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT04389944"
593,"NCT04400032","Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard","CIRCA-19","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome|Covid19","Biological: Mesenchymal Stromal Cells","Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Number of Participants alive by Day 28|Number of Participants with ventilator-free Days by Day 28","Ottawa Hospital Research Institute|Stem Cell Network","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20200243-01H","May 2020","January 2021","June 2021","May 25, 2020",,"May 25, 2020","The Ottawa Hospital, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04400032"
594,"NCT04346017","Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome",,"Recruiting","No Results Available","COVID-19","Diagnostic Test: Cytokines dosage|Diagnostic Test: Complement dosage","IL6 concentration|IL6 concentration change from baseline value|Complement parameters|Complement parameters change from baseline values|Inflammatory cytokines baseline concentrations|Inflammatory cytokines change from baseline values|Concentration of markers of macrophage activation|Markers of macrophage activation change from baseline values","Francis Corazza|Brugmann University Hospital","All","Child, Adult, Older Adult","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CHUB-IL6-COVID-19","March 20, 2020","December 2020","December 2020","April 15, 2020",,"April 15, 2020","CHU Brugmann, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04346017"
595,"NCT04344457","Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","COVID-19","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product","Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement","Perseverance Research Center, LLC|Athena Medical Group","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIZ-PRC-COVID-19","April 16, 2020","June 20, 2020","September 30, 2020","April 14, 2020",,"April 30, 2020","Perseverance Research Center, Scottsdale, Arizona, United States|Covidcraz 19, Llc, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04344457"
596,"NCT04386252","Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Frontline Healthcare Workers and First Responders",,"Not yet recruiting","No Results Available","COVID-19","Biological: AV-COVID-19","Confirm safety|Suggestion of efficacy|Optimal dose of SARS-CoV-2 antigen|Advantage of administering vaccine admixed with GM-CSF|Frequency of detecting IgG against SARS-CoV-2 in blood after vaccination","Aivita Biomedical, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CL-COV-P01-US","September 2020","October 2020","April 2021","May 13, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04386252"
597,"NCT04336332","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19",,"Recruiting","No Results Available","SARS-CoV-2|COVID-19","Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate","Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood","Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","002011|Pro2020000712","April 1, 2020","April 30, 2021","April 30, 2021","April 7, 2020",,"May 8, 2020","Saint Barnabas Medical Center, Livingston, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04336332"
598,"NCT04368988","Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant",,"Recruiting","No Results Available","COVID-19","Biological: SARS-CoV-2 rS|Other: Matrix-M Adjuvant|Other: NSS Saline Placebo","Subjects with solicited AEs - Phase 1|Safety Laboratory Values (serum chemistry, hematology) - Phase 1|Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) - Phase 1","Novavax","All","18 Years to 59 Years   (Adult)","Phase 1","131","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","2019nCoV-101","May 6, 2020","December 31, 2020","July 31, 2021","April 30, 2020",,"May 15, 2020","Investigational Research Site 1, Herston, Queensland, Australia|Investigational Research Site 2, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT04368988"
599,"NCT04341870","Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO","CORIMUNO-VIRO","Suspended","No Results Available","COVID19|SARS-CoV-2 Infection","Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine","Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale <= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines","Assistance Publique - Hôpitaux de Paris","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-3","April 11, 2020","May 8, 2020","August 2020","April 10, 2020",,"May 6, 2020","AP-HP Hôpital Avicenne, Bobigny, France|AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt, France|AP-HP Hôpital Beaujon, Clichy, France|AP-HP Hôpital Pitié Salpétrière, Paris, France|AP-HP Hôpital Saint Antoine, Paris, France",,"https://ClinicalTrials.gov/show/NCT04341870"
600,"NCT04331106","Survey of the Anxiety Associated With the COVID-19 Pandemic","CORA","Recruiting","No Results Available","Anxiety Related to the COVID-19 Pandemic","Diagnostic Test: Online Questionnaire","Characteristics of COVID-19-related anxiety|COVID-19-related anxiety symptoms|Self-efficacy and coping with COVID-19|Consequences of COVID-19 in the last three weeks.|General Illness Attitude|Media reporting|Ultra-brief screening scale for anxiety and depression|Change in characteristics of COVID-19-related anxiety|Change in COVID-19-related anxiety symptoms","Charite University, Berlin, Germany","All","18 Years and older   (Adult, Older Adult)",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EA1/071/20","March 27, 2020","September 2020","September 2021","April 2, 2020",,"April 13, 2020","Charité-Universitätsmedizin Berlin - Department of Psychiatry and Psychotherapy, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04331106"
601,"NCT04351152","Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia",,"Recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19) Pneumonia","Biological: Lenzilumab|Drug: Standard of Care","Incidence of invasive mechanical ventilation (IMV) and/or Mortality|Incidence of acute respiratory distress syndrome (ARDS)|Duration of Hospitalization|Duration of Intensive Care Unit (ICU) Stay|Ventilator-free Days|Incidence of Non-invasive Ventilation|Proportion of Participants Alive and Off Oxygen|Percentage of Participants Experiencing Adverse Events|Percentage of Participants Experiencing Serious Adverse Events","Humanigen, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","238","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","HGEN003-06","April 30, 2020","September 2020","September 2020","April 17, 2020",,"May 19, 2020","Mayo Clinic, Phoenix, Arizona, United States|Stanford University, Redwood City, California, United States|Mayo Clinic, Jacksonville, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Mayo Clinic, Rochester, Minnesota, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|Atrium Health, Charlotte, North Carolina, United States|Texas Health, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04351152"
602,"NCT04344938","Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality",,"Not yet recruiting","No Results Available","Covid 19 Pandemic From Ethical View","Other: questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality","Evaluate the ethical requirement of controlled disrupts of patients In case of infectious disease pandemic","Assiut University|Doaa M.EL Shehaby","All","18 Years to 60 Years   (Adult)",,"874","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","2020A10","April 2020","June 2020","July 2020","April 14, 2020",,"April 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04344938"
603,"NCT04336384","Impact of Covid-19 in Congenital Heart Disease","COVID-CHD","Recruiting","No Results Available","Congenital Heart Disease|Covid-19",,"Prevalence of Covid-19 infection in the overall CHD population|Prevalence of Covid-19 infection per CHD sub-group|Cardiovascular complications|Other complications|Number of deaths","University Hospital, Montpellier|Pr. Jean-Benoît THAMBO, Bordeaux (président)|Dr. Céline GRUNENWALD GRONIER, Strasbourg|Dr. Sébastien HASCOET, Le Plessis-Robinson|Dr. Adeline BASQUIN, Rennes|Dr. Nicolas COMBES, Toulouse|Dr. Xavier IRIART, Bordeaux|Dr. Daniela LAUX, Paris|Dr. Magalie LADOUCEUR, Paris|Pr. BERTRAND LEOBON, Toulouse|Pr. Caroline OVAERT, Marseille|Dr. Karine WARIN-FRESSE, Nantes|Alexis BLANC, Montpellier|Pr. Roland HENAINE, Lyon|Hamouda ABASSI, Montpellier","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0155","March 1, 2020","December 1, 2020","December 30, 2020","April 7, 2020",,"April 14, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04336384"
604,"NCT04392128","Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)","HYACINTHE","Not yet recruiting","No Results Available","COVID19|Hematologic Malignancy","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Azithromycin 250 MG Oral Capsule|Drug: Placebo oral tablet|Drug: Placebo oral capsule","Evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5.|Clinical evolution|Proportion of patients progressing to a severe form|Mortality|Evaluation of viral load drop|Tolerance of study treatment|Evaluation of the seroconversion|NK immunological study|Hospitalisation duration|Impact of the study treatment on the treatment of the hematological disease|Monitoring of the QT space|Dosage of residual concentration of azithromycine and hydroxychloroquine.|T immunological study","Institut de Cancerologie Strasbourg Europe","All","18 Years and older   (Adult, Older Adult)","Phase 2","114","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-005|2020-002002-45","May 12, 2020","December 31, 2020","January 31, 2021","May 18, 2020",,"May 20, 2020","Institut de Cancérologie Strasbourg Europe, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04392128"
605,"NCT04355052","Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus","COSTA","Recruiting","No Results Available","COVID - 19","Drug: hydroxychloroquine in combination with camostat mesylate|Drug: Hydroxychloroquine in combination of Azithromycin","clinical state as reflected by NEWS scoring|positive PCR|prevention of ICU|prevention of assisted ventilation|prevention of ECMO|death","Sheba Medical Center","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7092-20-SMC","April 11, 2020","October 11, 2020","December 11, 2020","April 21, 2020",,"April 21, 2020","Sheba Medical Center, Ramat Gan, Israel|Sheba Medical Center, Tel HaShomer, Israel",,"https://ClinicalTrials.gov/show/NCT04355052"
606,"NCT04334005","Vitamin D on Prevention and Treatment of COVID-19","COVITD-19","Not yet recruiting","No Results Available","Patients Infected With COVID-19","Dietary Supplement: Vitamin D","Composite of cumulative death (i.e. mortality) for all causes and for specific causes.|Necessity of invasive assisted ventilation|Necessity of non-invasive assisted ventilation|Intensive care unit admission|Post-anesthesia care unit admission|Hospital admission|Medical consultation|Home care and isolation time|Bed rest time|symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of COVID-19)|Subjective perception of recovery","Universidad de Granada","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVITD-19","April 10, 2020","June 30, 2020","June 30, 2020","April 3, 2020",,"April 7, 2020","Universidad de Granada, Granada, Andalucia, Spain|Medicine Faculty, Granada, Spain",,"https://ClinicalTrials.gov/show/NCT04334005"
607,"NCT04371510","Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients","PredictCovid-D","Recruiting","No Results Available","COVID-19 by SARS-CoV-2 Infection","Other: blood sample","Predictive value of IL-6 contents of whole blood samples after ex vivo stimulation","Centre Hospitalier Universitaire de Nice","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","115","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20-PP-08","April 22, 2020","October 22, 2020","February 22, 2021","May 1, 2020",,"May 1, 2020","CHU de nice, Nice, Alpes-Maritimes, France",,"https://ClinicalTrials.gov/show/NCT04371510"
608,"NCT04350099","Emotional Burden of Healthcare Professionals and Covid Infection 19","Emocovid","Not yet recruiting","No Results Available","Emotionnal Distress; COVID-19","Other: quetionnary","anxiety","University Hospital, Limoges","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","87RI20_0015/Emocovid","April 15, 2020","December 15, 2020","June 15, 2021","April 16, 2020",,"April 16, 2020","CH Esquirol, Limoges, France|CHU de Limoges, Limoges, France",,"https://ClinicalTrials.gov/show/NCT04350099"
609,"NCT04338100","Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients","POCUSCO","Not yet recruiting","No Results Available","COVID|Coronavirus Infection","Procedure: Follow-up at 14 days","Risk of unfavourable outcome at D14|Risk of unfavourable outcome over time|Risk-stratification threshold values|Adding value of POCUS score to previous risk-stratification clinical rules|POCUS score and patient clinical status at D14|POCUS and CT scan correlation|POCUS versus CT scan risk-stratification performances|POCUS score evolution performances","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2020-A00782-37","April 6, 2020","December 29, 2020","January 29, 2021","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04338100"
610,"NCT04362150","Long-term Impact of Infection With Novel Coronavirus (COVID-19)","LIINC","Recruiting","No Results Available","COVID",,"Participant age|Participant sex|Participant race/ethnicity|Proportion of participants previously hospitalized.","University of California, San Francisco","All","18 Years to 100 Years   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-30479","April 21, 2020","December 31, 2022","December 21, 2024","April 24, 2020",,"April 29, 2020","Zuckerberg San Francisco General Hospital (ZSFG), San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04362150"
611,"NCT04348877","Plasma Rich Antibodies From Recovered Patients From COVID19","PRA-001","Not yet recruiting","No Results Available","Coronavirus Disease (COVID-19)","Other: Antibody-Rich Plasma from COVID-19 recovered patients","viral COVID-19 clearance|Decrease of radiological abnormalities|Clinical improvement","Ain Shams University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FMASU P15/ 2020","April 20, 2020","October 2020","December 2020","April 16, 2020",,"April 20, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,"https://ClinicalTrials.gov/show/NCT04348877"
612,"NCT04349241","Efficacy and Safety of Favipiravir in Management of COVID-19","FAV-001","Not yet recruiting","No Results Available","Coronavirus Disease (COVID-19)","Drug: favipiravir|Drug: Standard of care therapy","Viral clearance|Clinical improvement|Radiological Improvement","Ain Shams University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FMASU P14 / 2020","April 20, 2020","October 1, 2020","December 1, 2020","April 16, 2020",,"April 20, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,"https://ClinicalTrials.gov/show/NCT04349241"
613,"NCT04375397","Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With CoronaVirus Induced Disease 2019 (COVID-19) and Pulmonary Distress",,"Not yet recruiting","No Results Available","CoronaVirus Induced Disease-2019 (COVID-19)","Drug: Ibrutinib|Drug: Placebo","Percentage of Participants Alive and Without Respiratory Failure|Change in the World Health Organization (WHO)-8 Point Ordinal Scale From Baseline|Median Reduction in Days Spent on Supplemental Oxygen|All-Cause Mortality|Percentage of Participants Experiencing Respiratory Failure or Death|Mechanical Ventilation-Free Survival|Days on Mechanical Ventilation|Duration of hospitalization|Time to Discharge|Partial Pressure of Oxygen in Arterial Blood (PaO2) to Fraction of Inspired Oxygen (FiO2) Ratio|Oxygenation Index|Number of Participants With Adverse Events|Number of Participants With Abnormal Laboratory Findings","AbbVie|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M20-310","May 6, 2020","July 30, 2020","August 27, 2020","May 5, 2020",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04375397"
614,"NCT03891420","A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19",,"Recruiting","No Results Available","COVID-19|Yellow Fever","Drug: Galidesivir|Drug: Placebo","number of subjects with treatment emergent adverse events and serious adverse events|number of subjects with change in laboratory parameters|exposure of galidesivir as measured by plasma concentrations|yellow fever virus (YFV) titer (Group A)|antiviral effect on SARS-CoV-2 in the respiratory tract - COVID-19 (Group B)|changes in clinical status using 8-point ordinal scale in COVID-19 (Group B)|changes from baseline and time to improvement using NEWS in COVID-19 (Group B)|mortality","BioCryst Pharmaceuticals|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 1","66","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BCX4430-108|272201300017C-18-0-1|DMID18-0022","April 9, 2020","May 31, 2021","May 31, 2021","March 27, 2019",,"April 15, 2020","Clinical Research Unit and Department of Infectious and Parasitic Diseases Hospital das Clínicas, School of Medicine, USP, São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT03891420"
615,"NCT04393805","Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto","HETHICO","Not yet recruiting","No Results Available","COVID-19|Hypercoagulability","Drug: Low Molecular Weight Heparin","Bleeding|Thrombosis|Mortality|Worsening|LOS","Quovadis Associazione|University of Padova","All","18 Years and older   (Adult, Older Adult)",,"877","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HETHICO","June 2020","December 2020","December 2020","May 19, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04393805"
616,"NCT04303299","Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial","THDMS-COVID-19","Not yet recruiting","No Results Available","SARS-COV-2 Infections|COVID-19","Drug: Oral","SARS-CoV-2 eradication time|Number of patient with Death|Number of patient with Recovery adjusted by initial severity in each arm|Number of day With ventilator dependent adjusted by initial severity in each arm|Number of patient developed Acute Respiratory Distress Syndrome After treatment","Rajavithi Hospital","All","16 Years to 100 Years   (Child, Adult, Older Adult)","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH-DMS-COVID19 study","April 15, 2020","October 31, 2020","November 30, 2020","March 11, 2020",,"April 10, 2020","Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT04303299"
617,"NCT04397523","Efficacy and Safety of COVID-19 Convalescent Plasma",,"Recruiting","No Results Available","Convalescent Plasma|COVID-19|SARS-CoV 2","Biological: anti-SARS-CoV-2 convalescent plasma","Duration of oxygenation and ventilation support|Hospital length of stay (LOS)|ICU admission|Ventilator free days|Incidence of serious adverse events|Type of respiratory support|Number of participants with different clinical outcomes including death, critical illness and recovery","Institute for Transfusion Medicine of RNM|University Clinic for Infectious Diseases, North Macedonia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ITM05/2020MKD","April 30, 2020","April 29, 2021","April 29, 2021","May 21, 2020",,"May 25, 2020","Institute for Transfusion Medicine of RNM, Skopje, North Macedonia",,"https://ClinicalTrials.gov/show/NCT04397523"
618,"NCT04352842","Echocardiographic Manifestation in Patient With COVID-19 （EARLY-MYO COVID-19）",,"Completed","No Results Available","Covid19|Echocardiography","Other: Echocardiography","Death","RenJi Hospital","All","18 Years and older   (Adult, Older Adult)",,"51","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID19-Echocardiography","January 21, 2020","April 8, 2020","April 8, 2020","April 20, 2020",,"May 19, 2020","Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04352842"
619,"NCT04380727","Almitrine and COVID-19 Related Hypoxemia",,"Completed","No Results Available","COVID-19|Hypoxic Respiratory Failure",,"Changes from baseline PaO2 (mmHg)|Changes from baseline ScvO2 (%)","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)",,"17","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","COVID-19_CHRU NANCY_2020PI080","March 20, 2020","April 14, 2020","April 25, 2020","May 8, 2020",,"May 8, 2020","Centre Hospitalier Universitaire NANCY, Vandoeuvre-les-Nancy, France",,"https://ClinicalTrials.gov/show/NCT04380727"
620,"NCT04330521","Impact of the Coronavirus (COVID-19) on Patients With Cancer",,"Not yet recruiting","No Results Available","Cancer|COVID-19",,"Number of participants who fill out the survey and participate in the semi-structured interviews.","Stanford University","All","18 Years to 99 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","55596","April 2020","May 2022","May 2022","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330521"
621,"NCT04394208","Silymarin in COVID-19 Pneumonia","SCOPE","Not yet recruiting","No Results Available","COVID-19|Viral Pneumonia Human Coronavirus","Drug: Silymarin|Drug: Placebo","Time to clinical improvement|Clinical outcome|Duration of Mechanical Ventilation|Hospitalization|Virologic Response|Adverse events","Cairo University","All","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","CairoU COVID-19 Study Group","June 1, 2020","August 30, 2020","September 30, 2020","May 19, 2020",,"May 19, 2020","Cairo University, Giza, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04394208"
622,"NCT04344288","Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection","CORTI-Covid","Recruiting","No Results Available","Viral Pneumonia Human Coronavirus|COVID-19","Drug: Prednisone|Other: Control group","Number of patients with a theoretical respiratory indication for transfer to intensive care unit evaluated by a SpO2 <90% stabilized at rest and under not more than 5 L / min of supplemental oxygen using medium concentration mask.|disease severity assessed on a 7-level ordinal scale|number of patients with a supplemental oxygen use|radiological signs on chest imaging|number of patients transferred to intensive care unit|number of patients requiring invasive ventilation|Duration of oxygen therapy|number of adverse events induced by corticosteroid treatment|number of patients with infections other than SARS-CoV-2|number of deaths","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","Phase 2","304","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","69HCL20_0321|2020-001553-48","April 2020","November 2020","November 2020","April 14, 2020",,"April 20, 2020","Hôpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France|Groupement Hospitalier Nord, Lyon, France|Groupement Hospitalier Nord, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpital St Joseph Saint Luc, Lyon, France|Hôpital St Joseph, Marseille, France|Centre hospitalier Lyon Sud, Pierre-Bénite, France|Centre hospitalier Lyon Sud, Pierre-Bénite, France|CHU St Etienne, Saint-Étienne, France|Clinique Charcot, Sainte-Foy-lès-Lyon, France|CHG Vienne, Vienne, France|Médipôle, Villeurbanne, France|Clinique des Portes du Sud, Vénissieux, France|CH Annecy-Genevois, Épagny, France",,"https://ClinicalTrials.gov/show/NCT04344288"
623,"NCT04343144","Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.","CORIMUNO-NIVO","Not yet recruiting","No Results Available","COVID19- Infection With SARS-CoV-2 Virus","Drug: Nivolumab Injection","Time to clinical improvement|Overall survival|Cumulative incidence of ICU admission|Length of hospital stay|Positive nasal PCR|Incidence of adverse events|Incidence of grade 3-4 adverse events|World Health Organisation (WHO) progression scale","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200389-5","April 15, 2020","July 31, 2020","September 30, 2020","April 13, 2020",,"April 14, 2020","Pneumologie hôpital Tenon, Paris, France",,"https://ClinicalTrials.gov/show/NCT04343144"
624,"NCT04357457","Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia","AIRVM-COVID","Not yet recruiting","No Results Available","Covid 19|Hypoxemic Respiratory Failure","Drug: Almitrine|Drug: Placebo","Rate of endotracheal intubation|28-day mortality|In-hospital mortality|Number of ventilator-free days|Number of days in the ICU|Number of days in the hospital|Discontinuation rate of the treatment","Assistance Publique - Hôpitaux de Paris|Centre Hospitalier de Chartres","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","212","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APHP200461|2020-001909-22","May 2020","July 2020","July 2020","April 22, 2020",,"May 13, 2020","Hospital Pitié-Salpêtrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04357457"
625,"NCT04386044","Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients",,"Not yet recruiting","No Results Available","COVID-19|Vitamin D Deficiency",,"COVID-19 infection|Oxygen therapy for COVID-19|Discharge following COVID-19 hospitalisation|Death due to COVID-19","Tameside General Hospital","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Other|Time Perspective: Other","TGH1234","June 1, 2020","December 31, 2020","June 1, 2021","May 13, 2020",,"May 13, 2020","Tameside Hospital NHS Foundation Trust, Ashton-under-Lyne, Greater Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04386044"
626,"NCT04344951","Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","HOPE","Recruiting","No Results Available","Pneumonia, Viral|Covid-19","Drug: UNIKINON (Chloroquine phosphate) 200mg tablets","50% reduction in symptom score for patients with lower respiratory tract infection|Lack of progression for patients with upper respiratory tract infection|Comparison of the primary endpoint with respective patients not receiving the treatment|Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment.|Frequency of AEs and SAEs","Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.|Athens General Hospital Hippokrateio|Athens General Hospital of Thoracic Diseases SOTIRIA|General Hospital of Athens Sismanoglio|Divine Providence Hospital Pammakaristos","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","60","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UNIKINON-01/HOPE","April 6, 2020","April 1, 2021","April 30, 2021","April 14, 2020",,"April 14, 2020","Divine Providence Hospital ""Pammakaristos"", Athens, Greece|Athens General Hospital ""Hippokrateio"", Athens, Greece|Athens General Hospital of Thoracic Diseases ""SOTIRIA"", 1st University Pulmonary Clinic, Athens, Greece|Athens General Hospital of Thoracic Diseases ""SOTIRIA"", 3rd University Pathology Clinic, Athens, Greece|General Hospital of Athens ""Sismanoglio"", Maroúsi, Greece",,"https://ClinicalTrials.gov/show/NCT04344951"
627,"NCT04350281","Double Therapy With IFN-beta 1b and Hydroxychloroquine",,"Recruiting","No Results Available","COVID","Drug: Interferon Beta-1B|Drug: Hydroxychloroquine","Time to negative NPS viral load|Time to NEWS 0|Length of Hospitalisation|Time to negative viral load in all clinical samples|Adverse events|Mortality|Inflammatory markers changes","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UW 20-211","April 9, 2020","March 31, 2022","July 31, 2022","April 17, 2020",,"April 17, 2020","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04350281"
628,"NCT04360122","Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19",,"Not yet recruiting","No Results Available","Coronavirus Disease (COVID-19)","Drug: Levamisole|Drug: Isoprinosine|Drug: Levamisole and Isoprinosine","Decrease the incidence of COVID-19 infection or its severity","Ain Shams University","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","FMASU P20a/ 2020","May 20, 2020","November 1, 2020","December 1, 2020","April 24, 2020",,"May 5, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,"https://ClinicalTrials.gov/show/NCT04360122"
629,"NCT04360876","Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial",,"Not yet recruiting","No Results Available","COVID-19|ARDS","Drug: Dexamethasone injection|Drug: Placebos","Ventilator Free Days (VFD) at Day 28|Clinical Status at day 14 as measured by World Health Organization (WHO) 7-point ordinal scale.|Clinical Status at day 28 as measured by WHO 7-point ordinal scale|In-Hospital Mortality at day 28|In-Hospital Mortality at day 90|Time to Mortality to day 28|ICU-free days to day 28|Hospital Length of Stay among survivors to day 90|Severity of ARDS to day 10|Days to resolution of fever|Change in C-Reactive Protein (CRP) level from baseline to day 10|Vasopressor-free days to day 28|Renal replacement-free days to day 28|Duration of mechanical ventilation to day 28|Oxygenation-free days to day 28|Incidence of New Mechanical Ventilation to day 28|Change in sequential organ failure assessment (SOFA) score from baseline to day 10|In-hospital adverse events to day 28|Discontinuation of study drug infusion","University of Colorado, Denver","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","20-0811","May 1, 2020","September 30, 2020","December 31, 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04360876"
630,"NCT04385095","Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection",,"Recruiting","No Results Available","SARS-CoV-2","Drug: Interferon beta 1a|Drug: Placebo","Ordinal Scale for Clinical Improvement|Progression to pneumonia|Time to clinical improvement|National Early Warning Score 2 (NEWS2) assessment of acute-illness severity|Changes in daily breathlessness, cough and sputum scale (BCSS)|Safety and tolerability - blood pressure II. Viral load|Safety and tolerability - heart rate II. Viral load|Safety and tolerability - temperature II. Viral load|Safety and tolerability - respiratory rate II. Viral load|Safety and tolerability - oxygen saturation II. Viral load|Safety and tolerability - adverse events II. Viral load|Safety and tolerability - concomitant medications II. Viral load","Synairgen Research Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SG016","March 16, 2020","August 31, 2020","May 31, 2021","May 12, 2020",,"May 12, 2020","Belfast City Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital,, Birmingham, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Hull and East Yorkshire NHS Trust, Castle Hill Hospital,, Hull, United Kingdom|Glenfield Hospital,, Leicester, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|City Campus of Nottingham University, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|University Hospital Southampton Nhs Foundation Trust, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04385095"
631,"NCT04356417","Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse","TRAPSAH","Not yet recruiting","No Results Available","AMD, ACEi's/ARB Prevent/Worsen Risk of COVID-19 Infection","Other: - Synthetic anti-malarial drugs","Identification of serious COVID-19 infections|Pneumonia infections|ICU stay|Oro-tracheal intubation|Death","Assistance Publique - Hôpitaux de Paris|GIS EPI-PHARE","All","18 Years and older   (Adult, Older Adult)",,"6000000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","APHP200412","April 2020","June 2020","June 2020","April 22, 2020",,"April 22, 2020","Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France",,"https://ClinicalTrials.gov/show/NCT04356417"
632,"NCT04365595","SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir)",,"Recruiting","No Results Available","SARS-CoV 2|COVID","Other: Questionnaires, spirometry","Health-related quality-of-life|Anxiety and depression|Symptom burden|Spirometry","University of Zurich","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2020-00745","May 2020","December 2020","December 2020","April 28, 2020",,"May 4, 2020","University Hospital Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04365595"
633,"NCT04350736","First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",,"Recruiting","No Results Available","Acute Lung Injury (ALI) Associated With COVID-19|Inflammatory Lung Conditions Associated With COVID-19","Drug: TD-0903|Drug: Placebo","Safety and Tolerability of SAD of TD-0903: Adverse Events|Safety and Tolerability of MAD of TD-0903: Adverse Events|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): AUC|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Cmax|Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Tmax|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): AUC|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Cmax|Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Tmax","Theravance Biopharma","All","18 Years to 50 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","0183|2020-000577-24","April 23, 2020","June 2020","June 2020","April 17, 2020",,"May 25, 2020","Theravance Biopharma Investigational Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04350736"
634,"NCT04392089","Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS","NIRS-COV","Recruiting","No Results Available","COVID-19|Respiratory Failure","Device: Masimo, LidCO","Changes in cerebral oxygenation (ScO2) during cardiovascular and pulmonary optimization|Changes in peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization|Changes in systolic arterial pressure (SAP) during cardiovascular and pulmonary optimization|Changes in diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization|Changes in mean arterial pressure (MAP) during cardiovascular and pulmonary optimization|Changes in heart rate (HR) during cardiovascular and pulmonary optimization|Changes in stroke volume (SV) during cardiovascular and pulmonary optimization|Changes in cardiac output (CO) during cardiovascular and pulmonary optimization|Changes in systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization|Changes in peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization|Changes in pH during cardiovascular and pulmonary optimization|Changes in PaO2 during cardiovascular and pulmonary optimization|Changes in PaCO2 during cardiovascular and pulmonary optimization|Changes in arterial saturation (SaO2) during cardiovascular and pulmonary optimization|Changes in PvO2 during cardiovascular and pulmonary optimization|Changes in PvCO2 during cardiovascular and pulmonary optimization|Changes in mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization|Changes in lacatate during cardiovascular and pulmonary optimization|Changes in hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization|Changes in muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and systemic arterial pressure (SAP) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and mean arterial pressure (MAP) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and stroke volume (SV) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and heart rate (HR) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and cardiac output (CO) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and pH during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PaO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PaCO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and arterial saturation (SaO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PvO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PvCO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and lactate during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization","Hvidovre University Hospital","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-20027818","May 1, 2020","May 1, 2021","May 1, 2021","May 18, 2020",,"May 18, 2020","Hvidovre Hospital, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04392089"
635,"NCT04350931","Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19",,"Not yet recruiting","No Results Available","Coronavirus Disease (COVID-19)","Biological: intradermal injection of BCG Vaccine|Other: placebo","incidence of confirmed COVID-19|Effectiveness of BCG vaccine","Ain Shams University","All","18 Years and older   (Adult, Older Adult)","Phase 3","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","FMASU P19a/ 2020","April 20, 2020","October 1, 2020","December 1, 2020","April 17, 2020",,"April 20, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,"https://ClinicalTrials.gov/show/NCT04350931"
636,"NCT04346797","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","CORIMUNO19-ECU","Recruiting","No Results Available","SARS-CoV-2|COVID19","Drug: Eculizumab","Survival without needs of intubation at day 14|Change in organ failure at day 3|Intubation free survival at day 14|WHO progression scale at days 4, 7 and 14|Survival at 14, 28 and 90 days|Time to discharge|Time to oxygen supply independency|Time to negative viral excretion|Incidence of secondary infections|Vasopressor-free survival|Ventilator-free survival|28-day ventilator-free days|Incidence of dialysis|PaO2/FiO2 ratio|Rate of respiratory acidosis at day 4|Time to ICU discharge","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-4","April 16, 2020","September 30, 2020","December 31, 2020","April 15, 2020",,"April 27, 2020","Saint Louis, Paris, Ile De France, France|Réanimation médicale, Paris, France|saint Louis, Paris, France",,"https://ClinicalTrials.gov/show/NCT04346797"
637,"NCT04346043","To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database","Strain","Not yet recruiting","No Results Available","Coronavirus Disease (COVID-19)",,"Dominant viral genome strain","Ain Shams University","All","18 Years to 80 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","FMASU P16a/ 2020","April 20, 2020","October 1, 2020","December 1, 2020","April 15, 2020",,"April 20, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,"https://ClinicalTrials.gov/show/NCT04346043"
638,"NCT04362176","Passive Immunity Trial of Nashville II for COVID-19","PassItOnII","Recruiting","No Results Available","COVID-19|Coronavirus|SARS-CoV-2","Biological: pathogen reduced SARS-CoV-2 convalescent plasma|Biological: Placebo","COVID Ordinal Outcomes Scale:Day 15|All-location, all-cause 14-day mortality|All-location, all-cause 28-day mortality|COVID Ordinal Outcomes Scale Day 3|COVID Ordinal Outcomes Scale Day 8|COVID Ordinal Outcomes Scale Day 29|Composite of death or receipt of ECMO through Day 28|Oxygen-free days through Day 28|Vasopressor-free days through Day 28|Ventilator-free days through Day 28|ICU-free days through Day 28|Hospital-free days through Day 28","Vanderbilt University Medical Center|Dolly Parton","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","200738","April 24, 2020","April 2021","April 2021","April 24, 2020",,"May 4, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04362176"
639,"NCT04347681","Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19",,"Recruiting","No Results Available","Convalescent Plasma for COVID 19","Other: convalescent plasma from recovered COVID 19 donor","ICU length of stay|Safety of convalescent plasma & Serious adverse reactions.|Number of days on mechanical ventilation|30 days of mortality|Days to clinical recovery .","King Fahad Specialist Hospital Dammam|King Fahad Medical City|King Faisal Specialist Hospital And Research Center|King Abdulaziz Medical City|King Fahad University Hospital|John Hopkins Aramco Healthcare|Taibah University|King Saud University|King Khaled University Hospital|King Fahad Military Medical Complex|Qatif Central Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HAEM0321","April 18, 2020","December 31, 2020","April 11, 2021","April 15, 2020",,"May 19, 2020","John Hopkins Aramco Healthcare, Dhahran, Eastern Provence, Saudi Arabia|Dammam Medical Complex, Dammam, Saudi Arabia|Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia|king Fahad specialist hospital, Dammam, Saudi Arabia|DHahran Military Medical Complex, Dhahran, Saudi Arabia|International Medical Center, Jeddah, Saudi Arabia|Madinah General Hospital, Medina, Saudi Arabia|Ohud Hospital, Medina, Saudi Arabia|Taibah University, Medina, Saudi Arabia|Qatif Central Hospital, Qatif, Saudi Arabia|King Abdulaziz Medical City, Riyadh, Saudi Arabia|King Fahad Medical City, Riyadh, Saudi Arabia|King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia|King Khalid University Hospital, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04347681"
640,"NCT04341116","Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)",,"Recruiting","No Results Available","Coronavirus Disease 2019 COVID-19","Drug: TJ003234|Drug: Placebo","Proportion (%) of subjects experiencing deterioration in clinical status|Treatment Emergent Adverse Events|Clinical status|Improvement in clinical status|Sequential Organ Failure Assessment (SOFA) score|Change from baseline in PaO2/ FiO2|Length of time to normalization of oxygen saturation|Change from baseline in percentage of subjects requiring mechanical ventilation|Change from baseline in Glucocorticoid use|Mortality rate from any cause|Length of hospitalization|Change from baseline in D-dimer|Serum concentration of TJ003234|Incidence and titer of anti-drug antibodies (ADA)","I-Mab Biopharma Co. Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","144","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TJ003234COV201","April 11, 2020","September 2020","September 2020","April 10, 2020",,"May 21, 2020","The GW Medical Faculty Associates, Washington, District of Columbia, United States|OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Medpharmics, LLC, Metairie, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple Univeristy Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04341116"
641,"NCT04342897","A Study of LY3127804 in Participants With COVID-19",,"Recruiting","No Results Available","COVID-19|Pneumonia","Drug: LY3127804|Drug: Placebo","Number of Ventilator Free Days|Number of Participants Reporting Each Severity Rating on the National Institute of Allergy and Infectious Diseases (NIAID) Ordinal Assessment|Percentage of Participants who are Alive and Respiratory Failure Free|Oxygen Saturation (SpO₂)|Oxygen Flow Rate|Mortality|Length of Hospitalization|Number of Participants with any Serious Adverse Event (SAE)|Number of Participants with any Treatment Emergent Adverse Event (TEAE)","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17824|I7W-MC-UDAA","April 20, 2020","June 12, 2020","July 16, 2020","April 13, 2020",,"May 19, 2020","NorthShore University HealthSystem, Evanston, Illinois, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT04342897"
642,"NCT04346147","Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19","Covid-19HUF","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Hidroxicloroquine|Drug: Lopinavir/ritonavir|Drug: Imatinib tablets|Drug: Baricitinib Oral Tablet","time to clinical improvement|Safety of treatments|Tolerability of treatments","Hospital Universitario de Fuenlabrada|Centro Nacional de Investigaciones Oncologicas CARLOS III","All","18 Years and older   (Adult, Older Adult)","Phase 2","165","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","24032020","April 13, 2020","August 2020","September 2020","April 15, 2020",,"May 8, 2020","Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04346147"
643,"NCT04373044","Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",,"Recruiting","No Results Available","Symptomatic COVID-19 Infection Laboratory-Confirmed","Drug: Baricitinib|Drug: Hydroxychloroquine|Drug: Placebo Administration","Proportion of patients requiring invasive mechanical ventilation or dying|Identification of clinical features (vitals signs - body temperature)|Identification of clinical features (vital signs - respiratory rate)|Identification of clinical features (vital signs - heart rate)|Identification of clinical features (vital signs - blood pressure)|Identification of clinical features (Imaging)|Identification of clinical features (Lab - White Blood Count)|Identification of clinical features (Lab - Absolute Lymphocyte Count)|Identification of clinical features (Lab - Hemoglobin)|Identification of clinical features (Lab - Creatinine)|Identification of biomarkers (C-reactive protein)|Identification of biomarkers (Interleukin-6)|Identification of biomarkers (Tumor Necrosis Factor-alpha)|Identification of adverse events","University of Southern California|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","144","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0S-20-3|NCI-2020-02685|P30CA014089","April 24, 2020","April 24, 2021","April 24, 2022","May 4, 2020",,"May 21, 2020","Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04373044"
644,"NCT04366856","PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study)","PROVID","Not yet recruiting","No Results Available","COVID|ARDS","Behavioral: 1: Prone positioning|Behavioral: 2: No instruction regarding positioning","Proportion of patients who meet one or both following criteria: need for intubation (for mechanical ventilation), occurrence of death during hospital stay.|Proportion of patients admitted to ICU (for patients included out of ICU)|Days alive and free from non invasive ventilation (NIV) or high flow nasal canula oxygen delivery (HFNC) (for those neither under NIV or HFNC at the time of study inclusion)|Days alive and out of ICU|Days alive and out of hospital|Maximum oxygenotherapy rate during hospital stay [Time Frame: At day28]","Assistance Publique - Hôpitaux de Paris","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200504","April 2020","May 2020","July 2020","April 29, 2020",,"April 29, 2020","Département d'Anesthésie Réanimation - Kremlin Bicêtre, Le Kremlin-Bicêtre, France",,"https://ClinicalTrials.gov/show/NCT04366856"
645,"NCT04359667","Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab","UHID-COVID19","Recruiting","No Results Available","COVID-19|Severe Pneumonia","Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]","serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab","University Hospital for Infectious Diseases, Croatia","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UHID-04","April 16, 2020","April 16, 2020","April 15, 2021","April 24, 2020",,"April 24, 2020","University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia",,"https://ClinicalTrials.gov/show/NCT04359667"
646,"NCT04373460","Convalescent Plasma to Limit SARS-CoV-2 Associated Complications","CSSC-004","Not yet recruiting","No Results Available","SARS-CoV 2","Biological: SARS-CoV-2 convalescent plasma|Biological: Plasma from a volunteer donor","Cumulative incidence of hospitalization or death prior to hospitalization|Cumulative incidence of treatment-related serious adverse events|Cumulative incidence of treatment-related grade 3 or higher adverse events|Change in serum SARS-CoV-2 antibody titers|Time to SARS-CoV-2 Polymerase Chain Reaction (PCR) negativity","Johns Hopkins University|State of Maryland|Bloomberg Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","1344","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00247590","May 19, 2020","December 21, 2022","January 31, 2023","May 4, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04373460"
647,"NCT04371354","Outcomes of Covid Protective Measures in Endoscopy",,"Not yet recruiting","No Results Available","Covid-19 Disease|Endoscopy Unit",,"Rate of new Covid infection of patients and staff members|Covid disease prevalence in the patients referred to endoscopy|Categorization by clinical triage and Covid Test|Influence of the fype of endoscopy procedure and staff protective equipment","Fundacion Miguel Servet","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","2020-COCHE","April 27, 2020","June 14, 2020","July 27, 2020","May 1, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04371354"
648,"NCT04326790","The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention","GRECCO-19","Recruiting","No Results Available","Corona Virus Disease 19 (Covid 19)","Drug: Colchicine|Drug: Standard treatment","Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&D committee|Maximal concentration of cardiac troponin","National and Kapodistrian University of Athens","All","18 Years and older   (Adult, Older Adult)","Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","906295542","April 3, 2020","August 31, 2020","September 30, 2020","March 30, 2020",,"May 8, 2020","AHEPA Hospital, Thessaloniki, Gibraltar",,"https://ClinicalTrials.gov/show/NCT04326790"
649,"NCT04374526","Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.","LIFESAVER","Not yet recruiting","No Results Available","Coronavirus Disease 2019 )COVID-19)","Biological: COVID-19 Convalescent Plasma","Rate of COVID-19 progression","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","All","65 Years and older   (Older Adult)","Phase 2|Phase 3","182","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","3205","May 15, 2020","September 30, 2020","June 30, 2021","May 5, 2020",,"May 5, 2020","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, RM, Italy|Ospedale SS Annunziata, Chieti, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT04374526"
650,"NCT04360733","Precision Immunology to Determine the Immune Response in Patients With COVID-19",,"Recruiting","No Results Available","SARS-CoV 2|COVID","Other: Blood draw","Immune response","University of Bonn","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Other|Time Perspective: Prospective","BOST-03","April 20, 2020","April 2022","September 2022","April 24, 2020",,"April 24, 2020","University Hospital Bonn, Bonn, Germany",,"https://ClinicalTrials.gov/show/NCT04360733"
651,"NCT04358042","PSYCHIATRIC Disorders and Covid-19","PSYCHIC","Not yet recruiting","No Results Available","Psychiatric Disorder|Covid19","Other: Brief Psychiatric Rating Scale|Other: Depression, Anxiety and Stress Scale|Other: Impact of Event Scale-Revised|Other: Connor-Davidson Resilience Scale 10 items (CD-RISC 10)","impact of the COVID-19 pandemic on psychiatric symptomatology","Nantes University Hospital","All","15 Years and older   (Child, Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC20_0165","April 25, 2020","January 1, 2022","January 1, 2023","April 22, 2020",,"April 22, 2020","Nantes University Hospital - IFAC, Nantes, France",,"https://ClinicalTrials.gov/show/NCT04358042"
652,"NCT04347876","Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?",,"Recruiting","No Results Available","COVID-19|BCG Vaccination","Diagnostic Test: Tuberculin test","Pneumonia severity index|Need for ICU admission|COVID -19 test conversion|Mortality","Assiut University","All","12 Years to 80 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","AssiutU12","April 11, 2020","June 16, 2020","June 30, 2020","April 15, 2020",,"April 15, 2020","AssiutU, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04347876"
653,"NCT04377308","Fluoxetine to Reduce Intubation and Death After COVID19 Infection",,"Recruiting","No Results Available","COVID-19|Cytokine Storm","Drug: Fluoxetine","Hospitalizations|Intubation|Death|Number of days of illness|PHQ-9 score for depressive symptoms,|generalized anxiety Disorder-7 scale","University of Toledo Health Science Campus","All","18 Years and older   (Adult, Older Adult)","Phase 4","2000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FRIDA COVID19","May 1, 2020","April 20, 2021","October 20, 2021","May 6, 2020",,"May 6, 2020","University of Toledo, Toledo, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04377308"
654,"NCT04354428","Treatment for COVID-19 in High-Risk Adult Outpatients",,"Recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid","Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|Rate of participant-reported adverse events","University of Washington|Bill and Melinda Gates Foundation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","630","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","STUDY00009878|INV-017062","April 16, 2020","July 2020","October 2020","April 21, 2020",,"May 19, 2020","Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04354428"
655,"NCT04331600","Chloroquine as Antiviral Treatment in Coronavirus Infection 2020",,"Recruiting","No Results Available","COVID-19","Drug: Chloroquine phosphate|Other: Telemedicine","COVID-19-related hospitalization or all-cause death|Decrease in COVID-19 symptoms|Development of pneumonia|Development of coronavirus infection-related complications","Wroclaw Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WROCLAW CORONA STUDY 2020","April 16, 2020","September 30, 2020","December 31, 2020","April 2, 2020",,"May 25, 2020","Uniwersytecki Szpital Kliniczny, Wrocław, Ul. Borowska 213, Poland|Wielospecjalistyczny Szpital Miejski, Poznań, Ul. Szwajcarska 3, Poland",,"https://ClinicalTrials.gov/show/NCT04331600"
656,"NCT04348214","Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals",,"Not yet recruiting","No Results Available","Coronavirus Disease (COVID-19)",,"Risk categorization of healthcare workers|COVID-19 infection rate among health care workers|Risk factors for COVID-19 among health care workers|Adherence of health care workers to infection prevention|Validity of the available rapid serological test for detecting COVID-19 virus infection|Clinical spectrum of COVID-19|Effectiveness of infection prevention in the health care facility|Emergency infection prevention and control needs|Isolation rate and emergency health care worker replacement needs|Rate of seroconversion","Ain Shams University","All","18 Years and older   (Adult, Older Adult)",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FMASU P18a/ 2020","April 20, 2020","October 1, 2020","December 1, 2020","April 16, 2020",,"April 20, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",,"https://ClinicalTrials.gov/show/NCT04348214"
657,"NCT04317040","CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment","SAC-COVID","Recruiting","No Results Available","Severe Coronavirus Disease (COVID-19)","Drug: CD24Fc|Drug: Placebo","Improvement of COVID-19 disease status|Disease progression of COVID-19|All cause of death|Conversion rate of clinical status at Day 8|Conversion rate of clinical status at Day 15|Hospital discharge time|Duration of mechanical ventilation|Duration of pressors|Duration of ECMO|Duration of oxygen therapy|Length of hospital stay|Absolute lymphocyte count","OncoImmune, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CD24Fc-007|20200674","April 8, 2020","May 2021","May 2022","March 20, 2020",,"April 22, 2020","Baptist Health Research Institute, Jacksonville, Florida, United States|Martin Army Community Hospital, Fort Benning, Georgia, United States|Anne Anundel Medical Center, Annapolis, Maryland, United States|Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States|White Oak Medical Center, Silver Spring, Maryland, United States|Cooper University Hospital, Camden, New Jersey, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Thomas Jefferson University Medical Center, Philadelphia, Pennsylvania, United States|University of Vermont Medical Center, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT04317040"
658,"NCT04348513","Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection","Thy-Support","Not yet recruiting","No Results Available","Pulmonary Infection|Covid-19","Drug: T3 solution for injection|Drug: Placebo","Assessment of weaning from cardiorespiratory support|Assessment of hemodynamic status|Assessment of pulmonary function|Assessment of hepatic function|Assessment of renal function|Assessment of cardiac function|Assessment of cardiac injury|Assessment of the course of COVID-19 infection|Assessment of clinical outcome and safety","Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.|ATTIKON University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","T3inj-02/ThySupport","May 2, 2020","May 2, 2021","May 31, 2021","April 16, 2020",,"April 16, 2020","Attikon University General Hospital, Haidari/Athens, Greece",,"https://ClinicalTrials.gov/show/NCT04348513"
659,"NCT04370171","Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic","TeleCoviDiab","Not yet recruiting","No Results Available","Diabetes|Covid-19","Other: care modalities|Other: Teleconsultation either by phone or by computer consultation","Comparison of metabolic control (HbA1C) between diabetic patients followed by teleconsultation and patients with a conventional follow-up during Covid-19 infection.|HbA1C measured at 6 months post-telemedicine consultation for the TC group / post-cancellation of the face-to-face consultation for the P group.|Total number of patients inaccessible to teleconsultation and number of patients inaccessible by type of associated reason.|Number of complications: severe hypoglycemia, ketoacidosis, myocardial infarction, stroke, foot ulcer.|Results of patient satisfaction questionnaire.|Results of doctor satisfaction questionnaire.|Number of patients infected with Covid-19 (positive smear by RT-PCR for SARS-CoV-2 virus).|Number of conventional hospitalizations, in intensive care and deaths.","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","7775","May 2020","December 2020","December 2020","April 30, 2020",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04370171"
660,"NCT04359290","Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS","RuXoCoil","Not yet recruiting","No Results Available","ARDS, Human|COVID","Drug: Ruxolitinib administration","Overall survival|Assessment of the duration of ventilation support|cytokine storm|time on ICU|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|time frame for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG)|pulmonary function assessed by a CT scan|overall survival","Philipps University Marburg Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KKS-278","May 2020","September 2020","November 2020","April 24, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04359290"
661,"NCT04332913","Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia","TOSCA","Recruiting","No Results Available","COVID-19 Pneumonia",,"Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.|Percentage of patients achieving a score <3 on the Brescia-COVID respiratory severity scale (BCRSS) after the last tocilizumab administration.|Percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab.|Duration of hospitalization|Time to the first negative SARS-CoV-2 negative RT-PCR test|Changes from the baseline in the white blood cell count|Changes from the baseline in the lymphocyte populations (cluster of differentiation (CD)3+CD4+, CD3+CD8+, CD19+, Th17)|Changes from the baseline of c-reactive protein (CRP) values|Changes from the baseline of Ferritin values|Changes from the baseline of BNP values|Changes from the baseline of CK-MB values|Changes from the baseline of Troponin values|Changes from the baseline of LDH values|Changes from the baseline of myoglobulin values|Changes in myocardial ischemia signs at the electrocardiographic trace (YES or NO)|Rate of adverse events report during and after tocilizumab|Mortality (number of Partecipants, cause and timing)|Percentage of patients who develop autoimmune diseases","University of L'Aquila","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0064468/20","April 1, 2020","December 31, 2020","March 31, 2021","April 3, 2020",,"April 13, 2020","Ospedale San Salvatore, L'Aquila, Italy",,"https://ClinicalTrials.gov/show/NCT04332913"
662,"NCT04374045","Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study","COVIDANS","Recruiting","No Results Available","SARS-CoV 2","Other: ECG-Holter","Percentage of dysautonomia patients found within the first 24 hours of hospitalization (%)|Analyse the other mathematical indices measuring autonomic balance, obtained by Holter-ECG recording over the first 24 hours and throughout their hospitalisation, in search of possible dysautonomia|To investigate whether the autonomic balance of patients with CoV-2 SARS correlates with the severity of their clinical condition during their hospital stay.|To investigate whether the various autonomic parameters recorded are predictive of clinical worsening or improvement, by calculating a prediction threshold for each of the parameters.","Centre Hospitalier Universitaire de Saint Etienne","All","18 Years and older   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20CH095|2020-A01082-37","April 30, 2020","September 2020","October 2020","May 5, 2020",,"May 6, 2020","CHU Hopital nord, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT04374045"
663,"NCT04375098","Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection",,"Recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Biological: COVID-19 convalescent plasma","Percentage Mechanical Ventilation, hospitalization longer than 14 days or death during hospitalization|Median duration of fever|Median duration of mechanical ventilation|Median length of ICU stay|Median length of admission|Hospital mortality rate (percentage)|30-day mortality (percentage)|Readmission rate (percentage)|Median length of viral clearance","Pontificia Universidad Catolica de Chile|Fundacion Arturo Lopez Perez","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200415015","May 4, 2020","December 2020","December 2021","May 5, 2020",,"May 5, 2020","Hospital Clínico Universidad Católica, Santiago, Chile",,"https://ClinicalTrials.gov/show/NCT04375098"
664,"NCT04359654","Nebulised Dornase Alfa for Treatment of COVID-19","COVASE","Not yet recruiting","No Results Available","COVID19|Hypoxia","Drug: Dornase Alfa Inhalation Solution [Pulmozyme]","Measuring the change in inflammation|Number of patients that are alive at 28 days|Amount of days that patient requires oxygen|Average oxygenation index|Days patient admitted to hospital|Percentage of patients that need mechanical ventilation","University College, London","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","132333","May 1, 2020","August 1, 2020","November 1, 2020","April 24, 2020",,"April 30, 2020","University College London Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04359654"
665,"NCT04399889","hCT-MSCs for COVID19 ARDS",,"Not yet recruiting","No Results Available","COVID|Corona Virus Infection|COVID19","Biological: human cord tissue mesenchymal stromal cells","Safety of the Investigational Product|Describe the potential for MSC therapy to favorably alter the course of COVID-ARDs","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00105410","June 1, 2020","April 1, 2021","July 31, 2021","May 25, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04399889"
666,"NCT04351243","A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19.",,"Recruiting","No Results Available","Lung Injury or Acute Respiratory Distress Syndrome Due to COVID-19","Drug: Gimsilumab|Drug: Placebo","Primary endpoint|Number of ventilator-free days.|Number of days in the ICU|Number of days of inpatient hospitalization|Incidence of subjects who are alive and not on mechanical ventilation","Kinevant Sciences GmbH|Roivant Sciences, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","KIN-1901-2001","April 12, 2020","July 2020","October 2020","April 17, 2020",,"May 21, 2020","UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|Piedmont Healthcare, Atlanta, Georgia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States|Mount Sinai Beth Israel, New York, New York, United States|Mount Sinai West, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor Scott & White Heart Hospital, Plano, Texas, United States|Baylor Scott & White Medical Center - Temple, Temple, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04351243"
667,"NCT04358939","Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19)",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID-19","Other: Prone decubitus","Therapeutic failure within 14 days of randomization|Evolution of oxygenation (PaO2/FiO2 ratio or SpO2/FiO2 surrogate) over the 14 days following randomization|Evolution of the SpO2/FiO2 ratio during the first prone session|Evolution of the ROX index during the first prone session|Evolution of the World Health Organization disease severity score of COVID|Patient comfort before, during and after the first prone position session|Occurrence of skin lesions on the anterior surface of the body|Displacement of invasive devices during reversals|Days of nasal High-Flow therapy use|Days spent in the intensive care unit and in the hospital|Mortality in the intensive care unit and in the hospital","University Hospital, Tours","All","18 Years and older   (Adult, Older Adult)","Not Applicable","248","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIGH-PRONE-COVID-19|2020-A01121-38|DR200125","April 27, 2020","November 10, 2020","November 24, 2020","April 24, 2020",,"April 29, 2020","Intensive Care Unit, Hospital, Argenteuil, Argenteuil, France|Medical Intensive Care Unit, University Hospital, Brest, Brest, France|Intensive Care Unit, Louis Mourier-APHP, Colombes, France|Intensive Care Unit, Hospital, Le Mans, Le Mans, France|Intensive Care Unit, University Hospital, Lille, Lille, France|Medical Intensive Care Unit, University Hospital, Nantes, Nantes, France|Medical Intensive Care Unit, University Hospital, Nice, NIce, France|Medical Intensive Care Unit, Hospital, Orléans, Orléans, France|Medical Intensive Care Unit, Tenon-APHP, Paris, France|Medical Intensive Care Unit, University Hospital, Poitiers, Poitiers, France|Medical Intensive Care Unit, University Hospital, Tours, Tours, France|Surgical Intensive Care Unit, University Hospital, Tours, Tours, France|Intensive Care Unit, Hospital, Vannes, Vannes, France",,"https://ClinicalTrials.gov/show/NCT04358939"
668,"NCT04389840","Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure",,"Not yet recruiting","No Results Available","COVID-19|Acute Lung Injury|SARS-CoV-2","Drug: Dociparastat sodium|Drug: Placebo","Proportion of participants who are alive and free of invasive mechanical ventilation|All-cause mortality","Chimerix","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","524","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CMX-DS-004","May 2020","February 2021","March 2021","May 15, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04389840"
669,"NCT04366830","Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection",,"No longer available","No Results Available","Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19","Drug: Remestemcel-L",,"Mesoblast International Sàrl|Mesoblast, Ltd.","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"MSB-MSC-ARDS001",,,,"April 29, 2020",,"April 29, 2020","Mount Sinai Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04366830"
670,"NCT04328012","COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2","COVIDMED","Recruiting","No Results Available","SARS-CoV-2 Infection","Drug: lopinavir/ritonavir|Drug: Hydroxychloroquine Sulfate|Drug: Losartan|Drug: Placebos","National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)|Hospital length of stay (LOS)|Intensive care unit level LOS|Mechanical ventilation|survival","Bassett Healthcare","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","4000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1581969","April 6, 2020","January 1, 2021","April 1, 2021","March 31, 2020",,"April 8, 2020","Bassett Medical Center, Cooperstown, New York, United States",,"https://ClinicalTrials.gov/show/NCT04328012"
671,"NCT04342104","NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure",,"Recruiting","No Results Available","Respiratory Failure|Covid-19","Other: Monitoring for aggravation|Other: Evaluate HACOR score effectivity in this patients","HACOR score efficacy|HACOR score addaptation","Hospital General Universitario Morales Meseguer","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","08-04-2020","April 1, 2020","June 1, 2020","July 1, 2020","April 10, 2020",,"April 13, 2020","Hospital General Universitario Morales Meseguer, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT04342104"
672,"NCT04346368","Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)",,"Not yet recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19)","Biological: BM-MSCs|Biological: Placebo","Changes of oxygenation index (PaO2/FiO2)|Side effects in the BM-MSCs treatment group|Clinical outcome|Hospital stay|CT Scan|Changes in viral load|Changes of CD4+, CD8+ cells count and concentration of cytokines|Rate of mortality within 28-days|Changes of C-reactive protein","Guangzhou Institute of Respiratory Disease|Guangzhou Eighth People's Hospital|Tongji Hospital, Huazhong University of Science & Technology|Guangzhou Cellgenes Biotechnology Co.,Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SC-2020-01","April 2020","December 2020","December 2020","April 15, 2020",,"April 15, 2020","Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04346368"
673,"NCT04351529","Austrian COVID-19 Registry",,"Recruiting","No Results Available","Infectious Disease|COVID-19",,"Documentation of natural course and the therapeutic landscape of patients with COVID-19.","Arbeitsgemeinschaft medikamentoese Tumortherapie","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Other|Time Perspective: Other","AGMT_COVID-19","April 1, 2020","December 2021","December 2021","April 17, 2020",,"April 20, 2020","IIIrd Medical Department, Private Medical University Hospital Salzburg, Salzburg, Austria",,"https://ClinicalTrials.gov/show/NCT04351529"
674,"NCT04394026","Imaging Feature of SARS-CoV2 Infection","COVID19IF","Recruiting","No Results Available","Viral Pneumonia|COVID",,"Describe qualitative and quantitative variables|Ability of imaging to predict disease progression|Ability of imaging to predict disease evolution|Imaging findings and demographic data|Imaging findings and laboratory exams","Francesco De Cobelli|IRCCS San Raffaele","All","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","COVID-19 IF","April 16, 2020","August 31, 2020","October 1, 2020","May 19, 2020",,"May 19, 2020","Deaprtment of Radiology, IRCCS Ospedale San Raffaele, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04394026"
675,"NCT04395170","Convalescent Plasma Compared to Anti-COVID-19 Human Immunoglobulin and Standard Treatment (TE) in Hospitalized Patients",,"Not yet recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19)","Biological: COVID-19 convalescent plasma|Biological: Anti-COVID-19 human immunoglobulin|Drug: Standard (specific) therapy for COVID-19","Admission to ICU and/or mechanical ventilation|Length of hospital stay|Neutralizing antibody (IgG) titers against COVID-19|Safety - Adverse events|Death","Lifefactors Zona Franca, SAS","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LFCOLCOVID-19-001","June 2020","December 2020","June 2021","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04395170"
676,"NCT04338932","COVID-19 and Deep Venous Thrombosis",,"Completed","No Results Available","COVID-19|Deep Vein Thrombosis (DVT)/Thrombophlebitis",,"the prevalence of a DVT in patients at the ICU.|Oxygen partial pressure and Carbon dioxide partial pressure levels in the blood|Potassium, Sodium, Calcium, Bicarbonate, Base excess, Lactate levels in the blood|glucose, haemoglobin, ureum, creatinine, total bilirubin levels in the blood|oxygen saturation, basophils, eosinophils, monocytes, neutrophils, haematocrit and prothrombine levels in the blood|white blood cells, red blood cells and platelets in the blood|PT (%)aPTT (sec)Fibrinogen (g/L)D-dimers (mg/L) PT (INR) (ratio) AST (U/L)ALT (U/L)Lactate dehydrogenase (U/L)Troponin T (ng/L)CRP (mg/L)Ferritin (mg/L)in the blood|prevalence of co-morbidities|prevalence of vital signs at icu admission|prevalence of complications during icu stay|evaluation of treatment|evaluation of the oxygen therapy","Jessa Hospital","All","18 Years and older   (Adult, Older Adult)",,"12","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","JessaH_COVID19_DVT","April 17, 2020","May 15, 2020","May 15, 2020","April 8, 2020",,"May 19, 2020","Jessa hospital, Hasselt, Belgium",,"https://ClinicalTrials.gov/show/NCT04338932"
677,"NCT04358406","Rhu-pGSN for Severe Covid-19 Pneumonia",,"Not yet recruiting","No Results Available","Sars-CoV2","Drug: Recombinant human plasma gelsolin (Rhu-pGSN)|Other: Placebo","Efficacy: Proportion of subjects alive not on vasopressors, mechanical ventilator, and dialysis|Safety and Tolerability: Proportion of subjects with serious adverse events (SAEs)|Efficacy: All cause mortality rate though Day 28|Efficacy: Change in World Health Organisation (WHO) 9-point severity score|Efficacy: Proportion of subjects discharged to home or immediate prior residence|Efficacy: Number of days alive and off the ventilator|Efficacy: Length of stay (LOS) of surviving subjects in the hospital|Efficacy: Proportion of subjects readmitted to the hospital|Safety and Tolerability: Proportion of subjects with Grade 3-4 clinically significant laboratory abnormalities.|Safety and Tolerability: Proportion of subjects with non-serious adverse events (AEs)|Immunogenicity: Proportion of subjects with anti-pGSN antibodies","BioAegis Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BTI-202","June 2020","August 2020","September 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04358406"
678,"NCT04382846","Novel Regimens in COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID|Corona Virus Infection","Drug: Nitazoxanide|Drug: Ivermectin|Drug: Chloroquine|Drug: Azithromycin","Number of patients with virological cure","Tanta University","All","18 Years and older   (Adult, Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","tanta covid treatment","May 8, 2020","December 1, 2030","December 1, 2030","May 11, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04382846"
679,"NCT04288102","Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)",,"Recruiting","No Results Available","Corona Virus Disease 2019(COVID-19)","Biological: MSCs|Biological: Saline containing 1% Human serum albumin（solution of MSC）","Size of lesion area and severity of pulmonary fibrosis by chest CT|mMRC (Modified Medical Research Council) dyspnea scale|Oxygenation index( PaO2/FiO2)|Duration of oxygen therapy(days)|Duration of hospitalization(days)|Blood oxygen saturation|CD4+ T cell count and cytokine level|Side effects in the MSCs treatment group|6-minute walk test|Maximum vital capacity (VCmax)|Diffusing Capacity (DLCO)","Beijing 302 Hospital|Huoshenshan Hospital|Maternal and Child Health Hospital of Hubei Province|General Hospital of Central Theater Command, Wuhan, China|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-013-D","March 5, 2020","July 15, 2020","July 31, 2020","February 28, 2020",,"April 7, 2020","Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China|Wuhan Huoshenshan Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04288102"
680,"NCT04341389","A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)","CTII-nCoV","Active, not recruiting","No Results Available","COVID-19","Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Other: Placebo","Occurrence of adverse reactions|Anti SARS-CoV-2 S IgG antibody response(ELISA)|Neutralizing antibody response to SARS-CoV-2|Occurrence of adverse events|Occurrence of serious adverse reaction|Neutralizing antibody response to Ad5-vector|IFN-γ ELISpot responses to SARS-CoV-2 spike protein","Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China|CanSino Biologics Inc.|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention|Zhongnan Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","508","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","JSVCT089","April 12, 2020","January 31, 2021","January 31, 2021","April 10, 2020",,"May 18, 2020","Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04341389"
681,"NCT04346342","PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID)",,"Recruiting","No Results Available","COVID|Mechanical Ventilation|Acute Respiratory Failure",,"Ventilation Mode|Tidal volume set|Expiratory tidal volume|Positive end-expiratory pressure|Maximum airway pressure or plateau pressure (Pplateau) or peak pressure (Ppeak) (cm H2O);|Level of pressure support above PEEP|Inspired fraction of oxygen|Set and measured respiratory rate|Inspiration to expiration ratio|Number of ventilation-free days and alive at day 28|Duration of ventilation in survivors;|Use of prone positioning|Use of recruitment maneuvers|Incidence of acute kidney injury|Duration of ICU stay|Duration of hospital stay|ICU mortality|Hospital mortality|28-day mortality|90-day mortality","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PRoVENT-COVID","March 6, 2020","May 2020","August 2020","April 15, 2020",,"April 15, 2020","Flevoziekenhuis, Almere, Netherlands|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Gelre hospitals, Apeldoorn, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Amphia Hospital, Breda, Netherlands|Reinier de Graaf Groep, Delft, Netherlands|Haga Hospital, Den Haag, Netherlands|Medical Center Haaglanden, Den Haag, Netherlands|Gelderse Vallei Hospital, Ede, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Maxima Medical Center, Eindhoven, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Dijklander Ziekenhuis, Hoorn, Netherlands|Medical Centre Leeuwarden, Leeuwarden, Netherlands|Maasstad Hospital, Rotterdam, Netherlands|Zuyderland Medical Centre, Sittard, Netherlands|UMC Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04346342"
682,"NCT04286503","The Clinical Study of Carrimycin on Treatment Patients With COVID-19",,"Not yet recruiting","No Results Available","Novel Coronavirus Infectious Disease (COVID-19)","Drug: Carrimycin|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|Drug: basic treatment","Fever to normal time (day)|Pulmonary inflammation resolution time (HRCT) (day)|Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment","Beijing YouAn Hospital|Shenyang Tonglian Group Co., Ltd.|Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences|Huangshi Central Hospital|Shenyang Pharmaceutical University|First Affiliated Hospital of Chongqing Medical University|The Second Affiliated Hospital of Harbin Medical University|No.2 People's Hospital of Fuyang City|First Affiliated Hospital Bengbu Medical College|Renmin Hospital of Wuhan University|The sixth people's hospital of Shenyang|Nanyang Central Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","520","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BeijingYouan Hospital","February 23, 2020","February 28, 2021","February 28, 2021","February 27, 2020",,"February 27, 2020",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04286503"
683,"NCT04374422","COVID-19 Pandemic and Female Sexual Behavior",,"Completed","No Results Available","Sexual Behavior|COVID","Behavioral: fsfi survey","FSFI (Female Sexual Function Index)SCORE difference","Acibadem University","Female","18 Years and older   (Adult, Older Adult)",,"58","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AcibademU cov","April 10, 2020","April 12, 2020","April 12, 2020","May 5, 2020",,"May 5, 2020","Haseki Training and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04374422"
684,"NCT04354701","COVID-19 and Cancer Consortium Registry","CCC19","Recruiting","No Results Available","COVID-19|Invasive Malignancy (Any Type)","Other: Web-based REDCap survey","Web-based REDCap survey","Vanderbilt-Ingram Cancer Center","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","VICC MD 2032","March 17, 2020","December 2021","December 2022","April 21, 2020",,"May 1, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04354701"
685,"NCT04339816","Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial","AZIQUINE-ICU","Not yet recruiting","No Results Available","COVID-19|Respiratory Failure","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo","Proportion of alive patients free off mechanical ventilation|Proportion of patients who avoided the need of mechanical ventilation|ICU LOS|Mortality28|Mortality90","Frantisek Duska, MD, PhD|Masaryk Hospital Usti nad Labem|University Hospital Pilsen|The Faculty Hospital Na Bulovce|St. Anne's University Hospital Brno, Czech Republic|University Hospital, Motol|General University Hospital, Prague|University Hospital Olomouc|Charles University, Czech Republic","All","18 Years and older   (Adult, Older Adult)","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","AZIQUINE-ICU-25032020|2020-001456-18","April 20, 2020","December 31, 2021","June 30, 2022","April 9, 2020",,"April 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04339816"
686,"NCT04380376","Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia","MICOV","Recruiting","No Results Available","COVID-19|Viral Pneumonia","Drug: Melphalan|Other: Standard of care","The changes of COVID Ordinal Outcomes Scale|Percentage of the patients with Clinical Recovery|The changes of the Borg's scale|CRP level|Lymphocyte count|D-dimer|IL-6|Percentage of patients without artificial lung ventilation","Federal State Budgetary Institution, Pulmonology Scientific Research Institute|Medsi Clinic #1, Moscow|Moscow State University of Medicine and Dentistry","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PSRI05-20","April 30, 2020","October 30, 2020","October 30, 2020","May 8, 2020",,"May 12, 2020","Kirill Zykov, Moscow, Russian Federation|Clinical hospital, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04380376"
687,"NCT04335071","Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","CORON-ACT","Recruiting","No Results Available","SARS-CoV-2 Infection","Drug: Tocilizumab (TCZ)|Drug: Placebo","Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days)","University Hospital Inselspital, Berne|Roche Pharma AG","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-00691|2020DR2044","April 26, 2020","October 2020","October 2020","April 6, 2020",,"April 28, 2020","University Hospital Bern (Inselspital), Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Ospedale Regionale di Lugano (EOC), Viganello, Switzerland|University Hospital Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04335071"
688,"NCT04364893","Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19","BRACE-CORONA","Recruiting","No Results Available","Corona Virus Infection|COVID-19","Other: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors","Median days alive and out of the hospital|Number of participants with adverse cardiovascular outcomes and new worsening heart failure|Cardiovascular biomarkers related to COVID-19","D'Or Institute for Research and Education|Brazilian Clinical Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRJ_2003","April 6, 2020","October 1, 2020","December 1, 2020","April 28, 2020",,"April 28, 2020","Idor, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04364893"
689,"NCT04368845","Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study","ATHLOS","Recruiting","No Results Available","COVID-19|Comorbidities and Coexisting Conditions","Device: Telerehabilitation","Physical Performance|Cardiorespiratory fitness|Lower limb Strength|Health Related Quality of Life|Anxiety and Depression|Physical Activity|Fatigue|Dyspnea","Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory|University of Athens|University of Ioannina|University of Thessaly","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1","May 11, 2020","July 31, 2020","March 2021","April 30, 2020",,"May 21, 2020","Clinical exercise Physiology and rehabilitation research laboratory, Lamia, Greece",,"https://ClinicalTrials.gov/show/NCT04368845"
690,"NCT04397380","COVID-19 Thales Thermography Triage : Thermal Camera Feasibility Study","COVID3T","Not yet recruiting","No Results Available","Pyrexia|COVID","Device: Thermography|Device: Tympanic Temperature","Temperature","NHS Greater Clyde and Glasgow","All","16 Years and older   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","INGC20AE209","May 20, 2020","June 3, 2020","July 1, 2020","May 21, 2020",,"May 25, 2020","Queen Elizabeth University Hospital, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04397380"
691,"NCT04392323","Incidence of COVID-19 Test Conversion in Post-surgical Patients",,"Recruiting","No Results Available","Sars-CoV2","Diagnostic Test: COVID-19 PCR and Serology","COVID-19 Test Conversion|Duration of Hospitalization|Rate of self-reported COVID-19 exposure|Rate of complications from COVID-19","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB #20-0404","May 13, 2020","July 1, 2020","July 31, 2020","May 18, 2020",,"May 18, 2020","North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States",,"https://ClinicalTrials.gov/show/NCT04392323"
692,"NCT04331054","Protective Role of Inhaled Steroids for Covid-19 Infection","INHASCO","Recruiting","No Results Available","Covid-19 Infection|Hospitalization in Respiratory Disease Department","Drug: 2: Usual practice + SYMBICORT RAPIHALER|Other: 1: Usual practice","Time (in days) to clinical improvement within 30 days after randomization|Mortality rate at D30|Time (in days) from randomization to death|Number of days alive outside ICU within 30 days|Number of days alive free of invasive or non-invasive ventilation within 30 days|Number of days alive with oxygen therapy within 30 days|Maximal oxygen rate within 30 days|Difference between PaO2/FiO2 ratio at randomization and at Day 7 (or at the time of stopping oxygen therapy or discharge if occurs before Day 7)|Number of days alive outside hospital within 30 days|Use of antibiotics for respiratory (proved or suspected) infection within 30 days|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Safety outcomes included events that occurred during treatment, serious adverse events, and premature discontinuation of treatment.","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","436","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P 200394|2020-001306-35","April 13, 2020","July 13, 2020","July 13, 2020","April 2, 2020",,"April 17, 2020","Hôpital Bichat - Service de Pneumologie, Paris, France",,"https://ClinicalTrials.gov/show/NCT04331054"
693,"NCT04344249","Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic","IBD-COVID-19","Recruiting","No Results Available","IBD|COVID",,"IgG and IgM anti SARS-CoV-2|Clinical factors and severity of COVID-19 infection|demographic factors and severity of COVID-19 infection|pharmacologic factors and severity of COVID-19 infection","Nantes University Hospital","All","18 Years to 100 Years   (Adult, Older Adult)",,"850","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC20_0150","April 10, 2020","September 30, 2020","September 1, 2021","April 14, 2020",,"April 30, 2020","Chu Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT04344249"
694,"NCT04347512","EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","TEACHCOVID","Not yet recruiting","No Results Available","Sars-CoV-2, Community-Acquired Pneumonia,COVID-19","Drug: Hydroxychloroquine and azithromycin treatment arm.|Drug: Hydroxychloroquine|Drug: Control arm","Rate of patients reaching a significant hypoxemia, in each arms.","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)","Phase 3","405","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7783","May 1, 2020","August 1, 2021","August 1, 2021","April 15, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04347512"
695,"NCT04387656","NCI COVID-19 in Cancer Patients, NCCAPS Study",,"Not yet recruiting","No Results Available","COVID-19 Infection|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm","Procedure: Biospecimen Collection|Other: Data Collection","Patient variables (factors) associated with severe acute respiratory syndrome (SARS) coronavirus 2 (COVID-19) severity|Effects of COVID-19 on cancer therapy and association with clinical outcomes","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)",,"2000","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NCI-2020-02986|NCICOVID","May 17, 2020","May 31, 2023","May 31, 2023","May 14, 2020",,"May 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04387656"
696,"NCT04377568","Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children","CONCOR-KIDS","Not yet recruiting","No Results Available","Hospitalized Children|Covid-19 Infection","Biological: Convalescent plasma (CP)","Clinical recovery|Combined mortality/intubation|Respiratory status-1|Respiratory status-2|Respiratory status-3|respiratory status -4|respiratory status -5|respiratory status-6|Mortality 1a|Mortality 1b|Mortality 2a|Mortality 2b|Care and Critical Care|organ systems: renal|organ systems: cardiac|Transfusion-associated adverse events (AE)|Safety of the intervention","The Hospital for Sick Children|C17 Council (regulatory sponsor)","All","up to 18 Years   (Child, Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1000070143","May 1, 2020","December 1, 2021","May 1, 2022","May 6, 2020",,"May 6, 2020","Alberta Children's Hospital, Calgary, Alberta, Canada|Stollery Children's Hospital, Edmonton, Alberta, Canada|BC Children's Hospital, Vancouver, British Columbia, Canada|Winnipeg Children's Hospital, Winnipeg, Manitoba, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Children's Hospital, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT04377568"
697,"NCT04385199","Convalescent Plasma for Patients With COVID-19",,"Recruiting","No Results Available","Coronavirus Infection|Coronavirus|COVID","Biological: Convalescent plasma","Improvement in respiratory disease|ICU Length of Stay|Length of Stay|Ventilator days|Tolerability of convalescent plasma|Radiographic improvement","Henry Ford Health System","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13807","May 4, 2020","August 1, 2020","August 1, 2020","May 12, 2020",,"May 12, 2020","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04385199"
698,"NCT04349202","Beaumont Health Large-scale Automated Serologic Testing for COVID-19","BLAST COVID-19","Recruiting","No Results Available","COVID-19|Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2","Diagnostic Test: EUROIMMUN assay","Prevalence COVID antibodies in employees of Beaumont Health","William Beaumont Hospitals","All","18 Years and older   (Adult, Older Adult)",,"50000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-134","April 10, 2020","June 2021","June 2021","April 16, 2020",,"April 28, 2020","Beaumont Health System, Royal Oak, Michigan, United States|Beaumont Health, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04349202"
699,"NCT04393948","Lung Irradiation for COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","SARS-CoV 2","Radiation: Lung Irradiation","Proportion with clinical improvement on a 7-point ordinal scale on day 4 after randomization|Improvement or worsening on the 7-point ordinal scale over additional intervals|Rate and duration of use of supplemental oxygen|Rate and duration of fever > 38ºC|Rate and duration of invasive mechanical ventilation|Duration of hospitalization|Proportion of participants with overall survival up to 30 days after randomization|Improvement in radiographic findings related to infection/inflammation; comparisons include on study versus baseline scans and irradiated vs. unirradiated lung in subjects randomized to receive single lung irradiation|Treatment-emergent adverse events","Brigham and Women's Hospital","All","40 Years and older   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020P001494","May 2020","October 2020","November 2020","May 19, 2020",,"May 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04393948"
700,"NCT04359212","Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19","VTE-COVID","Not yet recruiting","No Results Available","COVID-19 Disease|Thromboembolism, Venous","Drug: thromboprophylaxis with low-molecular-weight heparin or fondaparinux","the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism|the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism plus the asymptomatic incidentally detected pulmonary embolism","Quovadis Associazione|Azienda Ospedaliera di Padova","All","18 Years and older   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VTE-COVID","May 2020","June 2020","June 2020","April 24, 2020",,"May 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04359212"
701,"NCT04372199","SEVERITY SCORE FOR COVID-19 PNEUMONIA",,"Recruiting","No Results Available","COVID|Pneumonia",,"To identify the best predictors of critical coronavirus pneumonia and to realize a simple severity score able to early classify high-risk individuals admitted to Internal Medicine Department for COVID-19 disease, needing an intensive approach","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","All","18 Years and older   (Adult, Older Adult)",,"248","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","3112","April 29, 2020","May 27, 2020","May 27, 2020","May 1, 2020",,"May 1, 2020","Massimo Montalto, Roma, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04372199/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04372199"
702,"NCT04345653","Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers",,"Enrolling by invitation","No Results Available","COVID19","Drug: Hydroxychloroquine Sulfate (HCQ)","Recruitment Feasibility|Recourse utilization|Safety as reflected on the number and severity of adverse events and serious adverse events|Early feasibility as reflected on the number of participants contracting COVID-19 (10% or less) in comparison to the expected 30% as per CDC.|Effect of basic inflammatory regulation","Hackensack Meridian Health","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro2020-0356","April 14, 2020","April 8, 2021","April 8, 2022","April 14, 2020",,"April 16, 2020","Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04345653"
703,"NCT04365439","Convalescent Plasma for COVID-19",,"Not yet recruiting","No Results Available","Blood Plasma Therapy|COVID","Biological: Blood plasma","Titers of anti-SARS-CoV-2 antibodies in the plasma derived from convalescent donors|Change in titers of anti-SARS-CoV-2 antibodies in patients' plasma|Change in inflammatory cytokines concentration (e.g. IL-6, HMGB1)|Viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs|Number of patients with improvement in the 7-points Ordinal Scale|Proportion of patients with adverse events, severity of adverse events","Enos Bernasconi|Ente Ospedaliero Cantonale, Bellinzona","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-00895","April 27, 2020","May 30, 2020","June 30, 2020","April 28, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04365439"
704,"NCT04293692","Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus",,"Withdrawn","No Results Available","COVID-19","Biological: UC-MSCs|Other: Placebo","Size of lesion area by chest imaging|Blood oxygen saturation|Rate of mortality within 28-days|Sequential organ failure assessment|Side effects in the UC-MSCs treatment group|Electrocardiogram, the changes of ST-T interval mostly|Concentration of C-reactive protein C-reactive protein, immunoglobulin|CD4+ and CD8+ T cells count|Concentration of the blood cytokine (IL-1β, IL-6, IL-8,IL-10,TNF-α)|Concentration of the myocardial enzymes","Puren Hospital Affiliated to Wuhan University of Science and Technology|Wuhan Hamilton Bio-technology Co., Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Pr20200225","February 24, 2020","February 25, 2020","February 25, 2020","March 3, 2020",,"March 18, 2020","Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04293692"
705,"NCT04355702","Covid-19 in Lupus Patients",,"Recruiting","No Results Available","Systemic Lupus Erythematosus|Covid-19",,"prevalence and severity of Covid-19 infection in patients with SLE|prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine","University Hospital, Montpellier","All","18 Years to 90 Years   (Adult, Older Adult)",,"130","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL20_0219","March 1, 2020","May 1, 2020","May 30, 2020","April 21, 2020",,"April 27, 2020","Uhmontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04355702"
706,"NCT04395781","Pediatric Acute and Critical Care COVID-19 Registry of Asia","PACCOVRA","Not yet recruiting","No Results Available","COVID|Pediatric Disorder",,"Overall severity of illness|Respiratory complications|Other complications|Mortality","KK Women's and Children's Hospital|King Chulalongkorn Memorial Hospital|Ramathibodi Hospital|Postgraduate Institute of Medical Education and Research, Chandigarh|Rumah Sakit Anak dan Bunda Harapan Kita|National University Hospital, Singapore|St. Marianna University School of Medicine|Tokyo Metropolitan Children's Medical Center, Japan|Aichi Children's Health and Medical Center, Japan|General Hospital H. Adam Malik|Children's Hospital of Chongqing Medical University|Zhengzhou Children's Hospital, China|Universiti Kebangsaan Malaysia Medical Centre|Penang Hospital, Malaysia|Vicente Sotto Memorial Medical Center|Hyogo Prefectural Kobe Children’s Hospital|Singapore Clinical Research Institute","All","up to 21 Years   (Child, Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2020/2094","May 18, 2020","December 31, 2022","December 31, 2023","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04395781"
707,"NCT04374071","Early Short Course Corticosteroids in COVID-19",,"Completed","No Results Available","COVID|Pneumonia, Viral","Drug: Methylprednisolone","Transfer to Intensive care unit (ICU)|Need for Mechanical Ventilation|Mortality|Development and Severity of ARDS|Length of hospital stay (LOS).","Henry Ford Health System","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HFH IRB # 13739","March 12, 2020","March 27, 2020","April 30, 2020","May 5, 2020",,"May 5, 2020","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04374071"
708,"NCT04347980","Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19","DHYSCO","Recruiting","No Results Available","Respiratory Distress Syndrome, Adult|COVID-19","Drug: Dexamethasone and Hydroxychloroquine|Drug: Hydroxychloroquine","Day-28 mortality|Ventilator-free days|Intensive Care Unit mortality|Day-60 mortality|Nosocomial pneumonia|Bacteremia","Centre Chirurgical Marie Lannelongue","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","122","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2037815010","April 2020","June 2020","August 2020","April 15, 2020",,"April 17, 2020","Reanimation adulte. Hopital Marie Lannelongue, Le Plessis-Robinson, France",,"https://ClinicalTrials.gov/show/NCT04347980"
709,"NCT04386369","Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS","APRV-COVID19","Not yet recruiting","No Results Available","ARDS|COVID19","Other: Airway pressure release ventilation","Proportion of patients improving PaO2/FiO2 ratio at 6 hours of APRV|Number of interventions on ventilator settings|Change in mean blood pressure|Change in heart rate|Changes in catecholamine doses|Changes in static compliance at the end of 6 hours of APRV|Variations of minute ventilation|Changes in static compliance 4 hours after stopping APRV|Proportion of patients with a decrease of the PaO2/FiO2 ratio","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020PI076","May 15, 2020","June 30, 2020","June 30, 2020","May 13, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04386369"
710,"NCT04355624","Kidney Involvement in COVID-19 Disease (COVKID)","COVKID","Recruiting","No Results Available","COVID|Kidney Injury",,"Kidney involvement in COVID-19 disease|Physiopathologic mechanism of kidney involvement in SARS-CoV-2 infection|To identify risk factors for kidney involvement in in SARS-CoV-2 infection|To evaluate the impact of kidney involvement in SARS-CoV-2 infection|To assess the long-term health effect of kidney injury on survivors of SARS-CoV-2 infection in case of AKI KDIGO 2 or 3","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20reamedcovid02","April 15, 2020","April 30, 2020","July 30, 2020","April 21, 2020",,"May 13, 2020","Centre hospitalier d'Antibes Juan les pins, Antibes, France|Centre hospitalier de Cannes, Cannes, France|Centre hospitalier de Grasse, Grasse, France|CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT04355624"
711,"NCT04384029","The Geneva Covid-19 CVD Study",,"Active, not recruiting","No Results Available","COVID|CVD","Other: Covid-19 + patients","mobidity discharge|mobidity at 30 days|mobidity 1 year after hospitalization|mortality discharge|mortality 30 days after hospitalization|mortality 1 year after hospitalization|Clinical outcomes according to medication at admission|Clinical outcomes related to preexisting cardiovascular risk factors at admission|New onset of CVD induced by COVID-19 disease|Cost of hospital stay|Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).|Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).","François MACH|University Hospital, Geneva","All","18 Years and older   (Adult, Older Adult)",,"7000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","CCER-2020-00610","March 24, 2020","March 31, 2021","March 31, 2022","May 12, 2020",,"May 12, 2020","Geneva University Hospital (HUG), Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT04384029"
712,"NCT04389476","The Impact and Coping Strategy of COVID-19 Among Taiwan Society and Medical and Nursing Institutes",,"Not yet recruiting","No Results Available","The Psychological Impact of Coronavirus Disease 2019 (COVID-19)","Other: Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)","Psychological impacts by CoronaVirus Disease 2019(COVID-19)","Kaohsiung Kai-Suan Psychiatric Hospital","All","20 Years and older   (Adult, Older Adult)",,"2500","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","KSPH-2020-03","June 1, 2020","July 31, 2023","July 31, 2023","May 15, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04389476"
713,"NCT04392973","FAvipiravir and HydroxyChloroquine Combination Therapy","FACCT","Not yet recruiting","No Results Available","COVID19","Combination Product: Favipiravir and Hydroxychloroquine","Clinical Improvement|Viral shedding","King Abdullah International Medical Research Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","520","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RC20/174","May 2020","November 2021","November 2021","May 19, 2020",,"May 19, 2020","King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04392973"
714,"NCT04343339","Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment","EPILOGUE","Recruiting","No Results Available","Addiction, Substance|COVID-19",,"Evolution of consumption|health care access","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0195","April 8, 2020","July 30, 2020","September 30, 2020","April 13, 2020",,"April 15, 2020","Uhmontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04343339"
715,"NCT04395807","Helmet CPAP Versus HFNC in COVID-19","COVID HELMET","Not yet recruiting","No Results Available","COVID|Acute Hypoxemic Respiratory Failure","Device: Helmet CPAP|Device: HFNC","Ventilator-Free Days (VFD)|SpO2/FiO2-ratio|Patient comfort|Frequency of endotracheal intubation|Frequency of carbon dioxide rebreathing|Days alive within","Lund University|Region Skane","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","COVID HELMET","May 2020","December 2020","May 2021","May 20, 2020",,"May 20, 2020","Helsingborg's Hospital, Helsingborg, Region Skane, Sweden",,"https://ClinicalTrials.gov/show/NCT04395807"
716,"NCT04380961","A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19",,"Recruiting","No Results Available","Severe or Critical Confirmed Coronavirus Disease (COVID)-19","Drug: Sirukumab|Drug: Placebo|Other: Standard of Care (SOC)","Time to Improvement of at Least 2 Categories Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale|Percentage of Participants with an Improvement of at Least 2 Categories Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale on Day 28|Percentage of Participants with Serious Adverse Events (SAEs)|Percentage of Participants with Related Adverse Events|Percentage of Participants with Severe or Life Threatening Bacterial, Invasive Fungal, Viral or Opportunistic Infections|Percentage of Participants with Grade 3 and 4 Neutropenia|Percentage of Participants with Grade 3 and 4 Lymphocytopenia|Percentage of Participants with Increased Alanine Aminotransferase (ALT) Greater than or equal to 3 Times Upper Limit of Normal (ULN) Combined with Increased Bilirubin > 2 Times ULN|Time to Improvement of at least 1 Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale|Percentage of Participants with an Improvement of at Least 1 Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale on Day 28|Time from Study Intervention to end of Oxygen Supplementation|Time from Study Intervention to Hospital Discharge Among the Surviving Participants|Total Length of Hospitalization|Percentage of Participants with All-cause Mortality|Number of Ventilation Free Days|Participant's Clinical Status at Day 7, 14, 21, 28 as Assessed by 6-Point Ordinal Clinical Recovery Scale|Total Time on Invasive Mechanical Ventilation|Percentage of Participants with a Worse Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale over Time|Percentage of Participants on Extracorporeal Membrane Oxygenation (ECMO) Over Time|Total Time on ECMO|Percentage of Alive Participants at Day 28, Week 8 and Week 16|Percentage of Alive Participants that Required Readmission at Week 8 and Week 16","Janssen Pharmaceutica N.V., Belgium","All","18 Years to 84 Years   (Adult, Older Adult)","Phase 2","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR108820|CNTO136COV2001","April 24, 2020","June 25, 2020","September 16, 2020","May 8, 2020",,"May 13, 2020","Loyola University Medical Center, Maywood, Illinois, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Wayne State University/Detroit Medical Center, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Beaumont Health Systems, Royal Oak, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercury Street Medical Group, PLLC, Butte, Montana, United States|Saint Michael's Medical Center- Infectious Disease, Newark, New Jersey, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04380961"
717,"NCT04375774","Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE)","VADER","Recruiting","No Results Available","COVID","Device: FFP2|Device: Facial mask|Device: MFS","Evaluation of airtightness (Fit test)|User Comfort|Breathing easiness|Field of view quality|Ease of use","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","All","18 Years to 60 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020/15AVR/226","May 2020","May 2020","May 2020","May 5, 2020",,"May 5, 2020","Cliniques Universitaires Saint-Luc, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04375774"
718,"NCT04345276","Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Danoprevir+Ritonavir","Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event","Huoshenshan Hospital|Ascletis Pharmaceuticals Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASC-CTP-HS-01","March 18, 2020","April 30, 2020","May 31, 2020","April 14, 2020",,"April 14, 2020","Huoshenshan Hostipal, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04345276"
719,"NCT04361903","Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection","RESPIRE","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Drug: Ruxolitinib Oral Tablet","Number of patients who avoid mechanical assisted ventilation in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19|Improvement of respiratory performance - Arterial Blood Gas Analisys - pH|Improvement of respiratory performance - Arterial Blood Gas Analisys - pO2|Improvement of respiratory performance - Arterial Blood Gas Analisys - pCO2|Improvement of respiratory performance - ratio values|Evaluation of known adverse events related to the use of the drug - D-Dimer|Evaluation of known adverse events related to the use of the drug - fibrinogen|Evaluation of known adverse events related to the use of the drug - transaminases|Evaluation of known adverse events related to the use of the drug - aPTT|Evaluation of known adverse events related to the use of the drug - INR|Evaluation of known adverse events related to the use of the drug - glycemia|Evaluation of known adverse events related to the use of the drug - creatinine|Evaluation of known adverse events related to the use of the drug - Leucocytes count|Evaluation of known adverse events related to the use of the drug - Leucocytes formula|Evaluation of the epidemiological parameters: Chest CT|Evaluation of the epidemiological parameters: Eco Chest|Evaluation of the epidemiological parameters: CHEST X-ray|Monitoring of Serum levels of cytokines before and every 48 h from start to to end of treatment|Monitoring incidence of treatment Emergent Adverse Events of ruxolitinib therapy","Azienda USL Toscana Nord Ovest|Fondazione C.N.R./Regione Toscana ""G. Monasterio"", Pisa, Italy|Azienda Ospedaliera Universitaria Senese|Azienda Ospedaliero, Universitaria Pisana","All","18 Years and older   (Adult, Older Adult)",,"13","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020.COVID-19.RUXO106","April 25, 2020","May 24, 2020","May 31, 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04361903"
720,"NCT04291729","Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection",,"Completed","No Results Available","COVID-19","Drug: Ganovo+ritonavir+/-Interferon nebulization","Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event","The Ninth Hospital of Nanchang|Ascletis Pharmaceuticals Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","11","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASC-CTP-NC-01","February 17, 2020","March 19, 2020","March 19, 2020","March 2, 2020",,"April 13, 2020","The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China",,"https://ClinicalTrials.gov/show/NCT04291729"
721,"NCT04361344","Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection","MARNEVO-Covid","Recruiting","No Results Available","COVID-19 Infection|Encephalitis","Biological: blood samples","Change of neurodegeneration markers level","Centre Hospitalier de PAU","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CHPAU2020/02","May 19, 2020","January 19, 2021","January 19, 2021","April 24, 2020",,"May 21, 2020","CH de Pau, Pau, France",,"https://ClinicalTrials.gov/show/NCT04361344"
722,"NCT04385160","Myeloproliferative Neoplasms (MPN) and COVID-19","MPN-COVID","Not yet recruiting","No Results Available","Myeloproliferative Neoplasm|COVID",,"pulmonary embolism (PE)|fatal or non fatal thrombotic event|Continuous Positive Airway Pressure (CPAP)|invasive ventilation|admission in Intensive Care Unit (ICU)|death|treatments and interventions applied for MPN|treatments and interventions applied for COVID-19|thrombotic events association to patients characteristic and treatments","Fondazione per la Ricerca Ospedale Maggiore|European Leukemia Net","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Other","FROM - O-MPN-COVID-2020","May 1, 2020","July 15, 2020","September 1, 2020","May 12, 2020",,"May 12, 2020","Zealand University Hospital, Køge, Denmark|Hopital Saint-Louis, Paris, France|University Medical Center RWTH, Aachen, Germany|University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center, Minden, Germany|Ospedale San Gerardo di Monza, Monza, Monza Brianza, Italy|Asl AT - Ospedale ""Cardinal Massaia"" di Asti, Asti, Italy|ASST-Papa Giovanni XXIII, Bergamo, Italy|Policlinico S.Orsola-Malpighi, Bologna, Italy|ASST-Spedali Civili, Brescia, Italy|AOU Ospedale Careggi, Firenze, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Policlinico Universitario Fondazione Agostino Gemelli, Roma, Italy|A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy|Ospedale Policlinico ""G.B. Rossi"" Borgo Roma, Verona, Italy|Ospedale San Bortolo, Vicenza, Italy|Hospital Clínic De Barcelona, Barcelona, Barcellona, Spain|Hospital del Mar, Barcelona, Barcellona, Spain|Institut Català d' Oncologia - Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO L'Hospitalet - Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain|Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain|Hospital General de La Palma, Breña Alta, Santa Cruz De Tenerife, Spain|Servicio de Hematología Hospital General Universitario de Albacete, Albacete, Spain|Hospital General de Elche, Alicante, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|ICO Girona Hospital Josep Trueta Servei d'hematologia, Girona, Spain|FEA Hematología Hospital Universitario de Móstoles, Madrid, Spain|Hospital 12 de octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Moncloa, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario, Valencia, Spain|Guy's and St. Thomas' NHS Foundation Trust., London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04385160"
723,"NCT04337346","Evaluation of Covid 19 Anxiety in Endometriosis Patients",,"Completed","No Results Available","Endometriosis|Covid19",,"Covid 19 Anxiety levels in Endometriosis Patients","Kanuni Sultan Suleyman Training and Research Hospital","Female","18 Years to 45 Years   (Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","endocovid19","April 5, 2020","April 20, 2020","April 25, 2020","April 7, 2020",,"May 20, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04337346"
724,"NCT04375670","COVID19-FOIE National Observatory",,"Recruiting","No Results Available","Liver Diseases|COVID19",,"Mortality rate related to Covid-19 in patients with a chronic liver disease|mortality rate according the stage of fibrosis and the cirrhotic status|mortality related to Covid-19 according an history of hepatocellular carcinoma, an immunosuppressive treatment and this type the etiology-ies of liver disease at the infection and comorbidities.|Incidence of liver complications","Assistance Publique - Hôpitaux de Paris|Association Française pour l’Etude du Foie (AFEF)","All","18 Years to 80 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","IRB00006477","May 11, 2020","December 31, 2020","December 31, 2020","May 5, 2020",,"May 21, 2020","Ganne, Bondy, France",,"https://ClinicalTrials.gov/show/NCT04375670"
725,"NCT04386447","Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19","OsCOVID19","Not yet recruiting","No Results Available","Covid-19|Corona Virus Infection|SARS-CoV 2","Drug: Oxytocin|Drug: Standard of Care","Proportion of cases who during 14 exhibit one of the following conditions|Mortality 28 days after randomization","Azienda Ospedaliero-Universitaria di Parma|University of Parma","All","18 Years and older   (Adult, Older Adult)","Phase 2","145","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OsCOVID19","June 3, 2020","October 31, 2020","December 31, 2020","May 13, 2020",,"May 19, 2020","CNRS, Lyon, France|Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy|Ospedale San Francesco, Nuoro, Italy",,"https://ClinicalTrials.gov/show/NCT04386447"
726,"NCT04361123","Atrium COVID-19 Syndromic and Serologic Surveillance",,"Enrolling by invitation","No Results Available","Coronavirus|COVID","Other: daily syndromic surveillance|Diagnostic Test: monthly serologic IgM/G test","Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina|Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina|Cumulative incidence of SARS-CoV-2 infection|Monthly incidence of SARS-CoV-2 infection|Stratified incidence of SARS-CoV-2 infection by age group|Stratified incidence of SARS-CoV-2 infection by sex|Stratified incidence of SARS-CoV-2 by season|Stratified incidence of SARS-CoV-2 infection by geographic area (zip code)|Stratified incidence of SARS-CoV-2 infection by preexisting comorbidities|Stratified incidence of SARS-CoV-2 infection by COVID-2 contacts|•Stratified incidence of SARS-CoV-2 infection by use of personal protective equipment (PPE) by health workers|Relative risk of SARS-CoV-2 infection by age group|Relative risk of SARS-CoV-2 infection by sex|Relative risk of SARS-CoV-2 infection by season|Relative risk of SARS-CoV-2 infection by geographic area (zip code)|Relative risk of SARS-CoV-2 infection by preexisting comorbidities|Relative risk of SARS-CoV-2 infection by COVID-2 contacts|Relative risk of SARS-CoV-2 infection by use of PPE by health workers|Incidence of sequelae","Michael Runyon, MD|Atrium Health","All","18 Years and older   (Adult, Older Adult)",,"450000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","04-20-11A","April 2020","December 2021","December 2021","April 24, 2020",,"April 30, 2020","Atrium Health, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04361123"
727,"NCT04393155","Longitudinal COVID-19 Cohort Study",,"Recruiting","No Results Available","COVID-19|Acute Respiratory Failure","Other: COVID-19+ observational","Six minute walk distance (6MWD)|Hospital Anxiety and Depression Scale (HADS)|EuroQol Group standardized measure of health status (EQ-5D-5L)|MoCA-BLIND|Health Care Utilization Survey (HUS)|Death|Forced vital capacity (FVC)|Forced expiratory volume in 1 second (FEV1)|4-meter timed walk|Peripheral blood mononuclear cell type: CD4+ T cells (#cells/ml)|Peripheral blood mononuclear cell type: CD8+ T cells (#cells/ml)|Peripheral blood mononuclear cell type: B cells (#cells/ml)|Peripheral blood mononuclear cell type: NK cells (#cells/ml)|Peripheral blood mononuclear cell type: monocytes (#cells/ml)|Circulating markers of inflammation: C-Reactive Protein (CRP) (mg/l)|Circulating markers of inflammation: Interleukin 6 (IL-6) (pg/ml)|Circulating markers of inflammation: Interleukin 8 (IL-8) (pg/ml)|Circulating markers of inflammation: Interferon gamma (IFNg) (pg/ml)|Circulating markers of inflammation: Interferon alpha (IFNa) (pg/ml)|Circulating markers of inflammation: Tumor necrosis factor alpha (TNFa) (pg/ml)|Circulating markers of inflammation: Interleukin 1 beta (IL-1b) (pg/ml)","University of Vermont","All","18 Years and older   (Adult, Older Adult)",,"225","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHRMS 16-540","April 16, 2020","September 30, 2022","May 31, 2023","May 19, 2020",,"May 20, 2020","Johns Hopkins University, Baltimore, Maryland, United States|University of Vermont College of Medicine, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT04393155"
728,"NCT04395456","A Phase 2 Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)","SAVE","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)","Drug: AMY-101|Other: WFI 5% glucose","The proportion of patients who are alive, without evidence of ARDS (i.e. PaO2/FIO2 >300 mm Hg), who do not require any oxygen support (in room air).|The proportion of patients assigned to each category, of a six-category ordinal scale.|Proportion of patients surviving|Proportion of respiratory failure-free survival|Cumulative incidence of resolution of ARDS (defined as PaO2/FiO2 ≥200 in room air)|Cumulative incidence of freedom from oxygen requirement|Proportion of patients requiring invasive mechanical ventilation due to worsening of ARDS|Proportion of patients requiring non-invasive mechanical ventilation (NIV) due to worsening of ARDS|Proportion of patients developing thrombotic microangiopathies|Changes in PaO2 and PaO2/FIO2|Changes in quick Sequential Organ Failure Assessment Score (qSOFA: respiratory rate, systolic blood pressure, Glasgow Coma Scale (GCS)|Changes in maximal and minimal cardiovascular parameters: Respiratory rate|Changes in maximal and minimal cardiovascular parameters: Heart Rate|Changes in levels of biomarkers of inflammation (CBC, CRP, Ferritin, Procalcitonin, D-dimers, LDH)|Length of stay in ICU|Cumulative incidence of discharge from hospital|Number of adverse events|Changes in levels of anti-drug antibodies|Changes in levels of biomarkers of complement activity: C3, C3a, C5a, sC5b-9|Changes in levels of biomarkers of cytokine release syndrome: IL-1, IL-6, IL-12|Changes in levels of Club Cell protein CC16 (biomarker of lung damage )|Changes in levels of AMY-101 plasma level","Amyndas Pharmaceuticals S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 2","144","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","AMY-101_SAVE","July 2020","January 2021","March 2021","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04395456"
729,"NCT04346420","Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19",,"Recruiting","No Results Available","COVID|Hypoxemia","Other: Standard interface|Device: Double-Trunk Mask","Change in O2 output|Comfort with the interfaces|Changes in PaO2|Changes in PaCO2|Changes in pH|Changes in respiratory rate","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","DTM-001","April 9, 2020","June 30, 2020","June 30, 2020","April 15, 2020",,"April 15, 2020","Cliniques universitaires Saint-Luc, Brussels, Brussels Capital, Belgium",,"https://ClinicalTrials.gov/show/NCT04346420"
730,"NCT04387890","Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care Workers",,"Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2|Health Personnel","Diagnostic Test: Serologic SARS-CoV-2 screening","Prevalence of anti SARS-CoV-2 antibodies (IgM and IgG) in health personnel|COVID-19 incidence through serology-based screening and/or compatible symptoms in health personnel previously known to be unexposed to the virus|Incidence of reactivation/reinfection for COVID-19 in health personnel with a positive serology for SARS-CoV-2","Hospital Italiano de Buenos Aires|Roche Pharma AG","All","18 Years and older   (Adult, Older Adult)",,"50","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","5566","May 15, 2020","August 31, 2020","August 31, 2020","May 14, 2020",,"May 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04387890"
731,"NCT04386694","Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19",,"Recruiting","No Results Available","COVID-19|Respiratory Failure","Device: Active PBMT/sMF|Device: Placebo PBMT/sMF","Time until discharge|Survival rate|Diaphragm muscle function|Platelet count|Leukogram|Erythrogram|C-reactive protein|D-dimer|Immunoglobulin G|Immunoglobulin M|Levels of positive end-expiratory pressure (PEEP)|Fraction of inspired oxygen (FiO2)|Arterial partial pressure of oxygen (PO2)|Arterial partial pressure of oxygen (PO2)/Fraction of inspired oxygen (FiO2) ratio","University of Nove de Julho|Hospital Tacchini/RS","All","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3.985.226","May 18, 2020","July 2020","July 2020","May 13, 2020",,"May 20, 2020","Hospital Tacchini, Bento Gonçalves, RS, Brazil",,"https://ClinicalTrials.gov/show/NCT04386694"
732,"NCT04384055","Predicting Outcomes for Covid-19 Using Sonography","POCUS","Enrolling by invitation","No Results Available","COVID-19|Pneumonia, Viral","Diagnostic Test: Lung Ultrasound","Number of Patients Experiencing Death, ICU Admission, Mechanical Ventilation, or Use of High-Flow Nasal Cannula|Number of Patients Requiring Mechanical Ventilation|Number of Patients Requiring Supplemental Oxygen Usage|Duration of Supplemental Oxygen Usage|Length of Stay|Characterization of Ultrasound Findings","Stanford University","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB-55621","March 21, 2020","December 31, 2020","December 31, 2020","May 12, 2020",,"May 13, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04384055"
733,"NCT04390191","Early CPAP in COVID-19 Confirmed or Suspected Patients","PAP-COVID","Recruiting","No Results Available","COVID-19|COVID|Coronavirus","Device: Continuous Positive Airway Pressure","Efficacy Endpoint composite score|Time to ICU admission|Time to Intubation and mechanical ventilation|14 day and 28 day mortality|Conversion rate of COVID household members in CPAP vs control|Clinical COPD Questionnaire (CCQ)|Percentage of patients electing to continue CPAP for greater than 72 hours|Degree of improvement in oxygen saturation|Time to hospital admission or ED","Icahn School of Medicine at Mount Sinai|Itamar Medical LTD|Community Surgical Supply of Toms River, Inc|Philips Healthcare","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 20-0900","May 7, 2020","April 2021","May 2021","May 15, 2020",,"May 15, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04390191"
734,"NCT04344561","Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation","UPSAT","Not yet recruiting","No Results Available","COVID|Hypoxic Respiratory Failure","Other: Postural Positioning","Incidence of Mechanical Ventilation|Percentage of time in the assigned position|Number of participants with supplemental oxygen requirements|Change in mean oxyhemoglobin saturation|Change in Nocturnal Oxyhemoglobin saturation|Change in Heart Rate|Change in Respiratory Rate","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00246834","June 20, 2020","May 2021","May 2021","April 14, 2020",,"May 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04344561"
735,"NCT04399681","The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19",,"Recruiting","No Results Available","COVID|Pneumonia, Viral","Device: Bedside lung ultrasound","Presence of viral pneumonia caused by COVID 19","Kanuni Sultan Suleyman Training and Research Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","KSSEAH--","May 10, 2020","August 10, 2020","September 10, 2020","May 25, 2020",,"May 25, 2020","Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04399681"
736,"NCT04334850","Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia","MultiCov","Not yet recruiting","No Results Available","Covid19|Pneumonia","Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|Other: Usual antibiotic treatment","Number of antibiotic free days|Mortality rates|Number of defined daily dose (DDD) per 100 patient-days of broad- and narrow-spectrum antibiotics.|Antibiotics duration at D28|Number of organ-failure free days (based on SOFA)|Incidence rates of bacterial super-infections|Incidence rates of colonization/infection with multidrug resistant bacteria and Clostridium difficile infections|ICU and hospital lengths of stay|Quality of life Quality of life","Assistance Publique - Hôpitaux de Paris|BioMérieux","All","18 Years and older   (Adult, Older Adult)","Not Applicable","194","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200392|2020-001324-33","April 2020","July 2020","August 2020","April 6, 2020",,"April 6, 2020","Intensive care department-Hospital Tenon, Paris, France",,"https://ClinicalTrials.gov/show/NCT04334850"
737,"NCT04390074","COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality",,"Not yet recruiting","No Results Available","COVID-19|Critical Illness","Other: COVID-19 and Intensive Care","Chronic medications as risk factor of intensive care for COVID-19|Comorbidities as risk factor of intensive care for COVID-19|Chronic medications as risk factor of death during intensive care for COVID-19|Comorbidities as risk factor of death during intensive care for COVID-19","Uppsala University|Center for Clinical Research Dalarna, Sweden","All","18 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","UTN: U1111-1251-8195","June 2020","June 2020","June 2020","May 15, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04390074"
738,"NCT04352803","Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease",,"Not yet recruiting","No Results Available","Covid-19 Pneumonia|Cyotokine Storm","Biological: Autologous Adipose MSC's","Safety - Incidence of unexpected adverse events|Efficacy - Frequency of progression to mechanical ventilation|Efficacy - Changes in length of mechanical ventilation|Efficacy - Changes in length of weaning of mechanical ventilation|Efficacy - Changes in length of hospital stay|Efficacy - Changes in mortality rate","Regeneris Medical","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-MSCIV","April 2020","April 2024","April 2026","April 20, 2020",,"April 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04352803"
739,"NCT04348461","BAttLe Against COVID-19 Using MesenchYmal Stromal Cells",,"Not yet recruiting","No Results Available","COVID|Respiratory Distress Syndrome","Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells","Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate)|Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Instituto de Investigación Sanitaria y Biomédica de Alicante|Hospital General Universitario Gregorio Marañon|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Universitario de Salamanca|Hospital General Universitario de Alicante|Hospital Clínico Universitario Virgen de la Arrixaca","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BALMYS-19","April 6, 2020","September 15, 2020","September 30, 2020","April 16, 2020",,"April 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04348461"
740,"NCT04388813","Predictors of Severe COVID-19 Outcomes","PRESCO","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID-19",,"Performance (discrimination / calibration) of models","Verily Life Sciences LLC","All","21 Years and older   (Adult, Older Adult)",,"1500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","102293","May 2020","February 2021","March 2021","May 14, 2020",,"May 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04388813"
741,"NCT04344600","Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection","PROTECT","Not yet recruiting","No Results Available","Sars-CoV2","Drug: Peginterferon lambda alfa-1a subcutaneous injection|Other: Saline","Proportion of participants with no evidence of SARS-CoV-2 infection|Time (days) to no detection of SARS-CoV-2 in two upper respiratory samples","Johns Hopkins University|Eiger BioPharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","164","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","IRB00248163","May 2020","December 2020","June 2021","April 14, 2020",,"May 21, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04344600"
742,"NCT04364984","ARB, ACEi, DRi in COVID-19","BIRCOV","Recruiting","No Results Available","Hypertension|COVID-19","Drug: Angiotensin converting enzyme inhibitor","BP (hypertensive efficacy)|COVID-19 course","Medical Practice Prof D. Ivanov","All","18 Years to 90 Years   (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID20","April 1, 2020","April 1, 2021","August 1, 2021","April 28, 2020",,"April 28, 2020","Medical Practice Prof D.Ivanov, Kiev, Please Select, Ukraine",,"https://ClinicalTrials.gov/show/NCT04364984"
743,"NCT04346264","CoVid-19 - Infection and Antibody Formation in the Viennese Population",,"Enrolling by invitation","No Results Available","Virus Diseases|COVID-19","Diagnostic Test: NO intervention planned due to the observational study design only a diagnostic testing","Prevalence of SARS-CoV-2 antibody titres|Prevalence of SARS-CoV-2 antibody titres after 3 Months","Ludwig Boltzmann Institute for Lung Health","All","6 Years to 85 Years   (Child, Adult, Older Adult)",,"5500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LEAD CoVid-19","April 27, 2020","June 1, 2020","September 30, 2020","April 15, 2020",,"April 16, 2020","The LEAD Study Center, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04346264"
744,"NCT04333472","Piclidenoson for Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID-19|Coronavirus Infection","Drug: Piclidenoson","Duration of viral shedding in days|Time to clinical recovery (TTCR) in days|Treatment-emergent adverse events (AEs)|Requirement for non-invasive or mechanical ventilation|Length of hospital stay in days|Estimated PaO2/FiO2 ratio on day of discharge|All-cause mortality|Patients reaching undetectable COVID-19 virus levels in respiratory secretions|Duration of symptoms and signs of respiratory infection in days|Need for supportive respiratory management|Viral load|Treatment-emergent serious AEs (SAEs)|AEs leading to withdrawal|Treatment-emergent abnormalities in clinical laboratory parameters","Can-Fite BioPharma|Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAN-COR-1","April 6, 2020","June 6, 2020","July 6, 2020","April 3, 2020",,"April 3, 2020","Rabin Medical Center, Petah tikva, Israel",,"https://ClinicalTrials.gov/show/NCT04333472"
745,"NCT04361565","Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients",,"Enrolling by invitation","No Results Available","COVID-19 by SARS-CoV-2 Infection",,"Anosmia|Ageusia|Duration of the loss of anosmia ageusia","Centre Hospitalier Universitaire de Nice","All","Child, Adult, Older Adult",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","20odontocovid01","March 20, 2020","April 10, 2020","May 31, 2020","April 24, 2020",,"May 13, 2020","CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT04361565"
746,"NCT04379375","Nudges to Limit COVID-19",,"Not yet recruiting","No Results Available","Health Behavior|COVID-19","Behavioral: Behavioral Nudges (BN)","Hand Washing Behavior|Clinical Outcomes","Medical College of Wisconsin|Advancing a Healthier Wisconsin Endowment","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention",,"May 11, 2020","October 10, 2020","October 10, 2020","May 7, 2020",,"May 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04379375"
747,"NCT04364594","COVID-19 Search in Conjunctival Cells","COVID-T","Active, not recruiting","No Results Available","COVID 19|Pulmonary Disease","Diagnostic Test: conjunctival swab","Conjunctival swab results based on RT-PCR|Conjunctival swab positivity in relation to Pulmonary and blood abnormalities","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0013008/20","March 26, 2020","April 30, 2020","May 30, 2020","April 28, 2020",,"April 28, 2020","Maria Cristina Savastano, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04364594"
748,"NCT04350580","Polyvalent Immunoglobulin in COVID-19 Related ARds","ICAR","Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID-19","Drug: Human immunoglobulin|Drug: Placebo","Ventilator-free days|Mortality|Sequential Organ Failure Assessment Score|P/F ratio|Lung compliance|Radiological score|Biological efficacy endpoints - C-reactive protein|Biological efficacy endpoints - Procalcitonin|Immunological profile|Number of patients using other treatments for COVID-19 related ARDS|Occurrence of deep vein thrombosis or pulmonary embolism|Total duration of mechanical ventilation, ventilatory weaning and curarisation|Kidney Disease: Improving Global Outcomes (KDIGO) score and need for dialysis|Occurrence of adverse event related to immunoglobulins|Occurrence of critical illness neuromyopathy|Occurrence of ventilator-acquired pneumonia","Centre Hospitalier St Anne|Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences|Laboratoire français de Fractionnement et de Biotechnologies","All","18 Years and older   (Adult, Older Adult)","Phase 3","138","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","D20-P013|2020-001570-30","April 11, 2020","June 2020","August 2020","April 17, 2020",,"April 24, 2020","Centre Hospitalier Sainte-Anne, Paris, France",,"https://ClinicalTrials.gov/show/NCT04350580"
749,"NCT04348305","Hydrocortisone for COVID-19 and Severe Hypoxia","COVID STEROID","Recruiting","No Results Available","Covid-19|Hypoxia","Drug: Hydrocortisone|Drug: Sodium Chloride 9mg/mL","Days alive without life support at day 28|All-cause mortality at day 28|Days alive without life support at day 90|All-cause mortality at day 90|Number of participants with one or more serious adverse reactions|Days alive and out of hospital at day 90|All-cause mortality at 1 year after randomisation|Health-related quality of life at 1 year","Scandinavian Critical Care Trials Group|Rigshospitalet, Denmark|Copenhagen Trial Unit, Center for Clinical Intervention Research|University of Copenhagen|Aarhus University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RH-ITA-008|2020-001395-15","April 17, 2020","March 30, 2021","December 30, 2021","April 16, 2020",,"May 13, 2020","Aarhus University Hospital - Dept of Intensive care, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev Hospital - Dept. of Intensive Care, Herlev, Denmark|North Zealand Hospital, Hillerød, Denmark|Hvidovre Hospital - Dept of Infectious diseases, Hvidovre, Denmark|Hvidovre Hospital - Dept of Intensive Care, Hvidovre, Denmark|Hvidovre Hospital - Dept of Pulmonary Medicine, Hvidovre, Denmark|Kolding Hospital, Kolding, Denmark|Køge Hospital, Køge, Denmark|Roskilde Hospital, Roskilde, Denmark|Slagelse Hospital, Slagelse, Denmark|Viborg Hospital, Viborg, Denmark",,"https://ClinicalTrials.gov/show/NCT04348305"
750,"NCT04351490","Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19","ZnD3-CoVici","Not yet recruiting","No Results Available","SARS-CoV 2","Dietary Supplement: Zinc gluconate|Dietary Supplement: 25-OH cholecalciferol","Survival rate in asymptomatic subjects at inclusion|Survival rate in symptomatic subjects at inclusion|Survival rate in overall subjects|Cumulative incidence of Covid-19 infection in asymptomatic subjects at inclusion","University Hospital, Lille","All","60 Years and older   (Adult, Older Adult)","Not Applicable","3140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020_30|2020-A00873-36","April 2020","July 2020","July 2020","April 17, 2020",,"April 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04351490"
751,"NCT04337320","Evaluation of Postnatal Outcomes of Covid 19 Positive Mothers Newborns",,"Active, not recruiting","No Results Available","Covid19|Newborn Morbidity","Other: newborns from covid 19 positive mothers","Evaluation of apgar status of newborns from covid 19 positive mothers","Kanuni Sultan Suleyman Training and Research Hospital","All","up to 15 Minutes   (Child)",,"70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","covid19pregnancynewborn","April 1, 2020","June 15, 2020","June 20, 2020","April 7, 2020",,"April 7, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04337320"
752,"NCT04377724","Spread and Course of COVID-19 Infections","CoV-ETH","Active, not recruiting","No Results Available","Covid-19|Virus Disease",,"seroprevalence as well as the titer of serum antibodies (IgM, IgG and IgA) targeting SARS-CoV-2 antigens|the property of peripheral blood mononuclear cells before and after an infection with SARS-CoV-2 as opposed to other pathogens|the property of IgM and IgA antibody titers against the nucleocapsid protein of SARS-CoV-2 in symptomatic as well as asymptomatic COVID-19 infections over the course of time following an infection|the immune response to common-cold (corona)virus and influenza virus infections in patients with COVID-19 infections","Goldhahn Jörg|ETH Zurich","All","18 Years to 64 Years   (Adult)",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-05","April 27, 2020","June 30, 2021","June 30, 2021","May 6, 2020",,"May 15, 2020","ETH, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04377724"
753,"NCT04355507","Computed Tomography for COVID-19 Diagnosis","STOIC","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: Chest computed tomography (CT)|Diagnostic Test: Reverse-transcription polymerase chain reaction (RT-PCR)","Predictive values of CT criteria|Accuracy of CT composite severity score|Accuracy of deep-learning based score|Predictive values of deep-learning based diagnostic algorithms|Dice similarity coefficient between manual and automated segmentation of lung disease abnormalities","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|GE Healthcare|Orange healthcare|TheraPanacea","All","18 Years and older   (Adult, Older Adult)",,"10000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","APHP200434","April 2020","May 2020","July 2020","April 21, 2020",,"April 22, 2020","Cochin Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT04355507"
754,"NCT04353674","Modulation of Hyperinflammation in COVID-19",,"Recruiting","No Results Available","COVID-19|SARS","Device: Control group|Device: SLEDD with a L-MOD","Efficacy of a L-MOD against controls receiving supportive care in ICU.|Mortality|Hospital Discharge|Leukocyte Monitoring|Sequential Organ Failure Assessment (SOFA) Score|Intubation length|Markers of Inflammation|Leukocytes and Macrophages|Myocardial damage|Renal recovery","Lawson Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","115785","April 28, 2020","July 28, 2020","January 1, 2021","April 20, 2020",,"May 8, 2020","Victoria Hospital - Critical Care Trauma Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04353674"
755,"NCT04386564","Kidney Injury Severity and COVID-19",,"Not yet recruiting","No Results Available","COVID-19|Kidney Injury","Diagnostic Test: mRNA in urine test","The effect of COVID-19 severity on the severity of renal failure|The expression of viral RNA in the urine with the severity of renal failure|The severity of microalbuminuria in patients with COVID-19 of different conditions and renal failure|Assessment of the severity of renal impairment in patients who died from COVID-19|Estimation of the duration of urinary viral RNA isolation in patients undergoing COVID-19|Expression of ACE-2 receptors in the kidneys of patients with renal failure who died from COVID-19","I.M. Sechenov First Moscow State Medical University","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Sechenov-COVID19_AKI","May 15, 2020","October 15, 2020","November 15, 2020","May 13, 2020",,"May 13, 2020","Sechenov University., Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04386564"
756,"NCT04395872","Psychiatric Consultation for COVID-19 Patients",,"Not yet recruiting","No Results Available","Covid19|Psychiatric Problem|Isolation, Social","Behavioral: Psychiatric counseling","Change of PHQ-9 (Patient Health Questionnaire-9)|Change of GAD-7 (Patient Health Questionnaire-9)|Change of PC-PTSD-5 (Primary Care PTSD Screen for DSM-5)|Change of AIS (Athens Insomnia Scale)|Change of P4 (P4 Suicidality Screener)|Change of SF-36 (Short Form Health Survey Questionnaire)|Change of SCL-90-R","Daegu Catholic University Medical Center","All","Child, Adult, Older Adult",,"54","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CR-20-062","May 11, 2020","December 31, 2020","December 31, 2020","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04395872"
757,"NCT04356586","Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms",,"Enrolling by invitation","No Results Available","COVID-19|Serology",,"Percentage of serological positive healthcare workers|Percentage of HCW with positive Saliva-sabs","Sciensano|Jessa Hospital","All","18 Years to 70 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Jessa300","April 30, 2020","July 30, 2020","July 30, 2020","April 22, 2020",,"April 22, 2020","Sciensano, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04356586"
758,"NCT04353336","Efficacay of Chloroquine in COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID-19|Coronavirus Infection","Drug: Chloroquine","Number of patients with virological cure","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","chloroquine covid","April 17, 2020","December 1, 2030","December 1, 2030","April 20, 2020",,"April 20, 2020","Tanta University, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04353336"
759,"NCT04361253","Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy","(ESCAPE)","Recruiting","No Results Available","COVID|Infectious Disease","Biological: High-Titer COVID-19 Convalescent Plasma (HT-CCP)|Biological: Standard Plasma (FFP)","Modified WHO Ordinal Scale (MOS) score","Brigham and Women's Hospital","All","12 Months and older   (Child, Adult, Older Adult)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2020P001215","April 30, 2020","June 2021","December 2021","April 24, 2020",,"May 18, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04361253"
760,"NCT04367545","Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic","MolCOVID","Recruiting","No Results Available","COVID|RT-ddPCR Multiplex","Diagnostic Test: Saliva collection","Number of positive patient using saliva method compared to number of positive patient using standard method|Number of negative patient using saliva method compared to number of negative patient using standard method","University Hospital, Rouen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2020/0094/OB","April 2020","May 2020","May 2020","April 29, 2020",,"April 29, 2020","Rouen University Hospital, Rouen, France",,"https://ClinicalTrials.gov/show/NCT04367545"
761,"NCT04346160","A Study to Assess the Virus RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease",,"Not yet recruiting","No Results Available","COVID|Conjunctivitis","Diagnostic Test: Schirmer Test I","virus molecular analysis|host molecular analysis|Epidemiologic data","G. d'Annunzio University","All","18 Years and older   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","UChieti03","April 14, 2020","April 30, 2020","April 30, 2020","April 15, 2020",,"April 20, 2020","Ophtalmology Clinic, G.d'Annunzio University, Chieti, Italy",,"https://ClinicalTrials.gov/show/NCT04346160"
762,"NCT04387955","Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID)","ACROVID","Not yet recruiting","No Results Available","COVID-19|Chilblains","Diagnostic Test: Biological Sample Collection","Study of the link between SARS-CoV-2 infection and chilblains observed during COVID-19 epidemics.|Study of the SARS-CoV-2 virological profile of patients presenting chilblains during a COVID-19 epidemic.|Comparison of the clinical and biological profiles of patients presenting chilblains according to their SARS-CoV-2 virological status (in case of over-representation of SARS-CoV-2 positive patients, the results will be given without comparison).|Comparison of the capillaroscopic profiles of patients with chilblains according to their SARS-CoV-2 virological status (in case of overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison).|Comparison of the TCPO2 profiles of patients with chilblains according to their SARS-CoV-2 virological status (in case of overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison).|Comparison of the toe or Finger Pressure Index profiles of patients with chilblains according to their SARS-CoV-2 virological status (in case of overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison).|Comparison of histo-pathological profiles of chilblains according to their SARS-CoV-2 virological status of patients with the disease (in case of overrepresentation of SARS-CoV-2 positive patients, results will be given without comparison).|Comparison of the gene expression profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.|Comparison of the immunostaining profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.|Comparison of the ELISA assays profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.","Poitiers University Hospital","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ACROVID","May 2020","May 2021","June 2021","May 14, 2020",,"May 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04387955"
763,"NCT04399733","EMPOWER - BAME vs COVID",,"Not yet recruiting","No Results Available","SARS-CoV 2|Health Disparities",,"Identify COVID-19 specific host-defence (""protective"") or predisposing (""susceptibility"") genetic biomarkers|Epidemiological profiles of COVID-19 infections in different UK ethnic populations","Future Genetics Limited","All","6 Years and older   (Child, Adult, Older Adult)",,"12800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EMPOWER-BAME vs COVID","July 1, 2020","July 1, 2021","October 1, 2021","May 25, 2020",,"May 25, 2020","Future Genetics Limited, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04399733"
764,"NCT04394429","Endotracheal Tube Obstruction in Covid-19 Patients Requiring Mechanical Ventilation","TubeObs-Covid","Recruiting","No Results Available","Sars-CoV2",,"Analysis of risk factors for intubation tube obstruction","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"184","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7803","April 24, 2020","June 24, 2020","June 24, 2020","May 19, 2020",,"May 19, 2020","Service d'Anesthésie-Réanimation - Nouvel Hôpital Civil, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04394429"
765,"NCT04358926","Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)","HBOTCOVID19","Recruiting","No Results Available","COVID-19|Desaturation of Blood","Device: Hyperbaric oxygen therapy|Device: Normobaric oxygen therapy","PaO2/FiO2|SpO2|NEWS Score|Inflammation level -CRP|Inflammation level - ESR|white blood cells number|Cytokines - IL1|Cytokines - IL2|Cytokines - IL6|Cytokines - IL10|Cytokines - TNFalpha|Inflammation level - procalcitonin|Inflammation level - ferritin|Symptoms level|Average oxygen supply per day|Viral load|Chest Xray changes|Number of patients with IgG seroconversion|Number of patients with IgM seroconversion|FEV1/FVC|Time to symptoms recovery|Number of patients who required invasive ventilation|Time to negative virus PCR|Mortality rate|Number of barotrauma events (safety)","Assaf-Harofeh Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","120-20-ASF","April 30, 2020","June 30, 2020","July 30, 2020","April 24, 2020",,"May 5, 2020","Amir Hadanny, Zerifin, Israel",,"https://ClinicalTrials.gov/show/NCT04358926"
766,"NCT04351568","Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics;",,"Not yet recruiting","No Results Available","Evaluating the Effect of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics","Other: quesionnair","to evaluate the effect of social media usage in medical practice during covid 19 epidemic","Assiut University","All","18 Years to 60 Years   (Adult)",,"874","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","2020A20","April 2020","July 2020","August 2020","April 17, 2020",,"April 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04351568"
767,"NCT04357327","Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19)",,"Recruiting","No Results Available","COVID-19|SARS-CoV 2|Corona Virus Infection","Diagnostic Test: rapid salivary test","Sensibility|Specificity","Università degli Studi dell'Insubria","All","Child, Adult, Older Adult","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","68/2020","April 16, 2020","May 31, 2020","July 31, 2020","April 22, 2020",,"April 24, 2020","ASST dei Sette Laghi, Varese, VA, Italy",,"https://ClinicalTrials.gov/show/NCT04357327"
768,"NCT04383535","Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia",,"Not yet recruiting","No Results Available","SARS Virus|SARS-CoV-2|COVID-19","Other: Convalescent SARS COVID-19 plasma|Other: Placebo","Clinical status during follow-up at 30th day|Clinical status during follow-up at 7th day|Clinical status during follow-up at 14th day|Time until hospital discharge (days).|Time until discharge from ICU (days)|Time to death|Time until complete functional recovery|Percentage of participants with adverse events / serious adverse events|Percentage of patients with negative SARS-CoV-3 PCR at Day 14th|D Dimer plasma concentration at Day 14th|Ferritin plasma concentration at Day 13th|Plasma concentration of neutralizing antibodies at Day 2nd|Plasma concentration of neutralizing antibodies at Day 7th|Post-transfusion adverse reactions","Hospital Italiano de Buenos Aires","All","18 Years and older   (Adult, Older Adult)","Not Applicable","333","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","5565","May 15, 2020","July 15, 2020","August 20, 2020","May 12, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04383535"
769,"NCT04357834","WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories","WAVE","Not yet recruiting","No Results Available","COVID|COVID 19|SARS-CoV 2","Other: Equipment with smartwatch throughout hospital stay on the general ward","Diagnostic accuracy of smartwatch data in predicting ICU requirement in COVID-19 contracted inpatients quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.85).|Diagnostic accuracy of routine physiological data in predicting ICU requirement in COVID-19 contracted in-patients quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.85).|Diagnostic accuracy of predicting hospital discharge without ICU admission in COVID-19 contracted in-patients quantified as area under the receiver operator characteristics curve|Change of heart rate from baseline (hospitalization) to ICU admission|Change of heart rate variability from baseline (hospitalization) to ICU admission|Change of skin temperature from baseline (hospitalization) to ICU admission|Change of blood oxygen saturation from baseline (hospitalization) to ICU admission|Change of respiration rate from baseline (hospitalization) to ICU admission|Change of physical activity from baseline (hospitalization) to ICU admission|Change of stress level from baseline (hospitalization) to ICU admission|Change of sleep pattern from baseline (hospitalization) to ICU admission|Change of steps per day from baseline (hospitalization) to ICU admission|Change of systolic blood pressure from baseline (hospitalization) to ICU admission|Change of diastolic blood pressure from baseline (hospitalization) to ICU admission|Change of body temperature from baseline (hospitalization) to ICU admission|Change of oxygen partial pressure (pO2) from baseline (hospitalization) to ICU admission|Change of CO2 partial pressure (pCO2) from baseline (hospitalization) to ICU admission|Change of blood pH from baseline (hospitalization) to ICU admission|Change of bicarbonate from baseline (hospitalization) to ICU admission|Change of base excess from baseline (hospitalization) to ICU admission|Change of oxygen flow rate from baseline (hospitalization) to ICU admission","University Hospital Inselspital, Berne|ETH Zurich","All","18 Years to 120 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","WAVE","May 1, 2020","July 31, 2020","July 31, 2020","April 22, 2020",,"April 24, 2020","Emergency Department, University Hospital Bern, Inselspital, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04357834"
770,"NCT04337190","Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)","COVID-ARA2","Recruiting","No Results Available","COVID|Acute Respiratory Distress Syndrome","Biological: blood sampling","ACE2 level change over time|ACE2 activity over time|Mortality at day 28|ARDS severity|Duration of mechanical ventilation|Need for prone positionning|Need for extracorporeal membran oxygenation|Use of paralytic agents|Need for renal replacement therapy|Need for vasoactive drugs (norepinephrine, dobutamine,epinephrine)|Sequential Organ Failure Assessment (SOFA) score|Number of session(s) of prone positionning|Duration of extracorporeal membran oxygenation treatment|Type of vasoactive drugs|Duration of vasoactive treatment","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-ARA2","April 3, 2020","October 6, 2020","December 6, 2020","April 7, 2020",,"April 10, 2020","University Hospital Angers, Angers, France",,"https://ClinicalTrials.gov/show/NCT04337190"
771,"NCT04375735","London's Exogenous Surfactant Study for COVID19","LESSCOVID","Not yet recruiting","No Results Available","ARDS, Human|COVID-19","Drug: Bovine Lipid Extract Surfactant","Adverse events (patient) - Decrease in oxygenation|Adverse events (patient) - Decrease in hemodynamics|Adverse event (healthcare worker) - Circuit breach|Adverse event (healthcare worker) - COVID-19 symptoms|Change in oxygenation|Change in Lung compliance|Ventilated days|Length of ICU stay|Length of hospital stay|Mortality|G-CSF levels (serum inflammatory biomarker)|GM-CSF levels (serum inflammatory biomarker)|IFN gamma levels (serum inflammatory biomarker)|IL-1 beta levels (serum inflammatory biomarker)|IL-4 levels (serum inflammatory biomarker)|IL-6 levels (serum inflammatory biomarker)|IL-10 levels (serum inflammatory biomarker)|I levels (serum inflammatory biomarker)|MCP-1 levels (serum inflammatory biomarker)|TNF alpha levels (serum inflammatory biomarker)","Lawson Health Research Institute|London Health Sciences Centre","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9890","May 1, 2020","January 1, 2021","July 1, 2021","May 5, 2020",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04375735"
772,"NCT04361435","Lung Recruitment Device for COVID-19",,"Not yet recruiting","No Results Available","COVID-19|Physiotherapy","Procedure: Chest physiotherapy using a non-invasive oscillating device","SpO2/FIO2 Ratio|Blood pressures|Heart rates|Respiratory rate|Body temperature|Modified Wood Clinical Asthma Score (m-WCAS)|Expiratory tidal lung volume.|End-tidal CO2|Clinical Respiratory severity scores.","St. Justine's Hospital|Dymedso Inc.|Réseau de Recherche en Santé Respiratoire du Québec|Fonds de la Recherche en Santé du Québec","All","Child, Adult, Older Adult","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MP-21-2020-2871","May 1, 2020","July 31, 2020","December 31, 2020","April 24, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04361435"
773,"NCT04380935","Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome",,"Not yet recruiting","No Results Available","COVID|Acute Respiratory Distress Syndrome","Biological: Convalescent plasma|Drug: Standard of care","All-cause mortality|Length of stay in intensive care unit|Duration of mechanical ventilation|Body temperature (degree in Celsius)|The Sequential Organ Failure Assessment (SOFA) Score|PAO2/FIO2 ratio|C-Reactive Protein (CRP) in mg/L|D-Dimer in ng/mL|Procalcitonin in ng/mL|Interleukin 6 (IL-6) in pg/mL|Allergic/ anaphylaxis transfusion reaction|Hemolytic transfusion reaction|Transfusion Related Acute Lung Injury|Transfusion associated Circulatory Overload","Indonesia University|Dr Cipto Mangunkusumo General Hospital|Fakultas Kedokteran Universitas Indonesia","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","convalescent plasma RSCM-FKUI","May 11, 2020","August 31, 2020","August 31, 2020","May 8, 2020",,"May 8, 2020","Dr. Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia|St. Carolus Hospital, Jakarta, DKI Jakarta, Indonesia|PELNI Hospital, Jakarta, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04380935"
774,"NCT04393233","Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation","RHUMACOVID","Recruiting","No Results Available","Rheumatoid Arthritis|COVID",,"Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis","University Hospital, Brest","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RHUMACOVID ( 29BRC20.0110)","April 23, 2020","May 23, 2020","May 23, 2020","May 19, 2020",,"May 19, 2020","CHRU de Brest, Brest, France",,"https://ClinicalTrials.gov/show/NCT04393233"
775,"NCT04377503","Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19",,"Not yet recruiting","No Results Available","Cytokine Release Syndrome|Covid-19","Drug: Tocilizumab 180 MG/ML|Drug: Methylprednisolone Sodium Succinate","Patient clinical status 15 days after randomization|Improving oxygenation|Thorax CT improvement|ICU length of stay|Duration of mechanical ventilation|Incidence of acute kidney (AKI) with necessity of renal replacement therapy","Hospital Sao Domingos","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","covid-19 hsd","May 2020","August 2020","November 2020","May 6, 2020",,"May 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04377503"
776,"NCT04354519","The United Kingdom Multiple Sclerosis Register Covid-19 Substudy","UKMSRCV19","Recruiting","No Results Available","Multiple Sclerosis|COVID-19",,"Incidence of COVID-19 Infections within an MS Cohort in the UK|Hospitalisations in MS Patients with COVID-19|Mortality|Patient Reported Expanded Disability Status Score|Hospital Anxiety and Depression Scale|Multiple Sclerosis Impact Scale 29 V2|Multiple Sclerosis Walking Scale 12 V2|Fatigue Severity Scale|EuroQol 5D (3l)","Swansea University","All","18 Years and older   (Adult, Older Adult)",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","16SW0194","March 14, 2020","July 14, 2021","July 14, 2022","April 21, 2020",,"April 21, 2020","Swansea Univeristy, Swansea, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT04354519/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04354519"
777,"NCT04393324","The Critical Care Response to the COVID-19 Pandemic in Madrid","Tetrix","Recruiting","No Results Available","COVID-19|ARDS, Human",,"Mortality|Length of ICU stay","Hospital San Carlos, Madrid|Fundación de Investigación Hospital Clínico San Carlos","All","Child, Adult, Older Adult",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","Madrid COVID Tetrix","April 24, 2020","May 31, 2020","June 30, 2020","May 19, 2020",,"May 20, 2020","Hospital Clinico San Carlos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04393324"
778,"NCT04389450","Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID|ARDS","Biological: PLX-PAD|Biological: Placebo","Number of ventilator free days|All-cause mortality|Duration of mechanical ventilation","Pluristem Ltd.","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PLX-COV-01","May 2020","September 2020","September 2021","May 15, 2020",,"May 15, 2020","Maimonides Medical Center, New York, New York, United States|Assuta medical center, Ashdod, Israel",,"https://ClinicalTrials.gov/show/NCT04389450"
779,"NCT04381273","Oral Health and Psychosocial Factors During the Covid-19 Pandemic",,"Recruiting","No Results Available","Covid-19|Periodontal Diseases","Other: No intervention","How do people assess their oral health-related quality of life in times of the Covid-19 pandemic?|Does the periodontitis risk have an influence on the severety of the Covid-19 disease and its' treatment?|Do psychosocial stress factors in times of the Covid-19 pandemic have an impact on their oral health related quality of life?|Have people changed their oral hygiene practices in times of the Covid-19 pandemic?","Heidelberg University","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","S-303/2020","May 8, 2020","July 31, 2020","July 31, 2020","May 8, 2020",,"May 8, 2020","University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT04381273"
780,"NCT04375644","Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)","COVIDPROIMPACT","Not yet recruiting","No Results Available","Covid 19|Stress, Psychological","Other: Questionnaires on psychological quality of life","Stress state score, during the confinement period","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)",,"1800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL20_0413","May 11, 2020","August 2020","August 2020","May 5, 2020",,"May 5, 2020","Gynaecology Department, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France",,"https://ClinicalTrials.gov/show/NCT04375644"
781,"NCT04273321","Efficacy and Safety of Corticosteroids in COVID-19",,"Completed","No Results Available","COVID-19|Novel Coronavirus Pneumonia","Drug: Methylprednisolone","the incidence of treatment failure in 14 days|clinical cure incidence in 14 days|the duration of virus change to negative|mortality at day 30|ICU admission rate in 30 days","Beijing Chao Yang Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","86","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Methylprednisolone in COVID-19","February 14, 2020","April 15, 2020","April 15, 2020","February 18, 2020",,"May 11, 2020","Hubei province hospital of integrated Chinese & Western Medicine, Wuhan, Hubei, China|Yichang first people's Hospital, Yichang, Hubei, China|Beijing YouAn Hospital, Beijing, China|Renmin Hospital of Wuhan University, Wuhan, China|Tianyou Hospital Affiliated to Wuhan University of science and technology, Wuhan, China|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, China|the first peopel hospital of Xiangyang, Xiangyang, China",,"https://ClinicalTrials.gov/show/NCT04273321"
782,"NCT04390477","Study to Evaluate the Effect of a Probiotic in COVID-19",,"Recruiting","No Results Available","COVID-19|Coronavirus Infection","Dietary Supplement: Probiotic","Cases with discharge to ICU.|Patients with home discharge.|Mortality.|Treatment safety assessed by number of adverse events.|New cases of SARS-Cov-2 infection among healthcare personnel caring for the patients.|Patients with negative PCR result for SARS-CoV-2 infection.","Bioithas SL","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID.PROB","May 4, 2020","July 2020","May 2021","May 15, 2020",,"May 15, 2020","Hospital Universitario del Vinalopó, Elche, Alicante, Spain|Hospital Universitario de Torrevieja, Torrevieja, Alicante, Spain",,"https://ClinicalTrials.gov/show/NCT04390477"
783,"NCT04383886","Evaluation of Emergency Department (ED) Staff Stress Level During COVID-19 Pandemic","COVER-PRO","Recruiting","No Results Available","Emergency Department Staff During the COVID-19 Pandemic|Emergency Department Staff's Level of Stress","Other: stress and anxiety questionnaire","Change of emergency department staff's level of stress during the covid19 pandemic, measured using the Chamoux et Simard visual analogic scale","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL20_0330","April 18, 2020","August 18, 2020","August 18, 2020","May 12, 2020",,"May 12, 2020","SAMU Hospices Civils de Lyon, Lyon, France|Service d'accueil des urgences, Hôpital Edouard Herriot, Hospices Civlis de Lyon, Lyon, France|Service d'accueil des urgences, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France|Service d'accueil des urgences, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France|Hôpital de Villefranche-sur-Saône, Villefranche-sur-Saône, France",,"https://ClinicalTrials.gov/show/NCT04383886"
784,"NCT04335305","Checkpoint Blockade in COVID-19 Pandemic","COPERNICO","Recruiting","No Results Available","COVID-19|Pneumonia, Viral","Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475)","Percentage of patients with normalization of oxygen saturation by pulse oximetry (SpO2) ≥96%|Proportion of patients with temperature < 37,5 °C armpit.|Proportion of patients discharged from the emergency department and classified as low risk|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test|Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)","MedSIR","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MedOPP376","May 29, 2020","June 30, 2020","June 30, 2020","April 6, 2020",,"May 19, 2020","Hospital Quirónsalud Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Ruber Juan Bravo, Madrid, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Arnau de Vilanova-Lliria, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04335305"
785,"NCT04363541","Local Thermotherapy for Patients With Moderate Symptoms of COVID-19",,"Not yet recruiting","No Results Available","COVID-19|Thermotherapy","Device: Electric pad for human external pain therapy","Hospitalization time|Patients needing intensive care|Symptoms after hospitalization release","Instituto Nacional de Perinatologia|Hospital Juarez de Mexico|Direccion General de Calidad y Educacion en Salud|Laboratorios Silanes S.A. de C.V.","All","Child, Adult, Older Adult","Not Applicable","298","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U1111-1250-7416","April 2020","September 2020","November 2020","April 27, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04363541"
786,"NCT04391686","Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context","RECOVERY","Not yet recruiting","No Results Available","COVID-19|Obesity","Diagnostic Test: indirect calorimetry","The resting energy expenditure (in Kcal / 24h) measured by indirect calorimetry during the stay in intensive care.","Centre Hospitalier Arras","All","18 Years and older   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2020-04","June 1, 2020","December 31, 2020","December 31, 2020","May 18, 2020",,"May 18, 2020","Arras general hospital, Arras, France",,"https://ClinicalTrials.gov/show/NCT04391686"
787,"NCT04387786","Dornase Alfa Administered to Patients With COVID-19 (DACOVID)","DACOVID","Active, not recruiting","No Results Available","COVID-19|Mechanical Ventilation","Drug: Dornase Alfa","Number of participants discharged from the intensive care unit (ICU)|Number of participants who survived COVID-19|Mean change in FiO2","Feinstein Institute for Medical Research|Cold Spring Harbor Laboratory|Northwell Health","All","18 Years to 85 Years   (Adult, Older Adult)",,"5","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","216","March 31, 2020","April 24, 2020","July 2020","May 14, 2020",,"May 14, 2020","Feinstein Insitute for Medical Research at Northwell Health, Manhasset, New York, United States",,"https://ClinicalTrials.gov/show/NCT04387786"
788,"NCT04392388","Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis","SAPRIS-SERO","Recruiting","No Results Available","SARS-CoV 2","Biological: Non applicable","Cumulative incidence of SARS-Cov2 infection in the general population.|Characterize the ""immune"" fraction of the population and the durability of immunity","Institut National de la Santé Et de la Recherche Médicale, France","All","Child, Adult, Older Adult",,"110000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","C20-26|2020-A01195-34","May 1, 2020","December 31, 2020","December 31, 2020","May 18, 2020",,"May 18, 2020","Inserm, Paris, France",,"https://ClinicalTrials.gov/show/NCT04392388"
789,"NCT04355481","Dissemination of SARS-COV-2 (COVID-19) in the Environment of Infected Patients Admitted to Intensive Care Unit","ENVIROREA","Recruiting","No Results Available","Covid-19|Viral Infection",,"Estimate the proportion of patients hospitalized in intensive care for a SARS-Cov-2 viral lung infection and contaminating their environment at 1 meter.","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP200411|2020-A00897-32","April 17, 2020","October 17, 2020","December 17, 2020","April 21, 2020",,"April 24, 2020","Service de réanimation Hôpital Avicenne, Bobigny, France|Service de réanimation Hôpital Bichat, Paris, France|Service de réanimation Hôpital Tenon, Paris, France",,"https://ClinicalTrials.gov/show/NCT04355481"
790,"NCT04383613","Prone Positioning for Patients on General Medical Wards With COVID19","COVID-PRONE","Recruiting","No Results Available","Covid-19|ARDS","Other: Prone positioning","Composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for FiO2 of 60% or more|Length of hospitalization|Adverse events of prone positioning (i.e., venous thromboembolism, pneumonia)|In-hospital all-cause mortality|Invasive or non-invasive mechanical ventilation|Need for FiO2 of 60% or more|Ventilator-free days (i.e., the number of days in hospital the patient was not on a ventilator)|Composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for FiO2 of 60% or more assessed at 30 days, 90 days and 1 year|Time spent in prone positioning among patients achieving the composite outcome of in-hospital all-cause mortality, invasive or non-invasive mechanical ventilation, or need for FiO2 of 60% or more","St. Michael's Hospital, Toronto|Sunnybrook Health Sciences Centre|Sinai Health System|Toronto General Hospital|University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","2020-1","May 15, 2020","December 11, 2020","December 11, 2020","May 12, 2020",,"May 21, 2020","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04383613"
791,"NCT04341103","AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience","Al-COVE","Not yet recruiting","No Results Available","Solid Organ Transplant Rejection|COVID-19",,"Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19","CareDx","All","Child, Adult, Older Adult",,"500","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Al-COVE","April 1, 2020","December 1, 2020","March 1, 2021","April 10, 2020",,"April 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04341103"
792,"NCT04394000","Impact of an Intensified Thromboprofylaxis Protocol in COVID-19",,"Completed","No Results Available","COVID19|Thromboembolism","Other: thromboprofylaxis protocol|Other: standard protocol","2 week mortality|incidence of venous thromboembolism|1 week mortality|3 week mortality|1 month mortality|incidence of kidney failure|incidence of continuous renal replacement therapy (CRRT)|lowest PaO2/FiO2 (P/F) ratio|highest Sequential Organ Failure Assessment (SOFA) score|length of stay|highest bilirubin|highest ( AST|highest Aspartaat-Amino-Transferase (ALT)","Jessa Hospital","All","18 Years and older   (Adult, Older Adult)",,"72","Other","Observational","Observational Model: Cohort|Time Perspective: Other","Jessa_20.48","May 4, 2020","May 15, 2020","May 15, 2020","May 19, 2020",,"May 19, 2020","Jessa hospital, Hasselt, Belgium",,"https://ClinicalTrials.gov/show/NCT04394000"
793,"NCT04341285","Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)","ECMO-VID","Not yet recruiting","No Results Available","ARDS, Human|COVID-19","Procedure: ECMO Implantation","28 day all cause mortality|90 day all cause mortality|Sepsis-related organ failure assessment score at day 1-14, 28 and 90 days|duration of mechanical ventilation support|Ventilator Associated Pneumonia|Bleeding complications|Acute Renal Failure|Discharge Location","University Hospital Tuebingen|University Hospital Freiburg|RWTH Aachen University|University Hospital Muenster","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECMO-VID","June 1, 2020","June 1, 2024","December 1, 2025","April 10, 2020",,"April 16, 2020","University Hospital Tuebingen, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT04341285"
794,"NCT04354584","Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19","COV2ICU-DK","Recruiting","No Results Available","COVID-19|Respiratory Failure",,"White blood cell counts|Lymphocyte populations|Cytokines|Lectin complement pathway|Microorganisms|Respiratory pathogens|Ribosomal RNA in the airways|Levels of SARS-CoV-2 in the airways","Hvidovre University Hospital","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COV2ICU-DK|H-20023159|R349-2020-540","April 6, 2020","April 6, 2021","April 6, 2021","April 21, 2020",,"April 21, 2020","Dept. of Intensive Care 542, University Hospital Hvidovre, Hvidovre, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04354584"
795,"NCT04331665","Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19|Pneumonia","Drug: Ruxolitinib","Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more)|Number of adverse events|All cause mortality rate|Average duration of hospital stay","University Health Network, Toronto","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U-DEPLOY: RUX-COVID|20-5315","April 20, 2020","October 30, 2020","January 31, 2021","April 2, 2020",,"April 13, 2020","Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04331665"
796,"NCT04360759","Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19","CQOTE","Not yet recruiting","No Results Available","Covid-19|HIV","Drug: Chloroquine or hydroxychloroquine","Event-free survival at 28 days post-randomization between experimental group and standard of care group|Incidence of serious adverse events|Incidence of adverse events of special interest related to investigational product at time of hospitalisation|Premature discontinuation of treatment|Time from treatment initiation to death, ARDS (PF/SF ratio < 300), or mechanical ventilation|Proportion with moderate and severe ARDS|Duration of hospitalisation and ICU stay in survivors|Incidence of Covid-19 in household contacts","University of Cape Town","All","18 Years and older   (Adult, Older Adult)","Phase 3","560","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIV-COVID-19 CQOTE","May 1, 2020","May 31, 2021","July 31, 2021","April 24, 2020",,"April 27, 2020","Khayelitsha Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04360759"
797,"NCT04382417","Observational Cohort Study of Critically Ill Patients With Covid-19 in Sweden",,"Recruiting","No Results Available","Covid-19|Critical Illness","Other: Observational study","Demographic characteristics of patients with Covid-19 receiving intensive care|Survival rate in patients with Covid-19 receiving intensive care|Clinical course characteristics of patients with Covid-19 receiving intensive care|Number of days on mechanical ventilation","Region Västmanland","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RegionVastmanland","March 26, 2020","December 31, 2020","May 31, 2021","May 11, 2020",,"May 11, 2020","Intensive Care Unit, Västerås Hospital, Västerås, Västmanland, Sweden",,"https://ClinicalTrials.gov/show/NCT04382417"
798,"NCT04298814","Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19|Endotracheal Intubation","Other: severe covid-19 pneumonia with ET","Success rate of intubation|Infection rate of Anesthesiologist|Extubation time","Tongji Hospital","All","18 Years to 90 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COVEI","March 7, 2020","May 30, 2020","July 30, 2020","March 6, 2020",,"March 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04298814"
799,"NCT04362111","Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19",,"Not yet recruiting","No Results Available","Cytokine Storm|COVID-19","Drug: Anakinra|Drug: Normal saline","No increase in oxygen requirement and no increase in respiratory support measures|Improvement in Cytokine Storm markers|No requirement for mechanical ventilation","University of Alabama at Birmingham","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Chatham-Cytokine Covid-19","May 2020","July 2020","December 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04362111"
800,"NCT04278963","Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19",,"Suspended","No Results Available","CoVID-19|Chinese Medicine","Drug: YinHu QingWen Decoction|Drug: YinHu QingWen Decoction(low dose)|Other: Chinese medicine treatment|Other: standard western medicine treatment","Mean clinical recovery time (hours)|Time to CoVID-19 RT-PCR negative in upper respiratory tract specimen|Change (reduction) in CoVID-19 viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Frequency of respiratory progression|Severe case incidence|Proportion of re-hospitalization or admission to ICU|All-cause mortality|Frequency of serious adverse events","China Academy of Chinese Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","YHQW-V3.0","February 27, 2020","January 2021","January 2021","February 20, 2020",,"May 11, 2020","Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China|Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04278963"
801,"NCT04378920","A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease (LEAF-4L7520/4L6715)","LEAF-4L6715","Recruiting","No Results Available","COVID19|Acute Respiratory Distress Syndrome","Drug: LEAF-4L6715|Drug: LEAF-4L7520","proportion of patients showing an increase of at least 25% of PaO2/FiO2 ratio|proportion of patients with a PaO2/FiO2 ratio above 200 mm Hg|all cause mortality","Institut de Cancerologie Strasbourg Europe|LEAF4Life LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","180","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-003|2020-001393-30|2020-A00900-39","April 14, 2020","July 31, 2020","October 31, 2020","May 7, 2020",,"May 14, 2020","Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Institut de Cancerologie Strasbourg Europe, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04378920"
802,"NCT04395105","Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",,"Recruiting","No Results Available","Respiratory Distress Syndrome, Adult|Covid-19","Drug: Dexamethasone","Ventilator-free days at 28 days|28-days mortality|Frequency of nosocomila infections|Viral shedding|Serum C-reactive Protein variation|SOFA variation|Use of prone position|Delirium|Muscle weakness","Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno","All","18 Years and older   (Adult, Older Adult)","Phase 3","284","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1264","May 21, 2020","December 31, 2020","January 31, 2021","May 20, 2020",,"May 25, 2020","CEMIC (Centro de Educación Médica e Investigaciones Clínicas), Caba, Argentina",,"https://ClinicalTrials.gov/show/NCT04395105"
803,"NCT04389671","The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19",,"Not yet recruiting","No Results Available","COVID-19|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)","Drug: Lucinactant","Oxygenation index (OI) area under the curve (AUC)0-12|FiO2|PaO2|Oxygenation from pulse oximetry (SpO2)|P/F ratio|Ventilation Index (VI)|Lung compliance","Windtree Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","02-CL-2001a","June 1, 2020","October 2020","November 2020","May 15, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04389671"
804,"NCT04318444","Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)",,"Recruiting","No Results Available","COVID-19|Corona Virus Infection","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Number of participants with symptomatic, lab-confirmed COVID-19.","Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AAAS9676","March 29, 2020","March 2021","March 2022","March 24, 2020",,"April 27, 2020","Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04318444"
805,"NCT04341415","Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome","SOS-COVID19","Recruiting","No Results Available","Covid19|SARS-CoV Infection","Procedure: Auricular neuromodulation|Procedure: Control","Comparison of the percentage of clinically improved inpatients between D0 and D14","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","CRN_2020_8","April 9, 2020","July 2020","July 2020","April 10, 2020",,"May 13, 2020","Fondation Adolphe de Rothschild, Paris, France",,"https://ClinicalTrials.gov/show/NCT04341415"
806,"NCT04330144","Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)",,"Not yet recruiting","No Results Available","Contact Person From COVID-19 Confirmed Patient","Drug: Hydroxychloroquine as post exposure prophylaxis|Other: Others(No intervention)","The rate of COVID-19","Gangnam Severance Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","2486","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","3-2020-0036","April 1, 2020","March 30, 2021","March 30, 2022","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330144"
807,"NCT04357574","Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19","CORONA-SHIELD","Enrolling by invitation","No Results Available","COVID-19|Cancer","Other: Telehealth","Radiation Oncology providers perception of of telehealth for on treatment patients in lieu of in person on treatment visits during COVID-19|Number of missed telehealth clinical evaluation visits during COVID-19|Number of unplanned emergency department visits or hospital admissions during COVID-19|Number of acute care visits with listed reason as anemia, nutrition (including dehydration), diarrhea, emesis, infectious (including fever, pneumonia, and sepsis), nausea, neutropenia, pain category during COVID-19","Duke University","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Pro00105266","April 14, 2020","April 2021","April 2021","April 22, 2020",,"April 22, 2020","Duke Cancer Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04357574"
808,"NCT04388670","Epidemiological and Clinical Characteristics of Critically Ill Patients With COVID-19","2019nCoV_ICU","Recruiting","No Results Available","COVID-19|Critical Illness",,"Overall number and characteristics of patients with COVID-19 in ICU","Policlinico Hospital","All","18 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","PoliclinicoH","February 22, 2020","August 22, 2020","August 31, 2020","May 14, 2020",,"May 14, 2020","Fondazione IRCCS Ca'Granda - Ospedale Maggiore Policlinico, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT04388670"
809,"NCT04395599","Risk of Air Contamination During Visceral Surgery in COVID19 Patients","COELIOCOVID","Not yet recruiting","No Results Available","Sars-CoV2|Surgery|COVID","Other: Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.","Air contamination|Environment contamination|Surgical approach|Opening of the digestive tract|Biological fluids|Pneumoperitoneum","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020_44|2020-A01461-38","May 2020","October 2020","October 2020","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04395599"
810,"NCT04384731","Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19","Caards-1","Not yet recruiting","No Results Available","COVID-19|ARDS, Human","Drug: poractant alfa","Evolution of the PaO2 / FiO2 ratio between the measurements taken before (t0) and one hour after the end of the invasive procedure (H1).|Oxygenation : PaO2 / FiO2 ratio.|Oxygenation : area under the PaO2 / FiO2 curve.|Oxygenation : area under the SpO2 curve.|Evolution of thoraco-pulmonary compliance (mL / mbar) between before and one hour after the procedure.|Overall survival rate|Mortality rate at discharge from the intensive care unit.|Mortality rate at discharge from the hospital.|Number of ventilator-free days|Number of prone position sessions.|Time between inclusion and the last prone position session.","Dr Christophe LENCLUD|Versailles Hospital","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","P20/06","May 27, 2020","November 30, 2020","January 30, 2021","May 12, 2020",,"May 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04384731"
811,"NCT04353011","Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak","DolPsyCOVID","Completed","No Results Available","Sars-CoV2|Chronic Pain","Other: questionnaire assesment","Hospital Anxiety and Depression Scale questionnaire|Quality of life (SF36)|self-reported questionnaire for painful|qualitive questionnaire","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)",,"312","Other","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","EQ_2020_02|2020-A00912-37","April 20, 2020","April 27, 2020","April 27, 2020","April 20, 2020",,"May 21, 2020","Hopital Roger Salengro, CHU Lille, Lille, France",,"https://ClinicalTrials.gov/show/NCT04353011"
812,"NCT04351633","Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak","OsPsyCOVID","Completed","No Results Available","Sars-CoV2|Osteoporosis","Other: questionnaire assesment","percentage of patient with feeling of disabilities","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)",,"52","Other","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","EQ_2020_03|2020-A00911-38","April 23, 2020","April 30, 2020","April 30, 2020","April 17, 2020",,"May 21, 2020","Hopital Roger Salengro, CHU Lille, Lille, France",,"https://ClinicalTrials.gov/show/NCT04351633"
813,"NCT04366024","A Novel Nomogram to Predict Severity of COVID-19",,"Recruiting","No Results Available","COVID-19 Disease|Nomogram Model","Other: other","the consistency of predicted severe rate and observed severe rate of COVID-19 patients|Duration of severe illness","Xinqiao Hospital of Chongqing","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","XQonc-016","January 17, 2020","May 30, 2020","December 31, 2021","April 28, 2020",,"April 28, 2020","Xinqiao Hospital of Chongqing, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04366024"
814,"NCT04371289","Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up","CARDICoVRISK","Not yet recruiting","No Results Available","COVID-19|Cardiovascular Risk Factor",,"Predictive modeling of in-hospital outcome|Clinical, pathophysiological and molecular mechanisms|Short -Term Sequelae","Istituto Auxologico Italiano","All","18 Years and older   (Adult, Older Adult)",,"5500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CE_2020_03_26_02","April 2020","July 10, 2020","September 10, 2020","May 1, 2020",,"May 1, 2020","Istituto Auxologico Italiano, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT04371289"
815,"NCT04366154","Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers","COVIPACT","Recruiting","No Results Available","COVID-19|Cancer","Other: Questionnaire","To assess the impact of the COVID-19 pandemic on the modifications of treatments administered in hospital (day units) to patients with cancer or malignant hemopathy|To assess the impact of the COVID-19 pandemic on the change in the rate of treatment administration in hospital (day units) to patients with cancer or malignant hemopathy|To assess the impact of the COVID-19 pandemic on the number of cures administeredin hospital (day units) to patients with cancer or malignant hemopathy|To assess the impact of the COVID-19 pandemic on change of modality of administration in hospital (day units) to patients with cancer or malignant hemopathy|Evaluate the perceived stress on cancer patients treated in unit day of hospital|Evaluate the post-traumatic stress on cancer patients treated in unit day of hospital|Evaluate the sleep disorders on cancer patients treated in unit day of hospital|Evaluate the quality of life on cancer patients treated in unit day of hospital|Evaluate the cognitive complaints on cancer patients treated in unit day of hospital|Evaluate the perceived stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)|Evaluate the post-traumatic stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)|Evaluate the burnout on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)|Evaluate the feeling of personal effectiveness on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)","Centre Francois Baclesse","All","18 Years and older   (Adult, Older Adult)",,"385","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A00879-30","April 15, 2020","July 2020","December 2020","April 28, 2020",,"April 30, 2020","Centre François Baclesse, Caen, France",,"https://ClinicalTrials.gov/show/NCT04366154"
816,"NCT04318015","Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)","PHYDRA","Recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Symptomatic COVID-19 infection rate|Symptomatic non-COVID viral infection rate|Days of labor absenteeism|Rate of labor absenteeism|Rate of severe respiratory COVID-19 disease in healthcare personnel","National Institute of Respiratory Diseases, Mexico|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ProfilaxisCOVID","April 14, 2020","December 31, 2020","March 31, 2021","March 23, 2020",,"April 17, 2020","Instituto Nacional de Enfermedades Respiratorias, ""Ismael Cosío Villegas"", Mexico, City, Mexico",,"https://ClinicalTrials.gov/show/NCT04318015"
817,"NCT04341038","Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury","TACROVID","Recruiting","No Results Available","COVID-19|Lung Injury","Drug: Tacrolimus|Drug: Methylprednisolone","Time to reach clinical stability|Time to reach an afebrile state for 48 hours.|Time to reach PaO2 / FiO2> 400 and / or SatO2 / FiO2> 300|Time to reach FR ≤ 24 rpm for 48 hours|Time to normalization of D-dimer (<250 ug / L)|Time until PCR normalization (<5mg / L).|Time until normalization of ferritin (<400ug / L)|Study the impact of immunosuppressive treatment on viral load using quantitative PCR|Time until hospital discharge|Need for ventilatory support devices|Duration that it is necessary to maintain ventilatory support.|COVID-19 mortality|all-cause mortality|Analyze the expanded cytokine profile before the start of treatment and their evolution every 7 days after admission|Describe the side effects and their severity attributed to tacrolimus and / or methylprednisolone.","Hospital Universitari de Bellvitge|Institut d'Investigació Biomèdica de Bellvitge","All","18 Years and older   (Adult, Older Adult)","Phase 3","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","TACRO-BELL-COVID|2020-001445-39","April 1, 2020","June 1, 2020","July 1, 2020","April 10, 2020",,"April 10, 2020","Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04341038"
818,"NCT04381988","A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy",,"Recruiting","No Results Available","COVID-19|Cancer","Drug: Hydroxychloroquine|Other: Placebo|Radiation: Radiation therapy","cumulative incidence of SARS-CoV-2 infection|cumulative incidence of severe COVID-19 or death","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","20-176","May 7, 2020","May 2021","May 2021","May 11, 2020",,"May 13, 2020","Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States",,"https://ClinicalTrials.gov/show/NCT04381988"
819,"NCT04371029","Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS","COVISLEEP","Recruiting","No Results Available","ARDS|COVID-19","Other: PSG","Proportion of patients with altered spleep|Sleep architecture at hospital discharge|Sleep monitoring during hospital stay after ICU discharge|Sleep quality|Sleep architecture at month-3|Cost of ICU hospitalization","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CHUBX 2020/14","April 28, 2020","June 2020","September 2020","May 1, 2020",,"May 13, 2020","Hopital Pellegrin, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04371029"
820,"NCT04251767","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection",,"Withdrawn","No Results Available","COVID-19 Complicated With Refractory Intestinal Infections","Other: washed microbiota transplantation|Other: placebo","Number of participants with improvement from severe type to common type","The Second Hospital of Nanjing Medical University","All","14 Years to 70 Years   (Child, Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WMT-YJ-202001","February 5, 2020","April 30, 2020","April 30, 2020","February 5, 2020",,"March 17, 2020","Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04251767"
821,"NCT04341766","Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19",,"Recruiting","No Results Available","Pneumonia, Viral|COVID-19","Other: No special intervention","Characteristics of pulmonary ultrasound for Covid-19 patients|Charateristics of pulmonary CT-scan for Covid-19 patients","Centre Hospitalier Intercommunal Creteil","All","18 Years to 105 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-ECHO","March 31, 2020","September 1, 2020","September 30, 2020","April 10, 2020",,"May 25, 2020","CHU Amiens, Amiens, France|CH de la Côte Basque, Bayonne, France|CHU Ambroise Paré, Boulogne-Billancourt, France|CHU Caen, Caen, France|CHG de Chambery, Chambéry, France|Centre Hospitalier Intercommunal de Créteil, Créteil, France|CHU de Limoges, Limoges, France|APHM - Hopital Nord, Marseille, France|CHU de Nancy, Nancy, France|CHU Nîmes, Nîmes, France|CHR Orléans, Orléans, France|CHU Cochin, Paris, France|CHU Poitiers, Poitiers, France|CHU Rouen, Rouen, France|CH Saint-Quentin, Saint-Quentin, France|CHU Larrey - Toulouse, Toulouse, France|CHU de Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT04341766"
822,"NCT04338568","Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study","SCOUT","Recruiting","No Results Available","COVID-19 Pneumonia|Lung Ultrasound","Diagnostic Test: Lung ultrasound","Accuracy of the diagnosis of interstitial syndrome by lung ultrasound|Inter-observer variability","Hasselt University|Ziekenhuis Oost-Limburg","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CTU2020032","April 13, 2020","April 30, 2020","April 30, 2020","April 8, 2020",,"April 15, 2020","Ziekenhuis Oost Limburg, Genk, Limburg, Belgium",,"https://ClinicalTrials.gov/show/NCT04338568"
823,"NCT04397172","Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19",,"Recruiting","No Results Available","COVID|Corona Virus Infection|Sars-CoV2","Procedure: Study Arm","Short Form (36) Health Survey (SF-36)|Mortality|Modified Rankin Scale (mRS)|Duration of mechanical ventilation in days|Barthel Index|Beck's Depression Inventory II (BDI-II)|Essener Questionnaire for Coping with a Disease (EFK)|Number of patients with Critical Illness Myopathy","University Hospital Inselspital, Berne","All","18 Years to 80 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00730","April 9, 2020","April 2021","December 2021","May 21, 2020",,"May 25, 2020","Inselspital Bern, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04397172"
824,"NCT04376944","Barrier Measures to Limit Covid-19.Nosocomial Transmission: a Cross-sectional Evaluation","EMBELLIE","Recruiting","No Results Available","Caregivers|COVID-19","Other: Survey","Proportion of caregivers and agents with a positive serodiagnosis|Proportion of caregivers and agents with a positive RT-PCR","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","RECHMPL20_0261","April 1, 2020","December 1, 2020","December 30, 2020","May 6, 2020",,"May 6, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04376944"
825,"NCT04355364","Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alpha Administration in Patients With COVID19-induced ARDS (COVIDORNASE)","COVIDORNASE","Recruiting","No Results Available","COVID-19|Acute Respiratory Distress Syndrome","Drug: Dornase Alfa Inhalation Solution [Pulmozyme]|Procedure: standard procedure","Efficacy of intratracheal administration: occurrence of at least one grade improvement","Fondation Ophtalmologique Adolphe de Rothschild|University Hospital, Strasbourg, France|Centre Hospitalier Régional Metz-Thionville","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CGE_2020_9","April 15, 2020","April 15, 2020","August 15, 2020","April 21, 2020",,"May 8, 2020","Hôpital Fondation A. de Rotschhild, Paris, France",,"https://ClinicalTrials.gov/show/NCT04355364"
826,"NCT04335552","Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",,"Recruiting","No Results Available","SARS-CoV-2","Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin","World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events","Duke University","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00105339","April 17, 2020","August 1, 2020","August 1, 2020","April 6, 2020",,"April 24, 2020","Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04335552"
827,"NCT04379076","InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort","ILIAD-7-UK","Recruiting","No Results Available","COVID-19|Lymphocytopenia","Drug: Interleukin-7|Drug: Placebos","Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC≤1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whicheve|To obtain ""clinical improvement"" as defined by a 2 points improvement in a 7-point ordinal scale for Clinical Assessment, through day 30 or HD.|determine if CYT107 will lead to a significant decline of SARS-CoV-2 viral load through day 30 or HD|To compare the effect of CYT107 versus placebo on the frequency of secondary infections through day 45|To compare the effect of CYT107 versus placebo on the length of hospitalization|To compare the effect of CYT107 versus placebo on the length of stay in ICU|To compare the effect of CYT107 versus placebo on readmissions to ICU|To compare the effect of CYT107 versus placebo on organ support free days|To compare the effect of CYT107 versus placebo on the frequency of re-hospitalization through day 45|To assess the impact of CYT107 on all-cause mortality through day 45|To determine the effect of CYT107 on CD4+ and CD8+ T cell counts|To track and evaluate other known biomarkers of inflammation: Ferritin|To track and evaluate other known biomarkers of inflammation: CRP|To track and evaluate other known biomarkers of inflammation: D-dimer|Evaluation of physiological status through NEWS2 score","Revimmune|Amarex Clinical Research","All","25 Years to 80 Years   (Adult, Older Adult)","Phase 2","48","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLI107 COVID UK (ILIAD-7-UK)","May 14, 2020","October 30, 2020","December 30, 2020","May 7, 2020",,"May 15, 2020","Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04379076"
828,"NCT04333732","CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION","CROWN CORONA","Not yet recruiting","No Results Available","COVID 19","Drug: Low-dose chloroquine|Drug: Mid-dose chloroquine|Drug: High-dose chloroquine|Drug: Placebo","Symptomatic COVID-19|Peak severity of COVID-19 over the study period","Washington University School of Medicine|Bill and Melinda Gates Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","55000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","202004099","May 2020","February 2021","February 2021","April 3, 2020",,"May 7, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States|Population Health Resarch Institute, Hamilton, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada|St James's Hospital, Dublin, Leinster, Ireland|Universitas Academic Hospital, Bloemfontein, Free State, South Africa|Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa|Steve Biko Academic Hospital, Pretoria, Gauteng, South Africa|Tygerberg Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa|University College London, London, United Kingdom|Levy Mwanawasa University Teaching Hospital, Lusaka, Zambia|Centre for Infectious Disease Research in Zambia [CIDRZ], Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT04333732"
829,"NCT04377997","Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19",,"Not yet recruiting","No Results Available","Cardiovascular Diseases|COVID-19","Drug: Enoxaparin","Number of patients with the composite efficacy endpoint of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.|Number of patients with a major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition.","Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dartmouth-Hitchcock Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020P001136","May 15, 2020","January 1, 2021","January 1, 2022","May 7, 2020",,"May 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04377997"
830,"NCT04344977","Collection of Anti-SARS-CoV-2 Immune Plasma","NIAID","Recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19)",,"Identification of eligible donors and collection of anti-SARS-CoV-2 immune plasma","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)",,"1500","NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","200081|20-I-0081","May 15, 2020","July 1, 2024","April 1, 2025","April 14, 2020",,"May 8, 2020","Bloodworks Northwest, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04344977"
831,"NCT04393961","At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study",,"Recruiting","No Results Available","COVID19|COVID-19|Coronavirus","Device: Premier Biotech COVID-19 IgG/IgM Rapid test Cassette","Does Participant Accurately Read Result|Acceptability and Usability of Tests|Social Distancing Behavior Change|COVID-19 Related Anxiety","ProofPilot|Radish Health|Sanesco","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","600","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","2458","April 5, 2020","July 29, 2020","August 29, 2020","May 19, 2020",,"May 19, 2020","ProofPilot Online App (https://p.proofpilot.com), New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04393961"
832,"NCT04380714","Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19",,"Recruiting","No Results Available","People Incarcerated|COVID-19",,"percentage changes in the consumption of psychoactive substances|Assessment of the level of stress|Assessment of depression|Craving modification evaluation","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"700","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","RECHMPL20_0273","May 1, 2020","May 30, 2020","August 1, 2020","May 8, 2020",,"May 8, 2020","UH Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04380714"
833,"NCT04380896","COVID-19 Staff Testing of Antibody Responses Study (Co-Stars)","Co-Stars","Recruiting","No Results Available","SARS-CoV-2 Infection","Other: Blood test|Other: Standardised questionnaires","Change in serial monthly log-transformed antibody titre levels as measured|Proportion of completely asymptomatic healthcare workers with evidence of SARS-CoV-2 antibodies|The attack rate of SARS-CoV-2 in healthcare workers who have antibodies compared to those who do not|The immune correlates of protection against future exposure to SARS-CoV-2","Great Ormond Street Hospital for Children NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20CB17","April 27, 2020","July 27, 2026","July 27, 2026","May 8, 2020",,"May 15, 2020","Great Ormond Street Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04380896"
834,"NCT04367142","Rapid Detection of COVID-19 by Portable and Connected Biosensor","COR-DIAL-1","Not yet recruiting","No Results Available","Sars-CoV2","Diagnostic Test: COVID-19 RT-PCR|Diagnostic Test: Biosensor","Sensitivity and specificity of the COR-DIAL based on nasopharyngeal swabs taken on admission of the patient compared to the final diagnosis of COVID-19 made by the medical team|Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and COR-DIAL based on nasopharyngeal swabs taken on patient admission","University Hospital, Lille","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2020_36|2020-A01147-32","May 2020","September 2020","September 2020","April 29, 2020",,"April 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04367142"
835,"NCT04374149","Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS",,"Not yet recruiting","No Results Available","Cytokine Release Syndrome|COVID19","Procedure: Therapeutic Plasma Exchange|Drug: Ruxolitinib","Overall Response Rate","Prisma Health-Upstate","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHU COVID-19-001","April 30, 2020","September 1, 2020","April 30, 2021","May 5, 2020",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04374149"
836,"NCT04355351","Study of Immune Response During SARS-CoV-2 Infection - (COVID-19)","CovImmune","Not yet recruiting","No Results Available","New Coronavirus Disease (COVID-19), Infection With SARS-CoV-2","Other: blood sampling|Other: additional blood tubes","Level of IFN-gamma after a non-specific stimulation of T lymphocytes","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20-PP-05","April 22, 2020","October 22, 2020","October 22, 2020","April 21, 2020",,"April 24, 2020","Antibes Hospital, Antibes, France|Cannes Hospital, Cannes, France|Nice Hospital, Nice, France",,"https://ClinicalTrials.gov/show/NCT04355351"
837,"NCT04363853","Tocilizumab Treatment in Patients With COVID-19",,"Recruiting","No Results Available","Sars-CoV2","Drug: Tocilizumab","Hematic biometry|Blood chemistry|Blood gas|blood gas|thorax radiography","Instituto Nacional de Cancerologia de Mexico|Roche Pharma AG","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","200","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INF-3343-20-22-1","April 1, 2020","June 1, 2020","August 1, 2020","April 27, 2020",,"April 27, 2020","National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico",,"https://ClinicalTrials.gov/show/NCT04363853"
838,"NCT04388709","Interferon Lambda Therapy for COVID-19",,"Not yet recruiting","No Results Available","SARS-CoV-2","Drug: Peginterferon Lambda-1A","Number of participants with resolution of hypoxia|Number of adverse events.|Days with fever|Time to resolution of fever|Rate of progression to requiring critical care|Overall survival|Time to discharge","Icahn School of Medicine at Mount Sinai|Eiger BioPharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 20-0820","May 2020","May 2021","May 2021","May 14, 2020",,"May 18, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04388709"
839,"NCT04304690","COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","SEROCOV","Recruiting","No Results Available","Sars-CoV2","Other: blood sample","Quantify the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff|Identification of risk factors for seroconversion|Quantify the proportion of asymptomatic infections among staff who have seroconverted|"" Describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome ""","Assistance Publique - Hôpitaux de Paris","All","Child, Adult, Older Adult","Not Applicable","1000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","APHP200310","March 16, 2020","July 16, 2020","October 16, 2020","March 11, 2020",,"April 13, 2020","Hopital Pitié Salpetrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04304690"
840,"NCT04390061","TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia","TOFACoV-2","Not yet recruiting","No Results Available","Pneumonitis, Interstitial|COVID-19","Drug: Tofacitinib|Drug: Hydroxychloroquine","Prevention of severe Respiratory Failure requiring mechanical ventilation|Prevention of need of ICU admission|Prevention of COVID-19 related Deaths|Identification of predictors of outcome|Incidence of Treatment-Emergent Adverse Events","Università Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord|Ospedale Civile Santo Spirito, Pescara|Università Magna Grecia, Catanzaro|ASST Papa Giovanni XXIII, Bergamo|Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma|ASST Cremona, Cremona|Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano|Ospedale di Circolo e Fondazione Macchi, Varese","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-002035-30","June 2020","September 2020","October 2020","May 15, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04390061"
841,"NCT04343963","Pyridostigmine in Severe SARS-CoV-2 Infection","PISCO","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Pyridostigmine Bromide|Drug: Placebo","Critical condition or death|IL-6","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","436","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Inf-3323","April 4, 2020","September 30, 2020","April 30, 2021","April 14, 2020",,"April 15, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Tlalpan, Mexico",,"https://ClinicalTrials.gov/show/NCT04343963"
842,"NCT04387240","Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19",,"Not yet recruiting","No Results Available","Covid 19 Positive|Corona Virus Infection","Drug: Artemisinin / Artesunate|Other: placebo","length of stay in hospital|number of ICU admission|resolution of symptoms","Princess Nourah Bint Abdulrahman University","All","18 Years to 60 Years   (Adult)","Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20-0192","June 2020","October 2020","December 2020","May 13, 2020",,"May 20, 2020","Princess Nourah Bint Abdulrahman Univeristy, Riyadh, Central, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04387240"
843,"NCT04370249","Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19","VIRUS","Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID-19","Other: pulmonary ultrasound","Construction of a composite clinical-echo score (VIRUScore) predictive of risk of worsening respiratory impairment in COVID-19 adult patients admitted to the Emergency Department|Evaluate the prognostic performance of the VIRUScore on the risk of pulmonary aggravation|Evaluate the prognostic performance of the VIRUScore on the risk of severe pulmonary aggravation defined by resuscitation admission and/or death at D14 (sensitivity, specificity, positive predictive value, negative predictive value).|Construction of a decisional algorithm for triage and management of COVID-19 patients.|Search for ""ultrasound signature"" (lung fields and/or severity of involvement) associated with mild (return home) vs. moderate (oxygen therapy) vs. severe (resuscitation/death) clinical forms.|Evaluate the analytical concordance between the pulmonary ultrasound (LUScore) and the Gold-standard CT-scan (CT score)|Construction of a score predictive of aggravation in the sub-population of patients returned home","Nantes University Hospital|WINFOCUS-France","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","RC20_0164","April 9, 2020","June 2020","June 2020","April 30, 2020",,"April 30, 2020","Chu de Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT04370249"
844,"NCT04363671","Adolescents and Health Professionals Faced With the Necessity for Changing to Remote Care During the COVID-19 Outbreak Quarantine (AdoPro-Cov19)","AdoPro-Cov19","Not yet recruiting","No Results Available","Remote Consultation|Covid-19",,"Exploration of themes emerging from analysis of the content of the interview with the adolescents and therapists","Hôpital Cochin|Institut National de la Santé Et de la Recherche Médicale, France","All","11 Years and older   (Child, Adult, Older Adult)",,"30","Other","Observational","Observational Model: Other|Time Perspective: Prospective","P20-670","May 2020","June 2020","December 2020","April 27, 2020",,"April 27, 2020","Maison de Solenn, Cochin Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT04363671"
845,"NCT04322188","An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection","SISCO","Recruiting","No Results Available","Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection",,"Cohort A: reduction of the need of invasive ventilation or 30-day mortality|Cohort B: reduction of mortality|Cohort A Reduction of the need of time of ventilatory support|Cohort B Percentage of patients that undergo to tracheostomy|Cohort B Improvement of the lung function assessed by radiologic findings","A.O. Ospedale Papa Giovanni XXIII","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","v 0.9 16th March 2020","March 19, 2020","May 19, 2020","May 19, 2020","March 26, 2020",,"March 31, 2020","ASST - Papa Giovanni XXIII, Bergamo, Italy",,"https://ClinicalTrials.gov/show/NCT04322188"
846,"NCT04374552","Asymptomatic COVID-19 Trial","ACT","Not yet recruiting","No Results Available","SARS-CoV-2 Infection","Drug: Hydroxychloroquine sulfate &Azithromycin|Drug: Placebo","The primary outcome is the rate of decline in viral load over the 10 days after randomization","Rutgers, The State University of New Jersey","All","20 Years and older   (Adult, Older Adult)","Phase 2","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro2020000872","May 5, 2020","November 2020","April 2021","May 5, 2020",,"May 5, 2020","Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04374552"
847,"NCT04335019","Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +","eChoVid","Not yet recruiting","No Results Available","2019-nCoV (COVID-19)|Interstitial Pneumonia","Other: Pulmonary ultrasound","Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity|Assessment of the agreement between a newly trained operator and an experienced operator of classification in one of the three stages of ultrasound gravity, by Cohen's kappa coefficient.|Estimate in patients who had a CT-scan on D0, the agreement in the evaluation of the severity of lung lesions via ultrasound vs. CT-scan, by Cohen's kappa coefficient|Measurement of the cumulative incidence of invasive mechanical ventilation and measurement of survival","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Other|Time Perspective: Prospective","APHP200390|2020-A00768-31","April 2020","April 2020","May 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335019"
848,"NCT04386265","Compassionate Use of Hyperbaric Oxygen Therapy",,"Enrolling by invitation","No Results Available","COVID-19",,"Gather information on patients treated with hyperbaric oxygen therapy|Gather information on adverse events","SerenaGroup, Inc.|The Wound Treatment Center","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HBOT-COVID-19","May 11, 2020","May 11, 2022","May 11, 2022","May 13, 2020",,"May 19, 2020","White River Wound Healing Center, Batesville, Arkansas, United States|Community Hospital, Monterey, California, United States|Innovative Healing Systems, Tampa, Florida, United States|Decatur Memorial Hospital, Decatur, Indiana, United States|Providence Medical Wound Care Center, Kansas City, Kansas, United States|West Jefferson Medical Center, Marrero, Louisiana, United States|The Wound Treatment Center, Opelousas, Louisiana, United States|Christus Shreveport Bossier Hyperbaric & Wound Care Center, Shreveport, Louisiana, United States|Ascension Providence Rochester Hospital Wound Care Center, Rochester, Michigan, United States|CHI, Chattanooga, Tennessee, United States|Klinika Baromedical, Poznan, Wielkopolskie, Poland",,"https://ClinicalTrials.gov/show/NCT04386265"
849,"NCT04384588","COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID)","FALP-COVID","Recruiting","No Results Available","COVID-19 Infection|Cancer Patients|General Population","Biological: Convalescent Plasma from COVID-19 donors","in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma|safety of the use of convalescent plasma drom COVID 19 donors|Mortality at 30 days, 90 days, 6 months and 1 year|in-hospital Mortality COVID-19 related compared with non-treated population according to Chilean official reports|Number of days of hospitalization in high complexity facilities after convalescent plasma use|Number of days of hospitalization in intensive care unit after convalescent plasma use|Number of days of mechanical ventilatory support in patients after convalescent plasma use|Total number of days of mechanical ventilatory support|Total number of hospitalization days in patients treated with convalescent plasma|Number of hospitalization days in patients after treatment with convalescent plasma|Viral load measuring|Immunological response in treated patients (COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies)|Negativization of COVID 19 load since convalescent plasma use|Negativization of COVID 19 load since hospitalization|Negativization of COVID 19 load since first reported symptoms COVID-19 related|Donor Interferon Gamma profile characterization|Donor Granulocyte Macrophage Colony Stimulating Factor characterization|Donor Tumor Necrosis Factor Alfa characterization|Donor Interleukin -1 beta characterization|Donor Interleukin-2 characterization|Donor Interleukin-4 characterization|Donor Interleukin-6 characterization|Donor Interleukin-8 characterization|Donor Interleukin-10 characterization|Receptor Interferon Gamma profile characterization|Receptor Granulocyte Macrophage Colony Stimulating Factor characterization|receptor Tumor Necrosis Factor Alfa characterization|receptor Interleukin -1 beta characterization|Receptor Interleukin-2 characterization|Receptor Interleukin-4 characterization|Receptor Interleukin-6 characterization|Receptor Interleukin-8 characterization|Receptor Interleukin-10 characterization","Fundacion Arturo Lopez Perez|Confederación de la Producción y del Comercio (CPC)|Bolsa de Santiago","All","15 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FALP 001-2020","April 7, 2020","April 6, 2021","April 6, 2021","May 12, 2020",,"May 12, 2020","Fundacion Arturo Lopez Perez, Providencia, Santiago, Chile",,"https://ClinicalTrials.gov/show/NCT04384588"
850,"NCT04363333","Obstructive Sleep Apnea & Covid-19 Outcomes","OSACOVID-19","Recruiting","No Results Available","COVID|Obstructive Sleep Apnea|Pneumonia","Diagnostic Test: Polysomnography","The rate of clinical improvement|Clinical status","Koç University|Koc Healthcare Istanbul American Hospital, Marmara University Pendik Education and Research Hospital","All","18 Years and older   (Adult, Older Adult)",,"275","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020.140.IRB1.030","April 27, 2020","November 30, 2020","December 31, 2020","April 27, 2020",,"May 13, 2020","Koc University, Istanbul, Turkey|Koc Healthcare Istanbul American Hospital, İstanbul, Turkey|Marmara University Pendik Education and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04363333"
851,"NCT04393727","Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19","TSUNAMI","Recruiting","No Results Available","COVID|SARS-CoV 2","Biological: CONVALESCENT PLASMA","Need of invasive mechanical ventilation|Mortality rates|Time to invasive mechanical ventilation|Time to virologic cure|Length of hospital stay|Adverse events","Azienda Ospedaliero, Universitaria Pisana","All","18 Years and older   (Adult, Older Adult)","Phase 2","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TSUNAMI","May 1, 2020","September 30, 2020","October 30, 2020","May 19, 2020",,"May 20, 2020","Azienda Ospedaliero Universitaria Pisana, Pisa, Italy",,"https://ClinicalTrials.gov/show/NCT04393727"
852,"NCT04356937","Efficacy of Tocilizumab on Patients With COVID-19",,"Not yet recruiting","No Results Available","SARS-CoV 2","Drug: Tocilizumab|Drug: Placebos","Proportion of patients that require mechanical ventilation|Requirement for inotropes and/or vasopressors|8-level Clinical improvement Scale|Duration of mechanical ventalition|Hospital discharge|Mortality|Duration of ICU stay|Duration of time on supplemental oxygen|The proportion of patients who require renal replacement therapy or have doubling of creatinine","Massachusetts General Hospital|Genentech, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","300","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2020P001159","April 27, 2020","June 30, 2020","August 30, 2020","April 22, 2020",,"April 22, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04356937"
853,"NCT04385069","COVID-19 Hyperinflammation Syndrome (COV-HI): Protocol for a Rapidly Executed Cohort Study","COV-HI","Recruiting","No Results Available","COV-HI|COVID-19|COVID-19 (COV) Hyperinflammatory (HI) Syndrome",,"To collect retrospective demographic information on 500 people admitted to selected hospital sites across the UK with a COVID-19 diagnosis confirmed through positive laboratory PCR swab.|To record the results of each patient's measured medical observations, clinical investigations and outcomes during the course of their admission.|To conduct retrospective analysis of data collected to map each patient's clinical journey during their admission","University College, London|Newcastle-upon-Tyne Hospitals NHS Trust|Sheffield Teaching Hospitals NHS Foundation Trust|The Leeds Teaching Hospitals NHS Trust|Nottingham University Hospitals NHS Trust|University College London Hospitals","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","132388","April 16, 2020","July 5, 2020","July 5, 2020","May 12, 2020",,"May 12, 2020","The Leeds Teaching Hospitals NHS Trust, St James University Hospital, Leeds, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Sheffield Teaching Hospitals NHS Trust, Northern General Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04385069"
854,"NCT04383587","Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers",,"Enrolling by invitation","No Results Available","SARS-CoV 2|COVID-19","Other: Serologic testing","Prevalence of COVID19 Antibody Positivity|Ability to predict immune status/antibody positivity","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","20-004054","May 6, 2020","May 29, 2020","June 12, 2020","May 12, 2020",,"May 12, 2020","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04383587"
855,"NCT04350450","Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore",,"Not yet recruiting","No Results Available","COVID|Coronavirus|COVID-19","Drug: Hydroxychloroquine","Time to resolution of symptoms|Number of days from onset of illness to symptom resolution|Number of days to return to work|Rate of hospital admission in treated and untreated healthcare workers|Adverse effect of HCQ during treatment","Montefiore Medical Center","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-11445","April 2020","August 2020","August 2020","April 17, 2020",,"April 17, 2020","Montefiore Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT04350450"
856,"NCT04391101","Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)",,"Not yet recruiting","No Results Available","SARS-Cov-2","Drug: Convalescent plasma","Intrahospital mortality from any cause|Length of hospital stay|Free time for ventilatory support on day 60|Overall survival at day 60 since hospitalization|Cumulative incidence of adverse events: transfusion reactions (fever, flare), TRALI (transfusion-associated lung injury), TACO (transfusion-related circulatory overload), transfusion- related infections","Hospital San Vicente Fundación|Clínica León XIII|Grupo de Inmunodeficiencias primarias Universidad de Antioquia|Clínica Universitaria Bolivariana|Hospital Pablo Tobón Uribe|Clínica Rosario El Tesoro|Clínica Las Américas|Clínica Cardiovid","All","18 Years and older   (Adult, Older Adult)","Phase 3","231","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","002","June 2020","June 2021","December 2021","May 18, 2020",,"May 20, 2020","Hospital San Vicente Fundacion, Medellín, Antioquia, Colombia",,"https://ClinicalTrials.gov/show/NCT04391101"
857,"NCT04387838","Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff","SEROSARSCOV","Not yet recruiting","No Results Available","Sars-CoV2","Diagnostic Test: Anti-SARS-CoV2 Serology|Other: Questionnaire","Anti-SARS-Cov2 seroconversion between Day 0 and Day 60.|Anti-SARS-Cov2 seroconversion between Day 0 and Day 30.|Anti-SARS-Cov2 seroconversion between Day 30 and Day 60.|Anti-SARS-Cov2 seroprevalence at Day 0.|Correlation between seroconversion and socio-demographic factors - sex|Correlation between seroconversion and socio-demographic factors - age|Correlation between seroconversion and professional factors - job type|Correlation between seroconversion and professional factors - personal protective equipment type|Correlation between seroconversion and non-professional factors - contact with infected individuals|Correlation between seroconversion and non-professional factors - wearing of professional equipment|Correlation between seroconversion and non-professional factors - respect of barrier gestures","Direction Centrale du Service de Santé des Armées","All","18 Years to 62 Years   (Adult)",,"900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-COVID19-10","May 13, 2020","June 24, 2020","June 24, 2020","May 14, 2020",,"May 14, 2020","Hôpital d'Instuction des Armées Sainte-Anne, Toulon, France|Hôpital d'Instruction des Armées Robert Picqué, Villenave-d'Ornon, France",,"https://ClinicalTrials.gov/show/NCT04387838"
858,"NCT04344912","Impact of COVID19 Outbreak in Cardiac Acute Care","CCU-COVID19","Recruiting","No Results Available","Acute Coronary Syndrome|Heart Failure|COVID","Other: Data collection","Incidence of recurrent Major Cardiovascular Events (MACE) and urgent rehospitalization","Assistance Publique - Hôpitaux de Paris|Action, France","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","APHP200524|0522070420","March 20, 2020","June 2020","August 2020","April 14, 2020",,"April 28, 2020","Unité de Soins Intensifs de Cardiologie, Pitié Salpêtrière Hospital, AP-HP, Paris, France",,"https://ClinicalTrials.gov/show/NCT04344912"
859,"NCT04361032","Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia","TRONCHER","Not yet recruiting","No Results Available","COVID19|Intensive Care Unit","Drug: Tocilizumab Injection|Drug: Deferoxamine","the mortality rate","Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Datametrix","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECC2020-06","May 4, 2020","September 4, 2020","October 4, 2020","April 24, 2020",,"May 6, 2020","Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Ariana, Tunisia",,"https://ClinicalTrials.gov/show/NCT04361032"
860,"NCT04373200","Human Ab Response & immunoMONItoring of COVID-19 Patients","HARMONICOV","Not yet recruiting","No Results Available","SARS-CoV-2 Coronavirus|Acute Respiratory Distress Syndrome","Biological: Blood samples collection|Other: Saliva collection","Number of increased immune population|Number of decreased immune population|Number of statically different phenotypes compared to control patients|Gain or loss of functional phenotypic markers between D1 and D14|Gain or loss of functional phenotypic markers between between acute and mild infections|Gain or loss of functional phenotypic markers between D1 and month 4|Evaluation of V, D, J gene usage alterations in the immunoglobulin and T cell receptor (TCR) repertoires during ARDS linked to COVID-19|Identification of the Ig classes and of V, D, J sequences of anti-CoV-2 antibodies|Characterization of a new set of human antibodies from patients who have recovered of COVID-19","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","35RC20_9795_HARMONICOV|2020-A01100-39","May 15, 2020","November 15, 2020","November 15, 2020","May 4, 2020",,"May 11, 2020","CHU Rennes, Rennes, France",,"https://ClinicalTrials.gov/show/NCT04373200"
861,"NCT04368351","Bacteriotherapy in the Treatment of COVID-19","BACT-ovid","Active, not recruiting","No Results Available","COVID|Pneumonia|Diarrhea","Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine","delta of time of disappearance of acute diarrhea|Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital","University of Roma La Sapienza","All","18 Years and older   (Adult, Older Adult)",,"70","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","DPHID-UniRoma05","March 1, 2020","June 30, 2020","July 31, 2020","April 29, 2020",,"May 4, 2020","Department of Public Heath and Infectious Diseases. University of Rome ""Sapienza"" (Italy), Rome, Italy",,"https://ClinicalTrials.gov/show/NCT04368351"
862,"NCT04366063","Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome",,"Recruiting","No Results Available","Covid-19","Biological: Cell therapy protocol 1|Biological: Cell therapy protocol 2","Adverse events assessment|Blood oxygen saturation|Intensive care unit-free days|Clinical symptoms|Respiratory efficacy|Biomarkers concentrations in plasma","Royan Institute|Tehran University of Medical Sciences|Shahid Beheshti University of Medical Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","991919|IRCT20200217046526N2","April 5, 2020","June 6, 2020","December 10, 2020","April 28, 2020",,"April 30, 2020","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04366063"
863,"NCT04356833","Nebulised Rt-PA for ARDS Due to COVID-19","PACA","Recruiting","No Results Available","COVID","Drug: nebulised recombinant tissue-Plasminogen Activator (rt-PA)","treatment efficacy - Percentage change in PaO2/FiO2 ratio|Safety as measured by bleeds|Safety as measured by other (non-bleed related) adverse events|Safety as measured by fibrinogen levels|Absolute change in PaO2/FiO2 ratio|Changes in respiratory compliance|Clinical status as determined by a 7 point ordinal scale|Sequential Organ Failure Assessment (SOFA) score|Follow up period - oxygen free days|Follow up period - ventilator free days|Follow up period - intensive care stay|New oxygen via ventilation use - incidence|New oxygen via ventilation use - duration|Incidence of new mechanical ventilation use|Duration of new mechanical ventilation use|In hospital mortality","University College, London","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","132151","April 22, 2020","January 14, 2021","January 14, 2021","April 22, 2020",,"April 30, 2020","The Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04356833"
864,"NCT04372082","Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19","HYdILIC","Not yet recruiting","No Results Available","Sars-CoV2","Other: Standard of care (SOC)|Drug: Hydroxychloroquine|Drug: Association of diltiazem and niclosamide","death|clinical worsening (composite criteria)|Assisted-ventilation and/or hospitalization (composite criteria)|National Early Warning Score (NEWS)|cumulative incidence of hospitalizations|cumulative incidence of the use of oxygen therapy, non-invasive ventilation or invasive ventilation ( composite criteria)|Mortality|cumulative incidence of viral shedding on SARS-CoV-2 rt-PCR on nasopharyngeal swab;|adverse drug reactions","University Hospital, Lille|I-site University Lille North Europe","All","18 Years and older   (Adult, Older Adult)","Phase 3","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","2020_40|2020-002188-72","May 2020","May 2023","May 2023","May 1, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04372082"
865,"NCT04368793","Clinical Effects of Internet Assisted Pulmonary Rehabilitation of COVID-2019 Pneumonia Patients After Discharge",,"Recruiting","No Results Available","COVID-2019 Pneumonia|Pulmonary Rehabilitation","Behavioral: pulmonary rehabilitation","Pulmonary function|Respiratory muscle strength|Physical fitness assessment|Symptom|Psychological evaluation|Quality of life assessment scale|Physical activity level|Proportion of returning to society","Hongtao Niu|Wuhan lung Hospital|Wuhan central hospital|Wuhan University|Ai You Foundation|China-Japan Friendship Hospital","All","20 Years to 85 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-22-K17","April 6, 2020","April 6, 2020","October 30, 2020","April 30, 2020",,"April 30, 2020","Wuhan Lung Hospital, Wuhan, Hubei, China|Wuhan Central Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04368793"
866,"NCT04371107","Proactive Care of Ambulatory COVID19 Patients","AMBU-COVID","Not yet recruiting","No Results Available","Covid19|Azithromycin|Ambulatory","Other: consultation|Drug: Azithromycin","Length of symptom duration (in days) with azithromycin treatment","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)","Phase 3","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PI2020_843_0039","April 29, 2020","June 2020","July 2020","May 1, 2020",,"May 6, 2020","CHU Amiens, Amiens, France",,"https://ClinicalTrials.gov/show/NCT04371107"
867,"NCT04368338","Lung Ultrasound to Diagnose COVID-19","COVILUS","Recruiting","No Results Available","Covid-19|Lung Ultrasound|Respiratory Complication","Diagnostic Test: COVID-19 RT-PCR|Procedure: lung ultrasound","Lung ultrasound/biological correlation research modulating the severity of Covid-19 disease","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PI2020_843_0030","April 28, 2020","September 28, 2020","September 28, 2020","April 29, 2020",,"April 29, 2020","BAR, Amiens, France",,"https://ClinicalTrials.gov/show/NCT04368338"
868,"NCT04340479","The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation",,"Not yet recruiting","No Results Available","COVID|Trauma|Ultrasound","Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation","Correlation of FAST+ pulmonary findings with active COVID infection|Description of additional ancillary findings of the FAST+ examination among infected and non-infected patients","University of Colorado, Denver","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-0751","May 2020","May 2021","May 2021","April 9, 2020",,"May 6, 2020","Children's Hospital Colorado, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04340479"
869,"NCT04361526","Pilot Study on Cytokine Filtration in COVID-19 ARDS","CytokCOVID19","Recruiting","No Results Available","Coronavirus Infection|Acute Respiratory Distress Syndrome|COVID","Device: Cytokine Adsorption","Mechanical ventilation-free days|30-day mortality|length of ICU stay (days)|length of hospital stay|Duration of renal replacement and cathecolamines therapies|Need for extracorporeal membrane oxygenation (ECMO) support|multi-organ failure measured by the Sequential Organ Failure Assessment (SOFA) score","Manuel Castellà|Hospital Clinic of Barcelona","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCB/2020/0464","April 17, 2020","July 2020","July 2020","April 24, 2020",,"April 24, 2020","Hospital Clínic de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04361526"
870,"NCT04313127","Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults","CTCOVID-19","Active, not recruiting","No Results Available","COVID-19","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)","Safety indexes of adverse reactions|Safety indexes of adverse events|Safety indexes of SAE|Safety indexes of lab measures|Immunogencity indexes of GMT(ELISA)|Immunogencity indexes of GMT(pseudoviral neutralization test method)|Immunogencity indexes of seropositivity rates(ELISA)|Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method)|Immunogencity indexes of GMI(ELISA)|Immunogencity indexes of GMI(pseudoviral neutralization test method)|Immunogencity indexes of GMC(Ad5 vector)|Immunogencity indexes of GMI(Ad5 vector)|Immunogencity indexes of cellular immune","CanSino Biologics Inc.|Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention|Tongji Hospital","All","18 Years to 60 Years   (Adult)","Phase 1","108","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","JSVCT088","March 16, 2020","December 30, 2020","December 20, 2022","March 18, 2020",,"May 19, 2020","Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04313127"
871,"NCT04366778","Thrombosis and Covid-19","COVBIO","Recruiting","No Results Available","Thrombosis|Covid-19|SARS-CoV 2","Diagnostic Test: TEM-tPA","Coagulability|Venous thrombotic event (VTE) or arterial thrombosis","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL20_0401 - COVBIO|ID-RCB","May 1, 2020","December 2020","December 2020","April 29, 2020",,"May 6, 2020","Hôpital Louis Pradel, Bron, France",,"https://ClinicalTrials.gov/show/NCT04366778"
872,"NCT04334460","Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects",,"Recruiting","No Results Available","Sars-CoV2","Drug: BLD-2660","Time to recovery|Change in oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs)","Blade Therapeutics|Clinipace Worldwide","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B-2660-204","May 4, 2020","August 2020","September 2020","April 6, 2020",,"May 21, 2020","Blade Research Site, Irvine, California, United States|Blade Research Site, Los Angeles, California, United States|Blade Reseach Site, San Jose, California, United States|Blade Research Site, Washington, District of Columbia, United States|Blade Research Site, Tampa, Florida, United States|Blade Research Site, Peoria, Illinois, United States|Blade Research Site, Metairie, Louisiana, United States|Blade Research Site, Baltimore, Maryland, United States|Blade Research Site, Detroit, Michigan, United States|Blade Research Site, Saint Louis, Missouri, United States|Blade Research Site, North Las Vegas, Nevada, United States|Blade Research Site, Durham, North Carolina, United States|Blade Research Site, Fayetteville, North Carolina, United States|Blade Research Site, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04334460"
873,"NCT04393051","Baricitinib Compared to Standard Therapy in Patients With COVID-19","BARICIVID-19","Not yet recruiting","No Results Available","Covid-19|SARS-CoV 2|SARS Pneumonia","Drug: Baricitinib Oral Tablet","Need of invasive mechanical ventilation|Mortality|Time to invasive mechanical ventilation|Time to independence from non-invasive mechanical ventilation|Time to independence from oxygen therapy|Time to improvement in oxygenation for at least 48 hours|Length of hospital stay|Length of ICU stay|Instrumental response|Proportion of adverse events","Azienda Ospedaliero, Universitaria Pisana","All","18 Years and older   (Adult, Older Adult)","Phase 2","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BARICIVID-19","May 20, 2020","June 30, 2020","July 30, 2020","May 19, 2020",,"May 20, 2020","Azienda Ospedaliero Universitaria Pisana, Pisa, Italy",,"https://ClinicalTrials.gov/show/NCT04393051"
874,"NCT04367207","African Covid-19 Critical Care Outcomes Study",,"Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2",,"In-hospital mortality|Risk factors (resources, comorbidities and interventions) associated with mortality","University of Cape Town|University of KwaZulu","All","18 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ACCCOS","May 1, 2020","December 1, 2020","December 31, 2020","April 29, 2020",,"May 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04367207"
875,"NCT04351503","A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19",,"Recruiting","No Results Available","SARS Coronavirus (SARS-CoV-2) Infection","Other: Study A|Other: Study B|Other: Study C","Identification of factors associated with (i) infection (binary, yes/no), (ii) hospitalization (binary, yes/no), (iii) requirement for ICU treatment (binary, yes/no)|duration of hospitalization (in days)|duration of Intensive Care Unit (ICU) stay (in days)|in-hospital mortality (binary, yes/no)|Number of infected cases within the city of Basel|whole genome sequencing to study pathogen evolution (number, type, and complexity of viral genome)","University Hospital, Basel, Switzerland|sciCORE University of Basel|Leonhard Med IT ETH Zurich|Swiss Institute of Bioinformatics","All","Child, Adult, Older Adult",,"10000","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","2020-00769; qu20Egli2","April 9, 2020","April 2022","April 2022","April 17, 2020",,"April 24, 2020","Viollier AG, Allschwil, Switzerland|University Hospital Basel, Basel, Switzerland|Biozentrum University of Basel, Basel, Switzerland|sciCore University of Basel, Basel, Switzerland|Department of Biosystems Science and Engineering ETH Zurich, Basel, Switzerland|Swiss Institute of Bioinformatics, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT04351503"
876,"NCT04336657","Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?",,"Recruiting","No Results Available","COVID-19","Other: Questionnaire|Diagnostic Test: IgG","Measure frequency of people suffered from unusual flu-like symptoms before December 2019|Measure remote immunity for COVID-19 in subject with past history of severe flu before WHO announcement date- if possible","Assiut University","All","8 Years to 80 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","AssiutU11","April 2020","May 2020","May 2020","April 7, 2020",,"April 7, 2020","AssiutU, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04336657"
877,"NCT04374370","SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)",,"Available","No Results Available","COVID|SARSCoV2 Convalescent Plasma","Biological: SARSCoV2 Convalescent Plasma",,"AdventHealth","All","6 Years to 99 Years   (Child, Adult, Older Adult)",,,"Other","Expanded Access:Intermediate-size Population",,"1596191",,,,"May 5, 2020",,"May 5, 2020","AdventHealth Orlando, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04374370"
878,"NCT04359862","Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection","SEVO-COVID19","Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID19 Infection","Drug: Sevoflurane|Drug: Propofol","PaO2/FiO2|TNFα|IL-1b|IL-6|IL-8|Mortality","Fundación para la Investigación del Hospital Clínico de Valencia","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SEVO-COVID19","April 16, 2020","August 16, 2020","September 16, 2020","April 24, 2020",,"April 29, 2020","Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04359862"
879,"NCT04323644","Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)","CovidSurg","Recruiting","No Results Available","COVID-19|Coronavirus|Surgery","Procedure: Surgery","30-day mortality|7-day mortality|30-day reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis","University of Birmingham","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","CS-20200324","January 1, 2020","September 30, 2020","September 30, 2020","March 26, 2020",,"May 12, 2020","Hospital del Henares, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04323644"
880,"NCT04366245","Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection",,"Recruiting","No Results Available","SARS-CoV 2","Biological: Hyperimmune plasma|Drug: Hidroxicloroquina + Azitromicina o Lopinavir/ritonavir + Interferon β-1b + Hidroxicloroquina","Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.","Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PC/COVID-19","April 23, 2020","December 2021","December 2021","April 28, 2020",,"May 21, 2020","Hospital Unversitario Virgen Macarena, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT04366245"
881,"NCT04352959","COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses","BBCovid","Not yet recruiting","No Results Available","COVID19|Mouthwash|Saliva","Device: mouthrinse with bêta-cyclodextrin and citrox|Device: mouthrinse without bêta-cyclodextrin and citrox","Change from Baseline amount of SARS-CoV-2 in salivary samples at 7 days|Change from Baseline amount of SARS-CoV-2 virus in nasal samples at 7 days","Claude Bernard University|University Hospital, Tours|University Hospital, Montpellier|Hospices Civils de Lyon","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","178","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","BBCovid","April 27, 2020","May 20, 2020","June 20, 2020","April 20, 2020",,"April 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04352959"
882,"NCT04389489","Postpartum Sexual Function in Pregnant Women With COVID-19",,"Not yet recruiting","No Results Available","COVID-19|Dyspareunia|Postpartum Period",,"Evaluation of pregnant women diagnosed with COVID-19 using Carol Postpartum Sexual Function and Dyspareunia Scale","Kanuni Sultan Suleyman Training and Research Hospital","Female","18 Years to 45 Years   (Adult)",,"140","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","MTalmacCarol","May 14, 2020","August 1, 2020","August 3, 2020","May 15, 2020",,"May 15, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Halkali, Turkey",,"https://ClinicalTrials.gov/show/NCT04389489"
883,"NCT04319731","A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure",,"Recruiting","No Results Available","SARS CoV-2 Infection","Biological: Human Amniotic Fluid","Ventilator Free Days|Duration of supplemental oxygen use|All cause mortality|Systemic inflammation","University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","131618","March 20, 2020","March 20, 2021","March 20, 2021","March 24, 2020",,"April 17, 2020","University of Utah Health, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04319731"
884,"NCT04335786","Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease",,"Recruiting","No Results Available","Respiratory Distress Syndrome, Adult|SARS-CoV-2","Drug: Valsartan (Diovan)|Drug: Placebo oral tablet","first occurrence of intensive care unit admission, mechanical ventilation or death|Death|Mechanical ventilation|Intensive care unit admission|Occurrence of acute kidney injury","Radboud University","All","18 Years and older   (Adult, Older Adult)","Phase 4","651","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NL73547.091.20|2020-001320-34","April 17, 2020","October 2020","October 2021","April 6, 2020",,"May 8, 2020","Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Rijnstate, Arnhem, Netherlands|Radboudumc, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04335786"
885,"NCT04366141","COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box",,"Not yet recruiting","No Results Available","COVID-19","Device: COVID-19 barrier box","Time to tracheal intubation (TTI)|First pass success rate|Total time of airway manipulation|Number of intubation attempts|Number of Operators needed for intubation|Number of alternative techniques used for intubation|Cormack-Lehane Grade for the first attempt of intubation|Lifting force applied on laryngoscope blade|Laryngeal pressure application|Vocal cord position|Anesthesiologist perception of intubation difficulty|Anesthesiologist perception of contributors to difficulty in intubation, if any|Patient acceptability of the COVID Barrier Box|Patient comfort with the COVID Barrier Box|Patient comments on the COVID Barrier Box","University of British Columbia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","H20-01270","May 2020","April 2021","April 2021","April 28, 2020",,"May 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04366141"
886,"NCT04391400","The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines",,"Not yet recruiting","No Results Available","SARS-CoV-2","Diagnostic Test: nasal pharyngeal (NP) swab samples|Diagnostic Test: peripheral blood draw","Identification of nucleic acid sequencing, antibodies and antigens to be used in detection methods or treatments and/or vaccines","Invivoscribe, Inc.","All","Child, Adult, Older Adult",,"500","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IVS-000-002","June 1, 2020","June 30, 2021","June 30, 2021","May 18, 2020",,"May 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04391400"
887,"NCT04366323","Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19",,"Not yet recruiting","No Results Available","Sars-CoV2","Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS","Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate|Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate","Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AdiQure/COVID-19","April 2020","October 2021","October 2021","April 28, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04366323"
888,"NCT04398290","iNOPulse for COVID-19","NO-COVER","Not yet recruiting","No Results Available","COVID-19|Hypoxemia|Hypoxemic Respiratory Failure","Drug: Inhaled nitric oxide (iNO)|Drug: Nitrogen gas|Drug: Oxygen gas","Incidence of treatment emergent adverse events|Incidence of adverse events|Incidence of methemoglobinemia|Number of participants with progression of respiratory failure|Time until resolution of hypoxemia|Incidence of mortality|Duration of hospitalization","Roger Alvarez|Bellerophon Therapeutics|University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20200449","July 1, 2020","January 1, 2021","January 15, 2021","May 21, 2020",,"May 21, 2020","University of Miami Hospitals & Clinics, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04398290"
889,"NCT04369469","Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia",,"Not yet recruiting","No Results Available","COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome|Pneumonia, Viral","Biological: Ravulizumab|Other: Best Supportive Care","Survival (based on all-cause mortality) at Day 29|Number of days free of mechanical ventilation at Day 29|Change from baseline in SpO2/FiO2 at Day 29|Duration of intensive care unit stay at Day 29|Change from baseline in Sequential Organ Failure Assessment at Day 29|Survival (based on all-cause mortality) at Day 60 and Day 90|Duration of hospitalization","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1210-COV-305","May 2020","November 2020","February 2021","April 30, 2020",,"April 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04369469"
890,"NCT04379037","Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients",,"Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Device: Transcutaneous Auricular Vagus Nerve Stimulation","Survival without need of mechanical ventilation|WHO progression scale ≤ 5 at day 4 since admission.|Cumulative incidence of successful tracheal extubation at day 14 since symptom onset.|WHO progression scale ≤ 7 at day 4 since admission.|Survival at day 14 of hospitalization|Duration of hospitalization|Time to hospital discharge","Nemechek Technologies","All","60 Years and older   (Adult, Older Adult)","Not Applicable","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCM-001","July 2020","October 2020","January 2021","May 7, 2020",,"May 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04379037"
891,"NCT04378712","Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19)",,"Completed","No Results Available","Covid-19|Hydrogen/Oxygen Mixed Gas|Dyspnea","Device: Hydrogen Oxygen Generator with Nebulizer|Other: Standard-of-care","The proportion of patients with improved disease severity at day 2|The proportion of patients with improved disease severity at day 3|The proportion of patients with improved disease severity at the day before hospital discharge|The change from baseline in oxygen saturation at day 2.|The change from baseline in oxygen saturation at day 3.|The change from baseline in oxygen saturation at the day before hospital discharge|The change from baseline in dyspnea scale at day 2.|The change from baseline in dyspnea scale at day 3.|The change from baseline in dyspnea scale at the day before hospital discharge.|The change from baseline in cough scale at day 2|The change from baseline in cough scale at day 3|The change from baseline in cough scale at the day before hospital discharge|The change from baseline in chest pain scale at day 2.|The change from baseline in chest pain scale at day 3.|The change from baseline in chest pain scale at the day before hospital discharge.|The change from baseline in chest distress scale at day 2.|The change from baseline in chest distress scale at day 3.|The change from baseline in chest distress scale at the day before hospital discharge.","Guangzhou Institute of Respiratory Disease","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JT202005LZ","January 21, 2020","March 23, 2020","March 23, 2020","May 7, 2020",,"May 15, 2020","First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04378712"
892,"NCT04261517","Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19",,"Completed","No Results Available","Pneumonia, Pneumocystis|Coronavirus|COVID-19","Drug: Hydroxychloroquine","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The mortality rate of subjects at weeks 2|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2","Shanghai Public Health Clinical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HC-COVID-19","February 6, 2020","February 25, 2020","February 25, 2020","February 7, 2020",,"April 13, 2020","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04261517"
893,"NCT04390022","Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial","SAINT","Recruiting","No Results Available","Covid-19|Coronavirus Infection|SARS-CoV-2 Infection","Drug: Ivermectin|Drug: Placebo","Proportion of patients with a positive SARS-CoV-2 PCR|Mean viral load|Fever and cough progression|Seroconversion at day 21|Proportion of drug-related adverse events|Levels of IgG, IgM and IgA|Frequency of innate immune cells|Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T cells|Results from cytokine Human Magnetic 30-Plex Panel","Clinica Universidad de Navarra, Universidad de Navarra|Barcelona Institute for Global Health","All","18 Years to 59 Years   (Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SAINT","May 14, 2020","August 4, 2020","August 30, 2020","May 15, 2020",,"May 21, 2020","Clinica Universidad de Navarra, Pamplona, Navarra, Spain",,"https://ClinicalTrials.gov/show/NCT04390022"
894,"NCT04367831","Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19","IMPROVE","Recruiting","No Results Available","COVID-19|Venous Thromboses|Arterial Thrombosis","Drug: Enoxaparin Prophylactic Dose|Drug: Heparin Infusion|Drug: Heparin SC|Drug: Enoxaparin/Lovenox Intermediate Dose","Total Number of Patients with Clinically Relevant Venous or Arterial Thrombotic Events in ICU|Total Number of Patients with In hospital Clinically Relevant Venous or Arterial Thrombotic Events|ICU Length of Stay|Total Number of Patients with the Need for Renal Replacement Therapy in the ICU|Total Number of Patients with Major bleeding in the ICU|Hospital Length of Stay","Columbia University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AAAS8980","May 2, 2020","November 2020","April 2021","April 29, 2020",,"May 19, 2020","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04367831"
895,"NCT04329546","Understanding COVID-19",,"Recruiting","No Results Available","SARS-CoV-2 Viral Kinetics and Host Immune Responses","Other: NA (no intervention)","Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days|Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis","University Hospital, Geneva|University of Geneva, Switzerland","All","Child, Adult, Older Adult",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00516","March 27, 2020","January 31, 2022","March 31, 2022","April 1, 2020",,"April 13, 2020","University Hospitals of Geneva, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT04329546"
896,"NCT04389515","Postoperative Recovery Index, Patient Expectations and Satisfaction With Prenatal Care Instrument in Pregnant Patients With COVID-19",,"Not yet recruiting","No Results Available","COVID-19|Prenatal Care|Postoperative Care",,"Evaluation of pregnant women diagnosed with COVID-19 with ""Post-operative Recovery Index"" and ""Prenatal Care Satisfaction and Patient Expectations Scale""","Kanuni Sultan Suleyman Training and Research Hospital","Female","18 Years to 45 Years   (Adult)",,"75","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","MTalmac3","May 14, 2020","August 1, 2020","August 3, 2020","May 15, 2020",,"May 15, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Halkali, Turkey",,"https://ClinicalTrials.gov/show/NCT04389515"
897,"NCT04398004","Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early","ACHIEVE","Recruiting","No Results Available","COVID-19|Virus Diseases|Corona Virus Infection","Drug: Clarithromycin","Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% decrease of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% decrease of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFα ratio between days 1 and 8","Hellenic Institute for the Study of Sepsis","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ACHIEVE|2020-001882-36","May 6, 2020","May 6, 2022","May 6, 2022","May 21, 2020",,"May 21, 2020","COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece|2nd Department of Internal Medicine, General Hospital of Piraeus ""Tzaneio"", Piraeus, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece",,"https://ClinicalTrials.gov/show/NCT04398004"
898,"NCT04359251","Different PEEP Settings of COVID-19 Induced ARDS",,"Completed","No Results Available","COVID-19|Mechanical Ventilation Pressure High|Acute Respiratory Distress Syndrome","Other: Gas exchanges at different PEEP|Other: lung mechanics at different PEEP|Other: Hemodynamics changes at different PEEP","Respiratory system compliance improvement|Gas echanges improvement","Southeast University, China","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19 PEEP titration","March 5, 2020","March 25, 2020","March 25, 2020","April 24, 2020",,"April 24, 2020","Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04359251"
899,"NCT04381286","Transpulmonary Driving Pressure in ARDS COVID19 Patients","TRANSPULMONARY","Recruiting","No Results Available","Mechanical Ventilation|SARS-CoV-2|COVID-19",,"Duration of mechanical Ventilation|Number of Participants with during of Acute respiratory distress syndrom (SDRA)|Length of stay in intensive care unit|Mortality|number of patients with pulmonary complications|Number of Participants with pulmonary stress and strain","University Hospital, Montpellier","All","18 Years to 90 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0194","April 1, 2019","April 1, 2021","December 31, 2021","May 8, 2020",,"May 12, 2020","Uhmontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04381286"
900,"NCT04347928","Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19","PHYSIO-COVID","Recruiting","No Results Available","COVID-19|ARDS|Sars-CoV2",,"intrapulmonary shunt ratio|Evolution of respiratory variables|Evolution of hemodynamic stability variables","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)",,"15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_32|2020-A00957-32","April 20, 2020","September 2020","September 2020","April 15, 2020",,"May 21, 2020","Hopital Roger Salengro, CHU Lille, Lille, France",,"https://ClinicalTrials.gov/show/NCT04347928"
901,"NCT04360486","Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)",,"Available","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Other: Anti-Sars-CoV-2 Convalescent Plasma",,"U.S. Army Medical Research and Development Command","All","Child, Adult, Older Adult",,,"U.S. Fed","Expanded Access:Treatment IND/Protocol",,"S-20-02",,,,"April 24, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04360486"
902,"NCT04257656","A Trial of Remdesivir in Adults With Severe COVID-19",,"Terminated","No Results Available","COVID-19|Remdesivir|SARS-CoV-2","Drug: Remdesivir|Drug: Remdesivir placebo","Time to Clinical Improvement (TTCI) [Censored at Day 28]|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events","Capital Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 3","237","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAP-China remdesivir 2","February 6, 2020","March 30, 2020","April 10, 2020","February 6, 2020",,"April 15, 2020","Bin Cao, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04257656"
903,"NCT04366986","International Registry of Coronavirus (COVID-19) Exposure in Pregnancy","IRCEP","Not yet recruiting","No Results Available","Covid-19","Other: Tested for SARS-CoV-2 (regardless of the result)|Other: Clinical diagnosis of COVID-19 by a health care professional","Pregnancy outcomes|Birth outcomes","Pregistry|Harvard School of Public Health","Female","18 Years and older   (Adult, Older Adult)",,"25000","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0001","May 1, 2020","April 30, 2024","April 30, 2024","April 29, 2020",,"April 29, 2020","Pregistry, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04366986"
904,"NCT04333953","COVID-19 in Patients With HIV",,"Recruiting","No Results Available","HIV/AIDS|COVID-19|SARS-CoV-2","Other: No intervention","Mortality|Frequency of patients requiring hospital admissions|Frequency of patients requiring ICU admissions|Frequency of respiratory support use|Frequency of kidney injury|Frequency of liver injury","University of Missouri-Columbia","All","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","262095","April 1, 2020","October 1, 2020","October 1, 2020","April 3, 2020",,"April 7, 2020","University of Missouri-Columbia, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04333953"
905,"NCT04381013","Emergency Ventilator Splitting Between Two or More Patients (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19","Device: Emergency Ventilator Splitter","Completion of 1-minute test|Completion of 24-hour test","Stanford University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","55989","May 2020","June 2020","June 2020","May 8, 2020",,"May 8, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04381013"
906,"NCT04375176","Monocytes and NK Cells Activity in Covid-19 Patients",,"Recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2|Immunomodulation","Diagnostic Test: Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2","Immune cells activity|Protective factors and new therapeutic strategies","Università degli Studi dell'Insubria","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","67/2020","April 27, 2020","June 30, 2020","October 31, 2020","May 5, 2020",,"May 5, 2020","ATS Insubria, Varese, Italy",,"https://ClinicalTrials.gov/show/NCT04375176"
907,"NCT04399980","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation",,"Recruiting","No Results Available","COVID 19|SARS-CoV 2|Pneumonia","Drug: Mavrilimumab|Drug: Placebos","Proportion of subjects alive and off of oxygen at day 14|Proportion of subjects alive and without respiratory failure at 28 days","The Cleveland Clinic|Kiniksa Pharmaceuticals, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IND 149324|IRB 20-523","May 20, 2020","May 31, 2021","May 31, 2021","May 25, 2020",,"May 25, 2020","Cleveland Clinic Health System, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04399980"
908,"NCT04338698","Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT","PROTECT","Not yet recruiting","No Results Available","COVID 19","Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin","Laboratory Result|Clinical Outcome","Shehnoor Azhar|Federal Task Force on Science & Technology notified by Government of Pakistan|University of Health Sciences Lahore","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12(06)/2016-Coord","April 7, 2020","September 1, 2020","November 30, 2020","April 8, 2020",,"April 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04338698"
909,"NCT04397510","Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury",,"Not yet recruiting","No Results Available","Covid-19|ARDS, Human|Acute Lung Injury","Drug: Heparin|Drug: 0.9% Sodium-chloride","Mean daily PaO2 to FiO2 ratio|Duration of mechanical ventilation|ICU length of stay|Mortality Rate|Incidence of adverse drug events","Frederick Health","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FHHep518","June 1, 2020","December 31, 2020","December 31, 2020","May 21, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04397510"
910,"NCT04350710","Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID","Other: PEEP trial","Recruitment-to Inflation ratio (R/I ratio)|PaO2/FiO2 (mmHg)|Lung volume recruited (VRec)|Plateau pressure (cm H2O)|Oesophagal pressure (cm H2O)|weight (Kg)|urine output (mL)|serum creatinine (Umo/L)|Mean arterial pressure (mmHg)|Peak Pressure (cm H2O)|PEEP total (cm H2O)|PEP Set (cm H2O)|Height (cm)|Airway pening pressure (cm H2O)|Expired volume in PEEP setted at 15 cmH2O (mL)|Expired volume in PEEP setted at 5 cmH2O (mL)","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2030/31","March 18, 2020","April 20, 2020","December 31, 2020","April 17, 2020",,"April 17, 2020","CHU, Angers, France",,"https://ClinicalTrials.gov/show/NCT04350710"
911,"NCT04377490","Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy","THROMBCOVID2","Recruiting","No Results Available","COVID-19|Hemostasis|Coagulation","Other: venous ultrasound|Biological: blood sample","Variation of thrombin time (in secondes) in Hospitalized Covid-19 patients|Variation of factor V concentration (U/dL) in Hospitalized Covid-19 patients.|Variation of factor II concentration (U/dL) in Hospitalized Covid-19 patients|Variation of concentration of fibrin and fibrinogen degradation products (≥ 10 µgm/mL) in Hospitalized Covid-19 patients.","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PI2020_843_0040","May 4, 2020","October 2020","November 2020","May 6, 2020",,"May 8, 2020","CHU Amiens, Amiens, France",,"https://ClinicalTrials.gov/show/NCT04377490"
912,"NCT04395924","Maternal-foetal Transmission of SARS-Cov-2","TMF-COVID-19","Recruiting","No Results Available","Maternal Fetal Infection Transmission|COVID-19|SARS-CoV 2","Diagnostic Test: Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M derologies in the amniotoc fluid, the blood cord and the placenta","COVID-19 by positive PCR in cord blood and / or positive serologies|COVID-19 by positive PCR in amniotic fluid and placenta|New born infected by COVID-19","Centre Hospitalier Régional d'Orléans|Centre de Biophysique Moléculaire - Pr Chantal Pichon","Female","18 Years to 48 Years   (Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHRO-2020-10","May 5, 2020","May 2021","May 2021","May 20, 2020",,"May 20, 2020","CHR Orléans, Orléans, France",,"https://ClinicalTrials.gov/show/NCT04395924"
913,"NCT04393428","Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19)","COVID-AKI","Recruiting","No Results Available","COVID-19|Renal Replacement Therapy|Acute Kidney Injury","Other: [TIMP-2]*[IGFBP-7]","Sensibility and specificity of urinary","University Hospital, Montpellier","All","18 Years to 100 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL20_0294","March 1, 2020","June 1, 2020","June 30, 2020","May 19, 2020",,"May 21, 2020","Uhmontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04393428"
914,"NCT04390139","Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19","COVIDMES","Recruiting","No Results Available","COVID-19|SARS-CoV 2|Adult Respiratory Distress Syndrome","Drug: XCEL-UMC-BETA|Other: Placebo","All-cause mortality at day 28|Safety of WJ-MSC|Need for treatment with rescue medication|Need and duration of mechanical ventilation|Ventilator free days|Evolution of PaO2 / FiO2 ratio|Evolution of the SOFA index|Evolution of the APACHE II score|Duration of hospitalization|Evolution of markers of immune response (leucocyte count, neutrophils)|Feasibility of WJ-MSC administration|Evolution of disease biomarker: polymerase chain reaction (RT-PCR)|Evolution of disease biomarker: lactate dehydrogenase (LDH)|Evolution of disease biomarker: D-dimer|Evolution of disease biomarker: Ferritin","Banc de Sang i Teixits","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BST-COVID-01","May 13, 2020","October 2020","December 2020","May 15, 2020",,"May 15, 2020","Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Mútua de Terrassa, Terrassa, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04390139"
915,"NCT04325646","Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France","CORSER","Recruiting","No Results Available","SARS (Severe Acute Respiratory Syndrome)|COVID-19","Other: Human Biological samples","Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.|Percentage of asymptomatic forms in individuals with anti-SARS-CoV-2 antibodies","Institut Pasteur","All","5 Years and older   (Child, Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-007","March 13, 2020","February 28, 2021","February 28, 2023","March 27, 2020",,"April 29, 2020","CHU Amiens-Picardie, Amiens, France|CHU François Mitterand, Dijon, France|Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon, France|CHU Limoges, Limoges, France|Hôpital de la Croix Rousse, Lyon, France|CHRU de Nancy, Nancy, France|Hôpitaux de Brabois, Nancy, France|CHR Orléans, Orléans, France|Institut Pasteur, Paris, France|Hôpital la Pitié Salpetrière, Paris, France|CHU Poitiers, Poitiers, France|Hôpital Pontchaillou, Rennes, France|CHU Saint-Etienne, Saint-Étienne, France|CHRU de Strasbourg, Strasbourg, France|CH de Tourcoing, Tourcoing, France|Hôpital Bretonneau, Tours, France",,"https://ClinicalTrials.gov/show/NCT04325646"
916,"NCT04349631","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",,"Enrolling by invitation","No Results Available","COVID-19","Drug: HB-adMSCs","Incidence of hospitalization for COVID-19|Incidence of symptoms for COVID-19|absence of upper/lower respiratory infection|Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|TNFalpha|Interleukin-6|Interleukin-10|C-reactive protein|SF-36|PHQ-9","Hope Biosciences","All","Child, Adult, Older Adult","Phase 2","56","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Protection Against COVID-19","May 7, 2020","December 31, 2020","December 31, 2020","April 16, 2020",,"April 30, 2020","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04349631"
917,"NCT04351191","PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds","PRECISE","Recruiting","No Results Available","Sars-CoV2|Symptomatic Condition|Covid-19","Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo","RT-PCR result|Progression of symptoms|Mortality","Government of Punjab, Specialized Healthcare and Medical Education Department|Mayo Hospital Lahore|Services Hospital, Lahore|Pakistan Kidney and Liver Institute","All","20 Years to 50 Years   (Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NBC-COVID1902","April 15, 2020","May 30, 2020","June 30, 2020","April 17, 2020",,"May 1, 2020","Expo Covid Isolation Center / Mayo Hospital Field Hospital, Lahore, Punjab, Pakistan|Mayo Hospital / King Edward Medical University, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan|Services Hospital, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04351191"
918,"NCT04347694","Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.","CONEC","Recruiting","No Results Available","SARS-CoV 2|Immunization; Infection",,"Status of Immunization","Medical University of Vienna","All","18 Years to 100 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Prospective","1357/2020","April 11, 2020","April 11, 2021","April 11, 2021","April 15, 2020",,"April 22, 2020","Medical University of Vienna, Division for Nephrology and Dialysis, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04347694"
919,"NCT04379271","A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19","Drug: IMU-838|Other: Placebo","Proportion of patients without any need* for INV until end-of-study (EoS)|Duration of ICU treatment until EoS|28-day all-cause mortality|Time to clinical improvement|Duration of hospitalization|Proportion of patients both for all patients and surviving patients free of renal-replacement therapy (RRT)* until EoS|Proportion of patients both for all patients and surviving patients free from extracorporeal membrane oxygenation (ECMO)* until EoS|Proportion of patients free of INV until Days 6 and 14*|Proportion of patients free of RRT until Days 6 and 14*|Proportion of patients free ECMO until Days 6 and 14*|Proportion of patients with improvement of at least 2 points (from randomization) on the 9-category WHO ordinal scale1 on Days 6, 14, and 28|Proportion of patients with auxiliary oxygen therapy (including all types of oxygen therapy) on Days 6, 14, and 28|Proportion of patients with clinical recovery: Axillary temperature ≤36.6 ℃, or oral temperature ≤37.2 ℃, or rectal or tympanic temperature ≤37.8 ℃;|Proportion of patients with clinical recovery: Respiratory frequency ≤24 times/min without oxygen inhalation; and|Proportion of patients with clinical recovery: Oxygen saturation ≥98% without oxygen inhalation|Proportion of patients with clinical improvement, defined as the time from first dose of IMP to an improvement of at least 2 points on the WHO 9 category ordinal scale, or live discharge from hospital without oxygen supplementation, whichever comes first|Clinical patient status on the 9-category WHO ordinal scale1 on Days 6, 14, and 28|Duration of INV|Duration of ECMO|Duration of RRT|Duration of auxiliary oxygen therapy (including all types of oxygen therapy)|Duration of hospitalization for survivors|The rate of ICU* admission on Days 6, 14, and 28|Hospital-free days|Time from IMP treatment initiation to death|Time to first prescription of INV|Time to first prescription of RRT|Time to first prescription of ECMO|Time to first prescription of INV, RRT, and ECMO|Time to ICU admission|Cumulative dose of vasoactive therapies and days with vasoactive therapies (daily until Day 14)|Time to clinical recovery|Morning trough plasma levels of IMU-838 on Days 0, 1, 2, 3, 6, 14, and 28|Correlation of trough levels (quartiles) to selected clinical outcomes (Clinical improvement accoding to WHO criteria)|Adverse events (AEs) and serious AEs|Vital signs: height|Vital signs: weight|Vital signs: body temperature (ºC)|Vital signs: pulse rates,|Vital signs: systolic and diastolic blood pressures|Clinical laboratory parameters: blood chemistry|Clinical laboratory parameters: hematology|Clinical laboratory parameters: urinalysis|12-lead electrocardiogram: heart rate|12-lead electrocardiogram: PQ-interval|12-lead electrocardiogram: QRS-interval|12-lead electrocardiogram: QT interval|12-lead electrocardiogram: the heart rate-corrected QTc interval (according to Bazett's formula)|Temperature|D-dimer|Lactate dehydrogenase (LDH)|C-reactive protein|Troponin I|Procalcitonin|Correlation of disease markers to selected clinical outcomes (Clinical improvement accoding to WHO criteria)|Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Decrease of SARS-CoV-2 viral load|Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Time course of SARS-CoV-2 viral load|Qualitative virologic clearance in spontaneous sputum and nasopharyngeal swab samples (= 2 consecutive negative SARS-CoV-2 reverse transcriptase polymerase chain reaction tests at least 24 hours apart)|Rate of conversion to a negative SARS-CoV-2 (qualitative) test on Days 6, 14 and 28|Time to conversion to a negative SARS-CoV-2 (qualitative) test|Interleukin (IL)-17|Interleukin (IL)-1ß|Interleukin (IL)-6|interferon gamma (IFNγ)|tumor necrosis factor alpha|Immunoglobulin (Ig)A and IgG antibodies against SARS-CoV-2: • Time to appearance of IgA and/or IgG antibodies|Immunoglobulin (Ig)A and IgG antibodies against SARS-CoV-2: • Proportion of patients with IgA and/or IgG antibodies on Days 6, 14, and 28","Immunic AG|FGK Clinical Research GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","P2-IMU-838-COV","May 2020","October 2020","October 2020","May 7, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04379271"
920,"NCT04358510","COVID-19 Mortality Prediction Model",,"Completed","No Results Available","COVID-19|Pneumonia|Mechanical Ventilation","Device: COViage","Mortality outcome in COVID-19 ICU patients|Mortality outcome in mechanically ventilated ICU patients|Mortality outcome in pneumonia ICU patients","Dascena","All","18 Years and older   (Adult, Older Adult)",,"114","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","04202001","April 1, 2020","April 17, 2020","April 17, 2020","April 24, 2020",,"April 24, 2020","Dascena, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT04358510"
921,"NCT04386070","Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19","PROTECT-Surg","Not yet recruiting","No Results Available","Pulmonary Complications in Surgical Patients|COVID|Severe Acute Respiratory Syndrome","Drug: Lopinavir-Ritonavir|Drug: Hydroxychloroquine","Pneumonia free survival; acute respiratory distress syndrome (ARDS) free survival; or death|Rate of Pneumonia|Rate of ARDs|Death rate|Rate of unexpected ventilation|COVID-19 pulmonary complications|Overall SARS-CoV-2 infected rate|Duration of hospital stay|Pulmonary function","University of Birmingham|Christian Medical College and Hospital, Ludhiana, India|Tamale Teaching Hospital, Ghana.|University of Lagos, Nigeria|Kigali University Teaching Hospital|Hospital Español Veracruz|Université d'Abomey-Calavi|University of Witwatersrand, South Africa|University of Edinburgh|Istituto Clinico Humanitas|University of Cape Town","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","6400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RG_20-029 COVID-19|2020-001448-24","May 15, 2020","May 14, 2021","May 14, 2026","May 13, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04386070"
922,"NCT04371692","Prevalence of COVID-19 Infection Among HCW in a French University Hospital","EXPOCOVIA","Not yet recruiting","No Results Available","Sars-CoV2","Other: self-administered questionnaire|Diagnostic Test: SARS-Cov2 testing","the prevalence of SARS- Cov2 infection Health Care Worker with or without symptoms suggestive of a COVID-19 infection|Occupational exposures associated with the SARS-Cov2 infection|Environmental exposures associated with the SARS-Cov2 infection|immunologic status of health Care Worker|inflammatory biomarkers status of Health Care Worker","University Hospital, Lille|Fondation Santé Roquette","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_35|2020-A00951-38","April 2020","September 2020","September 2020","May 1, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04371692"
923,"NCT04377334","Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)",,"Not yet recruiting","No Results Available","ARDS|COVID-19","Biological: MSC","lung injury score|D-dimers|phenotype|pro-resolving lipid mediators|cytokines|chemokines|Survival|extubation|lymphocyte subpopulations|SARS-CoV-2-specific antibody titers|complement molecules (C5-C9)","University Hospital Tuebingen","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RESCOVID","May 2020","November 2020","February 2021","May 6, 2020",,"May 6, 2020","University Hospital Tuebingen, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT04377334"
924,"NCT04270383","Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children",,"Not yet recruiting","No Results Available","2019-nCoV",,"The cure rate of 2019-nCoV.|The improvement rate of 2019-nCoV.|The incidence of long-term adverse outcomes.|Duration of fever|Duration of respiratory symptoms|Duration of hospitalization|Number of participant(s) need intensive care|Number of participant(s) with acute respiratory distress syndrome|Number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al.|Number of participant(s) who died during the trial","Beijing Children's Hospital|Capital Institute of Pediatrics, China|The First Affiliated Hospital of Anhui Medical University|China-Japan Friendship Hospital|The First Affiliated Hospital of Xiamen University|Guangzhou Women and Children's Medical Center|Shenzhen Children's Hospital|First Affiliated Hospital of Guangxi Medical University|The Affiliated Hospital Of Guizhou Medical University|Hainan People's Hospital|Children's Hospital of Hebei Province|Wuhan Women and Children's Medical Center|Changchun Children's Hospital|Children’s Hospital of Nanjing Medical University|Jiangxi Province Children's Hospital|Shengjing Hospital|Shanxi Provincial Maternity and Children's Hospital|Xian Children's Hospital|Children's Hospital of Chongqing Medical University|Tianjin Children's Hospital|Tianjin Medical University Second Hospital|Kunming Children's Hospital|Second Affiliated Hospital of Wenzhou Medical University","All","up to 18 Years   (Child, Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BCH Lung 012","February 15, 2020","December 31, 2020","December 31, 2020","February 17, 2020",,"February 17, 2020","Beijing Children's Hospital,, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04270383"
925,"NCT04359693","Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections","COVAPID","Not yet recruiting","No Results Available","SARS-CoV 2",,"Cumulative incidence of ventilator-associated lower respiratory tract infection|Cumulative incidence of ventilator-associated tracheobronchitis|Cumulative incidence of ventilator-associated pneumonia|the cumulative incidence of ICU acquired bacteremia diagnosed|ICU mortality|Mortality|the duration of mechanical ventilation|Length of stay in Intensive Care Unit","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)",,"1071","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_27|2020-A00995-34","April 2020","July 2020","July 2020","April 24, 2020",,"April 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04359693"
926,"NCT04362267","Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital","PRECOVIA","Not yet recruiting","No Results Available","Sars-CoV2","Other: self-administered questionnaire|Diagnostic Test: SARS-Cov2 testing","the incidence of SARS- Cov2 infection Heath Care Worker diagnosed by the positivity of SARS-Cov2 RT-PCT and serological testing|Occupational exposures associated with the SARS-Cov2 infection|Environmental exposures associated with the SARS-Cov2 infection","University Hospital, Lille|Fondation Santé Roquette","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2020_34|2020-A00950-39","April 2020","September 2020","September 2020","April 24, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04362267"
927,"NCT04391738","Association Between BMI and COVID-19","BMI-SARS-CoV-2","Active, not recruiting","No Results Available","SARS-CoV 2","Other: Patients admitted to Intensive Care Unit with SARS-CoV2","Relationship between body mass index (BMI) and SARS-CoV-2|Associations between BMI and outcomes is independent of the known cardiometabolic risk factors|Investigate the modifying effects of age and sex on the associations between BMI and outcome: Invasive mechanical ventilation|Investigate the modifying effects of age and sex on the associations between BMI and outcome: mortality","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)",,"1200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","DEC20-095","February 1, 2020","May 15, 2020","September 30, 2020","May 18, 2020",,"May 20, 2020","Centre Hospitalier Régional & Universitaire de Lille (CHRU), Lille, France",,"https://ClinicalTrials.gov/show/NCT04391738"
928,"NCT04395300","Sleep Quality in Healthcare Personnel During COVID-19",,"Completed","No Results Available","COVID-19|Sleep Quality|General Health","Other: Web Based Survey","measure sleep quality in healthcare worker|impact of covid-19 pandemic on general health|correlate between sleep quality and general health","Assiut University","All","18 Years to 80 Years   (Adult, Older Adult)",,"143","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","AssiutU14","March 30, 2020","April 30, 2020","May 16, 2020","May 20, 2020",,"May 20, 2020","AssiutU, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04395300"
929,"NCT04341792","Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient","BIOCOVU","Not yet recruiting","No Results Available","Infection Viral|Coronavirus|COVID-19",,"Rate of secondary aggravation|Change of standart biological parameters|Change of Von willebrand factor (vWF) changes over time|Change of the Factor VIII (FVIII)|Prevalence of positivity of COVID-19 virus measured by PCR or serology","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_33|2020-A00906-33","April 2020","August 2020","August 2020","April 10, 2020",,"April 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04341792"
930,"NCT04328480","The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.","COLCOVID","Recruiting","No Results Available","COVID-19","Drug: Colchicine|Other: Local standard of care","All-cause mortality|Composite outcome:composite of intubation for mechanical ventilation or death.","Estudios Clínicos Latino América|Population Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","2500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COLCOVID version1.2","April 17, 2020","June 30, 2020","August 30, 2020","March 31, 2020",,"April 30, 2020","Sanatorio Parque, Rosario, Santa Fe, Argentina",,"https://ClinicalTrials.gov/show/NCT04328480"
931,"NCT04344210","Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus",,"Enrolling by invitation","No Results Available","COVID|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1","Behavioral: Tele-interventions related to diabetes management and mental well-being","Variation in HbA1c levels|COVID-19 infection|Variation in lipid profile|Variation in blood pressure levels|Comparison of emotional distress associated with the routine of living with diabetes after intervention between groups|Comparison of eating disorders between groups|Comparison of adherence to the proposed clinical treatment between groups|Comparison of minor psychiatric disorders between groups|Comparison of sleep pattern changes between groups","Federal University of Rio Grande do Sul","All","18 Years and older   (Adult, Older Adult)","Not Applicable","149","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2020241093","April 17, 2020","August 20, 2020","August 30, 2020","April 14, 2020",,"April 14, 2020","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT04344210"
932,"NCT04397939","Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19",,"Not yet recruiting","No Results Available","COVID-19|Myocardial Reperfusion Injury|Cardiovascular Diseases",,"Number of In-Hospital Death|Length of Stay|Number of Successful Treatment","Icahn School of Medicine at Mount Sinai","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GCO 20-0965","May 2020","March 2021","March 2022","May 21, 2020",,"May 21, 2020","Mount Sinai Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04397939"
933,"NCT04324190","DIgital Online SuPport for COVID-19 StrEss","DISPOSE","Recruiting","No Results Available","COVID-19|Psychosocial Stress|Mental Health","Behavioral: Guided online support program|Behavioral: WHO recommendations (waiting condition)","Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score|Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score|Chronic stress items (9 items)|Generalized Anxiety Disorder Scale (GAD-7)|Patient Health Questionnaire (PHQ8)|Somatic Symptom Disorder (SSD-12)|Somatic Symptom Scale (SSS-8)|Allgemeine Selbstwirksamkeit Kurzskala (ASKU)|Screening Tool for Psychological Distress (STOP-D) - selected items","Gunther Meinlschmidt|Selfapy GmbH|International Psychoanalytic University Berlin","All","18 Years and older   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","IPUB_2020_01","April 8, 2020","June 2020","December 2021","March 27, 2020",,"April 14, 2020","Selfapy GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04324190"
934,"NCT04272710","Prognositc Factors in COVID-19 Patients Complicated With Hypertension",,"Withdrawn","No Results Available","2019-nCoV",,"Occupancy rate in the intensive care unit (ICU)|Mechanical Ventilation|Death|All cause mortality|Time from onset of symptoms to main outcome and its components|Time to Clinical Recovery","Chongqing Medical University","All","18 Years to 100 Years   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-02","January 25, 2020","March 31, 2020","April 30, 2020","February 17, 2020",,"March 17, 2020","The First Affiliated Hospital of Chongqing Medical University, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04272710"
935,"NCT04347382","Honey & Nigella Sativa-COVID-Pakistan Trial Against COVID-19","HNS-COVID-PK","Recruiting","No Results Available","Coronavirus Infection|Sars-CoV2","Drug: Honey|Drug: Nigella Sativa / Black Cumin|Drug: Placebos","Days required to get a positive COVID-19 PCR to negative|HRCT/ X-ray findings of disease progression|Severity of symptoms progression|Duration of Hospital Saty|30 day mortality|Oxygen Saturation at room air|Incidence of viral myocarditis|Incidence of Acute respiratory Distress Syndrome","Sohaib Ashraf|Sheikh Zayed Federal Postgraduate Medical Institute","All","5 Years and older   (Child, Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SZMC/IRB/Internal/0026/2020","May 20, 2020","July 25, 2020","July 30, 2020","April 15, 2020",,"May 15, 2020","Mayo Hospital, Kingedward Medical University, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04347382"
936,"NCT04359706","Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19","MICROVID","Not yet recruiting","No Results Available","Sars-CoV2",,"Composition of the fecal bacterial and fungal microbiota|Analysis of the faecal microbiota from rectal swab|Analysis of the respiratory microbiota from the bronchoalveolar lavage liquid|Serum inflammatory markers changes|Inflammatory markers changes|Mortality|mechanical ventilation free days","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_28|2020-A01042-37","April 2020","September 2020","September 2020","April 24, 2020",,"April 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04359706"
937,"NCT04357028","Measles Vaccine in HCW","MV-COVID19","Not yet recruiting","No Results Available","Covid19","Drug: Measles-Mumps-Rubella Vaccine|Drug: Placebos","COVID-19 disease incidence|SARS-CoV-2 pneumonia|Critical care admission duration with SARS-CoV-2|Oxygen therapy with SARS-CoV-2","Kasr El Aini Hospital","All","18 Years to 50 Years   (Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","N-30-2020","May 1, 2020","October 1, 2020","November 1, 2020","April 22, 2020",,"May 6, 2020","Cairo University Hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04357028"
938,"NCT04333693","Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study","Covid-VAS","Not yet recruiting","No Results Available","Vascular Surgical Procedures|COVID-19|Postoperative Complications","Procedure: Vascular surgery","30-days mortality|7-days mortality|30-days reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis","Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RIV-2020-1","April 1, 2020","October 1, 2020","November 1, 2020","April 3, 2020",,"April 3, 2020","Spanish Society for Angiology and Vascular Surgery, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04333693"
939,"NCT04335032","EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)",,"Not yet recruiting","No Results Available","SARS-CoV-2","Drug: Eicosapentaenoic acid gastro-resistant capsules","Evaluation of EPA-FFA efficacy compared to standard of care|Increase in oxygen saturation|PaO2/FiO2 >300mmHg increase|Reduction of IL-6|Mortality rate reduction|Reduction in ICU stays|Reducing hospitalisation days|reduction in need for mechanical ventilation|Fever reduction","S.L.A. Pharma AG","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","240","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPA-COV-001","April 13, 2020","July 13, 2020","July 31, 2020","April 6, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04335032"
940,"NCT04356508","COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1",,"Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2|2019-nCoV|Pneumonia, Viral","Drug: Nivolumab","Viral clearance kinetics|Treatment-related adverse events of nivolumab (Intervention arm only)|Lymphocyte kinetics|Cytokine kinetics|Length of inpatient stay due to COVID-19","Dr Gerry Gin Wai Kwok|The University of Hong Kong|Queen Mary Hospital, Hong Kong","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UW20213","April 14, 2020","June 30, 2020","August 31, 2021","April 22, 2020",,"April 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04356508"
941,"NCT04323345","Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus",,"Recruiting","No Results Available","COVID-19","Dietary Supplement: Natural Honey|Other: Standard Care","Rate of recovery from positive to negative swaps|Fever to normal temperature in days|Resolution of lung inflammation in CT or X ray|30 days mortality rate|Number of days till reaching negative swab results","Misr University for Science and Technology","All","5 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MUST23032020","April 15, 2020","December 15, 2020","January 15, 2021","March 26, 2020",,"April 21, 2020","Mahmoud Tantawy, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04323345"
942,"NCT04366765","COVID-19 Survival - The COVIVA Study","COVIVA","Recruiting","No Results Available","COVID-19|SARS-CoV 2",,"short-term prognosis|Admission to the intensive care unit (ICU)|Invasive ventilation (Intubation)|Need for extracorporal membrane oxygenation (ECMO)|Hemodynamic support|Length of ICU stay|Acute respiratory distress Syndrome (ARDS)|Myocardial injury|ST-segment elevation myocardial infarction|In-hospital resource use|EQ-5D questionnaire","University Hospital, Basel, Switzerland","All","18 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","UHospital Switz","March 19, 2020","June 30, 2021","June 30, 2021","April 29, 2020",,"May 4, 2020","University Hospital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT04366765"
943,"NCT04372680","WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound","INVICTUS","Recruiting","No Results Available","COVID-19|ARDS, Human|Mechanical Ventilation","Diagnostic Test: CTUS examination","Delay from the start of Mechanical Ventilation weaning process to extubation|delay from intubation to extubation|Successful of extubation|mortality rate","University Hospital, Toulouse","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RC31/20/0138|2020-A00916-33","April 22, 2020","September 22, 2020","September 22, 2020","May 4, 2020",,"May 4, 2020","CHU de LIMOGES, Limoges, France|CHU de TOULOUSE, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04372680"
944,"NCT04326075","Early CPAP in COVID Patients With Respiratory Failure.","EC-COVID-RCT","Not yet recruiting","No Results Available","CPAP Ventilation|COVID-19|Emergency Departments","Device: CPAP treatment","Death or need of intubation|30-day mortality","Mario Negri Institute for Pharmacological Research","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC-COVID-RCT-Fenice","April 6, 2020","October 5, 2020","November 9, 2020","March 30, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04326075"
945,"NCT04393974","COVID-19 and Cancer Patients","OnCovid","Recruiting","No Results Available","Cancer|Sars-CoV2",,"Describe presenting characteristics and severity or SARS-CoV-2 infection in patients with cancer|Assessing what factors are involved in prognosis of cancer patients with COVID-19","Imperial College London","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","282140","March 24, 2020","March 24, 2022","March 24, 2022","May 19, 2020",,"May 21, 2020","Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04393974"
946,"NCT04361591","COVID-19 in Liver Transplant Recipients","COVID19-SETH","Recruiting","No Results Available","Liver Transplant; Complications|COVID19|Respiratory Failure","Other: Observational only","Incidence of COVID19 in LT recipients|Clinical characteristics of COVID19 in LT recipients|Survival and Mechanical ventilation / respiratory support|Observed treatments and immunosuppression management","Hospital Clinic of Barcelona|Sociedad Española de Trasplante Hepático","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HCB/2020/0384","March 1, 2020","March 1, 2021","March 2021","April 24, 2020",,"April 24, 2020","SETH-affiliated Liver Transplant Programs in Spain, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04361591"
947,"NCT04355494","SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19",,"Available","No Results Available","COVID-19|Pneumonia, Viral|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)","Biological: eculizumab",,"Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population",,"ECU-COV-401",,,,"April 21, 2020",,"April 21, 2020","Hôpital Henri Mondor, Creteil, France|Hôpital Garches Raymond Poincaré, Garches, France|Hôpital de Bicêtre, Le Kremlin Bicêtre, France|Hôpital Saint Louis, Paris, France|Hôpital Paul Brousse, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT04355494"
948,"NCT04347408","Seroprevalence of SARS-Cov-2 Antibodies in Children",,"Not yet recruiting","No Results Available","COVID|Corona Virus Infection","Diagnostic Test: Covid-19 Antibody testing (IgG and IgM)","Immunoglobulins (G and M) to SARS-Cov2 in plasma","Queen's University, Belfast|Belfast Health and Social Care Trust","All","2 Years to 15 Years   (Child)",,"700","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282617","May 6, 2020","December 13, 2020","December 13, 2020","April 15, 2020",,"May 8, 2020","Royal Belfast Hospital for Sick Children, Belfast, United Kingdom|Royal Hospital for Children, Glasgow, United Kingdom|Public Health England, London, United Kingdom|Public Health England, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04347408"
949,"NCT04334954","SARS-COV2 Pandemic Serosurvey and Blood Sampling",,"Recruiting","No Results Available","SARS-COV2 Virus",,"Number of people with detectable antibodies to SARS-COV2","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"15000","NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","200083|20-I-0083","May 28, 2020","March 31, 2022","March 31, 2022","April 6, 2020",,"May 25, 2020","University of Alabama, Birmingham, Alabama, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04334954"
950,"NCT04335773","COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology",,"Recruiting","No Results Available","Pediatric Respiratory Diseases|COVID|Fatigue Post Viral",,"Risk Factors for severe infection|Immunulogical mechanisms|Long term outcome","University Hospital, Akershus|St. Olavs Hospital|Helse Stavanger HF|Haukeland University Hospital|University Hospital of North Norway|Alesund Hospital|Norwegian Institute of Public Health|The University of New South Wales|University of Bristol|Sykehuset Ostfold|Nordlandssykehuset HF|Vestre Viken Hospital Trust|Helse Fonna|Levanger Hospital|Oslo University Hospital|Sykehuset Innlandet HF","All","up to 18 Years   (Child, Adult)",,"350","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20/03794","April 3, 2020","December 31, 2030","December 31, 2030","April 6, 2020",,"April 17, 2020","Akershus universistetssykehus, Lørenskog, Norway",,"https://ClinicalTrials.gov/show/NCT04335773"
951,"NCT04381845","Immunity and Infections in the Psychiatric Population","COVIDIMMUNOPSY","Not yet recruiting","No Results Available","COVID|Psychiatric Disorders","Diagnostic Test: COVID19 immunization testing","Number of COVID-positive patients","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","APHP200553","May 10, 2020","June 10, 2020","June 25, 2020","May 11, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04381845"
952,"NCT04358588","Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19",,"Available","No Results Available","Coronavirus Infection|COVID-19|Pneumonia, Viral","Drug: iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System",,"Bellerophon","All","18 Years to 95 Years   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population",,"PULSE-EAP-001",,,,"April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04358588"
953,"NCT04359927","Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry","CV-COVID-19","Recruiting","No Results Available","Sars-CoV2|Covid19|Cardiovascular Diseases|Cardiovascular Risk Factor",,"Cardiovascular mortality|Acute myocardial infarction|Stroke","Hospital Clinic of Barcelona","All","18 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","HCB/2020/0457","April 20, 2020","August 31, 2021","August 31, 2025","April 24, 2020",,"May 7, 2020","Hospital Clínic of Barcelona, Barcelona, Catalonia, Spain",,"https://ClinicalTrials.gov/show/NCT04359927"
954,"NCT04324021","Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.",,"Recruiting","No Results Available","SARS-CoV-2","Biological: Emapalumab|Biological: Anakinra","Treatment success|Time to mechanical ventilation|Change from baseline in Modified Early Warning system score|Change from baseline in resting peripheral capillary oxygen saturation (SpO2)|Change from baseline in partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2)|Change of pH in hemogasanalysis from baseline|Change of carbon dioxide tension (pCO2) in hemogasanalysis from baseline|Change of oxygen tension (pO2) in hemogasanalysis from baseline|Change of potassium in hemogasanalysis from baseline|Change of sodium in hemogasanalysis from baseline|Change of chloride in hemogasanalysis from baseline|Change of lactic acid in hemogasanalysis from baseline|Change of hemoglobin in hemogasanalysis from baseline|Change from baseline in oxygen supplementation|Change of findings of high-resolution computed tomography (CT) scan of the chest|Change from baseline in Ferritin|Change from baseline in lactate dehydrogenase (LDH)|Change from baseline in D-dimers|Change from baseline in White Blood Cells with differential counts|Change from baseline in Red Blood Counts|Change from baseline in Hemoglobin|Change from baseline in Platelet count|Change from baseline in Fibrinogen|Change from baseline in Complement factors C3/C4|Change from baseline in Prothrombin time|Change from baseline in Cardiac troponin|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in total bilirubin levels|Change from baseline in C-Reactive Protein|Change from baseline in Creatinine|Overall survival|Time to hospital discharge","Swedish Orphan Biovitrum","All","30 Years to 79 Years   (Adult, Older Adult)","Phase 2|Phase 3","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sobi.IMMUNO-101|2020-001167-93","April 2, 2020","July 2020","September 2020","March 27, 2020",,"April 9, 2020","ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica, Brescia, Italy|Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza, Milano, Italy|Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia, Parma, Italy|Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta Intensità di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04324021"
955,"NCT04373811","One-Year Quality of Life and Functional Prognosis of COVID-19 Patients in Post-ICU Setting","COVENTRY","Recruiting","No Results Available","COVID-19|ICU Acquired Weakness|Weaning Failure","Diagnostic Test: Lung ultrasound|Diagnostic Test: Muscle ultrasound","Mean in quality of life score at one year on the Short Form Health Survey (SF-36)|Mean in quality of life score at six months on the Short Form Health Survey (SF-36)|Mean in autonomy score on the Activities Daily Living (ADL) scale|Survival rate|Change from baseline in lung ultrasound aeration score|Change from baseline in diaphragm ultrasound thickness and excursion|Mean change from baseline in ultrasound muscle thickness|Mean change from baseline in ultrasound muscle cross-sectionnal area|Mean change from baseline in ultrasound muscle echogeneicity|Mean change from baseline in ultrasound muscle pennation|Mean change from baseline in Medical Research Council (MRC) sum score|Prevalence of adverse outcomes during early mobilization","Groupe Hospitalier Paris Saint Joseph|Hôpital Forcilles","All","18 Years to 100 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVENTRY","April 16, 2020","September 16, 2021","September 16, 2021","May 4, 2020",,"May 4, 2020","Hôpital Forcilles, Férolles-Attilly, Ile-de-France, France",,"https://ClinicalTrials.gov/show/NCT04373811"
956,"NCT04333914","Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection","IMMUNONCOVID","Recruiting","No Results Available","SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor","Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care","28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA)","Centre Leon Berard","All","18 Years and older   (Adult, Older Adult)","Phase 2","273","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ET20-076 - IMMUNONCOVID-20|2020-001373-70","April 15, 2020","June 2020","August 2020","April 3, 2020",,"May 11, 2020","Centre Léon Bérard, Lyon, Rhône, France|AP-HP Hôpital Saint Antoine, Paris, France|AP-HP La Pitié Salpétrière, Paris, France|Hôpital Saint-Joseph, Paris, France|AP-HP Tenon, Paris, France|AP-HP Hôpital Bichat Claude Bernard, Paris, France|Gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT04333914"
957,"NCT04336787","Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine",,"Not yet recruiting","No Results Available","Covid-19|Coronavirus Infection|Pregnancy Related","Other: Survey","International Physical Activity Questionnaire|Pittsburgh Sleep Quality Index|Perceived Stress Scale|Numerical Pain Rating Scale","Istanbul Kültür University|Istanbul University-Cerrahpasa","Female","18 Years to 45 Years   (Adult)",,"100","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","FADP-2","April 12, 2020","May 10, 2020","June 10, 2020","April 7, 2020",,"April 13, 2020","Istanbul University - Cerrahpaşa, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04336787"
958,"NCT04397900","Blood Collection Study From COVID-19 Convalescents to Identify Immunogenic Viral Epitopes",,"Recruiting","No Results Available","Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection|Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types",,"Identify the viral epitopes of memory CD8+ T cells from individuals that have recovered from SARS-CoV-2 infection.|Determine which SARS-CoV-2 proteins are frequently recognized by T cells in patients with varying HLA types.","TScan Therapeutics, Inc.","All","Child, Adult, Older Adult",,"80","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","1586788","April 9, 2020","May 2020","July 2020","May 21, 2020",,"May 21, 2020","Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Atlantic Health System, Morristown, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04397900"
959,"NCT04369066","COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie","Curie-O-SA","Recruiting","No Results Available","Volunteers From the Institute Curie Staff Who Are Not Showing Active SARS-CoV-2 Infection","Diagnostic Test: Blood samples (collection of 5 mL of blood in a dry tube)","Antibodies against the SARS-CoV-2 virus in serum at inclusion|Antibodies against the SARS-CoV-2 virus in serum at 1 month|Antibodies against the SARS-CoV-2 virus in serum at 3 months|Antibodies against the SARS-CoV-2 virus in serum at 6 months|Comparative performance of anti-SARS-CoV-2 antibody detection techniques|Prevalence of immune subjects for SARS-CoV-2|Nature and quantity of anti-SARS-CoV-2 antibodies|Evolution of the different antibodies against the SARS-CoV-2 virus over time.","Institut Curie","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IC 2020-07","April 28, 2020","October 28, 2020","January 28, 2021","April 30, 2020",,"April 30, 2020","Institut Curie, Paris, France",,"https://ClinicalTrials.gov/show/NCT04369066"
960,"NCT04292964","Prognostic Factors of Patients With COVID-19",,"Completed","No Results Available","SARS-CoV-2|Outcome, Fatal",,"all-cause mortality|Severe state","Chongqing Medical University","All","18 Years and older   (Adult, Older Adult)",,"201","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-02-2","March 1, 2020","March 13, 2020","March 13, 2020","March 3, 2020",,"March 17, 2020","The First Affiliated Hospital of Chongqing Medical University, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04292964"
961,"NCT04361604","Clinical Characterisation Protocol for COVID-19 in People Living With HIV","COVIDHIV","Not yet recruiting","No Results Available","Adult Patients Living With HIV (PLWHIV) With Confirmed Infection With SARS-CoV-2 Since 1st January 2020","Biological: Biological collection (patients co infected HIV Sras-CoV-2)|Other: Auto-questionnaires (patients co infected HIV Sras-CoV-2)|Other: Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)","Describe the course of COVID-19 disease in patients infected with HIV,","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"270","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2020-A00984-35","April 2020","October 2020","October 2020","April 24, 2020",,"April 24, 2020","Department of Internal Medicine and Clinical Immunology of Professor Cécile Goujard, Le Kremlin-Bicêtre, France",,"https://ClinicalTrials.gov/show/NCT04361604"
962,"NCT04323761","Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)",,"Available","No Results Available","SARS-CoV2 Infection","Drug: Remdesivir",,"Gilead Sciences","All","12 Years and older   (Child, Adult, Older Adult)",,,"Industry","Expanded Access:Treatment IND/Protocol",,"GS-US-540-5821|2020-001453-49",,,,"March 27, 2020",,"May 21, 2020","University of Alabama- Birmingham, Birmingham, Alabama, United States|Banner- University Medical Center Phoenix, Phoenix, Arizona, United States|Community Regional Medical Centers (CRMC), Fresno, California, United States|St. Jude Medical Center, Fullerton, California, United States|Scripps Memorial Hospital La Jolla, La Jolla, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Huntington Hospital, Pasadena, California, United States|Scripps Mercy Hospital, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of California, Medical Center (Parnassus Campus), San Francisco, California, United States|Regional Medical Center, San Jose, California, United States|San Mateo Medical Center, San Mateo, California, United States|Santa Rosa Memorial Hospital, Santa Rosa, California, United States|Los Robles Regional Medical Center, Thousand Oaks, California, United States|PIH Health Whittier Hospital, Whittier, California, United States|The Medical Center Of Aurora, Aurora, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Middlesex Health, Middletown, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Stamford Infectious Diseases LLC, Stamford, Connecticut, United States|George Washington University Hospital, Washington, District of Columbia, United States|Aventura Hospital and Medical Center, Aventura, Florida, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|AdventHealth Orlando, Investigational Drug Services, Orlando, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Wellstar Atlanta Medical Center, Atlanta, Georgia, United States|Piedmont Columbus Regional-Midtown Hospital, Columbus, Georgia, United States|Grady Health System- Grady Memorial Hospital, Decatur, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Swedish Hospital, Chicago, Illinois, United States|Mercy Hospital & Medical Center, Chicago, Illinois, United States|Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, United States|St. Vincent Hospital and Health Care Center, Inc., Carmel, Indiana, United States|Richard L Roudebush Indianapolis VA, Indianapolis, Indiana, United States|Riverview Health, Noblesville, Indiana, United States|Our Lady of the Lakes Regional Medical Center, Baton Rouge, Louisiana, United States|Touro Infirmary, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Slidell Memorial Hospital, Slidell, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Calvert Health Medical Center, Prince Frederick, Maryland, United States|University of Maryland St. Joseph Medical Center, Towson, Maryland, United States|Steward St. Elizabeth's Medical Center of Boston, Inc., Boston, Massachusetts, United States|Cambridge Health Alliance, Cambridge, Massachusetts, United States|Charlton Memorial Hospital, Fall River, Massachusetts, United States|Lawrence General Hospital, Lawrence, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|South Shore Hospital, South Weymouth, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Huron Valley-Sinai Hospital, Commerce, Michigan, United States|Wayne Statue University/ Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|McLaren Health Care Corporation, Flint, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CarePoint Health Bayonne Medical Center, Bayonne, New Jersey, United States|Clara Maass Medical Center, Belleville, New Jersey, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States|Trinitas Regional Medical Center, Elizabeth, New Jersey, United States|Englewood Health, Englewood, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|CentraState Medical Center, Freehold, New Jersey, United States|Robert Wood Johnson University Hospital Hamilton, Hamilton, New Jersey, United States|Jersey City Medical Center, Jersey City, New Jersey, United States|Christ Hospital- Carepoint Health, Jersey City, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Atlantic Health System/ Morristown Medical Center, Morristown, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Ocean Medical Center, Oakhurst, New Jersey, United States|Bayshore Medical Center, Red Bank, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Atlantic Health System/Overlook Medical Center, Summit, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Capital Health, Trenton, New Jersey, United States|Virtua Health Voorhees Campus, Voorhees, New Jersey, United States|St. Peter's Hospital, Albany, New York, United States|Mount Sinai Queens, Astoria, New York, United States|Good Samaritan Hospital Medical Center, Bay Shore, New York, United States|Southside Hospital, Bay Shore, New York, United States|Lincoln Medical Center, Bronx, New York, United States|St Barnabus Hospital, Bronx, New York, United States|Montefiore Medical Center, Weiler Campus, Bronx, New York, United States|Montefiore Health System Moses Medical Center, Bronx, New York, United States|The Brooklyn Hospital Center, Brooklyn, New York, United States|Kingsbrook Jewish Medical Center, Brooklyn, New York, United States|University Hospital Brooklyn (SUNY Downstate), Brooklyn, New York, United States|Woodhull Medical Center, Brooklyn, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|New York Harbor VA Medical Center, Brooklyn, New York, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|Interfaith Medical Center, Brooklyn, New York, United States|NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States|Mount Sinai Brooklyn, Brooklyn, New York, United States|New York City Health and Hospitals - Coney Island, Brooklyn, New York, United States|Kaleida Health System, Buffalo, New York, United States|Nassau University Medical Center, East Meadow, New York, United States|New York Presbyterian- Queens, Flushing, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Queens Hospital Center, Jamaica, New York, United States|NYU Langone Health, New York, New York, United States|Hospital for Special Surgery, New York, New York, United States|New York City Health and New York City Health and Hospitals - Metropolitan- Metropolitan, New York, New York, United States|NewYork-Presyterian/Columbia University Irving Medical Center- Milstein Hospital, New York, New York, United States|New York City Health + Hospitals / Harlem, New York, New York, United States|New York Presbyterian Lower Manhattan Hospital, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Mount Sinai South Nassau, Oceanside, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Rochester General Hospital, Rochester, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Ellis Hospital, Schenectady, New York, United States|Staten Island University Hospital- Northwell Health (North Campus), Staten Island, New York, United States|Stony Brook University Hospital/ Stony Brook Children's, Stony Brook, New York, United States|Samaritan Hospital, Troy, New York, United States|UNC Hospitals, Chapel Hill, North Carolina, United States|Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|The Ohio State University College of Medicine, Columbus, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Saint Francis Hospital, Tulsa, Oklahoma, United States|St. Luke's Hospital - Bethlehem Campus, Bethlehem, Pennsylvania, United States|Mercy Catholic Medical Center - Fitzgerald Campus, Darby, Pennsylvania, United States|St Mary Medical Center, Langhorne, Pennsylvania, United States|Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States|Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|UPMC, Pittsburgh, Pennsylvania, United States|Roger Williams Medical Center,, Providence, Rhode Island, United States|Kent Hospital, Warwick, Rhode Island, United States|St. Francis Hospital, Greenville, South Carolina, United States|Lexington Medical Center, West Columbia, South Carolina, United States|TriStar Centennial Medical Center, Nashville, Tennessee, United States|St. David's South Austin Medical Center, Austin, Texas, United States|Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States|HCA Houston Healthcare West, Houston, Texas, United States|Covenant Medical Center, Lubbock, Texas, United States|Methodist Mansfield Medical Center, Mansfield, Texas, United States|Methodist Healthcare System of San Antonio, Ltd. LLP, dha, Methodist Hospital, San Antonio, Texas, United States|Saint Mark's Hospital, Salt Lake City, Utah, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Henrico Doctors Hospital, Richmond, Virginia, United States|Carilion Medical Center, Roanoke, Virginia, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|University of Washington Medical Center- Montlake Campus, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Kepler Universitätsklinikum, Linz, Austria|Sozialmedizinisches Zentrum Süd - Kaiser-Franz-Josef-Spital, Wien, Austria|Ghent University Hospital, Ghent, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|Hôpital Civil Marie Curie, Lodelinsart, Belgium|William Osler Health System, Brampton, Ontario, Canada|The Ottowa Hospital, Ottawa, Ontario, Canada|Nicosia General Hospital, Nicosia, Cyprus|Všeobecná fakultní nemocnice v Praze, Prague, Czechia|Eticka komise pro multicentircke klinicke hodnoceni Fakultni nemocnice v Motole, Praha 5, Czechia|Nemocnice Na Bulovce, Praha 8, Czechia|Põhja-Eesti Regionaalhaigla, Tallinn, Estonia|Vilnius University, Tartu, Estonia|Hopital Avicenne, Bobigny, France|Centre Hospitalier Regional Universitaire Brest Hôpital de la Cavale Blanche à Brest, Brest Cedex, France|Centre Hospitalier Universitaire Gabriel-Montpied, Clermont Ferrand, France|Hôpitaux Civils de Colmar, Colmar, France|Centre Hospitalier Sud Francilien, Corbeil Essonnes, France|Hôpital Raymond Poincaré, Garches, France|Centre Hospitalier Régional d'Orléans, Orléans, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Hôpital Charles-Nicolle, Rouen, France|Saint Josef Hospital Ruhr Universitaet Bochum, Bochum, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitatsklinikum, Essen, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsmedizin Göttingen, Göttingen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Caritas-Krankenhaus St. Josef, Regensburg, Germany|Klinikum Würzburg Mitte, Würzburg, Germany|University General Hospital of Patras Panagia I Voithia, Patra, Greece|General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Greece|Kenézy Gyula Kórház És Rendelőintézet, Debrecen, Hungary|Landspítali, Reykjavik, Iceland|Kerry University Hospital, Tralee, Ireland|Shaare Zedek Medical Center, Jerusalem, Israel|Hasharon Hospital, Petah Tikva, Israel|Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Ospedaliero Universitaria, Bologna, Italy|Azienda Ospedaliero - Universitaria Careggi, Florence, Italy|Ospedale Policlinico San Martino, Genova, Italy|Ospedale San Gerardo di Monza, Monza, Italy|Azienda Ospedaliera dei Colli, Napoli, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|Azienda Ospedaliero Universitaria, Turin, Italy|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands|HagaZiekenhuis, The Hague, Netherlands|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wielospecjalistyczny Szpital Miejski Im Józefa Strusia Zakład Opiekuńczo Leczniczy, Poznan, Poland|Wojewódzki Szpital Specjalistyczny Megrez Sp. z o.o., Tychy, Poland|Centro Hospitalar Universitário de Lisboa Central - Hospital Curry Cabral, Lisboa, Portugal|Centro Hospitalar Universitário do Porto E.P.E., Porto, Portugal|Centro Hospitalar Universitário De São João, Porto, Portugal|Institutul National de Boli Infectioase Prof. Dr. Matei Bals, Bucharest, Romania|Spitalul Clinic de Boli Infecţioase Sfânta Parascheva Iaşi, Iasi, Romania|Univerzitná Nemocnica L. Pasteura Košice - Pracovisko Rastislavova 43, Košice, Slovakia|Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia|Univerzitetni Klinicni Center Maribor, Maribor, Slovenia|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Donostia, San Sebastian, Spain|Hospital Virgen De La Salud, Santa Cruz de Tenerife, Spain|Hospital Virgen De La Salud, Toledo, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Kantonsspital Aarau, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|Spitalzentrum Biel, Biel, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|St. George's Hospital, London, United Kingdom|Southampton University Hospital, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04323761"
963,"NCT04357769","COVID-19 Pandemic Burden in Severe Mental Disease Patients","PsyCOVID","Recruiting","No Results Available","Psychological Distress|COVID|Severe Mental Disorder","Other: PSS (Perceived Stress Scale)|Other: GAD-7 (7-item Generalized Anxiety Disorder)|Other: PHQ-9 (9-item Patient Health Questionnaire)|Other: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales|Other: Zaritt Burden Interview","Perceived Stress Scale (PSS) outcome|Generalized Anxiety Disorder (GAD-7) scale outcome|Patient Health Questionnaire (PHQ-9) scale outcome|Specific Psychotic Experiences Questionnaire (SPEQ) - Paranoia subscale outcome|Specific Psychotic Experiences Questionnaire (SPEQ) - Grandiosity subscale outcome|Caregiver Burden","Federico II University","All","18 Years to 70 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","152/20","April 10, 2020","April 20, 2020","April 25, 2020","April 22, 2020",,"April 22, 2020","University of Naples ""Federico II"", Napoli, Italy",,"https://ClinicalTrials.gov/show/NCT04357769"
964,"NCT04349618","Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia","VT4COVID","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID19|Sars-CoV2|Pneumonia","Other: PROTECTIVE VENTILATION|Other: ULTRAPROTECTIVE VENTILATION","A composite score based on all-cause mortality and the number of ventilator free-days (VFD)|All-cause mortality (intention to treat)|Ventilator-free days (VFD)|All-cause mortality with per protocol analysis|Time to successful extubation|Length of hospital stay|Respiratory parameters assessed daily from inclusion to weaning of deep sedation or 14 days whichever comes first|Daily sedation dose during the first 14 days of the study|Rate of use of rescue therapies|Incidence density rate of severe mixed acidosis|Incidence density rate of ventilator associated pneumonia|Incidence density rate of acute cor pulmonale|Incidence density rate of barotrauma|Incidence density rate of any serious adverse events|Cognitive impairment assessed by phone call using the Telephone Montreal Cognitive Assessment (T-MoCA) test|Quality of life assessed by the RAND 36-Item Health Survey (SF-36) score|Post-traumatic stress disorder assessed by the Impact of Event Scale - revised (IES-R) score by phone call|Cost-efficacy ratio of the innovative strategy compared to the reference strategy","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","69HCL20_0322","April 14, 2020","July 14, 2021","April 14, 2022","April 16, 2020",,"April 16, 2020","Service de Médecine Intensive Réanimation CHU Gabriel Montpied, Clermont-Ferrand, France|Service de Médecine Intensive Réanimation Hôpital Michallon - CHU Grenoble Alpes, La Tronche, France|Service de Médecine Intensive Réanimation Hôpital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de Réanimation Chirurgicale Hôpital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de Médecine Intensive Réanimation Hôpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de Réanimation Chirurgicale Hôpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de réanimation Polyvalente Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France|Service de Réanimation Clinique de la Sauvegarde, Lyon, France|Service de Réanimation Polyvalente Centre Hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-Bénite, France|Service de Réanimation Centre hospitalier Annecy Genevois, Pringy, France|Service de Médecine Intensive Réanimation Hôpital Nord - CHU Saint-Etienne, Saint-Priest-en-Jarez, France",,"https://ClinicalTrials.gov/show/NCT04349618"
965,"NCT04364711","EuRopean Study of MAjor Infectious Disease Syndromes Related to COVID-19","MERMAIDS 2","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2",,"Pneumonia Severity indexes|Need for supplemental oxygen; non-invasive or invasive mechanical ventilation; extra-corporeal life support|Hospital - and ICU/HCU length of stay|In-hospital mortality|Activities of daily life, quality of life, variations in home living status and employment status|Proportion of SARS-CoV2 positive patients","UMC Utrecht","All","Child, Adult, Older Adult",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ReCoVer - MERMAIDS 2.0","May 1, 2020","April 30, 2022","April 30, 2022","April 28, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04364711"
966,"NCT04378842","COVID-19 and ICU-acquired MDR Bacteria","COVID-BMR","Not yet recruiting","No Results Available","Sars-CoV2|Critical Illness",,"Cumulative incidence of ICU-acquired colonization related multidrug resistant bacteria|Cumulative incidence of ICU-acquired infection related to multidrug resistant bacteria|Mechanical ventilation duration|mortality|length of stay in intensive care unit","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)",,"690","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_37|2020-A01157-32","May 2020","May 2021","May 2021","May 7, 2020",,"May 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04378842"
967,"NCT04397705","Remote Monitoring of Cancer Patients With Suspected Covid-19","RECAP","Not yet recruiting","No Results Available","COVID|Oncology|Haematological Malignancy","Device: Patient Status Engine","Device Tolerability (Attrition)|Correlation of physiological data with clinical events|Device Tolerability (Questionnaire)|Device Tolerability (Semi-structured interviews)|Reliability of data transmission","The Christie NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CFTSp186","June 2020","August 2020","October 2020","May 21, 2020",,"May 21, 2020","The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04397705"
968,"NCT04384887","""Investigation of the Relationship Between New Coronary Virus Disease (COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women""",,"Active, not recruiting","No Results Available","COVID|Anxiety|Depression, Postpartum","Behavioral: covid-19 positive pregnant women","Evaluation of depression and anxiety score changes of covid-19 positive pregnants","Kanuni Sultan Suleyman Training and Research Hospital|Ayşegül Bestel|İbrahim Polat|Merve Aldıkaçtıoğlu Talmaç","Female","18 Years to 45 Years   (Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","beckcovid","April 25, 2020","July 25, 2020","July 26, 2020","May 12, 2020",,"May 12, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04384887"
969,"NCT04362930","Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences)","CoCo-Neuro","Recruiting","No Results Available","Neurologic Manifestations|Psychiatric Disorders|COVID-19",,"Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19|Progression of pre-existing neurological or psychiatric pathologies","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","APHP200525","April 27, 2020","April 24, 2022","April 24, 2022","April 27, 2020",,"May 13, 2020","Hôpital Pitié Salpétrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04362930"
970,"NCT04365153","Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function Due to COVID-19",,"Recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Canakinumab Injection 600mg|Drug: Canakinumab Injection 300mg|Drug: Placebos","Time to clinical improvement up to day 14, defined as the time in days from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever occurs first.|Mortality at day 28","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IND 149328","April 24, 2020","December 31, 2020","December 31, 2020","April 28, 2020",,"May 21, 2020","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04365153"
971,"NCT04386395","Immune Changes in Severe COVID-19 Pulmonary Infections","COVIDIMM","Active, not recruiting","No Results Available","SARS-CoV-2|Immune System Disorder",,"Changes in monocytes HLA-DR expression|Changes in lymphocytes subpopulations numbers|Changes in monocytes number|TNFalpha level|INFgamma level|IL1beta level|SOFA score|number of recorded deaths|presence of pneumonia|presence of bacteremia|presence of urinary tract infection|C reactive protein|D Dimers","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)",,"15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHRU NANCY : 2020PI080_1","March 30, 2020","May 1, 2020","May 30, 2020","May 13, 2020",,"May 13, 2020","Centre Hospitalier Universitaire NANCY, Vandoeuvre-les-Nancy, France",,"https://ClinicalTrials.gov/show/NCT04386395"
972,"NCT04344379","Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus","PREP-COVID","Recruiting","No Results Available","SARS-CoV-2 Infection","Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo","To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 3","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","APHP200386|2020-001273-73","April 15, 2020","July 31, 2020","August 31, 2020","April 14, 2020",,"April 24, 2020","Hopial Avicenne, Bobigny, France|Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France|Hôpital Saint Antoine, Paris, France|Hôpital Broca, Paris, France|Hôpital La Pitié-Salpétrière, Paris, France|Hôpital Cochin, Paris, France|Hôpital européen Georges Pompidou, Paris, France|Hôpital Necker, Paris, France",,"https://ClinicalTrials.gov/show/NCT04344379"
973,"NCT04336761","Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France","INCOVPED","Recruiting","No Results Available","Coronavirus|COVID|Infection Viral","Diagnostic Test: nasopharyngeal swab","Prevalence of positivity of COVID-19 virus measured by rt-PCR|Prevalence of positivity of COVID-19 virus measured by rt-PCR in the following subpopulations of emergency patients|Respiratory signs of children tested within 28 day|Percentage of children hospitalized tested within 28 day|Contact frequency|Prevalence of positivity of other respiratory viruses measured by rt-PCR","University Hospital, Lille","All","up to 18 Years   (Child, Adult)",,"914","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_21|2020-A00811-38","April 15, 2020","December 2020","December 2020","April 7, 2020",,"May 21, 2020","CH Louis MOURIER, Colombes, France|Hôpital Jeanne de Flandres, CHU, Lille, France|Hôpital Mère Enfant CHU, Nantes, France|Hôpitaux Pédiatriques de Nice CHU-Lenval, Nice, France|Hôpital des enfants - CHU, Toulouse, France|CHU de Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT04336761"
974,"NCT04357860","Clinical Trial of Sarilumab in Adults With COVID-19","SARICOR","Not yet recruiting","No Results Available","SARS-CoV 2|SARS","Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Drug: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Drug: Best available treatment","Ventilation requirements|Crude mortality|Time to clinical improvement|Time until improvement in oxygenation|Proportion of patients requiring invasive mechanical ventilation|Proportion of patients having negative COVID-19 CRP at each visit|Mean of serum cytokine levels|Adverse events related to medication and its administration|Incidence in the appearance of serious bacterial, fungal or opportunistic infections|Incidence of perforation of the gastrointestinal tract|Leukocyte and neutrophil count|Hemoglobin levels|Platelet count|Levels of creatinemia|Bilirubin levels|ALT and AST levels","Maimónides Biomedical Research Institute of Córdoba|Consejería de Salud y Familias - Junta de Andalucía|Red Andaluza de Ensayos Clínicos en Enfermedades Infecciosas (Red ANCRAID)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SARICOR","April 27, 2020","July 27, 2020","July 27, 2020","April 22, 2020",,"April 27, 2020","Hospital Universitario Reina Sofía, Córdoba, Spain",,"https://ClinicalTrials.gov/show/NCT04357860"
975,"NCT04356495","Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19)","COVERAGE","Not yet recruiting","No Results Available","Corona Virus Infection|Sars-CoV2","Dietary Supplement: Vitamins|Drug: Hydroxychloroquine|Drug: Imatinib|Drug: Favipiravir|Drug: Telmisartan","Proportion of participants with an occurrence of hospitalization|Death|Proportion of hospitalizations, overall and by cause, in each group|Death and causes of death|Proportion of intensive care hospitalizations, overall and by cause, in each group|Proportion of participants with negative nasopharyngeal SARS-CoV-2 RT-PCR|Proportion of participants with a loss of autonomy evaluated by the ADL and IADL scale|Haematological markers evolution|Biochemical markers evolution|Inflammatory markers evolution|Immunological markers evolution|Adverse events|Adverse reactions|Plasma concentration|Acceptability of the treatment","University Hospital, Bordeaux|University of Bordeaux","All","65 Years and older   (Older Adult)","Phase 3","1057","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHUBX 2020/12","April 15, 2020","July 31, 2020","August 15, 2020","April 22, 2020",,"April 22, 2020","Bordeaux university Hospital, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04356495"
976,"NCT04395794","SARS-CoV-2 Disguise Study","Disguise","Recruiting","No Results Available","Sars-CoV2","Diagnostic Test: SARS-CoV-2-test|Other: SARS-CoV-2 questionnaire survey","SARS-CoV-2 positive test|Transformation|Predictors (asymptomatic)|Predictors (symptomatic)|Percentage from different departments","Meshalkin Research Institute of Pathology of Circulation","All","18 Years and older   (Adult, Older Adult)",,"900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CS-COVID-19","May 7, 2020","August 31, 2020","November 30, 2020","May 20, 2020",,"May 20, 2020","Meshalkin National Medical Research Center, Novosibirsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04395794"
977,"NCT04320511","Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2",,"Recruiting","No Results Available","SARS-COV2|Severe Acute Respiratory Syndrome|COVID-19","Device: CT-V","Predictive association between CT-V, PBM score and disease progression","William Beaumont Hospitals","All","18 Years and older   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-087","June 2020","March 2021","March 2022","March 25, 2020",,"May 25, 2020","Beaumont Health, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04320511"
978,"NCT04390217","LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19|Coronavirus Disease 2019|Covid19|COVID-19 Pneumonia","Drug: LB1148|Drug: Placebo","Effect of LB1148 on disease progression via measurement of the proportion of patients who are alive and free of respiratory failure.|Clinical status at fixed time points|Duration of hospital stay|Measurement of the number and proportion of patients requiring admission to the intensive care unit (ICU) during hospitalization|Duration of ICU stay|Invasive mechanical ventilation requirements|Duration of invasive mechanical ventilation|All-cause 28-day mortality|Safety and tolerability of LB1148","Leading BioSciences, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LBS-COVID19-201","June 30, 2020","December 31, 2020","March 31, 2021","May 15, 2020",,"May 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04390217"
979,"NCT04344119","Assessment of Chilbains Occuring During Covid-19 Infection","ChilblainCOVID","Recruiting","No Results Available","Skin Manifestations|COVID|Chilblains",,"Clinical skin manifestations|Histology and biological data|Non invasive vascular examination","Centre Hospitalier Universitaire de Nice","All","up to 90 Years   (Child, Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20dermatocovid01","April 9, 2020","June 30, 2020","June 30, 2020","April 14, 2020",,"May 13, 2020","CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT04344119"
980,"NCT04360707","Solid Organ Transplant Recipients With SARS-CoV-2 French Registry","TX-COVID","Recruiting","No Results Available","SARS-CoV-2",,"Clinical Presentation and Incidence of Covid-19 Infection in Different Cohorts of Solid Organ Transplant Patients","University Hospital, Strasbourg, France","All","1 Year and older   (Child, Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","7766","April 8, 2020","April 8, 2021","April 8, 2021","April 24, 2020",,"May 5, 2020","Service de Néphrologie et Transplantation, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04360707"
981,"NCT04391179","Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19","DICER","Not yet recruiting","No Results Available","COVID|Corona Virus Infection|Covid-19|SARS-CoV-2 Infection","Drug: Dipyridamole 100 Milligram(mg)|Drug: Placebo oral tablet","Change in D-dimer|Global composite rank score","Yogendra Kanthi|University of Michigan","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HUM00179783","June 2020","December 2020","December 2020","May 18, 2020",,"May 18, 2020","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04391179"
982,"NCT04341441","Will Hydroxychloroquine Impede or Prevent COVID-19","WHIP COVID-19","Recruiting","No Results Available","COVID-19|Coronavirus|Coronavirus Infections|SARS-CoV 2","Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment","To determine if the use of hydroxychloroquine as preventive therapy decreases the rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease in Study Participants for each randomized treatment arm as compared to placebo.|Determine the effect of hydroxychloroquine dose in the prevention of COVID-19 viremia and disease.|Assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention.|Comparison of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo.|Compare the seroprevalence of SARS-CoV 2 IgM/IgG positive samples at study entry and study conclusion in all participants receiving HCQ compared to those receiving placebo.|Comparison of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm.|To examine the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care.|Determine the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events.|To examine other clinical determinants contributing to the risk of SARS-CoV 2 infection in healthcare workers and first responders.|Examine the association between HCQ drug levels and development of COVID-19 symptoms or positive test results.|identify immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease.","Henry Ford Health System","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","1410401","April 7, 2020","June 30, 2020","April 30, 2021","April 10, 2020",,"May 7, 2020","Henry Ford Hospital, Detroit, Michigan, United States|Detroit Department of Transportation (DDOT), Detroit, Michigan, United States|Detroit Fire Department & Detroit EMS, Detroit, Michigan, United States|Detroit Police Department, Detroit, Michigan, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04341441/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT04341441"
983,"NCT04331574","Renin-Angiotensin System Inhibitors and COVID-19","SARS-RAS","Recruiting","No Results Available","COVID-19|Hypertension|Cardiovascular Diseases",,"Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity","Societa Italiana dell'Ipertensione Arteriosa","All","18 Years to 120 Years   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","SARS-RAS","March 10, 2020","April 10, 2020","April 30, 2020","April 2, 2020",,"April 2, 2020","Spedali Civili di Brescia, Brescia, Italy",,"https://ClinicalTrials.gov/show/NCT04331574"
984,"NCT04340921","The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury",,"Recruiting","No Results Available","Cardiovascular Disease Acute|Cardiomyopathies|COVID","Biological: COVID-19 exposure","T-cell immunophenotype|Mortality|ITU admission|Myocardial injury","Barts & The London NHS Trust|Queen Mary University of London","All","18 Years and older   (Adult, Older Adult)",,"140","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282289","May 14, 2020","November 10, 2021","November 10, 2021","April 10, 2020",,"May 18, 2020","Barts Health Nhs Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04340921"
985,"NCT04268537","Immunoregulatory Therapy for 2019-nCoV",,"Not yet recruiting","No Results Available","2019 nCoV, PD-1","Drug: PD-1 blocking antibody+standard treatment|Drug: Thymosin+standard treatment|Other: standard treatment","lung injury score|absolute lymphocyte counts|serum level of CRP, PCT and IL-6|SOFA score|all cause mortality rate|ventilation free days|ICU free days","Southeast University, China","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2020YFC0841300-03","February 10, 2020","April 30, 2020","October 31, 2020","February 13, 2020",,"February 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04268537"
986,"NCT04342195","Acquiring Convalescent Specimens for COVID-19 Antibodies",,"Recruiting","No Results Available","COVID-19|Coronavirus Infection|Corona Virus Infection","Procedure: Blood draw","Number of antibodies against coronaviruses isolated and identified from patient samples","Columbia University","All","18 Years to 65 Years   (Adult, Older Adult)",,"12","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","AAAS9517","March 25, 2020","March 2021","March 2021","April 10, 2020",,"April 13, 2020","Columbia University Irving Medical Center/NYP, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04342195"
987,"NCT04367168","Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease","ColchiVID","Not yet recruiting","No Results Available","COVID","Drug: Colchicine|Drug: Placebo oral tablet","Number of patients with improvement in body temperature, myalgia, arthralgia, total lymphocyte count, D-dimer, fibrinogen and ferritin levels|Progression to severe disease","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","174","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","337420-21-1","April 27, 2020","April 27, 2021","April 27, 2021","April 29, 2020",,"May 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04367168"
988,"NCT04365517","The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients","SIDIACO","Not yet recruiting","No Results Available","Covid19|Diabetes Mellitus, Type 2|CKD","Drug: Sitagliptin","Time for clinical improvement|Clinical parameter of acute lung disease|Biochemical parameter of acute lung disease|Clinical parameters of acute lung disease|Dipeptilpeptidase 4 expression in biological samples|Cytokine-inflammatory profile|Glycemic variability","University of Milan","All","18 Years and older   (Adult, Older Adult)","Phase 3","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sacco FBF","May 29, 2020","June 30, 2020","December 30, 2020","April 28, 2020",,"May 12, 2020","ASST FBF Sacco, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT04365517"
989,"NCT04339686","Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.",,"Recruiting","No Results Available","The Gold Standard for Current SARS CoV2 Detection is RT-PCR","Diagnostic Test: Thoracic CT Scan","Diagnostic performance of chest CT in screening for pulmonary lesions in clinical suspicions of COVID.|Compare the diagnostic performance of chest CT and RT-PCR in COVID 19 at the initial consultation (screening).","Poitiers University Hospital","All","18 Years to 100 Years   (Adult, Older Adult)",,"56000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","POWER-COVID_CT","April 20, 2020","September 2020","November 2020","April 9, 2020",,"April 28, 2020","Chu de Poitiers, Poitiers, France",,"https://ClinicalTrials.gov/show/NCT04339686"
990,"NCT04385901","Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth",,"Not yet recruiting","No Results Available","SARS-CoV 2|SARS Pneumonia","Behavioral: Therapy Intervention","Change in 6 Minute Walk Test|Change in Short Form 35 (SF-36) Questionnaire|Change in Strength testing|Change in Peak Flow Meter Test","University of Missouri-Columbia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVID19Recovery","May 19, 2020","April 19, 2022","April 19, 2022","May 13, 2020",,"May 14, 2020","Missouri Orthopedic Institute, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04385901"
991,"NCT04383678","Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome",,"Recruiting","No Results Available","COVID-19|Extracorporeal Membrane Oxygenation Complication|Acute Respiratory Distress Syndrome","Device: Extracorporeal membrane oxygenation","In-hospital mortality|Death on ECMO|Stroke|Blood stream infection|Lung complications requiring surgical treatment|Blood transfusion|Acute kidney injury|Duration of mechanical ventilation|Deep vein thrombosis|Pulmonary embolism|Length of ICU stay|Length of hospital stay|Death after hospital discharge","Helsinki University Central Hospital","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COVID-19 ECMO","March 1, 2020","December 31, 2020","December 31, 2020","May 12, 2020",,"May 21, 2020","Helsinki University Hospital, Helsinki, Finland|University Hospital Jean Minjoz, Besançon, France|Nancy University Hospital, Nancy, France|Henri Mondon Unoversity Hospital, Paris, France|Robert Debré University Hospital, Reims, France|Hamburg University Heart Center, Hamburg, Germany|Münster University Hospital, Münster, Germany|S. Orsola Hospital, Bologna, Italy|Lecco Hospital, Lecco, Italy|Karolinska University Hospital, Stockholm, Sweden|University Hospitals of Leicester, Leicester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04383678"
992,"NCT04339998","Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)",,"Recruiting","No Results Available","Coronavirus Infection|COVID|Covid-19|SARS-CoV-2","Diagnostic Test: Point-of-Care Ultrasonography (POCUS)","POCUS Score - Lungs|POCUS Score - Heart","University of Minnesota","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STUDY00009429","April 15, 2020","October 2020","October 2020","April 9, 2020",,"May 12, 2020","University of Minnesota Medical Center (UMMC), Minneapolis, Minnesota, United States|M Health Fairview Bethesda Hospital, Saint Paul, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04339998"
993,"NCT04345601","Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)",,"Not yet recruiting","No Results Available","Sars-CoV2|Acute Respiratory Distress Syndrome|COVID-19","Genetic: Mesenchymal Stromal Cells","Incidence of unexpected adverse events|Improved oxygen saturations ≥93%|Decrease in oxygen supplementation by non-invasive or invasive interventions|Frequency of progression to mechanical ventilation or ECMO|Duration of mechanical ventilation|Duration of ICU stay|Duration of hospital stay|All-cause mortality at day 28","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-47561 MSC for COVID-19","May 2020","February 2022","February 2022","April 14, 2020",,"April 27, 2020","Houston Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04345601"
994,"NCT04316299","Acute Kidney Injury in Patients Hospitalized With COVID-19",,"Completed","No Results Available","COVID-19|Acute Kidney Injury|Kidney Function",,"Rate of Acute Kidney Injury|Rate of Death|the length of hospital stay","Zhenhua Zen|Nanfang Hospital of Southern Medical University","All","18 Years and older   (Adult, Older Adult)",,"287","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","hkyy2020-005 AKI","February 26, 2020","February 28, 2020","March 8, 2020","March 20, 2020",,"March 30, 2020","Hankou Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04316299"
995,"NCT04350086","Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection","PRODEX","Not yet recruiting","No Results Available","COVID-19 Infection|Sars-cov-2|Respiratory Failure|Palliative Situation","Drug: Treatment with Dexmedetomidine","Efficacy of mild to moderate palliative sedation induced by Dexmedetomidine.|Overall survival of patients on Dexmedetomidine|Daily analgesic effect of Dexmedetomidine|Other sedative pharmacological agents|Average dosage required for Dexmedetomidine to achieve mild to moderate sedation","University Hospital, Limoges","All","18 Years and older   (Adult, Older Adult)","Phase 4","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","87RI20_0011 (PRODEX)","April 20, 2020","November 20, 2020","November 20, 2020","April 16, 2020",,"April 20, 2020","University Hospital, Limoges, France",,"https://ClinicalTrials.gov/show/NCT04350086"
996,"NCT04310865","Yinhu Qingwen Granula for the Treatment of Severe CoVID-19",,"Suspended","No Results Available","COVID-19|Severe Pneumonia|Chinese Medicine","Drug: Yinhu Qingwen Granula|Drug: Yin Hu Qing Wen Granula(low does)|Other: standard medical treatment","changes in the ratio of PaO2 to FiO2 from baseline|PaO2|blood oxygen saturation (SpO2)|clinical status rating on the 7-point ordinal scale|Time to Clinical Improvement (TTCI)|Duration (hours) of non-invasive mechanical ventilation or high-flow nasal catheter oxygen inhalation use|Duration (hours) of invasive mechanical ventilation use|Duration (hours) of extracorporeal membrane oxygenation (ECMO) use|Duration (days) of Oxygen use|The proportion of the patients reporting 2019-nCoV RT-PCR negativity at Day 10 after treatment|The counts/percentage of Lymphocyte|Time to hospital discharge with clinical recovery from the randomisation|The incidence of critical status conversion in 30 days|All-cause mortality within 30 days|Frequency of severe adverse drug events","Zhong Wang|Wuhan Leishenshan Hospital|The First Affiliated Hospital of Dalian Medical University|Tanshan People's Hospital|North China University of Science and Technology Affiliated Hospital|Jizhong Energy Fengfeng Group Hospital|China Academy of Chinese Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","YHQW-Severe-V2.0","November 2020","March 30, 2021","June 30, 2021","March 17, 2020",,"May 11, 2020","Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital, Wuhan, Hubei, China|Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University/Tanshan People's Hospital, Wuhan, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04310865"
997,"NCT04379661","SUNLIGHT Study: Online Support Groups for MS to Address COVID-19",,"Recruiting","No Results Available","MS (Multiple Sclerosis)|COVID-19|Support Groups","Behavioral: Online support Group","Rate of completion|Rate of adherence|Score on the State Trait Anxiety Inventory (STAI)|Score on the Personal Health Questionnaire Depression Scale (PHQ-8)","Columbia University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","AAAS9939","April 3, 2020","April 2021","April 2021","May 7, 2020",,"May 7, 2020","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04379661"
998,"NCT04392232","A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection",,"Recruiting","No Results Available","Coronavirus|COVID-19|Convalescent Plasma","Drug: Convalescent Plasma","Survival Rate","TriHealth Inc.","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-045","May 5, 2020","December 31, 2020","December 31, 2020","May 18, 2020",,"May 20, 2020","Good Samaritan Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04392232"
999,"NCT04387279","The Impact of COVID-19 on the Health Care Utilization of Inflammatory Bowel Disease",,"Recruiting","No Results Available","COVID-19|Perception, Self|Facilities and Services Utilization","Other: Interview","Patient's perception of COVID-19 and medical use patterns|Exacerbation of symptoms","Keimyung University Dongsan Medical Center|Yeungnam University College of Medicine","All","18 Years and older   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2020-04-070","April 24, 2020","March 30, 2021","March 30, 2021","May 13, 2020",,"May 13, 2020","KeimyungUniversity, Daegu, Jung-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04387279"
1000,"NCT04336345","Outcomes of Patients With COVID-19 in the Intensive Care Unit","MexCOVID-19","Recruiting","No Results Available","Coronavirus Infections|COVID-19|Viral Pneumonia Human Coronavirus",,"Hospital mortality|Length of stay in the intensive care unit","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","3336","April 1, 2020","April 30, 2020","May 30, 2020","April 7, 2020",,"April 24, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico|All centres from Mexico willing to contribute are Welcome., Mexico, Mexico",,"https://ClinicalTrials.gov/show/NCT04336345"
1001,"NCT04351854","Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room","ReCovER","Not yet recruiting","No Results Available","Corona Virus Infection|SARS-CoV 2","Other: Retrospective data collection","Identification of risk factors present at the earliest stage of hospital care (i.e. in the ED) that warrant hospital admission.|Determination of the course of the disease (days since onset of symptoms, nature of symptoms, e.g. fever, chills, headache) and the state at which patients present to the ED|Identification of the ratio of patients with mild or moderate to severe disease","University of Cologne","All","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","ReCovER","April 20, 2020","December 31, 2025","August 31, 2026","April 17, 2020",,"April 22, 2020","University Hospital of Cologne, Cologne, Germany",,"https://ClinicalTrials.gov/show/NCT04351854"
1002,"NCT04355728","Use of UC-MSCs for COVID-19 Patients",,"Recruiting","No Results Available","Corona Virus Infection|ARDS|ARDS, Human|Acute Respiratory Distress Syndrome|COVID-19","Biological: Umbilical Cord Mesenchymal Stem Cells|Other: Standard of Care","Incidence of pre-specified infusion associated adverse events|Incidence of Severe Adverse Events|Survival rate after 90 days post first infusion|Ventilator-Free Days|Change in Oxygenation Index (OI)|Plat-PEEP|Sequential Organ Failure Assessment (SOFA) Scores|Small Identification Test (SIT) scores|Troponin I levels|C-Reactive Protein levels|Arachidonic Acid (AA)/Eicosapentaenoic Acid (EPA) Ratio|D-dimer levels|25-Hydroxy Vitamin D levels|Alloantibodies levels|Blood white cell count|Platelets count","Camillo Ricordi|University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","20200370","April 25, 2020","December 31, 2020","May 1, 2021","April 21, 2020",,"April 28, 2020","Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04355728"
1003,"NCT04347226","Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19",,"Recruiting","No Results Available","Solid Tumor|Sars-CoV2|Hematological Malignancy","Drug: BMS-986253","Time to Improvement in the 7-point ordinal scale|Time to Death|Time to Intubation|Proportion of patients requiring ICU admission|Percentage Rate of Mortality at 1 month","Matthew Dallos|Bristol-Myers Squibb|Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","138","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAS9881","April 16, 2020","September 2021","September 2022","April 15, 2020",,"May 1, 2020","Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04347226"
1004,"NCT04378829","Platelet Count, Platelet, Mean Platelet Volume and Platelet Distribution Width in COVID-19",,"Not yet recruiting","No Results Available","Covid-19|Mean Platelet Volume|Platelet Destruction","Diagnostic Test: Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19","Change in PDW and MPV parameters","Konya Training and Research Hospital","All","Child, Adult, Older Adult",,"40","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","COVID-19","May 4, 2020","May 11, 2020","May 13, 2020","May 7, 2020",,"May 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04378829"
1005,"NCT04344327","Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF","CCF","Completed","No Results Available","Infection Viral|Infection, Hospital|COVID",,"Death rate|Transfer to intensive care unit|Ventilation analysis|Construction of a predictive score for COVID-19 severe form","French Cardiology Society|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)",,"2878","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-02","April 10, 2020","April 21, 2020","April 21, 2020","April 14, 2020",,"April 28, 2020","CHU d'Amiens, Amiens, France|CHU Annecy, Annecy, France|CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|Cotentin hospital, Cherbourg, France|CHU Dijon, Dijon, France|Elbeuf Louviers Val de Reuil, Elbeuf, France|CHU de Fréjus / Saint-Raphael, Fréjus, France|Lille Catholic Institute Hospital Group, Lille, Lille, France|CHU de Lyon, Lyon, France|APHM, Marseille, France|Jacques Cartier Private Hospital, Massy, Massy, France|CHR d'Orléans, Orléans, France|Bichat (APHP), Paris, France|Georges Pompidou European Hospital (AP-HP), Paris, France|Institut Mutualiste Montsouris, Paris, Paris, France|CHU de Reims, Reims, France|CHU de Rouen, Rouen, France|CHU Saint Etienne, Saint-Étienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|Saint Gatien hospital, Tours, France|CHU de Nancy, Vandœuvre-lès-Nancy, France",,"https://ClinicalTrials.gov/show/NCT04344327"
1006,"NCT04365764","Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study",,"Recruiting","No Results Available","Covid-19|ARDS|Pneumonia",,"Composite of death and mechanical ventilation|Death|Mechanical ventilation|World Health Organization score","Groupe Hospitalier Pitie-Salpetriere|Centre Hospitalier Intercommunal Robert Ballanger|Centre Hospitalier Intercommunal Montfermeil-Le Raincy|CMC Ambroise Paré","All","Child, Adult, Older Adult",,"400","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","CIC1421-20-06","March 14, 2020","May 31, 2020","December 31, 2020","April 28, 2020",,"May 20, 2020","Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France",,"https://ClinicalTrials.gov/show/NCT04365764"
1007,"NCT04364009","Anakinra for COVID-19 Respiratory Symptoms","ANACONDA","Recruiting","No Results Available","COVID-19 Infection|ANAKINRA Treatment|Optimized Standard of Care (oSOC)","Drug: Anakinra plus oSOC|Drug: oSOC","Treatment success|OMS progression scale (on a 7 point ordinal scale)|Overall survival|Time to ICU admission|Time to ventilatory support|Change in National Early Warning Score (NEW)from baseline to Day 3, Day 10, Day 14 and Day 28|Change in inflammatory parameter|Hospital length of stay|ICU parameter|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Predictors of efficacy of Anakinra","University Hospital, Tours|INSERM CIC-P 1415, University Hospital Center of Tours|Swedish Orphan Biovitrum (SOBI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANACONDA-COVID-19|2020-001734-36|DR200111","April 27, 2020","September 10, 2020","September 24, 2020","April 27, 2020",,"May 14, 2020","CHRU de TOURS, Tours, France",,"https://ClinicalTrials.gov/show/NCT04364009"
1008,"NCT04364737","Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients",,"Recruiting","No Results Available","COVID-19|Coronavirus|Coronavirus Infection","Biological: Convalescent Plasma|Biological: Lactated ringer's solution or sterile saline","Percentage of subjects reporting each severity rating on WHO ordinal scale for clinical improvement","NYU Langone Health|Albert Einstein College of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-00541","April 17, 2020","January 31, 2023","April 30, 2023","April 28, 2020",,"May 7, 2020","Montefiore Medical Center, Bronx, New York, United States|NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04364737"
1009,"NCT04339881","NOsocomial Dissemination Risk of SARS-Cov2","NODS-Cov2","Not yet recruiting","No Results Available","Sars-CoV2",,"Understanding the dissemination of SARS Cov2 in hospital|Optimizing hospital strategies to prevent transmission to caregivers and not infected hospitalized patients with SARSCov2","Assistance Publique - Hôpitaux de Paris","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","APHP200417","April 13, 2020","May 15, 2020","June 15, 2020","April 9, 2020",,"April 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04339881"
1010,"NCT04349982","ICU Trial in Critical Ill COVID‐19 Patients","POINT-C","Recruiting","No Results Available","Risk Factor, Cardiovascular|Covid19|Critical Illness|Course Illness","Diagnostic Test: Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)","ICU CV risk and Biomarker (e.g. Troponin)|CV risk and Outcome during ICU stay","Medical University of Graz","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","250320","April 8, 2020","June 30, 2020","July 31, 2020","April 16, 2020",,"April 16, 2020","Medical University of Graz, Graz, Styria, Austria",,"https://ClinicalTrials.gov/show/NCT04349982"
1011,"NCT04345289","Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia","CCAP","Not yet recruiting","No Results Available","COVID|Corona Virus Infection|Viral Pneumonia","Biological: Convalescent anti-SARS-CoV-2 plasma|Drug: Sarilumab|Drug: Baricitinib|Drug: Hydroxychloroquine|Other: Injective placebo|Other: Oral placebo","All-cause mortality or need of invasive mechanical ventilation|Frequency of adverse events|Frequency of severe adverse events|Time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status|Ventilator-free days|Organ failure-free days|Duration of ICU stay|Mortality rate|Length of hospital stay|Duration of supplemental oxygen","Thomas Benfield|Hvidovre University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","25032020|2020-001367-88","April 20, 2020","June 15, 2021","June 15, 2021","April 14, 2020",,"April 14, 2020","Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Arhus, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Herning Hospital, Herning, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Kolding Hospital, Kolding, Denmark|Odense University Hospital, Odense, Denmark|Roskilde Hospital, Roskilde, Denmark|Vejle Hospital, Vejle, Denmark",,"https://ClinicalTrials.gov/show/NCT04345289"
1012,"NCT04360837","PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients",,"Recruiting","No Results Available","COVID-19|Virus; Pneumonia|Atelectasis","Procedure: alveolar recruitment","Changes in lung compliance|Change in global impedance|Change in recruitability|Gas exchange|Plateau pressure|End expiratory lung impedance (EELI)|Antero-to-posterior ventilation ratio|Center of ventilation|Global inhomogeneity index","Szeged University|Furtwangen University|BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","COVID-19EIT","May 6, 2020","June 1, 2021","June 1, 2021","April 24, 2020",,"May 21, 2020","University of Szeged, Szeged, Hungary",,"https://ClinicalTrials.gov/show/NCT04360837"
1013,"NCT04303507","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting","COPCOV","Recruiting","No Results Available","COVID19|Coronavirus|Acute Respiratory Illnesses","Drug: Chloroquine or Hydroxychloroquine|Drug: Placebo","Number of symptomatic COVID-19 infections|Symptoms severity of COVID-19|Number of asymptomatic cases of COVID-19|Number of symptomatic acute respiratory illnesses|Severity of symptomatic acute respiratory illnesses","University of Oxford","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","40000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","VIR20001","April 29, 2020","April 2021","April 2021","March 11, 2020",,"May 21, 2020","Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT04303507"
1014,"NCT04385121","Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection","Familles-COVID","Not yet recruiting","No Results Available","Covid-19|Stress Disorders, Post-Traumatic|Anxiety|Depression","Other: Questionnary","Existence of a post-intensive care syndrome-family ((combined score of the HAD ( Hospital Anxiety and Dépression scale) and IES-R ( Impact of Event Scale-Revised) questionnaires))","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","7761","May 2020","May 2020","February 2021","May 12, 2020",,"May 12, 2020","Les Hôpitaux Universitaires de Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04385121"
1015,"NCT04355442","Evolution of Facial Trauma During COVID Containment Measures","Traumax","Enrolling by invitation","No Results Available","Maxillofacial Injuries|Skull Fractures|COVID-19","Procedure: Facial fractures reduction or osteosynthesis","evolution of number of maxillofacial trauma|variability in terms of type of trauma|Comparative assessment of types of trauma by the inter-regional variability","University Hospital, Montpellier|Unités de CMF des CHU de Paris (Dr Davrou - Pitié salpetrière)|Amiens (Dr Dapke)|Nantes (Pr Corre)|Toulouse (Pr Lauwers - Purpan)|Marseille (Dr Foletti – La conception)|Nice (Dr Savoldelli)|Clermont Ferrand (Dr Sesque)|Perpignan (Dr Llobet)|Lyon (Dr Bourlet – Croix Rousse)","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL20_0228","April 1, 2020","May 1, 2020","May 30, 2020","April 21, 2020",,"April 30, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04355442"
1016,"NCT04395911","Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections",,"Not yet recruiting","No Results Available","AKI|ARDS|COVID","Device: SCD","Mortality at Day 60|Dialysis Dependency|Ventilation at Day 28|Mortality at Day 28|Urinary output change|P02/FiO2 change|Safety Assessments|SCD Integrity","SeaStar Medical","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","35","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCD-005","June 2020","September 2020","December 2020","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04395911"
1017,"NCT04370015","Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.",,"Not yet recruiting","No Results Available","SARS-CoV-2|Healthcare Workers","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Prevention of SARS-CoV-2 as determined by negative RT-PCR at the end of 12 week study period|Safety as determined by presence or absence of any adverse event related with hydroxychloroquine treatment|Confirmed SARS-CoV-2 infection based on symptoms and confirmed by RT-PCR|Clinical disease severity in confirmed SARS-CoV-2 participants|Incidence of any acute respiratory infection","Services Institute of Medical Sciences, Pakistan","All","18 Years to 60 Years   (Adult)","Not Applicable","374","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","16082019","May 15, 2020","June 30, 2020","October 15, 2020","April 30, 2020",,"May 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04370015"
1018,"NCT04347941","Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE","APPROVE-CARE","Not yet recruiting","No Results Available","ARDS, Human|Mechanical Ventilation Complication|COVID19","Procedure: Prone Positioning|Procedure: Standard of care.","The effect of prone positioning on requirement for invasive mechanical ventilation in patients with COVID 19 induced respiratory failure.|Length of time tolerating prone positioning|PaO2/FiO2 measured before prone positioning|PaO2/FiO2 ratio after 1 hours of prone positioning|SpO2/FiO2 ratio measured before prone positioning|SpO2/FiO2 ratio after 1 hours of prone positioning|Number requiring increase in ventilatory assistance (CPAP+BIPAP+IMV etc)|Work of breathing assessment (Respiratory distress scale)|Changes in bioimpedance measures of lung edema in patients in PP|Use of awake prone positioning as a rescue intervention in control patients","University College Hospital Galway","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APPROVE-CARE-2020","April 11, 2020","March 11, 2021","May 11, 2021","April 15, 2020",,"April 15, 2020","Galway University Hospital, Galway, Ireland",,"https://ClinicalTrials.gov/show/NCT04347941"
1019,"NCT04352699","Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All?",,"Completed","No Results Available","Surgery|Complication of Surgical Procedure|COVID",,"Rate of UCI admission for surgery-related complication|Rate of surgery-specific death|Rate of coronaviruse positive serologies","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20urocovid01","March 15, 2020","April 17, 2020","May 1, 2020","April 20, 2020",,"May 15, 2020","CHU de Nice, Nice, France",,"https://ClinicalTrials.gov/show/NCT04352699"
1020,"NCT04352556","COVID19-hematological Malignancies: the Italian Hematology Alliance",,"Recruiting","No Results Available","SARS-CoV-2 Infection|Hematological Malignancies",,"To evaluate mortality.|To evaluate potential predictive biochemical parameters of mortality.|To evaluate potential predictive HM-related parameters of mortality.|To evaluate COVID severity as predictive parameter of mortality.|Epidemiology of patients with HM infected by SARS-CoV-2with any spectrum of illness severity|Definition of complete clinical picture of COVID-19 in HM|Evolution of HM|To evaluate admission to ICU requiring mechanical ventilation or death per characteristics|Viral dynamics in infected HM patients","Ospedale di Circolo - Fondazione Macchi","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Other","HM-COVID19-Italy","April 7, 2020","April 30, 2021","April 30, 2021","April 20, 2020",,"May 4, 2020","SC Ematologia Ospedale SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|UOC Ematologia, Ospedali Riuniti, Ancona, Italy|UOC Ematologia e Terapia Cellulare, Ospedale Mazzoni, Ascoli Piceno, Italy|SC Oncologia Medica, CRO, Aviano, Italy|SC Ematologia, Policlinico Bari, Bari, Italy|UOC Ematologia, I.R.C.C.S Istituto Tumori Giovanni Paolo II, Bari, Italy|SSD Ematologia, Ospedale degli Infermi, Biella, Italy|UOC Ematologia, Azienda Ospedaliero-Universitaria Policlinico S.Orsola-Malpighi,, Bologna, Italy|Ematologia e Centro Trapianto Midollo Osseo, Ospedale di Bolzano, Bolzano, Italy|UO Ematologia e CTMO, ASST Spedali Civili, Brescia, Italy|UO Ematologia e CTMO, ASST Spedali Civili, Brescia, Italy|UOC Onco-Ematologia ASST Valle Olona, Busto Arsizio, Italy|SC Ematologia e CTMO AZIENDA OSPEDALIERA ""G. BROTZU"" - OSPEDALE ONCOLOGICO BUSINCO, Cagliari, Italy|UOC Ematologia, AOU Policlinico Vittorio Emanuele, Catania, Italy|Ematologia, Ospedale Valduce, Como, Italy|UOC Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy|UO Ematologia e CTMO, ASST Cremona, Cremona, Italy|SC Ematologia Ospedale S. Croce, Cuneo, Italy|UOC, Ematologia Azienda Ospedaliero Universitaria Arcispedale S. Anna, Ferrara, Italy|S.O.D. Ematologia, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|UOC Ematologia, Policlinico Ospedali Riuniti, Foggia, Italy|IRST-IRCC di Meldola, Forlì, Italy|UO Ematologia, Ospedale Policlinico S.Martino IRCCS, Genova, Italy|UO Ematologia, Ospedale Policlinico San Martino, Genova, Italy|UOC di Ematologia e Trapianto di Cellule Staminali, P.O. Vito Fazzi, Lecce, Italy|UOC di Ematologia, Ospedale di Legnano, Legnano, Italy|UO Dipartimento di Ematologia, USL 6, Livorno, Italy|UOC Oncologia ASST Lodi, Lodi, Italy|UOC Ematologia Azienda Ospedaliera Universitaria ""G.Martino"", Messina, Italy|UO Ematologia, Ospedale dell'Angelo di Mestre, Mestre, Italy|Ematologia, IEO, Milano, Italy|SC Ematologia, Istituto Nazionale dei Tumori, Milano, Italy|SC Ematologia, Ospedale Niguarda, Milano, Italy|UO Ematologia, IRCCS Ospedale San Raffaele, Milano, Italy|UO Servizio di Ematologia e Medicina Trasfusionale, Ospedale Luigi Sacco, Milano, Italy|UOC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|UO Ematologia Policlinico di Modena, Modena, Italy|UOC Ematologia, Ospedale S. Gerardo, Monza, Italy|SC Ematologia Istituto Nazionale Tumori - IRCCS ""Fondazione G. Pascale"",, Napoli, Italy|UOC Ematologia e Trapianti di Midollo, AOU Federico II, Napoli, Italy|UOC Ematologia, Ospedale Antonio Cardarelli, Napoli, Italy|UOC Ematologia, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy|Ospedale san Luigi Gonzaga, Orbassano, Italy|Ematologia Azienda Ospedaliera di Padova, Padova, Italy|UO Ematologia, Policlinico Paolo Giaccone, Palermo, Italy|UOC Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy|SC Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|SC Ematologia e Trapianto di Midollo Osseo, Azienda Ospedaliera di Perugia, Perugia, Italy|UO Ematologia e CTMO, Azienda Ospedaliera Ospedali Riuniti, Pesaro, Italy|UOC di Ematologia, Ospedale Civile Spirito Santo, Pescara, Italy|UO Ematologia e CTMO, Presidio Ospedaliero di Piacenza, Piacenza, Italy|UO Ematologia, AOU Pisana- Santa Chiara, Pisa, Italy|UO Ematologia dell'Ospedale Santa Maria delle Croci, Ravenna, Italy|UOC Ematologia, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|SC Ematologia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|UO Ematologia, Ospedale Infermi, Rimini, Italy|AOU Azienda Ospedaliera Universitaria Sant'Andrea, Roma, Italy|IFO - Ematologia e Trapianto Cellule -Istituto Nazionale del Cancro di Regina Elena, Roma, Italy|SC Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy|UO Ematologia e Trapianti di Cellule Staminali, A.O. S. Camillo-Forlanini, Roma, Italy|UO Ematologia, Policlinico Tor Vergata, Roma, Italy|UOC Ematologia e trapianto di cellule staminali, Policlinico Universitario Campus Bio-Medico, Roma, Italy|UOC Ematologia Policlinico Umberto I, Roma, Italy|UOC Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy|UOC Ematologia- Azienda Ospedaliera San Giovanni Addolorata, Roma, Italy|UO Ematologia, Istituto Clinico Humanitas, Rozzano, Italy|UOC Ematologia e centro trapianti cellule staminali emopoietiche, AOU San Giovanni Di Dio e Ruggi D'aragona, Salerno, Italy|Ematologia ASL Imperiese, Sanremo, Italy|Medicina Interna ed Ematologia, Asl 1, Savona, Italy|UOC Ematologia, Policlinico Santa Maria alle Scotte, Siena, Italy|UOC Ematologia e Trapianto Midollo Osseo, Ospedale S. G. Moscati, Taranto, Italy|SCDU Ematologia e terapie cellulari, Ospedale Mauriziano Umberto I, Torino, Italy|UO Ematologia, Ospedale Universitario Molinette San Giovanni Battista, Torino, Italy|UO Ematologia, Ospedale Universitario Molinette San Giovanni Battista, Torino, Italy|UO Ematologia, Ospedale Civili Ca' Foncello, Treviso, Italy|SC Ematologia, Azienda sanitaria universitaria Giuliano Isontina, Trieste, Italy|Clinica Ematologia, Azienda Ospedaliera-Universitaria Santa Maria della Misericordia, Udine, Italy|UOC Ematologia, ASST Sette Laghi, Osp. Di Circolo e Fondazione Macchi, Varese, Italy|UOC Ematologia, Azienda Ospedaliera Integrata di Verona, Verona, Italy|UOC Ematologia, Azienda Ospedaliera Integrata di Verona, Verona, Italy|UOC Ematologia, Ospedale San Bortolo, Vicenza, Italy",,"https://ClinicalTrials.gov/show/NCT04352556"
1021,"NCT04379492","A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19",,"Recruiting","No Results Available","COVID-19|COVID19|Sars-CoV2|SARS-Cov-2","Drug: Hydroxychloroquine|Other: Placebo","Clinical improvement on the Ordinal Scale for Clinical Improvement (OSCI)|Number of participants requiring mechanical ventilation for respiratory failure","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-187","May 5, 2020","May 2021","May 2021","May 7, 2020",,"May 12, 2020","Memorial Sloan - Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04379492"
1022,"NCT04330495","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection",,"Not yet recruiting","No Results Available","COVID 19|Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors","Drug: Hidroxicloroquina|Drug: Control group","Incidence rate of new COVID-19 cases in both arms|Prevalence of COVID-19 cases in both arms|Mortality rate secondary to COVID-19 cases in both groups|Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups|Adverse events","Instituto de Investigación Marqués de Valdecilla","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","EnCOVID-HidroxiCLOROQUINA","April 6, 2020","November 6, 2020","November 6, 2020","April 1, 2020",,"April 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04330495"
1023,"NCT04388514","Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure","CORMOR","Recruiting","No Results Available","SARS-CoV-2 Respiratory Failure","Procedure: Medical Ozone procedure","Time of respiratory improvement and earlier weaning from oxygen support|The time of respiratory improvement and earlier weaning from oxygen support|Assessment of the length of hospitalization|Assessment of the length of Intensive Care Unit (ICU) stay|Improvment in chest imaging finding|Improvment in cytokine release syndrome","Azienda Sanitaria-Universitaria Integrata di Udine|Fondazione Toscana Gabriele Monasterio|Policlinico Militare, Roma - Italy|Ospedale San Liberatore di Atri|Ospedale Umberto I di Torino|Università di Siena|Ospedale Civile di Lucca|Ospedale di Siracusa|Azienda Sanitaria Locale di Vercelli","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","CIG: Z7C2CA5837","April 8, 2020","October 8, 2020","October 8, 2020","May 14, 2020",,"May 14, 2020","Dott. Amato De Monte, Udine, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04388514/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04388514"
1024,"NCT04334876","Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers","COVID-Antibody","Not yet recruiting","No Results Available","SARS-CoV-2","Diagnostic Test: SARS-CoV-2 IgG Antibody Testing Kit","Validation of SARS-CoV-2 IgG Antibody Test|Incidence of Seroconversion|Identify Candidacy","Indiana University","All","18 Years and older   (Adult, Older Adult)",,"340","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","2003973826","April 1, 2020","November 1, 2020","January 1, 2021","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04334876"
1025,"NCT04397588","Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19","ECMO-SARS","Recruiting","No Results Available","ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2|Acute Refractory Heart Failure Related to SARS-CoV 2",,"Hospital mortality|Mortality Day 28|Mortality Day 90|Ventilator-free days|Intensive care unit-free days|Hospital-free days","Rennes University Hospital","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","35RC20_8979 ECMO-SARS","April 21, 2020","October 21, 2020","October 21, 2020","May 21, 2020",,"May 21, 2020","Angers University Hospital, Angers, France|Besançon Hospital, Besançon, France|Brest university Hospital, Brest, France|Caen University Hospital, Caen, France|Clermont ferrand University hospital, Clermont-Ferrand, France|APHP Henri Mondor Paris University Hospital, Créteil, France|Dijon University Hospital, Dijon, France|Vendée Hospital, La Roche-sur-Yon, France|Grenoble University Hospital, La Tronche, France|APHP Kremli Bicetre Paris University Hospital, Le Kremlin-Bicêtre, France|Marie Lannelongue Hospital, Le Plessis-Robinson, France|Lens Hospital, Lens, France|Lille University Hospital, Lille, France|Limoges University Hospital, Limoges, France|Clinique de la Sauvegarde, Lyon, France|Lyon University Hospital, Lyon, France|Marseille Européen Hospital, Marseille, France|APHM la Timone- Marseille University Hospital, Marseille, France|Metz University Hospital, Metz, France|Montpellier University Hospital, Montpellier, France|Emile Muller Hospital, Mulhouse, France|Nancy University Hospital, Nancy, France|Nantes University Hospital, Nantes, France|Ambroise Paré Hospital, Neuilly-sur-Seine, France|Nimes University Hospital, Nimes, France|Institut Mutualiste Montsouris, Paris, France|APHP Hopital Européen Georges Pompidou - Paris University Hospital, Paris, France|APHP necker Paris University Hospital, Paris, France|APHP Bichat - Paris University Hospital, Paris, France|Bordeaux University Hospital, Pessac, France|Poitiers University hospital, Poitiers, France|Reims University hospital, Reims, France|Rennes University hospital, Rennes, France|Rouen University Hospital, Rouen, France|Saint brieuc Hospital, Saint brieuc, France|La Réunion University Hospital, Saint-Denis, France|Saint Etienne University Hospital, Saint-Étienne, France|Strasbourg University Hospital, Strasbourg, France|Toulouse University Hospital - Rangueil Hospital, Toulouse, France|Tours University Hospital, Tours, France|Bretagne Atlantique Hospital, Vannes, France",,"https://ClinicalTrials.gov/show/NCT04397588"
1026,"NCT04376840","Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia",,"Not yet recruiting","No Results Available","Severe SARS-CoV2 Pneumonia","Other: Blood sample and data record","medium-term respiratory complications|long-term respiratory complications","CHU de Reims","All","18 Years and older   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PO20066","May 15, 2020","January 15, 2021","October 15, 2021","May 6, 2020",,"May 6, 2020","Damien JOLLY, Reims, France",,"https://ClinicalTrials.gov/show/NCT04376840"
1027,"NCT04375410","Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic",,"Enrolling by invitation","No Results Available","Hand Eczema|Hand Dermatitis|Covid19",,"Dermal reaction to frequent hand wash and disinfection in children","Vendsyssel Hospital|Aalborg University Hospital","All","up to 13 Years   (Child)",,"7000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","SH042020","April 22, 2020","April 30, 2020","May 1, 2020","May 5, 2020",,"May 5, 2020","Tine Caroc Warner, Hjørring, Nordjylland, Denmark",,"https://ClinicalTrials.gov/show/NCT04375410"
1028,"NCT04381338","Rehabilitation for People With COVID-19 in ICU","COVID_REHAB","Not yet recruiting","No Results Available","Corona Virus Disease 19 (COVID-19)|COVID|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Critical Illness","Other: Pulmonary and Motor Rehabilitation","Length of ICU stay|Length of hospital stay","University of Padova|Prof. S Masiero, University of Padova, Italy|Dr. A. Venturin, General Hosipital, Padova, Italy|Dr. I. Tiberio, General Hospital, Padova, Italy|Dr. D. Zampieri, University of Padova, Italy|Dr.ssa M Cattelan, University of Padova, Italy|Prof. P. Zanatta, University Hosiptal, Verona, Italy|Dr.ssa C. Carollo, General Hospital, Padova, Italy|Prof. E. Polati, University Hospital, Verona, Italy|Prof. K. Donadello, University Hospital, Verona, Italy","All","18 Years and older   (Adult, Older Adult)","Not Applicable","92","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPadova_1","May 10, 2020","September 30, 2020","September 30, 2020","May 8, 2020",,"May 8, 2020","Teaching Hospital, University of Padova, Padova, Italy|Teaching Hospital, University of Verona, Verona, Italy",,"https://ClinicalTrials.gov/show/NCT04381338"
1029,"NCT04273763","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)",,"Active, not recruiting","No Results Available","Novel Coronavirus Pneumonia|2019-nCoV","Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon α2b Spray","Time to clinical recovery after treatment|Rate of aggravation|Clinical remission rate|Dynamic changes of oxygenation index|Time to cure|rate to cure|Time to defervescence|Time to cough remission|Time to dyspnea remission|Days of supplemental oxygenation|Rate of patients with requring supplemental oxygen|Rate of patients with mechanical ventilation|Time of negative COVID-19 nucleic acid results|Rate of negative COVID-19 nucleic acid results|Rate of ICU admission|28-day mortality","Second Affiliated Hospital of Wenzhou Medical University|WanBangDe Pharmaceutical Group Co.,Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019NCP1.0","February 16, 2020","May 10, 2020","June 1, 2020","February 18, 2020",,"May 1, 2020","The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04273763"
1030,"NCT04354441","Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women","HyPreC","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2|Pregnant Women|Hydroxychloroquine","Drug: hydroxychloroquine sulfate 200 MG|Drug: Placebo oral tablet","COVID-19-related hospital admissions|Symptoms related to COVID-19 infection|Adverse Events|Maternal outcomes|Newborn outcomes","Sir Mortimer B. Davis - Jewish General Hospital","Female","18 Years to 50 Years   (Adult)","Phase 2","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1, March 30, 2020","May 2020","November 2020","November 2020","April 21, 2020",,"April 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04354441"
1031,"NCT04337424","Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2","EasyCoV","Recruiting","No Results Available","SARS-CoV-2","Diagnostic Test: Sampling salivary","Specific detection of SARS-CoV-2 specific RNA|Analytical sensitivity of the LAMP test.|The correlation between the measurement of the assayed viral load (CT value) by the standard method and by the LAMP developed by SYS2DIAG / SKILLCELL.|Evaluation of the use of saliva samples compared to nasopharyngeal samples","University Hospital, Montpellier|SkillCell|Sys2Diag (CNRS-Alcediag UMR9005)","All","18 Years to 90 Years   (Adult, Older Adult)",,"180","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","RECHMPL20_0170","April 13, 2020","July 13, 2020","July 20, 2020","April 7, 2020",,"April 30, 2020","UCH Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04337424"
1032,"NCT04320017","Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19","JOCOVID","Recruiting","No Results Available","COVID-19|Myocardial Injury|Myocarditis","Diagnostic Test: Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care","Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay|Description of cardiovascular outcomes in the cohort|Prognosis role of baseline cardio-vascular caracteristics on patients survival|Prediction of cardio-vascular events with baseline characteristics|Characterization of inflammation on cardio-vascular outcomes|Prognosis role of baseline clinico-biological caracteristics on patients transfer to ICU and survival","Groupe Hospitalier Pitie-Salpetriere","All","16 Years and older   (Child, Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIC1421-20-05","March 20, 2020","May 20, 2020","May 20, 2020","March 24, 2020",,"April 22, 2020","Clinical Investigation Center Pitié-Salpêtrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04320017"
1033,"NCT04370119","Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers","SeCo","Recruiting","No Results Available","SARS-Cov-2","Diagnostic Test: Nasal swab|Diagnostic Test: Serum testing","Number of people with detectable antibodies to SARS-COV2|Number of people with detectable SARS-COV2 nucleic acid","University Medicine Greifswald|Friedrich Loefler Institute for Animal Health|EUROIMMUN AG","All","18 Years and older   (Adult, Older Adult)",,"4000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BB 068/20","April 27, 2020","May 2021","May 2025","April 30, 2020",,"April 30, 2020","Greifswald University Medicine, Greifswald, Germany",,"https://ClinicalTrials.gov/show/NCT04370119"
1034,"NCT04376476","Host-pathogen Interactions During SARS-CoV-2 Infection","HPI-COVID-19","Recruiting","No Results Available","Infection, Coronavirus|Severe Acute Respiratory Syndrome Coronavirus 2","Biological: Blood sample|Biological: Low or upper respiratory tract sample|Biological: Stool collection or fecal swab|Genetic: Blood sample for whole genome sequencing|Other: phone call","Initial biological profile of children and adults with COVID-19 infection|Initial immunological profile of children and adults with COVID-19 infection|Clinical worsening|Evolution of the immunological profile of children and adults with COVID-19|Nasopharyngeal swabs SARS-CoV-2 viral loads of children and adults with COVID-19|titers in specific Immunoglobulin G (IgG) antibodies of children and adults with COVID-19|titers in specific Immunoglobulin M (IgM) antibodies of children and adults with COVID-19|titers in specific Immunoglobulin G (IgM) antibodies of children and adults with COVID-19|Genetic profile of adults with COVID-19 infection","Hospices Civils de Lyon","All","up to 70 Years   (Child, Adult, Older Adult)","Not Applicable","450","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","69HCL20_0342|2020-A01102-37","May 5, 2020","June 5, 2021","June 5, 2021","May 6, 2020",,"May 8, 2020","Groupement Hospitalier Nord-Daupine, Bourgoin-Jallieu, France|Hôpital femme-mère-enfant, Bron, France|Hôpital Louis Pradel, Bron, France|Hôpital Louis Mourier, Colombes, France|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France|Hopital de la Croix-Rousse, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpital mère - enfant Nantes, Nantes, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|Hôpital Nord de Saint Etienne, Saint-Priest-en-Jarez, France|Hôpital Nord-Ouest, Villefranche-sur-Saône, France|Centre Hospitalier D'Annecy-Genevois, Épagny, France",,"https://ClinicalTrials.gov/show/NCT04376476"
1035,"NCT04355429","Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)","CAPTOCOVID","Not yet recruiting","No Results Available","Pneumonia|Coronavirus Infection|COVID-19","Drug: captopril 25mg","Efficacy of captopril nebulization addition to standard of care compared to standard of care.","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200410","May 5, 2020","July 2020","August 2020","April 21, 2020",,"April 28, 2020","CH Victor Dupuy- Argenteuil, Argenteuil, France|Hôpital Avicenne,, Bobigny, France|Hôpital Avicenne, Bobigny, France|Hôpital Avicenne, Bobigny, France|Hôpital Antoine Béclère, Clamart, France|CH de Compiègne-Noyon, Compiègne, France|Groupe hospitalier Sud Ile de France, Melun, France|Hôpital de la Pitié- Salpêtrière, Paris, France|Hôpital Tenon, Paris, France|CHRU de Tours, Hôpital Bretonneau, Tours, France|Hôpital de Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT04355429"
1036,"NCT04353609","Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases","covid19 fai2r","Recruiting","No Results Available","Sars-CoV2|Chronic Inflammatory Rheumatism|Autoimmune Diseases",,"Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death|Proportion of patients who die from a severe form of covid-19|Proportion of patients who present an history of diabetes according to medical records|Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2)|Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records|Proportion of patients who present an history of Asthma according to medical records|Proportion of patients who present an history of Hypertension according to medical records|Proportion of patients who present an history of cardiac disease according to medical records|Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records|Proportion of patients who present an history of stroke according to medical records|Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records|Proportion of patients who present an history of cancer according to medical records","University Hospital, Lille|FAI²R (Auto-immune and auto-inflammatory rare diseases French network)","All","Child, Adult, Older Adult",,"13770","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","NI_2020_03","April 18, 2020","December 2020","December 2020","April 20, 2020",,"April 22, 2020","Hôpital Huriez, Lille, France",,"https://ClinicalTrials.gov/show/NCT04353609"
1037,"NCT04391829","Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males","COVIDSPERM","Not yet recruiting","No Results Available","COVID-19|Sars-CoV2|Corona Virus Infection|Semen","Diagnostic Test: Ejaculated semen sample","detection of SARS-CoV-2 in the semen|duration of SARS-CoV-2 presence in semen|semen viscosity|semen volume|semen pH|Sperm motility|Sperm morphology|Sperm density","Universitair Ziekenhuis Brussel","Male","18 Years to 50 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","COVIDSPERM","May 12, 2020","July 15, 2020","August 31, 2020","May 18, 2020",,"May 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04391829"
1038,"NCT04321265","Outcomes and Prognostic Factors in COVID-19","COVIP","Recruiting","No Results Available","COVID-19|Elderly Patients|Critical Illness|Survival|Old Age",,"Survival|Fragilty","Heinrich-Heine University, Duesseldorf","All","70 Years and older   (Older Adult)",,"4000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-004","March 19, 2020","September 2020","December 2020","March 25, 2020",,"April 8, 2020","Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark|Hôpitaux de Paris, Hôpital Saint-Antoine, service de réanimation médicale, Paris, France|INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France|Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France|Division of Cardiology, Pulmonary Disease and Vascular Medicine, Duesseldorf, Germany|Department of Anaestesia and Intensive Care, Haukeland University Hospital, Bergen, Norway|Department of Clinical Medecine,University of Bergen, Bergen, Norway",,"https://ClinicalTrials.gov/show/NCT04321265"
1039,"NCT04378244","CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19","CORONA","Not yet recruiting","No Results Available","COVID-19|Cytokine Storm|Acute Respiratory Distress Syndrome","Drug: DeltaRex-G","Maximum Tolerated Dose|Survival|Hospital Stay|Ventilator Therapy|Intensive Care Unit Stay|Cytokine Pattern","Aveni Foundation","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AF20-203","June 12, 2020","January 12, 2021","March 12, 2021","May 7, 2020",,"May 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04378244"
1040,"NCT04346277","Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)",,"Available","No Results Available","COVID|ARDS, Human|Ards|Sars-CoV2","Biological: IC14, a monoclonal antibody against CD14",,"Implicit Bioscience","All","18 Years to 70 Years   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population",,"COV02",,,,"April 15, 2020",,"April 16, 2020","IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04346277"
1041,"NCT04261426","The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia",,"Not yet recruiting","No Results Available","2019-nCoV","Drug: Intravenous Immunoglobulin|Other: Standard care","Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of Adverse Drug Events|Frequency of Serious Adverse Drug Events","Peking Union Medical College Hospital|Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IVIG-001","February 10, 2020","April 30, 2020","June 30, 2020","February 7, 2020",,"February 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04261426"
1042,"NCT04388618","Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia",,"Not yet recruiting","No Results Available","Anosmia|Ageusia|Covid19|Corona Virus Infection","Other: NHANES smell and taste tests","correlation of anosmia and ageusia to covid19 positive patients|objective assessment of severity of smell and taste senses alterations in covid19 patients","Princess Nourah Bint Abdulrahman University","All","12 Years to 65 Years   (Child, Adult, Older Adult)",,"250","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","H-01-R-059","June 1, 2020","October 31, 2020","December 31, 2020","May 14, 2020",,"May 21, 2020","Princess Nourah Bint Abdulrahman Univeristy, Riyadh, Central, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04388618"
1043,"NCT04336215","Rutgers COVID-19 Cohort Study",,"Recruiting","No Results Available","Coronavirus|SARS-CoV-2","Other: Non-Interventional","Prevalence|Incidence","Rutgers, The State University of New Jersey","All","20 Years and older   (Adult, Older Adult)",,"750","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020000679","April 7, 2020","September 1, 2020","October 21, 2021","April 7, 2020",,"April 15, 2020","Clinical Research Center Rutgers-Robert Wood Johnson Medical School RWJUH East Tower -, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Clinical Research Unit Rutgers New Jersey Medical School, Newark, New Jersey, United States|Rutgers School of Dental Medicine, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey, United States|RUCDR Infinite Biologics, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04336215"
1044,"NCT04327206","BCG Vaccination to Protect Healthcare Workers Against COVID-19","BRACE","Recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19)|Respiratory Illness|Corona Virus Infection|COVID-19","Drug: BCG Vaccine|Drug: 0.9%NaCl","COVID-19 disease incidence|Severe COVID-19 disease incidence|COVID-19 incidence by 12 months|Severe COVID-19 incidence by 12 months|Time to first symptom of COVID-19|Episodes of COVID-19|Asymptomatic SARS-CoV-2 infection|Work absenteeism due to COVID-19|Bed confinement due to COVID-19|Symptom duration of COVID-19|SARS-CoV-2 pneumonia|Oxygen therapy with SARS-CoV-2|Critical care admissions with SARS-CoV-2|Critical care admission duration with SARS-CoV-2|Mechanical ventilation with SARS-CoV-2|Mechanical ventilation duration with SARS-CoV-2|Hospitalisation duration with COVID-19|Mortality with SARS-CoV-2|Fever or respiratory illness|Episodes of fever or respiratory illness|Work absenteeism due to fever or respiratory illness|Bed confinement due to fever or respiratory illness|Symptom duration of fever or respiratory illness|Pneumonia|Oxygen therapy|Critical care admissions|Mechanical ventilation|Mortality|Hospitalisation duration with fever or respiratory illness|Unplanned work absenteeism|Hospitalisation cost to treat COVID-19|Local and systemic adverse events to BCG vaccination in healthcare workers","Murdoch Childrens Research Institute|Royal Children's Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","10078","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","62586","March 30, 2020","October 30, 2020","March 30, 2022","March 31, 2020",,"May 19, 2020","Royal Adelaide Hospital, Adelaide, South Australia, Australia|South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia|Women's and Children's Hospital, North Adelaide, South Australia, Australia|Epworth Victoria Parade, Melbourne, Victoria, Australia|Royal Children's Hospital, Melbourne, Victoria, Australia|Epworth Richmond, Melbourne, Victoria, Australia|Epworth Eastern, Melbourne, Victoria, Australia|Monash Health- Monash Medical Centre, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Perth Children's Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT04327206"
1045,"NCT04342728","Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation","COVIDAtoZ","Enrolling by invitation","No Results Available","COVID|Corona Virus Infection","Dietary Supplement: Ascorbic Acid|Dietary Supplement: Zinc Gluconate|Dietary Supplement: Ascorbic Acid and Zinc Gluconate|Other: Standard of Care","Symptom Reduction|Symptom Resolution: Fever|Symptom Resolution: Cough|Symptom Resolution: Shortness of Breath|Symptom Resolution: Fatigue|Day 5 Symptoms|Hospitalizations|Severity of Symptoms|Adjunctive Medications|Supplementation Side Effects","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","520","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB 20-361","April 8, 2020","December 30, 2020","April 30, 2021","April 13, 2020",,"May 14, 2020","Cleveland Clinic, Weston, Florida, United States|Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04342728"
1046,"NCT04255017","A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia",,"Recruiting","No Results Available","2019-nCoV","Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir","Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery|Rate of undetectable viral RNA","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TJ20200128","February 1, 2020","June 1, 2020","July 1, 2020","February 5, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04255017"
1047,"NCT04382040","A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",,"Recruiting","No Results Available","COVID-19|Corona Virus Infection|SARS-CoV 2|Coronavirus|Coronavirus Infection","Drug: ArtemiC|Drug: Placebo","Time to clinical improvement, defined as a national Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours in comparison to routine treatment|Percentage of participants with definite or probable drug related adverse events|Time to negative COVID-19 PCR|Proportion of participants with normalization of fever and oxygen saturation through day 14 since onset of symptoms|COVID-19 related survival|Incidence and duration of mechanical ventilation|Incidence of Intensive Care Init (ICU) stay|Duration of ICU stay|Duration of time on supplemental oxygen","MGC Pharmaceuticals d.o.o","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MGC-006","May 8, 2020","July 31, 2020","July 31, 2020","May 11, 2020",,"May 15, 2020","Hillel Yaffe Medical Center, Hadera, Haifa, Israel|Nazareth Hospital EMMS, Nazareth, North, Israel",,"https://ClinicalTrials.gov/show/NCT04382040"
1048,"NCT04334512","A Study of Quintuple Therapy to Treat COVID-19 Infection","HAZDpaC","Not yet recruiting","No Results Available","COVID-19|Corona Virus Infection|Coronavirus-19|Sars-CoV2","Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy|Reduction or Progression of Symptomatic Days|Assess the safety of Quintuple Therapy|Assess the safety of Quintuple Therapy via pulse|Assess the safety of Quintuple Therapy via oxygen saturation|Assess the safety of Quintuple Therapy via EKG|Assess Tolerability of Quintuple Therapy","ProgenaBiome","All","18 Years and older   (Adult, Older Adult)","Phase 2","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRG-044","May 2020","May 2021","August 2021","April 6, 2020",,"May 12, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04334512"
1049,"NCT04388657","COVID-19, bLOod Coagulation and Thrombosis","CLOT","Recruiting","No Results Available","COVID|Embolism and Thrombosis|Pneumonia, Viral","Diagnostic Test: Echo-Doppler","percentage of patients with one or more DVTs.","Ramsay Générale de Santé|Hôpital Privé Jacques Cartier, service réanimation Dr Bougouin","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A00","May 1, 2020","September 1, 2020","September 1, 2020","May 14, 2020",,"May 14, 2020","Hôpital Ambroise Paré, Boulogne-Billancourt, IDF, France|Hôpital Privé Jacques Cartier, Massy, IDF, France|Centre Cardiologique du Nord, Saint-Denis, IDF, France",,"https://ClinicalTrials.gov/show/NCT04388657"
1050,"NCT04254874","A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia",,"Recruiting","No Results Available","2019-nCoV","Drug: Abidol hydrochloride|Drug: Abidol Hydrochloride combined with Interferon atomization","Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery|Rate of undetectable viral RNA","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TJ20200131","February 1, 2020","June 1, 2020","July 1, 2020","February 5, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04254874"
1051,"NCT04362995","St. Jude Tracking of Viral and Host Factors Associated With COVID-19",,"Recruiting","No Results Available","COVID-19|Coronavirus Infection|Coronavirus|SARS-CoV-2",,"Proportion of asymptomatic subjects|Positive CD4 and CD8 cell epitope positive response|Proportion of seroprevalence|T-cell response","St. Jude Children's Research Hospital","All","18 Years and older   (Adult, Older Adult)",,"1517","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SJTRC","April 23, 2020","April 20, 2021","March 20, 2025","April 27, 2020",,"May 25, 2020","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04362995"
1052,"NCT04328961","Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)",,"Recruiting","No Results Available","COVID-19|Corona Virus Infection|SARS (Severe Acute Respiratory Syndrome)|SARS-CoV-2","Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid","Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection|Rate of participant-reported adverse events|Incidence rates of COVID-19 through study completion","University of Washington|Bill and Melinda Gates Foundation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","2000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","STUDY00009750|INV-016204","March 31, 2020","September 30, 2020","October 31, 2020","April 1, 2020",,"May 14, 2020","University of California Los Angeles, Los Angeles, California, United States|Tulane, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04328961"
1053,"NCT04366089","Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora","PROBIOZOVID","Recruiting","No Results Available","COVID|SARS-CoV 2|Pneumonia, Viral|Coronavirus Infection","Other: Oxygen-ozone therapy, probiotic supplementation and Standard of care|Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine","Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital|delta in the value of interleukin (IL)-1|delta in the value of IL-6|delta in the value of IL-10|delta in the value of Tumor Necrosis Factor (TNF)-alpha|delta in the value of cluster of differentiation (CD)4+ CD38/ Human Leukocyte Antigen-DR isotype (HLA-DR)|delta in the value of CD8+ CD38/ HLA-DR|delta in the value of fecal calprotectin|delta in the value of lipopolysaccharide (LPS)|delta in the value of zonulin|delta in the value of alpha1-antitrypsin","Roberto Poscia MD, PhD|Azienda Policlinico Umberto I","All","18 Years and older   (Adult, Older Adult)","Phase 2","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","110/2020","March 26, 2020","October 30, 2020","December 31, 2020","April 28, 2020",,"April 28, 2020","Francesco Pugliese, Rome, RM, Italy",,"https://ClinicalTrials.gov/show/NCT04366089"
1054,"NCT04346212","Oropharyngeal Dysphagia in Patients With COVID-19",,"Recruiting","No Results Available","Oropharyngeal Dysphagia|COVID-19|Sars-CoV2|Nutrition","Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)","Prevalence of oropharyngeal dysphagia|Swallowing screening|Swallowing status.|Nutritonal status of study patient's.|Needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation).|Needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation).|Clinical complications at 6 months follow up from patient's medical history (incidence of readmissions).|Clinical complications at 6 months follow up from patient's medical history (prevalence of readmissions).|Clinical complications at 6 months follow up from patient's medical history (number of visits to emergency department).|Clinical complications at 6 months follow up from patient's medical history (percentage of visits to emergency department).|Clinical complications at 6 months follow up from patient's medical history (respiratory complications).|Clinical complications at 6 months follow up from patient's medical history (mortality).","Hospital de Mataró|Centro Investigación Biomédica en Red de Enfermedades Hepáticas Digestivas","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID_OD","April 14, 2020","July 2020","August 2020","April 15, 2020",,"April 22, 2020","Consorci Sanitari del Maresme (Hospital de Mataró), Mataró, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04346212"
1055,"NCT04381923","COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia","COVIDNOCHE","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|Hypoxemic Respiratory Failure|Pneumonia, Viral|COVID","Device: Helmet Continuous Positive Airway Pressure (CPAP)|Device: High Flow Nasal Oxygen (HFNO)","Ventilator-Free Days (VFD)|ICU and Hospital Length of Stay|Intubation|Renal Replacement Therapy (RRT)|Mortality|Dyspnea","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","843124","May 2020","August 2020","October 2020","May 11, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04381923"
1056,"NCT04394078","Impact of Covid-19 Pandemic on Depression and Quality of Life",,"Enrolling by invitation","No Results Available","Depression|Quality of Life|Covid 19|Social Isolation","Other: Online survey","Sociodemographic information form|Zung Depression Scale|World Health Organization Quality of Life - Bref","Okan University|Yuksek Ihtisas University","All","15 Years to 65 Years   (Child, Adult, Older Adult)",,"500","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","56665618-204.01.07","May 6, 2020","May 18, 2020","May 18, 2020","May 19, 2020",,"May 21, 2020","Okan University, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04394078"
1057,"NCT04378881","Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations",,"Not yet recruiting","No Results Available","COVID|Drug Effect|Drug Interaction|Adverse Drug Event",,"To determine the Medication Risk Score of de-identified participants from Medicare/Medicaid and commercial health insurance plans using their current drug regimen.|To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.|To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.|To assess and compare the effects of various repurposed drugs for COVID-19 on each of the five factors computed by algorithms to derive the Medication Risk Score.|To compare the Medication Risk Score and the effects of the addition of repurposed drugs on the drug regimen between participants with Medicare/Medicaid vs. commercial health insurance plans.|To explore the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used and the impact of various covariables.","Tabula Rasa HealthCare|Cambia Health Solutions","All","18 Years and older   (Adult, Older Adult)",,"100","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COVID19-TRHC-2020-002","May 5, 2020","November 30, 2020","April 30, 2021","May 7, 2020",,"May 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04378881"
1058,"NCT04339712","Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction","ESCAPE","Recruiting","No Results Available","COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection","Drug: Anakinra|Drug: Tocilizumab","Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function","Hellenic Institute for the Study of Sepsis","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ESCAPE|2020-001039-29","April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",,"April 22, 2020","2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece|Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece|Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece|4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece|Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece|Intensive Care Unit, ""Latsio"", Thriasio Elefsis General Hospital, Elefsína, Greece|Intensive Care Unit, ""Koutlimbaneio & Triantafylleio"" Larissa General Hospital, Larissa, Greece|Department of Internal Medicine, Larissa University Hospital, Larissa, Greece|Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece|Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT04339712"
1059,"NCT04361448","Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR",,"Not yet recruiting","No Results Available","Covid-19|SARS-CoV-2|Diagnosis|Polymerase Chain Reaction","Other: samling of oropharynx and nasopharynx","sensitivity","Jessa Hospital","All","Child, Adult, Older Adult","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20.43","April 20, 2020","May 20, 2020","May 20, 2020","April 24, 2020",,"April 24, 2020","Jessa Hospital, Hasselt, Belgium",,"https://ClinicalTrials.gov/show/NCT04361448"
1060,"NCT04316949","Predictors of Respiratory Failure in SARS-Cov-2 Infection",,"Recruiting","No Results Available","SARS-CoV-2 Pneumonia",,"Respiratory failure|Occurence of bacterial superinfection","University of Bologna","All","18 Years to 99 Years   (Adult, Older Adult)",,"350","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PREDI-CO","March 20, 2020","April 30, 2020","May 31, 2020","March 20, 2020",,"April 7, 2020","University of Bologna - Department of Medical and Surgical Sciences, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT04316949"
1061,"NCT04385251","International SARS-CoV-2 (COVID-19) Infection Observational Study","ICOS","Not yet recruiting","No Results Available","COVID|COVID19|SARS-CoV 2|Dyspnea","Other: Data Collection","Time to Hospitalization|Time to Expiration|Rate of Death at 7 Days|Rate of Death at 14 Days|Rate of Death at 28 Days|Rate of Hospitalization at 7 Days|Rate of Hospitalization at 14 Days|Rate of Hospitalization at 28 Days|Participant Health at 7 Days|Participant Health at 14 Days|Participant Health at 28 Days|Modified Borg Dyspnea Scale at 7 Days|Modified Borg Dyspnea Scale at 14 Days|Modified Borg Dyspnea Scale at 28 Days","University of Minnesota|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)",,"10000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ICOS|75N91019D00024","May 15, 2020","June 30, 2021","June 30, 2021","May 12, 2020",,"May 12, 2020","Denver Public Health, Denver, Colorado, United States|Hospital General de Agudos JM Ramos Mejia Servicio de Inmunocomprometidos, Buenos Aires, Argentina|CHIP Department of Infectious Diseases, Copenhagen, Denmark|University College London Medical School Centre for Sexual Health and HIV Research, London, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04385251"
1062,"NCT04367857","ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers",,"Recruiting","No Results Available","Covid-19|Coronavirus Infection|Coronavirus","Other: COVID-19 Serology|Behavioral: Health Care Worker Survey","Proportion seropositive","Columbia University","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAAS9998","April 18, 2020","October 2021","October 2021","April 29, 2020",,"April 30, 2020","NewYork-Presbyterian Hosptial/Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04367857"
1063,"NCT04374110","Drug Safety and the Occurrence of Complications During Hospitalization in Patients With COVID-19","COR-CARDIO","Recruiting","No Results Available","COVID|Hypertension|Cardiovascular Diseases|Cardiovascular Risk Factor","Other: Clinical data","Adverse events|Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke|Ventilation during hospitalization","Institute of Cardiology, Warsaw, Poland","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1860/2020","May 5, 2020","June 24, 2020","August 24, 2021","May 5, 2020",,"May 6, 2020","National Institute of Cardiology, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT04374110"
1064,"NCT04343053","Pro-thrombotic Status in Patients With SARS-Cov-2 Infection","ATTAC-Co","Recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Other: SARS-Cov-2 infection","on-treatment platelet reactivity|apoptosis rate in human umbilical vein endothelial cells (HUVEC)|Nitric oxide (NO) intracellular levels|reactive oxygen species (ROS) levels|coagulation factors levels|respiratory function|cardiac function|clinical outcome","University Hospital of Ferrara","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","250320","April 8, 2020","June 30, 2020","June 30, 2021","April 13, 2020",,"May 14, 2020","Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy",,"https://ClinicalTrials.gov/show/NCT04343053"
1065,"NCT04354779","Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.",,"Recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|SARS-CoV 2|Coronavirus Infection|Covid19","Diagnostic Test: a specifically designed self-administered questionnaire","Antibody status in HCW|Active virus carriers in HCW|Incubation time|Background incidence rate|Occupation associated infection risk","AUVA|Paracelsus Medical University","All","15 Years to 90 Years   (Child, Adult, Older Adult)",,"4000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","AUVA SARS-CoV-2 Studie","May 11, 2020","August 2020","November 2020","April 21, 2020",,"May 12, 2020","Allgemeine Unfallversicherungsanstalt, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04354779"
1066,"NCT04378686","Serological Testing for COVID-19 (SARS-CoV-2) in ESKD",,"Recruiting","No Results Available","SARS-CoV 2|End Stage Renal Failure on Dialysis","Other: dialysis","Antibodies against SARS-CoV-2","Universitaire Ziekenhuizen Leuven","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","S64000","April 23, 2020","May 1, 2021","May 1, 2022","May 7, 2020",,"May 12, 2020","Jessa Ziekenhuis, Hasselt, Limburg, Belgium|University Hospitals Leuven, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT04378686"
1067,"NCT04261270","A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia",,"Recruiting","No Results Available","2019-nCoV Pneumonia","Drug: ASC09F+Oseltamivir|Drug: Ritonavir+Oseltamivir|Drug: Oseltamivir","Rate of comprehensive adverse outcome|Time of clinical remission|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no need for oxygen inhalation|Rate of undetectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery","Tongji Hospital","All","18 Years to 55 Years   (Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ASC09F-CTP-TJ-01","February 1, 2020","May 1, 2020","July 1, 2020","February 7, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04261270"
1068,"NCT04356482","CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19","COPLASCOV19","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2|Convalescence|Plasma|Doses","Biological: convalescent plasma","Clinical improvement|improvement in tomographic image|test positivity for COVID-19|early and late complications associated to convalescent plasma|days at ICU","Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado|SECRETARIA DE SALUD DEL ESTADO DE SONORA|CENTRO ESTATAL DE LA TRANSFUSION SANGUINEA|HOSPITAL CENTRAL NACIONAL PEMEX NORTE|HOSPITAL DE ZONA No. 2 IMSS|HOSPITAL DE ZONA No.14 IMSS|HOSPITAL ANGELES DE CHIHUAHUA|HOSPITAL GENERAL DEL ESTADO DE SONORA","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TERAPLASCOV2","May 2020","November 2020","December 2020","April 22, 2020",,"April 28, 2020","Hospital Del Issste Regional En Guadalajara Jalisco, Guadalajara, Jalisco, Mexico|Secretaria de Salud Del Estado de Sonora, Hospital General Del Estado, Hermosillo, Sonora, Mexico|Hospital Central Norte Pemex, Mexico City, Mexico|hospital general de Mexico, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04356482"
1069,"NCT04357938","Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections","SCout","Active, not recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Device: CT-imaging","Sensitivity and specificity of chest CT in detecting pneumonia in unspecific symptomatic patients who are to be admitted to hospital and who are rt-PCR negative for SARS-CoV-2.|Sensitivity and specificity of chest CT in patients with pulmonary comorbidities|Sensitivity and specificity of chest CT in patients with cardiovascular comorbidities|Sensitivity and specificity of chest CT in patients with malignancy|Sensitivity and specificity of chest CT in patients with immunodeficiency","Jena University Hospital","All","18 Years and older   (Adult, Older Adult)",,"145","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IDIR-001-2020","April 15, 2020","April 20, 2020","April 30, 2020","April 22, 2020",,"April 22, 2020","Jena University Hospital, Jena, Thuringia, Germany",,"https://ClinicalTrials.gov/show/NCT04357938"
1070,"NCT04366934","Study of the Pathogenesis of Olfactory Disorders in COVID-19","COVIDSMELL","Recruiting","No Results Available","Coronavirus Infection|Severe Acute Respiratory Syndrome|Sars-CoV2","Other: Nasal swab|Other: Taste and olfactory function evaluation","Molecular and cellular defects in olfactory epithelium|Biological mechanisms involved in the pathogenesis of the disease|Epidemiological characteristics|Olfactory and taste dysfunction","Institut Pasteur|Hôpital Lariboisière, AP-HP","All","18 Years and older   (Adult, Older Adult)",,"24","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2020-021","May 4, 2020","September 15, 2022","September 15, 2022","April 29, 2020",,"May 7, 2020","Hôpital Lariboisière, Policlinique, Paris, France|Hôpital Lariboisière, Service ORL, Paris, France",,"https://ClinicalTrials.gov/show/NCT04366934"
1071,"NCT04329195","ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic","ACORES-2","Recruiting","No Results Available","History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection","Drug: 1: discontinuation of RAS blocker therapy|Drug: 2: continuation of RAS blocker therapy","Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)|Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28|Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.|Number of days alive free of oxygen.|Number of days alive outside hospital until day28|Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of ICU admission until day28|Rate of all-cause mortality at day 28|Rate of cardiovascular death at day 28|Number of days alive free of acute kidney injury until hospital discharge","Assistance Publique - Hôpitaux de Paris|Groupe Hospitalier Pitié-Salpêtrière","All","18 Years and older   (Adult, Older Adult)","Phase 3","554","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200409","April 9, 2020","May 9, 2020","May 9, 2020","April 1, 2020",,"April 14, 2020","Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04329195"
1072,"NCT04353401","WGS ANALYSIS OF SARS-COV-2 POSITIVE PATIENTS","CALYPSO","Enrolling by invitation","No Results Available","Coronavirus Infection|SARS-CoV-2",,"Associations with severity and outcomes","Vanda Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"5000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","VP-01-01 CALYPSO","April 2020","November 2020","December 2020","April 20, 2020",,"April 20, 2020","Vanda Pharmaceuticals, Inc., Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT04353401"
1073,"NCT04332042","TOFAcitinib in SARS-CoV2 Pneumonia",,"Not yet recruiting","No Results Available","SARS-COv2 Related Interstitial Pneumonia","Drug: Tofacitinib","need of mechanical ventilation|need of admission in intensive care unit|death|rate of adverse events","Università Politecnica delle Marche","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOFACoV","April 10, 2020","June 20, 2020","July 10, 2020","April 2, 2020",,"April 2, 2020","Ospedali Riuniti di Ancona, Ancona, Marche, Italy",,"https://ClinicalTrials.gov/show/NCT04332042"
1074,"NCT04366791","Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19","RESCUE 1-19","Recruiting","No Results Available","Pneumonia|Coronavirus Infection in 2019 (COVID-19)|Severe Acute Respiratory Syndrome (SARS) Pneumonia","Radiation: Low Dose Radiation Therapy","Rate of extubation (for intubated patients)|Clinical outcome - Temperature|Clinical outcome - Heart Rate|Clinical outcome - Systolic blood pressure|Clinical outcome - Oxygenation|Clinical outcome - Respirations|Clinical outcome - FiO2|Clinical outcome - PEEP|Clinical outcome - Tidal volume|Clinical outcome - Intubation/Extubation events|Clinical outcome - Overall survival|Radiographic outcome - Chest xray|Radiographic outcome - CT can|Serologic outcome - WBC|Serologic outcome - Hgb|Serologic outcome - Procalcitonin|Serologic outcome - ANC|Serologic outcome - Creatine kinase|Serologic outcome - Myoglobin|Serologic outcome - Albumin|Serologic outcome - PT/PTT|Serologic outcome - D-Dimer|Serologic outcome - GGT|Serologic outcome -Triglycerides|Serologic outcome -Ferritin|Serologic outcome -Fibrinogen|Serologic Immune markers flow cytometry|Serologic outcome -Bilirubin|Serologic outcome - LDH|Serologic outcome - Creatinine|Serologic outcome - EGFR|Serologic outcome - CRP|Serologic outcome - ALT|Serologic outcome - AST|Serologic outcome - Troponin-I|Serologic outcome - BNP|Serologic outcome - Blood Gases pH|Serologic outcome - Blood Gases pO2|Serologic outcome - Blood Gases pCO2|Serologic outcome - Lactic Acid|Serologic outcome - IL-6|Serologic outcome - Potassium","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000476|NCI-2020-02676|RAD5002-20|P30CA138292","April 23, 2020","June 1, 2020","July 1, 2020","April 29, 2020",,"May 25, 2020","Emory University Hospital Midtown/Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04366791"
1075,"NCT04320472","Acute Encephalopathy in Critically Ill Patients With COVID-19","NeuroCOVID19","Recruiting","No Results Available","COVID-19|Encephalopathy|Critically Ill","Other: Follow up","prevalence|Favorable outcome","Ictal Group","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Neuro-COVID-19","March 23, 2020","December 2020","December 2020","March 25, 2020",,"May 19, 2020","Jackson Memorial Health System; University of Miami, Miller School of Medicine, Miami, Florida, United States|Universidade Federal de São Paulo, São Paulo, Brazil|Fundación Valle del Lili, University Hospital, Cali, Colombia|Centre Hospitalier d'Argenteuil, Argenteuil, France|Centre Hospitalier de Beauvais, Beauvais, France|Centre Hospitalier Universitaire Ambroise Paré, Boulogne, France|Centre Hospitalier de Bourg en Bresse, Bourg-en-Bresse, France|Centre Hospitalier Régional Universitaire de Brest, Brest, France|Centre Hospitalier de Brives, Brive-la-Gaillarde, France|Centre Hospitalier Universitaire Beaujon, Clichy, France|Centre Hospitalier Universitaire Louis Mourier, Colombes, France|Centre Hospitalier Universitaire Henri Mondor, Créteil, France|Centre hospitalier de Dieppe, Dieppe, France|Centre Hospitalier Universitaire de Dijon, Dijon, France|Centre Hospitalier d'Etampes, Etampes, France|Grand Hôpital de l'Est Francilien - Site de Marne-la-Vallée, Jossigny, France|Centre Hospitalier de la Roche-sur-Yon, La Roche-sur-Yon, France|Centre Hospitalier de La Rochelle, La Rochelle, France|Centre Hospitalier de Versailles, Le Chesnay, France|Centre Hospitalier Universitaire de Lille, Lille, France|Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon, France|Hôpital privé Jacques Cartier, Massy, France|Groupe Hospitalier Sud Ile-de-France, Melun, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalier Régional d'Orléans, Orléans, France|Centre Hospitalier Universitaire Cochin, Paris, France|Groupe hospitalier Paris Saint-Joseph, Paris, France|Hôpital Fondation Adolphe de Rothschild, Paris, France|Hopital Privé Claude Galien, Quincy-sous-Sénart, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Centre Hospitalier de Roanne, Roanne, France|Hopital Foch, Suresnes, France|Centre Hospitalier de Toulon, Toulon, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Tours, Tours, France|Gustave-Roussy, Villejuif, France|Hospital Clinic Universitari, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04320472"
1076,"NCT04330300","Coronavirus (COVID-19) ACEi/ARB Investigation","CORONACION","Recruiting","No Results Available","Hypertension|COVID-19","Drug: Thiazide or Thiazide-like diuretics|Drug: Calcium Channel Blockers|Drug: ACE inhibitor|Drug: Angiotensin receptor blocker","Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)|Number of Covid-19 positive participants who die|Number of Covid-19 positive participants who require intubation in intensive care unit (ICU)|Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV)|Number of SARS-CoV-2 positive participants|Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization|24 hour mean systolic BP (mmHg) on ambulatory BP monitoring|All-cause mortality","National University of Ireland, Galway, Ireland","All","60 Years and older   (Adult, Older Adult)","Phase 4","2414","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","C.A. 2348","March 30, 2020","January 31, 2021","March 1, 2021","April 1, 2020",,"April 13, 2020","University Hospital Galway, Galway, Ireland",,"https://ClinicalTrials.gov/show/NCT04330300"
1077,"NCT04382547","Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells",,"Not yet recruiting","No Results Available","COVID|Covid-19|Coronavirus|Pneumonia|Pneumonia, Viral|Pneumonia, Interstitial|Sars-CoV2","Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols","Number of cured patients|Number of patients with treatment-related adverse events","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC2(Covid)","May 11, 2020","June 30, 2021","June 30, 2021","May 11, 2020",,"May 11, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04382547"
1078,"NCT04346667","Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds","PEACE","Recruiting","No Results Available","SARS-CoV-2|Coronavirus Infection|Asymptomatic Condition|COVID-19","Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo","RT-PCR negative status|Progression of symptoms|Development of Symptoms|Adverse events","Government of Punjab, Specialized Healthcare and Medical Education Department|Mayo Hospital Lahore|Services Institute of Medical Sciences, Pakistan|Pakistan Kidney and Liver Institute|Forman Christian College|Harvard School of Public Health","All","20 Years to 50 Years   (Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","NBC-COVID19-02","April 14, 2020","May 30, 2020","June 30, 2021","April 15, 2020",,"May 1, 2020","Expo Covid Center, Lahore, Punjab, Pakistan|Mayo Hospital, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04346667"
1079,"NCT04368143","COVID-19 Immune Repertoire Sequencing","IMSEQ","Recruiting","No Results Available","COVID|SARS-CoV 2|Corona Virus Infection|RDT|B Cell",,"provide proof-of-concept that (longitudinal) B cell repertoire mining allows identification of emerging virus specific B cell receptor variable regions.|study evolutions in B and T cell repertoires to understand COVID-19 specific immune responses fundamentally.|clinical and epidemiological description of UZA hospitalized COVID-19 patients","Institute of Tropical Medicine, Belgium|University Hospital, Antwerp","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IMSEQ","April 1, 2020","June 30, 2020","December 31, 2020","April 29, 2020",,"April 29, 2020","Universitairy hospital of Antwerp, Antwerp, Belgium",,"https://ClinicalTrials.gov/show/NCT04368143"
1080,"NCT04384042","Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study",,"Not yet recruiting","No Results Available","SARS-CoV Infection|COVID-19|Anosmia|Dysgeusia","Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances","Presence or absence of olfactory and taste disturbances in study participants|Adjusted odds ratio of olfactory & taste disturbances in COVID-19 infection|Clinical manifestations of study participants|Other pre-existing health conditions|Positive predictive value (PPV) of olfactory and taste disturbances in predicting diagnosis of COVID-19 infection|Negative predictive value (NPV) of olfactory and taste disturbances in predicting absence of COVID-19 infection|Sensitivity of olfactory and taste disturbances in predicting COVID-19 infection|Specificity of olfactory and taste disturbances in predicting COVID-19 infection","Hospital Sultanah Bahiyah|Hospital Tuanku Fauziah, Kangar, Perlis|Hospital Sultanah Maliha, Langkawi, Kedah|Penang Hospital, Malaysia|Hospital Raja Permaisuri Bainun|Hospital Sungai Buloh, Selangor|Kuala Lumpur General Hospital|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan|Hospital Melaka, Melaka|Hospital Sultan Ismail, Johor Bahru, Johor|Hospital Permai, Johor Bahru, Johor|Hospital Sultanah Aminah Johor Bahru|Hospital Enche Besar Hajjah Khalsom, Kluang, Johor|Hospital Raja Perempuan Zainab II, Kota Bahru, Kelantan|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu|Hospital Tengku Ampuan Afzan, Kuantan, Pahang|Sarawak General Hospital|Hospital Queen Elizabeth, Malaysia","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","MCO-002","May 2020","July 2020","August 2020","May 12, 2020",,"May 14, 2020","Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia|Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia|Hospital Permai, Johor Bahru, Johor, Malaysia|Hospital Enche' Besar Hajjah Khalsom, Kluang, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Sultanah Maliha, Langkawi, Kedah, Malaysia|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Penang Hospital, George Town, Penang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia|Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia|Hospital Melaka, Melaka, Malaysia",,"https://ClinicalTrials.gov/show/NCT04384042"
1081,"NCT04366219","Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer: an Ambispective Study Extended Over 2 Time Periods.","CBP-COVID","Not yet recruiting","No Results Available","COVID|SARS-CoV 2|Lung Cancer",,"Comparison of clinical characteristics|Comparison of diagnostic procedures|Comparison of treatments (according to stage of disease)|Comparison of patients management deadlines|Comparison of survival","Centre Hospitalier le Mans|ONCOPL","All","18 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Other|Time Perspective: Other","CHM-2020/S15/03","June 2020","August 28, 2020","August 28, 2022","April 28, 2020",,"May 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04366219"
1082,"NCT04390165","Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study",,"Not yet recruiting","No Results Available","SARS-CoV Infection|COVID-19|Anosmia|Dysgeusia","Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances","Presence or absence of olfactory and taste disturbances in COVID-19 patients|Prevalence of olfactory disturbances in COVID-19 patients|Prevalence of taste disturbances in COVID-19 patients|Clinical manifestations of study participants|Other pre-existing health conditions|Rating of baseline sense of smell & taste in COVID-19 patients prior to diagnosis of their infection|Rating of sense of smell & taste in COVID-19 patients at time of diagnosis of their infection|Rating of sense of smell & taste in COVID-19 patients at time of answering questionnaire survey","Hospital Sultanah Bahiyah|Hospital Tuanku Fauziah, Kangar, Perlis|Hospital Sultanah Maliha, Langkawi, Kedah|Penang Hospital, Malaysia|Hospital Raja Permaisuri Bainun|Hospital Sungai Buloh, Selangor|Kuala Lumpur General Hospital|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan|Hospital Melaka, Melaka|Hospital Sultan Ismail, Johor Bahru, Johor|Hospital Permai, Johor Bahru, Johor|Hospital Sultanah Aminah Johor Bahru|Hospital Enche Besar Hajjah Khalsom, Kluang, Johor|Hospital Raja Perempuan Zainab II, Kota Bahru, Kelantan|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu|Hospital Tengku Ampuan Afzan, Kuantan, Pahang|Sarawak General Hospital|Hospital Queen Elizabeth, Malaysia","All","18 Years and older   (Adult, Older Adult)",,"760","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","MCO-001","May 2020","July 2020","August 2020","May 15, 2020",,"May 15, 2020","Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia|Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia|Hospital Permai, Johor Bahru, Johor, Malaysia|Hospital Enche' Besar Hajjah Khalsom, Kluang, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Sultanah Maliha, Langkawi, Kedah, Malaysia|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Penang Hospital, George Town, Penang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia|Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia|Hospital Melaka, Melaka, Malaysia",,"https://ClinicalTrials.gov/show/NCT04390165"
1083,"NCT04357366","suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)","SAVE","Recruiting","No Results Available","COVID-19|Virus Diseases|Corona Virus Infection|Lower Respiratory Tract Infection Viral","Drug: Anakinra|Drug: trimethoprim/sulfamethoxazole","The ratio of patients who will not develop serious respiratory failure (SRF)|Comparison of the rate of patients who will not develop serious respiratory failure (SRF) until day 14 with historical comparators from Hellenic Sepsis Study Group Database|Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 7|Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 14|Change of SOFA score in enrolled subjects between days 1 and 7|Change of Sequential organ failure assessment (SOFA) score in enrolled subjects between days 1 and 14|Change of cytokine production between days 1 and 7|Change of plasma inflammatory mediators levels between days 1 and 7","Hellenic Institute for the Study of Sepsis","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SAVE|2020-001466-11","April 15, 2020","April 15, 2022","April 15, 2022","April 22, 2020",,"April 27, 2020","COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece|1st University Department of Internal Medicine, General Hospital of Athens LAIKO, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens, Athens, Greece|Department of Infectious Diseases, General Hospital of Kerkira, Corfu, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece|Department of Internal Medicine, University General Hospital of Larissa, Larissa, Greece|Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA, Patra, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece",,"https://ClinicalTrials.gov/show/NCT04357366"
1084,"NCT04362956","Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection",,"Not yet recruiting","No Results Available","Covid19|Pregnancy Related|Neonatal Infection",,"Vertical transmission|Neonatal protection due to maternal antibodies|Increase risk of neonatal morbidity|Increase risk of obstetric complications","Fundacion Infant","Female","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Perinatal COVID-19","May 1, 2020","September 30, 2020","September 30, 2020","April 27, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04362956"
1085,"NCT04351399","Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak","PRPsyCOVID","Completed","No Results Available","Sars-CoV2|Rheumatic Diseases|Rheumatoid Arthritis|Chronic Pain","Other: questionnaire assesment","Frequency of RA patients with emotional impact (feeling of isolation)|self-reported questionnaire for painful","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)",,"318","Other","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","EQ_2020_01|2020-A00907-32","April 27, 2020","May 4, 2020","May 4, 2020","April 17, 2020",,"May 21, 2020","Hopital Roger Salengro, CHU Lille, Lille, France",,"https://ClinicalTrials.gov/show/NCT04351399"
1086,"NCT04392401","COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study","RICO","Recruiting","No Results Available","Intensive Care Unit|SARS-Cov-2","Biological: Collection of blood samples in order to create a biocollection","Kinetics over time of HLA-DR expression on the surface of monocytes","Hospices Civils de Lyon|BioMérieux","All","18 Years and older   (Adult, Older Adult)",,"200","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL20_0358|2020-A01079-30","May 11, 2020","February 2021","February 2021","May 18, 2020",,"May 18, 2020","Hôpital Pierre Wertheimer, Bron, France|Hôpital Gabriel Montpied, Clermont-Ferrand, France|Centre hospitalier universitaire de Grenoble Alpes, Grenoble, France|Hôpital Edouard Herriot, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpial de la Croix Rousse, Lyon, France|Hôpital Lyon Sud, Pierre-Bénite, France|CH de St Etienne, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT04392401"
1087,"NCT04263402","The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia",,"Recruiting","No Results Available","2019-nCoV Severe Pneumonia","Drug: Methylprednisolone","Rate of disease remission|Rate and time of entering the critical stage|Rate of normal tempreture|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of laboratory indicator recovery|Rate of undetectable viral RNA","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TJ20200201","February 1, 2020","June 1, 2020","July 1, 2020","February 10, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04263402"
1088,"NCT04335630","Cardiovascular Manifestations of COVID-19",,"Recruiting","No Results Available","Cardiovascular Diseases|COVID","Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values","Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.|Prevalence of pericarditis, pericardial effusion, valvular disease.|Identification of characteristic electrocardiographic patterns related to COVID-19|Role of active cardiovascular disease in clinical outcomes of patients with COVID-19 including length of ICU stay, length of hospitalization and mortality.|Role of pre-existing cardiovascular comorbidities in clinical course of COVID-19|Role of treatment with ACE inhibitors or ARBs in the clinical course of COVID-19|Role of insurance type on clinical outcomes of patients with COVID-19|Effect of age, gender and race on clinical course of COVID-19 and prevalence of cardiovascular complications|Role of active smoking on clinical course of COVID-19 and prevalence of cardiovascular complications","Memorial Hermann Health System","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","HSC-MS-20-0286","March 30, 2020","March 2021","March 2022","April 6, 2020",,"April 7, 2020","Memorial Hermann Hospital-Texas Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04335630"
1089,"NCT04339634","Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy",,"Active, not recruiting","No Results Available","COVID|Drug Effect|Drug Interaction|Adverse Drug Event","Other: Simulation of Repurposed Drugs for COVID-19","To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.|To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.|To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.|To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.|To investigate the effects of various covariables on the Medication Risk Score in the presence of repurposed drugs for COVID-19.|To explore the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used.","Tabula Rasa HealthCare","All","55 Years and older   (Adult, Older Adult)",,"12123","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COVID-PACE-2020-001","April 7, 2020","July 7, 2020","April 6, 2021","April 9, 2020",,"April 14, 2020","Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04339634"
1090,"NCT04321616","The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients",,"Recruiting","No Results Available","SARS-CoV Infection|COVID 19|Acute Respiratory Distress Syndrome ARDS","Drug: Hydroxychloroquine|Drug: Remdesivir|Other: (Standard of Care) SoC","In-hospital mortality|Occurrence and duration of mechanical ventilation|Occurrence and duration of intensive care unit (ICU) treatment|Duration of hospital admittance|28 Day mortality|Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen|Occurrence of co-infections|Occurrence of organ dysfunction","Oslo University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","118684","March 28, 2020","August 2020","November 2020","March 25, 2020",,"April 14, 2020","Andreas Barratt-Due, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT04321616"
1091,"NCT04355611","Epidemiological Characteristics of COVID-19 in Patients With MS or NMO","COVISEP","Recruiting","No Results Available","Multiple Sclerosis|NMO Spectrum Disorder|COVID-19","Other: Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)","Clinical severity|EDSS (Expanded Disability Status Scale)","Assistance Publique - Hôpitaux de Paris","All","Child, Adult, Older Adult",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","APHP200482","April 20, 2020","April 20, 2022","April 20, 2022","April 21, 2020",,"April 29, 2020","Hôpital Pitié Salpétrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04355611"
1092,"NCT04392778","Clinical Use of Stem Cells for the Treatment of Covid-19",,"Recruiting","No Results Available","Covid19|Pneumonia|Multiple Organ Failure|Corona Virus Infection","Biological: MSC Treatment|Biological: Saline Control","Clinical improvement|Lung damage improvement|Sars-Cov-2 viral infection laboratory test|Blood test","SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi|Istinye University|Regenerative Medicine and Stem Cell Production Center Liv MedCell|Liv Hospital (Ulus)","All","40 Years to 60 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bak. Sadi Konuk-Istinye Uni.","April 1, 2020","July 2020","September 2020","May 19, 2020",,"May 19, 2020","Istinye University, Istanbul, Turkey|SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04392778"
1093,"NCT04363632","Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection","ONCOVID-19","Recruiting","No Results Available","Sars-CoV2|Cancer",,"Mortality of cancer patients under active anticancer treatment|Overall survival|Hospitalizations|Death|Complications|Patients' characteristics","Centre Leon Berard","All","Child, Adult, Older Adult",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Other","ET20-069","April 2, 2020","June 2020","June 2020","April 27, 2020",,"May 11, 2020","Institut Bergonié, Bordeaux, France|Centre François Baclesse, Caen, France|Centre Hospitalier Métropole Savoie, Chambéry, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|CH Annecy-Genevois, Metz-Tessy, France|Institut de Cancérologie de Montpellier, Montpellier, France|Groupement Hospitalier Porte de Provence, Montélimar, France|Centre Antoine Lacassagne, Nice, France|Centre Hospitalier Lyon-Sud, Pierre-Bénite, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest, Saint-Herblain, France|Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg, France|Institut Universitaire du Cancer de Toulouse - IUCT Oncopole, Toulouse, France|CH Valence, Valence, France",,"https://ClinicalTrials.gov/show/NCT04363632"
1094,"NCT04376905","Extra Vascular Lung Water and Pulmonary Permeability in Critically Ill Patients With SARS-CoV-2 (COVID-19)","PiCCOVID","Recruiting","No Results Available","COVID-19|Pneumonia|Acute Respiratory Distress Syndrome",,"Changes of Extra Vascular Lung Water|Changes of Pulmonary Vascular Permeability Index|Changes of pulmonary compliance","University Hospital, Montpellier","All","18 Years to 99 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0193","April 1, 2020","September 1, 2020","September 30, 2020","May 6, 2020",,"May 7, 2020","Uhmontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04376905"
1095,"NCT04357782","Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation","AVoCaDO","Recruiting","No Results Available","COVID-19|Hypoxia","Drug: L-ascorbic acid","Incidence of adverse events|Incidence of serious adverse reactions|Incidence of adverse reactions|Ventilator-free days|ICU-free days|Hospital-free days|All-cause mortality|Change in S/F ratio during HDIVC infusion|C-reactive protein (CRP)|Lactate dehydrogenase (LDH)|D-dimer|Lymphocyte count|Neutrophil to Lymphocyte ratio (NLR)|Serum Ferritin","Hunter Holmes Mcguire Veteran Affairs Medical Center|McGuire Research Institute","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","U.S. Fed|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Davis 001","April 16, 2020","June 1, 2020","August 1, 2020","April 22, 2020",,"April 22, 2020","Hunter Holmes Mcguire Veteran Affairs Medical Center, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04357782"
1096,"NCT04373707","Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19","COVI-DOSE","Recruiting","No Results Available","COVID|Thrombosis|Pulmonary Embolism|Deep Vein Thrombosis","Drug: Enoxaparin","Venous thromboembolism|Major bleeding|Major Bleeding and Clinically Relevant Non-Major Bleeding|Net Clinical Benefit|Venous Thromboembolism at other sites|Arterial Thrombosis|All-Cause Mortality|Factors associated with the risk of venous thromboembolism","Central Hospital, Nancy, France|Ministry of Health, France|Grand Est Region|University Hospital of Saint-Etienne","All","18 Years and older   (Adult, Older Adult)","Phase 4","602","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","2020-001709-21","May 13, 2020","September 2020","October 2020","May 4, 2020",,"May 14, 2020","Amiens Academic Hospital, Amiens, France|Besançon Academic Hospital, Besançon, France|Brest Academic Hospital, Brest, France|Civil Hospital, Colmar, France|Dijon Academic Hospital, Dijon, France|Marseille Academic Hospital, Marseille, France|Metz-Thionville Regional Hospital, Metz, France|Montpellier Academic Hospital, Montpellier, France|Emile Muller Hospital, Mulhouse, France|Nancy Academic Hospital, Nancy, France|George Pompidou European Hospital, Paris, France|St Etienne Academic Hospital, Saint-Étienne, France|Strasbourg Academic Hospital, Strasbourg, France|Toulouse Academic Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04373707"
1097,"NCT04363840","The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations","LEAD COVID-19","Not yet recruiting","No Results Available","COVID|Vitamin D Deficiency|Coagulopathy|Disseminated Intravascular Coagulation","Drug: Aspirin 81 mg|Dietary Supplement: Vitamin D","Hospitalization","Louisiana State University Health Sciences Center in New Orleans","All","18 Years and older   (Adult, Older Adult)","Phase 2","1080","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-063","May 2020","December 2020","December 2020","April 27, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04363840"
1098,"NCT04372056","The COVID-ICU Healthcare Professional Study",,"Recruiting","No Results Available","COVID-19|Critical Care|Intensive Care Units|Health Personnel","Behavioral: Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic","Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic","Oslo University Hospital","All","20 Years and older   (Adult, Older Adult)",,"2200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","136144","May 6, 2020","May 6, 2021","May 6, 2021","May 1, 2020",,"May 8, 2020","Oslo university hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT04372056"
1099,"NCT04397497","Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)","COMBAT-19","Not yet recruiting","No Results Available","Covid-19|Acute Respiratory Failure|ARDS, Human|Sars-CoV2|Viral Pneumonia","Drug: Mavrilimumab|Drug: Placebo","Reduction in the dependency on oxygen supplementation|Proportion of responders (using the WHO 7-point ordinal scale)|Time to response (using the WHO 7-point ordinal scale)|Proportion of improving patients (using the WHO 7-point ordinal scale)|Time to resolution of fever|Reduction in case fatality|Proportion of patient requiring mechanical ventilation/deaths|Change in biochemical markers|Median changes in the National Early Warning Score 2 (NEWS2)|Time to clinical improvement as evaluated with the National Early Warning Score 2 (NEWS2)|Variations in radiological findings|Safety of mavrilimumab in patients with severe COVID-19-pneumonia","Ospedale San Raffaele","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COMBAT-19","May 22, 2020","September 22, 2020","November 22, 2020","May 21, 2020",,"May 21, 2020","IRCCS Policlinico San Donato, San Donato, MI, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|IRCCS Istituto Ortopedico Galeazzi, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04397497"
1100,"NCT04384406","COVID-19 Outbreak Consequences for Outpatients Followed in PRM","Handicall","Completed","No Results Available","Chronic Disabling|COVID-19",,"Proportion of patients necessitating the scheduling of a medical consultation|the reason for this urgent need of a medical consultation|the access to other medical services during the quarantine period|the interruption of home-based rehabilitation services","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"467","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RECHMPL20_0262","April 1, 2020","May 1, 2020","May 9, 2020","May 12, 2020",,"May 21, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04384406"
1101,"NCT04369794","COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement","BATTLE","Not yet recruiting","No Results Available","COVID-19|Therapeutic Vaccine|BCG|SARS-CoV 2|Transmission","Biological: BCG|Biological: Placebo","Clinical evolution of COVID-19|SARS-CoV-2 elimination|Seroconversion rate and titration|Local and systemic adverse events to BCG vaccination","University of Campinas, Brazil|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Instituto de Infectologia Emílio Ribas|Universidade Estadual de Campinas, Unicamp|Pontifícia Universidade Católica de Campinas, PUC-Campinas|Faculdade de Medicina de Ribeirão Preto/USP|Faculdade de Medicina de Botucatu, Unesp|Federal University of São Paulo|State Hospital Dr. Leandro Franceschini, Sumaré, Unicamp|Paulinia Municipal Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVID-19 BATTLE trial","June 2020","June 2021","May 2022","April 30, 2020",,"April 30, 2020","Hospital das Clínicas Unicamp, Campinas, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT04369794"
1102,"NCT04344197","Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey",,"Enrolling by invitation","No Results Available","Surgery|COVID|Asymptomatic Patient|Covid-19|Preventive Measures","Other: global survey","overview of surgical management on preventive measures of hospital infection spread during covid 19|testing policies and preventive measures for Covid-19, and their association with asymptomatic cases.","University of Rome Tor Vergata","All","Child, Adult, Older Adult",,"1200","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","s-covid survey","April 2, 2020","April 8, 2020","April 15, 2020","April 14, 2020",,"April 14, 2020","Tor Vergata Hospital, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT04344197"
1103,"NCT04363268","ACCESS A Master Digital Surveillance Protocol for COVID-19","ACCESS","Recruiting","No Results Available","Coronavirus|COVID|COVID-19|COVID19|Corona Virus Infection|Coronavirus Infection",,"Development of population-based models of disease risk|Relation between disease burden and geolocation|Effect of medications on symptoms of COVID19|Effect of medications on disease severity of COVID19|Rate of COVID19 infection and disease outcomes|Effect of COVID19 on health outcomes|Long-term follow up and recontact","Medable Inc.|Datavant|American Heart Association|BioIntelliSense|PWNHealth","All","18 Years and older   (Adult, Older Adult)",,"1000000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00041635","April 20, 2020","April 20, 2030","October 1, 2031","April 27, 2020",,"April 28, 2020","Medable Inc., Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT04363268"
1104,"NCT04373109","Stroke Rehabilitation Outcome During COVID-19 Lockdown","SROCL","Recruiting","No Results Available","Stroke|Rehabilitation|COVID-19|Cohort Studies","Behavioral: Observation","Rehabilitation data|Motor Activity Log - 14 Item Version|International Physical Activity Questionnaire|Patient-Reported Outcomes Measurement Information System - 29 Version|Global Rating of Perceived Changes (physical activity engagement and upper limb use)|Fatigue Severity Scale|Hospital Anxiety and Depression Scale|Montreal Cognitive Assessment|Functional Ambulation Categories|Ten-Meter Walk Test|Rivermead Mobility Index|Activities-specific Balance Confidence Scale|Fugl-Meyer Motor Assessment|Action Research Arm Test|modified Rankin Scale|National Institutes of Health Stroke Scale","Jeremia Held|University of Zurich","All","18 Years and older   (Adult, Older Adult)",,"70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BASEC-Nr. 2020-00761","April 16, 2020","April 2021","April 2021","May 4, 2020",,"May 4, 2020","University Hospital Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04373109"
1105,"NCT04360538","Long Term Outcomes of Patients With COVID-19","COVID19 LTFU","Recruiting","No Results Available","Critical Illness|Corona Virus Infection|Respiratory Failure|Covid-19","Other: Quality of Life|Other: Impact Event Score|Other: Hospital anxiety and depression scale","Quality of Life score|cognitive dysfunction|Functional Status Score|Physical Disability|Psychological Sequelae","University of Chicago","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-0538","April 8, 2020","July 1, 2021","December 30, 2021","April 24, 2020",,"April 24, 2020","University of Chicago Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04360538"
1106,"NCT04373005","Screening of Cancer Patients to Assess Impact of COVID-19",,"Not yet recruiting","No Results Available","Covid-19|Cancer","Diagnostic Test: Nasopharyngeal (NP) swab","Rate of asymptomatic COVID-19 infection among cancer patients receiving cancer therapy|Rate of sero-conversion in cancer patients","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","U-DEPLOY: RESPONSE|CAPCR 20-5337","May 4, 2020","December 4, 2020","December 4, 2020","May 4, 2020",,"May 4, 2020","Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04373005"
1107,"NCT04372589","Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC )",,"Not yet recruiting","No Results Available","COVID-19|Heparin|Pneumonia|Anticoagulant","Drug: Heparin","Intubation and mortality|Hospital-free days|Thrombocytopenia|Bleeding|Transfusion|ICU-free days|Ventilator-free days|Type of ventilator used|Organ support-free|Myocardial infarction|Ischaemic stroke","University of Manitoba|University Health Network, Toronto|Hopital Montfort|Hamilton Health Sciences Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATTACC|OZM-113","May 2020","January 2021","January 2021","May 4, 2020",,"May 12, 2020","Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Research Institute, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04372589"
1108,"NCT04365985","Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","SINK COVID-19","Recruiting","No Results Available","COVID-19|Acute Respiratory Distress Syndrome|Severe Acute Respiratory Syndrome (SARS)|Coronavirus Infections","Drug: Naltrexone|Drug: Ketamine|Other: Placebo","Progression of oxygenation needs|Renal failure|Liver failure|Cytokine Storm|Mortality|Length of hospital stay|Intensive Care Unit (ICU) admission|Intensive Care Unit (ICU) duration|Intubation|Intubation duration|Time until recovery","William Beaumont Hospitals","All","18 Years and older   (Adult, Older Adult)","Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2020-097","April 29, 2020","May 2020","August 2020","April 28, 2020",,"May 11, 2020","William Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04365985"
1109,"NCT04386551","Detection of COVID-19 in Saliva Collection","SALICOV","Recruiting","No Results Available","Sars-CoV2|RT-PCR|Saliva Collection|Nasopharyngeal Sample",,"Detection of SARS-CoV-2 RNA in the saliva sample|Concordance between the Saliva sample and the nasonasopharyngeal sample SARS-CoV-2 RT-PCR results","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)",,"225","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PI2020_843_0045","May 11, 2020","August 2020","August 2020","May 13, 2020",,"May 14, 2020","CHU Amiens, Amiens, France",,"https://ClinicalTrials.gov/show/NCT04386551"
1110,"NCT04333368","Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS","STROMA-CoV2","Recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|Severe Acute Respiratory Distress Syndrome","Biological: Umbilical cord Wharton's jelly-derived human|Other: NaCl 0.9%","Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group|Lung injury score|Oxygenation index|In-hospital mortality|Mortality|Ventilator-free days|Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 > 200 (out of a prone positioning session)|Cumulative use of sedatives|Cumulative duration of use of sedatives|Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)|Cumulative use of neuromuscular blocking agents (other than used for intubation)|ICU-acquired weakness and delirium|Treatment-induced toxicity rate and adverse events up to day 28|Quality of life at one year (EQ5D-3L quality of life questionnaire)|Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level|Anti-HLA antibodies plasmatic dosage","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","APHP200395|2020-001287-28","April 6, 2020","August 31, 2020","July 31, 2021","April 3, 2020",,"May 21, 2020","Hôpital Pitié-Salpêtrière - APHP, Paris, France|Hôpital Européen Georges Pompidou - APHP, Paris, France",,"https://ClinicalTrials.gov/show/NCT04333368"
1111,"NCT04352634","The Covid-19 HEalth caRe wOrkErS (HEROES) Study","HEROES","Recruiting","No Results Available","Covid-19|Mental Health Disorder|Stress Disorder|Anxiety|Depression|SARS-CoV-2","Other: Exposure to the SARS-CoV-2 and its consequences","Anxiety and depressive symptoms|Experiences, fears and concerns about the Covid-19|Training and resource prioritization|Suicide ideation (presence)|Suicide ideation (frequency)|Acute stress symptoms|Psycho/social support and network|Resilience","University of Chile","All","18 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HEROES Covid-19","April 26, 2020","December 31, 2021","December 31, 2021","April 20, 2020",,"May 21, 2020","Columbia University, New York, New York, United States|Universidad del Chubut, Rawson, Chubut, Argentina|University of Sydney, Sidney, New South Wales, Australia|Salud Global, Sucre, Chuquisaca, Bolivia|University of Chile, Santiago, Chile|Universidad Nacional de Costa Rica, Heredia, Costa Rica|Society for Emergecy and Disaster Medicine CzMA JEP, Kladno, Bohemia, Czechia|Hochschule Emden/Leer, Emden, Niedersachsen, Germany|Centro de Investigaciones de las Ciencias de la Salud -CICS- Facultad de Ciencias Médicas Universidad de San Carlos de Guatemala -USAC-, Guatemala City, Guatemala|University of Cagliari, Cagliari, CA, Italy|University of Cagliari, Cagliari, Italy|The Institute for Development Research Advocacy and Applied Care (IDRAAC), Beirut, Lebanon|Logotipo del comercio Instituto Jalisciense De Salud Mental (SALME), Guadalajara, Jalisco, Mexico|Maastricht University, Maastricht, Limburg, Netherlands|University of Ibadan, Ibadan, Oyo State, Nigeria|Ponce Health Sciences University, Ponce, Puerto Rico|King Abdullah International medical research center, Riyadh, Central, Saudi Arabia|Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain|Razi Hospital La Manouba, Tunis, La Manouba, Tunisia|Koc University, Istanbul, Sariyer, Turkey|PNFA Salud Colectiva Instituto de Altos Estudios Dr Arnoldo Gabaldon, Maracay, Aragua, Venezuela",,"https://ClinicalTrials.gov/show/NCT04352634"
1112,"NCT04396197","Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care",,"Completed","No Results Available","COVID-19|Critical Illness|Ards|ICU Acquired Weakness","Other: Physiotherapy","Mobility level|Time taken to first mobilise|Discharge location","University Hospital Birmingham NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)",,"92","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PhysioCOVID-19","March 1, 2020","May 8, 2020","May 8, 2020","May 20, 2020",,"May 20, 2020","UHB NHS Foundation Trust, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04396197"
1113,"NCT04357418","Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives","ICOS","Active, not recruiting","No Results Available","Anxiety State|COVID-19|Isolation, Social|Health Personnel Attitude","Other: it is a survey","State Anxiety assessed by the State-Trait Anxiety Inventory (STAI)|Visual numeric scales assessing anger and stress the ongoing week.|Beck Depression Inventory","Centre hospitalier de Ville-Evrard, France","All","18 Years and older   (Adult, Older Adult)",,"1320","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","10477M-ICOS","April 1, 2020","June 30, 2020","June 30, 2020","April 22, 2020",,"April 28, 2020","URC Ville Evrard, Neuilly-sur-Marne, France",,"https://ClinicalTrials.gov/show/NCT04357418"
1114,"NCT04390516","Respiratory Decompensation and Model for the Triage of COVID-19 Patients",,"Active, not recruiting","No Results Available","COVID-19|Coronavirus|Mortality|Mechanical Ventilation","Device: COViage","Mechanically ventilated patient outcome|Mortality or mechanically ventilated patient outcome","Dascena","All","18 Years and older   (Adult, Older Adult)","Not Applicable","197","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","051420","March 24, 2020","May 4, 2020","May 30, 2020","May 15, 2020",,"May 25, 2020","Dascena, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT04390516"
1115,"NCT04396210","Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic",,"Recruiting","No Results Available","Coronavirus|COVID|ART|Fertility Issues","Other: Questionnaire","Patients perspectives on the abruptly discontinuation of their fertility treatment by using a questionnaire|Patients reproductive behaviour by using a questionnaire|Patients views on resuming fertility treatment by using a questionnaire","University Hospital, Ghent","All","18 Years to 47 Years   (Adult)",,"2000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","B6702020000247","May 14, 2020","August 31, 2020","December 31, 2020","May 20, 2020",,"May 21, 2020","Ghent University Hospital, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT04396210"
1116,"NCT04353128","Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.","MeCOVID","Not yet recruiting","No Results Available","Covid19|SARS-CoV 2|Coronavirus Infection","Drug: Melatonin 2mg|Drug: Placebo oral tablet","SARS-CoV 2 infection rate","Instituto de Investigación Hospital Universitario La Paz","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MeCOVID","April 2020","April 2021","July 2021","April 20, 2020",,"April 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04353128"
1117,"NCT04382534","A Cross-sectional and Cohort Study of COVID-19 Patients With Post - Discharge Dysfunction",,"Recruiting","No Results Available","Covid19|Respiratory Rehabilitation|Cross-sectional Study|Cohort Study","Combination Product: Respiratory rehabilitation","Symptoms and signs|Respiratory function|The body function|ADL","Peking University Third Hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","M20200421","March 10, 2020","September 30, 2020","December 31, 2020","May 11, 2020",,"May 11, 2020","Huarunwugang general hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04382534"
1118,"NCT04344184","Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI)",,"Not yet recruiting","No Results Available","COVID-19|Lung Injury, Acute","Drug: L-ascorbic acid|Other: Placebo","Number of ventilator-free days|All-cause-mortality|Acute-inflammation-free days|Organ-failure-free days","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HM20018977","June 2020","May 2021","May 2021","April 14, 2020",,"April 24, 2020","Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04344184"
1119,"NCT04349228","Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals","COVID_2Pro","Recruiting","No Results Available","COVID19|Sars-CoV2|Hydroxychloroquine|Prophylaxis|Healthcare Worker","Drug: Hydroxychloroquine (HCQ)|Drug: Placebo oral tablet","Symptomatic COVID(+) infection rate","Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Datametrix","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","530","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","ECC2020-03","April 28, 2020","July 15, 2020","July 15, 2020","April 16, 2020",,"May 6, 2020","Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Tunis, Tunisia",,"https://ClinicalTrials.gov/show/NCT04349228"
1120,"NCT04374656","Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic",,"Recruiting","No Results Available","Conjunctivitis|SARS-CoV-2|COVID-19|Ocular Infection, Viral|Ocular Inflammation",,"Proportion of conjunctival samples tested positive for SARS-CoV-2|Proportion of nasal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples|Proportion of nasopharyngeal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples|Rate of development of COVID-19 in the study patient population|Positive conjunctival sample rate in patient developed COVID-19","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00249598","May 18, 2020","May 2021","May 2021","May 5, 2020",,"May 25, 2020","Wilmer Eye Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04374656"
1121,"NCT04367883","Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection",,"Recruiting","No Results Available","COVID19|Influenza Vaccination|ACE Inhibitors|ARB","Drug: ACE inhibitor|Drug: ARB","hospital output|length of ICU admission","Consorci Sanitari de Terrassa|Jordi Gol i Gurina Foundation|Institut Català de la Salut","All","Child, Adult, Older Adult",,"2574","Other","Observational","Observational Model: Other|Time Perspective: Other","02-20-161-021","March 1, 2020","July 30, 2020","August 31, 2023","April 29, 2020",,"April 29, 2020","Hospital de Terrassa, Terrassa, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04367883"
1122,"NCT04395755","Impact of COVID-19 on Psychological Status in Case of IVF Interrupted or Postponed",,"Completed","No Results Available","Infertility, Female|ART|IVF|COVID-19","Behavioral: Generalized Anxiety Disorder-7 (GAD-7)|Behavioral: Patient Health Questionnaire-9 (PHQ-9)","Severity of anxiety|Severity of depression","Ospedale Policlinico San Martino","Female","18 Years and older   (Adult, Older Adult)",,"503","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19-NOIVF","April 1, 2020","May 15, 2020","May 15, 2020","May 20, 2020",,"May 20, 2020","IRCCS Ospedale Policlinico San Martino, Genoa, Italy",,"https://ClinicalTrials.gov/show/NCT04395755"
1123,"NCT04352946","HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial","HERO","Not yet recruiting","No Results Available","Prophylaxis|COVID-19|Health Care Worker|Hydroxychloroquine","Drug: Hydroxychloroquine Pre-Exposure Prophylaxis|Drug: Placebo oral tablet","Cumulative Incidence of COVID-19 Infection|Adverse events incidence|Duration of symptomatic COVID-19 disease|Days hospitalized attributed to COVID-19|Number or respiratory failure attributable to COVID-19 disease|Mortality Incidence|Days of work lost","GeoSentinel Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","374","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","GFICOVID-19-1","April 24, 2020","June 24, 2020","August 24, 2020","April 20, 2020",,"April 22, 2020","The New York Center for Travel and Tropical Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04352946"
1124,"NCT04384926","Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis","CovidSurg-Can","Recruiting","No Results Available","COVID-19|Coronavirus|Cancer|Surgery","Procedure: Elective Cancer Surgery","30-day postoperative COVID-19 infection rate|30-day postoperative mortality rate|Postoperative critical care utilisation rate in high-risk cancer surgery patients.|Proportion of patients with delay of greater than 4 weeks from decision for surgery to date of surgery|Proportion of non-operated patients with progression to incurable disease by 3-months after decision for surgery","University of Birmingham","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","CSC-20200324","March 30, 2020","December 31, 2020","December 31, 2020","May 12, 2020",,"May 12, 2020","Hospital del Henares, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04384926"
1125,"NCT04379258","Analysis of Mortality of Critically Ill Patients With COVID-19",,"Not yet recruiting","No Results Available","COVID-19|Critical Illness|Effectiveness|Outcome, Fatal",,"ICU mortality|hospital mortality|28-day mortality|effectiveness of treatment|length of ICU stay|length of hospital stay|ventilator-associated pneumonia|bacteriemia|barotrauma|duration of mechanical ventilation","Hospital Universitario Getafe|Hospital Universitario del Tajo|Puerta de Hierro University Hospital|Hospital de Henares|Hospital Universitario Ramon y Cajal|Hospital Universitario de Móstoles|Hospital Universitario Severo Ochoa|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa|Hospital Universitario Madrid Sanchinarro|Hospital Universitario Santa Creu i Sant Pau|Hospital Universitario Infanta Cristina|Hospital General Universitario Gregorio Marañon|Hospital Universitario de Torrejón|Hospital Universitario La Paz|Hospital Universitario 12 de Octubre","All","18 Years to 99 Years   (Adult, Older Adult)",,"650","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-UCI_Spain","May 11, 2020","May 30, 2020","May 30, 2020","May 7, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04379258"
1126,"NCT04356378","Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation","CAPACoV19","Not yet recruiting","No Results Available","Infection With Coronavirus SARS-CoV2","Other: Data record","Physical functional limitations","CHU de Reims","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PO20055","May 1, 2020","September 1, 2021","February 1, 2022","April 22, 2020",,"April 22, 2020","Damien JOLLY, Reims, France",,"https://ClinicalTrials.gov/show/NCT04356378"
1127,"NCT04384445","Organicell Flow for Patients With COVID-19",,"Not yet recruiting","No Results Available","Corona Virus Infection|COVID-19|SARS|Acute Respiratory Distress Syndrome","Biological: Organicell Flow|Other: Placebo","Incidence of any infusion associated adverse events|Incidence of Severe Adverse Events|All Cause Mortality|Survival Rate|Cytokine Levels|D-dimer Levels|C-reactive protein Levels|Quantification of the COVID-19|Improved Organ Failure|Chest Imaging Changes","Organicell Regenerative Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","19881","May 2020","September 30, 2020","December 31, 2020","May 12, 2020",,"May 21, 2020","Landmark Hospital, Naples, Florida, United States|Landmark Hospital, Athens, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04384445"
1128,"NCT04279197","Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu",,"Recruiting","No Results Available","Pulmonary Fibrosis Due to 2019-nCoV","Drug: N-acetylcysteine+ Fuzheng Huayu Tablet|Drug: N-acetylcysteine+Placebo","High-resolution computed tomography (HRCT) score|Lung function including FVC, FVC as a percentage of projected value and DLco|Times of acute exacerbation|Six-minute walk distance|Dyspnea Scores|Composite physiological index","ShuGuang Hospital|Hubei Hospital of Traditional Chinese Medicine|Jingmen No.1 People’s Hospital|Tongji Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Fzhy-ncp-2","February 15, 2020","December 2022","December 2022","February 21, 2020",,"February 21, 2020","Shuguang Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04279197"
1129,"NCT04369599","Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest for COVID-19",,"Enrolling by invitation","No Results Available","Acute Respiratory Distress Syndrome|COVID-19","Device: V/Q Vest","Change in Arterial Oxygenation Levels|Number of participants requiring advanced therapy|Number of participants avoiding proning ventilation|Number of participants delaying proning ventilation","Emory University|Georgia Tech Research Foundation|Georgia Clinical & Translational Science Alliance","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000402","May 2020","March 2021","March 2021","April 30, 2020",,"May 14, 2020","Emory University Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04369599"
1130,"NCT04342806","Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19",,"Recruiting","No Results Available","Health Care Worker (HCW)|COVID-19",,"Number and percent of participants who enroll in the HERO Registry Study by geographic region, age, COVID-19 risk factors, and past COVID-19 diagnosis|Distribution of COVID-19 risk factors by participant characteristics|Proportion of participants undergoing changes in health status (e.g. new diagnosis of COVID-19, ER visits, hospitalization)|Proportion of all participants enrolled in the HERO Registry who participate in an ancillary research study|Proportion of participants who continue to supple information about their health to the HERO Registry at various time points after their enrollment","Duke University|Patient-Centered Outcomes Research Institute","All","18 Years to 89 Years   (Adult, Older Adult)",,"100000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00105284","April 10, 2020","December 31, 2099","December 31, 2099","April 13, 2020",,"May 7, 2020","Duke Clinical Research Institute, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04342806"
1131,"NCT04284046","CT Scores Predict Mortality in 2019-nCoV Pneumonia",,"Completed","No Results Available","CT Scores Predict Mortality in 2019-nCoV Pneumonia","Other: CT score","7-day mortality","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","All","Child, Adult, Older Adult",,"39","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CT2019-nCoV","January 31, 2020","February 18, 2020","February 18, 2020","February 25, 2020",,"February 25, 2020","Wuhan third hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04284046"
1132,"NCT04397835","Psychological Impact of COVID-19 Quarantine and Worsening of Cardiovascular Risk in the French General Population","PSYCOV-CV","Recruiting","No Results Available","COVID-19|Anxiety|Depression|Stress",,"worsening of cardiovascular risk (treatments)|worsening of cardiovascular risk (smoking consumption)|worsening of cardiovascular risk (food balance)|worsening of cardiovascular risk (weight gain)|worsening of cardiovascular risk (physical activity)|psychological impact of the quarantine on anxiety|psychological impact of the quarantine on health|psychological impact of the quarantine on stress","University Hospital, Toulouse","All","50 Years to 89 Years   (Adult, Older Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC31/20/0135","April 17, 2020","April 20, 2021","April 20, 2021","May 21, 2020",,"May 21, 2020","CHU de Toulouse, Toulouse, Occitanie, France",,"https://ClinicalTrials.gov/show/NCT04397835"
1133,"NCT04347798","IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT","IMPACT","Enrolling by invitation","No Results Available","Covid-19 Infection|Rheumatoid Arthritis|Psoriatic Arthritis|Hydroxychloroquine","Other: Hydroxychloroquine/Chloroquine","Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group|Incidence of Covid-19 infection in the anti-malarial group compared to the non-anti-malarial group|Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action","University of Alberta","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Pro00100000","April 15, 2020","April 2021","April 2021","April 15, 2020",,"April 20, 2020","University of Alberta, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04347798"
1134,"NCT04331613","Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS",,"Recruiting","No Results Available","COVID-19|Acute Respiratory Distress Syndrome|Virus; Pneumonia|Acute Lung Injury","Biological: CAStem","Adverse reaction (AE) and severe adverse reaction (SAE)|Changes of lung imaging examinations|Time to SARS-CoV-2 RT-PCR negative|Duration of fever (Celsius)|Changes of blood oxygen (%)|Rate of all-cause mortality within 28 days|Lymphocyte count (*10^9/L)|Alanine aminotransferase (U/L)|Creatinine (umol/L)|Creatine kinase (U/L)|C-reactive protein (mg/L)|Procalcitonin (ng/L)|Lactate (mmol/L)|IL-1beta (pg/mL)|IL-2 (pg/mL)|IL-6 (pg/mL)|IL-8 (pg/mL)","Chinese Academy of Sciences|Beijing YouAn Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ChineseASZQ-006","January 27, 2020","December 2020","December 2020","April 2, 2020",,"April 2, 2020","Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China, China",,"https://ClinicalTrials.gov/show/NCT04331613"
1135,"NCT04321928","Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary","PROACTIVE-19","Not yet recruiting","No Results Available","SARS-CoV-2|Coronavirus|COVID-19|2019-nCoV|2019nCoV","Behavioral: Personalized health education|Behavioral: General health education","Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases|The number of general practitioner visits|The number of emergency, hospital admission and intensive care admission|Length of hospitalization and intensive care unit stay|Organ dysfunction|Lifestyle changes|The cost of care","University of Pecs","All","60 Years and older   (Adult, Older Adult)","Not Applicable","7576","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","IV/2428- 2 /2020/EKU","April 1, 2020","April 21, 2021","August 21, 2021","March 25, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04321928"
1136,"NCT04334967","Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care",,"Enrolling by invitation","No Results Available","COVID-19|Corona Virus Infection|SARS-CoV-2|2019-nCoV|2019 Novel Coronavirus","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C","Total Hospitalization|Total Mechanical Ventilation|Fever intensity measure|Shortness of breath measure|Changes in daytime cough measure|Changes in nighttime cough measure|Total mortality","Providence Health & Services|Center for Outcomes Research and Education|Providence Cancer Center, Earle A. Chiles Research Institute","All","45 Years and older   (Adult, Older Adult)","Phase 4","1250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020000186","March 30, 2020","September 30, 2021","September 30, 2023","April 6, 2020",,"April 6, 2020","Portland Providence Medical Center, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04334967"
1137,"NCT04346810","Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit",,"Not yet recruiting","No Results Available","COVID-19|Burnout, Caregiver|Intensive Care Unit|Stress, Psychological","Other: Patient management suffering of coronavirus infection","Stress in a recovery room transformed into an intensive care unit versus a conventional intensive care unit","Hôpital Raymond Poincaré|Dominique FLETCHER MD-PhD|Guillaume GERI MD-PhD|Clement DURET MD","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","CSC19APR","April 15, 2020","August 15, 2020","September 1, 2020","April 15, 2020",,"April 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04346810"
1138,"NCT04351789","Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark","PISCA","Not yet recruiting","No Results Available","COVID-19|Mental Health|Psychoeducation|Anxiety","Other: Psychoeducational intervention","Anxiety 1 month|Anxiety 3 months|Depression 3 months|Post Traumatic Stress Disorder (PTSD) symptoms 3 months|Anxiety 12 months|Post Traumatic Stress Disorder (PTSD) symptoms 12 months|Depression 12 months","Copenhagen University Hospital, Hvidovre","All","18 Years and older   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","PISCA Study","April 2020","April 2023","April 2023","April 17, 2020",,"April 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04351789"
1139,"NCT04363827","Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)","PROTECT","Not yet recruiting","No Results Available","COVID19|Hydroxychloroquine|Prophylaxis|Treatment|SARS-CoV-2","Drug: Hydroxychloroquine","the proportion of subjects of Group 1 who become symptomatic and/or swab positive in each arm within 1 month from randomization.|the proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.|The proportion of subjects with positive swabs in Group 1 within 1 month from randomization in both arms|The proportion of subjects of Group 1 who become symptomatic in each arm within 1 month from randomization|The proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.|The proportion of subjects of Group 2 who become swab negative in each arm within 1 month from randomization in overall population and in subgroup population|Absolute and relative frequencies of Serious Adverse Events|Variation in Quality of Life scores in different time points","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|University of Bologna","All","18 Years and older   (Adult, Older Adult)","Phase 2","2300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRST100.47","May 2020","September 2020","March 2021","April 27, 2020",,"April 29, 2020","Irst Irccs, Meldola, FC, Italy",,"https://ClinicalTrials.gov/show/NCT04363827"
1140,"NCT04362319","Burnout and Medical Errors in the Anaesthesiology Fraternity During Covid-19 Pandemic",,"Not yet recruiting","No Results Available","Burnout, Professional|Depression|Medical Errors|Covid-19","Diagnostic Test: Questionnaire forms","Prevalence of burnout among anaesthesiology clinicians during Covid-19|Prevalence of depression risk among anaesthesiology clinicians during Covid-19|Prevalence of self-perceived medical errors among anaesthesiology clinicians during Covid-19|Association of burnout, depression and medical errors among anaesthesiology clinicians during Covid-19","University of Malaya|Ministry of Health, Malaysia","All","18 Years and older   (Adult, Older Adult)",,"88","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","54753","May 1, 2020","May 31, 2020","June 30, 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04362319"
1141,"NCT04396353","EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19","WHO","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2|Corona Virus Infection|Sedentary Behavior","Other: Electronic questionnaire","Number of hospitalizations|Percentage of symptoms of the disease|Length of hospital stay|Percentage of mechanical ventilation","University of Sao Paulo General Hospital","All","Child, Adult, Older Adult",,"850","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","COVID-19","June 1, 2020","December 20, 2020","January 20, 2021","May 20, 2020",,"May 20, 2020","Marcelo Rodrigues dos Santos, São Paulo, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04396353"
1142,"NCT04395833","National Survey on the Lockdown of Children With Disabilities","ECHO","Completed","No Results Available","Identify Emerging Health Challenges for Children With Motor Disabilities and Their Parents Facing the COVID-19 Pandemic",,"Experience during lockdown|Health risk during lockdown|Impact on medical and rehabilitation follow up|Impact on daily living","University Hospital, Brest","All","up to 18 Years   (Child, Adult)",,"2500","Other","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","CHRU de BREST ECHO","April 7, 2020","May 11, 2020","May 11, 2020","May 20, 2020",,"May 20, 2020","CHRU de Brest, Brest, France",,"https://ClinicalTrials.gov/show/NCT04395833"
1143,"NCT04338802","Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19",,"Not yet recruiting","No Results Available","COVID-19|Nintedanib|Safety|Effect of Drugs","Drug: Nintedanib 150 MG|Other: Placebo","Changes in forced vital capacity (FVC)|Changes in carbon monoxide dispersion (DLco%)|Changes in the six-minute walk test (6MWT)|Changes in High resolution CT score","Huilan Zhang|Tongji Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","huilanz Zhang","April 2, 2020","May 4, 2020","August 1, 2020","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04338802"
1144,"NCT04385771","Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","CYCOV-II","Not yet recruiting","No Results Available","Coronavirus Infection|COVID|SARS-CoV 2|Respiratory Failure|Cytokine Storm|Extracorporeal Membrane Oxygenation","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption)","IL-6 reduction by 75% or more after 72 hours as compared to the baseline measurement|time to successful ECMO-explantation|Ventilator free days (VFD)|Time to extubation from ventilation and explantation from ECMO|Overall survival time|Days on intensive care unit (ICU)|Vasopressor dosage|Fluid substitution and fluid balance|Serum lactate|Urine output|Willebrand factor|d-dimers|interleukin-6 levels|SOFA-Score|serious adverse device effects|adverse event of special interest: air in the ECMO system|adverse event of special interest: blood-clotting in the ECMO system|adverse event of special interest: bleeding complications","Dr. Alexander Supady|Klinikum Ibbenbüren|Ludwig-Maximilians - University of Munich|University Hospital, Saarland|Klinikum Ludwigsburg|University of Ulm|SLK-Kliniken Heilbronn|Martin-Luther-Universität Halle-Wittenberg|University Hospital Freiburg","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CYCOV-II","June 1, 2020","May 31, 2021","October 31, 2021","May 13, 2020",,"May 14, 2020","University Clinic Freiburg, Freiburg, Germany",,"https://ClinicalTrials.gov/show/NCT04385771"
1145,"NCT04363450","Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)","HCQPreP","Recruiting","No Results Available","COVID-19|Corona Virus Infection|Wuhan Coronavirus|Prophylaxis|Healthcare Worker|Sars-CoV2|Hydroxychloroquine","Drug: Hydroxychloroquine|Drug: Placebo","Incidence of symptomatic COVID-19 infection in healthcare workers|Absenteeism from work due to COVID-19|Severity of COVID-19 infection","Louisiana State University Health Sciences Center in New Orleans|Lafayette General Health|University of Louisiana at Lafayette","All","18 Years and older   (Adult, Older Adult)","Phase 3","1700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","LSU NO HSC IRB 20-050","April 27, 2020","July 6, 2020","August 3, 2020","April 27, 2020",,"April 29, 2020","Lafayette General Medical Center, Lafayette, Louisiana, United States|University Hospital and Clinics, Lafayette, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04363450"
1146,"NCT04357496","COVID-19 Epidemic Response Study","COVeR","Not yet recruiting","No Results Available","Fever|Pneumonia|Cough",,"Identification of prognostic parameters for SARS-CoV-2 infected participants.|Investigation of the kinetics of immune activation and antibody production against SARS-CoV-2 and correlation with clinical course","Centogene AG Rostock","All","60 Years and older   (Adult, Older Adult)",,"400","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVER-2020","April 20, 2020","October 30, 2020","October 30, 2020","April 22, 2020",,"April 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04357496"
1147,"NCT04319445","Mindfulness During COVID-19",,"Recruiting","No Results Available","Migraine Disorders|Stress|Anxiety","Behavioral: Mindfulness session(s)","Helpfulness of the session|Platform effectiveness|Change in Anxiety Level|Change in Stress Level|Value of the session|Satisfaction with the session|Percentage of participants that showed interest in a future session|Percentage of participants that would recommend this session to a family member|Percentage of participants by session frequency preference","Wake Forest University Health Sciences","All","Child, Adult, Older Adult","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00064587","March 22, 2020","December 2020","December 2020","March 24, 2020",,"April 24, 2020","Wake Forest Health Sciences, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04319445"
1148,"NCT04376814","Safety and Efficacy of Hydroxychloroquine + Favipiravir Drug Regimen in Comparison With Hydroxychloroquine + Kaletra on the Need for Intensive Care Unit Treatment in Patients With COVID-19",,"Enrolling by invitation","No Results Available","COVID-19|Favipiravir|Kaletra|Hydroxychloroquine","Drug: Favipiravir|Drug: Hydroxychloroquine|Drug: Kaletra","Admission to the ICU|Mortality|length of stay in hospital|Radiological Treatment Response|Laboratory Treatment Response (Blood cell count)|Laboratory Treatment Response (CRP )|Fever|Dyspnea|Oxygen saturation without supplemental oxygen.|Allergic drug|Oxygen therapy|Adverse drug","Baqiyatallah Medical Sciences University","All","16 Years to 100 Years   (Child, Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IR.BMSU.REC.1399.017","March 29, 2020","April 5, 2020","May 25, 2020","May 6, 2020",,"May 6, 2020","Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04376814"
1149,"NCT04385147","Advanced Endoscopy During COVID-19",,"Recruiting","No Results Available","Cholangitis, Secondary Biliary|Cholangiocarcinoma|Obstructive Jaundice|Pancreas Cancer|COVID-19|SARS-CoV-2","Other: Endoscopic management according to standard of care","Age, gender, nationality|Indication for procedure, status of SARS-CoV-2 infection|Complete blood count and liver functions tests|procedure related complications|Effect of COVID-19 precautions on procedure time|Effect of COVID-19 precautions on staff number","Al-Azhar University|Helwan University|National Liver Institute, Egypt","All","Child, Adult, Older Adult",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Global-Endo-COVID","May 18, 2020","June 18, 2020","June 20, 2020","May 12, 2020",,"May 20, 2020","Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Al-Azhar Univerisity, Cairo, Egypt|University Medicine Greifswald, Greifswald, Germany|2- Hospital Guillermo Kaelin De la Fuente - EsSalud, Lima, Peru|Singapore General Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04385147"
1150,"NCT04366908","Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome","COVIDIOL","Not yet recruiting","No Results Available","SARS-CoV 2|COVID19|SARS (Severe Acute Respiratory Syndrome)|Cytokine Release Syndrome|Cytokine Storm","Drug: BAT + Calcifediol|Drug: BAT","Admission to Intensive Care Unit|Death|Time from onset of symptoms to discharge of patients in conventional hospitalization|ICU - Time until admission|ICU - Time mechanical ventilation is removed|Evaluation of the inflammatory markers related with the disease|Vitamin D metabolites|Evolution in SatO2|Evolution in the Sat O2/FiO2 ratio.|Evolution in the degree of dyspnea|Evolution of the improvement of radiological findings by simple radiology|Incidence of adverse events|Appearance of hemorrhagic or thrombotic phenomena","Maimónides Biomedical Research Institute of Córdoba|Junta de Andalucía - Consejería de Salud y Familias|Dynamic Solutions|FAES Farma","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","1008","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVIDIOL","April 28, 2020","July 28, 2020","August 28, 2020","April 29, 2020",,"April 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04366908"
1151,"NCT04359836","A Study to Explore the Role of Gut Flora in COVID-19 Infection",,"Recruiting","No Results Available","Gut Microbiome|Gastrointestinal Microbiome|COVID|COVID-19|Corona Virus Infection|Coronavirus|Coronaviridae Infections|Coronavirus 19|Coronavirus-19|COVID 19","Other: There is no intervention in this study","Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing|Validation of Sequencing Methods","ProgenaBiome","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Other|Time Perspective: Other","PRG-041","April 16, 2020","April 30, 2021","July 31, 2021","April 24, 2020",,"April 24, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04359836"
1152,"NCT04377165","Innovative Tool to Limit Spread of SARS-CoV-2 in Residential Aged Care Facilities",,"Not yet recruiting","No Results Available","COVID|Influenza|Gastroenteritis","Behavioral: Gamification|Behavioral: Newsfeed function","To compare the hours of sick leave used over the course of the 4-week period post randomisation for each group|To compare handwashing behaviour|To compare self-testing rates|To compare the level of surface wipe down|To compare number of COVID-19 tests completed in Facilities|To compare the number of COVID 19 infections in facilities|To compare the other types of outbreaks (Flu, gastroenteritis)|To compare the awareness of COVID 19 training available to workers in the facilities|To compare the awareness of PPE training available to workers in the facilities|To compare the levels of PPE material used in|To compare the wellbeing and self-efficacy of the two groups","The University of Queensland","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","9000","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Care Collective Study","May 6, 2020","June 4, 2020","June 4, 2020","May 6, 2020",,"May 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04377165"
1153,"NCT04327505","Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19","COVID-19-HBO","Recruiting","No Results Available","SARS (Severe Acute Respiratory Syndrome)|Cytokine Storm|ARDS, Human|COVID-19|Sars-CoV2|Acute Respiratory Failure","Drug: Hyperbaric oxygen","ICU admission|30-day mortality|Time-to-intubation|Time-to-ICU|Inflammatory response|Overall survival","Karolinska Institutet|Karolinska Trial Alliance|University of California, San Diego|Blekinge County Council Hospital|JK Biostatistics AB|The Swedish Research Council","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19-HBO|2020-001349-37|K-1199/2020","May 22, 2020","December 31, 2021","December 31, 2022","March 31, 2020",,"May 20, 2020","Bergmannsheil und Kinderklinik Buer GmbH, Gelsenkirchen, Germany|Krankenhaus St. Joesf, Regensburg, Germany|Blekingesjukhuset, Karlskrona, Blekinge, Sweden",,"https://ClinicalTrials.gov/show/NCT04327505"
1154,"NCT04366752","Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy","THROMBOCOVID","Recruiting","No Results Available","COVID-19|Pneumonia|ARDS|Hemostasis|Coagulation","Other: venous ultrasound|Other: blood sample","Variation of thrombin time (in secondes) in Covid-19 patients with pneumonia admitted in ICU.|Variation of factor V concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU.|Variation of factor II concentration (U/dL) in Covid-19 patients with pneumonia admitted in ICU.|Variation of concentration of fibrin and fibrinogen degradation products (≥ 10 µgm/mL) in Covid-19 patients with pneumonia admitted in ICU.","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PI2020_843_0036","April 22, 2020","August 22, 2020","September 22, 2020","April 29, 2020",,"April 29, 2020","CHU Amiens, Amiens, France",,"https://ClinicalTrials.gov/show/NCT04366752"
1155,"NCT04354558","French Single Centre Experience of Critically Ill Patients With Covid 19","CovidAmiens20","Not yet recruiting","No Results Available","Epidemiology|Sars-CoV2|COVID 19|Critical Care|Prognostic|Survival",,"Variation of age between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU|Variation of medical history between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU|Variation of chronic drug used between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU|Variation of chest CT scan at admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU|Variation of respiratory support at ICU admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PI2020_843_0026","April 2020","April 2021","April 2021","April 21, 2020",,"April 21, 2020","CHU Amiens, Amiens, France",,"https://ClinicalTrials.gov/show/NCT04354558"
1156,"NCT04363463","Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress","PROVID-19","Not yet recruiting","No Results Available","COVID19|Oxygen Therapy|Prone Position|Spontaneous Ventilation|Respiratory Distress Syndrome","Other: prone position","Percent age of patients who will have endotracheal intubation or non-invasive ventilation at two pressure levels and/or die, in each of the 2 randomization groups.|Duration in days for the change of 2 points on the WHO ordinal scale|Rate (%) of intubation and invasive ventilation in the 2 randomization groups.|Rate (%) of non-invasive ventilation at two pressure levels in the 2 randomization groups|Duration of oxygen therapy in the 2 randomization groups.|Duration of hospitalization in the 2 randomization groups.|Hospital mortality and mortality at D28 in the 2 randomization groups|Rate (%) of need for transfer to intensive care unit|Rate (%) of use of non-invasive ventilation at two pressure levels, intubation throughout the entire stay when the stay is longer than 28 days.","Centre Hospitalier Régional d'Orléans","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CHRO-2020-09","May 2020","May 2022","May 2022","April 27, 2020",,"April 27, 2020","CH de DAX, Dax, France|CHD de VENDEE, La Roche sur Yon, France|CH de LA ROCHELLE, La Rochelle, France|CHR d'Orléans - Service Pneumologie, Orléans, France|CHR d'Orleans - Service Maladies Infectieuses, Orléans, France|HOPITAL LARIBOISIERE - Service diabétologie, endocrinologie, nutrition, Paris, France|Hopital Lariboisiere - Medecine Interne, Paris, France|Hopital Lariboisiere, Paris, France|CH de PERPIGNAN - Service Maladies infectieuses, Perpignan, France|CH de Perpignan - pneumologie, Perpignan, France|Centre Hospitalier Intercommunal de Cornouaille - Quimper Concarneau, Quimper, France|CHRU de Tours - Service Médecine interne et immunologie Clinique, Tours, France|CHRU de Tours - Service Pneumologie, Tours, France|CHRU DE TOURS - Service Médecine interne et maladies infectieuses, Tours, France",,"https://ClinicalTrials.gov/show/NCT04363463"
1157,"NCT04340050","COVID-19 Convalescent Plasma",,"Active, not recruiting","No Results Available","Coronavirus","Biological: anti-SARS-CoV-2 convalescent plasma","Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients|Type of respiratory support|Cardiac arrest|Transfer to ICU|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Ventilator-free days|Overall survival (28-day mortality)","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0523","April 10, 2020","December 31, 2020","December 31, 2021","April 9, 2020",,"May 14, 2020","University of Chicago Medicine, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04340050"
1158,"NCT04378452","Assessment of the Psycho-social Impact of COVID-19 Outbreak","COM-COVID","Recruiting","No Results Available","SARS-CoV 2|COVID-19|Quality of Life|Mental Health Wellness 1|Social Distance|SARS (Disease)|Psychological","Behavioral: COM-COVID anonimous survey","Psychological impact of the outbreak, total score|Psychological impact of the outbreak: depression questions score|Psychological impact of the outbreak: anxiety questions score|Psychological impact of the outbreak: stress questions score|Psychological impact of the outbreak: PSTD questions score|Descriptive statistics for the non-psychological questions","Fundació Institut Germans Trias i Pujol|Anaxomics|Fundació Lluita contra la Sida (FLS)","All","16 Years and older   (Child, Adult, Older Adult)",,"65000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","COM-COVID","March 31, 2020","September 2020","December 2020","May 7, 2020",,"May 7, 2020","Fundació Institut Germans Trias i Pujol, Badalona, Catalonia, Spain|Fundació Lluita contra la Sida (FLS, Fight AIDS Foundation), Badalona, Catalonia, Spain|Anaxomics biotech, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04378452"
1159,"NCT04370834","Tocilizumab for Patients With Cancer and COVID-19 Disease",,"Not yet recruiting","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Pneumonia|Symptomatic COVID-19 Infection Laboratory-Confirmed","Biological: Tocilizumab","Frequency of response|Length of time from level of care to step down level of care|Survival","National Cancer Institute (NCI)","All","2 Years and older   (Child, Adult, Older Adult)","Phase 2","200","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NCI-2020-02987|TRC-10446","June 1, 2020","January 1, 2022","January 1, 2022","May 1, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04370834"
1160,"NCT04264858","Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients",,"Not yet recruiting","No Results Available","2019-nCoV|Immunoglobulin of Cured Patients","Drug: Immunoglobulin of cured patients|Drug: γ-Globulin","Time to Clinical Improvement (TTCI)|Clinical status assessed by the ordinal scale|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|The lesions of the pulmonary segment numbers involved in pulmonary CT [ every 7 days]|Time to 2019-nCoV RT-PCR negativity in respiratory tract specimens [every 3 days]|Dynamic changes of 2019-nCoV antibody titer in blood|Length of hospital stay (days)|All cause mortality","Wuhan Union Hospital, China","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WuhanUH-2019 nCoV-Ig","March 17, 2020","April 30, 2020","May 31, 2020","February 11, 2020",,"March 17, 2020","Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04264858"
1161,"NCT04397848","Mental Health Outcomes in Healthcare Workers During COVID-19",,"Recruiting","No Results Available","Mental Health Wellness 1|PTSD|Anxiety|Stress|Depression|COVID-19|Healthcare Workers",,"Impact of Event Scale - Revised (IES-R)|General Anxiety Disorder (GAD-7)|Patient Health Questionnaire (PHQ-9)|Qualitative Data","University Health Network, Toronto|William Osler Health System|University of Toronto|Sunnybrook Health Sciences Centre","All","18 Years and older   (Adult, Older Adult)",,"1200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","3189","May 14, 2020","June 15, 2020","June 24, 2020","May 21, 2020",,"May 21, 2020","University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04397848"
1162,"NCT04368897","In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity",,"Not yet recruiting","No Results Available","SARS-CoV 2|COVID|COVID-19|Androgenetic Alopecia|Androgen Receptor Abnormal|Androgen Deficiency","Diagnostic Test: CAG length <24|Diagnostic Test: CAG length >=24","Hospital-free days to Day 28 [ Time Frame: 28 days]|1. Severity of Disease","Applied Biology, Inc.|Hospital Universitario Ramon y Cajal","Male","18 Years and older   (Adult, Older Adult)",,"200","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","AB-IVD-CoV-001","May 1, 2020","September 1, 2020","December 1, 2020","April 30, 2020",,"April 30, 2020","Hospital Universitario Ramon y Cajal, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04368897"
1163,"NCT04348864","COVID-19 Antibody Self-testing Using Virtual Point-of-care",,"Recruiting","No Results Available","Communicable Disease|COVID-19|Sars-CoV2|Infectious Disease|Coronavirus|Virus Diseases","Diagnostic Test: COVID-19 IgM/IgG Rapid Testing, mobile device image capture and telemedicine support|Other: Telemedicine","Clinical accuracy of the antibody-based rapid tests compared to PCR-based test result|Clinical accuracy of the rapid tests based on Clinical diagnosis|Self-test interpretation of result vs expert clinical image interpretation of result|Ease of self-testing procedure","Neuroganics LLC","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2020/03/18","April 16, 2020","April 2021","April 2021","April 16, 2020",,"April 20, 2020","Neuroganics, Northglenn, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04348864"
1164,"NCT04398147","Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Canada",,"Not yet recruiting","No Results Available","COVID-19","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Placebo","Solicited AE in all groups|Unsolicited AE in all groups|Serious adverse events (SAE) in all groups|Geometric mean titer (GMT) of the IgG antibody against SARS-CoV-2 (ELISA method);|Seroconversion rate of the IgG antibody against SARS-CoV-2(ELISA method )|Geometric Mean Increase Ratio (GMI) of the specific antibody against SARS-CoV-2(ELISA method);|Geometric mean titer (GMT) of the neutralizing antibody against SARS-CoV-2(Pseudo-viral neutralization assay)|Seroconversion rate of the neutralizing antibody against SARS-CoV-2(Pseudo-viral neutralization assay)|Geometric mean increase ratio (GMI) of neutralizing antibody against SARS-CoV-2 (Pseudo-viral neutralization assay)|Geometric Mean Titer (GMT) of the neutralizing antibody against adenovirus type 5 vector|Geometric mean increase ratio (GMI) of the neutralizing antibody against adenovirus type 5 vector|cellular immune response by ELISpot|cellular immune response by ICS","CanSino Biologics Inc.|Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China|Canadian Center for Vaccinology","All","18 Years to 84 Years   (Adult, Older Adult)","Phase 1|Phase 2","696","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Ad5-nCoV-2020003","May 2020","March 2021","August 2021","May 21, 2020",,"May 21, 2020","Canadian Center for Vaccinology, Halifax, Canada",,"https://ClinicalTrials.gov/show/NCT04398147"
1165,"NCT04332666","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","ATCO","Not yet recruiting","No Results Available","Coronavirus|Respiratory Failure|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|SARS-CoV-2","Drug: Angiotensin 1-7|Drug: Placebos","ventilator free days|ICU free days|Hospital length of stay|Time to wean from mechanical ventilation|PaO2/FiO2 changes during drug administration|Deep vein thrombosis incidence|Changes in inflammatory markers|RAS effectors levels|Radiological findings","Erasme University Hospital|Fonds Erasme pour la Recherche Médicale","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P2020/201","March 31, 2020","May 30, 2020","June 15, 2020","April 3, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04332666"
1166,"NCT04378582","Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU","EpiCoV-Brazil","Not yet recruiting","No Results Available","SARS-CoV 2|Respiratory Distress Syndrome, Adult|Corona Virus Infection|Critical Illness","Other: risk factors","ICU survival at 28 days|Hospital survival at 60 days|Duration of mechanical ventilation|Need for renal replacement therapy|Complications during the ICU stay","University of Sao Paulo General Hospital","All","14 Years to 100 Years   (Child, Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","31382620.0.0000.0068","May 10, 2020","August 30, 2020","December 31, 2020","May 7, 2020",,"May 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04378582"
1167,"NCT04357340","The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19",,"Not yet recruiting","No Results Available","Covid-19|Pneumonia|SARS Pneumonia","Other: Pulmonary Physiotherapy Techniques","Mixed venous O2 pressure (PVO2)|Mixed venous CO2 pressure (PVCO2)|PH|HCO3|Oxygen saturation (O2 Sat) from VBG|Six minute walk test|O2 Sat after one minute walking|O2 Sat after two minutes use of Partial Rebreather|O2 Sat after two minutes free air breathing|O2 sat/ Fio2|breathlessness|Mortality rate|Number of participants with Rehospitalization|The Health-Related Quality of Life (HRQOL)","Tehran University of Medical Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","99-1-103-47429","April 20, 2020","June 20, 2020","August 1, 2020","April 22, 2020",,"April 22, 2020","Imam Khomeini Hospital Complex, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04357340"
1168,"NCT04332991","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","ORCHID","Recruiting","No Results Available","Coronavirus|Acute Respiratory Infection|SARS-CoV Infection","Drug: Hydroxychloroquine|Drug: Placebo","COVID Ordinal Outcomes Scale on Day 15|all-location, all-cause mortality assessed on day 15|all-location, all-cause mortality assessed on day 29|COVID Ordinal Outcomes Scale on Study Day 3|COVID Ordinal Outcomes Scale on Study Day 8|COVID Ordinal Outcomes Scale on Study Day 29|Number of patients dead or with receipt of ECMO between enrollment and Day 28|Oxygen-free days through Day 28|Ventilator-free days through Day 28|Vasopressor-free days through Day 28|ICU-free days to Day 28|Hospital-free days to Day 28","Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","510","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PETAL 05 Orchid","April 2, 2020","April 2021","July 2021","April 3, 2020",,"May 21, 2020","University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04332991"
1169,"NCT04400019","Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)","PREVICHARM","Not yet recruiting","No Results Available","Sars-CoV2|Coronavirus Infection|Prevention & Control|Nursing Home|Hydroxychloroquine","Drug: Hydroxychloroquine Only Product in Oral Dose Form","Number of secondary cases of SARS-CoV2 infection among residents at six days|Number of secondary cases of SARS-CoV2 infection among residents at 14 days|Number of secondary cases of SARS-CoV2 infection among residents at 28 days|SARS-CoV-2 infection in nursing home staff who provide direct care at six days|SARS-CoV-2 infection in nursing home staff who provide direct care at 14 days|SARS-CoV-2 infection in nursing home staff who provide direct care at 28 days|Mortality|Compliance with treatment|Symptoms of SARS-CoV-2 infection at six days|Symptoms of SARS-CoV-2 infection at 14 days|Symptoms of SARS-CoV-2 infection at 28 days|Hospitalization|Adverse events at six days|Adverse events at 14 days|Adverse events at 28 days","University of Malaga|Instituto de Investigacion Biomedica de Malaga|Carlos III Health Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1930","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","COV20/00565","May 15, 2020","December 15, 2020","April 1, 2021","May 25, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04400019"
1170,"NCT04320238","Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff",,"Recruiting","No Results Available","2019 Novel Coronavirus Infection","Drug: recombinant human interferon Alpha-1b|Drug: thymosin alpha 1","new-onset COVID-19|Number of Participants with coronavirus related symptoms|Number of Participants with adverse effect","Shanghai Jiao Tong University School of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","2944","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Interferon_prophylaxis","January 21, 2020","May 2020","June 2020","March 24, 2020",,"March 31, 2020","Taihe Hospital, Shiyan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04320238"
1171,"NCT04357275","The RIsk Stratification in COVID-19 Patients in the ICU Registry","RISC-19-ICU","Recruiting","No Results Available","Critical Illness|ARDS|Inflammatory Response|COVID-19|Circulatory Shock","Other: ICU treatment","ICU mortality|Hospital mortality|ICU length of stay","University of Zurich","All","Child, Adult, Older Adult",,"10000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KEK-ZH-req-2020-00322","March 13, 2020","March 2021","March 2022","April 22, 2020",,"April 22, 2020","University Hospital of Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04357275"
1172,"NCT04391140","Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS",,"Recruiting","No Results Available","COVID|ARDS|Acute Respiratory Distress Syndrome|Acute Respiratory Failure|Corona Virus Infection","Other: Prone position","Therapeutic failure death or intubation|Feasibility and safety of prone position in HFNC patients|Efficacy of prone position in HFNC patients","Hospital Universitari Vall d'Hebron Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","248","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PR(AG)198/2020","May 1, 2020","December 2020","June 2021","May 18, 2020",,"May 18, 2020","Hospital Universitari Vall d'Hebron, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04391140"
1173,"NCT04397692","Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)",,"Not yet recruiting","No Results Available","Corona Virus Infection|COVID-19|SARS-CoV 2|Nitric Oxide|Respiratory Disease|Pneumonia, Viral|Inhaled Nitric Oxide","Device: Nitric Oxide delivered via LungFit system","Time to deterioration|Time to non-invasive ventilation|Time to HFNC|Time to intubation|Time to patient having stable oxygen saturation (SpO2) greater than 92%","Beyond Air Ltd","All","22 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","BAI_COV19_01_US","May 18, 2020","August 24, 2020","September 30, 2020","May 21, 2020",,"May 21, 2020","Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT04397692"
1174,"NCT04352517","Influence Physical Activity Psychological Responses COVID-19 Pandemic",,"Recruiting","No Results Available","Sedentary Behavior|Mental Health Wellness 1","Other: Online Survey","Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on avoidance impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on intrusion impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on hyperarousal impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on depression health status through DASS-21|IImpact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on anxiety health status through DASS-21|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on stress health status through DASS-21","University of Extremadura","All","18 Years and older   (Adult, Older Adult)",,"3500","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","3.954.038","March 16, 2020","August 31, 2020","September 30, 2020","April 20, 2020",,"April 21, 2020","Universidade da Sao Paulo, Ribeirão Preto, Sao Paulo, Brazil|Universidad Autonoma de Chile, Santiago, Región Metropolitana, Chile|Universidad de la República, Rivera, Uruguay","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT04352517/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04352517"
1175,"NCT04369989","Observational Study of COVID-19 Treatment Efficacy",,"Enrolling by invitation","No Results Available","Coronavirus|Coronavirus Infection|Corona Virus Infection|COVID|Sars-CoV2|Coronavirus as the Cause of Diseases Classified Elsewhere|SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere|COVID-19|Coronavirus Disease|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere","Other: No intervention","Mortality during the COVID-19 treatment hospital encounter|ICU admission during the COVID-19 treatment hospital encounter|Ventilator use during the COVID-19 treatment hospital encounter","OSF Healthcare System","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","1589936","April 14, 2020","April 14, 2021","April 14, 2021","April 30, 2020",,"April 30, 2020","OSF HealthCare St Francis Medical Center, Peoria, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04369989"
1176,"NCT04323787","Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry","COVID-19","Recruiting","No Results Available","Coronavirus","Other: observational","ICU and hospital mortality of COVID-19 patients|30 days mortality","Mayo Clinic","All","Child, Adult, Older Adult",,"50000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","20-002610","March 30, 2020","April 30, 2021","April 30, 2021","March 27, 2020",,"April 14, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Society of Critical Care Medicine (150+ sites), Chicago, Illinois, United States|Rahul Kashyap, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04323787"
1177,"NCT04359914","Neurocognitive Impairment in Patients With COVID-19","NCoV","Recruiting","No Results Available","Critical Illness|COVID-19|Central Nervous System Injury|Delirium|Encephalopathy",,"Incidence of delirium/neurocognitive impairment in adult and pediatric patients with COVID-19 compared to patients without COVID-19|Change in neuroaxonal injury biomarker levels in patients with COVID-19 compared to patients without COVID-19|Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19|Quality of life in patients with COVID-19 compared to patients without COVID-19 after hospital discharge|Length of hospital stay in patients with COVID-19 compared to patients without COVID-19|90-day survival in patients with COVID-19 compared to patients without COVID-19","University of Rostock|Ludwig-Maximilians - University of Munich|University College, London","All","Child, Adult, Older Adult",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","COVID-BRAIN","April 15, 2020","December 31, 2020","April 1, 2021","April 24, 2020",,"April 24, 2020","Department of Anesthesiology and Intensive Care Medicine, University Medical Center Rostock, Rostock, Mecklenburg-Vorpommern, Germany",,"https://ClinicalTrials.gov/show/NCT04359914"
1178,"NCT04374565","Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia",,"Recruiting","No Results Available","Corona Virus Infection|SARS-CoV 2|SARS Pneumonia|Pneumonia","Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma","Transfer to ICU|28 day mortality|Cumulative incidence of serious adverse events|Rates and duration of SARS-CoV-2|Serum of plasma antibody titer to SARS-CoV-2|Cellular and humoral immune response|Supplemental oxygen free days|Ventilator free days|ICU free days|Sequential organ failure assessment score|Need for vasopressors|Need for renal replacement therapy|Need for extracorporeal membrane oxygenation (ECMO)|Hospital length of stay (LOS)|ICU LOS|Grade 3 or 4 Adverse Events (AEs)","University of Virginia","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200114","May 5, 2020","April 5, 2021","April 5, 2021","May 5, 2020",,"May 8, 2020","University of Virginia Medical Center, Charlottesville, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04374565"
1179,"NCT04324528","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","CYCOV","Recruiting","No Results Available","Coronavirus|COVID-19|SARS-CoV Infection|Respiratory Failure|Cytokine Storm","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption)","interleukin-6 (IL-6) level after 72 hours|30-day-survival|vasopressor dosage|fluid balance|lactate","Dr. Alexander Supady|University Hospital Freiburg","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CYCOV","March 27, 2020","September 26, 2020","November 26, 2020","March 27, 2020",,"March 31, 2020","University Clinic Freiburg, Freiburg, Germany",,"https://ClinicalTrials.gov/show/NCT04324528"
1180,"NCT04395716","A Study of ResCure™ to Treat COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID|Covid-19|Corona Virus Infection|Sars-CoV2|Coronavirus-19|SARS Pneumonia|SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere","Biological: ResCure™","The rate of recovery of mild or moderate COVID-19 in patients using ResCure™|Reduction or progression of symptomatic days|Assess the safety of ResCure™ via pulse|Assess the safety of ResCure™ via oxygen saturation|Assess the safety of ResCure™ via EKG|Assess Tolerability of ResCure™","ProgenaBiome|Rinati Skin, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRG-048","May 2020","May 2021","October 2021","May 20, 2020",,"May 20, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04395716"
1181,"NCT04361461","Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)",,"Not yet recruiting","No Results Available","Coronavirus Infections|SARS-CoV 2|SARS (Severe Acute Respiratory Syndrome)|Pulmonary Disease","Drug: Hydroxychloroquine Sulfate|Drug: Hydroxychloroquine Sulfate + Azythromycin","Individual response rate|All-cause mortality|Duration of mechanical ventilation|Proportion of patients which needed mechanical ventilation during study|World Health Organization (WHO) Ordinal scale|Duration of hospitalization|Rates of drug discontinuation","Apsen Farmaceutica S.A.|Hospital São Paulo","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APS001/2020","May 4, 2020","November 4, 2020","November 4, 2020","April 24, 2020",,"April 24, 2020","Apsen Farmacêutica S.A., São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04361461"
1182,"NCT04343651","Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19",,"Recruiting","No Results Available","Coronavirus Disease 2019","Drug: Placebos|Drug: Leronlimab (700mg)","Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)|Time to clinical resolution (TTCR)|Change from baseline in National Early Warning Score 2 (NEWS2)|Change from baseline in pulse oxygen saturation (SpO2)|Change from baseline in the patient's health status on a 7-category ordinal scale|Incidence of hospitalization|Duration (days) of hospitalization|Incidence of mechanical ventilation supply|Duration (days) of mechanical ventilation supply|Incidence of oxygen use|Duration (days) of oxygen use|Mortality rate|Time to return to normal activity","CytoDyn, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CD10_COVID-19","April 1, 2020","December 4, 2020","April 4, 2021","April 13, 2020",,"May 12, 2020","University of California, Los Angeles, Los Angeles, California, United States|Palmtree Clinical Research, Inc., Palm Springs, California, United States|Eisenhower Health, Rancho Mirage, California, United States|Yale, New Haven, Connecticut, United States|Atlantic Health System Hospital, Morristown, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Novant Health, Charlotte, North Carolina, United States|Ohio Health, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04343651"
1183,"NCT04381364","Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)","HALT","Not yet recruiting","No Results Available","Covid-19|Pneumonia, Viral|ARDS|ARDS, Human|Sars-CoV2|Coronavirus Infection|Corona Virus Infection","Drug: Ciclesonide Inhalation Aerosol","Duration of received supplemental oxygen therapy|Invasive mechanical ventilation or all-cause death|All cause death|Invasive mechanical ventilation|Maximum oxygen therapy|Duration of hospitalization|Remaining dyspnea symptoms","Ola Blennow, MD, PhD|Karolinska University Hospital|Danderyd Hospital|Centrallasarettet Västerås|St Goran's Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","446","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-02183","May 15, 2020","December 1, 2020","December 31, 2020","May 8, 2020",,"May 12, 2020","Danderyd Hospital, Danderyd, Entrévägen 2, Sweden|Capio S:t Görans Hospital, Stockholm, Sankt Göransplan 1, Sweden|Västmanland County Hospital Västerås, Västerås, Sigtunagatan, Sweden|Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04381364"
1184,"NCT04398277","A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic",,"Recruiting","No Results Available","Psychological Stress","Behavioral: Daily Coping Toolkit","Patient Health Questionnaire - 4|World Health Organization Well Being Questionnaire|Affective Experience|Treatment Acceptability Questionnaire","Kent State University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20-183","May 1, 2020","April 2021","April 2021","May 21, 2020",,"May 21, 2020","Akron Children's Hospital, Akron, Ohio, United States|Summa Health Systems, Akron, Ohio, United States|Kent State University, Kent, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04398277"
1185,"NCT04285190","The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19",,"Not yet recruiting","No Results Available","Coronavirus Disease 2019|Novel Coronavirus Pneumonia","Drug: T89","The time to oxygen saturation recovery to normal level (≥97%)|The proportion of patients with normal level of oxygen saturation(≥97%)|The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, etc.|The time to the myocardial enzyme spectrum recovery to normal after treatment|The proportion of the patients with normal myocardial enzyme spectrum after treatment|The time to the electrocardiogram recovery to normal level after treatment|The proportion of the patients with normal electrocardiogram after treatment|The time to the hemodynamics recovery to normal after treatment|The proportion of the patients with normal hemodynamics after treatment|The time to exacerbation or remission of the disease after treatment;|The proportion of the patients with exacerbation or remission of disease after treatment|The proportion of patients who need other treatment (e.g. heparin, anticoagulants) due to microcirculation disorders|The all-cause mortality rate|The proportion of patients with acidosis|The total duration of the patients in-hospital|The total duration of oxygen inhalation during treatment|The oxygen flow rate during treatment|The oxygen concentration during treatment","Tasly Pharmaceuticals, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T89-NCP-01","February 26, 2020","June 15, 2020","September 15, 2020","February 26, 2020",,"February 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04285190"
1186,"NCT04360096","Inhaled Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19","AVINALI","Not yet recruiting","No Results Available","SARS-CoV 2|COVID|ARDS|ALI|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Dyspnea","Drug: Aviptadil (VIP)|Drug: Placebo","Progression to ARDS|Blood oxygenation|RDP Dsypnea Scale|Distance walked in six minutes","NeuroRx, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","144","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RLF-100_002","June 1, 2020","August 1, 2020","October 1, 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04360096"
1187,"NCT04352985","Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19",,"Available","No Results Available","Septic Shock|Endotoxemia|COVID|Corona Virus Infection|Sepsis, Severe","Device: Toraymyxin PMX-20R (PMX Cartridge)",,"Spectral Diagnostics (US) Inc.","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population",,"SDI-PMX-013",,,,"April 20, 2020",,"April 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04352985"
1188,"NCT04324606","A Study of a Candidate COVID-19 Vaccine (COV001)",,"Active, not recruiting","No Results Available","Coronavirus","Biological: ChAdOx1 nCoV-19|Biological: MenACWY|Biological: ChAdOx1 nCoV-19 boost|Drug: Paracetamol","Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases|Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited systemic reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of unsolicited adverse events (AEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV through standard blood tests|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV by measuring the number of disease enhancement episodes|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19","University of Oxford","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","1090","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","COV001","April 23, 2020","May 2021","May 2021","March 27, 2020",,"May 19, 2020","University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom|St Georges University Hospital NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04324606"
1189,"NCT04384380","Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19",,"Recruiting","No Results Available","Coronavirus Infection","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]","Time to negatively RT-PCR|Virologic assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Taoyuan General Hospital|Center for Drug Evaluation, Taiwan|Centers for Disease Control, Taiwan|Taiwan Food and Drug Administration|National Health Research Institutes, Taiwan","All","20 Years to 79 Years   (Adult, Older Adult)","Phase 4","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TYGH109014","April 1, 2020","June 30, 2020","September 30, 2020","May 12, 2020",,"May 12, 2020","Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04384380/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04384380"
1190,"NCT04325048","Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients",,"Not yet recruiting","No Results Available","Coronavirus Infection","Device: Cordio App","Voice anaysis","Cordio Medical","All","18 Years and older   (Adult, Older Adult)",,"5000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","COV001","April 2020","June 2021","September 2021","March 27, 2020",,"April 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04325048"
1191,"NCT04321096","The Impact of Camostat Mesilate on COVID-19 Infection","CamoCO-19","Recruiting","No Results Available","Corona Virus Infection","Drug: Camostat Mesilate|Drug: Placebo oral tablet","Cohort 1: Days to clinical improvement from study enrolment|Cohort 2: Days to clinical improvement from study enrolment|Safety evaluation, as measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs)|Cohort 1: Clinical status as assessed by the 7-point ordinal scale at day 7, 14 and 30|Cohort 1: Day 30 mortality|Cohort 1: Change in NEW(2) score from baseline to day 30|Cohort 1: Admission to ICU|Cohort 1: Use of invasive mechanical ventilation or ECMO|Cohort 1: Duration of supplemental oxygen (days)|Cohort 1+2: Days to self-reported recovery (e.g. limitations in daily life activities) during telephone interviews conducted at day 30|Cohort 2: Number participant-reported secondary infection of housemates|Cohort 2: Time to hospital admission related to COVID-19 infection","University of Aarhus","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 1|Phase 2","580","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-001200-42","April 4, 2020","December 31, 2020","May 1, 2021","March 25, 2020",,"April 30, 2020","Department of Infectious Diseases, Aalborg, Denmark|Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark|Herning Regional Hospital, Herning, Denmark|Northzealands hospital - Hillerød, Hillerød, Denmark|Horsens Regional Hospital, Horsens, Denmark|Bispebjerg hospital, København, Denmark|Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Silkeborg Hospital, Silkeborg, Denmark",,"https://ClinicalTrials.gov/show/NCT04321096"
1192,"NCT04342650","Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection","CloroCOVID19II","Recruiting","No Results Available","COVID-19|SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia|Clinical Trial","Drug: Chloroquine Diphosphate|Drug: Placebo oral tablet","Proportion of patients with onset of severe acute respiratory syndrome (SARS)|Mortality rate|Number of participants in need of intensive care support|Viral concentration|Cumulative incidence of serious adverse events|Cumulative incidence of grade 3 and 4 adverse events|Proportion of patients with discontinued treatment|Incidence of cardiac lesions|Incidence of cardiac disfunctions|Change in respiratory capacity","Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","All","18 Years and older   (Adult, Older Adult)","Phase 2","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAAE: 30504220.5.0000.0005","April 8, 2020","September 2020","September 2020","April 13, 2020",,"April 14, 2020","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",,"https://ClinicalTrials.gov/show/NCT04342650"
1193,"NCT04306705","Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19","TACOS","Recruiting","No Results Available","Covid-19|SARS|Cytokine Storm|Cytokine Release Syndrome|Tocilizumab","Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy","Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Duration of hospitalization|Proportion of Participants With Normalization of Fever Through Day 14|Change from baseline in white blood cell and differential count|Time to first negative in 2019 novel Corona virus RT-PCR test|All-cause mortality|Change from baseline in hsCRP|Change from baseline in cytokines IL-1β, IL-10, sIL-2R, IL-6, IL-8 and TNF-α|Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells","Tongji Hospital|Hubei Xinhua Hospital|Wuhan No.1 Hospital|Wuhan central hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","WHTJCOVID-19","February 20, 2020","May 30, 2020","June 20, 2020","March 13, 2020",,"March 17, 2020","Tongji Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04306705"
1194,"NCT04382131","Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19","ELVIS COVID-19","Not yet recruiting","No Results Available","Upper Respiratory Tract Infections|Virus|COVID|Virus Shedding|Virus Diseases","Other: NaCl Solution","Time to resolution of symptoms as defined by the single question 'how unwell do you feel today'.|Severity of all symptoms|The length of time for individual symptoms to resolve|Severity of individual symptoms|Contacting healthcare (NHS 24, OOH, GP)|Participants needing GP appointments|Participants attending hospital|Length of stay in hospital if admitted|Number of participants reporting over the counter medication use|Reduction in transmission to household contacts|Number of participants reporting side effects of nasal irrigation|Types and severity of side effects reported|Cost of over the counter medication used","University of Edinburgh","All","18 Years and older   (Adult, Older Adult)","Not Applicable","405","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC20042","May 1, 2020","July 31, 2020","July 31, 2020","May 11, 2020",,"May 11, 2020","NHS Lothian, Edinburgh, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04382131"
1195,"NCT04395144","COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss","COVAYDE","Recruiting","No Results Available","Coronavirus Infection|COVID|Severe Acute Respiratory Syndrome|Respiratory Failure|Respiratory Insufficiency|Respiratory Distress Syndrome|ARDS|Lung Diseases","Procedure: Awake Prone Positioning|Procedure: Standard care","Rate of Therapeutic failure, defined as a combined outcome of rate of intubation or death|Intubation rate|Mortality|Days spent on mechanical ventilation|Days spent in the ICU|Hospital stay (in days)","Hôpital de Verdun","All","18 Years and older   (Adult, Older Adult)","Not Applicable","346","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021-01","May 15, 2020","October 30, 2020","December 31, 2020","May 20, 2020",,"May 20, 2020","Hôpital de Verdun, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04395144"
1196,"NCT04397237","Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe","Euro-COVIMID","Not yet recruiting","No Results Available","COVID-19|Systemic Lupus Erythematosus|Sjogren's Syndrome|Axial Spondyloarthritis|Rheumatoid Arthritis|Giant Cell Arteritis",,"COVID-19 seroconversion|COVID-19 infection|Seroconversion rate by disease|Penetration across Europe|COVID-19 severity|COVID-19 mortality rate|COVID-19 impact on immunomodulatory treatment|Patient-reported flares|Patient's fears towards COVID-19|Patient's beliefs in their medicines towards COVID-19","Pitié-Salpêtrière Hospital|Groupe d'Études et de Recherche de l'Appareil Locomoteur (GERPAL)|Università degli Studi di Ferrara|Rheumazentrum Ruhrgebiet|University College, London|University of Coimbra|Universidad Complutense de Madrid","All","18 Years and older   (Adult, Older Adult)",,"3600","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2020-A01371-38","May 2020","September 2020","December 2020","May 21, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04397237"
1197,"NCT04298060","DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)","STOP-Flu","Not yet recruiting","No Results Available","Influenza Infection|SAD-RV Infection and COVID-19","Drug: DAS181|Drug: Placebo","Percent of subjects who have returned to room air|Percent change of subjects return to baseline oxygen requirement","Ansun Biopharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DAS181-2-07","April 2020","March 2021","September 2022","March 6, 2020",,"April 2, 2020","Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04298060"
1198,"NCT04356950","Analysis of the Coagulopathy Developed by COVID-19 Infected Patients","COVID-TGT","Not yet recruiting","No Results Available","Sepsis|Blood Coagulation Disorders|Thrombin|Disseminated Intravascular Coagulation|COVID-19","Other: Thrombin generation test assay|Other: Fibrin generation markers assays","28-day survival rate|Absolute thrombin generation test latent period|Relative thrombin generation test latent period compared to reference plasma|Absolute thrombin generation test initial velocity|Relative thrombin generation test initial velocity compared to reference plasma|Relative thrombin generation test peak thrombin compared to reference plasma|Absolute thrombin generation test peak thrombin|Absolute thrombin generation test peak thrombin time|Relative thrombin generation test peak thrombin time compared to reference plasma|Absolute thrombin generation test total thrombin generation time|Relative thrombin generation test total thrombin generation time compared to reference plasma|Absolute thrombin generation test endogenous thrombin potential|Relative thrombin generation test endogenous thrombin potential compared to reference plasma|3-month survival rate|Transfer to intensive care unit during hospitalization|Thrombotic complication during hospitalization|Plasma concentrations of D-dimers|Plasma concentrations of soluble fibrin monomers","Centre Hospitalier Universitaire de Nīmes","All","18 Years and older   (Adult, Older Adult)",,"175","Other","Observational","Observational Model: Other|Time Perspective: Prospective","PHRC-I/2020/JCG-01","April 2020","October 2020","January 2021","April 22, 2020",,"April 29, 2020","CHU de Bordeaux, Bordeaux, France|CHU de Limoges, Limoges, France|CHU de Montpellier, Montpellier, France|CHU de Nimes, Nîmes, France",,"https://ClinicalTrials.gov/show/NCT04356950"
1199,"NCT04347239","Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)",,"Recruiting","No Results Available","Coronavirus Disease 2019","Drug: Placebos|Drug: Leronlimab (700mg)","All-cause mortality at Day 28|All-cause mortality at Day 14|Change in clinical status of subject at Day 14 (on a 7 point ordinal scale)|Change in clinical status of subject at Day 28 (on a 7 point ordinal scale)|Change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14.","CytoDyn, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","390","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CD12_COVID-19","April 15, 2020","December 31, 2020","April 1, 2021","April 15, 2020",,"May 12, 2020","UCLA, Los Angeles, California, United States|Eisenhower Health, Rancho Mirage, California, United States|Yale, New Haven, Connecticut, United States|Beth Israel, Harvard, Boston, Massachusetts, United States|St. Barnabas, Livingston, New Jersey, United States|Atlantic Health System Hospital, Morristown, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Novant Health, Winston-Salem, North Carolina, United States|Ohio Health, Columbus, Ohio, United States|Oregon Health and Sciences University, Portland, Oregon, United States|University of Texas, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04347239"
1200,"NCT04361474","Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity","COVIDORL","Recruiting","No Results Available","Budesonide|Olfaction Disorders|SARS-CoV-2|Anosmia","Drug: Budesonide Nasal|Other: Physiological serum","Patient with more than 2 points on the ODORATEST","Fondation Ophtalmologique Adolphe de Rothschild|Hopital Lariboisière","All","18 Years and older   (Adult, Older Adult)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MDL_2020_10","May 18, 2020","May 18, 2020","May 25, 2021","April 24, 2020",,"May 20, 2020","Amélie YAvchitz, Paris, France",,"https://ClinicalTrials.gov/show/NCT04361474"
1201,"NCT04356443","Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection",,"Recruiting","No Results Available","Respiratory Failure|Ventilatory Failure|COVID-19|Pneumonia|ARDS, Human","Device: AirGo Respiratory Monitor","Endotracheal intubation during present hospitalization, recorded through chart review|Improvement in hypoxemia as indicated by oxygen saturation and requirement for supplemental oxygen, recorded through chart review|Premature need for removal of the band, recorded through investigator report|In-hospital mortality, recorded through chart review","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020P000881","April 15, 2020","December 31, 2020","December 31, 2020","April 22, 2020",,"April 22, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04356443"
1202,"NCT04381377","Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19",,"Recruiting","No Results Available","Infections, Coronavirus","Drug: azoximer bromide|Other: Placebo","Clinical status of the patient (according to 7-point ordinal scale)|NEWS|Oxygenation|Mechanical Ventilation|Mortality","NPO Petrovax","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","394","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PО-COV-III-20","April 29, 2020","April 2021","April 2021","May 8, 2020",,"May 8, 2020","Regional state budgetary institution of public health ""City hospital No. 5 of Barnaul"", Barnaul, Russian Federation|Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow, Russian Federation|The state healthcare institution of the city of Moscow ""City Clinical Hospital No. 15 named after OM Filatov"" in ""Moscow City Department of Health"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution ""Infectious Clinical Hospital No. 1 of the Moscow Department of Healthcare"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution ""City Clinical Hospital No. 24 of the Moscow Department of Healthcare"", Moscow, Russian Federation|State budgetary institution ""Research Institute of Emergency Care named after N.V. Sklifosovsky in Department of Health of the city of Moscow"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution ""City Clinical Hospital No. 40 of the Moscow Department of Healthcare"", Moscow, Russian Federation|State budgetary institution of health care of the Nizhny Novgorod region ""Infectious clinical hospital No. 2 of Nizhny Novgorod"", Nizhny Novgorod, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Orenburg State Medical University"" of the Ministry of Health of the Russian Federation, Orenburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""First St. Petersburg State Medical University named after Academician I.P. Pavlov, Saint Petersburg, Russian Federation|State budgetary health institution of the Vladimir region ""Regional Clinical Hospital"", Vladimir, Russian Federation|Yaroslavl State Medical University of Ministry of Health of the Russian Federation, Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04381377"
1203,"NCT04355962","Sevoflurane in COVID-19 ARDS (SevCov)",,"Recruiting","No Results Available","ARDS, Human|Coronavirus","Drug: Sevoflurane|Drug: Intravenous drug","Composite outcome of death rate (rate of patients that did not survive) and organ failure rate (rate of patients surviving with persistent organ dysfunction) at day 28|Length of stay ICU|Plasma Inflammatory markers|Length of stay at hospital|Sex-related differences in complications","University of Zurich","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2020-00719","April 23, 2020","March 31, 2021","March 31, 2021","April 21, 2020",,"April 27, 2020","University Hospital Zuirch, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04355962"
1204,"NCT04354818","Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)","CORIA","Not yet recruiting","No Results Available","HIV-1-infection|Cancer|Primary Immune Deficiency Disorder|Immunosuppression Disorders|COVID-19",,"percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died","Kirby Institute|St Vincent's Hospital, Sydney|Garvan Institute of Medical Research|Westmead Hospital, Sydney, Australia|Blacktown Hospital, Sydney, Australia|Holdsworth House Medical Practice|Royal North Shore Hospital|Melanoma Institute Australia|Prince of Wales Hospital, Sydney|Gilead Sciences|Cancer Institute NSW|Cancer Council New South Wales|Positive Life NSW","All","18 Years and older   (Adult, Older Adult)",,"1000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-04-CORIA","April 27, 2020","April 27, 2022","April 27, 2022","April 21, 2020",,"April 22, 2020",,,"https://ClinicalTrials.gov/show/NCT04354818"
1205,"NCT04373291","Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic",,"Not yet recruiting","No Results Available","COVID-19|Non-specific Effects of Vaccines|Morbidity|Absenteeism|Heterologous Immunity","Biological: BCG-Denmark|Biological: Saline","Number of days of unplanned absenteeism for any reason|The cumulative incidence of documented COVID|The cumulative incidence of hospital admission for any reason|The number of days of unplanned absenteeism, because of documented COVID|The number of days of absenteeism, because of imposed quarantine as a result of exposure to SARS-CoV-2|The number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented SARS- CoV-2 infection|The number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|The number of days of self-reported fever (≥38 °C)|The number of days of self-reported acute respiratory symptoms|The cumulative incidence of self-reported acute respiratory symptoms|The cumulative incidence of death for any reason|The cumulative incidence of death due to documented COVID|The cumulative incidence of Intensive Care Admission for any reason|The cumulative incidence of Intensive Care Admission due to documented COVID|The cumulative incidence of Hospital Admission due to documented COVID","Bandim Health Project|University of Southern Denmark","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","BCG-DENMARK-COVID|2020-001888-90","May 2020","December 2020","January 2021","May 4, 2020",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04373291"
1206,"NCT04349098","Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection","Coronavirus","Recruiting","No Results Available","Coronavirus Infection","Drug: Selinexor|Other: Placebo","Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale|Time to Clinical Improvement (TTCI)|Overall Death Rate|Rate of Mechanical Ventilation|Time to Mechanical Ventilation|Overall Survival|Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale|Time to Intensive Care Unit (ICU) Admission|Rate of Intensive Care Unit (ICU) Admission|Length of Stay in Hospital|Percentage of Participants Discharged from Hospital|Length of Stay in Intensive Care Unit (ICU)|Duration of Oxygen Supplementation|Duration of Mechanical Ventilation|Time to Clinical Improvement in Participants ≤ 70 Years Old|Time to Clinical Improvement in Participants > 70 Years Old|Time to Clinical Improvement in Participants with Pre-existing Diseases|Change in Oxygenation Index|Time to Improvement of One Point Using WHO Ordinal Scale Improvement|Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point|Change from Baseline in C-reactive protein (CRP) Levels|Change from Baseline in Ferritin Levels|Change from Baseline in Lactate Dehydrogenase (LDH) Levels|Changes from Baseline in Blood Plasma Cytokines Levels|Number of Participants with Adverse Events (AE)","Karyopharm Therapeutics Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","XPORT-CoV-1001|2020-001411-25","April 17, 2020","August 31, 2020","August 31, 2020","April 16, 2020",,"May 8, 2020","UCLA, Los Angeles, California, United States|Kaiser Permanente Oakland, Oakland, California, United States|UC Davis Health, Sacramento, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|Kaiser Permanente San Francisco, San Francisco, California, United States|Miami Cancer Institute at Baptist Health, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Norton Healthcare, Louisville, Kentucky, United States|Boston Medical Center, Boston, Massachusetts, United States|Karmanos, Detroit, Michigan, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Michigan Center of Medical Research, Royal Oak, Michigan, United States|Columbia University, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute-Atrium Health University City, Charlotte, North Carolina, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Baylor Scott & White Dallas, Dallas, Texas, United States|MultiCare Institute for Research & Innovation (Puget Sound), Tacoma, Washington, United States|Hospital Hietzing, 2. Medical department - Center for Diagnosis and Therapy of Rheumatic Diseases, Vienna, Austria|CHU Bordeaux, Bordeaux, France|CHU Lyon, Lyon, France|CHU Nantes, Nantes, France|Hadassah MC, Jerusalem, Israel|Hasharon Medical Center, Petah Tiqva, Israel|Sheba Medical Center, Tel HaShomer, Israel|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Servicio de Medicina Interna, Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Spain|Princess Royal University Hospital, Kent, United Kingdom|Kings College Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04349098"
1207,"NCT04382495","The Impact of COVID-19 Pandemic on Cancer Care",,"Not yet recruiting","No Results Available","Cancer","Other: survey","patients' and survivors' perspective of their cancer care during COVID-19 pandemic","El Zaitoun Specialized Hospital","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","Cancer Care during Covid-19","May 23, 2020","June 30, 2020","July 31, 2020","May 11, 2020",,"May 18, 2020","EgyBrit Medical Centre, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04382495"
1208,"NCT04337788","Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease","COVIDeHPAD","Not yet recruiting","No Results Available","Coronavirus Infection","Other: telehealth applications","Impact of Gerontological telemonitoring on healthcare management for older adults living in Nursing Homes with symptoms of confirmed or probable COVID-19 disease (Death within 30 days).","University Hospital, Limoges","All","75 Years and older   (Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","87RI20_0013","April 2020","July 2020","September 2020","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04337788"
1209,"NCT04343664","Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia","New","Not yet recruiting","No Results Available","Mental Stress|Mental Health Wellness 1|Depression|Anxiety|Behavior Problem|Emotional Problem",,"Depression|Anxiety symptoms|Stress related problems|Behavior and emotional problem among children and adolescents","Tjhin Wiguna|Fakultas Kedokteran Universitas Indonesia|Dr Cipto Mangunkusumo General Hospital","All","4 Years and older   (Child, Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","MH-Covid19","April 12, 2020","June 30, 2020","December 31, 2020","April 13, 2020",,"April 14, 2020","dr. Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04343664"
1210,"NCT04351139","Impact of the COVID-19 Pandemic in Gynecological Oncology","COVID-GYN","Recruiting","No Results Available","Gynecologic Cancer|Breast Neoplasm Female|Uterine Neoplasms|Ovarian Neoplasms|Uterine Cervical Neoplasms|Vulvar Neoplasms|Vaginal Neoplasms","Other: modification of the planned therapeutic management","percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy)","Hospices Civils de Lyon","Female","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","69HCL20_0346|2020-A01036-33","May 6, 2020","November 6, 2020","November 6, 2020","April 17, 2020",,"May 13, 2020","Service de Gynécologie, HFME, Hospices Civils de Lyon, Bron, France|Service de Gynécologie, Croix-Rousse, Hospices Civils de Lyon, Lyon, France|Service Gynécologie, CHLS, Hospices Civils de Lyon, Pierre-Bénite, France",,"https://ClinicalTrials.gov/show/NCT04351139"
1211,"NCT04334928","Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel","EPICOS","Recruiting","No Results Available","Coronavirus Infection","Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine","Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)|Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)|Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in days","Plan Nacional sobre el Sida (PNS)|Effice Servicios Para la Investigacion S.L.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","4000","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PrEP COVID-19","April 15, 2020","June 30, 2020","July 31, 2020","April 6, 2020",,"April 28, 2020","Hospital Universitario de Ferrol, Ferrol, A Coruña, Spain|Hospital Clínico Universitario de Santiago, Santiago De Compostela, A Coruña, Spain|Hospital General de Elche, Elche, Alicante, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Sant Joan de Deu de Esplugues, Esplugues De Llobregat, Barcelona, Spain|Parc Sanitari Sant Joan de Déu de Sant Boi, Sant Boi De Llobregat, Barcelona, Spain|Hospital Infanta Margarita, Cabra, Córdoba, Spain|Hospital Insular de Las Palmas, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de Canarias, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital de Donostia, San Sebastián, Guipuzcoa, Spain|Hospital San Pedro, Logroño, La Rioja, Spain|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain|Hospital Colllado Villalba, Collado-Villalba, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Quirón Pozuelo, Pozuelo De Alarcón, Madrid, Spain|Hospital de Torrejón, Torrejón De Ardoz, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital Virgen del Castillo, Yecla, Murcia, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Arnau de Vilanova, Llíria, Valencia, Spain|Hospital de Araba, Alava, Vitoria, Spain|Hospital General Universitario de Albacete, Albacete, Spain|Centro Médico Teknon, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Dexeus, Barcelona, Spain|Hospital Quirón Barcelona, Barcelona, Spain|Hospital Sant Pau, Barcelona, Spain|Hospital Universitario Sagrat Cor, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Clínico San Cecilio, Granada, Spain|Hospital Universitario de León, León, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Reina Sofía, Murcia, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Clinico Universitario, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital de Valladolid, Valladolid, Spain|Hospital Rio Hortega, Valladolid, Spain|Hospital Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Hospital Nuestra Señora de Sonsoles, Ávila, Spain",,"https://ClinicalTrials.gov/show/NCT04334928"
1212,"NCT04355676","Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19",,"Not yet recruiting","No Results Available","Coronavirus Infection","Drug: Selinexor","Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale|Time to Clinical Improvement (TTCI)|Overall Death Rate|Rate of Mechanical Ventilation|Time to Mechanical Ventilation|Overall Survival|Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale|Time to Intensive Care Unit (ICU) Admission|Rate of Intensive Care Unit (ICU) Admission|Length of Stay in Hospital|Percentage of Participants Discharged From Hospital|Length of Stay in Intensive Care Unit (ICU)|Duration of Oxygen Supplementation|Duration of Mechanical Ventilation|Time to Clinical Improvement in Participants ≤ 70 Years Old|Time to Clinical Improvement in Participants > 70 Years Old|Time to Clinical Improvement in Participants with Pre-existing Diseases|Change in Oxygenation Index|Time to Improvement of One Point Using WHO Ordinal Scale Improvement|Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point|Change from Baseline in C-reactive protein (CRP) Levels|Change from Baseline in Ferritin Levels|Change from Baseline in Lactate Dehydrogenase (LDH) Levels|Number of Participants with Adverse Events (AE)","Karyopharm Therapeutics Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XPORT-CoV-1002","April 30, 2020","August 30, 2020","August 30, 2020","April 21, 2020",,"April 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04355676"
1213,"NCT04332380","Convalescent Plasma for Patients With COVID-19: A Pilot Study","CP-COVID-19","Not yet recruiting","No Results Available","Coronavirus|Coronavirus Infection","Drug: Plasma","Change in Viral Load|Change in Immunoglobulin M COVID-19 antibodies Titers|Change in Immunoglobulin G COVID-19 antibodies Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality","Universidad del Rosario|CES University|Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud|Fundación Universitaria de Ciencias de la Salud","All","18 Years to 60 Years   (Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABN011-1","May 1, 2020","August 31, 2020","December 31, 2020","April 2, 2020",,"April 28, 2020","Universidad del Rosario, Bogota, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT04332380"
1214,"NCT04358380","Liver Injury in Patients With COVID-19",,"Enrolling by invitation","No Results Available","Liver Injury","Other: Liver injury","Liver injury in patients with COVID-19|Prognostic factors associated with death|Clinical characteristics of patients who developed liver injury","Austral University, Argentina","All","17 Years and older   (Child, Adult, Older Adult)",,"34","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","CIE N° P 20-011","April 15, 2020","December 31, 2020","December 31, 2020","April 24, 2020",,"April 24, 2020","Universidad Austral, Pilar, Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT04358380"
1215,"NCT04367350","Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement",,"Recruiting","No Results Available","COVID|Sars-CoV2|Corona Virus Infection|Myositis|Myocarditis","Diagnostic Test: laboratory biomarkers|Diagnostic Test: muscle ultrasound","Rate of elevated creatine kinase in hyperacute phase|Rate of elevated creatine kinase|Rate of two-peak elevation of creatine kinase during acute phase|Rate of myositis-specific antibodies|Rate of antimyocardial antibodies|Area under the curve (AUC) of elevated creatine kinase|Peak-levels of elevated creatine kinase|Peak-levels of troponin|Peak-levels of urine myoglobin|Rate of muscle hyperechogenicity|Peak-muscle hyperechogenicity","University Hospital Tuebingen","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","246/2020BO2","March 20, 2020","March 31, 2021","March 31, 2022","April 29, 2020",,"April 29, 2020","University Hospital Tuebingen, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT04367350"
1216,"NCT04335084","A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","HELPCOVID-19","Not yet recruiting","No Results Available","COVID-19|Coronavirus Infection|Sars-CoV2|Corona Virus Infection|COVID|Coronavirus|Coronavirus-19|Coronavirus 19","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","Prevention of COVID-19 symptoms as recorded in a daily diary|Safety as determined by presence or absence of Adverse Events and Serious Adverse Events","ProgenaBiome","All","18 Years and older   (Adult, Older Adult)","Phase 2","600","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PRG-042","May 2020","May 2021","August 2021","April 6, 2020",,"May 12, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04335084"
1217,"NCT04389580","Combination Therapy With Isotretinoin and Tamoxifen May Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus","Combination","Not yet recruiting","No Results Available","COVID-19","Drug: Drug: Isotretinoin plus Tamoxifen|Drug: Aerosolized Isotretinoin plus Tamoxifen","lung injury score|Absolute lymphocyte counts|Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon|Serum level of COVID19 RNA|All cause mortality rate|Ventilation free days|ICU free days|d-dimers|Time to first negative SARS-CoV-2 PCR in NP swap","Kafrelsheikh University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COV-19 Treatment This is","May 2020","July 2020","August 2020","May 15, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04389580"
1218,"NCT04357106","COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma","COPLA","Recruiting","No Results Available","COVID-19","Biological: Convalescent plasma","Lung injury|Overall survival|Adverse reactions to plasma","Centro de Hematología y Medicina Interna|Laboratorios Clínicos de Puebla (Laboratorios Ruiz)","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHMI-030420-01","April 13, 2020","July 2020","August 2020","April 22, 2020",,"April 22, 2020","Centro de Hematología y Medicina Interna, Puebla, Mexico",,"https://ClinicalTrials.gov/show/NCT04357106"
1219,"NCT04338009","Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019","REPLACECOVID","Enrolling by invitation","No Results Available","COVID-19","Other: Discontinuation of ARB/ACEI|Other: Continuation of ARB/ACEI","Hierarchical composite endpoint|All-Cause Death|Length of Hospital Stay|Length of ICU Stay, invasive mechanical ventilation or extracorporeal membrane oxygenation|AUC SOFA","University of Pennsylvania|Jordana B. Cohen, MD, MSCE|Thomas C. Hanff, MD, MPH|Vicente Corrales-Medina, MD, PhD|James Brian Byrd, MD|Roberto Viau Colindres","All","18 Years and older   (Adult, Older Adult)","Not Applicable","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","842810","March 31, 2020","December 31, 2020","December 31, 2020","April 8, 2020",,"April 24, 2020","University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04338009"
1220,"NCT04337008","Renin Angiotensin System - CoronaVirus","SRA-COV","Recruiting","No Results Available","COVID 19","Other: blood draw","overactivity of the renin / aldosterone system","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2020-16|2020-A00795-34","April 3, 2020","June 3, 2020","July 31, 2020","April 7, 2020",,"April 24, 2020","ASSISTANCE PUBLIQUE HÖPITAUX de MARSEILLE, Marseille, France",,"https://ClinicalTrials.gov/show/NCT04337008"
1221,"NCT04334265","Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019",,"Recruiting","No Results Available","COVID-19","Drug: Anluohuaxian","Changes in high-resolution computer tomography of the lung|Change in 6-minute walking distance|Changes in compound physiological index|Changes in the scores of the St. George's Hospital Respiratory Questionnaire|Changes in modified British Medical Research Council Dyspnea Scale (mMRC) scores|Changes in vital capacity of the lung","Peking University First Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","750","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020 research 110","April 1, 2020","June 1, 2020","December 1, 2020","April 6, 2020",,"April 24, 2020","The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04334265"
1222,"NCT04334148","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","HERO-HCQ","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Number of participants with clinical infection with COVID-19 infection|Number of participants with COVID-19 viral shedding|Safety as measured by number of adverse events","Adrian Hernandez|Patient-Centered Outcomes Research Institute|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 3","15000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Pro00105274","April 22, 2020","July 2020","July 2020","April 6, 2020",,"May 14, 2020","University of Florida, Gainesville, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins, Baltimore, Maryland, United States|Mayo Clinic Hospital Rochester, Rochester, Minnesota, United States|University of Missouri-Columbia, Columbia, Missouri, United States|Hospital for Special Surgery, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials Center of Middle Tennessee, Franklin, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor Scott & White Medical Center-Temple, Temple, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Marshfield Clinic Health System, Marshfield, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04334148"
1223,"NCT04333589","Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive",,"Recruiting","No Results Available","COVID-19","Drug: Favipiravir","Viral nucleic acid test negative conversion rate|Clinical cure rate","Peking University First Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020 research 112","April 1, 2020","June 1, 2020","September 15, 2020","April 3, 2020",,"April 24, 2020","The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Hospital of Traditional Chinese Medicine, Ezhou, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04333589"
1224,"NCT04311398","Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System",,"Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform","Sensitivity， spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform","Huashan Hospital","All","16 Years to 100 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","KY2020-COVID-19","May 13, 2020","June 1, 2020","December 1, 2020","March 17, 2020",,"May 14, 2020","Huashan Hospital of Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04311398"
1225,"NCT04310228","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019",,"Recruiting","No Results Available","COVID-19","Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab","Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time","Peking University First Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020YFC0844100","March 8, 2020","May 2020","May 2020","March 17, 2020",,"April 10, 2020","Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04310228"
1226,"NCT04302519","Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells",,"Not yet recruiting","No Results Available","COVID-19","Biological: Dental pulp mesenchymal stem cells","Disppear time of ground-glass shadow in the lungs|Absorption of Lung shadow absorption by CT Scan-Chest|Changes of blood oxygen","CAR-T (Shanghai) Biotechnology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KT005HB001","March 5, 2020","June 30, 2021","July 30, 2021","March 10, 2020",,"March 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04302519"
1227,"NCT04295551","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)",,"Not yet recruiting","No Results Available","COVID-19","Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection|Drug: Lopinavir/ritonavir treatment","Clinical recovery time","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QF-XYP1990-1","March 14, 2020","July 14, 2020","April 14, 2021","March 4, 2020",,"March 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04295551"
1228,"NCT04357639","Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP )",,"Not yet recruiting","No Results Available","HIV Patients","Other: No intervention","Comparison of the incidence of COVID-19 infection in PLWHIV treated with long-term antiretroviral drugs including a protease inhibitor and those without a protease inhibitor|Determination of the seroprevalence of COVID-19 infection in both groups of the study|Comparison of the severity of COVID-19 infection symptoms in both groups of the study.|Identification of potential risk factors for COVID-19 infection in HIV patients treated with protease inhibitor or without protease inhibitor","Centre Hospitalier Intercommunal Creteil|Centre Hospitalier Intercommunal Villeneuve St Georges","All","18 Years and older   (Adult, Older Adult)",,"794","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIP","May 30, 2020","May 31, 2020","October 31, 2020","April 22, 2020",,"May 19, 2020","CHI Créteil, Créteil, France|CHU Henri Mondor, Créteil, France|Centre hospitalier de Melun (GHSIF), Melun, France|Hôpital universitaire de Hôtel Dieu, Paris, France|CHI Villeneuve St Georges, Villeneuve-Saint-Georges, France",,"https://ClinicalTrials.gov/show/NCT04357639"
1229,"NCT04365881","Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology",,"Completed","No Results Available","Loneliness, Worry, Rumination, Health Anxiety, Depression, Anxiety","Other: Cross-sectional observational study","UCLA Loneliness Scale-8 (ULS-8)|Patient Health Questionnaire-9 (PHQ-9)|Generalized Anxiety Disorder-7 (GAD-7)","Modum Bad|University of Oslo","All","18 Years and older   (Adult, Older Adult)",,"10084","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","REK12345","March 31, 2020","April 7, 2020","April 7, 2020","April 28, 2020",,"April 28, 2020","University of Oslo, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT04365881"
1230,"NCT04371978","Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19",,"Not yet recruiting","No Results Available","COVID 19|Coronavirus|Diabetes Mellitus, Type 2|Diabetes Mellitus|Glucose Metabolism Disorders|Metabolic Disease|Endocrine System Diseases|Dipeptidyl-Peptidase IV Inhibitors|Linagliptin|Severe Acute Respiratory Syndrome Coronavirus 2|Sars-CoV2|Hypoglycemic Agents|Respiratory Tract Diseases|Incretins|Hormones","Drug: Linagliptin 5 MG","Time to clinical change|Percent of serious adverse events and premature discontinuation of treatment.|Percent of patients with clinical improvement.|Length of hospitalization.|All-cause mortality.|Percent of supplemental oxygen use.|Supplemental oxygen-free days.|Percent of mechanical ventilation use.|Ventilator-free days.|Percent of ICU admissions.|ICU-free days.|Percent of 50% decrease in C-reactive protein (CRP) levels|Time to virologic response, defined as no detection of SARS-CoV-2 in a PCR test.","Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0303-20-RMC","May 15, 2020","June 30, 2021","September 30, 2021","May 1, 2020",,"May 5, 2020","Rabin Medical Center, Petah tikva, Israel",,"https://ClinicalTrials.gov/show/NCT04371978"
1231,"NCT04366921","European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO","EuroECMO-COVID","Recruiting","No Results Available","COVID|SARS-CoV-2|ARDS, Human|Refractory Hypoxemia|Cardiogenic Shock|Septic Shock|Extracorporeal Membrane Oxygenation",,"Age|Gender|Weight|Height|BMI|Pre-existing pulmonary disease y/n|Main co-morbidities y/n|Date of signs of COVID-19 infection|Date of positive swab|Pre-ECMO length of hospital stay|Pre-ECMO length of ICU stay|Pre-ECMO length of mechanical ventilation days|Use of antibiotics|Use of anti-viral treatment|Use of second line treatment|Indications for ECMO-implant|Type of ECMO-implant|Type of access|Date of ECMO implant|ECMO blood flow rate|ECMO gas flow rate|ECMO configuration change|Date of ECMO configuration change|New ECMO configuration|Indications for ECMO configuration change|Ventilator setting on ECMO|Anticoagulation during ECMO|Frequency of ECMO circuit change|ECMO complications|ECMO Weaning|ICU discharge|Main cause of death|Type of discharge|Alive/deceased","Maastricht University Medical Center|European chapter of the Extracorporeal Life Support Organization|Erasmus Medical Center|Leiden University Medical Center|UMC Utrecht|St. Orsola Hospital|Papa Giovanni XXIII Hospital|Niguarda Hospital|Ospedale San Donato|Ospedale S. Giovanni Bosco|IRCCS Policlinico S. Matteo|The Mediterranean Institute for Transplantation and Advanced Specialized Therapies|Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia|Ospedale dell'Angelo, Venezia-Mestre|University Hospital, Udine, Italy|San Gerardo Hospital|Ospedali Riuniti Ancona|San Camillo Hospital, Rome|San Giorgio Clinic|GVM Care & Research|San Raffaele University Hospital, Italy|Ospedale San Bortolo di Vicenza|Klinik Hirslanden, Zurich|University of Zurich|Cardiocentro Ticino|Vilnius University Hospital Santaros Klinikos|Universitätsklinikum Düsseldorf|Klinikum Nürnberg|Hannover Medical School|Heart Center Leipzig - University Hospital|University Hospital Regensburg|University Hospital, Essen|German Heart Center|University Hospital, Aachen|University Heart Center Freiburg - Bad Krozingen|Klinikum Kassel|General University Hospital, Prague|Universitaire Ziekenhuizen Leuven|Onze Lieve Vrouwziekenhuis Aalst|Erasme University Hospital|University Hospital, Antwerp|Hôpital Civil Marie Curie de Charleroi|University Hospital, Ghent|Centre Hospitalier Universitaire Saint Pierre|Hospital Vall d'Hebron|Hospital Universitario Ramon y Cajal|Hospital Miguel Servet|Henri Mondor University Hospital|Hospices Civils de Lyon|Pitié-Salpêtrière Hospital|Rennes University Hospital|Guy's and St Thomas' NHS Foundation Trust|Karolinska University Hospital|Hospital Sao Joao|Medical University of Warsaw|Universitätskliniken Innsbruck|Medical University of Vienna|University Hospital, Alexandroupolis|Novosibirsk City Hospital #2|City Clinical Hospital No. 67, Moscow, Russia|City Hospital No 40, Saint Petersburg, Russia|Krasnodar Regional Hospital no 1|Kemerovo Regional Clinical Cardiological Center named after academician L.S. Barbarash|City Hospital No 41, Ekaterinburg, Russia|G. Pasquinucci Heart Hospital, Massa|Charles University, Czech Republic|University Hospital, Bordeaux|Bambino Gesù Hospital and Research Institute|Policlinico Hospital Milan|Gaslini Children's Hospital|Children's Medical Hospital, University of Essen, Essen, Germany|University Hospital, Geneva|Newcastle-upon-Tyne Hospitals NHS Trust|Paediatric Intensive Care Glasgow|Paris South University Hospitals|University of Groningen|Great Ormond Street Hospital for Children NHS Foundation Trust|Hospital Sant Joan de Deu|Heim Pal Children's Hospital|University Hospital, Montpellier|Royal Brompton & Harefield NHS Foundation Trust|Lund University Hospital|Landesklinikum Sankt Polten|Chelyabinsk Regional Clinical Hospital|ECMO Centers Israel|Copenhagen University Hospital at Herlev|Ospedale Maurizio Bufalini|A.O.U. Città della Salute e della Scienza - Molinette Hospital|Mauriziano Umberto I Hospital|University of Bern|University Hospital, Basel, Switzerland|University of Lausanne Hospitals|University Hospital Tuebingen|Universitätsklinikum Köln|Chirec|Universitair Ziekenhuis Brussel|CHU de Liege|La Louvière Hopital|Leicester Royal Infirmary NHS Trust","All","Child, Adult, Older Adult",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","METC 2020-1343","April 10, 2020","April 2021","April 2021","April 29, 2020",,"April 29, 2020","Universitätskliniken Innsbruck, Innsbruck, Austria|Landesklinikum Sankt Polten, St.Pölten, Austria|Medical University of Vienna, Vienna, Austria|Onze Lieve Vrouwziekenhuis Aalst, Aalst, Belgium|University Hospital, Antwerp, Antwerp, Belgium|Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium|Chirec, Brussels, Belgium|Erasme University Hospital, Brussel, Belgium|Universitair Ziekenhuis Brussel, Brussel, Belgium|Hôpital Civil Marie Curie de Charleroi, Charleroi, Belgium|University Hospital, Ghent, Ghent, Belgium|La Louvière Hopital, La Louvière, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|CHU de Liege, Liège, Belgium|Charles University, Czech Republic, Praha, Czechia|General University Hospital, Prague, Praha, Czechia|Copenhagen University Hospital at Herlev, Copenhagen, Denmark|University Hospital, Bordeaux, Bourdeaux, France|Hospices Civils de Lyon, Lyon, France|University Hospital, Montpellier, Montpellier, France|Henri Mondor University Hospital, Paris, France|Paris South University Hospitals, Paris, France|Pitié-Salpêtrière Hospital, Paris, France|Rennes University Hospital, Rennes, France|University Hospital, Aachen, Aachen, Germany|German Heart Center, Berlin, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Children's Medical Hospital, University of Essen, Essen, Germany, Essen, Germany|University Hospital, Essen, Essen, Germany|University Heart Center Freiburg - Bad Krozingen, Freiburg, Germany|Hannover Medical School, Hannover, Germany|Klinikum Kassel, Kassel, Germany|Universitätsklinikum Köln, Köln, Germany|Heart Center Leipzig - University Hospital, Leipzig, Germany|Klinikum Nürnberg, Nürnberg, Germany|University Hospital Regensburg, Regensburg, Germany|University Hospital Tuebingen, Tuebingen, Germany|University Hospital, Alexandroupolis, Alexandroupolis, Greece|Heim Pal Children's Hospital, Budapest, Hungary|ECMO Centers Israel, Jerusalem, Israel|San Giorgio Clinic, Alessandria, Italy|Ospedali Riuniti Ancona, Ancona, Italy|Papa Giovanni XXIII Hospital, Bergamo, Italy|St. Orsola Hospital, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Ospedale Maurizio Bufalini, Cesena, Italy|Gaslini Children's Hospital, Genua, Italy|G. Pasquinucci Heart Hospital, Massa, Massa, Italy|Policlinico Hospital Milan, Milano, Italy|Niguarda Hospital, Milan, Italy|Ospedale San Donato, Milan, Italy|San Raffaele University Hospital, Italy, Milan, Italy|San Gerardo Hospital, Monza, Italy|IRCCS Policlinico S. Matteo, Pavia, Italy|GVM Care & Research, Puglia, Italy|Bambino Gesù Hospital and Research Institute, Roma, Italy|San Camillo Hospital, Rome, Roma, Italy|A.O.U. Città della Salute e della Scienza - Molinette Hospital, Turin, Italy|Mauriziano Umberto I Hospital, Turin, Italy|Ospedale S. Giovanni Bosco, Turin, Italy|University Hospital, Udine, Italy, Udine, Italy|Ospedale dell'Angelo, Venezia-Mestre, Venice, Italy|Ospedale San Bortolo di Vicenza, Vicenza, Italy|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|University of Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands|Medical University of Warsaw, Warsaw, Poland|Hospital Sao Joao, Porto, Portugal|Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation|City Hospital No 41, Ekaterinburg, Russia, Ekaterinburg, Russian Federation|Kemerovo Regional Clinical Cardiological Center named after academician L.S. Barbarash, Kemerovo, Russian Federation|Krasnodar Regional Hospital no 1, Krasnodar, Russian Federation|City Clinical Hospital No. 67, Moscow, Russia, Moscow, Russian Federation|Novosibirsk City Hospital #2, Novosibirsk, Russian Federation|City Hospital No 40, Saint Petersburg, Russia, Saint Petersburg, Russian Federation|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Miguel Servet, Zaragoza, Spain|Lund University Hospital, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden|University Hospital, Basel, Switzerland, Basel, Switzerland|University of Bern, Bern, Switzerland|University Hospital, Geneva, Geneva, Switzerland|University of Lausanne Hospitals, Lausanne, Switzerland|Cardiocentro Ticino, Lugano, Switzerland|Klinik Hirslanden, Zurich, Zürich, Switzerland|University of Zurich, Zürich, Switzerland|Royal Brompton & Harefield NHS Foundation Trust, Brompton, United Kingdom|Paediatric Intensive Care Glasgow, Glasgow, United Kingdom|Leicester Children's Hospital, Leicester, United Kingdom|Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Newcastle-upon-Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04366921"
1232,"NCT04399252","Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19",,"Not yet recruiting","No Results Available","Microbiome","Dietary Supplement: Lactobaciltus rhamnosus GG|Dietary Supplement: Lactobaciltus rhamnosus GG Placebo","Change in Shannon Diversity|Change in Shannon Diversity in patients that develop COVID-19","Duke University","All","1 Year and older   (Child, Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","Pro00105674","May 25, 2020","May 25, 2022","May 25, 2022","May 25, 2020",,"May 25, 2020","Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04399252"
1233,"NCT04316884","Mechanisms for Organ Dysfunction in Covid-19","UMODCOVID19","Recruiting","No Results Available","COVID-19|Organ Dysfunction Syndrome Sepsis|Organ Dysfunction Syndrome, Multiple|Septic Shock|Acute Kidney Injury|Acute Respiratory Distress Syndrome",,"Acute Kidney Injury|ARDS|30 day mortality|1 year mortality|Chronic Kidney Disease|SOFA-score","Uppsala University","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EPN 2017/043 Covid19","March 12, 2020","December 31, 2020","December 31, 2021","March 20, 2020",,"March 20, 2020","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT04316884"
1234,"NCT04329533","Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic",,"Recruiting","No Results Available","Perceived Stress|Anxiety|Sleep Disturbance","Other: ""Calm"" is a mindfulness meditation mobile app","Perceived Stress Scale|Hospital Anxiety and Depression Scale|PROMIS Sleep Disturbance Short Form Survey|Adherence|Participant Satisfaction|Coronavirus Questionnaire","University of Arizona","Female","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2003524869","April 13, 2020","June 30, 2020","July 30, 2020","April 1, 2020",,"April 21, 2020","Banner University Medicine Women's Institute, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04329533"
1235,"NCT04374786","Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic",,"Not yet recruiting","No Results Available","Perceived Stress|Anxiety|Sleep Disturbance|Burnout|PTSD","Device: Calm Meditation App","Perceived Stress Scale|Hospital Anxiety and Depression Scale|PROMIS Sleep Disturbance Short Form Survey|Impact of Event Scale-6|Maslach Burnout Inventory|Adherence|Coronavirus Questionnaire|Participant Satisfaction","University of Arizona","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","328","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2003524869 [Sub-study]","May 15, 2020","September 1, 2020","October 1, 2020","May 5, 2020",,"May 18, 2020","Banner University Medical Center Phoenix, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04374786"
1236,"NCT04374617","Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19",,"Completed","No Results Available","COVID-19|Critical Illness|Venous Thromboembolism|Venous Thromboses|Venous Thromboses, Deep|Venous Thrombosis Pulmonary|Pulmonary Embolism|Pulmonary Embolism and Thrombosis|Sars-CoV2|SARS-CoV Infection","Diagnostic Test: Duplex ultrasound and Computed Tomography Angiography","Venous thromboembolisms|Deaths","Hospital Universitari Vall d'Hebron Research Institute","All","18 Years and older   (Adult, Older Adult)",,"230","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PR(AG)213/2020","April 1, 2020","April 25, 2020","May 1, 2020","May 5, 2020",,"May 6, 2020","Vall d´Hebron Research Institute VHIR, Barcelona, Catalunya, Spain|Hospital Germans Trias i Pujol. Universitat Autònoma de Barcelona, Badalona, Spain|Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04374617"
1237,"NCT04319172","Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients","COVIDSOT","Not yet recruiting","No Results Available","Transplant Recipient|Infections, Coronavirus",,"Incidence of coronavirus infection in Solid Organ Transplant Recipients|Clinical manifestations of coronavirus infection in Solid Organ Transplant Recipients|Presence of other risk factors|Establish the frequency and type of complications related to the net state of the patient immunosuppression|Frequency of co-infections|Mortality|Laboratory characteristics|Determination of coronavirus viral load|Microbiological testing","Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|Spanish Network for Research in Infectious Diseases|GESITRA-IC","All","16 Years and older   (Child, Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIDSOT","March 2020","March 2022","April 2022","March 24, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04319172"
1238,"NCT04332835","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","CP-COVID-19","Not yet recruiting","No Results Available","Coronavirus|Coronavirus Infection","Drug: Plasma|Drug: Hydroxychloroquine","Change in Viral Load|Change in Immunoglobulin M COVID-19 Titers|Change in Immunoglobulin G COVID-19 Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality","Universidad del Rosario|Fundación Universitaria de Ciencias de la Salud|CES University|Instituto Distrital de Ciencia Biotecnología e Innovacion en Salud","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABN011-2","May 1, 2020","August 31, 2020","December 31, 2020","April 3, 2020",,"April 28, 2020","Universidad del Rosario, Bogota, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT04332835"
1239,"NCT04389996","COVID-19 Pandemic Impact on Patients With Cancer - a Danish Survey","COPICADS","Recruiting","No Results Available","Cancer","Other: No intervention","Overall Quality of Life","Odense University Hospital","All","18 Years to 125 Years   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","OP_1132","May 14, 2020","June 14, 2020","May 1, 2023","May 15, 2020",,"May 19, 2020","Department of Oncology, Odense University Hospital, Odense C, Denmark",,"https://ClinicalTrials.gov/show/NCT04389996"
1240,"NCT04312100","Sequential Oxygen Therapy Strategy for Patients With COVID-19","SOTSPC","Recruiting","No Results Available","Coronavirus Disease-2019","Other: oxygen treatment","Incidence of respiratory failure|28 day mortality rate","Henan Provincial People's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SOT-C","February 1, 2020","October 2020","February 2021","March 18, 2020",,"March 18, 2020","Henan Provincial People's Hospital, Zhengzhou, Henan, China",,"https://ClinicalTrials.gov/show/NCT04312100"
1241,"NCT04375501","A Study of Outcomes in Patients With Fractured Neck of Femur During the COVID-19 Pandemic",,"Completed","No Results Available","Femoral Neck Fractures|SARS-CoV 2","Other: Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail","Mortality|Morbidity|Discharge","Barts & The London NHS Trust|University College London Hospitals|Barking, Havering and Redbridge University Hospitals NHS Trust|Basildon and Thurrock University Hospitals NHS Foundation Trust|Frimley Park Hospital NHS Trust|The Hillingdon Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)",,"442","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","284104","February 1, 2020","April 15, 2020","April 15, 2020","May 5, 2020",,"May 20, 2020","Barts Health NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04375501"
1242,"NCT04371328","Emergency Management in a Dedicated Respiratory Unit of Patients With a Possible COVID Infection (Unit ""COVID Possible""°","RECOP","Recruiting","No Results Available","Emergencies","Other: RECOP unit patient","Describe the characteristics of patients admitted to reCOP units according to their virological status vis-à-vis COVID-19|Develop a predictive model of the risk of being COVID for patients admitted to the emergency room for dyspnea","University Hospital, Toulouse","All","15 Years and older   (Child, Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC31/20/0094","March 13, 2020","August 2020","March 2021","May 1, 2020",,"May 1, 2020","University Hospital of Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04371328"
1243,"NCT04312009","Losartan for Patients With COVID-19 Requiring Hospitalization",,"Recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Losartan|Other: Placebo","Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days|Daily Hypotensive Episodes|Hypotension Requiring Vasopressors|Acute Kidney Injury|Sequential Organ Failure Assessment (SOFA) Total Score|Oxygen Saturation / Fractional Inhaled Oxygen (F/S)|28-Day Mortality|90-Day Mortality|ICU Admission|Number of Ventilator-Free Days|Number of Therapeutic Oxygen-Free Days|Number of Vasopressor-Free Days|Length of ICU Stay|Length of Hospital Stay|Incidence of Respiratory Failure|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Disease Severity Rating|Viral Load by Nasopharyngeal Swab Day 9|Viral Load by Nasopharyngeal Swab Day 15|Viral Load by Blood Day 9|Viral Load by Blood Day 15","University of Minnesota|Bill and Melinda Gates Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SURG-2020-28675|INV-017069","April 13, 2020","April 1, 2021","April 1, 2021","March 17, 2020",,"May 11, 2020","Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04312009"
1244,"NCT04315948","Trial of Treatments for COVID-19 in Hospitalized Adults","DisCoVeRy","Recruiting","No Results Available","Corona Virus Infection","Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care","Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)","Phase 3","3100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C20-15","March 22, 2020","March 2023","March 2023","March 20, 2020",,"April 29, 2020","Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France|Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France|Centre Hospitalier Régional Universitaire de Besançon, Besançon, France|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France|APHP - hôpital Henri-Mondor, Créteil, France|Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France|Centre Hospitalier Universitaire de Martinique, Fort De France, France|AP-HP Hôpital Bicêtre, Kremlin-Bicêtre, France|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France|Centre Hospitalier Régional Universitaire de Lille, Lille, France|Hospices Civils de Lyon, Lyon, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France|Centre Hospitalier Régional et Universitaire de Nancy, Nancy, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalo-Universitaire de Nice, Nice, France|APHP - Hôpital Saint Antoine, Paris, France|APHP - Hôpital Universitaire Pitié Salpêtrière, Paris, France|APHP - Hôpital Cochin, Paris, France|Hôpital Paris Saint-Joseph et Marie Lannelongue, Paris, France|APHP- Hôpital Européen Georges-Pompidou, Paris, France|APHP - Hôpital Bichat Claude Bernard, Paris, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Hopital DELAFONTAINE, Saint-Denis, France|Hôpital d'Instruction des Armées BEGIN, Saint-Mandé, France|Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France|Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier de Tourcoing, Tourcoing, France|Centre Hospitalier Universitaire de Tours, Tours, France|Centre Hospitalier Annecy Genevois, Épagny, France|Centre Hospitalier Luxembourg, Luxembourg, Luxembourg|Hôpitaux Robert Schuman, Luxembourg, Luxembourg",,"https://ClinicalTrials.gov/show/NCT04315948"
1245,"NCT04311177","Losartan for Patients With COVID-19 Not Requiring Hospitalization",,"Recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Losartan|Other: Placebo","Hospital Admission|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Daily Maximum Temperature|Emergency Department/Clinic Presentations|Disease Severity Rating Day 7|Disease Severity Rating Day 15|Disease Severity Rating Day 28|Viral Load by Oropharyngeal Swab Day 9|Viral Load by Oropharyngeal Swab Day 15|Ventilator-Free Days|Therapeutic Oxygen-Free Days|Need for Hospital Admission at 15 Days|Need for Oxygen Therapy at 15 Days","University of Minnesota|The Minnesota Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","580","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SURG-2020-28683","April 9, 2020","April 1, 2021","April 1, 2021","March 17, 2020",,"May 4, 2020","Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Health System, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04311177"
1246,"NCT04382391","Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms","SAVIORII","Recruiting","No Results Available","COVID|Corona Virus Infection|Respiratory Failure|Respiratory Distress Syndrome, Adult|ARDS, Human|SARS (Severe Acute Respiratory Syndrome)","Device: gammaCore® Sapphire (non-invasive vagus nerve stimulator)|Other: Standard of care therapies","change in initiation of mechanical ventilation in patients with CoViD-19 compared to the control group.|evaluate cytokine trends|evaluate supplemental oxygen requirements|decrease mortality of CoViD-19 patients|delay onset of ventilation","Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)|ElectroCore INC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-132-AGH","May 8, 2020","September 1, 2020","December 30, 2020","May 11, 2020",,"May 13, 2020","AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04382391"
1247,"NCT04367363","Social Media and COVID-19",,"Recruiting","No Results Available","Coronavirus|Depression|Anxiety|Stress","Behavioral: Social media & news consumption","Change in DASS scores across 9 days|Changes in fear with regards the COVID-19 situation across 1 week|Changes in amount of thinking about the COVID-19 situation across 1 week","Jean Liu|Yale-NUS College","All","21 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-CERC-001B","March 8, 2020","May 31, 2020","May 31, 2020","April 29, 2020",,"April 29, 2020","Yale-NUS College, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04367363"
1248,"NCT04373733","A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe","PIONEER","Not yet recruiting","No Results Available","Coronavirus Infection","Drug: Favipiravir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Other: Standard of care management","Time to improvement by two points on a seven-category ordinal scale|Clinical status on a seven-category ordinal scale (Day 7)|Clinical status on a seven-category ordinal scale (Day 14)|Overall survival|Time to improvement by two points on the NEWS score|Time to improvement by two points on the NEWS element score for temperature|Time to improvement by two points on the NEWS element score for heartrate|Time to improvement by two points on the NEWS element score for respiratory rate|Time to improvement by two points on the NEWS element score for oxygen saturation.|Admission to intensive care|Requirement for mechanical ventilation|Requirement for non-invasive ventilation, continuous positive airways pressure or high-flow oxygen|Incidence of bacterial or fungal infection|Incidence of adverse events not directly caused by COVID-19 infection.","Chelsea and Westminster NHS Foundation Trust|NEAT ID Foundation|FUJIFILM Toyama Chemical Co., Ltd.|Imperial College London|Universitaire Ziekenhuizen Leuven","All","18 Years and older   (Adult, Older Adult)","Phase 3","450","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CW002|2020-001449-38","May 1, 2020","March 31, 2021","March 31, 2021","May 4, 2020",,"May 4, 2020","Chelsea and Westminster Hospital, London, United Kingdom|West Middlesex University Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04373733"
1249,"NCT04313946","Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays","AI-COVID-Xr","Recruiting","No Results Available","COVID-19|Pneumonia, Viral|Influenza With Pneumonia|Flu Symptom|Flu Like Illness|Pneumonia, Interstitial|Pneumonia, Ventilator-Associated|Pneumonia Atypical","Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images","COVID-19 positive X-Rays|COVID-19 negative X-Rays","Professor Adrian Covic|Falcon Trading Iasi|Romanian Academy of Medical Sciences|Grigore T. Popa University of Medicine and Pharmacy","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","0110","March 18, 2020","August 16, 2020","August 18, 2020","March 18, 2020",,"April 27, 2020","U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale; Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute Università degli Studi di Trieste, Cremona, Italy|University of Medicine and Pharmacy Gr T Popa, Iaşi, Romania|Department of Cardiology at Chelsea and Westminster NHS hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04313946"
1250,"NCT04381936","Randomized Evaluation of COVID-19 Therapy","RECOVERY","Recruiting","No Results Available","Severe Acute Respiratory Syndrome","Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Tocilizumab","All-cause mortality|Duration of hospital stay|Need for (and duration of) ventilation|Need for renal replacement","University of Oxford|UK Research and Innovation|National Institute for Health Research, United Kingdom|Wellcome|Bill and Melinda Gates Foundation|Department for International Development, United Kingdom|Health Data Research UK|Medical Research Council Population Health Research Unit|NIHR Clinical Trials Unit Support Funding","All","Child, Adult, Older Adult","Phase 2|Phase 3","12000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NDPHRECOVERY|2020-001113-21|ISRCTN50189673","March 19, 2020","December 2020","June 2021","May 11, 2020",,"May 11, 2020","Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04381936"
1251,"NCT04394169","Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.","PAIN-COVID","Not yet recruiting","No Results Available","Post ICU Syndrome|Chronic Pain|Covid-19","Behavioral: Intervention program","Impact of intervention program on health-related quality of life (VAS)|Impact of intervention program on health-related quality of life (Index)|Impact of intervention program on chronic pain (intensity)|Impact of intervention program on chronic pain (limitation of daily activities)|Impact of intervention program on chronic pain (Pain catastrophization)|Impact of intervention program on anxiety or depression incidence|Impact of intervention on probable post-traumatic stress syndrome incidence","Hospital Clinic of Barcelona","All","18 Years and older   (Adult, Older Adult)","Not Applicable","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","HCB/2020/0549","May 25, 2020","September 25, 2020","March 25, 2021","May 19, 2020",,"May 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04394169"
1252,"NCT04387253","Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID",,"Not yet recruiting","No Results Available","Identification of the Mother or Fetus Contamination by SARS Cov-2|Research the Presence of Viruses at Different Sites of the Mother and the Fetus or Father|The Survey Builds on a Network Work Already Organized Around the CPDPN of Poitou-Charentes|Analysis Laboratories of the Poitiers CHU","Diagnostic Test: Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus","Estimate the prevalence of SARS-CoV-2 infection in women with late fetal loss of unexplained cause.","Poitiers University Hospital","All","Child, Adult, Older Adult","Not Applicable","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","GYNE-COVID","May 20, 2020","July 20, 2021","July 20, 2021","May 13, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04387253"
1253,"NCT04367740","ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19",,"Enrolling by invitation","No Results Available","Asymptomatic Condition|Infection Viral|Coronavirus Infections|Severe Acute Respiratory Syndrome Coronavirus 2|Coronaviridae Infections|RNA Virus Infections|Virus Diseases|Communicable Disease","Diagnostic Test: To assess for development of IgG antibodies against SARS-CoV2","Percentage of Asymptomatic patients with an IgG response from SARS-CoV-2 infection.|Percentage of Asymptomatic patients with viral presence of SARS-CoV-2 infection.","University of North Carolina, Chapel Hill","All","18 Years to 99 Years   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","20-0937","April 28, 2020","April 2021","April 2021","April 29, 2020",,"April 29, 2020","Center for Environmental Medicine, Asthma and Lung Biology, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04367740"
1254,"NCT04335162","Cardiovascular Complications and COVID-19 (CovCardioVasc)","CovCardioVasc","Recruiting","No Results Available","COVID|Acute Coronary Syndrome|Myocardial Infarction|Myocarditis|Venous Thromboembolism|Deep Vein Thrombosis|Pulmonary Embolism",,"Determine the incidence of cardiomyopathies and venous thromboembolism|Mortality|Duration of mechanical ventilation|shock at day 28|length of stay in the intensive care unit","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20reamedcovid01","February 28, 2020","August 28, 2020","August 28, 2020","April 6, 2020",,"May 13, 2020","Centre Hospitalier de Cannes, Cannes, France|Centre Hospitalier de Draguignan, Draguignan, France|Centre Hospitalier de Grasse, Grasse, France|CHU de Nice, Nice, France|Hôpitaux Universitaires Paris Centre - Hôpital Cochin, Paris, France",,"https://ClinicalTrials.gov/show/NCT04335162"
1255,"NCT04340466","French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study","FRENCH CORONA","Recruiting","No Results Available","Pneumonia, Viral|Critically Ill|Corona Virus Infection","Other: No intervention","Mortality at day 28|severe complications|Imaging|Delay in Microbiological diagnosis|Antiviral therapy|Antibiotic therapy|Covid-19 treatments|Patients receiving renal replacement therapy|Patients receiving mechanical ventilation|Vital status","Centre Hospitalier Universitaire de Nīmes","All","18 Years and older   (Adult, Older Adult)",,"220","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A00797-32","April 3, 2020","June 30, 2020","April 30, 2021","April 9, 2020",,"April 14, 2020","CHU Nimes, Nîmes, France",,"https://ClinicalTrials.gov/show/NCT04340466"
1256,"NCT04348929","Birth Experience During COVID-19 Confinement","CONFINE","Recruiting","No Results Available","Postpartum Depression","Other: Self-administered questionnaires","""Labor Agentry Scale questionnaire"" score in immediate post-partum (duration of hospital stay)|""Labor Agentry Scale questionnaire"" score at two months after birth|Edinburg Postnatale Depression Scale questionnaire"" score at two months after birth|""Impact of Event Scale - Revised questionnaire"" score at two months after birth|Breastfeeding statement at two months after birth|""SF-12 Quality of life questionnaire"" score at two months after birth|""SF-12 Quality of life questionnaire"" score in immediate post-partum","Central Hospital, Nancy, France","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2020-A00881-38","April 16, 2020","August 16, 2021","November 1, 2021","April 16, 2020",,"April 22, 2020","Centre Hospitalier Régional Universitaire de Nancy, Nancy, France",,"https://ClinicalTrials.gov/show/NCT04348929"
1257,"NCT04377581","COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior",,"Recruiting","No Results Available","Public Health|Demography|Pandemics|Corona Virus Infection|News|Global Health|Perception",,"Knowledge and Confidence in Knowledge of COVID-19|Beliefs about the effectiveness of public health recommendations|Intent to comply with public health recommendations|Perception of Risk of COVID-19 and other health threats|Perceptions of trust in common health information sources|Single most trusted news source|Intention to change consumption of news because of COVID-19 (yes/no)|For participants who will change their news consumption, in what way will they change?|Secondary information sources|Concerns about COVID-19","Milton S. Hershey Medical Center|The Huck Institutes of the Life Sciences|The Social Science Research Institute|The Department of Family and Community Medicine, Penn State College of Medicine|The College of Healthcare Information Management Executives (CHIME)","All","18 Years and older   (Adult, Older Adult)",,"25000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","STUDY00014798","April 9, 2020","May 31, 2020","May 31, 2020","May 6, 2020",,"May 6, 2020","Penn State College of Medicine, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04377581"
1258,"NCT04358640","Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey","PSY_CO_CHU","Recruiting","No Results Available","Critical Illness|Sars-CoV2|SARS Pneumonia|Coronavirus Infection|Stress Disorders, Post-Traumatic",,"Anxiety|Insomnia|Catastrophism","Centre Hospitalier Universitaire de Nīmes","All","18 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","LOCAL COVID 2019/JYL-01)","April 9, 2020","April 22, 2020","April 22, 2020","April 24, 2020",,"April 24, 2020","Intensive care unit CHU Nimes, Nîmes, France",,"https://ClinicalTrials.gov/show/NCT04358640"
1259,"NCT04373135","Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19","UC-COVID","Recruiting","No Results Available","Covid-19|Critical Illness|Attitude of Health Personnel|Attitude to Health|Health Behavior|Health Care Utilization","Behavioral: Brief educational video","Improvement in knowledge surrounding SRA policy|Improvement in anxiety surrounding SRA policy|Improvement in trust surrounding SRA policy","University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","UCLA-20-000683","May 8, 2020","October 2020","December 2020","May 4, 2020",,"May 12, 2020","University of California, Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04373135"
1260,"NCT04380766","Covid-19 Pandemic and Pancreatic Surgery in Italy","PanCOVID","Recruiting","No Results Available","Pancreatic Cancer","Procedure: Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer","Changes in pancreatic cancer management during the COVID-19 pandemic","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","All","18 Years and older   (Adult, Older Adult)",,"700","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","FPGemelliIRCCS","January 1, 2019","June 30, 2020","June 30, 2020","May 8, 2020",,"May 8, 2020","Fondazione Policlinico Universitario Agostino Gemelli IRCCS di Roma, Roma, Lazio, Italy",,"https://ClinicalTrials.gov/show/NCT04380766"
1261,"NCT04327570","In-depth Immunological Investigation of COVID-19.","COntAGIouS","Not yet recruiting","No Results Available","Coronavirus Infections","Other: Patient sampling","Clinical Features|Immune host response at systemic level|Immune host response at local level|Host genetic variation|Comparison severe and non-severe COVID-19 hospitalised patients|Correlation of findings with outcome|Correlation of immune profiling - microbiome","Universitaire Ziekenhuizen Leuven","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","COntAGIouS","March 27, 2020","September 30, 2020","September 30, 2020","March 31, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04327570"
1262,"NCT04382196","Impact of COVID-19 on Mental Health of Health Care Workers","COVID-Impact","Active, not recruiting","No Results Available","Mental Health|Quality of Life","Other: Online survey","Depressive symptoms at baseline|Change in depressive symptoms|Anxiety levels at baseline|Change in anxiety levels|Stress levels at baseline|Change in stress levels|Quality of life at baseline|Change in Quality of life|Covid-19 related psychological distress|Change in Covid-19 related psychological distress|Post traumatic stress symptoms|Change in post traumatic stress symptoms|Perceived social support at baseline|Change in perceived social support","University Hospital, Ghent","All","Child, Adult, Older Adult",,"497","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BC-07564","April 17, 2020","December 31, 2022","December 31, 2022","May 11, 2020",,"May 11, 2020","Ghent University Hospital, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT04382196"
1263,"NCT04332016","COVID-19 Biological Samples Collection","COLCOV19-BX","Recruiting","No Results Available","Infection Viral","Other: biological samples collection","COVID-19 desease description","University Hospital, Bordeaux","All","up to 100 Years   (Child, Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CHUBX 2020/11","April 2, 2020","March 2023","March 2023","April 2, 2020",,"April 3, 2020","Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04332016"
1264,"NCT04314232","Mechanisms to Morbidity and Mortality for Covid-19","COVID MECH","Not yet recruiting","No Results Available","Coronavirus|SARS",,"Change in viral expression in association to organspecific biomarkers","University Hospital, Akershus","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","117589","March 23, 2020","December 31, 2021","December 31, 2021","March 19, 2020",,"March 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04314232"
1265,"NCT04322565","Colchicine Counteracting Inflammation in COVID-19 Pneumonia","ColCOVID-19","Recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral","Drug: Colchicine","Clinical improvement|Hospital discharge|Death|Clinical status|Mechanical ventilhation|Hospitalization|Time from treatment initiation to death|Time to Negativization COVID 19|Fever","Azienda Ospedaliero-Universitaria di Parma","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","310","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ColCOVID-19","April 20, 2020","June 20, 2020","July 20, 2020","March 26, 2020",,"May 18, 2020","Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy",,"https://ClinicalTrials.gov/show/NCT04322565"
1266,"NCT04260594","Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus",,"Not yet recruiting","No Results Available","2019-nCoV","Drug: Arbidol|Other: basic treatment","Virus negative conversion rate in the first week|Virus negative conversion rate|Antipyretic rate|Symptom relief time|Finger oxygen improvement rate|Disease progression rate|Mortality rate|Incidence of severe adverse reactions|Change curve of peripheral blood lymphocyte count","Jieming QU|Ruijin Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","380","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Abdrcspc202001","February 7, 2020","July 1, 2020","December 30, 2020","February 7, 2020",,"February 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04260594"
1267,"NCT04336748","HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers",,"Not yet recruiting","No Results Available","Sars-CoV2|Infection Viral|Healthcare Worker|Prophylaxis","Drug: Hydroxychloroquine","Symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR|Viral load during SARS-CoV-2 infection|Seroconversion during the study period|Incidence of any acute respiratory infection|Days of sick leave","Medical University of Vienna","All","18 Years and older   (Adult, Older Adult)","Phase 3","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","HCQ prophylaxis for COVID19","April 2020","July 2020","August 2020","April 7, 2020",,"April 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04336748"
1268,"NCT04368832","imPROving prenaTal carE During ConfinemenT","PROTECT","Not yet recruiting","No Results Available","Pregnancy Related|COVID","Other: Remote consultation","Score of perceived quality of prenatal care|Level of stress during pregnancy|level of health and digital literacy|Obstetrical outcomes|Characteristics of medical supervision during pregnancy","Central Hospital, Nancy, France","Female","18 Years and older   (Adult, Older Adult)",,"108","Other","Observational","Observational Model: Other|Time Perspective: Prospective","2020-A01023-36","May 1, 2020","July 31, 2021","September 30, 2021","April 30, 2020",,"April 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04368832"
1269,"NCT04365101","Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNK-001-COVID-19)","CYNK001COVID","Recruiting","No Results Available","Coronavirus|Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2|Pneumonia|Pneumonia, Viral|Lung Diseases|Respiratory Tract Disease|Respiratory Tract Infections|Coronaviridae Infections|Nidovirales Infections|RNA Virus Infections|Virus Disease|Immunologic Disease|ARDS|Immunologic Factors|Physiological Effects of Drugs|Antiviral Agents|Anti-infective Agents|Analgesics|Antimetabolites, Antineoplastic","Biological: CYNK-001","Phase 1: Frequency and Severity of Adverse Events (AE)|Time to Clearance of SARS-CoV-2|Time to Clinical Improvement of cough|Time to Clinical Improvement in radiological evaluation of disease related chest x-ray|Rate of Pulmonary Clearance|Rate of Clinical Improvement of radiological evaluation of disease related chest x-ray|Phase 2: Frequency and Severity of Adverse Events (AE)|Overall Clinical Benefit by time to medical discharge|Overall Clinical Benefit by hospital utilization|Overall Clinical Benefit by measuring mortality rate|Impact of CYNK-001 on sequential organ failure assessment (SOFA) score|Time to Pulmonary Clearance|Rate of Clinical Improvement of cough|Rate of Clinical Improvement of fever|Time to Clinical Improvement of fever|Rate of Clearance of SARS-CoV-2","Celularity Incorporated|IDRI|Lung Biotechnology PBC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","86","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CYNK-001-COVID-19","May 13, 2020","November 30, 2020","November 30, 2021","April 28, 2020",,"May 19, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04365101"
1270,"NCT04367870","COVID-19 Detection Test in Oncology","EVIDENCE","Not yet recruiting","No Results Available","Oncology",,"To evaluate the ability of SARS-CoV-2 immunoassays, following a positive result, to identify patients with very low risk of recurrence of COVID-19 within 3 months.|To estimate the prevalence of patients immunized to the SARS-CoV-2 virus in an oncology population over the whole study duration and within one-month periods.|To estimate the discordance rate between local immunoassay and a centralized ELISA in patients with a positive immunoassay, whatever the immunoassay.|To identify patients with very low risk of recurrence of COVID-19 within 6 months following a positive immunoassay result.|To characterize the evolution over time of the serologic response against SARS-CoV-2 (in a subgroup of patients).","UNICANCER","All","18 Years and older   (Adult, Older Adult)",,"2500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UC-TRA-2002|2020-A01002-37","May 2020","August 2020","May 2021","April 29, 2020",,"April 29, 2020","Centre Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Hopitaux Civils de Colmar, Colmar, France|Centre Leon Berard, Lyon, France|Institut Paoli Calmettes, Marseille, France|Institut Regional Du Cancer Montpellier Val D Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Universitaire Pitié Salpêtrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut Curie, Saint-Cloud, France",,"https://ClinicalTrials.gov/show/NCT04367870"
1271,"NCT04321811","Behavior, Environment And Treatments for Covid-19","BEAT19","Recruiting","No Results Available","Coronavirus","Other: Observation of patients with known, suspected, or at risk for COVID-19 infection","Define Natural Symptom Course|Time to Hospitalization|Time to Symptomatic Recovery","xCures|Genetic Alliance|LunaDNA|Cancer Commons|REDCap Cloud","All","18 Years and older   (Adult, Older Adult)",,"100000","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","XC-PCOR-COVID19","March 21, 2020","March 20, 2021","March 20, 2022","March 25, 2020",,"April 2, 2020","BEAT19.org, San Francisco, California, United States","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04321811/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04321811"
1272,"NCT04341935","Effects of DPP4 Inhibition on COVID-19",,"Not yet recruiting","No Results Available","Coronavirus Infection|Type 2 Diabetes","Drug: Linagliptin|Drug: Insulin regimen","Changes in Glucose Llevels|Changes in SpO2 levels|Changes in Interleukin 6 (IL6)|Changes in chest structures","University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20200384","June 30, 2020","October 30, 2020","December 30, 2020","April 10, 2020",,"May 15, 2020","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04341935"
1273,"NCT04345159","Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease","COVCALL","Active, not recruiting","No Results Available","SARS-CoV-2|Systemic Lupus Erythematosus|Rheumatoid Arthritis|Sjogren's Syndrome|Psoriatic Arthritis","Other: Questionnaire by phone call","Adjusted Odds Ratio","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)",,"572","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GDE_2020_11","April 17, 2020","April 30, 2020","July 2020","April 14, 2020",,"May 13, 2020","Fondation Adolphe de Rothschild, Paris, France",,"https://ClinicalTrials.gov/show/NCT04345159"
1274,"NCT04385238","Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic",,"Recruiting","No Results Available","COVID-19|Pregnancy Complications|Mental Health Wellness 1|Anxiety|Depression|Ptsd|Coronavirus","Other: This is an online survey with no intervention.","Post-traumatic Stress Disorder|Anxiety and Depression","Pregistry|Harvard School of Public Health","Female","18 Years and older   (Adult, Older Adult)",,"2500","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","0002","May 15, 2020","August 31, 2020","August 31, 2020","May 12, 2020",,"May 19, 2020","Pregistry, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04385238"
1275,"NCT04367077","MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)","MACoVIA","Recruiting","No Results Available","ARDS","Biological: MultiStem|Biological: Placebo","Ventilator-Free Days|Safety and Tolerability as measured by the incidence of treatment-emergent adverse events as assessed by CTCAE v5.0.|All-cause mortality|Ranked hierarchical composite outcome of alive and ventilator-free|Ventilator-free days","Athersys, Inc","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 2|Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B04-03","April 28, 2020","September 2021","August 2022","April 29, 2020",,"May 15, 2020","Athersys Investigational Site 101, Cleveland, Ohio, United States|Athersys Investigational Site 102, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04367077"
1276,"NCT04371601","Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019",,"Active, not recruiting","No Results Available","COVID-19 Pneumonia","Drug: Oseltamivir|Drug: hormones|Device: oxygen therapy|Procedure: mesenchymal stem cells","Changes of oxygenation index (PaO2/FiO2) ,blood gas test|Detection of TNF-α levels, IL-10 levels|Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells).|Changes of c-reactive protein and calcitonin","Fuzhou General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-CoViD-2020","March 1, 2020","December 31, 2021","December 31, 2022","May 1, 2020",,"May 1, 2020","Fuzhou General Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT04371601"
1277,"NCT04275414","Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia","BEST-CP","Recruiting","No Results Available","Coronavirus Infections","Drug: Bevacizumab Injection","Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio|Degree of dyspnea (Liker scale)|Degree of dyspnea (VAS)|The area of lung lesions on Chest CT|The degree of lung exudation on Chest CT|SpO2|PaO2|CRP|hs-CRP|All-cause mortality","Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Moriggia-Pelascini Gravedona Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QLEmer20200214","February 15, 2020","April 2020","May 2020","February 19, 2020",,"April 3, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy",,"https://ClinicalTrials.gov/show/NCT04275414"
1278,"NCT04386083","Neurologic Manifestations of COVID-19","CORONA","Not yet recruiting","No Results Available","Coronavirus Disease 2019",,"Mortality (binary outcome)|Respiratory failure (binary outcome)|Duration of ventilator dependence (continuous outcome)|Intensive care unit (ICU) admission (binary outcome)","University of the Philippines|Asian Hospital and Medical Center, Muntinlupa City, Philippines|Baguio General Hospital and Medical Center, Baguio City, Philippines|Cagayan Valley Medical Center, Tuguegarao City, Philippines|Capitol Medical Center, Quezon City, Philippines|Cardinal Santos Medical Center, San Juan City, Philippines|Chong Hua Hospital, Cebu City, Philippines|De La Salle University Medical Center|East Avenue Medical Center, Philippines|Jose B. Lingad Memorial Regional Hospital, San Fernando, Pampanga, Philippines|Jose R. Reyes Memorial Medical Center|Lung Center of the Philippines|Manila Doctors Hospital, Philippines|Manila Medical Center, Philippines|Makati Medical Center|New Era General Hospital, Philippines|Quirino Memorial Medical Center, Philippines|Ospital ng Makati, Philippines|Dr. Pablo O. Torre Memorial Hospital, Bacolod City, Philippines|Philippine Heart Center|Research Institute for Tropical Medicine, Philippines|San Juan De Dios Educational Foundation Inc. - Hospital, Philippines|San Lazaro Hospital, Philippines|Southern Isabela Medical Center, Philippines|St. Luke's Medical Center, Philippines|St Lukes Medical Center, Bonifacio Global City, Philippines|Southern Philippines Medical Center|The Medical City, Philippines|University of the East Ramon Magsaysay Memorial Medical Center, Inc, Philippines|University of Santo Tomas Hospital, Philippines|Veterans Memorial Medical Center, Philippines","All","19 Years and older   (Adult, Older Adult)",,"1342","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RGAO-2020-0348","May 2020","December 2020","March 2021","May 13, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04386083"
1279,"NCT04359810","Plasma Therapy of COVID-19 in Critically Ill Patients",,"Recruiting","No Results Available","SARS-CoV Infection","Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Non-convalescent Plasma (control plasma)","Time to Improvement|Rate of SARS-CoV-2 PCR Positivity|Duration of SARS-CoV-2 PCR Positivity|Duration of Need for Supplemental Oxygen|Duration of Hospitalization|In-hospital 28-day Mortality Rate","Max R. O'Donnell|New York Blood Center|Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","AAAS9924","April 21, 2020","December 2020","April 2021","April 24, 2020",,"April 30, 2020","Columbia University Irving Medical Center/NYP, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04359810"
1280,"NCT04368208","Impact of Giving Birth During the Covid 19 Pandemia on Postnatal Women's Depression","DEPRECOVID","Not yet recruiting","No Results Available","Postnatal Depression","Other: Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery","Report postnatal depression between 4 of 6 weeks during the covid 19 pandemia|Report factors associated with postnatal depression between 4 of 6 weeks during the covid 19 pandemia|Describe the experience and the satisfaction about delivery during the covid 19 pandemia","Poitiers University Hospital","Female","18 Years to 50 Years   (Adult)",,"900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A01065-34","May 2020","May 2020","December 2020","April 29, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04368208"
1281,"NCT04378595","Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin",,"Recruiting","No Results Available","Food Insecurity","Other: During COVID-19 Pandemic|Other: After COVID-19 Pandemic","Food Insecurity Score","University of Texas at Austin","All","18 Years to 100 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-004-0019","April 10, 2020","December 30, 2020","July 30, 2021","May 7, 2020",,"May 8, 2020","Dell Medical School, Austin, Texas, United States|CommUnity Care Clinic - Southeast Health and Wellness Clinic, Austin, Texas, United States|CommUnity Care Clinic - Rundberg, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04378595"
1282,"NCT04323839","COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)","PRIORITY","Recruiting","No Results Available","Pregnancy|Coronavirus|COVID-19","Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19","Clinical presentation|Disease prognosis outcomes|Pregnancy outcomes|Obstetric outcomes|Neonatal outcomes|Modes of transmission of COVID-19","University of California, San Francisco|University of California, Los Angeles","Female","13 Years and older   (Child, Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-30410","March 20, 2020","March 31, 2024","March 31, 2024","March 27, 2020",,"April 24, 2020","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04323839"
1283,"NCT04380818","Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19",,"Recruiting","No Results Available","Pneumonia, Viral","Radiation: Low-dose radiotherapy|Drug: Hydroxychloroquine Sulfate|Drug: Ritonavir/lopinavir|Drug: Tocilizumab Injection [Actemra]|Drug: Azithromycin|Drug: Corticosteroid|Drug: Low molecular weight heparin|Device: Oxygen supply","Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change of the radiological image|Overall mortality|Measure of pro-inflammatory interleukins|Measure of trasforming growth factor (TGF-b)|Measure of tumor necrosis factor alpha (TNF-a)|Determining overexpression of pro-inflammatory selectin|Determining cell adhesion molecules (CAMs)|Measure of marker of oxidative stress PON-1","Grupo de Investigación Clínica en Oncología Radioterapia|Hospital Universitario Madrid Sanchinarro|Hospital del Mar|Hospital Universitari Sant Joan de Reus","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","106","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IPACOVID","May 8, 2020","May 4, 2021","July 1, 2021","May 8, 2020",,"May 8, 2020","Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04380818"
1284,"NCT04325919","Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong",,"Recruiting","No Results Available","Coronavirus Infections","Other: No intervention","Clinical|Virological|Microbiological","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"170","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","COVID-19 study 2020.076","February 24, 2020","February 28, 2021","June 17, 2021","March 30, 2020",,"March 30, 2020","Prince of Wales Hospital, Sha Tin, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04325919"
1285,"NCT04370197","Covid-19 Epidemic on Acute Stroke Management","Stroke-Covid19","Recruiting","No Results Available","Stroke, Acute",,"Study of the effect of pandemic covid-19 on the management of stroke patients","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7826","March 3, 2020","April 30, 2020","April 30, 2020","April 30, 2020",,"April 30, 2020","Service de Neuroradiologie Interventionnelle, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04370197"
1286,"NCT04383717","Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial",,"Not yet recruiting","No Results Available","Respiratory Tract Infections","Drug: Levamisole and isoprinosine|Drug: Azithromycin and hydroxychloroquine","COVID 19 induced fever in both groups|COVID 19 induced dyspnea in both groups|COVID 19 viral load in both groups|laboratory clearance in both groups: CRP in mg/dL","Cairo University","All","6 Years to 90 Years   (Child, Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Levamisole and isoprinosine","May 5, 2020","August 30, 2020","October 30, 2020","May 12, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04383717"
1287,"NCT04371835","COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings",,"Not yet recruiting","No Results Available","HIV-infection/Aids|Coronavirus Infection",,"Clinical features of symptomatic COVID-19 in people living with HIV (PLWH)|Clinical outcomes of symptomatic COVID-19 in PLWH|Seroprevalence of COVID-19 in all parent study participants","Kirby Institute|University of Witwatersrand, South Africa|University of Liverpool|Université Montpellier|UNITAID","All","18 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-04-COHIVE","May 15, 2020","December 31, 2021","December 31, 2021","May 1, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04371835"
1288,"NCT04376775","Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting Transplantation","COWAIT","Recruiting","No Results Available","Transplantation","Other: Transplant patient","Compliance precautions with COVID-19|Clinical impact of COVID-19","University Hospital, Bordeaux|Société Francophone de Transplantation","All","18 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHUBX 2020/19","May 11, 2020","December 11, 2020","December 11, 2020","May 6, 2020",,"May 19, 2020","Hopital Pellegrin, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04376775"
1289,"NCT04379063","COVID-19 Pandemic Short Interval National Survey Gauging Psychological Distress","COPING","Not yet recruiting","No Results Available","Burnout, Professional|Psychological Distress","Other: COVID-19 pandemic","Burnout|Psychological Distress|Post-traumatic stress symptoms|Post-traumatic growth","Jon Bailey|Nova Scotia Health Authority","All","Child, Adult, Older Adult",,"10000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NSHA REB#1025690","May 2020","May 2021","May 2022","May 7, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04379063"
1290,"NCT04338672","The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients",,"Recruiting","No Results Available","Emergency Service, Hospital|General Surgery","Other: COVID-19 Pandemic","Rates of emergency visits needing surgical consult|The ratio of severe presentations to non-severe presentations|The impact of age on ED attendance rates|Differences in ED surgical visits (in terms of capacity and severity) of surgical patients depending on the presentation and the co morbidity","Sheba Medical Center","All","18 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","SMC-20-7078-YZ-CTIL","April 5, 2020","April 1, 2021","April 1, 2022","April 8, 2020",,"April 21, 2020","Sheba Medical Center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT04338672"
1291,"NCT04324866","Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy",,"Not yet recruiting","No Results Available","Coronavirus Infection","Diagnostic Test: Nasopharyngeal swab","Point prevalence of COVID-19 infection|Incidence of COVID-19 infection|Percentage of subjects presenting fever or respiratory symptoms|Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments|Evaluate the relationship between COVID-19 infection and comorbid medical conditions","Universita di Verona|Azienda Ospedaliera Universitaria Integrata Verona","All","18 Years to 75 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Gisondi 4","April 1, 2020","November 2020","December 2020","March 27, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04324866"
1292,"NCT04327349","Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial",,"Enrolling by invitation","No Results Available","Coronavirus Infections","Biological: Convalescent Plasma","Mortality changes in day 10|Mortality changes in day 30|Changes of C-reactive protein|Changes of Interleukin 6|Changes of tumor necrosis factor-α|Changes of PaO2/FiO2 Ratio|Changes of CD3|Changes of CD4|Changes of CD8|Changes of CD4/CD8 ratio|Changes of lymphocyte count|Changes of leukocyte count|Changes of alanine transaminase (ALT)|Changes of aspartate transaminase (AST)|Changes of alkaline phosphatase (ALP)|Changes of lactate dehydrogenase (LDH)|Changes of creatine phosphokinase (CPK)|Changes of Creatine kinase-MB (CK-MB)|Changes of Specific IgG|Radiological findings|Number of days ventilated|Length of hospitalization","Mazandaran University of Medical Sciences","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IR.MAZUMS.REC.1399.7330|IRCT20181104041551N1","March 28, 2020","May 20, 2020","September 30, 2020","March 31, 2020",,"March 31, 2020","Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04327349"
1293,"NCT04368637","Acute Cardiovascular Events Triggered by COVID-19-Related Stress","JoCORE","Recruiting","No Results Available","Acute Myocardial Infarction|Ventricular Tachycardia|Sudden Cardiac Death|Stroke, Acute",,"Acute cardiovascular event triggered by COVID-19 stress|Ventricular tachycardia|acute stroke|Implantable cardioverter defibrillator (ICD) shock","Jordan Collaborating Cardiology Group","All","18 Years to 100 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","JCCG.JoCORE.4.4040","May 3, 2020","July 30, 2020","August 30, 2020","April 30, 2020",,"May 5, 2020","Istishari Hospital, Amman, Jordan|Abdelhadi Hospital, Amman, Jordan|Farah Hospital, Amman, Jordan|Jordan Hospital, Amman, Jordan|Specialty Hospital, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04368637"
1294,"NCT04360863","The Impact of COVID-19 Pandemic on the Smoking Behaviour of Young Smokers and the Youth Quitline Service in Hong Kong",,"Recruiting","No Results Available","Smoking Cessation","Other: Telephone survey","Smoking behaviors|Knowledge|Readiness to quit","The University of Hong Kong","All","up to 25 Years   (Child, Adult)",,"150","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","NCT02758028_1","April 24, 2020","June 30, 2020","June 30, 2020","April 24, 2020",,"April 27, 2020","The University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04360863"
1295,"NCT04388605","Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic","ASPIRE","Recruiting","No Results Available","Corona Virus Infection|COVID|Pregnancy Related|Early Pregnancy",,"Prevalence of SARS-CoV-2 infection throughout pregnancy in women|Incidence of SARS-CoV-2 infection throughout pregnancy in women|Risk ratios of adverse obstetric in women infect with SARS-CoV-2 during early pregnancy onward compared to non-infected pregnant women|Risk ratios of adverse neonatal outcomes in women infected with SARS-CoV-2 during early pregnancy onward compared to non-infected pregnant women|Clinical, behavioral, and sociodemographic determinants","University of California, San Francisco","Female","18 Years and older   (Adult, Older Adult)",,"11000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-30559","April 21, 2020","September 2021","September 2022","May 14, 2020",,"May 15, 2020","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04388605"
1296,"NCT04395859","Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents","COVIDIV","Not yet recruiting","No Results Available","Age Related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion","Procedure: Questionnaire|Other: Data collection up to 1 year","Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MMT_2020_15","May 2020","December 2021","December 2021","May 20, 2020",,"May 20, 2020","Centre Pôle Vision du val d'Ouest, Ecully, France|Fondation Adolphe de Rothschild, Paris, France|Hôpital Lariboisière, Paris, France|Centre ophtalmologique Maison Rouge, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04395859"
1297,"NCT04357730","Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection",,"Recruiting","No Results Available","Severe Acute Respiratory Syndrome|Respiratory Failure|Acute Respiratory Distress Syndrome","Drug: Alteplase 50 MG [Activase]|Drug: Alteplase 100 MG [Activase]","PaO2/FiO2 improvement from pre-to-post intervention|Achievement of PaO2/FiO2 ≥ 200 or 50% increase in PaO2/FiO2|National Early Warning Score 2 (NEWS2)|National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale|48 hour in-hospital mortality|14 days in-hospital mortality|28 days in-hospital mortality|ICU-free days|In-hospital coagulation-related event-free (arterial and venous) days|Ventilator-free days|Successful extubation|Successful weaning from paralysis|Survival to discharge","Denver Health and Hospital Authority|Genentech, Inc., University of Colorado Denver, National Jewish, Beth Israel Deaconess Medical Center, and Long Island Jewish Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-0880","May 14, 2020","September 2020","November 2020","April 22, 2020",,"May 25, 2020","Denver Health Medical Center, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04357730"
1298,"NCT04348695","Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.","Ruxo-Sim-20","Recruiting","No Results Available","Coronavirus Infection","Drug: Ruxolitinib plus simvastatin|Other: Standard of Care","Percentage of patients who develop severe respiratory failure.|Length of ICU stay.|Length of hospital stay|Survival rate at 6 months|Survival rate at 12 months|Survival rate at 28 days|Percentage of patients with each AE by grade|Percentage of patients who discontinued due to AEs","Fundación de investigación HM|Apices Soluciones S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 2","94","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ruxo-Sim-20|2020-001405-23","April 12, 2020","May 13, 2020","May 13, 2020","April 16, 2020",,"April 17, 2020","Hospital Universitario Madrid Sanchinarro, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04348695"
1299,"NCT04328129","Household Transmission Investigation Study for COVID-19 in French Guiana","EPI-COVID-19","Recruiting","No Results Available","Coronavirus Infections|Severe Acute Respiratory Syndrome|SARS-CoV Infection","Procedure: Human biological samples","Evaluation of the extent of the virus transmission within households|Characterization of the secondary cases","Institut Pasteur|Institut Pasteur de la Guyane|Centre Hospitalier Andrée Rosemon de Cayenne","All","Child, Adult, Older Adult","Not Applicable","450","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2020-009","March 23, 2020","March 23, 2022","March 23, 2022","March 31, 2020",,"May 18, 2020","Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana|Institut Pasteur de la Guyane, Cayenne, French Guiana",,"https://ClinicalTrials.gov/show/NCT04328129"
1300,"NCT04341922","A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic",,"Not yet recruiting","No Results Available","Dysfunctional Worry","Behavioral: Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic","• Covid-19-adapted version of the self-rated Generalized Anxiety Disorder Scale-7 (GAD-7)|Montgomery Åsberg Depression Rating Scale - Self report (MADRS-S)|Adapted Covid-19 version of the Work and Social Adjustment Scale (WSAS)|Insomnia Severity Index (ISI)|Adapted Swedish version of the CoRonavIruS Health Impact Survey (CRISIS)|Intolerance of uncertainty Scale (IUS)|Patient Satisfaction Questionnaire (PSQ)|Adverse events (AE)","Karolinska Institutet","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","670","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-01719","May 11, 2020","September 10, 2020","September 10, 2021","April 10, 2020",,"May 11, 2020","Karolinska Institutet, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04341922"
1301,"NCT04357847","Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection","Covid-Thelium","Recruiting","No Results Available","Covid-19|Endothelial Dysfunction|Thrombosis|Critically Ill",,"Association of InterCellular Adhesion Molecule-1 plasma level with 28 days mortality|Association of Endothelin-1 plasma level with 28 days mortality|Association of Vascular Endothelial Growth Factor A plasma level with 28 days mortality|Association of soluble Vascular Endothelial Growth Factor Receptor type 1 with 28 days mortality|Association of syndecan -1 plasma level with 28 days mortality|Association of D-dimers plasma levels with thrombotic events|Association of von Willebrandt Factor with thrombotic events|Association of Viscoelastic testing with thrombotic events","University Hospital, Rouen","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020/097/OB","April 9, 2020","July 31, 2020","August 31, 2020","April 22, 2020",,"April 22, 2020","Rouen University Hospital, Rouen, France",,"https://ClinicalTrials.gov/show/NCT04357847"
1302,"NCT04342169","University of Utah COVID-19 Hydrochloroquine Trial",,"Recruiting","No Results Available","Coronavirus Infection|Coronavirus|Infectious Disease","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Duration of viral shedding|Duration of COVID-19-attributable symptoms|Hospitalization|Adult household contact viral acquisition","University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB_00131893","April 14, 2020","April 2022","April 2023","April 10, 2020",,"April 16, 2020","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04342169"
1303,"NCT04316728","Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19",,"Not yet recruiting","No Results Available","Coronavirus Infections","Device: VivaDiag™ COVID-19 lgM/IgG Rapid Test","Number of patients with constant negative results|Number of patients with positive test with a positive PCR for COVID-19|Overall Number of patients positive for COVID-19|Overall Number of patients negative for COVID-19|Number of patients with contrasting results|Reliability of the test|Positive HCW|Number of Chronic Patients","Centro Studi Internazionali, Italy|VivaChek Laboratories, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","VivaDiag-2020","March 2020","September 2020","November 2020","March 20, 2020",,"March 20, 2020","Unità' Complesse di cure primarie (UCCP), ASP Catanzaro, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04316728"
1304,"NCT04334434","Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)",,"Not yet recruiting","No Results Available","Telerehabilitation","Other: Telerehabilitation","Physical Activity Scale for the Elderly|Nottingham Health Profile|Loneliness Scale for the Elderly","Kubra Koce, MSc PT|Istanbul University-Cerrahpasa","All","65 Years and older   (Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","002","April 20, 2020","June 1, 2020","July 31, 2020","April 6, 2020",,"April 16, 2020","Istanbul university Cerrahpasa, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04334434"
1305,"NCT04311697","Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","COVID-AIV","Enrolling by invitation","No Results Available","Acute Respiratory Distress Syndrome|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Corona Virus Infection","Drug: Aviptadil by intravenous infusion + maximal intensive care|Drug: Normal Saline Infusion + Maximal intensive care","Mortality|PaO2:FiO2 ratio|TNF alpha|Multi-system organ failure free days","NeuroRx, Inc.|Relief Therapeutics Holding SA|Target Health Inc.|Lavin Consulting, LLC","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","144","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVID-AIV","May 15, 2020","August 2020","September 2020","March 17, 2020",,"May 19, 2020","University of California - Irvine, Irvine, California, United States|Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|Robert I Grossman School of Medicine / NYU Langone Medical Center, New York, New York, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Rambam Health Care Campus, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT04311697"
1306,"NCT04394377","Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial","ACTION","Not yet recruiting","No Results Available","Coronavirus Infection","Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|Drug: Group 2: control group with enoxaparin 40mg/d","Hierarchical composite endpoint composed of mortality, number of days alive, number of days in the hospital and number of days with oxygen therapy at the end of 30 days.|Incidence of Venous thromboembolism|Incidence of acute myocardial infarction|Incidence of stroke|Number of days using oxygen therapy|Peak of troponin|Peak of D-dimer|Incidence of Major bleeding and clinically relevant non-major bleeding by the ISTH criteria","Brazilian Clinical Research Institute|Hospital Israelita Albert Einstein|Hospital do Coracao|Hospital Sirio-Libanes|Hospital Moinhos de Vento|Hospital Alemão Oswaldo Cruz|Beneficência Portuguesa de São Paulo|Brazilian Research In Intensive Care Network","All","18 Years and older   (Adult, Older Adult)","Phase 4","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","002/2020","May 2020","December 2020","December 2020","May 19, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04394377"
1307,"NCT04358081","Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease",,"Recruiting","No Results Available","Pneumonia","Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo","Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","444","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CJWT629A12301","May 1, 2020","June 25, 2020","July 24, 2020","April 22, 2020",,"May 21, 2020","Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Columbia, Missouri, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04358081"
1308,"NCT04366817","Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic Short Title : Isolement and Childbirth: Psychological Impact","COVMUM","Not yet recruiting","No Results Available","Post Partum Depression","Behavioral: psychological assessment","Proportion of patients with postpartum depression defined by an EPDS score >12|Socio-demographic data|Occurrence of a maternal or fetal pathology in a previous pregnancy|Pregnant maternal pathology (hypertension, diabetes, threat of premature delivery)|Presence of psycological maternal risk factor|Dyadic adjustment scale 16 (DAS-16)|Perinatal post traumatic stress disorder questionnaire (PPQ scale)|Mother to infant bonding scale (MIBS) autoquestionnaire|Measure Qualitative Interviews by Grounded theory","Assistance Publique - Hôpitaux de Paris","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","APHP200471","April 2020","April 2020","June 2020","April 29, 2020",,"April 29, 2020","Service médecine foetale-Hôpital Trousseau, Paris, France",,"https://ClinicalTrials.gov/show/NCT04366817"
1309,"NCT04325867","Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19","eCardioCovid19","Recruiting","No Results Available","Angina Pectoris|Acute Coronary Syndrome|Coronary Syndrome|Coronary Artery Disease|Angioplasty|Stent Restenosis|Hypertension|Heart Failure, Systolic|Depression, Anxiety|Covid-19|Isolation, Social","Other: Tele-medicine platform","Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients|Number of patients included in this platform|Number of consultations/sessions given","Professor Adrian Covic|Medical Sciences Academy - Romania|Victor Babes Clinical Hospital of Infectious Diseases - Bucharest|Grigore T. Popa University of Medicine and Pharmacy","All","Child, Adult, Older Adult","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","GTP0032","March 31, 2020","October 1, 2020","October 1, 2020","March 30, 2020",,"April 1, 2020","Medical Sciences Academy, Bucharest, Romania|University of Medicine and Pharmacy Gr T Popa, Iasi, Romania",,"https://ClinicalTrials.gov/show/NCT04325867"
1310,"NCT04341480","The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19",,"Not yet recruiting","No Results Available","Gynecological Cancer","Drug: Chemotherapy","SARS-CoV-2 infection|Tumor response|Safety and tolerability|Patient-reported outcomes","Tongji Hospital","Female","18 Years to 80 Years   (Adult, Older Adult)",,"207","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-TJ-COVID-19","April 10, 2020","July 10, 2020","July 10, 2020","April 10, 2020",,"April 10, 2020","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04341480"
1311,"NCT04341012","Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases",,"Recruiting","No Results Available","Liver Diseases|Liver Cancer|COVID19","Diagnostic Test: Collection of breath sample","Breath volatile organic compound profiles|Utility of breath profiles for disease diagnosis or prognosis","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","19-001971","September 10, 2019","December 31, 2021","December 31, 2021","April 10, 2020",,"April 13, 2020","Mayo Clinic Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04341012"
1312,"NCT04346589","Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients",,"Recruiting","No Results Available","Pneumonia, Ventilator-Associated|Coronavirus Infection","Biological: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients","Number of mechanical ventilation days.|Survival|Shift to Continuous Positive Airway Pressure (CPAP) ventilation|Referral to a sub-intensive care unit or discharge","A.O. Ospedale Papa Giovanni XXIII|Aferetica - Italy (BO)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DFPP COVID 19","April 15, 2020","July 2020","July 2020","April 15, 2020",,"May 8, 2020","IRFMN - Clinical Research Center for Rare Diseases, Ranica, BG, Italy|ASST HPG23 - Unit of Nephrology, Bergamo, Italy|ASST Papa Giovanni XXIII - Microbiology and Virology Unit, Bergamo, Italy|Asst Pg23 - S.I.M.T, Bergamo, Italy|ASST-PG23 - Intensive Care Unit, Bergamo, Italy",,"https://ClinicalTrials.gov/show/NCT04346589"
1313,"NCT04355234","Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns","COVIPREG","Not yet recruiting","No Results Available","Pregnancy","Diagnostic Test: identify SARS-CoV-2 infection by serology|Biological: collection of biological samples","Seroprevalence or Number of women who are positive for SARS-CoV-2 in parturient woman|Consequences of SARS-CoV-2 infection in pregnant women and their newborns : Pregnancy outcome, maternal or neonatal complications|Assessment of the vertical transmission of SARS-CoV-2 and the possible routes of this transmission in women who are positive for SARS-CoV-2 during pregnancy|Assessment of susceptibility to infection during the 3 trimesters of pregnancy|Evaluation of the confinement on the risk of exposure to the virus during pregnancy .|collection of biological samples for new investigations in women who are positive for SARS-CoV-2 during pregnancy.|Assessment of the rate of SARS-CoV-2 infection in pregnant women the risk factors for the disease.|Assessment of the rate of SARS-CoV-2 infection in newborns and the risk factors for the disease.","Assistance Publique - Hôpitaux de Paris","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","2200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","APHP 200448","April 24, 2020","August 31, 2021","August 31, 2021","April 21, 2020",,"April 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04355234"
1314,"NCT04372030","Health Care Use During the Covid19 Crisis","US3R","Not yet recruiting","No Results Available","Health Care Utilization","Other: Online questionnaire","Health care use|Postponed heath care use|Foregone health care use","Université Catholique de Louvain","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","US3R","May 1, 2020","June 30, 2020","October 31, 2021","May 1, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04372030"
1315,"NCT04379453","Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses",,"Recruiting","No Results Available","Coronary Artery Disease","Procedure: Robot Assisted Percutaneous Cardiovascular Intervention","Successful cardiovascular intervention|Performed with the professional team positioned at> 2 meters from the patient for at least 50% of the duration of the intervention|absence of fatal complications caused by the procedure or acute non-fatal vessel occlusion during index admission","Hospital Israelita Albert Einstein","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4094-20","April 27, 2020","April 27, 2020","April 27, 2020","May 7, 2020",,"May 8, 2020","Hospital Israelita Albert Einstein, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04379453"
1316,"NCT04340349","Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals","ELEVATE","Enrolling by invitation","No Results Available","Hydroxychloroquine|Antimalarials|Enzyme Inhibitors|Antirheumatic Agents","Drug: Hydroxychloroquine Sulfate|Drug: Bromhexine 8 MG","Polymerase chain reaction assay (PCR) negative at day 0 plus negative serological panel for COVID-19 antibodies at enrolment.|Polymerase chain reaction assay (PCR) negative at day 30.|Polymerase chain reaction assay (PCR) negative at day 60.","Instituto Nacional de Rehabilitacion","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","25/20","May 11, 2020","July 20, 2020","August 20, 2020","April 9, 2020",,"May 13, 2020","National Institute of Rehabilitation, Mexico City, Cdmx, Mexico",,"https://ClinicalTrials.gov/show/NCT04340349"
1317,"NCT04339322","Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt","COVID-19","Not yet recruiting","No Results Available","Characteristics Diseases|Outcome, Fatal","Other: Follow up","Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group|Clinical manifestations of Coronavirus Disease 2019 (COVID-19)|Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort|Radiological features of Coronavirus Disease 2019 (COVID-19) cohort|outcomes of Coronavirus Disease 2019 (COVID-19) infection in the cohort group","Assiut University","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 in Egypt","May 1, 2020","July 30, 2020","July 30, 2020","April 9, 2020",,"April 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04339322"
1318,"NCT04367129","Electrocardiogram Analysis in COVID-19 Patients","ELCOVID","Recruiting","No Results Available","SARS-CoV Infection","Diagnostic Test: ECG","Phase 1: ECG characteristics in patients presenting with severe form of SARS-CoV-2 infection|Phase 2: Correlation between ECG signs and needs for invasive mechanical ventilation and/or mortality in the acute phase|Phase 3: Correlation between ECG signs and cardiac involvement and mortality in the chronic phase","University Hospital of Ferrara","All","18 Years to 100 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","385/2020/Oss/AOUFe","April 14, 2020","December 1, 2020","December 1, 2021","April 29, 2020",,"April 29, 2020","Arcispedale S. Anna, Ferrara, Italy",,"https://ClinicalTrials.gov/show/NCT04367129"
1319,"NCT04377737","Incidence of Covid-19 in School Children","COVIDECOLE","Not yet recruiting","No Results Available","Infection; Viral, Coronavirus","Diagnostic Test: RT-PCR Covid-19","evaluation of the prevalence of positive real-time-polymerase chain reaction (rt-PCR) in school children during the pandemic period in Nice|evaluation of the serological prevalence of the Covid-19 infection|evaluation of the COVID-19 reinfection among seropositive children at the inclusion time|evaluation of the prevalence of positive rt-PCR of other respiratory viruses (including others coronavirus)|comparison of inflammatory response level between different coronavirus strains|Estimation of medico-social risk factors associated with COVID-19 infection","Fondation Lenval","All","3 Years to 10 Years   (Child)","Not Applicable","914","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20-HPNCL-02","May 15, 2020","August 2020","September 2020","May 6, 2020",,"May 6, 2020","Hôpitaux Pédiatrique de Nice CHU Lenval, Nice, France",,"https://ClinicalTrials.gov/show/NCT04377737"
1320,"NCT03042143","Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19)","REALIST","Recruiting","No Results Available","Acute Respiratory Distress Syndrome","Biological: Human umbilical cord derived CD362 enriched MSCs|Biological: Placebo (Plasma-Lyte 148)","Oxygenation index (OI)|Incidence of Serious Adverse Events (SAEs)|Oxygenation index|Sequential Organ Failure Assessment (SOFA) score|Respiratory compliance (Crs)|Partial pressure of arterial oxygen to the fraction of inspired oxygen ratio (P/F ratio)|Driving Pressure|Extubation and reintubation|Ventilation free days at day 28|Length of ICU and hospital stay|28-day and 90-day mortality","Belfast Health and Social Care Trust|Queen's University, Belfast|Northern Ireland Clinical Trials Unit|NHS Blood and Transplant","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16154DMcA-AS","January 7, 2019","September 2020","October 2022","February 3, 2017",,"April 15, 2020","Belfast Health and Social Care Trust, Royal Hospitals, Belfast, Northern Ireland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03042143"
1321,"NCT04256395","Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19","COVID-19","Recruiting","No Results Available","Susceptibility to Viral and Mycobacterial Infection","Other: mobile internet survey on self-test","positive number diagnosed by national guideline in the evaluated population|distribution map of evaluated people|Effect of medical guidance by designated feedback questionnaire|mental scale of relief the mental anxiety and avoid unnecessary outpatient","Beijing Tsinghua Chang Gung Hospital|Institute for precision medicine of Tsinghua University|Institute for artificial intelligent of Tsinghua University|Chinese Medical Doctor Association|Institute for network behavior of Tsinghua University|school of clinical medicine of Tsinghua University","All","Child, Adult, Older Adult",,"300000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","RWS-BTCH-002","February 1, 2020","July 31, 2020","July 31, 2020","February 5, 2020",,"April 22, 2020","Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04256395"
1322,"NCT04252274","Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19","DC-COVID-19","Recruiting","No Results Available","Pneumonia, Pneumocystis|Coronavirus","Drug: Darunavir and Cobicistat","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2|The mortality rate of subjects at weeks 2","Shanghai Public Health Clinical Center","All","Child, Adult, Older Adult","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DC-COVID-19","January 30, 2020","August 31, 2020","December 31, 2020","February 5, 2020",,"April 13, 2020","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04252274"
1323,"NCT04339387","COVID-19 Risk Stratification",,"Recruiting","No Results Available","Coronavirus|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere",,"Suitable for discharge","Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2020P000944","March 1, 2020","April 15, 2020","April 15, 2020","April 9, 2020",,"April 9, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04339387"
1324,"NCT04393142","Serologic Testing of Household Contacts of Confirmed Cases of COVID-19",,"Recruiting","No Results Available","Coronavirus Infection",,"Identify antibodies|Determine antibody sensitivity|IgM determination|IgG determination","Hospital Universitario Dr. Jose E. Gonzalez","All","1 Year and older   (Child, Adult, Older Adult)",,"92","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","IF20-00004","May 5, 2020","May 30, 2020","June 1, 2020","May 19, 2020",,"May 19, 2020","Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT04393142"
1325,"NCT04385186","Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19",,"Not yet recruiting","No Results Available","Infections, Coronavirus","Drug: Inactivated convalescent plasma|Drug: Support treatment","Mortality reduction in CoViD-19 patients treated with inactivated convalescent plasma + support treatment|Clinical evolution|Clinical evolution by seven-parameter ordinal scale|Multi-organ failure progression|Change in hemoglobin concentration|Change in blood cell count|Change in serum creatinine level|Change in aspartate aminotransferase level|Change in alanin aminotransferase level|Change in bilirubin level|Change in lactate dehydrogenase level|Change in creatine kinase level|Change in creatine kinase MB level|Change in C reactive protein concentration|Change in D Dimer concentration|Change in Procalcitonin concentration|Change in IL6 level|Radiography imaging|Tomography imaging|Assessment of oxygenation|Viral Load|Antibody titer|Oxygen-free days through Day 60|Mechanical ventilation-free days through Day 28|Intensive Care Unit (ICU)-free days through Day 28|Hospital-free days through Day 60","National Blood Center Foundation, Hemolife|Universidad de Antioquia","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","CT01","May 20, 2020","September 30, 2020","November 30, 2020","May 12, 2020",,"May 25, 2020","Clínica Antioquía, Medellín, Antioquía, Colombia|Clínica IPS Universitaria, Medellín, Antioquía, Colombia|Clínica Sagrado Corazón, Medellín, Antioquía, Colombia|Universidad de Antioquia, Medellín, Antioquía, Colombia|Clínica Rosales, Pereira, Risaralda, Colombia|Clinica Nuestra, Cali, Valle, Colombia|Clínica Corpas, Bogotá, Colombia|Fundación Banco Nacional de Sangre Hemolife, Bogotá, Colombia|E.S.E Hospital San Rafael Facatativa, Facatativa, Colombia|Clínica la Estancia, Popayán, Colombia",,"https://ClinicalTrials.gov/show/NCT04385186"
1326,"NCT04305457","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19","NoCovid","Recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral|Acute Respiratory Distress Syndrome","Drug: Nitric Oxide","Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation|Mortality|Time to clinical recovery","Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","18 Years and older   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NOgas mildCOVID-19","March 21, 2020","April 1, 2021","April 1, 2022","March 12, 2020",,"April 9, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04305457"
1327,"NCT04391816","COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study",,"Recruiting","No Results Available","Alcohol Drinking|Alcohol-Related Disorders|Pandemic|Psychological Stress",,"AUDIT Score|ADS Score|Life Events Questionnaire (LEQ) Score|UCLA Loneliness Scale (UCLALS) Score|Perceived Stress Scale (PSS) Score","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"700","NIH","Observational","Observational Model: Other|Time Perspective: Prospective","999920115|20-AA-N115","May 28, 2020","December 31, 2022","December 31, 2024","May 18, 2020",,"May 25, 2020","NIAAA Section on Human Psychopharmacology, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04391816"
1328,"NCT04390269","Immunogenetics Predictors With COVID-19",,"Not yet recruiting","No Results Available","Genetic Predisposition to Disease",,"for the patients","Mansoura University","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","R.20.05.830.R1","May 10, 2020","May 10, 2020","May 9, 2022","May 15, 2020",,"May 18, 2020","Mansoura Faculty of Medicine, Mansoura, Dakahlyia, Egypt",,"https://ClinicalTrials.gov/show/NCT04390269"
1329,"NCT04318314","COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","COVID19-HCW","Recruiting","No Results Available","Health Care Worker Patient Transmission|Coronavirus|Coronavirus Infections|Immunological Abnormality","Diagnostic Test: COPAN swabbing and blood sample collection","Seroconversion to SARS-CoV-2 positivity","University College, London|St. Bartholomew's Hospital|Royal Free Hospital NHS Foundation Trust|UCLH","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","130852","March 18, 2020","December 31, 2020","December 31, 2021","March 23, 2020",,"May 21, 2020","Barts Heart Center, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04318314"
1330,"NCT04392115","The PREPARE for COVID Trial",,"Not yet recruiting","No Results Available","Comorbidities and Coexisting Conditions|Social Isolation","Behavioral: The PREPARE program","Patient-reported disability 90 days after enrollment|Mental Health|Function|Health-related quality of life|Frailty|All-cause mortality.|Health System - Emergency Department Visits|Health System - Re-admission|Health System - Transfer to Long-Term Care|COVID-19 test results|Safety [Adverse Events]","Ottawa Hospital Research Institute","All","65 Years and older   (Older Adult)","Not Applicable","372","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research",,"June 15, 2020","December 15, 2020","September 15, 2021","May 18, 2020",,"May 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04392115"
1331,"NCT04344834","Impact of Covid-19 on Egyptian Health Care Workers and General Population Mental Health",,"Not yet recruiting","No Results Available","Mental Health Issue","Diagnostic Test: Online questionnaire","Depression|Anxiety|Obsessive compulsive disorder","Assiut University","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","Covid-19 mental health","May 2020","October 2020","October 2020","April 14, 2020",,"April 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04344834"
1332,"NCT04320277","Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","BARI-COVID","Not yet recruiting","No Results Available","Pharmacological Action","Drug: Baricitinib","The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.|The percentage of patients achieving the remission; CRP, IL-6 and TNFα values at baseline and during the treatment course; the number of AEs.","Hospital of Prato","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HPrato-3","May 16, 2020","June 30, 2020","July 30, 2020","March 24, 2020",,"April 22, 2020","Fabrizio Cantini, Prato, Tuscany, Italy",,"https://ClinicalTrials.gov/show/NCT04320277"
1333,"NCT04398264","Characteristics of COVID-19 Infection Among PREGnant Women","CCOVID-PREG","Not yet recruiting","No Results Available","Corona Virus Infection|Pregnancy Related","Other: COVID-19 positive via testing","Asymptomatic COVID-19 positive pregnant women|Asymptomatic Hispanic COVID-19 positive pregnant women|Follow up of asymptomatic COVID-19 positive pregnant women|COVID-19 positive newborns|Severe COVID-19 disease in pregnant women","Inova Health System","Female","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Other","U20-05-4055","May 30, 2020","June 30, 2020","March 17, 2021","May 21, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04398264"
1334,"NCT04394182","Ultra Low Doses of Therapy With Radiation Applicated to COVID-19","ULTRA-COVID","Recruiting","No Results Available","Pneumonia, Viral|Cytokine Storm","Radiation: Ultra-Low-dose radiotherapy|Device: ventilatory support with oxygen therapy|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Piperacillin/tazobactam|Drug: Low molecular weight heparin|Drug: Corticosteroid injection|Drug: Tocilizumab","Oxygen Therapy Status at Day 2|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2|Blood Gas Analysis at Day 2|Blood Test at Day 2|Oxygen Therapy Status at Day 5|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 5|Blood Test at Day 5|Oxygen Therapy Status at Day 7|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 7|Blood Test at Day 7|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan at Day 7|Recovery time|COVID-19 status|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan al Month 1|Acute Toxicity","Fundacion GenesisCare|Hospital La Milagrosa|Hospital Vithas Valencia Consuelo","All","18 Years to 120 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20.4.1597-GHM","April 21, 2020","December 31, 2020","April 21, 2021","May 19, 2020",,"May 19, 2020","Hospital La Milagrosa, GenesisCare, Madrid, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04394182"
1335,"NCT04389463","Patient Outcome of Cardiac Surgery During the COVID-19 Pandemic",,"Recruiting","No Results Available","Patients Undergoing Cardiac or Thoracic Surgery","Other: No intervention","Highest VIS (Vasoactive-Inotropic Score) in the first 12 hours postoperatively.|Post-operative organ failure|Post-operative outcome","Nantes University Hospital","All","18 Years and older   (Adult, Older Adult)",,"350","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HEART-19 Study","May 11, 2020","May 11, 2022","June 30, 2022","May 15, 2020",,"May 18, 2020","University Hospital, Nantes, France",,"https://ClinicalTrials.gov/show/NCT04389463"
1336,"NCT04358952","Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients","COCARDE","Recruiting","No Results Available","Cardiomyopathies","Diagnostic Test: Global Longitudinal Strain","Left ventricular function|inflammatory biological parameters","University Hospital, Toulouse","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Other|Time Perspective: Prospective","RC31/20/0117|2020-A00852-37","April 4, 2020","November 4, 2020","November 4, 2020","April 24, 2020",,"April 24, 2020","UHToulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04358952"
1337,"NCT04377425","COVID-19 Prevalence and Cognitive Deficits in Neurological Patients","Neuro-Covid","Not yet recruiting","No Results Available","Neurological Diseases or Conditions|Stroke, Acute|Seizure Disorder","Diagnostic Test: COVID-19 swap test PCR","Prevalence of COVID-19 infection in consecutive patients with neurological symptoms|Three months cognitive function of COVID-19 positive patients|Clinical presentation of neurological symptoms in COVID-19 positive patients|Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients|Anosmia in COVID-19 positive patients|Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection|Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients","Aarhus University Hospital","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Neuro-Covid-19","May 7, 2020","November 29, 2020","June 30, 2022","May 6, 2020",,"May 6, 2020","Aalborg University Hospital, Aalborg, DK, Denmark|Aarhus University Hospital, Aarhus, DK, Denmark|Regional Hospital West Jutland, Hostebro, Holstebro, DK, Denmark|Regional Hospital Central Jutland, Viborg, Viborg, DK, Denmark",,"https://ClinicalTrials.gov/show/NCT04377425"
1338,"NCT04342156","Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19","SHARP COVID-19","Not yet recruiting","No Results Available","Coronavirus Infection|Hydroxychloroquine Adverse Reaction","Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab","positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until day 28.|Positive serology at day 28.|Symptoms of COVID-19.","Tan Tock Seng Hospital|National Center for Infectious Diseases|Singapore Clinical Research Institute|Singapore Eye Research Institute|Saw Swee Hock School of Public Health|Duke-NUS Graduate Medical School|Netherlands: Ministry of Health, Welfare and Sports","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020/00402","April 2020","August 2020","October 2020","April 10, 2020",,"April 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04342156"
1339,"NCT04327401","COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III","CoDEX","Recruiting","No Results Available","Coronavirus Infection|Pneumonia, Viral|Acute Respiratory Distress Syndrome","Drug: Dexamethasone","Ventilator-free days|Evaluation of the clinical status|All-cause mortality|Mechanical ventilation duration|Sequential Organ Failure Assessment (SOFA) Score","Luiz F. L. Reis, Ph.D.|Hospital Israelita Albert Einstein|Hospital do Coracao|Brazilian Research In Intensive Care Network|Ache Laboratorios Farmaceuticos S.A.|Hospital Sirio-Libanes","All","18 Years and older   (Adult, Older Adult)","Phase 3","290","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAAE: 30227020.5.1001.0008","April 13, 2020","August 30, 2020","August 30, 2020","March 31, 2020",,"April 15, 2020","Hospital Ana Nery, Salvador, Bahia, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Esoírito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Eurolatino Natal Pesquisas Médicas Ltda, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP - HCFMRP, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Santa Casa de Misericórdia, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04327401"
1340,"NCT04394104","COVID-19 Wellness Survey",,"Not yet recruiting","No Results Available","Health Behavior","Other: Survey","Health Behavior Change Regression Questionnaire","Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","Pro2020001009","May 15, 2020","May 31, 2020","May 31, 2020","May 19, 2020",,"May 19, 2020","Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04394104"
1341,"NCT04361877","Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial)",,"Recruiting","No Results Available","Cardiovascular Prevention Behaviour",,"Change of physical activity|change of nutrition behaviour|semiquantitative change of alcohol intake|change of smoking behaviour|change of stress level|step count","Klinikum der Universitaet Muenchen","All","18 Years and older   (Adult, Older Adult)",,"1900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-268 KB","March 30, 2020","April 20, 2020","April 20, 2020","April 24, 2020",,"May 1, 2020","University Hospital Munich (LMU Klinikum), Munich, Germany",,"https://ClinicalTrials.gov/show/NCT04361877"
1342,"NCT04358003","Plasma Adsorption in Patients With Confirmed COVID-19",,"Recruiting","No Results Available","Respiratory Failure|ARDS","Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)","All-cause mortality|Change in Sequential Organ Failure Assessment [SOFA] scores","Marker Therapeutics AG|Terumo BCT","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2000","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MH-007/B","May 2020","August 1, 2020","December 1, 2020","April 22, 2020",,"May 18, 2020","UT Southwestern/Parkland Hospital, Dallas, Texas, United States|UTMB, Galveston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04358003"
1343,"NCT04397575","The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients","CACOVID-19","Recruiting","No Results Available","Cancer|COVID|Solid Tumor|Social Inequality|French National Cohort|Chemotherapy|Immunotherapy|Surgery|Radiotherapy",,"Number of cases of SARS-COV-2 infection and mortality rate directly related to the infection in patients being followed for digestive, thoracic, head and neck, gynecologic, cerebral, urologic or cutaneous cancer|Number of cases of SARS-COV-2 infection|Percentage of severe and fatal forms.of cases of SARS-COV-2 infection|Social characteristics of individuals on treatment|Link between socio-territorial determinants and the characteristics/severity of SARS-COV-2 infection.","Federation Francophone de Cancerologie Digestive|ARCAGY/ GINECO GROUP|GERCOR - Multidisciplinary Oncology Cooperative Group|GORTEC|IFCT|Association de Neuro-Oncologues d’Expression Francaise","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GCO002 CACOVID-19","April 3, 2020","June 1, 2020","September 1, 2020","May 21, 2020",,"May 21, 2020","Ch D'Abbeville, Abbeville, France|CHU - Hôtel Dieu, Angers, France|CH Victor Dupouy, Argenteuil, France|AP - HP - Pitié Salpêtrière, Paris, France|Bichat, Paris, France|Centre Hospitalier Universitaire, Reims, France",,"https://ClinicalTrials.gov/show/NCT04397575"
1344,"NCT04325412","Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY","CAPACITY-COVID","Recruiting","No Results Available","COVID-19; Cardiovascular Diseases",,"The incidence of cardiovascular complications in patients with COVID-19","UMC Utrecht","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-161/C","March 23, 2020","March 23, 2021","June 23, 2021","March 27, 2020",,"March 27, 2020","University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04325412"
1345,"NCT04385576","Taiwan ""Aerosol Box"" Versus UMMC ""Intubation Box""",,"Recruiting","No Results Available","COVID-19|Airway","Device: Aerosol Box|Device: Intubation Box","Time to successful intubation|Number of intubation attempts|Evaluation of the intubator's experience using both boxes","University of Malaya","All","Child, Adult, Older Adult","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2020410-8498","May 15, 2020","September 15, 2020","December 30, 2020","May 13, 2020",,"May 13, 2020","University Malaya Medical Centre, Kuala Lumpur, Selangor, Malaysia","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT04385576/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04385576"
1346,"NCT04384549","Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers","COVID-BCG","Not yet recruiting","No Results Available","Infection|Viral, Agent as Cause of Disease Classified Elsewhere","Biological: BCG GROUP|Other: PLACEBO GROUP","Incidence of documented COVID-19 among health care workers exposed to SARS CoV2 and vaccinated with BCG compared to placebo.|Numbers of COVID-19 patients requiring hospitalization in ICU and O2, artificial ventilation or extracorporal membrane oxygenation, or deaths in BCG-vaccinated health care workers compared to placebo|Incidence of asymptomatic SARS CoV2 seropositive subjects among BCG-vaccinated health care workers compared to placebo.|Incidence of subjects with any respiratory infection among BCG-vaccinated health care workers compared to placebo.|Numbers of sick days and numbers of sick leaves among BCG-vaccinated health care workers compared to placebo.|Numbers of subjects with BCG-related advers events among BCG-vaccinated health care workers compared to placebo.|Numbers and intensity of changes in innate immune markers after SARS CoV2 infection among BCG-vaccinated health care workers compared to placebo.","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 3","1120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","APHP200462|2020-001678-31","May 11, 2020","February 11, 2021","February 11, 2021","May 12, 2020",,"May 12, 2020","I-REIVAC/CIC 1417 Cochin Hospital, APHP, Paris, France",,"https://ClinicalTrials.gov/show/NCT04384549"
1347,"NCT04366297","Intravascular Access of COVID-19 Patient Under Personal Protective Equipment",,"Completed","No Results Available","Cardiac Arrest|Emergencies","Device: Intravenous access|Device: Intraosseous access","successful rate of first intravascular access attempt|time to successful access|number of attempts to successful access|time to infusion|complication rates|ease of use|Preferred intravascular access method","Lazarski University|Poznan University of Medical Sciences|Medical University of Bialystok|Wroclaw Medical University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","41","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IO_PPE_MS_1","January 12, 2020","February 25, 2020","February 25, 2020","April 28, 2020",,"April 28, 2020","Lazarski Univeristy, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT04366297"
1348,"NCT04361396","Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients","LAPTRANSCOV","Recruiting","No Results Available","Coronavirus Infection","Other: Collection of samples","Assessment of the presence of the SARS-COV-2 virus at T4|Assessment of the presence of the SARS-COV-2 virus at T1|Assessment of the presence of the SARS-COV-2 virus in the peritoneal effusion at T2 or T4|Assessment of the presence of the SARS-COV-2 virus at T3|Assessment of the presence of the SARS-COV-2 virus at T5","Centre Hospitalier René Dubos","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CHRD 0420","May 2020","October 2020","October 2020","April 24, 2020",,"April 30, 2020","Department of General and Digestive Surgery, Hospital René Dubos, Pontoise, France|Department of Gynecology-Obstetrics, Hospital René Dubos, Pontoise, France",,"https://ClinicalTrials.gov/show/NCT04361396"
1349,"NCT04339790","Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers",,"Recruiting","No Results Available","Healthy Volunteer|Mood Disorder|Anxiety Disorder|Preexisting Medical Condition",,"NIMH COVID Study survey - adult responses|DSM XC and KS survey","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"10000","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999920085|20-M-N085","May 28, 2020","March 1, 2022","April 1, 2022","April 9, 2020",,"May 25, 2020","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04339790"
1350,"NCT04345861","Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)","COVIDOC","Recruiting","No Results Available","Coronavirus Infection|Pneumonia, Viral","Drug: Hydroxychloroquine + placebo|Drug: hydroxychloroquine + azithromycin","Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment).|Clinical status assessed by ordinal scale|transfer to ICU|Length of hospital day|Hospital Mortality|Need to Mechanical Ventilation|Occurence of grade 3-4 adverse event|QTc Lengthening|Evolution of pulmonary CT scan images","University Hospital, Montpellier","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RECHMPL20_168","April 11, 2020","September 6, 2020","April 6, 2021","April 15, 2020",,"April 24, 2020","Montpellier University hospital, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04345861"
1351,"NCT04389385","COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo)",,"Active, not recruiting","No Results Available","Corona Virus Infection|Pneumonia","Biological: COVID-19 Specific T Cell derived exosomes (CSTC-Exo)","Adverse reaction (AE) and severe AE (SAE)|Efficacy Assessment|The Rate of Recovery Without Mechanical Ventilator","TC Erciyes University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","EruCovid2020","May 1, 2020","September 30, 2020","May 31, 2021","May 15, 2020",,"May 15, 2020","GENKOK, Kayseri, Melikgazi, Turkey",,"https://ClinicalTrials.gov/show/NCT04389385"
1352,"NCT04321278","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)",,"Recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral","Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine","Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death","Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|Cristália Produtos Químicos Farmacêuticos Ltda.","All","18 Years and older   (Adult, Older Adult)","Phase 3","440","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","30155020.5.1001.0071","March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",,"April 22, 2020","Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Hospital Adventista de Belém, Belém, Pará, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Hospital Universitário Onofre Lopes, Natal, Rio Grande Do Norte, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|AMICO Saude LTDA, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital Vila Santa Catarina, São Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Santa Casa de Misericórdia, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04321278"
1353,"NCT04373382","Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic",,"Not yet recruiting","No Results Available","Burnout","Behavioral: Peer Resilience Champion|Behavioral: Enriched Survey Feedback","Change in instances of burnout for hospital staff due to the Peer Resilience Champion intervention|Change in instances of burnout for hospital staff due to the Enriched Feedback Survey intervention","Mount Sinai Hospital, Canada|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20-0084-E","June 2020","February 2022","February 2022","May 4, 2020",,"May 5, 2020","Sinai Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04373382"
1354,"NCT04367337","Health Behavior Change During COVID-19 Pandemic",,"Recruiting","No Results Available","Health Behavior","Other: No intervention","Handwashing adherence|Frequency of handwashing|Self-efficacy|Risk perception|Outcome expectancy|Intention|Planning|Action control|Perceived effectiveness of hand hygiene|Anxiety|Country-level COVID-19 morbidity and mortality rates","University of Social Sciences and Humanities, Warsaw","All","18 Years and older   (Adult, Older Adult)",,"5600","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","3228-1BPSYPSBEH-30","March 25, 2020","March 24, 2021","March 24, 2021","April 29, 2020",,"April 29, 2020","the University of Melbourne, Melbourne, Australia|University of New Brunswick, Fredericton, Canada|Peking University, Beijing, China|University of Bordeaux, Bordeaux, France|London School of Hygiene and Tropical Medicine (in collaboration with MRC Unit The Gambia at LSHTM), Fajara, Gambia|Freie Universität Berlin, Berlin, Germany|Bar-Ilan University, Ramat Gan, Israel|University of Padova, Padova, Italy|Perdana University, Serdang, Malaysia|SWPS University of Social Sciences and Humanities, Wroclaw, Lower Silezia, Poland|University of Lisbon, Lisbon, Portugal|Babes-Bolyai Unversity, Cluj-Napoca, Romania|Nanyang Technological University, Singapore, Singapore|University of Zurich, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04367337"
1355,"NCT04323592","Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","MP-C19","Recruiting","No Results Available","Severe Acute Respiratory Syndrome (SARS) Pneumonia|Coronavirus Infections|ARDS, Human","Drug: Methylprednisolone|Other: standard care","Composite primary end-point|death|Admission to ICU|Endotracheal intubation (invasive mechanical ventilation)|reduction of C-reactive protein or CRP|Reduction of mechanical ventilation","University of Trieste","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","104","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-19 023_2020","March 23, 2020","May 20, 2020","May 30, 2020","March 26, 2020",,"March 27, 2020","Marco Confalonieri, Trieste, TS, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04323592"
1356,"NCT04360811","Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic","COroFet","Recruiting","No Results Available","Pregnancy","Diagnostic Test: COVID 19 diagnostic test by PCR","number of positive COVID-19 women","University Hospital, Toulouse","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","3600","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","RC31/20/0123","April 17, 2020","April 2021","April 2022","April 24, 2020",,"April 24, 2020","University Hospital of Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04360811"
1357,"NCT04380701","A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults",,"Recruiting","No Results Available","Infections, Respiratory|Virus Diseases|Infection Viral|Vaccine Adverse Reaction|RNA Virus Infections","Biological: BNT162a1|Biological: BNT162b1|Biological: BNT162b2|Biological: BNT162c2","Solicited local reactions at the injection site (pain, tenderness, erythema/redness, induration/swelling) recorded up to 7±1 days after each immunization.|Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7±1 days after each immunization.|The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE):|For BNT162a1, BNT162b1, BNT162b2 (P/B):|For BNT162c2 (SD):","Biontech RNA Pharmaceuticals GmbH|Biontech SE","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","200","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BNT162-01|2020-001038-36|U1111-1249-4220","April 23, 2020","August 2020","August 2020","May 8, 2020",,"May 12, 2020","Contract Research Organization, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04380701"
1358,"NCT04345614","A Study of CM4620-Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia",,"Recruiting","No Results Available","Pneumonia","Drug: CM4620-Injectable Emulsion","Improvement on a 7-point Ordinal Scale|Incidence of treatment-emergent adverse events (TEAE) (safety and tolerability)|Change in estimated PaO2/FiO2|Number of days alive and free of mechanical ventilation|Time to discharge alive from hospital|Number of patients alive on day 30 and day 60|Change in interleukin (IL)-6 level|Change in IL-17 level|Change in tumor necrosis factor-alpha level|Change in cytokine levels|CM4620-IE serum concentration|Procalcitonin levels|Normalization of oxygen saturation|Time to first normalization of oxygen saturation","CalciMedica, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CM4620-204","April 8, 2020","July 2020","September 2020","April 14, 2020",,"May 5, 2020","Henry Ford Hospital, Detroit, Michigan, United States|Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04345614"
1359,"NCT04290858","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection","NoCovid","Withdrawn","No Results Available","Coronavirus Infections|Pneumonia, Viral|Dyspnea","Drug: Nitric Oxide","Reduction in the incidence of intubation and mechanical ventilation|Mortality|Negative conversion of COVID-19 RT-PCR from upper respiratory tract|Time to clinical recovery","Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID19 NOgas mild","March 1, 2020","March 1, 2021","February 1, 2022","March 2, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04290858"
1360,"NCT04383457","Covid-19 Triage Using Camera-based AI",,"Not yet recruiting","No Results Available","Coronavirus Infections","Device: RIA-device (Remote Investigation and Assessment)","Agreement between the new camera based method and reference standard to estimate body temperature|Agreement between the new camera based method and reference standard to estimate heart rate|Agreement between the new camera based method and reference standard to estimate blood oxygen saturation|Agreement between the new camera based method and reference standard to estimate systolic blood pressure|Agreement between the new camera based method and reference standard to estimate diastolic blood pressure|Agreement between the new camera based method and reference standard to estimate respiratory rate|Prediction of hospital admission using vital signs estimated using reference standard methods|Prediction of death using vital signs estimated using reference standard methods|Prediction of hospital admission using vital signs estimated using the new camera based method|Prediction of death using vital signs estimated using the new camera based method|Prediction of hospital admission using raw camera data|Prediction of death using raw camera data","Vastra Gotaland Region|Detectivio AB","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","U1111-1251-4114","May 2020","December 2020","December 2020","May 12, 2020",,"May 12, 2020","Östra Sjukhuset, Gothenburg, Sweden",,"https://ClinicalTrials.gov/show/NCT04383457"
1361,"NCT04383470","Collaborative Outcomes Study on Health and Functioning During Infection Times During COVID-19 Pandemic","COH-FIT","Recruiting","No Results Available","Mental Health Wellness 1|Pandemic",,"Mental health symptoms, well-being change from last 2 weeks before the pandemic to last 2 weeks during COVID-19 pandemic|Mental health symptoms, well-being change from last 2 weeks before the pandemic to last 2 weeks 6 months after WHO declares pandemic over COVID-19 pandemic|Mental health symptoms change, well-being change from last 2 weeks before the pandemic to last 2 weeks 12 months after WHO declares pandemic over COVID-19 pandemic|Change in alcohol abuse, as change in units used from last 2 weeks before the pandemic to last 2 weeks during pandemic|Change in cigarettes use, as change in number of cigarettes per day from last 2 weeks before the pandemic to last 2 weeks during pandemic|Change in grams of cannabinoids smoked from last 2 weeks before the pandemic to last 2 weeks during pandemic|Change in general physical health, self-rated, on a VAS scale from 0 to 100.|Change in general mental health, self-rated, on a VAS scale from 0 to 100.|Change in easiness of access to care, self-rated a on a VAS scale from 0 to 100.|Change in medication adherence, self-rated a on a VAS scale from 0 to 100.|Change in functioning in self-care, school/work, social, and family, self-rated a on a VAS scale from 0 to 100.","University of Padova|Northwell Health|Donald and Barbara Zucker School of Medicine at Hofstra/Northwell","All","6 Years and older   (Child, Adult, Older Adult)",,"100000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","COH-FIT","April 26, 2020","December 2021","June 2022","May 12, 2020",,"May 14, 2020","Aristotle University of Thessaloniki, Thessaloníki, Greece",,"https://ClinicalTrials.gov/show/NCT04383470"
1362,"NCT04376684","Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease","OSCAR","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome","Biological: Otilimab|Biological: Placebo|Drug: Standard of care","Proportion of participants alive and free of respiratory failure at Day 28|Number of deaths due to all causes at Day 60|Time to number of deaths due to all causes at Day 60|Proportion of participants alive and free of respiratory failure at Day 7|Proportion of participants alive and free of respiratory failure at Day 14|Proportion of participants alive and free of respiratory failure at Day 42|Proportion of participants alive and free of respiratory failure at Day 60|Time to recovery from respiratory failure|Proportion of participants alive and independent of supplementary oxygen at Day 7|Proportion of participants alive and independent of supplementary oxygen at Day 14|Proportion of participants alive and independent of supplementary oxygen at Day 28|Proportion of participants alive and independent of supplementary oxygen at Day 42|Proportion of participants alive and independent of supplementary oxygen at Day 60|Time to last dependence on supplementary oxygen|Proportion of participants admitted to Intensive Care Unit (ICU)|Time to final Intensive Care Unit (ICU) discharge|Time to final hospital discharge|Number of participants with Adverse events (AEs) and Serious adverse events (SAEs)","GlaxoSmithKline","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","800","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","214094","May 28, 2020","December 21, 2020","December 21, 2020","May 6, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04376684"
1363,"NCT04359875","A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment","COVIQuest","Not yet recruiting","No Results Available","Cardiovascular Diseases|Mental Disorder","Behavioral: Phone-call screening and management by a medical student/general practitioner tandem","Hospitalization(s) at 1 month|Phone-call from the general practitioner (in the experimental group only)|Mortality at 1 month|Use of primary care|Use of secondary care|Number of prescriptions related to the chronic disease dispensed by the pharmacy|Number of hospitalization(s)|Time to hospitalization(s)|Hospitalization(s)' durations|Reasons for hospitalization(s)|Mortality at 6 months|Cardiovascular events (MACE)|Psychotropic drugs","University Hospital, Tours","All","18 Years to 110 Years   (Adult, Older Adult)","Not Applicable","22000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2020-CD-COVIQuest (COVID-19)","April 2020","June 2020","December 2020","April 24, 2020",,"April 24, 2020","Dibao-Dina, Tours, France",,"https://ClinicalTrials.gov/show/NCT04359875"
1364,"NCT04387968","Epidemiological Study of the Covid-19 Presto Test","COVIDOR","Not yet recruiting","No Results Available","Coronavirus Infection","Diagnostic Test: Covid-19 presto test","o study the prevalence of Covid-19 infection, coronavirus (SARS coronavirus-2) in territorial agents in the 3 structures Department, 45 and CDG Orleans Metropolitan|Determine if there is a relationship between the profession carried out by the agents of the territorial community of Orleans metropolis, the Department, the Loiret Management Center and contamination by covid-19","Raphael Serreau|François Rabelais University|Orléans Métropole Service de Médecine Préventive","All","18 Years to 65 Years   (Adult, Older Adult)",,"700","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","2020-A01414-35","June 18, 2020","June 18, 2021","January 18, 2022","May 14, 2020",,"May 14, 2020","Unité de Recherche PARADICT-O - Service de Médecine - Orléans Métropole, Orléans, France",,"https://ClinicalTrials.gov/show/NCT04387968"
1365,"NCT04322487","Simple, Safe, Same: Lung Ultrasound for COVID-19","LUSCOVID19","Recruiting","No Results Available","Coronavirus|Epidemic Disease|Pneumonia, Viral","Diagnostic Test: Lung ultrasound","Lung ultrasound grading system for COVID-19 pneumonia","Catholic University of the Sacred Heart|Valle del Serchio General Hospital, Lucca, Italy|University of Trento, Trento, Italy|Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy|Bresciamed, Brescia, Italy|118 USL Nordovest Toscana, Lucca, Italy|General Hospital, Voghera, Italy|Lodi General Hospital, Lodi, Italy","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","0013226/20","April 8, 2020","December 31, 2020","January 15, 2021","March 26, 2020",,"April 17, 2020","Bresciamed, Brescia, Italy|Pulmonary Medicine Unit, Lodi General Hospital, Lodi, Italy|118 USL Nordovest Toscana, Lucca, Italy|Diagnostic and Interventional Ultrasound Unit, Valle del Serchio General Hospital, Lucca, Italy|Emergency Department, Fondazione IRCCS Policlinico San Matteo, and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy|Department of woman and child health and public health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Pulmonary Medicine Unit, Dept. Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Department of Information Engineering and Computer Science, Ultrasound Laboratory Trento, University of Trento, Trento, Italy|Emergency Medicine Unit, General Hospital, Voghera, Italy",,"https://ClinicalTrials.gov/show/NCT04322487"
1366,"NCT04371302","Nursing Perspective on Burnout and Medical Errors in the Intensive Care Unit During Covid-19 Pandemic",,"Not yet recruiting","No Results Available","Burnout, Professional|Medical Errors|Depression","Diagnostic Test: Questionnaire","Prevalence of burnout among ICU nurses during Covid-19|Prevalence of depression among ICU nurses during Covid-19|Prevalence of self-perceived medical errors among ICU nurses during Covid-19|Association of burnout, depression and medical errors among anaesthesiology clinicians during Covid-19","University of Malaya","All","18 Years and older   (Adult, Older Adult)",,"145","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","54843","May 1, 2020","June 30, 2020","June 30, 2020","May 1, 2020",,"May 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04371302"
1367,"NCT04375748","Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases","MYOCOVID","Recruiting","No Results Available","Acute Myocarditis","Diagnostic Test: Performing routine care (clinical and paraclinical tests)|Diagnostic Test: Examinations for the research:","Evolution of the proportion of positive SARS-COV-2 cases.|Ultrasound characteristics.|Assess prognosis of the acute myocarditis .|The factors associated with acute myocarditis cases .|Biological characteristics|Describe at the admission and during the treatment cardiac MRI parameters","University Hospital, Toulouse","All","Child, Adult, Older Adult",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC31/20/0139","April 15, 2020","October 15, 2021","October 15, 2021","May 5, 2020",,"May 5, 2020","CHU de TOULOUSE, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04375748"
1368,"NCT04393792","SINUS WASH Pilot Study in Adults Testing Positive for COVID-19",,"Recruiting","No Results Available","Coronavirus Infection","Drug: Povidone-Iodine|Drug: Normal saline","Change in viral load in the oral and nasopharyngeal cavity|Symptom severity in primary participants and co-residents","Hampshire Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SPON-AK-0420|2020-001721-31","May 2020","August 2020","August 2020","May 19, 2020",,"May 19, 2020","Hampshire Hospitals NHS Foundation Trust, Basingstoke, Hampshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04393792"
1369,"NCT04377776","Observational Study Concerning COVID-19 Infection in Transplanted Kidney, Pancreas or Pancreatic Islet Patients",,"Recruiting","No Results Available","Kidney Transplant|Pancreas Tranplant|Pancreatic Islet Transplantation","Other: Practice details","Global Prevalence of COVID-19 TX|Hospitalization rate in COVID-19 TX|Correlation COVID-19 TX and type of transplantation|Prevalence of COVID-19 TX in italian provinces|Symptoms in COVID-19 TX|Correlation COVID-19 TX and comorbidities|COVID-19 TX Therapies|COVID-19 TX in family settings","IRCCS San Raffaele","All","18 Years to 90 Years   (Adult, Older Adult)",,"700","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","COVID-19 MITRA","May 4, 2020","May 18, 2020","May 18, 2020","May 6, 2020",,"May 6, 2020","IRCCS San Raffaele, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04377776"
1370,"NCT04327388","Sarilumab COVID-19",,"Recruiting","No Results Available","Corona Virus Infection","Drug: Sarilumab SAR153191|Drug: Placebo","Time to improvement of 2 points in clinical status assessment from baseline using the 7-point ordinal scale|Percent of patients alive at Day 29|Proportion of patients with one point improvement from baseline in clinical status assessment at days 4, 7, 15, 21, 29 using the 7-point ordinal scale|Mean change in the 7-point ordinal scale from baseline to Days 4, 7, 15, 21, and 29 (or until discharge)|Time to resolution of fever|Time to resolution of fever and improvement in oxygenation|Days with fever|Time to change in NEWS2 from baseline|Time to NEWS2 of <2 and maintained for 24 hours|Mean change from baseline to days 4, 7, 15, 21, and 29 in NEWS2|Time-to-improvement in oxygenation|Alive off supplemental oxygen at day 29|Days of hypoxemia|Days of supplemental oxygen use|Days of resting respiratory rate >24 breaths/min|Time to saturation ≥94% on room air|Ventilator free days in the first 28 days (to day 29)|The number of patients with Initiation of mechanical ventilation, non-invasive ventilation, or use of high flow nasal cannula|Proportion of patients requiring rescue medication during the 28-day period|The number of patients transferred to the ICU or the need to transfer to the ICU (if the ICU is not available)|Days of hospitalization among survivors|Incidence of serious adverse events|The incidence of major or opportunistic bacterial or fungal infections|The incidence of major or opportunistic bacterial or fungal infections in patients with grade 4 neutropenia|The incidence of hypersensitivity reactions, infusion reactions, gastrointestinal perforation|The number of patients with clinically significant laboratory abnormalities","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16844|2020-001162-12","March 28, 2020","July 2020","August 2020","March 31, 2020",,"May 18, 2020","Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2500001, Bordeaux Cedex, France|Investigational Site Number 2500007, Clamart, France|Investigational Site Number 2500006, La Roche Sur Yon Cedex 9, France|Investigational Site Number 2500002, Nantes, France|Investigational Site Number 2500005, Paris Cedex 18, France|Investigational Site Number 2500003, Strasbourg, France|Investigational Site Number 2500004, Suresnes, France|Investigational Site Number 2760003, Bonn, Germany|Investigational Site Number 2760006, Braunschweig, Germany|Investigational Site Number 2760002, Essen, Germany|Investigational Site Number 2760004, Köln, Germany|Investigational Site Number 2760001, Münster, Germany|Investigational Site Number 3760003, Ashdod, Israel|Investigational Site Number 3760002, Jerusalem, Israel|Investigational Site Number 3760001, Ramat Gan, Israel|Investigational Site Number 3800005, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Modena, Italy|Investigational Site Number 3800004, Parma, Italy|Investigational Site Number 3800006, Rozzano, Italy|Investigational Site Number 3920002, Fuchu-Shi, Japan|Investigational Site Number 3920001, Kamakura-Shi, Japan|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240005, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04327388"
1371,"NCT04371419","COVID-19 Health Messaging to Underserved Communities",,"Recruiting","No Results Available","Coronavirus","Behavioral: Messaging","Knowledge Beliefs and Practices related to COVID-19","National Bureau of Economic Research, Inc.|Massachusetts General Hospital|Stanford University|Yale University|Massachusetts Institute of Technology|Harvard University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2003000118","May 13, 2020","May 31, 2021","June 30, 2021","May 1, 2020",,"May 18, 2020","JPAL North America, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04371419"
1372,"NCT04326387","Evaluation of Novel Diagnostic Tests for COVID-19","COVIDx","Recruiting","No Results Available","Acute Disease|Coronavirus|Respiratory Viral Infection","Diagnostic Test: SAMBA II (Diagnostic for the Real World)|Diagnostic Test: Public Health England Gold Standard|Diagnostic Test: Cambridge Validated Viral Detection Method|Diagnostic Test: Radiological Detection","SAMBA COVID-19 POC PCR Test|Patient acceptability|Immune Response Positivity","CCTU- Cancer Theme|Cambridge University Hospitals NHS Foundation Trust","All","16 Years and older   (Child, Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIDx","April 6, 2020","April 7, 2021","October 7, 2021","March 30, 2020",,"May 18, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04326387"
1373,"NCT04390126","COVID-19 Related Lockdown Effects On Chronic Diseases","CLEO-CD","Active, not recruiting","No Results Available","Chronic Coronary Syndrome|Heart Failure|AMD and Macular Edema|Chronic Respiratory Failure|Hemophilia|Malignant Hemopathy|Multiple Sclerosis|Horton's Disease","Other: life questionnaires|Other: questionnaire","% adherence to each pharmacological class|number of occurrence of medical events at 1 year|Expressed in %: Non-pharmacological treatment/lifestyle:|Expressed in %: Difficulties accessing care: medical appointments, prescriptions, medication|Measurement of psychological distress: Kessler's specific questionnaire (score between 0 and 24)","Centre Hospitalier Universitaire Dijon","All","18 Years and older   (Adult, Older Adult)",,"1200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BOULIN AOIc 2020","April 20, 2020","May 7, 2021","November 7, 2021","May 15, 2020",,"May 18, 2020","CHU Dijon Bourgogne, Dijon, France",,"https://ClinicalTrials.gov/show/NCT04390126"
1374,"NCT04324463","Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","ACT COVID19","Recruiting","No Results Available","Coronavirus|Severe Acute Respiratory Syndrome","Drug: Azithromycin|Drug: Hydoxychloroquine or Chloroquine|Drug: Interferon-Beta","Outpatients: Hospital Admission or Death|Inpatients: Invasive mechanical ventilation or mortality","Population Health Research Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","1500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHRI.ACT.COVID19","April 21, 2020","September 30, 2020","December 31, 2020","March 27, 2020",,"April 24, 2020","Hamilton Health Sciences, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04324463"
1375,"NCT04365608","Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment",,"Recruiting","No Results Available","Intubation Complication|Intubation; Difficult or Failed|Cardiac Arrest|Influenza|Safety Issues","Procedure: Direct laryngoscopy|Procedure: Vie Scope laryngoscopy","Intubation success rate during at the first laryngoscopy|Intubation difficulty Scale score|Complications related to tracheal intubation|Time to completion of tracheal intubation (TI) procedure|Duration of the interruption of chest compression during ETI procedure|Laryngeal View during intubation|POGO score","Lazarski University|Poznan University of Medical Sciences|Wroclaw Medical University|Medical University of Bialystok","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","INT_EMS_PPE_1","March 20, 2020","May 20, 2020","May 20, 2020","April 28, 2020",,"April 29, 2020","Emergency Medical Service, Poznan, Poland|Emergency Medical Service, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT04365608"
1376,"NCT04288713","Eculizumab (Soliris) in Covid-19 Infected Patients","SOLID-C19","Available","No Results Available","Coronavirus","Drug: Eculizumab",,"Hudson Medical","All","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Individual Patients|Treatment IND/Protocol",,"COVID19",,,,"February 28, 2020",,"March 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04288713"
1377,"NCT04379544","Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19","CLUSCO","Recruiting","No Results Available","Coronavirus|Respiratory Failure","Other: Observation only","Patient requires invasive mechanical ventilation and suffers from acute respiratory failure.|Patient is discharged|Patient is hospitalized, but does not require mechanical ventilation through the duration of hospital stay.|Lung ultrasound findings|Cardiac ultrasound findings","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)",,"105","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","843008","April 23, 2020","December 2020","December 2020","May 7, 2020",,"May 11, 2020","University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04379544"
1378,"NCT04321174","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","CORIPREV-LR","Recruiting","No Results Available","Coronavirus Infections|Post-exposure Prophylaxis","Drug: Lopinavir/ritonavir","Microbiologic evidence of infection|Adverse events|Symptomatic COVID-19 disease|Seropositivity|Days of hospitalization attributable to COVID-19 disease|Respiratory failure requiring ventilatory support attributable to COVID-19 disease|Mortality|Short-term psychological impact of exposure to COVID-19 disease|Long-term psychological impact of exposure to COVID-19 disease|Health-related quality of life","Darrell Tan|St. Michael's Hospital, Toronto","All","18 Months and older   (Child, Adult, Older Adult)","Phase 3","1220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","CORIPREV-1","April 17, 2020","March 31, 2021","March 31, 2022","March 25, 2020",,"April 21, 2020","St. Paul's Hospital, Vancouver, British Columbia, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04321174"
1379,"NCT04363593","Serology COVID-19 From the Cornwall Hospital Union","ROCOCO","Recruiting","No Results Available","Corona Virus Infection","Biological: Serological test|Biological: Serum test","Serological test evaluation|Population seroprevalence","Centre Hospitalier de Cornouaille|Centre Hospitalier Régional et Universitaire de Brest","All","18 Years and older   (Adult, Older Adult)","Not Applicable","3200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","29BRC20.0122","May 4, 2020","November 4, 2020","November 4, 2020","April 27, 2020",,"May 6, 2020","CH de Cornouaille, Quimper, France",,"https://ClinicalTrials.gov/show/NCT04363593"
1380,"NCT04385797","Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia","CONNECTDEM","Not yet recruiting","No Results Available","Mild Cognitive Impairment|Dementia","Other: Telephone interview","Change on cognitive function in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on quality of life in Alzheimer´s Disease in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on quality of life in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on mood in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on technophilia in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on perceived stress in people with mild cognitive impairment or mild dementia during and after confinement.|Change on caregiver burden prior to, during and after confinement.|Change on healthcare and social support services access prior to, during and after confinement.|Change from health, cognitive, social, informative and entertainment related uses of ICT during and after confinement.","Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|Consorci Sanitari de Terrassa","All","55 Years and older   (Adult, Older Adult)",,"414","Other","Observational","Observational Model: Cohort|Time Perspective: Other","CONNECT DEM","May 4, 2020","May 29, 2020","June 30, 2020","May 13, 2020",,"May 14, 2020","Consorci Sanitaria de Terrassa, Terrassa, Barcelona, Spain|Instituto de Investigacion Biomedica de Malaga-IBIMA, Málaga, Spain",,"https://ClinicalTrials.gov/show/NCT04385797"
1381,"NCT02735707","Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","REMAP-CAP","Recruiting","No Results Available","Community-acquired Pneumonia, Influenza, COVID-19","Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab","All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome","MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht","All","18 Years and older   (Adult, Older Adult)","Phase 4","7100","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584","April 11, 2016","December 2021","December 2023","April 13, 2016",,"April 16, 2020","St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02735707"
1382,"NCT04390555","The Global PCHF-COVICAV Registry","PCHF-COVICAV","Recruiting","No Results Available","COVID-19|Cardiovascular Diseases|Cardiovascular Risk Factor|Heart Failure",,"In-hospital mortality.|The length of stay in the intensive care unit.|The duration of hospitalization.|The need and duration of invasive mechanical ventilation.|Hospitalization for cardiovascular causes or cardiovascular deaths within 3 months after hospitalization.|Hospitalization for cardiovascular causes or cardiovascular deaths within 6 months after hospitalization.","University of Zurich|Wroclaw Medical University","All","18 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Other","PCHF-COVICAV","April 30, 2020","December 2020","July 2021","May 15, 2020",,"May 15, 2020","Zurich Heart Center, Unispital Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04390555"
1383,"NCT04383730","Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)","ISCA","Not yet recruiting","No Results Available","Critically Illness|Sedation|Invasive Mechanical Ventilation|Acute Respiratory Distress Syndrome","Drug: Intravenous sedation|Drug: Inhaled sedation","Number of days off the ventilator (VFD28, for ventilator-free days), taking into account death as a competing event|All-cause mortality|Ventilator-free days|ICU-free days|Duration of invasive mechanical ventilation|Duration of controlled mechanical ventilation|Physiological measures of lung function|Development of complications|Duration of vasopressor use|Duration of renal replacement therapy|Duration (in days) of any adjuvant therapies|Duration of continuous neuromuscular blockade|Type of sedation practices|Duration of sedation practices|Modalities of sedation practices","University Hospital, Clermont-Ferrand|Hospital Clínico Universitario de Valencia|University of Schleswig-Holstein|Groupe Hospitalier Pitie-Salpetriere","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ISCA Study","May 31, 2020","November 30, 2020","December 31, 2020","May 12, 2020",,"May 12, 2020","CHU, Clermont-Ferrand, France|Centre Hospitalier, Dunkerque, France|Pitié-Salpêtrière Hospital - APHP, Paris, France|CH Privé de la Loire, Saint-Étienne, France|University Medical Center Schleswig-Holstein, Kiel, Germany|Hospital Clínico Universitario de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04383730"
1384,"NCT04370210","Sleep Quality During COVID-19 Containment in Children Whether or Not Usually Followed in Child Psychiatry","CONFIDODO","Not yet recruiting","No Results Available","Sleep Disturbance","Behavioral: Questionnaires","Comparison of sleep quality during COVID-19 containment between children usually followed in child psychiatry and children without follow-up|Assessment of child depression in both groups|Assessment of child anxiety in both groups|Assessment of the influence of socio-demographic factors on sleep in both groups|Measure of the correlation between child sleep quality and parents sleep quality (anxiety level) in both groups|Assessment of sleep disturbance based on psychiatry diagnoses in the group of children usually followed in child psychiatry|Assessment of child anxiety based on psychiatry diagnoses in the group of children usually followed in child psychiatry|Assessment of child depression based on psychiatry diagnoses in the group of children usually followed in child psychiatry","Centre Hospitalier René Dubos","All","7 Years to 12 Years   (Child)",,"464","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHRD 0520","May 2020","June 2020","June 2020","April 30, 2020",,"May 8, 2020","Centre Hospitalier René Dubos, Pontoise, France",,"https://ClinicalTrials.gov/show/NCT04370210"
1385,"NCT04398043","SARS-CoV 2 in Personal Protective Equipment",,"Not yet recruiting","No Results Available","rt PCR|COVID|Personal Protective Equipment PPE|SARS-CoV 2|Health Personnel Attitude|Virus Diseases",,"Asses surface contamination personel protective equipment|Virus charge cuantification|Place in PPE contamination","Hospital de Clinicas José de San Martín|Claudio Yaryour|Fermepin Marcelo|Luis Sarotto|Federico Rodriguez Cairoli|Angela Famiglieti|Francisco Appiani|Lucía Gallo Vaulet","All","16 Years and older   (Child, Adult, Older Adult)",,"16","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","rt PCR en EPP","May 15, 2020","June 30, 2020","July 30, 2020","May 21, 2020",,"May 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04398043"
1386,"NCT04371848","Impact of the COVID-19 Pandemic on Diet Quality and Food Insecurity: a NutriQuébec Sub-study",,"Active, not recruiting","No Results Available","Eating Habits",,"Change in diet quality|Change in food insecurity|Change in intake of sodium|Change in intake of sugar|Change in intake of saturated fat|Change in intake of vegetables and fruits|Change in intake of dairy products|Change in physical activity|Change in sleep quality|Change in health-related quality of life","Laval University","All","18 Years and older   (Adult, Older Adult)",,"2465","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-042Phase IIA6/09-04-2020","April 16, 2020","May 7, 2020","May 7, 2020","May 1, 2020",,"May 1, 2020","Université Laval, Québec, Canada",,"https://ClinicalTrials.gov/show/NCT04371848"
1387,"NCT04354155","COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial",,"Not yet recruiting","No Results Available","Infection Viral|Thromboses, Venous","Drug: Enoxaparin Prefilled Syringe [Lovenox]","Safety of in-hospital thromboprophylaxis|Median twice-daily enoxaparin dose","Neil Goldenberg|Johns Hopkins All Children's Hospital","All","up to 18 Years   (Child, Adult)","Phase 2","38","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","COVAC-TP","May 15, 2020","September 15, 2022","October 15, 2022","April 21, 2020",,"April 21, 2020","Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04354155"
1388,"NCT04377074","Parental Stress During the COVID-19 Pandemic and Its Association With Depression and Anxiety",,"Completed","No Results Available","Parental Stress|Depression|Anxiety",,"Measure of parental stress|Patient Health Questionnaire 9|Generalized Anxiety Disorder 7","University of Oslo|Modum Bad Psychiatric Center|Oslo Metropolitan University|University of Bergen","All","18 Years and older   (Adult, Older Adult)",,"2880","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","REK125510(3)","March 31, 2020","April 7, 2020","April 7, 2020","May 6, 2020",,"May 6, 2020","University of Oslo, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT04377074"
1389,"NCT04374097","Level and Predictors of Trauma-symptoms Among Health Workers and Public Service Providers During the COVID-19 Outbreak",,"Completed","No Results Available","Post Traumatic Stress Disorder|Anxiety|Depression",,"PTSD Checklist for DSM-5 (PCL-5)|Patient Health Questionnaire 9 (PHQ-9)|The Generalized Anxiety Disorder 7 (GAD-7)|Health anxiety","University of Oslo|Modum Bad Psychiatric Center","All","18 Years and older   (Adult, Older Adult)",,"1778","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","REK125510(2)","March 31, 2020","April 7, 2020","April 7, 2020","May 5, 2020",,"May 6, 2020","University of Oslo, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT04374097"
1390,"NCT04361019","Physical Activity in University Students Around COVID-19 Confinement",,"Recruiting","No Results Available","Physical Activity","Other: On-Line Survey",": International Physical Activity Questionnaire - Short Form|Pittsburgh Sleep Quality Index: Subjective Sleep Quality and Sleep Duration domains|Short Form 36 Health Survey: Bodily Pain domain|EuroQol 5D: Self rated health","Basque Country University|University of Cadiz|University of Extremadura|Universidad de Zaragoza|Universidad de Granada|University of Castilla-La Mancha|University of Las Palmas de Gran Canaria|Universidad de León|University of Seville|University of Valencia|Universidad Miguel Hernandez de Elche|Technical University of Madrid|Universidad Pública de Navarra|University of the Balearic Islands|Universitat Jaume I|University of Cantabria","All","Child, Adult, Older Adult",,"25000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Covid_PA2020","April 16, 2020","October 20, 2020","October 20, 2020","April 24, 2020",,"April 24, 2020","Basque Country University (UPV-EHU),, Bilbao, Bizkaia, Spain",,"https://ClinicalTrials.gov/show/NCT04361019"
1391,"NCT04335747","COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases",,"Not yet recruiting","No Results Available","Rheumatoid Arthritis|Psoriatic Arthritis|Axial Spondyloarthritis|Systemic Lupus Erythematosus|Giant Cell Arteritis","Other: COVID-19 infection","Disease activity|Immune modulating treatments|Biomarkers","Salome Kristensen|Aalborg University Hospital","All","18 Years and older   (Adult, Older Adult)",,"333","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20200401","April 8, 2020","August 1, 2021","September 1, 2021","April 6, 2020",,"April 7, 2020","Aalborg University Hospital, Aalborg, Denmark",,"https://ClinicalTrials.gov/show/NCT04335747"
1392,"NCT04381000","Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.",,"Recruiting","No Results Available","Chronic Pain","Other: Exercise Group","Anxiety and Depression|Quality of Life and overall health|Pain Intensity|Quality and patterns of sleep|Patients' illness perceptions|Disability","Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory|University of Thessaly","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","170","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3","April 1, 2020","May 20, 2020","June 30, 2020","May 8, 2020",,"May 11, 2020","Clinical Exercise Physiology and Rehabilitation Laboratory, Lamia, Sterea Ellada, Greece",,"https://ClinicalTrials.gov/show/NCT04381000"
1393,"NCT04358783","Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia","COP-COVID-19","Recruiting","No Results Available","Coronavirus Infection","Biological: Plasma|Other: Best Available Therapy","Early all-cause mortality|Time in days for SARS-CoV-2 RT-PCR negatives|The serum anti-SARS-CoV-2 antibody titres|Detection of serum antibodies","Hospital Universitario Dr. Jose E. Gonzalez","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IF20-00002","April 27, 2020","February 1, 2021","May 30, 2021","April 24, 2020",,"May 19, 2020","Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT04358783"
1394,"NCT04370938","Provider Burnout During COVID-19",,"Recruiting","No Results Available","Perceived Organizational Support, Anxiety, Burnout","Behavioral: Coping strategies video","Feasibility of undertaking task","University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","STUDY20040051","April 29, 2020","October 29, 2020","October 29, 2020","May 1, 2020",,"May 1, 2020","UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04370938"
1395,"NCT04389320","Antimalarial and Covid 19 in Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Hydroxychloroquine","immunoglobulin mesurement","Assiut University","All","20 Years to 70 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","covid 19 in RA","March 15, 2020","May 1, 2020","May 1, 2020","May 15, 2020",,"May 15, 2020","Manal Hassanien, Assiut, Yes, Egypt",,"https://ClinicalTrials.gov/show/NCT04389320"
1396,"NCT04371393","MSCs in COVID-19 ARDS",,"Recruiting","No Results Available","Mesenchymal Stromal Cells|Remestemcel-L","Biological: Remestemcel-L|Drug: Placebo","Number of all-cause mortality|Number of days alive off mechanical ventilatory support|Number of adverse events|Number of participants alive at day 7|Number of participants alive at day 14|Number of participants alive at day 60|Number of participants alive at day 90|Number of participants with resolution and/or improvement of ARDS|Change from baseline of the severity of ARDS|Length of stay|Clinical Improvement Scale|Change in serum hs-CRP concentration|Change in IL-6 inflammatory marker level|Change in IL-8 inflammatory marker level|Change in TNF-alpha inflammatory marker level","Icahn School of Medicine at Mount Sinai|Mesoblast, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","300","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 08-1078-0014","April 30, 2020","April 2021","April 2022","May 1, 2020",,"May 21, 2020","University of Southern California, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|Lutheran Hospital, Fort Wayne, Indiana, United States|Ochsner Clinic, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|Mount Sinai Health, New York, New York, United States|Northwell Health, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Baylor, Smith & White, Plano, Texas, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04371393"
1397,"NCT04340219","Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic","ONCOVID","Active, not recruiting","No Results Available","Cancer","Other: Survey administration","Distress at baseline measured by the COVID-19 Peritraumatic Distress Index (CPDI); in terms of proportions (0-28 vs ≥ 29).|Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21—Depression); in terms of proportions (0-4 vs ≥ 5).|Anxiety at baseline measured by the 7-item anxiety subscale of the DASS-21 (DASS-21—Anxiety); in terms of proportions (0-3 vs ≥ 4).|Stress at baseline measured by the 7-item stress subscale of the DASS-21 (DASS-21—Stress); in terms of proportions (0-7 vs ≥ 8).|Distress measured at baseline by the CPDI; in terms of continuous values.|Depression at baseline measured by the DASS-21—Depression; in terms of continuous values.|Anxiety at baseline measured by the DASS-21—Anxiety; in terms of continuous values.|Stress at baseline measured by the DASS-21—Stress; in terms of continuous values.|Domain-specific quality of life at baseline measured by the 7-item physical health domain of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire (WHOQOL-BREF—Physical health); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 6-item psychological health domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF—Psychological health); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 3-item social relationships domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF—Social relationships); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 8-item environment domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF—Environment); in terms of continuous values.|Overall perception of quality of life and overall perception of health at baseline measured by the two items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire—in terms of continuous values.|Change from baseline in distress measured by CDPI; in terms of continuous values.|Change from baseline in depression measured by the DASS-21—Depression; in terms of continuous values.|Change from baseline in anxiety measured by the DASS-21—Anxiety; in terms of continues values.|Change from baseline in stress measured by the DASS-21—Stress; in terms of continuous values.|Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF—Physical health; in terms of continuous values.|Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF—Psychological health; in terms of continuous values.|Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF—Social relationship; in terms of continuous values.|Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF—Environment; in terms of continuous values.|Change from baseline in overall perception of quality of life and overall perception of health measured by the 2 items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire; in terms of continuous values.|The real-life impact of COVID-19 on systemic treatment administration will be assessed using descriptive statistics","University Hospital, Ghent","All","18 Years and older   (Adult, Older Adult)",,"394","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BC-07505-LGE","March 30, 2020","April 10, 2020","September 2020","April 9, 2020",,"May 11, 2020","University Hospital Gent, Gent, Belgium",,"https://ClinicalTrials.gov/show/NCT04340219"
1398,"NCT04368975","ARDS Caused by COVID-19",,"Recruiting","No Results Available","Acute Respiratory Failure With Hypoxia",,"Discontinuation from mechanical ventilation","Hospital Clinic of Barcelona|Ubikare company","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 ARDS","March 12, 2020","April 21, 2020","December 31, 2020","April 30, 2020",,"April 30, 2020","Ricard Mellado, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04368975"
1399,"NCT04400279","The COVID-19 Pandemic and Exercise Study","COPE","Not yet recruiting","No Results Available","Depressive Symptomatology|Psychological Distress|Health Behavior","Behavioral: Yoga group|Behavioral: High Intensity Interval Training group|Behavioral: Combination","Changes in depressive symptomology over the course of the exercise intervention|Changes in psychological stress as measured by the SCSQ over the course of the exercise intervention.|Changes in psychological distress as measured by the K10 over the course of the exercise intervention.|Changes in flourishing over the course of the exercise intervention|Changes in resilience over the course of the exercise intervention|Changes in life satisfaction over the course of the exercise intervention|Changes in weekly strain as a result of health problems, financial/work issues, and relationship trouble using the Chronic Burden Scale over the course of the exercise intervention.|Changes in general affect over the course of the exercise intervention|Changes in leisure time physical activity over the course of the exercise intervention|Changes in physical health symptomology over the course of the exercise intervention|Changes in alcohol habits over the course of the exercise intervention|Tracking the amount of exercise variety participants feel they engage in","University of British Columbia","All","18 Years to 64 Years   (Adult)","Not Applicable","490","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","H20-01497","May 2020","August 2020","October 2020","May 25, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04400279"
1400,"NCT04377412","Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic","MindCOVID","Recruiting","No Results Available","Anxiety|Depression|Pregnancy Related","Other: Pandemic control measures","Anxiety|Depression","Żelazna Medical Centre, LLC|University of Medicine, Tirana|Royal Prince Alfred Hospital, Sydney, Australia|Charles University, Czech Republic|Hôpital Necker-Enfants Malades|Charite University, Berlin, Germany|Chinese University of Hong Kong|Meir Medical Center|Università degli Studi di Brescia|American University of Beirut Medical Center|Karolinska Institutet|Pomeranian Medical University Szczecin|Nicolaus Copernicus University|Centre of Postgraduate Medical Education|Polish Academy of Sciences|Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland|Fundación Para la Investigación y el Desarrollode la Medicina Materno-Fetal y Neonatal “iMaterna”, Madrid|Taiji Clinic, Taipei|Wayne State University|Chang Gung University|University of Tromso","Female","18 Years and older   (Adult, Older Adult)",,"8500","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","Maternal axiety and COVID-19","May 1, 2020","August 31, 2020","October 31, 2020","May 6, 2020",,"May 6, 2020","Wayne State University, Detroit, Michigan, United States|University of Medicine Tirana, Tirana, Albania|Royal Prince Alfred Hospital, Sydney, Australia|Charles University, Prague, Czechia|Université de Paris, Paris, France|Charité - University Medicine Berlin, Berlin, Germany|The Chinese University of Hong Kong, Hong Kong, Hong Kong|Meir Medical Center, Kafr Saba, Israel|University of Brescia, Brescia, Italy|American University of Beirut, Beirut, Lebanon|The Arctic University of Norway, Tromsø, Norway|Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland|Pomeranian Medical University, Szczecin, Poland|Centre of Postgraduate Medical Education, Warsaw, Poland|11. Fundación Para la Investigación y el Desarrollode la Medicina Materno-Fetal y Neonatal ""iMaterna"", Madrid, Spain|Karolinska Institutet, Stockholm, Sweden|Taiji Clinic, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04377412"
1401,"NCT04377672","Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)",,"Not yet recruiting","No Results Available","Corona Virus Infection","Biological: Anti-SARS-CoV-2 Human Convalescent Plasma","Safety of treatment with high-titer anti-SARS-CoV-2 plasma as assessed by adverse events|Proportion of subjects with disease worsening event|Pharmacokinetics of anti-SARS-CoV-2 antibodies as defined by changes in antibody titers|Proportion of subjects with a natural antibody response to SARS-CoV-2 infection","Johns Hopkins University","All","1 Month to 18 Years   (Child, Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00247557","May 18, 2020","May 18, 2021","May 18, 2022","May 6, 2020",,"May 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04377672"
1402,"NCT04374474","Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19)",,"Not yet recruiting","No Results Available","Olfactory Disorder","Other: Olfactory retraining|Drug: corticosteroid nasal irrigation|Other: smell household Items|Other: Nasal Irrigation","Change from Baseline Snap and Sniff Threshold Test at 3 months|Change from baseline Smell Identification Test (SIT) at 3 months|Change from Baseline Snap and Sniff Threshold Test at 6 months|Change from baseline Smell Identification Test (SIT) at 6 months|Change from baseline QOD-NS at 3 months|Change from baseline SF-36 health survey at 3 months|Change from baseline QOD-NS at 6 months|Change from baseline SF-36 health survey at 6 months|Adherence to the Study Protocol|Recovery","Lawson Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Anosmia_CoVID 19","June 2020","June 2021","December 2021","May 5, 2020",,"May 5, 2020","St. Joseph's Health Care, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04374474"
1403,"NCT04320953","Non-contact Endoscopy at Covid-19 Outbreak",,"Completed","No Results Available","Gastrointestinal Disease|Infectious Disease","Device: Non-contact MCE system","Technical success|Clinical success|Adverse events","Changhai Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ncMCE1","March 16, 2020","March 26, 2020","April 9, 2020","March 25, 2020",,"April 17, 2020","Changhai Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04320953"
1404,"NCT04345887","Spironolactone in Covid-19 Induced ARDS",,"Not yet recruiting","No Results Available","Respiratory Distress Syndrome, Adult","Drug: Spironolactone 100mg|Drug: Placebo oral tablet","p/f ratio|SOFA","Istanbul University-Cerrahpasa","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","10042020","April 21, 2020","July 21, 2020","October 21, 2020","April 15, 2020",,"April 15, 2020","Istanbul University-Cerrahpaşa, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04345887"
1405,"NCT04378738","Social Media and Covid19 Pandemic",,"Enrolling by invitation","No Results Available","Social Media|Corona Virus Infection","Behavioral: survey","the role of social media","Acibadem University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","212","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","AcibademU social media","May 1, 2020","May 7, 2020","May 8, 2020","May 7, 2020",,"May 7, 2020","Bahar Yuksel, Istanbul, Turkey|Haseki Training and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04378738"
1406,"NCT04369690","The Psychological, Social, and Economic Impacts of COVID-19","C19Survey","Recruiting","No Results Available","COVID-19|Chronic Disease|Psychiatric Disorder|Cardiovascular Diseases",,"Mental health - Stress|Mental health - Anxiety|Mental health - Depression|Moral distress in healthcare workers|Moral resilience in healthcare workers|Social life|COVID-9 symptoms|Adverse health long-term outcome|Health care utilization - Inpatient|Health care utilization - ER|Health care utilization - Outpatient|Sleep","University of Ottawa|Hopital du Sacre-Coeur de Montreal|Sunnybrook Health Sciences Centre|Southlake Regional Health Centre|The Ottawa Hospital Research Institute|Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal|Centre for Addiction and Mental Health|CHEO Research Institute|Ottawa Heart Institute Research Corporation|McGill University|Johns Hopkins University|Université de Montréal|The Royal's Institute of Mental Health Research","All","12 Years and older   (Child, Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2131","April 3, 2020","April 3, 2021","April 3, 2021","April 30, 2020",,"April 30, 2020","Southlake Regional Health Centre, Newmarket, Ontario, Canada|CHEO Research Institute, Ottawa, Ontario, Canada|The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|The Centre for Addiction and Mental Health, Ottawa, Ontario, Canada|The University of Ottawa Heart Institute, Ottawa, Ontario, Canada|The Royal's Institute of Mental Health Research, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Hôpital en santé mentale Rivière-des-Prairies (CIUSSS du Nord-de-l'Île-de-Montréal), Montréal, Quebec, Canada|McGill University, Montréal, Quebec, Canada|University of Montréal, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04369690"
1407,"NCT04368312","Psychological Impairment Due to Covid-19",,"Not yet recruiting","No Results Available","Psychological Distress|Quality of Life","Other: No intervention","PCL5 Questionnaire|BSI - Brief symptom inventory|PHQD|WHO - QoL BREF|STAXI|AUDIT questionnaire","University Hospital, Essen","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TEMP553914-BO","May 6, 2020","May 30, 2020","May 30, 2020","April 29, 2020",,"April 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04368312"
1408,"NCT04356885","COVID-19 and Psychotic Symptoms in France","SCHIZOVID-19","Recruiting","No Results Available","Mental Disorder",,"Total score of the Cardiff Anomalous Perceptions Scale (CAPS)|Paranoia Scale","University Hospital, Montpellier|Epsylon Laboratory, EA 4556, University Paul Valéry Montpellier 3, France|Laboratoy LIP/PC2S, University Grenobles-Alpes, Grenoble, France|Centre référent de réhabilitation psychosociale de Grenoble, Grenoble, France","All","18 Years to 65 Years   (Adult, Older Adult)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0225","April 1, 2020","July 30, 2020","August 1, 2020","April 22, 2020",,"May 7, 2020","UH Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04356885"
1409,"NCT04376515","Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19)",,"Active, not recruiting","No Results Available","Anxiety","Behavioral: HOPE intervention","Anxiety","University of California, Irvine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","UCaliforniaIrvineSYoung","March 20, 2020","June 1, 2020","September 1, 2020","May 6, 2020",,"May 6, 2020","UC Irvine, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT04376515"
1410,"NCT04380870","Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19",,"Recruiting","No Results Available","Coronavirus Infection","Dietary Supplement: Chinese Herbal Medicine","Patient reported main complaint|Conduct qualitative analyses of data","Center for Integrated Care|University of Utah|University of California, San Francisco","All","18 Years to 114 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","01-04-20","April 11, 2020","April 11, 2021","April 11, 2025","May 8, 2020",,"May 8, 2020","Seattle Intstitute of East Asian Medicine, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04380870"
1411,"NCT04334629","LIBERATE Trial in COVID-19","LIBERATE","Not yet recruiting","No Results Available","Coronavirus|Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Ibuprofen","Disease progression|Time to mechanical ventilation|Overall survival|Reduction in proportion of patients who require ventilation|Reduction in length of Critical Care stay|Reduction in length of Hospital stay|Modulation of serum pro- and anti-inflammatory cytokines|Reduction in duration of ventilation|Increase in ventilator-free days","King's College London|Guy's & St Thomas NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Phase 4","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","282009","April 27, 2020","August 26, 2020","November 26, 2020","April 6, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04334629"
1412,"NCT04368377","Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19","PIC-19","Completed","No Results Available","Pneumonia, Viral|Corona Virus Infection|Respiratory Failure|Embolism and Thrombosis","Drug: Tirofiban Injection|Drug: Clopidogrel|Drug: Acetylsalicylic acid|Drug: Fondaparinux","P/F ratio|PaO2 difference|A-a O2 difference|CPAP duration|In-hospital change in intensity of the respiratory support|PaCO2 difference|HCO3- difference|Lactate difference|Hb difference|Plt difference|Adverse effects","University of Milan|Fondazione ""Un Cuore per Milano"" - a no profit foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18275/2020","April 6, 2020","April 23, 2020","April 23, 2020","April 29, 2020",,"April 29, 2020","L. Sacco Hospital, Milano, Lombardia, Italy",,"https://ClinicalTrials.gov/show/NCT04368377"
1413,"NCT04356365","The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's)",,"Completed","No Results Available","Depression|Generalized Anxiety|Adherence to Non-pharmacological Epidemiological Interventions (NPIs)","Other: Cross-sectional study investigating the association of NPIs with mental health","Patient Health Questionnaire 9|Generalized Anxiety Disorder 7|Measures of adherence","University of Oslo|Modum Bad Psychiatric Hospital","All","18 Years and older   (Adult, Older Adult)",,"10084","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","REK125510","March 31, 2020","April 7, 2020","April 7, 2020","April 22, 2020",,"April 24, 2020","University of Oslo, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT04356365"
1414,"NCT04384458","COVID-19 Prophylaxis With Hydroxychloroquine Associated With Zinc For High-Risk Healthcare Workers",,"Not yet recruiting","No Results Available","Coronavirus Infections","Drug: Hydroxychloroquine","Proportion of participants in whom there was a clinical finding of COVID-19.|Symptomatic COVID-19 infections.|Healthcare Workers who developed mild, moderate, or severe forms of COVID-19.|Measurement of the QT interval.|Widening of the corrected QT interval or with changes in heart rate on the ECG.|Comparison of hematological and biochemical parameters.|Occurrence of adverse events.","Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HCQZn","May 2020","October 2020","October 2020","May 12, 2020",,"May 12, 2020","Drug Research and Development Center (NPDM), Federal University of Ceará (UFC), Fortaleza, Ceará, Brazil",,"https://ClinicalTrials.gov/show/NCT04384458"
1415,"NCT04395885","Sexual Function During COVID 19 Pandemic",,"Not yet recruiting","No Results Available","Sexual Dysfunction","Other: Electronic questionnaire","The percentage of study participants diagnosed with sexual dysfunction","Assiut University","All","18 Years to 40 Years   (Adult)",,"120","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","SFCOV","June 1, 2020","July 2020","August 2020","May 20, 2020",,"May 20, 2020","Assiut Faculty of Medicine, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04395885"
1416,"NCT04386460","Covid-19 and Prevention of Malnutrition After Confinement by Dentists",,"Recruiting","No Results Available","Nutrition Poor|Infection Viral|Oral Disease",,"Body Mass Index|Weight changes during confinement|prescription of nutritional supplements and observance","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20odontocovid-02","May 11, 2020","June 5, 2020","May 11, 2021","May 13, 2020",,"May 13, 2020","University Nice Hospital, Nice, France",,"https://ClinicalTrials.gov/show/NCT04386460"
1417,"NCT04308187","Influence of the COvid-19 Epidemic on STRESS","COVISTRESS","Not yet recruiting","No Results Available","Stress, Psychological",,"Stress|Perception and knowledge of the epidemic|Feeling of information on the part of companies / establishments / governments|Means of protection|Feelings of fear generated and its impact on feelings of stigmatization towards ethnic groups or categories of patients|Sociodemographic factors and lifestyle habits","University Hospital, Clermont-Ferrand|Faculty of Medicine, Clermont-Ferrand, France|UMR CNRS 6024 LaPSCo, Clermont-Ferrand, France|Wittyfit, Paris, France","All","Child, Adult, Older Adult",,"50000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2020 COVISTRESS","March 11, 2020","March 2022","March 2022","March 13, 2020",,"March 13, 2020","University Hospital, Clermont-Ferrand, Clermont-Ferrand, France",,"https://ClinicalTrials.gov/show/NCT04308187"
1418,"NCT04348227","How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?",,"Active, not recruiting","No Results Available","Ventilator Associated Pneumonia","Behavioral: Enhanced hygiene measures","MDR pathogens in endotracheal aspirates|Microorganisms in endotracheal aspirates","Hôpital Universitaire Fattouma Bourguiba","All","Child, Adult, Older Adult",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Other","KM2020-1","January 1, 2019","January 1, 2020","February 4, 2021","April 16, 2020",,"April 17, 2020","Department of anesthesia and intensive care, Fattouma Bourguiba Hospital, Monastir, Tunisia",,"https://ClinicalTrials.gov/show/NCT04348227"
1419,"NCT04365309","Protective Effect of Aspirin on COVID-19 Patients","PEAC","Enrolling by invitation","No Results Available","Novel Coronavirus Pneumonia|Aspirin|Treatment","Drug: Aspirin 100mg","clinical recovery time (TTCR)|the time of SARS-CoV2 overcasting","Xijing Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Xi jingH","February 10, 2020","April 2020","June 2020","April 28, 2020",,"April 28, 2020","Cai Yue, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT04365309"
1420,"NCT04379531","LDCT in COVID-19 Pneumonia: a Prospective Moscow Study","LDCTiP","Not yet recruiting","No Results Available","Pneumonia|Coronavirus Infection","Diagnostic Test: Low-dose Chest CT","Evaluate the correlation between standard CT and low-dose CT scans for the detection of community-acquired pneumonia.|Threshold value of the infiltration zone size detected by low-dose CT scan compared to standard CT scan.|Number of infiltration zones of pulmonary parenchyma corresponding to viral pneumonia detected by low-dose CT scan in comparison with standard CT scan.","Research and Practical Center of Medical Radiology, Department of Health Care of Moscow","All","18 Years and older   (Adult, Older Adult)","Not Applicable","230","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2020-1","May 31, 2020","June 30, 2020","July 31, 2020","May 7, 2020",,"May 7, 2020","Victor Gombolevskiy, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04379531"
1421,"NCT04335279","Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program","SPIN-CHAT","Recruiting","No Results Available","Scleroderma|Scleroderma, Systemic|Systemic Sclerosis","Other: SPIN-CHAT Program","Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0|Depression symptoms: Patient Health Questionnaire (PHQ-8)|Stress: Perceived Stress Scale (PSS)|Loneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6)|Boredom: Multidimensional State Boredom Scale (MSBS-8)|Physical activity: International Physical Activity Questionnaire - modified for the elderly (IPAQ-E)|Frequency of social interactions|Adverse Effects","Lady Davis Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","195","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SPIN-CHAT-001","April 9, 2020","June 3, 2020","June 3, 2020","April 6, 2020",,"April 24, 2020","Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04335279"
1422,"NCT04353583","Renal Outcome in Patients With COVID-19",,"Recruiting","No Results Available","Acute Kidney Injury|Corona Virus Infection",,"Incidence of AKI|Renal function changes during hospital stay|Incidence of chronic kidney disease","University of Giessen","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AZ 58/20","April 21, 2020","August 2020","August 2020","April 20, 2020",,"May 6, 2020","University Hospital Giessen and Marburg, Giessen, Giessen, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT04353583"
1423,"NCT04393415","Using Cord Blood in Treatment of Covid -19",,"Not yet recruiting","No Results Available","Virus","Combination Product: stem cells","the number of patients with positive covid 19 who will improve after receiving stem cells","Aljazeera Hospital","All","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","covid -19","May 20, 2020","July 25, 2020","August 1, 2020","May 19, 2020",,"May 19, 2020","Aljazeera( Al Gazeera) hospital, Giza, Egypt",,"https://ClinicalTrials.gov/show/NCT04393415"
1424,"NCT04326452","Treating COVID-19 With a Bidirectional Oxygenation Valve",,"Recruiting","No Results Available","Coronavirus Infection","Device: bidirectional oxygenation mouthpiece","Pulse oximetry level|Respiratory rate|Heart rate|Blood pressure|Systemic carbon dioxide","TMC HealthCare|PEEP Medical, LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID19PEEP2020|GO2 PEEP Study","March 27, 2020","May 1, 2020","June 1, 2020","March 30, 2020",,"April 1, 2020","TMC HealthCare, Tucson, Arizona, United States|Stanford University, Stanford, California, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04326452"
1425,"NCT04327180","PREdiction of DIagnosed Covid-19 infecTion in IUC Patients","PREDICT","Recruiting","No Results Available","Infection Viral|Coronavirus|ARDS|Pneumonia",,"Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU|Coinfections|Respiratory dysfunction requiring mechanical ventilation|Sequential Organ Failure Assessment (SOFA) Score|SAPS II score|Disseminated Intravascular Coagulation (DIC) score|Number of days on vasopressive amines|Occurrence of an event of venous or arterial thromboembolic disease|Number of days with extra renal treatment (ERA)|Number of patients alive after ICU stay less than 28 days will be tracked|Short Form 36|Hospital anxiety and depression scale (HADS)|Impact of Event Scale - revised (IES-R)|Post-traumatic stress disorder Checklist version DSM-5 (PSL-5)|Modified Medical Research Council (MMRC) Dyspnea Scale|Correlation between number of patient deaths and all predictors for Covid-19 including anamnestic, clinical, biological, radiological parameters|Viral clearance","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_20|2020-A00763-36","March 30, 2020","September 2021","September 2021","March 30, 2020",,"April 6, 2020","Hôpital Roger Salengro, ICU, CHU Lille, Lille, France",,"https://ClinicalTrials.gov/show/NCT04327180"
1426,"NCT04322344","Escin in Patients With Covid-19 Infection","add-on-COV2","Recruiting","No Results Available","Coronavirus Infections","Drug: Escin|Drug: standard therapy","Mortality rate|Clinical status evaluated in agreement with guidelines|The differences in oxygen intake methods|Time of hospitalization (days)|Time of hospitalization in intensive care units|Pulmonary function","University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico ""Mater Domini""","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","covid-19 add-on therapy","March 23, 2020","June 30, 2020","August 30, 2020","March 26, 2020",,"March 27, 2020","Luca Gallelli, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04322344"
1427,"NCT04312243","NO Prevention of COVID-19 for Healthcare Providers","NOpreventCOVID","Not yet recruiting","No Results Available","Coronavirus Infections|Healthcare Associated Infection","Drug: Inhaled nitric oxide gas","COVID-19 diagnosis|Positive SARS-CoV-2 rt-PCR test","Massachusetts General Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","470","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NOpreCOVID-19","April 2, 2020","March 20, 2021","March 20, 2022","March 18, 2020",,"April 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04312243"
1428,"NCT04337047","Distress in Crisis Situations During COVID-19",,"Completed","No Results Available","Stress, Psychological","Other: questionnaire assesment","quantify and qualify distress over a large population in times of pandemic crisis.|qualify demographic data vs distress over a large population in times of pandemic crisis.","Wefight","All","18 Years and older   (Adult, Older Adult)",,"2000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","WefightDistress20","March 31, 2020","April 30, 2020","May 3, 2020","April 7, 2020",,"May 5, 2020","Wefight, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04337047"
1429,"NCT04337502","Clinical and Radiomic Model of COVID-19",,"Completed","No Results Available","Coronavirus|Machine Learning","Diagnostic Test: Machine learning model","Predictive performance","Maastricht University|The Central Hospital of Wuhan","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","UM_2020_GY_COVID-19","December 23, 2019","January 20, 2020","March 3, 2020","April 7, 2020",,"April 7, 2020","The central hospital of Wuhan, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04337502"
1430,"NCT04359849","Sequencing and Tracking of Phylogeny in COVID-19 Study","STOP COVID 19","Recruiting","No Results Available","Coronavirus Infection",,"To produce whole genome sequences for the SARS-CoV-2 virus from viral RNA samples|To develop a phylogenetic map of the SARS-CoV-2 virus","Portsmouth Hospitals NHS Trust|University of Portsmouth","All","7 Years and older   (Child, Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PHT/2020/34","May 2020","May 2022","September 2022","April 24, 2020",,"April 24, 2020","Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04359849"
1431,"NCT04363229","Psychological Impact of COVID19 Among Doctors in Assiut University Hospitals",,"Not yet recruiting","No Results Available","Occupational Stress","Other: maslach burnout inventory questionnair","The MBI-HSS (MP) addresses three scales:Emotional Exhaustion ,Depersonalization and Personal Accomplishment|GHQ-12 questionnaire for measuring of current mental health","Assiut University|shima abdelsameaa|Ahmed khier","All","22 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","pshycological impact COVID19","May 2020","May 2021","June 2021","April 27, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04363229"
1432,"NCT04324684","Prognostic Factors Keeping Track for COVID-19 Pneumonia","NIKE_C19","Completed","No Results Available","Pneumonia, Viral|Hypertension|Diabetes Mellitus|Obesity|Cardiovascular Diseases|Obstructive Lung Disease",,"rate of recovery|time to improvement|efficacy of treatments|organ failure","Catholic University of the Sacred Heart","All","18 Years to 100 Years   (Adult, Older Adult)",,"198","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20202503","March 31, 2020","May 7, 2020","May 7, 2020","March 27, 2020",,"May 14, 2020","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04324684"
1433,"NCT04382768","Inhaled Ibuprofen to Treat COVID-19","CórdobaTrail","Active, not recruiting","No Results Available","Coronavirus Infection|Respiratory Disease|SARS (Disease)","Drug: Inhaled Hypertonic ibuprofen","Change in the scale of ordinary COVID results at 7, 14 and 28 days in patients with acute respiratory infection, induced by SARS-CoV-2, treated with inhaled Ibuprofen.|Change to Negativization of the swab to the following treatment points on day 7, day 14, 21 and 28 after treatment with inhaled Ibuprofen.|Chage in length of Hospital stay|Chage in duration of ventilation|Chage in length of Critical Care stay|Average score of National Early Warning (NEWS2) between days 1, 7, 14 and 28.|Average change in quick sepsis-related organ failure assessment score (qSOFA) score between day 1, 7, 14 and 28.|Time from first dose to conversion to normal or mild pneumonia|Antibiotic requirement|Glucocorticoids requirement|Incidence of adverse event|Incidence of serious adverse event|Number of deaths from any cause at 28 days|Lymphocyte count","Química Luar SRL|National Council of Scientific and Technical Research, Argentina|Centro de Excelencia en Productos y Procesos Córdoba","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DNL000004","May 1, 2020","January 2021","January 2021","May 11, 2020",,"May 19, 2020","Centro de Excelencia en Productos y Procesos Córdoba, Córdoba, Argentina",,"https://ClinicalTrials.gov/show/NCT04382768"
1434,"NCT04357041","COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being","CoVS","Recruiting","No Results Available","ALL, Adult",,"Automated Self-Administered 24-Hour Dietary Recall (ASA24)|International Physical Activity Questionnaire (IPAQ)|Health-Related Quality of Life SF-12 Scale|State trait inventory for cognitive and somatic anxiety (STISA).|Beck Depression inventory (BDI)","Clinical Nutrition Research Center, Illinois Institute of Technology","All","18 Years and older   (Adult, Older Adult)",,"500","Industry","Observational","Observational Model: Case-Only|Time Perspective: Other","IRB-2020-91","April 17, 2020","December 2020","April 2021","April 22, 2020",,"April 29, 2020","Clinical Nutrition Research Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04357041"
1435,"NCT04379245","COVID-19 Infection in Patients Infected With HIV and/or on PrEP","COVIDHIVPrEP","Completed","No Results Available","HIV|Pre-exposure Prophylaxis","Other: Data research, database analysis","Covid attack rate","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)",,"4200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CRC_GHN_2020_002","April 30, 2020","April 30, 2020","May 4, 2020","May 7, 2020",,"May 7, 2020","Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France",,"https://ClinicalTrials.gov/show/NCT04379245"
1436,"NCT04306055","Blood Donor Recruitment During Epidemic of COVID-19",,"Completed","No Results Available","Blood Donation","Other: Questionnaire with precaution information|Other: Experimental: Questionnaire without precaution information","Differences of attitude about blood donation towards different questionnaires|Rates of blood donation during 3 weeks","Guangzhou Blood Center","All","18 Years to 60 Years   (Adult)","Not Applicable","19491","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Blood donor recruitment","March 13, 2020","March 13, 2020","April 3, 2020","March 12, 2020",,"April 13, 2020","Guangzhou Blood Center, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04306055"
1437,"NCT04359225","A Comparison of 3D and 2D Telemedicine During Covid 19",,"Not yet recruiting","No Results Available","Telehealth","Other: 3D Telemedicine|Other: 2D Telemedicine","University Hospitals of North Northway questionnaire|Mental effort rating scale|Telehealth Usability Questionnaire|Subjective feedback interview","NHS Greater Glasgow and Clyde|University of Strathclyde|Glasgow Royal Infirmary","All","1 Year to 95 Years   (Child, Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","GN20HS182","June 30, 2020","December 31, 2021","December 31, 2021","April 24, 2020",,"April 28, 2020","Canniesburn Regional Plastic Surgery and Burns Unit, Glasgow, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04359225"
1438,"NCT04400006","Ozone Therapy in the Prevention of COVID-19 Infection",,"Completed","No Results Available","Corona Virus Infection",,"The survey that was taken by telephone calls","Marmara University","All","18 Years to 90 Years   (Adult, Older Adult)",,"71","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2761","May 6, 2020","May 16, 2020","May 17, 2020","May 25, 2020",,"May 25, 2020","Kardelen Gencer Atalay, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04400006"
1439,"NCT04365361","The Psychological Impact of the COVID-19 on Students.",,"Recruiting","No Results Available","Mental Health Wellness 1",,"Stress level|Anxiety and depressive symptoms|Insomnia symptoms and the associated daytime impairment|Psychological response to trauma|Resilience|Attitude and practice students regarding preventive measures","The University of Hong Kong","All","18 Years to 100 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","UW20-298","April 26, 2020","December 30, 2020","March 31, 2021","April 28, 2020",,"May 19, 2020","LAI Agnes, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04365361"
1440,"NCT04357613","IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.","IMAGE-19","Not yet recruiting","No Results Available","SARS Virus","Drug: Experimental drug","To evaluate the benefit of early imatinib therapy to prevent severe COVID-19 disease in hospitalized aged patients.|To evaluate the feasibility of imatinib therapy.|To evaluate safety of imatinib therapy|To evaluate the clinical evolution|To evaluate the progression rate to severe COVID-19 disease|To evaluate mortality|To evaluate viral load|To evaluate plasmatic levels of imatinib","Versailles Hospital","All","70 Years and older   (Older Adult)","Phase 2","99","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P20/05_IMAGE19","May 1, 2020","November 1, 2020","December 1, 2020","April 22, 2020",,"April 22, 2020","CHU Bordeaux, Bordeaux, France|CH de Versailles, Le Chesnay, France",,"https://ClinicalTrials.gov/show/NCT04357613"
1441,"NCT04344041","COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)",,"Recruiting","No Results Available","Coronavirus","Drug: cholecalciferol 200,000 IU|Drug: cholecalciferol 50,000 IU","Number of death of any cause, during the 14 days following the inclusion and intervention.|Number of death of any cause, during the 28 days following the inclusion and intervention.|Clinical evolution between day 0 and day 14 based on the change of the WHO Ordinal Scale for Clinical Improvement (OSCI) for COVID-19|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19|Rate of patients with at least one severe adverse event at day 28, according to the regulations|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at baseline|Number of death of any cause during the 14 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Number of death of any cause during the 14 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7|Number of death of any cause during the 28 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7|Number of death of any cause during the 14 days following the inclusion and intervention, compared to mortality data in French hospital geriatric units from the current national survey by the French Society of Geriatrics and Gerontology","University Hospital, Angers|Mylan Laboratories","All","70 Years and older   (Older Adult)","Phase 3","260","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001602-34","April 15, 2020","July 2020","July 2020","April 14, 2020",,"May 6, 2020","CHU Angers, Angers, France|CHU Bordeaux, Bordeaux, France|CH Le Mans, Le Mans, France|CHU Lille, Lille, France|CHU Limoges, Limoges, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|CHU Saint Etienne, Saint Etienne, France|CH Saumur, Saumur, France|CHU Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT04344041"
1442,"NCT03808922","Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study",,"Recruiting","No Results Available","Lower Respiratory Tract Infection|Parainfluenza|Immunocompromised|COVID-19","Drug: DAS181|Drug: Placebo|Drug: DAS181 COVID-19|Drug: DAS181 OL","Percent of subjects who Return to Room Air (RTRA) (main study)|Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)|All-cause mortality rate (main study)|Time (in days) to RTRA (main study)|Percent of subjects who achieve clinical stability (main study)|Percent of subjects discharged (without mortality and hospice) (main study)|Time (in days) to first hospital discharge (without hospice) (main study)|Total number of inpatient days (main study)|Baseline SAD-RV infection-related mortality rate (main study)|Change in pulmonary function (FEV1% predicted) (main study)|Time to improved COVID19 clinical status (Sub-study)|Time to RTRA|Time to Clinical stability|Time to SARS-CoV-2 RNA in the respiratory specimens being undetectable|Time to Clinical deterioration|Time to Discharge from hospital (without readmission before Day 28).|Time to Death (all causes)","Ansun Biopharma, Inc.","All","Child, Adult, Older Adult","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DAS181-3-01|2018-004318-16","May 23, 2019","April 30, 2021","December 28, 2021","January 18, 2019",,"April 17, 2020","City of Hope cancer Center, Duarte, California, United States|UCLA, Los Angeles, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cook Children's, Fort Worth, Texas, United States|MD Anderson, Houston, Texas, United States|VCU Health System, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Westmead Hospital, Sydney, New South Wales, Australia|The Wesley Hospital, Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Seoul National University Bundang Hospital, Seongnam-si, Guenoggi-do, Korea, Republic of|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|National Taiwan University Hospital, Zhongzheng Dist., Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03808922"
1443,"NCT04370886","Recruit Blood Donors Via SMS During Epidemic of COVID-19",,"Enrolling by invitation","No Results Available","Blood Donation","Behavioral: blood donation SMS","Blood donation rate","Guangzhou Blood Center","All","18 Years to 60 Years   (Adult)","Not Applicable","394578","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Recruit Blood Donors via SMS","April 30, 2020","April 30, 2020","May 10, 2020","May 1, 2020",,"May 4, 2020","Guangzhou Blood Center, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04370886"
1444,"NCT04320732","Risk Factors for Community- and Workplace Transmission of COVID-19",,"Recruiting","No Results Available","Coronavirus","Behavioral: Observation of behavior and COVID-19 infection will be conducted.","Rate of COVID-19 infection","Oslo University Hospital|Age Labs AS","All","18 Years and older   (Adult, Older Adult)",,"50000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","REK-124170","March 27, 2020","March 27, 2022","March 20, 2030","March 25, 2020",,"March 31, 2020","Oslo University Hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT04320732"
1445,"NCT04369859","Obstetric and Perinatal Outcomes of Women With COVID-19","GROCO","Recruiting","No Results Available","Pregnant Women","Behavioral: Examine the impact of COVID-19 during pregnancy","Compare the complications rates|Clinical presentation","Assistance Publique Hopitaux De Marseille","Female","18 Years and older   (Adult, Older Adult)",,"1300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-18|ID RCB","April 23, 2020","April 22, 2021","April 22, 2021","April 30, 2020",,"May 4, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, Paca, France",,"https://ClinicalTrials.gov/show/NCT04369859"
1446,"NCT04386291","Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19",,"Recruiting","No Results Available","Generalized Anxiety|Health Anxiety","Behavioral: Anxiety Reduction Training|Behavioral: Kundalini Yoga and Anxiety Reduction Training|Behavioral: Meditation and Anxiety Reduction Training","GAD-7|Whiteley 8|PHQ-8|GSQ-30|Applied Cognition 1.0|PROMIS-4 Sleep Disturbance|ERQ|Perceived Stress Scale|Brief Hypervigilance Scale","Research Foundation for Mental Hygiene, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7987","May 25, 2020","May 19, 2021","January 30, 2022","May 13, 2020",,"May 25, 2020","Columbia University Department of Psychiatry, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04386291"
1447,"NCT04354272","Evaluation of Dental Emergency Treatments During COVID19 Crisis","URGDENTCOVID","Not yet recruiting","No Results Available","Orofacial Pain|Orofacial Edema|Dental Trauma|Oral Infection","Other: Questionnaire","Pain score evolution measured by a 0-10 numeric scale (NS) where 0 is no pain and 10 the worst pain imaginable|Pain scores evolution 3 days and 7 days after first visit measured by a numeric scale where 0 is no pain and 10 the worst pain imaginable|welcoming quality from hospital staff|anxiety score|perception of the technical quality of the emergency treatment","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"840","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP200464","April 13, 2020","June 20, 2020","June 20, 2020","April 21, 2020",,"April 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04354272"
1448,"NCT04375137","Correlation Between Oxidative Stress Status and COVID-19 Severity",,"Recruiting","No Results Available","Oxidative Stress","Diagnostic Test: Oxidative Stress ELISA Kit","MDA concentration|Biopterin concentration|Neopterin rate of increase","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","SBMU.12543","April 20, 2020","June 20, 2020","July 1, 2020","May 5, 2020",,"May 6, 2020","Nooshin Dalili, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04375137"
1449,"NCT04371523","Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers","PROVIDE","Not yet recruiting","No Results Available","Corona Virus Infection","Drug: Apo-Hydroxychloroquine|Drug: Matched Placebo","Positive for SARS-CoV-2|Hospital admissions|Intensive care unit admissions|Intubation and mechanical ventilation|ICU length of stay|Hospital length of stay|Mortality|Incidence of adverse events","St. Joseph's Healthcare Hamilton","All","18 Years and older   (Adult, Older Adult)","Phase 3","1100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","3190","May 1, 2020","July 31, 2020","August 30, 2020","May 1, 2020",,"May 1, 2020","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04371523"
1450,"NCT04373148","Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19",,"Recruiting","No Results Available","Coronavirus","Other: There is no intervention","Testing Immunity to SARS-CoV-2 over time","Stanford University|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)",,"1000","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB-55689|2U19AI057229","April 8, 2020","April 30, 2022","April 30, 2022","May 4, 2020",,"May 4, 2020","Stanford University, Hospital, and Clinics, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04373148"
1451,"NCT04355637","Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia",,"Recruiting","No Results Available","Coronavirus Infection","Drug: Inhaled budesonide","Proportion of patients in both arms fulfilling the criteria for treatment failure|ICU admission|ICU refusal|Occurrence of complications|lactate dehydrogenase (LDH)|C Reactive Protein (CRP)|ferritin|D-dimer|leukocyte counts","Sara Varea|Fundacion Clinic per a la Recerca Biomédica","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 4","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TACTIC-COVID|2020-001616-18","April 21, 2020","August 31, 2020","October 18, 2020","April 21, 2020",,"May 6, 2020","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Sabadell-Parc Tauli, Sabadell, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic of Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04355637"
1452,"NCT04351542","Ayurveda for Flu Like Illness During Covid-19 Outbreak",,"Completed","No Results Available","Flu Like Illness","Dietary Supplement: Ayurveda|Other: Usual Care","Time to achieve afebrile|Severity of symptom score|Patient reported improvement","Aarogyam UK","All","18 Years to 60 Years   (Adult)","Not Applicable","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care","AU09","March 6, 2020","April 6, 2020","April 12, 2020","April 17, 2020",,"April 17, 2020","Aarogyam, Leicester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04351542"
1453,"NCT04337489","Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)","REMOTE-COVID","Not yet recruiting","No Results Available","Coronavirus","Device: SensiumVitals wearable sensor","Deterioration resulting in healthcare review|Hospitalisation|Participant anxiety|Participant depression","Imperial College London|CW+ Charity","All","18 Years to 95 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REMOTE-COVID","April 1, 2020","April 1, 2021","April 1, 2021","April 7, 2020",,"April 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04337489"
1454,"NCT04385914","Demographics and Outcomes of COVID 19 in Pregnancy at a Community Based Hospital",,"Not yet recruiting","No Results Available","Corona Virus Infection","Other: COVID positive via testing","Pregnancy Outcome","Atlantic Health System","Female","18 Years to 50 Years   (Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1595116-1","May 2020","September 2020","December 2020","May 13, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04385914"
1455,"NCT04296643","Medical Masks vs N95 Respirators for COVID-19",,"Not yet recruiting","No Results Available","Coronavirus|N95|Medical Mask","Device: Medical Mask|Device: N95 respirator","RT-PCR confirmed COVID-19 infection|Acute respiratory illness|Absenteeism|Lower respiratory infection|Pneumonia|ICU admission|Mechanical ventilation|Death","McMaster University|Vancouver Coastal Health|University of Alberta|Dalhousie University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","576","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","20006014","April 1, 2020","December 1, 2020","January 1, 2021","March 5, 2020",,"March 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04296643"
1456,"NCT04343898","Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19","STOP-COVID","Recruiting","No Results Available","Coronavirus Infection","Other: No intervention","28-Day Mortality|60-Day Mortality|90-Day Mortality|1-Year Mortality","Brigham and Women's Hospital|Icahn School of Medicine at Mount Sinai|Montefiore Medical Center|Baylor College of Medicine|Baylor Health Care System|Beth Israel Deaconess Medical Center|University of Colorado, Denver|Cook County Hospital|The Cooper Health System|Duke University|Georgetown University|Hackensack mountainside hospital|Hackensack Meridian Health|Indiana University Health Methodist Hospital|Johns Hopkins University|Loma Linda University|Mayo Clinic|Medical College of Wisconsin|Northwestern|Weill Medical College of Cornell University|NYU Langone Health|Ochsner Health System|Oregon Health and Science University|Renown Health|Rush University Medical Center|New Jersey Medical School|Rutgers Robert Wood Johnson Medical School|Stanford University|Temple University|Tufts Medical Center|Tulane University|University of California, Davis|University of California, Los Angeles|University of California, San Diego|University of California, San Francisco|University of North Carolina, Chapel Hill|University Hospitals Cleveland Medical Center|University Medical Center of Southern Nevada|University of Alabama at Birmingham|University of Chicago|University of Florida|University of Illinois at Chicago|University of Kentucky|University of Miami|University of Michigan|University of Oklahoma|University of Pennsylvania|University of Pittsburgh Medical Center|University of Tennessee Health Science Center|University of Washington|University of Texas, Southwestern Medical Center at Dallas|Yale University","All","18 Years and older   (Adult, Older Adult)",,"4000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2007P000003","April 1, 2020","June 15, 2020","June 1, 2022","April 13, 2020",,"May 7, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04343898"
1457,"NCT04319016","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy","COVID-preg","Recruiting","No Results Available","Infection Viral","Other: pregnant women with laboratory-confirmed 2019-n-CoV","Maternal and perinatal outcomes","Federico II University","Female","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Other","145/20","January 1, 2020","April 30, 2020","May 1, 2020","March 24, 2020",,"April 28, 2020","Gabriele Saccone, Napoli, Italy",,"https://ClinicalTrials.gov/show/NCT04319016"
1458,"NCT04333654","Hydroxychloroquine in Outpatient Adults With COVID-19",,"Recruiting","No Results Available","Coronavirus Infection","Drug: Hydroxychloroquine SAR321068|Drug: Placebo","Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)|Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)|Change from baseline to Day 5 in nasopharyngeal SARS-CoV-2 viral load|Number of participants by PCR result status (positive or negative)|Number of participants with COVID-19 symptoms by severity|Time to resolution of COVID-19 Symptoms|Time to resolution of fever|Percentage of participants with resolution of fever|Percentage of participants hospitalized|Number of participants with Adverse Events","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16855|2020-001269-35|U1111-1249-6168","April 12, 2020","August 2020","August 2020","April 3, 2020",,"May 18, 2020","Investigational Site Number 8400001, Boston, Massachusetts, United States|Investigational Site Number 0561001, Bruxelles, Belgium|Investigational Site Number 0561002, Lodelinsart, Belgium|Investigational Site Number 2501001, Bordeaux Cedex, France|Investigational Site Number 2501002, Paris, France|Investigational Site Number 5281001, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04333654"
1459,"NCT04302688","Accurate Classification System for Patients With COVID-19 Pneumonitis",,"Completed","No Results Available","Pneumonitis",,"survival status","Renmin Hospital of Wuhan University","All","Child, Adult, Older Adult",,"669","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","COVID-19 WU1","December 10, 2019","February 10, 2020","March 4, 2020","March 10, 2020",,"March 10, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04302688"
1460,"NCT04373798","C-reactive Protein Levels Among Individuals With COVID-19",,"Not yet recruiting","No Results Available","Coronavirus Infection","Diagnostic Test: C-reactive protein","Hospitalisation|Death|Transfer to Intensive Care Unit|Oxygen treatment during hospitalisation","Henning Bliddal|Frederiksberg University Hospital","All","18 Years and older   (Adult, Older Adult)",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APPI2-CV-2020-02","May 4, 2020","November 30, 2020","November 30, 2020","May 4, 2020",,"May 4, 2020","The Parker Institute, Frederiksberg Hospital, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04373798"
1461,"NCT04357314","Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study","MODIF","Not yet recruiting","No Results Available","Myocardial Infarction",,"Rates of patients presenting with acute myocardial infarction|Patient profile during admission for acute myocardial infarction|Medical care times analysis|Proportion of patients who underwent systemic thrombolysis|Proportion of patients infected with COVID-19|Clinical evolution of patients","French Cardiology Society|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-03","May 31, 2020","July 31, 2020","July 31, 2020","April 22, 2020",,"May 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04357314"
1462,"NCT04395742","1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study","TMX COVID","Not yet recruiting","No Results Available","Coronavirus Disease 2019","Other: Data collection","Comparison of vital status|Comparaison of duration of hospital stay|Comparaison of severity|Comparaison of secondary effects (adverse events that needed disruption of treatment (anemia, tachycardia, osteoporosis) : secondary effects of coffee).|Comparaison of use of antibiotics","Poitiers University Hospital","All","18 Years to 100 Years   (Adult, Older Adult)",,"93","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","TMX COVID","May 2020","December 2020","December 2020","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04395742"
1463,"NCT04394195","sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?","COVIDsFlt1","Recruiting","No Results Available","CORONAVIRUS INFECTIONS","Other: measurement of circulating sFlt1 concentration","Association between concentration of circulating sFlt1 and use of vasopressor","CHU de Reims","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PO20043*","March 25, 2020","July 1, 2020","September 1, 2020","May 19, 2020",,"May 19, 2020","Chu Reims, Reims, France",,"https://ClinicalTrials.gov/show/NCT04394195"
1464,"NCT04333849","Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19","TOVID-49","Recruiting","No Results Available","Coronavirus",,"Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).|proportion of elderly people with loss of functional independence to communicate with their relatives.|level of satisfaction of patients who have benefited from a telephone call.|level of satisfaction of patients who have benefited from a videophone call.|satisfaction level of older people according to the means of communication used.|impact of age on the preferred means of communication.","University Hospital, Angers","All","70 Years and older   (Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020/29","March 27, 2020","September 2020","September 2020","April 3, 2020",,"April 8, 2020","Angers University Hospital, Angers, France",,"https://ClinicalTrials.gov/show/NCT04333849"
1465,"NCT04366947","Intravascular Access in Suspected/Confirmed COVID-19 Patient",,"Active, not recruiting","No Results Available","Emergency Medicine|Cardiopulmonary Arrest|Shock","Device: NIO® (Intraosseous access)|Device: Standard of Care (Intravenous access)","Success rate of first intravascular access attempt|time to successful access|number of attempts to successful access|time to infusion|complication rates|ROSC","Lazarski University|Poznan University of Medical Sciences|Medical University of Bialystok|Wroclaw Medical University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IO_PPE_1","April 14, 2020","May 20, 2020","May 20, 2020","April 29, 2020",,"April 29, 2020","Lazarsku University, Warsaw, Masovian, Poland",,"https://ClinicalTrials.gov/show/NCT04366947"
1466,"NCT04279899","The Investigation of the Neonates With or With Risk of COVID-19",,"Recruiting","No Results Available","Neonatal Infection|Perinatal Problems|Infectious Disease",,"The death of newborns with COVID-19|The SARS-CoV-2 infection of neonates born to mothers with COVID-19|The Chinese standardized Denver Developmental Screening Test (DDST) in neonates with or with risk of COVID-19|The small for gestational age newborns in the neonates born to mothers with COVID-19|The preterm delivery of neonates born to mothers with COVID-19|The disease severity of neonates with COVID-19","Children's Hospital of Fudan University","All","up to 28 Days   (Child)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CHFudanU_NNICU14","February 1, 2020","November 30, 2020","December 31, 2020","February 21, 2020",,"February 21, 2020","Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China|Children Hospital of Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04279899"
1467,"NCT04377100","Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses",,"Not yet recruiting","No Results Available","Anxiety|Healthy Volunteers","Behavioral: Computer task questionnaires","Patterns of neural connectivity as predictors","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","999920112|20-M-N112","May 28, 2020","February 28, 2021","February 28, 2021","May 6, 2020",,"May 25, 2020","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04377100"
1468,"NCT04290871","Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.","NOSARSCOVID","Withdrawn","No Results Available","Coronavirus|SARS (Severe Acute Respiratory Syndrome)","Drug: Nitric Oxide Gas","SARS-free patients at 14 days|Survival at 28 days|Survival at 90 days|SARS-free days at 28 days|SARS -free days at 90 days|Renal Replacement Therapy|Liver Failure|Mechanical Support of Circulation|PaO2/FiO2 ratio in ambient air","Xijing Hospital|Massachusetts General Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","NO-SARS-COVID-19","March 23, 2020","March 1, 2021","March 1, 2022","March 2, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04290871"
1469,"NCT04092478","'' The Abdominal Crunch Position for COVID-19 Patients ''",,"Completed","No Results Available","Anesthesia, Spinal","Other: Spinal Anesthesia Position","Inter spinal distance","Konya Training and Research Hospital","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","YTire","October 23, 2019","January 8, 2020","January 31, 2020","September 17, 2019",,"April 21, 2020","Yasin Tire, Konya, Meram, Turkey",,"https://ClinicalTrials.gov/show/NCT04092478"
1470,"NCT04365348","The Psychological Impact of COVID-19 Outbreak on COVID-19 Survivors and Their Families",,"Recruiting","No Results Available","Mental Health Wellness 1",,"Stress level|Negative emotion|Psychological response to trauma|Severity of insomnia symptoms and the associated daytime impairment|Resilience|Quality of family functioning|Social support|Psychological effects","The University of Hong Kong|Queen Mary Hospital, Hong Kong","All","18 Years to 100 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UW20-300","April 27, 2020","March 31, 2021","June 30, 2021","April 28, 2020",,"May 19, 2020","Agnes, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04365348"
1471,"NCT04337151","Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment",,"Recruiting","No Results Available","MAGEC Rod","Device: MAGEC Spine Rod|Diagnostic Test: Titanium blood test","Titanium level","Royal National Orthopaedic Hospital NHS Trust","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","RNOH MAGEC","April 2020","January 2021","March 2021","April 7, 2020",,"April 7, 2020","Royal National Orthopaedic Hospital, Stanmore, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04337151"
1472,"NCT04341493","Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19",,"Recruiting","No Results Available","Coronavirus Infection","Drug: Nitazoxanide 500 MG|Drug: Hydroxychloroquine","Mechanical ventilation requirement","Hugo Mendieta Zeron|Materno-Perinatal Hospital of the State of Mexico","All","5 Years and older   (Child, Adult, Older Adult)","Phase 4","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2020-03-681","April 6, 2020","August 30, 2020","December 30, 2020","April 10, 2020",,"April 24, 2020","Materno-Perinatal Hospital ""Mónica Pretelini"", Toluca, Mexico",,"https://ClinicalTrials.gov/show/NCT04341493"
1473,"NCT04315480","Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis",,"Active, not recruiting","No Results Available","SARS Pneumonia","Drug: Tocilizumab","arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death","Università Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","38","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOCICOV-1","March 12, 2020","April 9, 2020","May 2020","March 19, 2020",,"April 13, 2020","Università Politecnica delle Marche, Ancona, AN, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04315480"
1474,"NCT04328454","Clinical Characteristics and Prognostic Factors of Patients With COVID-19",,"Recruiting","No Results Available","Coronavirus","Other: retrospective analysis","Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation","Shanghai 10th People's Hospital|Chibi People's Hospital, Hubei Province","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HBCBH-IEC-2020-101","January 30, 2020","April 2, 2020","April 15, 2020","March 31, 2020",,"March 31, 2020","Shanghai 10th People's Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04328454"
1475,"NCT04362059","A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19","COVSurf","Not yet recruiting","No Results Available","Respiratory Infections","Device: COVSurf Drug Delivery System|Other: Standard of Care","Oxygenation Improvement|Pulmonary ventilation Improvement|Safety Assessment of Frequency and Severity of Adverse Events","University Hospital Southampton NHS Foundation Trust|Bill and Melinda Gates Foundation|University College, London","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RHM CRI0399","April 27, 2020","July 27, 2020","November 2, 2020","April 24, 2020",,"April 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04362059"
1476,"NCT04342208","Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak",,"Not yet recruiting","No Results Available","Musculoskeletal Pain",,"The Rapid Office Strain Assessment (ROSA)|The Standardised Nordic Questionnaries (NMQ)","Istanbul University-Cerrahpasa","All","18 Years to 65 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","GPA1347","April 10, 2020","June 1, 2020","July 1, 2020","April 10, 2020",,"April 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04342208"
1477,"NCT04374942","Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?","HEROs","Enrolling by invitation","No Results Available","Pre-Exposure Prophylaxis|Coronavirus|SARS-CoV 2","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Microbiologically confirmed COVID-19 (SARS-CoV-2 infection)|Adverse events|Symptom duration of COVID-19|Days of hospitalization attributable to COVID-19|Respiratory failure requiring ventilatory support attributable to COVID-19|Mortality|Impact on work eligibility|Seropositivity|Short-term psychological impact","Megan Landes|University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Phase 3","988","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HEROs Protocol 1.5|ISRCTN14326006","April 30, 2020","August 27, 2020","January 30, 2022","May 5, 2020",,"May 8, 2020","University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04374942"
1478,"NCT04322786","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?",,"Active, not recruiting","No Results Available","Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom","Drug: ACE inhibitor","Incidence of influenza","University College, London","All","18 Years and older   (Adult, Older Adult)",,"1302508","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ISAC17_205R","January 1, 1998","May 31, 2016","March 31, 2020","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04322786"
1479,"NCT04399798","Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial","BREATH","Not yet recruiting","No Results Available","Corona Virus Infection","Drug: Baricitinib","Response to treatment: absence of moderate to severe oxygenation impairment (Berlin criteria)|Response to treatment: survival|To quantify the rate of each of: moderate or severe oxygenation impairment within 8 days|To quantify the rate of each of: moderate or severe oxygenation impairment within 15 days|Mortality|Peripheral capillary oxygen saturation (SpO2)|Partial pressure of oxygen/fraction inspired oxygen (PaO2/FiO2)|To assess the rate of patients admitted to the intensive care unit|To measure the length of hospital stay|28-day mortality|To quantify the rate of re-admission within 28 days|To quantify the cumulative incidence and severity of adverse events|Interleukin (IL)-1; IL-2; IL-10; IL-6; IL-8; IL-17; IL-2 receptor levels;|TNFalpha; vascular endothelial growth factor (VEGF); interferon gamma (IFNgamma) levels|Viral load analyses","IRCCS Policlinico S. Matteo","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 2","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001185-11","May 15, 2020","September 15, 2020","November 15, 2020","May 25, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04399798"
1480,"NCT04344106","Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study","ProCov","Recruiting","No Results Available","Coronavirus Infection|Oxygen Deficiency","Procedure: Prone positioning","Proportion of ""responder"" patients to prone position|proportion of ""persistent responders"" patients after prone position|Evolution of PaO2|Duration of prone positioning and PaO2 evolution|Evolution of Spo2|EVA Dyspnea|Intolerance to prone positioning|Tolerance to prone positioning","ELHARRAR Xavier|Centre Hospitalier Intercommunal Aix-Pertuis","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20202703-2","April 1, 2020","April 15, 2020","May 1, 2020","April 14, 2020",,"April 14, 2020","CHI Aix-Pertuis, Aix-en-Provence, France",,"https://ClinicalTrials.gov/show/NCT04344106"
1481,"NCT04360850","Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic",,"Recruiting","No Results Available","Online Therapy","Behavioral: online survey","responses to the survey questions","University of Washington","All","18 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","STUDY00010090","April 24, 2020","October 2025","October 2025","April 24, 2020",,"April 28, 2020","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04360850"
1482,"NCT04363606","Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability","FatCovid-19","Not yet recruiting","No Results Available","Chronic Fatigue Syndrome|Intensive Care Unit|Muscle","Other: Questionnaires|Biological: blood test|Other: Maximal effort test|Device: actigraphy|Device: Neuromuscular evaluation","voluntary maximum force reduction|Neuromuscular function : cortical activity|Neuromuscular function : Peripheral function|Maximal oxygen uptake (VO2max)|quality of sleep|muscle volume|metabolic fatigue","Centre Hospitalier Universitaire de Saint Etienne|University of Saint-Etienne","All","40 Years to 75 Years   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20CH085|2020-A00982-37","April 2020","April 2021","December 2021","April 27, 2020",,"April 27, 2020","Chu Saint-Etienne, Saint Etienne, France|Clinique Mutualiste Saint Etienne, Saint Etienne, France|Hôpital privé de la Loire, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT04363606"
1483,"NCT04363437","COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19","COMBATCOVID19","Recruiting","No Results Available","Coronavirus Infection","Drug: Colchicine|Drug: Usual Care","Percentage of Patients requiring supplemental oxygen beyond 8L nasal cannula|Percentage of patients who will require mechanical ventillation|Hospital length of stay|Mortality|Maximum CRP|Maximum troponin elevation","Maimonides Medical Center","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-04-12","April 26, 2020","May 31, 2020","June 14, 2020","April 27, 2020",,"May 8, 2020","Maimonides Medical Center, Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT04363437"
1484,"NCT04327804","A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research",,"Recruiting","No Results Available","SARS-CoV Infection","Diagnostic Test: Odd/Even birth year intervention groups","Detection of SARS-CoV-2 virus|Trajectory of COVID-19 and antibody development","Dr. Deneen Vojta|PATH|Mayo Clinic|Bill and Melinda Gates Foundation|UnitedHealth Group","All","Child, Adult, Older Adult",,"120","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20-002","March 25, 2020","April 3, 2020","April 10, 2020","March 31, 2020",,"April 14, 2020","Everett Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04327804"
1485,"NCT04345640","The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.",,"Recruiting","No Results Available","Liver Cirrhoses","Other: no intervention","Spontaneous recovery or death in both groups|Severity of prior as well as present decompensation in both groups|Duration of prior as well as present decompensation in both groups|Improvement in severity assessment Indices Model for End Stage Liver Disease (MELD) scores in both groups|Improvement in severity assessment Indices Child-Turcotte-Pugh (CTP) scores in both groups|Improvement in severity assessment Indices Sequential Organ Failure Assessment (SOFA) scores in both groups|Improvement in severity assessment Indices Acute Physiology And Chronic Health Evaluation (APACHE) scores II in both groups|Improvement in severity assessment Indices Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF SOFA) scores in both groups.","Institute of Liver and Biliary Sciences, India","All","18 Years to 70 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ILBS-COVID-01","April 14, 2020","June 30, 2020","June 30, 2020","April 14, 2020",,"April 15, 2020","Institute of Liver and Biliary Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04345640"
1486,"NCT04372576","Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients",,"Recruiting","No Results Available","Ventilator Associated Pneumonia|Corona Virus Infection","Diagnostic Test: Assessment of ventilator-associated pneumonia criteria","28-day all-cause mortality|Days of mechanical ventilation|ICU length-of-stay|Antibiotic utilization|Ventilator-associated pneumonia rate","Semmelweis University","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","57/2020.","April 16, 2020","August 2020","August 2020","May 4, 2020",,"May 4, 2020","Semmelweis University, Budapest, Hungary",,"https://ClinicalTrials.gov/show/NCT04372576"
1487,"NCT04372043","Evaluation of the Sleep Hygiene in the Lebanese Population During the COVID-19 Confinement Period.",,"Not yet recruiting","No Results Available","Sleep Hygiene","Other: Questionnaire","Sleep Hygiene","Saint-Joseph University","All","18 Years to 100 Years   (Adult, Older Adult)",,"1200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEHDF1650","April 30, 2020","September 30, 2020","September 30, 2020","May 1, 2020",,"May 1, 2020","Saint Joseph University, Beirut, Lebanon",,"https://ClinicalTrials.gov/show/NCT04372043"
1488,"NCT04325906","Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS",,"Recruiting","No Results Available","Prone Positioning|High Flow Nasal Cannula|Acute Respiratory Distress Syndrome|Corona Virus Infection","Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP)","Treatment failure|Intubation rate|Efficacy of PP","Rush University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","346","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19-HFNC+PP","April 2, 2020","May 31, 2020","June 30, 2020","March 30, 2020",,"April 22, 2020","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04325906"
1489,"NCT04344964","Endoscopy-related Phone Consultation During the COVID-19 Outbreak",,"Not yet recruiting","No Results Available","Colon Polyp|Colon Disease|Reflux, Gastroesophageal|Varices, Esophageal","Other: None - NA","Failed to attend patients|Patient satisfaction with the phone consult|Consultant satisfaction with the phone consult","Austin Health","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","38839","April 15, 2020","June 15, 2020","June 15, 2020","April 14, 2020",,"April 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04344964"
1490,"NCT04345549","Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak",,"Completed","No Results Available","Flu Like Symptom|Flu Like Illness","Other: Individualised Ayurveda","Time to achieve afebrile|Severity of influenza symptom score","Aarogyam UK","All","18 Years to 60 Years   (Adult)","Not Applicable","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","AU08","February 26, 2020","March 30, 2020","March 30, 2020","April 14, 2020",,"April 14, 2020","Aarogyam, Leicester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04345549"
1491,"NCT04391166","Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic",,"Not yet recruiting","No Results Available","Visual Impairment","Other: Non invasive visual acuity testing","Best Corrected Visual Acuity (BCVA) Per Eye","Vanderbilt University Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","200826","May 15, 2020","May 1, 2022","May 1, 2022","May 18, 2020",,"May 19, 2020","Vanderbilt Eye Institute, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04391166"
1492,"NCT04384965","Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic",,"Recruiting","No Results Available","Major Depressive Disorder","Device: MagPro X100 Stimulator, B70 Fluid-Cooled Coil","Proportion achieving remission on Hamilton Rating Scale for Depresion 24-it (HRSD-24)|Change in HRSD-24|Response on HRSD-24|Remission on Patient Health Questionnaire (PHQ-9)|Response on PHQ-9|Change in PHQ-9|Remission on General Anxiety Disorder 7 item (GAD-7)|Response on GAD-7|Change in GAD-7|Remission on Beck Depression Inventory (BDI-II)|Response on BDI-II|Change on BDI-II|Remission on Beck Scale for Suicidal Ideation (SSI)|Change on SSI|Change in WHO Disability Assessment Schedule (WHODAS)|Proportion of Patients Maintaining Response During Relapse Prevention","Centre for Addiction and Mental Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","059/2020","May 1, 2020","May 1, 2022","November 1, 2022","May 12, 2020",,"May 12, 2020","CAMH, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04384965"
1493,"NCT04379232","Surgical Activity During the Covid-19 Pandemic: Results for 112 Patients in a French Tertiary Care Center","SurgiCovid","Completed","No Results Available","Digestive Cancer|Gynaecological Cancer|Head and Neck Cancer","Biological: Screening test for covid ( RT PCR and CT Chest)","Symptoms of Covid after surgery","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)",,"112","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CRC_GHN_2020_001","March 19, 2020","April 20, 2020","April 25, 2020","May 7, 2020",,"May 7, 2020","Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France",,"https://ClinicalTrials.gov/show/NCT04379232"
1494,"NCT04376658","Quality of Life and Patient-centered Outcomes After Hospitalization for COVID-19",,"Not yet recruiting","No Results Available","Quality of Life|Long-term Outcomes|Coronavirus Infection","Other: COVID-19","One-year utility score of health-related quality of life|Incidence of all-cause mortality|Incidence of rehospitalizations|Percentage of return to work or study|Score of Instrumental Activities of Daily Living|Percentage of long-term ventilatory support need|Symptoms of anxiety and depression|Symptoms of posttraumatic stress disorder|Utility score of health-related quality of life at 3, 6, and 9 months|Score self-rated health","Hospital Moinhos de Vento|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital do Coracao|Hospital Alemão Oswaldo Cruz|Beneficência Portuguesa de São Paulo|Brazilian Clinical Research Institute|Brazilian Research In Intensive Care Network","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Coalition COVID-19: Long-term","June 15, 2020","September 15, 2021","September 15, 2021","May 6, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04376658"
1495,"NCT04325893","Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease","HYCOVID","Recruiting","No Results Available","Coronavirus","Drug: Hydroxychloroquine|Drug: Placebo","Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|Number of all-cause mortality at day 14|Number of all-cause mortality at day 28|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|Number of all-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|Number of all-cause mortality at day 14 in patients aged 75 and older","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)","Phase 3","1300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","49RC20_0071","April 1, 2020","September 2020","September 2020","March 30, 2020",,"May 19, 2020","CH Agen, Agen, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|CH Auxerre, Auxerre, France|APHP Avicenne, Bobigny, France|CHU Brest, Brest, France|CHU Caen, Caen, France|CH Chalon Sur Saône, Chalon Sur Saône, France|CH Cherbroug, Cherbourg, France|CH Cholet, Cholet, France|CH Colmar, Colmar, France|CH Compiègne, Compiègne, France|APHP Henri Mondor, Créteil, France|CH Intercommunal Créteil, Créteil, France|CHU Dijon, Dijon, France|APHP Joffre Dupuytren, Draveil, France|CHD Vendée, La Roche-sur-Yon, France|CH Laval, Laval, France|CH Le Mans, Le Mans, France|CH Emile Roux, Le Puy-en-Velay, France|APHP Emile ROUX, Limeil-Brevannes, France|CHU Limoges, Limoges, France|CH Lorient, Lorient, France|Hôpital Européen - Marseille, Marseille, France|Hôpital Saint-Joseph, Marseille, France|CH Melun, Melun, France|CHU Nantes, Nantes, France|Hôpital Privé du Confluent, Nantes, France|CH Niort, Niort, France|CHR Orléans, Orléans, France|APHP Saint-Antoine, Paris, France|GH Croix Saint Simon, Paris, France|La Pitié-Salpétrière, Paris, France|CHU Poitiers, Poitiers, France|CH Pointoise, Pontoise, France|CH Quimper, Quimper, France|CH Saint-Brieuc, Saint-Brieuc, France|CH Saint-Nazaire, Saint-Nazaire, France|CHU Saint-Etienne, Saint-Étienne, France|CHU Toulouse, Toulouse, France|CH Tourcoing, Tourcoing, France|CHU Tours, Tours, France|CH Valenciennes, Valenciennes, France|Clinique Tessier Valenciennes, Valenciennes, France|CH Vannes, Vannes, France|CH Versailles, Versailles, France|CH Princesse Grace, Monaco, Monaco",,"https://ClinicalTrials.gov/show/NCT04325893"
1496,"NCT04373213","Evaluation of the Fluid Response of SARS-CoV-2 (COVID-19) Patients in Intensive Care; Pleth Variability Index",,"Not yet recruiting","No Results Available","Pleth Variability Index","Diagnostic Test: Pleth variability index","Pleth variability index","Erzincan University","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","EBYU COVİD PVI","May 5, 2020","June 5, 2020","June 15, 2020","May 4, 2020",,"May 4, 2020","Erzincan University, Erzincan, Turkey",,"https://ClinicalTrials.gov/show/NCT04373213"
1497,"NCT04379518","Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients",,"Not yet recruiting","No Results Available","Malignant Neoplasm|SARS Coronavirus 2 Infection","Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod","Incidence of adverse events (AEs)|Reduction of progression of infection requiring hospitalization|Reduction of acute respiratory distress syndrome (ARDS)|30-day mortality|Kinetics of viral load in the peripheral blood and nasal swabs|Kinetics of changes of the immune subsets and circulating inflammatory mediators in peripheral blood","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","80","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","I 659920|NCI-2020-02317|P30CA016056","May 30, 2020","April 6, 2021","April 30, 2021","May 7, 2020",,"May 7, 2020","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT04379518"
1498,"NCT04341714","Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic",,"Recruiting","No Results Available","Efficacy, Self|Satisfaction, Patient|Telemedicine","Other: Satisfaction evaluation","Efficiency of the telephone consultation|Satisfaction of the telephone consultation","Pierre and Marie Curie University","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GREEN GRC01","March 16, 2020","May 30, 2020","June 15, 2020","April 10, 2020",,"April 10, 2020","Department of Neuro- Urology, Hôpital Tenon, Paris, France",,"https://ClinicalTrials.gov/show/NCT04341714"
1499,"NCT04326725","Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia",,"Recruiting","No Results Available","Pneumonitis|Coronavirus Infection","Drug: Plaquenil 200Mg Tablet","Protection against COVID-19","Istinye University","All","20 Years to 90 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2020-2/1","March 20, 2020","July 1, 2020","September 1, 2020","March 30, 2020",,"April 10, 2020","Istinye University Medical School, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04326725"
1500,"NCT04321369","Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals",,"Completed","No Results Available","Infections, Respiratory|Fever|Cough","Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals","Accuracy of patient administered tests","Dr. Deneen Vojta|Quest Diagnostics|Bill and Melinda Gates Foundation|UnitedHealth Group","All","Child, Adult, Older Adult",,"533","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","20-001","March 9, 2020","March 23, 2020","March 23, 2020","March 25, 2020",,"April 13, 2020","Everett Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04321369"
1501,"NCT04374539","Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial","REP-COVID","Recruiting","No Results Available","Coronavirus","Biological: Plasma exchange|Drug: Standar medical treatmen","Impact of plasma exchange","Fundacion Clinic per a la Recerca Biomédica","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001722-66","April 29, 2020","May 5, 2021","August 29, 2021","May 5, 2020",,"May 5, 2020","Hospital Clinic i Provincial de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04374539"
1502,"NCT04369456","Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients","PredictCovidT","Recruiting","No Results Available","Kidney Transplant; Complications|Coronavirus Infection","Other: blood sample","Predictive value of IL-6 contents of whole blood samples after ex vivo stimulation","Centre Hospitalier Universitaire de Nice","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","115","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20-PP-09","April 22, 2020","October 22, 2020","October 22, 2020","April 30, 2020",,"May 1, 2020","Lyon Univerity Hospital, Lyon, France|APHM, Marseille, France|Montpellier University Hospital, Montpellier, France|University Nice Hospital, Nice, France|APHP, Paris, France|Saint Etienne University Hospital, Saint-Étienne, France|Strasbourg Univeristy Hospital, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04369456"
1503,"NCT04251871","Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection",,"Recruiting","No Results Available","Pneumonia Caused by Human Coronavirus (Disorder)","Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)","The incidents of acute respiratory distress syndrome (ARDS) development|The time to fever resolution rate|Time to recovery of lung injury","Beijing 302 Hospital","All","14 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020001D","January 22, 2020","January 22, 2021","January 22, 2021","February 5, 2020",,"May 5, 2020","The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04251871"
1504,"NCT04292340","Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19",,"Recruiting","No Results Available","Coronavirus",,"The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|Numbers of participants with different Clinical outcomes|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0","Shanghai Public Health Clinical Center","All","Child, Adult, Older Adult",,"15","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Anti-SARS-CoV-2","February 1, 2020","July 31, 2020","December 31, 2020","March 3, 2020",,"March 3, 2020","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04292340"
1505,"NCT04380909","ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation","ROCO","Recruiting","No Results Available","Psychological Distress|Adjustment, Psychological|Coronavirus","Behavioral: Internet-based self-help|Behavioral: Internet-based self-help after 3 weeks","Patient Health Questionnaire (Löwe et al., 2002)|Suicide Behavior Questionnaire Revised (Glaesmer et al., 2018)|DASS-21: Depression, Angst, Stress-Skala (Lovibond & Lovibond, 1995)|SF-12: Short Form Health Survey (Ware et al., 1996)|LOT-R: Revised Life Orientation Test (Herzberg et al., 2006)|Berner Verbitterungsinventar Kurzversion (Znoj, 2008)|Emotion regulation skills SEK-27 (Berking & Znoj, 2008)|SWE: Skala zur Allgemeinen Selbstwirksamkeit (Jerusalem & Schwarzer, 2003)|UCLA Loneliness Scale (Döring & Bortz, 1993)|Connor-Davidson Resilience Scale (Sarubin et al., 2015)|ZUF-8: Zufriedenheitsfragebogen (Attkisson & Zwick, 1982)|SUS: System Usability Scale (Brooke, 1996)","University of Bern","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-00990","May 6, 2020","April 2021","April 2021","May 8, 2020",,"May 8, 2020","Universität Bern, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04380909"
1506,"NCT04346082","Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak",,"Not yet recruiting","No Results Available","Stress","Behavioral: online mindfulness group","rate of recruitment|rate of attendence|Depression, Anxiety and Stress Scale (DASS-21)|Sense of Coherence Scale","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","online-mind","May 1, 2020","April 30, 2021","April 30, 2021","April 15, 2020",,"May 6, 2020","School of public health and primary care, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04346082"
1507,"NCT04326114","Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19",,"Not yet recruiting","No Results Available","Disease, Infectious|Respiratory Disease|Safety Issues|Effectiveness","Device: Inspiratory training device|Device: Expiratory training device","COVID-19 disease diagnosis|COVID-19 disease symptoms severity|Adverse effects","Universidad Complutense de Madrid","All","18 Years and older   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Covid_ISCIII 20/265-E_BS","April 26, 2020","September 26, 2020","October 12, 2020","March 30, 2020",,"March 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04326114"
1508,"NCT04369378","Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic",,"Not yet recruiting","No Results Available","Anxiety|Well-being","Behavioral: Meditation app usage","Anxiety|Well-being|Future outlook & hopefulness|Sleep habits|Nutrition habits|Meditation app continued usage","Lake Erie College of Osteopathic Medicine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","27-126","May 2, 2020","September 15, 2020","October 31, 2020","April 30, 2020",,"April 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04369378"
1509,"NCT04389684","Clinical and Psycho-social Impact of COVID-19 Related Confinement on Patients With Digestive Tumors","COVIDICA","Not yet recruiting","No Results Available","Chemeotherapy|Immunotherapy|Treatment Mofidied|Coronavirus|Quality of Life","Other: Psycho-Social Questionnaire","Overall survival of patients with metastatic colorectal cancer or metastatic pancreatic cancer","Poitiers University Hospital","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A01301-38","May 15, 2020","May 15, 2021","May 15, 2021","May 15, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04389684"
1510,"NCT04388579","Screening Patients for a Strategic Shift to Pulmonary Telerehabilitation Because of COVID-19","PRAISE@COVID","Completed","No Results Available","Respiratory Disease","Other: Pulmonary Rehabilitation","Patient's self-efficacy|Respiratory exercises|Physical activity","University of Lisbon|Centro Hospitalar Lisboa Norte|Fundação para a Ciência e a Tecnologia|Nippon Gases Portugal, Unipessoal, Lda.","All","18 Years to 88 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","046i/17","March 20, 2020","March 27, 2020","March 27, 2020","May 14, 2020",,"May 14, 2020","Nippon Gases Portugal Unipessoal Lda, Maia, Porto, Portugal|Universidade de Lisboa, Faculdade de Medicina, Instituto de Saúde Ambiental (ISAMB), Lisboa, Portugal|Centro Hospitalar Universitário Lisboa Norte, Hospital Pulido Valente, Unidade de Reabilitação Respiratória, Lisboa, Portugal",,"https://ClinicalTrials.gov/show/NCT04388579"
1511,"NCT04389333","Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic",,"Recruiting","No Results Available","Gastrointestinal Disease|Infectious Disease|Capsule Endoscopy","Device: non-contact magnetically-controlled capsule endoscopy","Maneuverability score|Gastric examination time(GET)|the comfort and acceptability of patients|diagnostic yield","Changhai Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","nc-MCE pilotRCT","March 26, 2020","April 26, 2020","May 20, 2020","May 15, 2020",,"May 15, 2020","Changhai Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04389333"
1512,"NCT04371315","Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children",,"Recruiting","No Results Available","Corona Virus Infection|Pediatric Cancer|Adult Children|Cancer",,"Characteristics and outcomes of acute respiratory infections due to COVID-19 in children.|Clinical risk factors of acute respiratory infection due to COVID-19 in children.|Immunologic response to acute respiratory infection due to COVID-19 in children.|Duration of viral shedding and evolution in children longitudinally.","St. Jude Children's Research Hospital","All","up to 24 Years   (Child, Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Prospective","COVID-19","April 27, 2020","June 1, 2021","June 30, 2022","May 1, 2020",,"May 1, 2020","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04371315"
1513,"NCT04327479","Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection",,"Recruiting","No Results Available","Cardiovascular Diseases|Cardiovascular Risk Factor|SARS","Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors","All-cause mortality|30-day mortality|Major adverse cardiovascular events","University Hospital, Essen","All","18 Years and older   (Adult, Older Adult)",,"728","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-9213-BO","March 26, 2020","March 25, 2026","March 25, 2026","March 31, 2020",,"April 27, 2020","University Hospital Essen, Essen, NRW, Germany",,"https://ClinicalTrials.gov/show/NCT04327479"
1514,"NCT04367636","The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19","OCAT","Not yet recruiting","No Results Available","Rumination|Anxiety|Stress|Depressive Symptoms","Behavioral: Behavioral: OCAT-sham|Behavioral: Behavioral: OCAT|Other: psycho-education video","Changes in depression-, anxiety- and psychosomatic stress symptoms|Changes in rumination.|Changes in cognitive emotion regulation strategies.|Changes in emotional attention","University Ghent","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","EC/2019/0841","April 20, 2020","August 2020","August 2020","April 29, 2020",,"April 29, 2020","Ghent University, Gent, Oost-Vlaanderen, Belgium",,"https://ClinicalTrials.gov/show/NCT04367636"
1515,"NCT04394013","A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period",,"Not yet recruiting","No Results Available","Mental Health Issue","Behavioral: Mindfulness intervention|Behavioral: Non-Mindfulness intervention","Loneliness (UCLA-8 Loneliness Scale)|Mindfulness (FFMQ)|Quality of life (EQ-5D-5L Questionnaire)","Monash University Malaysia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","180320201","June 2020","August 2020","December 2020","May 19, 2020",,"May 19, 2020","Monash University Malaysia, Bandar Sunway, Selangor, Malaysia",,"https://ClinicalTrials.gov/show/NCT04394013"
1516,"NCT04322123","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)","Coalition-I","Active, not recruiting","No Results Available","Coronavirus Infections","Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin","Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days","Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS","All","18 Years and older   (Adult, Older Adult)","Phase 3","630","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Brazil COVID Coalition I Trial","April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",,"May 21, 2020","Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil|Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil|HHospital SAMUR, Vitória Da Conquista, BA, Brazil|Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil|Hospital de Brasília, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil|Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil|Hospital Vila da Serra, Nova Lima, MG, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil|Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil|Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São José, Criciuma, SC, Brazil|Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil|Hospital Nereu Ramos, Florianópolis, Sc, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil|Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil|Hospital Albert Einstein, São Paulo, SP, Brazil|Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil|Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil|Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil|Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil|Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil|Hospital Sírio-Libanês, São Paulo, SP, Brazil|Hospital SEPACO, São Paulo, S, Brazil",,"https://ClinicalTrials.gov/show/NCT04322123"
1517,"NCT04358627","Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients","COVID-DEX","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome|Inflammation|Dexmedetomidine|Cytokine Storm|Delirium, Emergence","Drug: Dexmedetomidine Injectable Product","Mechanical ventilation|Duration of mechanical ventilation|Delirium on recovery from sedation","Hospital Clinic of Barcelona","All","18 Years to 99 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","SPEC-M|SPEC-M COVID-19","April 15, 2020","May 30, 2020","June 30, 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04358627"
1518,"NCT04381819","Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19",,"Recruiting","No Results Available","SARS Virus|Severe Acute Respiratory Syndrome","Diagnostic Test: SARS-CoV-2 PCR","Death|Recovery from COVID-19|Progression to ICU care or ventilation|Clearance of SARS-CoV-2 from respiratory specimen|Immune response to COVID-19","Oslo University Hospital|University Hospital, Akershus|Vestre Viken Hospital Trust|Østfold Hospital Trust|Haukeland University Hospital|University Hospital of North Norway|St. Olavs Hospital","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-04072","March 2, 2020","February 28, 2022","December 31, 2023","May 11, 2020",,"May 11, 2020","Vestre Viken Drammen Hospital, Drammen, Viken, Norway|Haukeland University Hospital, Bergen, Norway|Østfold Hospital Trust, Fredrikstad, Norway|Akershus University Hospital, Lørenskog, Norway|Oslo University Hospital, Oslo, Norway|University Hospital North Norway, Tromsø, Norway|St Olavs Hospital, Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT04381819"
1519,"NCT04385823","Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure",,"Completed","No Results Available","Respiratory Syndrome, Acute, Severe|Hypoxic Respiratory Failure|Viral Pneumonia","Device: patients receiving nasal high flow","Changes in ROX index|NHF failure|NHF flow|NHF inspired fraction in oxygen|oxygenation|respiratory status|prediction of intubation|prediction of NHF success","Hôpital Louis Mourier","All","18 Years and older   (Adult, Older Adult)",,"62","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HLM_JDR9","March 1, 2020","May 4, 2020","May 4, 2020","May 13, 2020",,"May 13, 2020","Hôpital Louis Mourier, Assistance Publique - Hôpitaux de Paris, Colombes, France",,"https://ClinicalTrials.gov/show/NCT04385823"
1520,"NCT04346953","Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19)",,"Not yet recruiting","No Results Available","Healthy Lifestyle","Behavioral: Video based exercise","International Physical Activity Questionnaire - Short Form|Nottingham Health Profile|Beck Depression Inventory|Beck Anxiety Inventory|Pittsburgh Sleep Quality Index|Timed Get Up and Go Test|Flamingo Balance Test","Istinye University","All","40 Years to 60 Years   (Adult)","Not Applicable","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","002","April 20, 2020","June 1, 2020","July 31, 2020","April 15, 2020",,"April 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04346953"
1521,"NCT04324047","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients","CORIMUNO-19","Recruiting","No Results Available","Corona Virus Infection",,"Survival|WHO progression scale COVID 19","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP200375|2020-001246-18","March 27, 2020","March 27, 2021","December 31, 2021","March 27, 2020",,"April 1, 2020","Kremlin Bictre APHP, Le Kremlin-Bicêtre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|Hegp Aphp, Paris, Ile De France, France",,"https://ClinicalTrials.gov/show/NCT04324047"
1522,"NCT04392453","Upper Limb Robotic Rehabilitation During COVID-19 Outbreak",,"Not yet recruiting","No Results Available","Stroke","Device: Robotic therapy","System Usability Scale (SUS)|Technology Acceptance Model (TAM)|Likert Scale|Fugl-Meyer Assessment for upper extremity (FMA-UE)|Motricity Index for the upper extremity (MI-UE)|Modified Ashworth Scale (MAS)|Numeric Pain Rating Scale (NPRS)|Modified Barthel Index (mBI)|Montreal Cognitive Assessment (MoCA)|Kinematic parameters","Fondazione Don Carlo Gnocchi Onlus","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FDG_Icone","May 2020","December 2020","December 2020","May 18, 2020",,"May 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04392453"
1523,"NCT04384419","Death Number Perception in Depression, Anxiety, and Schizoypal Personnality in General Population (Covid-19 Pandemic)","DeathPercep","Not yet recruiting","No Results Available","Mental Disorder|General Population",,"number of perception distortions|Recall number of deaths","University Hospital, Montpellier|University of Montpellier 3 (Pr. Stéphane Raffard, PhD)|University of Reims Champagne-Ardenne (Ali Oker PhD)","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","RECHMPL20_0276","May 29, 2020","May 30, 2021","June 1, 2021","May 12, 2020",,"May 12, 2020","UH Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04384419"
1524,"NCT04315870","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.","I-COVID","Recruiting","No Results Available","Infection Viral","Other: pregnant women with laboratory-confirmed 2019-n-CoV","Maternal and perinatal outcomes","Federico II University","Female","18 Years to 50 Years   (Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Other","5/20","January 1, 2020","April 20, 2020","April 30, 2020","March 20, 2020",,"March 20, 2020","University of Naples Federico II, Napoli, Italy",,"https://ClinicalTrials.gov/show/NCT04315870"
1525,"NCT04397471","A Study to Collect Bone Marrow for Process Development and Production of BM-MSC to Treat Severe COVID19 Pneumonitis","COMET20d","Not yet recruiting","No Results Available","Healthy Volunteers for Bone Marrow Donation","Procedure: Bone Marrow Harvest","Determine feasibility of recruiting healthy volunteers in a clinically useful timeframe.|Manufacture a cell-based product suitable for clinical use|Establishment of a robust process of production|Production of stability data to be used in the MHRA dossier for the COMET clinical trial.|Production of cell-based products to be administered to COVID-19 patients with severe pneumonitis.|Analysis of cells for understanding production, manufacture and related research.","CCTU- Cancer Theme|Cambridge Cellular Therapies Laboratory|The Evelyn Trust|Cambridge University Hospitals NHS Foundation Trust","All","18 Years to 40 Years   (Adult)",,"10","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COMET20d","May 2020","December 2021","December 2021","May 21, 2020",,"May 21, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04397471"
1526,"NCT04396314","Effectiveness of Basic Body Awareness Therapy in Survivors of Covid-19 and Health Workers Regarding Post-traumatic Stress Disorders","BATEP","Not yet recruiting","No Results Available","PostTraumatic Stress Disorder","Behavioral: Basic Body Awareness Therapy|Behavioral: Psychological treatment","Change in Davidson Trauma Scale (DTS)|Change in Beck Depression Inventory (BDI)|Change in State-Trait Anxiety Inventory (STAI)|Change in Short Form 36 (SF36)|Change in Visual Analogue Scale (VAS)|Change in Pittsburgh Sleep Quality Index (PSQI)","Universitat de Lleida|Francesc Rubí Carnacea","All","18 Years and older   (Adult, Older Adult)","Not Applicable","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UL-002","September 1, 2020","December 31, 2020","April 30, 2021","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04396314"
1527,"NCT04365335","Stress Biomarkers Leading to Professional Burnout Among People Involved in a Mobile Intensive Care Unit During the COVID-19 Pandemic","AUTONOMIC","Recruiting","No Results Available","Occupational Stress","Behavioral: Assessment of work-related stress|Biological: Saliva sample collection|Other: Cardiac and electrodermal recordings|Behavioral: Assessment of behavioral response to emotional stimulation","Professional burnout|Mindfulness level|Perceived stress level following the emotional stimulation|Parasympathetic flexibility evolution during emotional recall|Sympathetic tone at rest|Corticotropic activation at rest|Mood disorders (anxiety / depression)|Post-traumatic stress disorder|Sleep quality","Direction Centrale du Service de Santé des Armées|Institut de Recherche Biomedicale des Armees","All","18 Years to 60 Years   (Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-COVID19-11","April 25, 2020","June 13, 2020","June 13, 2020","April 28, 2020",,"May 14, 2020","Elément Militaire de Réanimation (EMR), Mulhouse, France",,"https://ClinicalTrials.gov/show/NCT04365335"
1528,"NCT04351906","Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome",,"Recruiting","No Results Available","ARDS|Hypercapnic Respiratory Failure|AKI","Device: ECCO2R","Delta change in arterial partial pressure of carbon dioxide during ECCO2R treatment|Change in vasopressor use during ECCO2R|Assessment of changes in tidal volume during ECCO2R|Assessment of changes in pH during ECCO2R|Assessment of changes in Positive End-Expiratory Pressure during ECCO2R|Number of participants with adverse events directly related to ECCO2R|Rate of technical adverse events related to ECCO2R|Delta change in venous partial pressure of carbon dioxide before and after ECCO2R membrane","University of Giessen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZ 63/20","May 3, 2020","July 2020","September 2020","April 17, 2020",,"May 6, 2020","University Hospital Giessen and Marburg, Giessen, Giessen, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT04351906"
1529,"NCT04337918","Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection","NOCOVID","Recruiting","No Results Available","Corona Virus Infection","Drug: NORS (Nitric Oxide Releasing Solution)","Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19|Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19|Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19|Prevention Study: Measure the tolerability of NORS treatments|Treatment Sub Study: Measure the virucidal effect of NORS Treatments|Treatment Sub Study: Determine effect of NORS on the speed of clinical recovery|Treatment Sub Study: Determine the reduction in clinical symptoms|Treatment & Sub Study: Determine positive sero-conversion for SARS-CoV-2","Sanotize Research and Development corp.|The Emmes Company, LLC","All","19 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","COVID-CTP-01","May 8, 2020","July 31, 2020","September 30, 2020","April 8, 2020",,"May 12, 2020","BC Diabetes, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT04337918"
1530,"NCT04326036","Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection","GARM-COVID19","Enrolling by invitation","No Results Available","Pulmonary Alveolar Proteinosis|COPD|Idiopathic Pulmonary Fibrosis|Viral Pneumonia|Coronavirus Infection|Interstitial Lung Disease","Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme (Roche)|Drug: Sterile Normal Saline for Intravenous Use","Incidence of Treatment-Emergent Adverse Events|Pulmonary Function Analysis|Digital Oximetry","Healeon Medical Inc|Robert W. Alexander, MD","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","10","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GARM COVID19","March 25, 2020","November 1, 2021","December 31, 2021","March 30, 2020",,"March 31, 2020","Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States",,"https://ClinicalTrials.gov/show/NCT04326036"
1531,"NCT04391946","Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19","COVID19_LLC-MW","Not yet recruiting","No Results Available","Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease","Behavioral: Data registry","Prognostic factors for healing of COVID-19 infection|Medical care of Coronavirus infection|national epidemiological monitoring","French Innovative Leukemia Organisation|Institut de Cancerologie Strasbourg Europe","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FILO-COVID19_LLC-MW","June 1, 2020","May 1, 2022","December 31, 2022","May 18, 2020",,"May 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04391946"
1532,"NCT04371250","Study of Resilience and Loneliness in Youth (18 - 25 Years Old) During the COVID-19 Pandemic Lock-down Measures.",,"Active, not recruiting","No Results Available","Resilience, Psychological|Loneliness|Youth|Surveys and Questionnaires","Other: Survey and Questionnaire","Self-rated measure of Resilience|Self-rated measure of Loneliness","Erasme University Hospital|Université Libre de Bruxelles|King Baudouin Foundation","All","18 Years to 25 Years   (Adult)",,"800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SRB2020_158","April 30, 2020","May 31, 2020","December 30, 2020","May 1, 2020",,"May 8, 2020","Erasme University Hospital, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04371250"
1533,"NCT04347031","An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19",,"Enrolling by invitation","No Results Available","Pneumonia, Viral|Respiratory Failure","Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab","1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2","Burnasyan Federal Medical Biophysical Center","All","18 Years to 60 Years   (Adult)","Phase 2","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FL-01/20","April 8, 2020","August 1, 2020","August 1, 2020","April 15, 2020",,"April 15, 2020","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04347031"
1534,"NCT04346693","An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19",,"Enrolling by invitation","No Results Available","Acute Respiratory Tract Infection|Acute Respiratory Insufficiency|Pneumonia|Septic Shock|Hypoxemia","Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation","The change of viral load in patients with SARS-COVID-19.|The frequency of development of Acute Respiratory Distress Syndrome (ADRS)|Duration of hospitalization|The frequency of early mortality|The frequency of late mortality|Clinical status at the time of completion of participation in the study","Burnasyan Federal Medical Biophysical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAL-05-04-2020","April 8, 2020","December 2020","December 2020","April 15, 2020",,"April 15, 2020","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04346693"
1535,"NCT04393818","Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19","PsyCovid_App","Not yet recruiting","No Results Available","Mental Health Disorder|Depression|Posttraumatic Stress Disorder|Burnout|Anxiety Disorders","Behavioral: Intervention App","Depression, anxiety and stress|Post-traumatic stress syndrome|Insomnia|Self Efficacy","Fundació d'investigació Sanitària de les Illes Balears|Universidad de las Islas Baleares|Hospital Universitario Miguel Servet|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Andalusian School of Public Health|Hospital Son Espases","All","18 Years and older   (Adult, Older Adult)","Phase 3","560","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","COVID-19/06","May 2020","July 2020","October 2020","May 19, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04393818"
1536,"NCT04322396","Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19","ProPAC-COVID","Recruiting","No Results Available","Virus Diseases|Infection Viral|Corona Virus Infection","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark","All","Child, Adult, Older Adult","Phase 2","226","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KronLungesyg_COVID_19_protokol","April 6, 2020","October 31, 2020","March 31, 2021","March 26, 2020",,"May 11, 2020","Aalborg Sygehus, Aalborg, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Herlev-Gentofte Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Odense Universitetshospital, Odense, Denmark|Roskilde Sygehus, Roskilde, Denmark|Slagelse Sygehus, Slagelse, Denmark",,"https://ClinicalTrials.gov/show/NCT04322396"
1537,"NCT04341610","ASC Therapy for Patients With Severe Respiratory COVID-19","ASC COVID-19","Not yet recruiting","No Results Available","Respiratory Tract Diseases","Drug: Stem Cell Product","Changes in clinical critical treatment index|Days of respirator treatment|Improvement of clinical symptoms including duration of fever and respiratory need|Mortality|Marker of Immunological function -CD4+ and CD8+ T cell count|C-reactive protein and leucocyte|Cytokine profile|Glomerular Filtration Rate|Duration of hospitalization","Rigshospitalet, Denmark","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EudraCT number: 2020-001330-36","April 20, 2020","January 30, 2021","April 30, 2021","April 10, 2020",,"April 10, 2020","2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04341610"
1538,"NCT04337983","Hemodynamic Characteristics of Patients With SARS-CoV-2","PiCCOVID","Not yet recruiting","No Results Available","Coronavirus|SARS-CoV-2|COVID-19|Acute Respiratory Distress Syndrome|Shock|Acute Circulatory Failure|Left Ventricular Dysfunction|Fluid Overload","Device: Transpulmonary thermodilution|Device: Echocardiography","Body temperature|Blood pressure|Pulse (heart rate)|Respiratory rate|Data provided by transpulmonary thermodilution-CI|Data provided by transpulmonary thermodilution-GEDV|Data provided by transpulmonary thermodilution-EVLW|Data provided by transpulmonary thermodilution-PVPI|Incidence of abnormal laboratory test results|Incidence of new-onset or reversible systolic left ventricular dysfunction|Changes of extravascular lung water measured by transpulmonary thermodilution|Changes of pulmonary vascular permeability index measured by transpulmonary thermodilution|Correlation between the hemodynamic characteristics and 90-day mortality","Bicetre Hospital","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A00793-36","April 15, 2020","October 2020","April 2021","April 8, 2020",,"April 8, 2020","Bicetre Hospital, Paris, Val-de-Marne, France",,"https://ClinicalTrials.gov/show/NCT04337983"
1539,"NCT04341519","Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers","BURDENCOV","Not yet recruiting","No Results Available","Corona Virus Infection|Post-traumatic Stress Disorder","Behavioral: PTSD|Behavioral: Burnout","PTSD Family members sup 22|PTSD Family members|PTSD Patients|PTSD healthcare providers|HADS Family members|HADS Patients|SF36 Patients|Questionnaire Family members|Questionnaire Patients|Questionnaire healthcare providers|MBI healthcare providers|Karasec instrument healthcare providers","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"1464","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP200389","April 9, 2020","November 30, 2020","December 31, 2021","April 10, 2020",,"April 10, 2020","Saint-Louis Hospital, Paris, Ile De France, France",,"https://ClinicalTrials.gov/show/NCT04341519"
1540,"NCT04400305","""Increasing Physical Activity in Canadian Adults Who Have Been Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""","COVID-19","Recruiting","No Results Available","Physical Activity, Healthy Promotion","Behavioral: Digital Health Online Platform","Recruitment rate (monthly)|Participant retention|Participant intervention satisfaction/evaluation|Change in self-reported physical activity from baseline to 6 weeks|Change in physical activity beliefs, attitudes, barriers, and motivation from baseline to 6 weeks.|Change in physical activity behaviour regulation from baseline to 6 weeks.|Change in physical activity habits from baseline to 6 weeks|Change in physical activity identity from baseline to 6 weeks|Change in quality of life measured using the Short Form 12 questionnaire","University of Victoria","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","05-281983","May 20, 2020","September 2020","September 2020","May 25, 2020",,"May 25, 2020","University of Victoria, Victoria, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT04400305"
1541,"NCT04274322","Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool",,"Active, not recruiting","No Results Available","Critically Ill|Coronavirus Infections","Other: Nutrition support","28-day all cause mortality|All cause infection|The rate of complications|Length of ICU stay|Duration of mechanical ventilation","Peking University Third Hospital|School of Pharmaceutical Sciences, Peking University, Beijing, China|Department of Medicine, Queen's University, Kingston, Ontario, Canada","All","18 Years and older   (Adult, Older Adult)",,"117","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COV_NUTRIC","February 19, 2020","April 4, 2020","July 2020","February 18, 2020",,"April 8, 2020","Peking University Third Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04274322"
1542,"NCT04342702","A Study on the Prospective Cohort Library of COVID-19 in Southeran",,"Active, not recruiting","No Results Available","Follow-up|COVID-19|Infectious Diseases|Respiratory",,"36-Item Short Form Survey Instrument (SF-36)|the value of FEV1 by lung function test|the ratio of FEV1 to FVC by lung function test|the predicted value of FEV1 by lung function test|the predicted ratio of FEV1 to FVC by lung function test|Lymphocyte value|Neutrophil value|DDI value|the proportion of applying ACEIs/ARBs medication|number of clinical symptoms after hospital discharge|number of cases returning to positive result in RT-PCR test|Number of positive outcome of IgG for antibody of COVID-19","Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Medical University|First Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital And Sixth People's Hospital of Wenzhou Medical University|Yueqing Hospital of Wenzhou Medical University|Ruian Hospital of Wenzhou Medical University|Cangnan Hospital of Wenzhou Medical University|Pingyang Hospital of Wenzhou Medical University|Yongjia People's Hospital","All","Child, Adult, Older Adult",,"504","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SAHoWMU-CR2020-NCP-202","March 16, 2020","March 2021","March 2021","April 13, 2020",,"May 5, 2020","Wenzhou Medical University, Wenzhou, Zhejiang, China|The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04342702"
1543,"NCT04378257","Efficacy of Therapist Guided e-Therapy Versus Self-Help Therapy on Psychological Distress Among Individuals in Oman During COVID-19 Pandemic",,"Not yet recruiting","No Results Available","Depressive Symptoms|Generalized Anxiety","Behavioral: Therapist Guided E-Therapy|Behavioral: Self-Help Therapy","Change in Depressive symptoms measured by Patient Health Questionnaire-9|Change in Anxiety symptoms measured by Generalized Anxiety Disorder-7|Proportion of subjects with Significant Depression|Proportion of subjects with Significant Anxiety","Sultan Qaboos University|The Research Council|Oman Medical Specialty Board","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12/2020","June 1, 2020","September 30, 2020","October 20, 2020","May 7, 2020",,"May 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04378257"
1544,"NCT04324073","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","CORIMUNO-SARI","Active, not recruiting","No Results Available","Corona Virus Infection","Drug: Sarilumab","Survival without needs of ventilator utilization at day 14.|WHO progression scale <=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14|WHO progression scale at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","239","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-2","March 27, 2020","March 27, 2021","December 31, 2021","March 27, 2020",,"April 15, 2020","Kremlin Bicetre hospital APHP, Le Kremlin-Bicêtre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|HEGP, Paris, Ile De France, France|NECKER Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT04324073"
1545,"NCT04384705","HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital","H-Cov-Run","Not yet recruiting","No Results Available","SARS-CoV Infection","Other: research specific blood sample","Change of lipid profile during exposure to SARS-Cov-2|HDL-cholesterol size|circulating plasma cytokine levels|ACE2 gene polymorphisms","Centre Hospitalier Universitaire de la Réunion","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020/CHU/08","May 2020","May 2021","June 2021","May 12, 2020",,"May 12, 2020","Centre Hospitalier Universitaire de la Réunion, Saint-Pierre, France",,"https://ClinicalTrials.gov/show/NCT04384705"
1546,"NCT04348370","BCG Vaccine for Health Care Workers as Defense Against COVID 19","BADAS","Recruiting","No Results Available","Coronavirus|Coronavirus Infection|Coronavirus as the Cause of Diseases Classified Elsewhere","Biological: BCG Vaccine|Biological: Placebo Vaccine","Incidence of COVID 19 Infection|Disease Severity","Texas A&M University|Baylor College of Medicine|M.D. Anderson Cancer Center|Cedars-Sinai Medical Center|Harvard University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","1800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","2020-0432F","April 20, 2020","May 2021","November 2021","April 16, 2020",,"May 8, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States|Texas A&M Family Care Clinic, Bryan, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Harris Health System - Ben Taub Hospital, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04348370"
1547,"NCT04362358","Online Cognitive Behavioral Therapy (CBT) for Stress Disorders in Health Workers Involved in the Care of Patients During the Covid-19 Epidemic","REST","Not yet recruiting","No Results Available","Stress - Prevention of Sleep Disorders, PTSD and Depression","Behavioral: Online cognitive behavioral therapy (CBT)|Behavioral: Online bibliotherapy programme","Significant score reduction at the Perceived Stress Scale","University Hospital, Strasbourg, France","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","7799","May 1, 2020","October 1, 2021","October 1, 2021","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04362358"
1548,"NCT04390152","Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19",,"Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome","Drug: Wharton's jelly derived Mesenchymal stem cells.|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)","Intergroup mortality difference with treatment|Number of patients with treatment related adverse events|Difference in days of mechanical ventilation between groups|Median reduction of days of hospitalization|Median reduction of days of oxygen needs|Difference between ""Sequential Organ Failure Assessment"" score between groups|Difference between median Murray score between groups|Difference in APACHE II score between groups|Difference in lymphocyte count between groups|Changes in C reactive protein concentration between groups|Changes in D dimer concentration|Changes in ferritin concentration|Changes in lactate dehydrogenase concentration|Impact on interleukin 6 concentrations between groups.|Impact on interleukin 8 concentrations between groups.|Impact on interleukin 10 concentrations between groups.|Impact on tumor necrosis factor alpha concentrations between groups.","BioXcellerator|Clinical Somer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BIOXSOMCOV001","June 2020","November 2020","May 2021","May 15, 2020",,"May 19, 2020","Clinical Somer, Rionegro, Antioquia, Colombia",,"https://ClinicalTrials.gov/show/NCT04390152"
1549,"NCT04359407","Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID Patients","COVID_EIT","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|Electric Impedance|Prone Positioning","Other: Prone positioning","Tidal electrical Impedance|Intrapulmonary shunt|Volumetric capnography","Walid HABRE|University Hospital, Geneva","All","18 Years to 80 Years   (Adult, Older Adult)",,"16","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2020-00896","April 27, 2020","December 31, 2020","January 31, 2021","April 24, 2020",,"April 24, 2020","University Hospitals of Geneva, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT04359407"
1550,"NCT04386720","Measurement of Airway Opening Pressure (AOP) in Patients With Acute Respiratory Distress Syndrom and With or Without Covid 19.","POVA-TIE","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome",,"Comparison of the PV curves|Comparison of regional AOP|Comparison of the different AOPs with the level of PEEP","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CHUBX 2020/15","May 20, 2020","May 20, 2021","May 20, 2021","May 13, 2020",,"May 20, 2020","HOPITAL HAUT-LEVEQUE - Service Réanimation thoracique, Pessac, France",,"https://ClinicalTrials.gov/show/NCT04386720"
1551,"NCT04363528","Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU","COVIDOP-DVT","Not yet recruiting","No Results Available","Deep Vein Thrombosis","Other: Doppler Echo","Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU","Versailles Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","P20/08","April 27, 2020","October 30, 2020","October 30, 2020","April 27, 2020",,"April 27, 2020","Centre Hospitalier de Versailles, Le Chesnay, France",,"https://ClinicalTrials.gov/show/NCT04363528"
1552,"NCT04279795","Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations",,"Recruiting","No Results Available","Coronavirus",,"Positive rate of 2019 Novel Coronavirus RNA|Survival rate","Third Affiliated Hospital, Sun Yat-Sen University","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PL11","January 20, 2020","January 31, 2021","February 28, 2021","February 21, 2020",,"February 21, 2020","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04279795"
1553,"NCT04395508","An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic",,"Available","No Results Available","HER2-positive Breast Cancer","Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC)",,"Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Treatment IND/Protocol",,"AL42478",,,,"May 20, 2020",,"May 20, 2020","City of Hope, Duarte, California, United States|Univ of Calif, San Francisco; Breast Cancer Center, San Francisco, California, United States|Stanford Univ School of Med; Oncology, Stanford, California, United States|MedStar Washington Hosp Center, Washington, District of Columbia, United States|John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University of Pennsylvania; School of Medicine, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04395508"
1554,"NCT04385004","Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in ICU","PR-Covid-19","Recruiting","No Results Available","Acute Respiratory Distress Syndrome",,"Characterisation of Clinical, Biological and Histological Pulmonary and Renal Impairment Related to SARS-CoV-2","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"320","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","7815","April 27, 2020","July 2020","July 2020","May 12, 2020",,"May 12, 2020","Service Reanimation Medicale, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04385004"
1555,"NCT04343404","PLACE OF VENOVENOUS ECMO IN THE MANAGEMENT OF SEVERE REFRACTORY ARDS ASSOCIATED WITH SARS-COV-2","ECMO-COVID-19","Recruiting","No Results Available","Respiratory Distress Syndrome",,"Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","7772","April 1, 2020","April 15, 2020","April 15, 2020","April 13, 2020",,"April 13, 2020","Service de Chirurgie Thoracique Nouvel Hôpital Civil Hôpitaux Universitaires de Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04343404"
1556,"NCT04279782","Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection",,"Recruiting","No Results Available","Coronavirus","Other: Comprehensive treatment","Survival rate|Chest computed tomography|Recovery Time|Depression evaluation","Third Affiliated Hospital, Sun Yat-Sen University","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","XWX3","January 20, 2020","January 31, 2021","February 28, 2021","February 21, 2020",,"February 24, 2020","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04279782"
1557,"NCT04353037","PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine",,"Recruiting","No Results Available","Coronavirus|Corona Virus Infection","Drug: Group A HCQ|Drug: Group B Control","Sub Study 1: Patients|Sub Study 2: Health Care Workers|Sub Study 1: Patients: Rate of secondary infection of co-inhabitants|Sub Study 1: Patients: Adverse Events|Sub Study 1: Patients: Negative for COVID-19|Sub Study 2:Health Care Workers:Number of shifts missed|Sub Study 2:Health Care Workers:Rate of adverse events|Sub Study 2:Health Care Workers:Rate of hospitalization","UnitedHealth Group|ProHealth Care Associates|University of Pennsylvania Perelman School of Medicine","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 2","850","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2020-0003","April 7, 2020","April 2021","June 15, 2021","April 20, 2020",,"April 24, 2020","ProHealth New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04353037"
1558,"NCT04357977","A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device",,"Not yet recruiting","No Results Available","Coronavirus|COVID","Diagnostic Test: RBA-2","Covid +","Kaligia Biosciences, LLC|University of South Florida","All","18 Years and older   (Adult, Older Adult)",,"300","Industry|Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","KBS005","April 2020","August 2020","December 2020","April 22, 2020",,"April 22, 2020","Tampa General Hospital, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|AdventHealth Tampa, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04357977"
1559,"NCT04387409","A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune System",,"Not yet recruiting","No Results Available","Infection, Respiratory Tract","Biological: VPM1002|Biological: Placebo","Number of days absent from work due to respiratory disease (with or without documented SARS-CoV-2 infection)|Cumulative incidence of documented SARS-CoV-2 infection|Number of days absent from work due to documented SARS-CoV-2 infection|Number of days absent from work due to exposure to person with documented SARS-CoV-2 infection|Number of days absent from work due to symptoms of respiratory disease, documented SARS-CoV-2 infection, or fever (≥ 38 °C)|Number of days of self-reported fever (≥ 38 °C)|Number of days of self-reported acute respiratory symptoms|Cumulative incidence of self-reported acute respiratory symptoms|Cumulative incidence of death for any reason|Cumulative incidence of death due to documented SARS-CoV-2 infection|Cumulative incidence of ICU admission for any reason|Cumulative incidence of ICU admission due to documented SARS-CoV-2 infection|Cumulative incidence of hospital admission for any reason|Cumulative incidence of hospital admission due to documented SARS-CoV-2 infection","Vakzine Projekt Management GmbH|FGK Clinical Research GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 3","1200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VPM1002-DE-3.06CoV","May 18, 2020","June 30, 2021","June 30, 2021","May 13, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04387409"
1560,"NCT04343729","Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19","MetCOVID","Recruiting","No Results Available","SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia","Drug: Methylprednisolone Sodium Succinate|Drug: Placebo solution","Mortality rate at day 28|Proportion of patients with SARS|Mortality rate on days 7, 14 and 28|Incidence of orotracheal intubation|Change in oxygenation index","Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","All","18 Years and older   (Adult, Older Adult)","Phase 2","420","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAEE: 30615920.2.0000.0005","April 18, 2020","September 2020","September 2020","April 13, 2020",,"May 1, 2020","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",,"https://ClinicalTrials.gov/show/NCT04343729"
1561,"NCT04320056","Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19)",,"Recruiting","No Results Available","Coronavirus|Pneumonia|Oxygen Toxicity","Other: Standard administration of oxygen flow|Device: Automated oxygen administration - FreeO2","The number of interventions|Duration of interventions|Mean oxygen flow|Time within theSpO2 target|Time with hypoxemia|Time with hyperoxemia|Rate of ICU admission|Rate of needed non invasive respiratory support|Rate of intubation|NEWS 2 score evolution|EWSO2 score evolution|Cost-effectiveness|length of stay","Laval University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","216","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","21909","April 20, 2020","April 30, 2021","October 31, 2021","March 24, 2020",,"April 21, 2020","Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04320056"
1562,"NCT04330261","Clinical Characteristics and Outcomes of Pediatric COVID-19","PERN-COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection|Pediatric ALL|Pneumonia, Viral|Pandemic Response","Other: Exposure (not intervention) - SARS-CoV-2 infection","Clinical characteristics of children with SARS-CoV-2|Factors associated with severe COVID-19 outcomes|Health care resource utilization for COVID-19 patient management|Sensitivity and specificity of COVID-19 case screening policies","University of Calgary","All","up to 18 Years   (Child, Adult)",,"12500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REB18-0107_MOD9","March 18, 2020","March 17, 2021","March 17, 2022","April 1, 2020",,"April 1, 2020","University of Calgary/Alberta Children's Hospital, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04330261"
1563,"NCT04324736","""COVID-19 and Diabetes Outcomes""","CORONADO","Recruiting","No Results Available","Coronavirus|Diabetes","Other: no interventional study","Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19|describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19|describe the prognosis of hospitalized subjects with diabetes and COVID-19|describe the care management of hospitalized subjects with diabetes and COVID-19","Nantes University Hospital","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","RC20_0148","March 10, 2020","April 10, 2020","May 8, 2020","March 27, 2020",,"April 14, 2020","CHU Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT04324736"
1564,"NCT04341584","CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection","CORIMUNO-ANA","Not yet recruiting","No Results Available","Corona Virus Infection","Drug: Anakinra","Survival without needs of ventilator utilization at day 14|WHO progression scale ≤ 5|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) or withdrawal of NIV or high flow (for > 48h), at day 14|Decrease of at least one point in WHO progression scale score|WHO progression scale|Survival|28-day ventilator free-days|Respiratory acidosis|PaO2/FiO2 ratio|Time to oxygen supply independency|Duration of hospitalization|Time to negative viral excretion|Time to ICU discharge|Time to hospital discharge","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-5","April 2020","May 2020","December 31, 2020","April 10, 2020",,"April 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04341584"
1565,"NCT04340414","Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP",,"Recruiting","No Results Available","COVID-19|ECMO","Device: Low flow ECMO driving by CVVH machine","PaCO2|Driving Pressure|Tidal volume","Peking Union Medical College Hospital","All","14 Years and older   (Child, Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Low flow-ECMO by CVVH in NCP","March 3, 2020","August 15, 2020","October 15, 2020","April 9, 2020",,"April 9, 2020","Yun Long, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04340414"
1566,"NCT04331886","An Observational Study of Patients With Coronavirus Disease 2019","COVID-19","Recruiting","No Results Available","COVID-19|Coronavirus",,"Natural history of COVID-19: Characteristics of COVID-19|Natural history of COVID-19: Participant demographics|Natural history of COVID-19: Treatment use|Time point of clinical response","Target PharmaSolutions, Inc.","All","18 Years and older   (Adult, Older Adult)",,"5000","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","TARGET-COVID-19","April 13, 2020","March 2021","March 2021","April 2, 2020",,"May 14, 2020","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04331886"
1567,"NCT04293887","Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients",,"Not yet recruiting","No Results Available","COVID-19|Recombinant Human Interferon α1β","Drug: Recombinant human interferon α1β","The incidence of side effects|Time from patient enrollment to clinical remission|Proportion of patients with normal body|Proportion of patients without dyspnea|Proportion of patients without cough|Proportion|The negative conversion rate of new coronavirus nucleic acid|Frequency of serious adverse drug events.","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","328","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Zhaojp","March 1, 2020","May 30, 2020","June 30, 2020","March 3, 2020",,"March 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04293887"
1568,"NCT04368026","SARS-CoV-2 and Surgery",,"Recruiting","No Results Available","Surgical Procedure, Unspecified","Other: No intervention (survey study for medical doctors).","Descriptive data on perceptions of current status of surgical wards during the pandemic and impact of the pandemic on conducting surgery.","Jagiellonian University","All","25 Years and older   (Adult, Older Adult)",,"350","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","1072.6120.103.2020","March 30, 2020","June 1, 2020","July 1, 2020","April 29, 2020",,"April 29, 2020","2nd Department of General Surgery, Jagiellonian University Medical College, Cracovia, Małopolska, Poland",,"https://ClinicalTrials.gov/show/NCT04368026"
1569,"NCT04354792","Asymptomatic COVID-19 Infection Among Healthcare Workers",,"Recruiting","No Results Available","Immunologic Activity Alteration","Diagnostic Test: Serum SARs COV 2 IGg screening in health care workers","Number of IGg seropositive health care workers|Differentiation between low risk and high risk HCWs","Kasr El Aini Hospital","All","25 Years to 60 Years   (Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","N-31-2020","May 1, 2020","June 30, 2020","July 10, 2020","April 21, 2020",,"May 11, 2020","Cairo University Hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04354792"
1570,"NCT04374643","Descriptive Study of the PSYchological Impact of CONFinement Measures in Subjects With Mood Disorders","PsyConf","Recruiting","No Results Available","Depression, Unipolar|COVID 19","Other: Questionnaire to study the psychological impact of confinement","Depressive Symptomatology","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0197","April 1, 2020","May 30, 2020","November 1, 2020","May 5, 2020",,"May 5, 2020","University hospital, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04374643"
1571,"NCT04326426","ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection",,"Enrolling by invitation","No Results Available","Coronavirus Infection","Drug: Tradipitant|Drug: Placebo","Time to improvement on a 7-point ordinal scale as compared to baseline|Treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (IL-6)|Rate of Decline of COVID-19 viral load assessed by RT-PCR from nasopharyngeal samples|In-hospital mortality|Mean change in NEWS2 score from baseline|Understand the effect of genetics for treatment response through whole genome sequence of the participant and the COVID-19 virus|Reduction from baseline of NRS for cough|Reduction from baseline of NRS for nausea|Time to normalization of fever for at least 48 hours|Time to improvement in oxygenation for at least 48 hours","Vanda Pharmaceuticals","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VLY-686-3501","April 13, 2020","August 1, 2020","August 31, 2020","March 30, 2020",,"April 20, 2020","Lenox Hill Hospital Northwell Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04326426"
1572,"NCT04292327","Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus","2019-nCoV","Active, not recruiting","No Results Available","Pneumonia Caused by Human Coronavirus",,"Mortality|The time interval of Nucleic acid detection become negative","Fujian Provincial Hospital","All","18 Years to 75 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","KY-2020-24.01","January 1, 2020","April 30, 2020","July 31, 2020","March 3, 2020",,"March 3, 2020","Fujian Provincial Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT04292327"
1573,"NCT04259892","Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.","Cov-CONTACT","Recruiting","No Results Available","Coronavirus","Biological: 2019-nCoV PCR","Time to SARS-CoV-2 nasopharyngeal excretion, from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.|Time to apparition of any symptom suggestive of SARS-CoV-2 from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.|Factors associated with the time to SARS-CoV-2 nasopharyngeal excretion|Factors associated with the time to apparition of any symptom suggestive of SARS-CoV-2 infection|Proportion of contact subjects with apparition of any symptom suggestive of SARS-CoV-2 infection|Proportion of contact subjects with positive serology defined as the presence of SARS-CoV-2 IgM or IgG at day 30 (+/-7) following last contact|Host genetic variants|The time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology.","Institut National de la Santé Et de la Recherche Médicale, France","All","Child, Adult, Older Adult",,"345","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","C20-06|2020-A00280-39","February 4, 2020","October 4, 2020","February 4, 2021","February 7, 2020",,"May 25, 2020","Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon, Besançon, France|Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin, Bordeaux, France|Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand, Clermont-Ferrand, France|Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne, Dijon, France|Centre d'investigation clinique 1406 CHU Grenoble, Grenoble, France|Centre d'Investigation Clinique 1403 -CHU Lille, Lille, France|Centre Investigation Clinique 1433 CHRU de NANCY, Nancy, France|Centre d'investigation clinique Infectiologie Hôtel-Dieu CHU Nantes, Nantes, France|Centre d'Investigation Clinique Hôpital Saint Louis, Paris, France|Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard, Paris, France|Centre Investigation Clinique 1417 Hôpital Cochin Bâtiment Lavoisier, Paris, France|Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou, Rennes, France|Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord, Saint Denis, France|Centre d'Investigation Clinique Ile de la Réunion CHU sud, Saint-Pierre, France|Département maladie infectieux CHU Saint Etienne, Saint-Étienne, France|Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau, Tours, France|Service de Maladies infectieuses et tropicales Centre hospitalier, Cayenne, French Guiana",,"https://ClinicalTrials.gov/show/NCT04259892"
1574,"NCT04290780","COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus","NOSO-COR","Recruiting","No Results Available","Infection Viral","Other: nosocomial infection/hospital acquired infection","nosocomial infection","Hospices Civils de Lyon","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL20_0214","March 9, 2020","October 10, 2020","October 30, 2020","March 2, 2020",,"April 13, 2020","Service Hygiène, Epidémiologie et Prévention, Lyon, France|Service Hygiène, Epidémiologie et Prévention, Lyon, France",,"https://ClinicalTrials.gov/show/NCT04290780"
1575,"NCT04280224","NK Cells Treatment for COVID-19",,"Recruiting","No Results Available","Novel Coronavirus Pneumonia","Biological: NK Cells","Improvement of clinical symptoms including duration of fever|Improvement of clinical symptoms including respiratory frequency|Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0|Time of virus nucleic acid test negative|CD4+ and CD8+ T cell count|Rate of mortality within 28-days|Size of lesion area by thoracic imaging","Xinxiang medical university|First Affiliated Hospital of Xinjiang Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","xinxiangM","February 15, 2020","September 30, 2020","December 30, 2020","February 21, 2020",,"April 14, 2020","The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China",,"https://ClinicalTrials.gov/show/NCT04280224"
1576,"NCT04269525","Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia",,"Recruiting","No Results Available","Pneumonia, Viral|Pneumonia, Ventilator-Associated","Biological: UC-MSCs","Oxygenation index|28 day mortality|Hospital stay|2019-nCoV nucleic acid test|Improvement of lung imaging examinations|White blood cell count|Lymphocyte count|Lymphocyte percentage|Procalcitonin|interleukin(IL)-2|IL-4|IL-6|IL-8|IL-10|tumor necrosis factor(TNF)-α|γ-interferon(IFN)","ZhiYong Peng|Tuohua Biological Technology Co. Ltd|Zhongnan Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020002","February 6, 2020","April 30, 2020","September 30, 2020","February 13, 2020",,"February 17, 2020","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04269525"
1577,"NCT04322513","Biomarkers for Identification of COVID-19 Infection","B-DT-COV2","Recruiting","No Results Available","Coronavirus","Diagnostic Test: Biomarkers expression","Biomarkers expression|Liver Biomarkers expression|biomarkers expression (microRNAs, oxidative stress, Neuron-Specific Enolase, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) after treatment","University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico ""Mater Domini""","All","14 Years to 75 Years   (Child, Adult, Older Adult)",,"110","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","covid-19 biomarkers","March 24, 2020","June 30, 2020","August 30, 2020","March 26, 2020",,"May 6, 2020","Luca Gallelli, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04322513"
1578,"NCT04388826","COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111",,"Not yet recruiting","No Results Available","Respiratory Distress Syndrome, Adult","Drug: Veru-111","Proportion of subjects that are alive without respiratory failure at Day 29.|WHO clinical Improvement|Normalization of Fever and Oxygen|Discharge from Hospital|Patients alive and free of respiratory failure","Veru Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","V0211901","May 25, 2020","July 30, 2020","August 30, 2020","May 14, 2020",,"May 21, 2020","HonorHealth, Scottsdale, Arizona, United States|Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|WC-CRCN at North Vista Hospital, Las Vegas, Nevada, United States|Inspira Medical Center, Vineland, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04388826"
1579,"NCT04318366","COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","COVID-BioB","Recruiting","No Results Available","Coronavirus Infections","Other: Observational Study","Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response","Università Vita-Salute San Raffaele","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-BioB/OSR","March 19, 2020","March 19, 2022","March 19, 2022","March 24, 2020",,"March 31, 2020","Autoimmunity and Vascular Inflammation Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|AIDS Immunopathogenesis Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Department of Infection Diseases - IRCCS San Raffaele Scientific Institute -, Milan, Lombardy, Italy|Department of Internal Medicine - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Diabetes Research Institute -IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Division of Immunology, Transplantation and Infectious Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Division of Research of Regenerative Medicine, Cell and Gene Therapy - IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Laboratory of Microbiology and Virology - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Nephrology Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Strategic Program in Nephrology and Dialysis - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Viral pathogens and biosafety Unit - IRCCS San Raffaele Scietific Institute, Milan, Lombardy, Italy|Unit of Immunology, Rheumatology, Allergy and Rare Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Università Vita-Salute San Raffaele, Milano, Mi, Italy",,"https://ClinicalTrials.gov/show/NCT04318366"
1580,"NCT04376034","Convalescent Plasma Collection and Treatment in Pediatrics and Adults",,"Recruiting","No Results Available","COVID19|Coronavirus Infection|Coronavirus|Virus Diseases|RNA Virus Infections","Biological: Convalescent Plasma 1 Unit|Biological: Convalescent Plasma 2 Units|Other: Standard of Care","Plasma Donor|Plasma Recipient","West Virginia University","All","31 Days and older   (Child, Adult, Older Adult)","Phase 3","240","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004965705","April 16, 2020","March 30, 2021","March 30, 2021","May 6, 2020",,"May 6, 2020","WVU Medicine, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04376034"
1581,"NCT04320862","COVID-19 Pandemic Response Network",,"Recruiting","No Results Available","COVID-19|SARS-CoV-2|Coronavirus|Influenza -Like Illness|Lower Resp Tract Infection|Upper Resp Tract Infection",,"Number of participants who experience inpatient admission|Number of participants admitted to the intensive care unit|Number of participants requiring mechanical ventilation|Number of deceased participants","Duke University","All","Child, Adult, Older Adult",,"200000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00105189","April 3, 2020","December 31, 2021","December 31, 2021","March 25, 2020",,"April 27, 2020","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04320862"
1582,"NCT04307459","Acute Respiratory Failure and COVID-19 in Real Life",,"Recruiting","No Results Available","Coronavirus Infections|Respiratory Failure|Ventilator Lung","Other: standard operating procedures","Real life data of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection|in-hospital mortality|30 days mortality|6 months mortality|Intubation rate|Time to Intubation|Time to ventilation|Non invasive to Invasive time|Recovery rate|Recurrence rate|Risk factor for COVID19|Blood tests and outcome|Antiviral therapy|Coinfections|Radiological findings|Ultrasound findings|Myocardial injury|Medical management","University of Milan","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17263/2020","March 19, 2020","September 1, 2020","December 31, 2020","March 13, 2020",,"May 13, 2020","Luigi Sacco University Hospital, Milan, Lombardia, Italy",,"https://ClinicalTrials.gov/show/NCT04307459"
1583,"NCT04322279","Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID19.",,"Recruiting","No Results Available","Coronavirus","Diagnostic Test: Serology|Genetic: Sequencing","Proportion of subjects with SARS-CoV-2 positive serology at day 30 following the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.|Factors associated with a SARS-CoV-2 positive serology at day 30 (+/-7);|Time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology.","Institut National de la Santé Et de la Recherche Médicale, France","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","C20-16|2020-A00609-30","March 9, 2020","March 1, 2021","June 1, 2021","March 26, 2020",,"May 25, 2020","Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon, Besançon, France|Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin, Bordeaux, France|Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand, Clermont Ferrand, France|Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne, Dijon, France|Centre d'investigation clinique 1406 CHU Grenoble, Grenoble, France|Centre d'Investigation Clinique 1403 -CHU Lille, Lille, France|Centre d'investigation clinique Infectiologie Hôtel-Dieu CHU Nantes, Nantes, France|Centre d'Investigation Clinique Hôpital Saint Louis, Paris, France|Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard, Paris, France|Hôpital Cochin CIC 1417 Bâtiment Lavoisier, Paris, France|Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou, Rennes, France|Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord, Saint Denis, France|Département maladie infectieux CHU Saint Etienne, Saint Etienne, France|Centre d'Investigation Clinique Ile de la Réunion CHU sud, Saint-Pierre, France|Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau, Tours, France|Centre Investigation Clinique 1433 CHRU de NANCY, Vandœuvre-lès-Nancy, France|Service de Maladies infectieuses et tropicales Centre hospitalier, Cayenne, French Guiana",,"https://ClinicalTrials.gov/show/NCT04322279"
1584,"NCT04365166","Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19)","REACOVIM","Recruiting","No Results Available","Respiratory Tract Infections|Respiratory Tract Disease",,"Mortality|Immune response - Plasma cytokine profile|Immune response - Phenotype of circulating cells|Severity criteria - Duration of stay in intensive care unit|Severity criteria - Duration of hospitalization stay|Severity criteria - Duration of period out of hospital|Severity criteria - Duration without mechanical ventilation|Severity criteria - Duration without ventilation|Severity criteria - Duration without intubation|Severity criteria - Number of transfusions|Severity criteria - Duration of the period without cathecholamines|Severity criteria - Duration of the period without dialysis|Severity criteria - SOFA|Severity criteria - LIS|SARS-Cov2 viral load|Emergence of concomitant infections|Emergence of concomitant infections - Phenotype of circulating cells|Stress physiological profile - Sympathetic tone|Stress physiological profile - Temperature|Stress physiological profile - Glucocorticoids|Angiotensin converting enzyme type II (ACE2) polymorphism - ACE|Angiotensin converting enzyme type II (ACE2) polymorphism - ACE2/ACE1|Comorbidities - diabetes|Comorbidities - Heart disease|Comorbidities - organ failure|Plasma concentrations of several metabolic pathways - GABA|Plasma concentrations of several metabolic pathways - Glucocorticoid|Plasma concentrations of several metabolic pathways - Tryptophan|Plasma concentrations of several metabolic pathways - Serotonin|Plasma concentrations of several metabolic pathways - Dopamin|Plasma concentrations of several metabolic pathways - Cathecholamines|Plasma concentrations of several metabolic pathways - Arachidonic acid derivatives|Plasma concentrations of several metabolic pathways - Endocannabinoids","Direction Centrale du Service de Santé des Armées","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2020-COVID19-05","April 21, 2020","April 21, 2022","April 21, 2022","April 28, 2020",,"May 14, 2020","Percy Military Teaching Hospital, Clamart, France|Bégin Military Teaching Hospital, Saint-Mandé, France",,"https://ClinicalTrials.gov/show/NCT04365166"
1585,"NCT04261907","Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection",,"Not yet recruiting","No Results Available","2019-nCoV","Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group","The incidence of composite adverse outcome|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requring supplemental oxygen|Rate of undectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Time and rate of laboratory indicators related to disease improvement to return to normal","First Affiliated Hospital of Zhejiang University|Ascletis Pharmaceuticals Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASC09F-CTP-ZY-01","February 7, 2020","May 31, 2020","June 30, 2020","February 10, 2020",,"February 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04261907"
1586,"NCT04299152","Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19",,"Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome (SARS) Pneumonia","Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis","Determine the number of Covid-19 patients who were unable to complete SCE Therapy|Examine the percentage of activated T cells after SCE therapy by flow cytometry|Assess the percentage of Th17 cells after SCE therapy by flow cytometry|Chest imaging changes by computed tomography (CT) scan of the chest|Quantification of the SARS-CoV-2 viral load by real time RT-PCR","Tianhe Stem Cell Biotechnologies Inc.","All","18 Years to 60 Years   (Adult)","Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","2020-TH-001","May 10, 2020","October 9, 2020","November 10, 2020","March 6, 2020",,"April 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04299152"
1587,"NCT04340557","Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection",,"Recruiting","No Results Available","SARS-CoV Infection","Drug: Losartan","Mechanical ventilation|ICU transfer|Oxygen therapy","Sharp HealthCare","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","COVID-ARB|2003902","March 27, 2020","October 6, 2020","December 31, 2020","April 9, 2020",,"April 9, 2020","Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Sharp Coronado Hospital, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT04340557"
1588,"NCT04365322","Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19)","COV-CREM","Recruiting","No Results Available","SARS-CoV Infection","Other: Additional biological samples","Specific immune responses","Centre Hospitalier Universitaire de Besancon","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020/502","April 20, 2020","June 1, 2020","April 20, 2025","April 28, 2020",,"April 29, 2020","CHU Jean Minjoz, Besançon, France",,"https://ClinicalTrials.gov/show/NCT04365322"
1589,"NCT04306393","Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19","NOSARSCOVID","Recruiting","No Results Available","SARS (Severe Acute Respiratory Syndrome)|Coronavirus","Drug: Nitric Oxide Gas","Change of arterial oxygenation at 48 hours from enrollment|Time to reach normoxemia during the first 28 days after enrollment|Proportion of SARS-nCoV-2 free patients during the first 28 days after enrollment|Survival at 28 days from enrollment|Survival at 90 days from enrollment","Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Niguarda Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NO-SARS-COVID-19","March 21, 2020","March 21, 2021","March 21, 2022","March 12, 2020",,"May 21, 2020","University of Alabama, Birmingham, Alabama, United States|Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04306393"
1590,"NCT04385212","Outcomes in Hospitalized Older Patients With COVID-19",,"Completed","No Results Available","Coronavirus Infection|Sars-CoV2|Elderly Infection|Old Age; Debility",,"To evaluate the relative contributions of comorbidities on intra-hospitalized death|To evaluate the relative contributions of functional characteristics on intra-hospitalized death|To explore specific clinical profiles that may influence COVID-19 disease outcomes in the elderly based on geriatrics syndromes","University Hospital, Geneva","All","65 Years and older   (Older Adult)",,"230","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-00819","March 13, 2020","April 14, 2020","April 14, 2020","May 12, 2020",,"May 12, 2020","Department of Rehabilitation and Geriatrics, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT04385212"
1591,"NCT04361552","Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)",,"Recruiting","No Results Available","Cerebrovascular Accident|Chronic Obstructive Pulmonary Disease|Chronic Renal Failure|Coronary Artery Disease|Diabetes Mellitus|Malignant Neoplasm|SARS Coronavirus 2 Infection","Other: Best Practice|Biological: Tocilizumab","7-day length of invasive mechanical ventilation (MV)|30-day mortality rate|Rate of intensive care (ICU) transfer|Rate of invasive mechanical ventilation|Rate of tracheostomy|Length of ICU stay|Length of hospital stay","Emory University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","180","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000419|NCI-2020-02314|WINSHIP4998-20|P30CA138292","May 30, 2020","May 30, 2022","May 30, 2022","April 24, 2020",,"April 24, 2020","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04361552"
1592,"NCT04322773","Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure","TOCIVID","Recruiting","No Results Available","Corona Virus Disease","Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care","Time to independence from supplementary oxygen therapy|Number of deaths|Days out of hospital and alive|Ventilator free days alive and out of hospital|C-reactive protein (CRP) level|Number of participants with serious adverse events","Marius Henriksen|Lars Erik Kristensen|Frederiksberg University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APPI2-CV-2020-01","April 5, 2020","June 1, 2021","June 1, 2021","March 26, 2020",,"April 7, 2020","Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark|Hillerød Hospital, Hillerød, Denmark",,"https://ClinicalTrials.gov/show/NCT04322773"
1593,"NCT04336410","Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers",,"Recruiting","No Results Available","Coronavirus Infection","Drug: INO-4800|Device: CELLECTRA® 2000","Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Administration (Injection) Site Reactions|Percentage of Participants with Adverse Events of Special Interest (AESIs)|Change from Baseline in Antigen-Specific Binding Antibody Titers|Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-γ) Cellular Immune Response","Inovio Pharmaceuticals|Coalition for Epidemic Preparedness Innovations (CEPI)","All","18 Years to 50 Years   (Adult)","Phase 1","40","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","COVID19-001","April 3, 2020","April 2021","April 2021","April 7, 2020",,"April 24, 2020","Center for Pharmaceutical Research, Kansas City, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04336410"
1594,"NCT04264533","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia",,"Recruiting","No Results Available","Vitamin C|Pneumonia, Viral|Pneumonia, Ventilator-Associated","Drug: VC|Drug: Sterile Water for Injection","Ventilation-free days|28-days mortality|ICU length of stay|Demand for first aid measuments|Vasopressor days|Respiratory indexes|Ventilator parameters|APACHE II scores|SOFA scores","ZhiYong Peng|Zhongnan Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","2020001","February 14, 2020","September 30, 2020","September 30, 2020","February 11, 2020",,"March 10, 2020","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04264533"
1595,"NCT04338841","HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection","HOME-CoV","Recruiting","No Results Available","Coronavirus Infection","Other: HOME-CoV rule implementation","the composite rate of adverse outcomes|The rate of hospitalization","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-A00831-38","April 9, 2020","June 1, 2020","June 1, 2020","April 8, 2020",,"April 13, 2020","Clinique Universitaire Saint-Luc, Bruxelles, Belgium|CHU de Liège, Liege, Belgium|Ch Argenteuil, Argenteuil, France|CHU Brest, Brest, France|CH Cholet, Cholet, France|CHU Clermont Ferrand, Clermont Ferrand, France|Ch Colmar, Colmar, France|CH Alpes Lemant, Contamine-sur-Arve, France|CHU Dijon, Dijon, France|CH Le Mans, Le Mans, France|CH Libourne, Libourne, France|CH Limoges, Limoges, France|Ch Longjumeau, Longjumeau, France|Hospices Civils de Lyon (University Hospital of Lyon), Lyon, France|Chu Montpellier, Montpellier, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|CH Niort, Niort, France|Hopital Paris Saint Joseph, Paris, France|Hopital Saint Antoine, Paris, France|Hôpital Bichat, Paris, France|Hôpital Lariboisière, Paris, France|CHU de Poitiers, Poitiers, France|CH Reims, Reims, France|Ch Remiremont, Remiremont, France|Chu Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de St Etienne, Saint Etienne, France|CH de Saint-Brieuc, Saint-Brieuc, France|Ch Troyes, Troyes, France|CH VICHY, Vichy, France|CH Princesse Grace, Monaco, Monaco",,"https://ClinicalTrials.gov/show/NCT04338841"
1596,"NCT04349163","Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort.","Resi-CoV","Recruiting","No Results Available","Psychological","Other: Questionnaire","compare the level of resilience between physicians and caregivers of different specialties and in different workplaces according to the covid-19 epidemic.","University Hospital, Angers","All","Child, Adult, Older Adult",,"280","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A00831-39","May 10, 2020","May 15, 2020","May 25, 2020","April 16, 2020",,"May 12, 2020","CHU, Angers, France",,"https://ClinicalTrials.gov/show/NCT04349163"
1597,"NCT04275388","Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia",,"Not yet recruiting","No Results Available","2019 Novel Coronavirus Pneumonia","Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride","Clinical recovery time|Complete fever time|Cough relief time|Virus negative time|Incidence of severe or critical neocoronavirus pneumonia","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","All","up to 100 Years   (Child, Adult, Older Adult)",,"426","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","QF-XYP2001-1","May 15, 2020","July 14, 2020","December 14, 2021","February 19, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04275388"
1598,"NCT04323527","Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2","CloroCOVID19","Recruiting","No Results Available","SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia","Drug: Chloroquine diphosphate","Mortality rate reduction of 50% by day 28|Absolute mortality on days 7 and 14|Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28|Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Absolute duration of hospital stay in days|Prevalence of grade 3 and 4 adverse events|Prevalence of serious adverse events|Change in serum creatinine level|Change in serum troponin I level|Change in serum aspartate aminotransferase level|Change in serum CK-MB level|Change in detectable viral load in respiratory tract swabs|Viral concentration in blood samples|Absolute number of causes leading to participant death (if applicable)","Fundação de Medicina Tropical Dr. Heitor Vieira Dourado|Marcus Vinícius Guimarães de Lacerda|Mayla Gabriela Silva Borba|Wuelton Marcelo Monteiro|Gisely Cardoso de Melo|Fernando Fonseca de Almeida e Val|Felipe Gomes Naveca|Maria Paula Gomes Mourão|Ludmila Abrahão Hajjar|Jorge Souza Mendonça","All","18 Years and older   (Adult, Older Adult)","Phase 2","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAAE: 30152620.1.0000.0005","March 23, 2020","August 31, 2020","August 31, 2020","March 26, 2020",,"April 15, 2020","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",,"https://ClinicalTrials.gov/show/NCT04323527"
1599,"NCT04245631","Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV",,"Recruiting","No Results Available","New Coronavirus","Diagnostic Test: Recombinase aided amplification (RAA) assay","Detection sensitivity is greater than 95%|Detection specificity is greater than 95%|Consistent with existing universal reagent detection rates greater than 95%","Beijing Ditan Hospital","All","1 Year to 90 Years   (Child, Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DTXY022","January 1, 2020","December 31, 2020","December 31, 2020","January 29, 2020",,"April 10, 2020","Department of Hepatology Division 2, Beijing Ditan Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04245631"
1600,"NCT04323800","Convalescent Plasma to Stem Coronavirus (CSSC-001)","CSSC-001","Not yet recruiting","No Results Available","Coronavirus|Convalescence","Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma","Cumulative incidence of composite outcome of disease severity|Anti-SARS-CoV-2 titers|Rates of SARS-CoV-2 PCR positivity|Duration of SARS-CoV-2 PCR positivity|Peak quantity levels of SARS-CoV-2 RNA|Cumulative incidence of disease severity","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00245634","May 15, 2020","December 31, 2022","January 2023","March 27, 2020",,"May 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04323800"
1601,"NCT04322682","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","COVID-19","Recruiting","No Results Available","Corona Virus Infection","Drug: Colchicine|Drug: Placebo oral tablet","Number of participants who die or require hospitalization due to COVID-19 infection|Number of participants who die|Number of participants requiring hospitalization due to COVID-19 infection|Number of participants requiring mechanical ventilation","Montreal Heart Institute|DACIMA Software","All","40 Years and older   (Adult, Older Adult)","Phase 3","6000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MHIPS-2020-001","March 23, 2020","September 2020","September 2020","March 26, 2020",,"April 24, 2020","University of California, San Francisco - San Francisco General Hospital, San Francisco, California, United States|New York University School of Medecine, New York, New York, United States|Montreal Heart Institute, Montreal, Quebec, Canada|Hospital Universitario La Paz, IdiPaz, La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04322682"
1602,"NCT04255940","2019-nCoV Outbreak and Cardiovascular Diseases",,"Recruiting","No Results Available","Cardiovascular Death; Major Adverse Cardiovascular Events",,"Cardiovascular Death|Major Adverse Cardiovascular Events|Times From symptom onset to hospital arrival|Anxiety","Qilu Hospital of Shandong University","All","Child, Adult, Older Adult",,"12000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2019nCoV-CVD","January 20, 2020","April 30, 2020","April 30, 2020","February 5, 2020",,"February 5, 2020","Affiliated Hospital of Binzhou Medical Universty, Binzhou, Shandong, China|Heze Municipal Hospital, Heze, Shandong, China|Shandong University Qilu Hospital, Jinan, Shandong, China|Jinan Central Hospital, Shandong University, Jinan, Shandong, China|First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China|Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|Jining Hospital of Traditional Chinese Medicine, Jining, Shandong, China|Qihe People's Hospital, Qihe, Shandong, China|Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong, China|Weihai Municipal Hospital, Weihai, Shandong, China|Central Hospital of Zibo, Zibo, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04255940"
1603,"NCT04305574","Social Media Use During COVID-19",,"Recruiting","No Results Available","Coronavirus|Depression|Anxiety|Stress","Behavioral: Use of social media during COVID-19","Assessment of COVID-19 situation|Depression, Anxiety and Stress Scale|Familiarity and trust in COVID-related rumours|Availability heuristic","Jean Liu|Yale-NUS College","All","21 Years and older   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2020-CERC-001","March 8, 2020","May 31, 2020","May 31, 2020","March 12, 2020",,"March 17, 2020","Yale-NUS College, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04305574"
1604,"NCT04262921","French COVID Cohort","FrenchCOVID","Recruiting","No Results Available","Coronavirus Infections",,"Clinical features|Response to treatment|Pathogen replication, excretion and evolution, within the host|Immune host responses to infection and therapy|Host genetic variants","Institut National de la Santé Et de la Recherche Médicale, France","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","C20-05|2020-A00256-33","February 8, 2020","August 7, 2020","August 7, 2023","February 10, 2020",,"May 7, 2020","CHG Agen, Agen, France|Centre Hospitalier Du Pays D'aix, Aix-en-Provence, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|CH Annecy Genevois, Annecy, France|Hopital privé d'Antony, Antony, France|Hôpital de Mercy. CHR METZ-THIONVILLE, Ars-Laquenexy, France|Centre Hospitalier Henri Duffaut, Avignon, France|Chu Jean Minjoz, Besançon, France|Hôpital Avicenne AP-HP, Bobigny, France|CHU Pellegrin, Bordeaux, France|CHU Ambroise Paré, Boulogne-Billancourt, France|Ch Fleyriat, Bourg-en-Bresse, France|Chru Hopital Cavale Blanche, Brest, France|CHU Brest, Brest, France|Centre hospitalier de Béziers, Béziers, France|CH Cahors, Cahors, France|Chms Chambery Nh, Chambéry, France|Centre Hospitalier De Cholet, Cholet, France|CHU Gabriel Montpied, Clermont-Ferrand, France|CH Colmar - Hopital Pasteur, Colmar, France|Centre hospitalier Alpes Leman, Contamine-sur-Arve, France|Centre hospitalier Intercommunal de Créteil, Créteil, France|Hôpital Henri Mondor, Créteil, France|Centre Hospitalier Dax, Dax, France|CHU Dijon Bourgogne, Dijon, France|Hopital Raymond Poincare, Garches, France|CHU Grenoble, Grenoble, France|Grand Hopital de l'Est Francilien site Marne-la-Vallée, Jossigny, France|Chd Les Oudairies, La Roche-sur-Yon, France|Hôpital Universitaire Bicêtre, Le Kremlin-Bicêtre, France|Centre Hospitalier Emile Roux, Le Puy-en-Velay, France|Centre Hospitalier Universitaire de Lille, Lille, France|CHRU Lille, Hôpital Salengro, Lille, France|CHU de Lille, Lille, France|Hôpital de la Croix-Rousse, Lyon, France|Hôpital Louis Raffalli, Manosque, France|Assistance publique hopitaux de Marseille, hopital Nord, Marseille, France|Hôpital Conception, Marseille, France|Groupe Hospitalier Sud Ile De France, Melun, France|CH de Mont Marsan, Mont de Marsan, France|CHU Montpellier, Montpellier, France|CHU Nantes, Nantes, France|Hopital Américain de Paris, Neuilly-sur-Seine, France|CHU de Nice, Nice, France|CHU Caremeau, Nîmes, France|APHP Bichat, Paris, France|APHP Tenon, Paris, France|CH Lariboisière, Paris, France|Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France|Hopital Cochin-CIC1417, Paris, France|Hopital Européen Georges Pompidou, Paris, France|Hopital Saint Antoine, Paris, France|Hopital Saint Louis, Paris, France|La pitié salpetrière, Paris, France|Centre Hospitalier de Pau, Pau, France|CH de Perpignan, Perpignan, France|CHU de Poitiers, Poitiers, France|Centre Hospitalier de Périgueux, Périgueux, France|Ch Cornouaille, Quimper, France|Chu Reims, Reims, France|Hôpital Pontchaillou, Rennes, France|CHU Rouen Normandie, Rouen, France|Hopital d'instruction des armées Begin 69, Saint-Mandé, France|Centre hospitalier Louis Constant Fleming, Saint-Martin, France|CHU de Saint-Etienne, Saint-Étienne, France|CH de Saintonge, Saintes, France|Centre Hospitalier de Soissons, Soissons, France|N.H.C. - Nouvel Hopital Civil, Strasbourg, France|Hopital Foch, Suresnes, France|CHR Metz-Thionville -Hopital Bel Air, Thionville, France|Hopitaux du Leman, Thonon-les-Bains, France|Centre Hospitalier Universitaire de Rangueil, Toulouse, France|CHU de Toulouse, Toulouse, France|CHU Toulouse IUCT Institut Universitaire de Cancer de Toulouse, Toulouse, France|Hôpital Gustave Dron, Tourcoing, France|Centre Hospitalier Régional Universitaire de Tours, Tours, France|CHRU de Tours, Tours, France|CHU Nancy, Vandœuvre-lès-Nancy, France|Centre Hospitalier Intercommunal, Villeneuve Saint Georges, France|CH Annecy Genevois, Épagny, France",,"https://ClinicalTrials.gov/show/NCT04262921"
1605,"NCT04281693","A New Screening Strategy for 2019 Novel Coronavirus Infection",,"Not yet recruiting","No Results Available","Novel Coronavirus Infection Pneumonia","Diagnostic Test: Standard screening strategy|Diagnostic Test: New screening strategy","Screening accuracy|Cost-effectiveness analysis","Affiliated Hospital to Academy of Military Medical Sciences|The Fifth Medical Center of Chinese PLA General Hospital","All","Child, Adult, Older Adult","Not Applicable","230","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","307-nCoV","February 2020","March 2020","March 2020","February 24, 2020",,"February 24, 2020","the Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04281693"
1606,"NCT04344509","Microbial Etiology of Ventilator-associated Pneumonia in SARS-CoV-2 Infected Patients",,"Not yet recruiting","No Results Available","Ventilator Associated Pneumonia","Other: Bacterial species isolated","Prevalence of the microorganisms responsible for VAP among patients infected or not by the SARS-CoV-2|Prevalence of multi-drug resistant bacteria responsible for VAP among patients infected or not by the SARS-CoV-2","Poitiers University Hospital","All","18 Years to 100 Years   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","PAVM COVID","April 2020","September 2020","December 2020","April 14, 2020",,"April 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04344509"
1607,"NCT04388631","Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.","COVID-19","Recruiting","No Results Available","Coronavirus Disease 2019","Other: Coronavirus Disease 2019","Sperm density|Sperm activity|Erection hardness and duration|IIEF-5/QEQ questionnaire score|Detection rate of SARS-CoV-2 in male genitourinary system|Semen volume|Sperm survival rate|Serum testosterone/luteinizing hormone (LH)/follicle stimulating hormone (FSH) level|SCL-90 questionnaire score","Tongji Hospital","Male","18 Years to 60 Years   (Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-S073","May 10, 2020","May 1, 2021","May 1, 2021","May 14, 2020",,"May 18, 2020","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04388631"
1608,"NCT04260308","A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia",,"Recruiting","No Results Available","Virus; Pneumonia",,"GHQ-12(general health questionnaire-12)|IES-R(Impact of Event Scale-Revised)","Huazhong University of Science and Technology","All","Child, Adult, Older Adult",,"30000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRBID:TJ-C 20200107","February 3, 2020","April 15, 2020","April 20, 2020","February 7, 2020",,"February 7, 2020","Tongji Hospital，Tongji Medical College Affiliated，Huazhong University of Science ＆ Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04260308"
1609,"NCT04385836","Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)",,"Recruiting","No Results Available","Coronavirus","Drug: alpha one antitrypsin inhalation","clinical improvement","Ministry of Health, Saudi Arabia","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","4-0520- 076-K-02-H","June 1, 2020","September 1, 2020","September 1, 2020","May 13, 2020",,"May 13, 2020","Ministry of Health, Mecca, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04385836"
1610,"NCT04275245","Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia",,"Recruiting","No Results Available","2019-nCoVs Infection Pneumonia","Drug: Meplazumab for Injection","2019 nCoV nucleic acid detection|Recovery of body temperature|Recovery of resting respiratory rate|Recovery of SPO2|Chest CT / chest film changes|PaO2 / FiO2|Time to reach the isolation release standard|Changes of inflammatory immune status","Tang-Du Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20200101","February 3, 2020","December 31, 2020","December 31, 2020","February 19, 2020",,"February 19, 2020","Tangdu Hospital, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT04275245"
1611,"NCT04377607","Haemoglobin Concentration on COVID-19",,"Recruiting","No Results Available","Corona Virus Infection","Other: File scanning","Relationship between severity of disease and values of erythrocyte indices|Sensitivity of haemoglobin concentration on severity of the disease","Nevsehir Public Hospital","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","145/2020","May 1, 2020","May 20, 2020","May 30, 2020","May 6, 2020",,"May 11, 2020","Konya Training and Research Hospital, Konya, Turkey",,"https://ClinicalTrials.gov/show/NCT04377607"
1612,"NCT04325672","Convalescent Plasma to Limit Coronavirus Associated Complications",,"Withdrawn","No Results Available","Coronavirus","Biological: Convalescent Plasma","RNA in SARS-CoV-2|ICU Admissions|Hospital Mortality|Hospital Length of Stay (LOS)|Type of respiratory support|Duration of respiratory support","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20-002864","April 1, 2020","December 31, 2022","December 31, 2022","March 27, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04325672"
1613,"NCT04341727","Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection","WU352","Recruiting","No Results Available","Coronavirus Infection","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate","Hours to recovery|Time fever resolution","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202003188","April 4, 2020","April 1, 2021","August 1, 2021","April 10, 2020",,"April 10, 2020","Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04341727"
1614,"NCT04344665","Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology (PVC-RAM) Trial","PVC-RAM","Not yet recruiting","No Results Available","Surgery|Perioperative Complication|COVID","Other: Virtual Care and Remote Automated Monitoring","Composite of hospital re-admission and emergency department or urgent-care centre visit|Hospital re-admission|Emergency Department visit|Urgent Care centre visit|COVID-19 Infection|Number of days alive and at home|Medication error detection|Medication error correction|Delirium|Surgeon, family physician, or specialist in-person clinic visit|Surgeon, family physician, or specialist virtual visit|Sepsis|Acute Heart Failure|Death|Pain","Population Health Research Institute|Hamilton Health Sciences Corporation|McMaster University","All","40 Years and older   (Adult, Older Adult)","Not Applicable","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","v1.0, 2020.04.06","April 2020","August 2020","September 2020","April 14, 2020",,"April 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04344665"
1615,"NCT04399967","Building Capacity and Promoting Smoking Cessation in the Community Via ""Quit to Win"" Contest 2020","QTW2020","Not yet recruiting","No Results Available","Smoking Cessation","Behavioral: Chat-based support|Behavioral: AWARD plus COVID-specific advice|Behavioral: AWARD advice|Behavioral: COVID-19 related health warning leaflet|Behavioral: Health warning leaflet|Behavioral: SMS-based support|Behavioral: Referral card|Behavioral: COSH Self-help smoking cessation booklet","Biochemical validated quit rate|Smoking quit rate change from baseline at 3-month follow-up|Smoking quit rate change from baseline at 6-month follow-up|Smoking reduction rate change from baseline at 3-month follow-up|Smoking reduction rate change from baseline at 6-month follow-up|Smoking quit attempt change from baseline at 3-month follow-up|Smoking quit attempt change from baseline at 6-month follow-up|Use of smoking cessation service|Engagement in chat-based support","The University of Hong Kong|Hong Kong Council on Smoking and Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","842","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","QTW 2020","June 13, 2020","June 30, 2021","June 30, 2022","May 25, 2020",,"May 25, 2020","Hong Kong Council on Smoking and Health (COSH), Hong Kong, Hong Kong, China",,"https://ClinicalTrials.gov/show/NCT04399967"
1616,"NCT04302766","Expanded Access Remdesivir (RDV; GS-5734™)",,"Available","No Results Available","Coronavirus Disease 2019","Drug: Remdesivir",,"U.S. Army Medical Research and Development Command","All","Child, Adult, Older Adult",,,"U.S. Fed","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"S-20-01",,,,"March 10, 2020",,"April 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04302766"
1617,"NCT04374058","Less Frequency Hemodialysis and COVID-19",,"Active, not recruiting","No Results Available","End Stage Renal Disease","Other: less-frequency hemodialysis","Mortality|Anemia, Nutrition, Adequation of dialysis, total ultrafiltration, ultrafiltration rate,|Hospitalization|Vascular Access","Dialisis Madariaga","All","18 Years to 85 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","coronavirus","March 20, 2020","March 2021","March 2021","May 5, 2020",,"May 5, 2020","Dialisis Madariaga, General Juan Madariaga, Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT04374058"
1618,"NCT04061382","Sero-epidemiological Survey of England in 2019/2020","STORY","Recruiting","No Results Available","Serogroup C Meningococcal Meningitis|Diphtheria|COVID-19","Procedure: Venepuncture","Feasibility of developing an England based sero-epidemiological programme in 0-24 year olds|Feasibility of developing an England based sero epidemiological survey in 0-24 year olds|Recruitment rate|Cost|To assess, in relevant age groups, immunity against infections and vaccine preventable diseases|Sera collection|Exploratory","University of Oxford","All","up to 24 Years   (Child, Adult)",,"3500","Other","Observational","Observational Model: Other|Time Perspective: Prospective","ID 263097","October 15, 2019","November 30, 2020","November 30, 2020","August 19, 2019",,"April 24, 2020","Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04061382"
1619,"NCT02765191","MR-Evaluation of Renal Function In Septic Patients","MERSEP","Recruiting","No Results Available","Sepsis, Severe|Acute Kidney Injury|COVID-19","Drug: Ringer's Acetate","Change in renal blood flow and renal oxygenation after standardized fluid bolus|Descriptive renal oxygenation and blood flow in critical illnes due to sepsis|Descriptive renal oxygenation and blood flow in critical illnes in no/low grade AKI or high grade AKI.","Uppsala University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","MERSEP-523-2014-2569","April 2016","October 2021","October 2025","May 6, 2016",,"May 8, 2020","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT02765191"
1620,"NCT04383483","CoV-ICU Score, Intensive Care Unit, SARS-CoV-2",,"Not yet recruiting","No Results Available","Coronavirus as the Cause of Diseases Classified Elsewhere","Other: COVICU","COVICU score|Values","Bursa Yüksek İhtisas Education and Research Hospital","All","18 Years to 100 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","BYIEAH-202005","June 1, 2020","July 31, 2020","August 31, 2020","May 12, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04383483"
1621,"NCT04353141","International Lung UltraSound Analysis (ILUSA) Study","ILUSA","Recruiting","No Results Available","COVID|Pregnancy Complications, Infectious|Pregnancy Related|Pregnancy, High Risk|Pregnancy Disease|Pneumonia|Pneumonia, Viral|Diagnoses Disease","Diagnostic Test: standardized Lung Ultrasound (LUS) examination","Diagnostic performance of LUS to predict poor outcome","KU Leuven","Female","Child, Adult, Older Adult",,"1850","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19: ILUSA (S63988)","April 28, 2020","May 31, 2020","December 31, 2020","April 20, 2020",,"May 7, 2020","University Hospitals Leuven, Leuven, Belgium|University of Brescia, Brescia, Italy|University of Foggia, Foggia, Italy|University of Milan, Milan, Italy|University of Parma, Parma, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Queen Charlotte's & Chelsea Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04353141"
1622,"NCT03331445","Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections","NONTM","Active, not recruiting","No Results Available","Respiratory Tract Infections|Corona Virus Infection","Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects|Measure the effect of 160ppm inhaled nitric oxide delivery on lung spirometry in NTM subjects|Measure the antimicrobial effect of 160ppm inhaled nitric oxide on lung NTM bacterial load in the sputum|Measure the effect of 160ppm inhaled nitric oxide on Quality of Life (CRISS) Score","University of British Columbia|Mallinckrodt","All","14 Years and older   (Child, Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NTM-CTP-01: H17-02107","October 24, 2017","December 31, 2020","March 31, 2021","November 6, 2017",,"March 31, 2020","Diamond Centre, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT03331445"
1623,"NCT04361838","The COVID-19 ICU PRAYER Study",,"Not yet recruiting","No Results Available","Coronavirus Infection","Behavioral: prayer","Impact of multi-denominational prayer on clinical outcomes of critically ill COVID-19 patients in the Intensive Care Unit on mortality.|Difference in patient outcomes - Acute Physiology and Chronic Health Enquiry. APACHE II score.|Difference in patient outcomes - Sequential Organ Failure Assessment - SOFA Score|Difference in patient outcomes - Length of stay in ICU.|Difference in patient outcomes - Length of ventilator support|Difference in patient outcomes - length of vasopressor support","Kansas City Heart Rhythm Institute","All","18 Years to 110 Years   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","Covid Prayer Study","May 1, 2020","August 31, 2020","August 31, 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04361838"
1624,"NCT04370067","Hungarian COVID-19 Epidemiological Research",,"Recruiting","No Results Available","Coronavirus Infection",,"COVID-19 rate","Semmelweis University Heart and Vascular Center|Semmelweis University|Szeged University|University of Pecs|University of Debrecen","All","14 Years and older   (Child, Adult, Older Adult)",,"11200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Other","H-UNCOVER","May 1, 2020","May 1, 2021","August 1, 2021","April 30, 2020",,"May 12, 2020","Semmelweis University - Heart and Vascular Center, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|University of Pecs, Pecs, Hungary|University of Szeged, Szeged, Hungary",,"https://ClinicalTrials.gov/show/NCT04370067"
1625,"NCT04363788","Needle Stick Injuries in Emergency Medical Service Practice",,"Completed","No Results Available","Cardiac Arrest|Needle Stick|Injuries|Glowe","Procedure: double gloves","Number of visible puncture|WLT","Lazarski University|Medical University of Bialystok|Poznan University of Medical Sciences",,"Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","OH_PPE_1","February 28, 2020","April 24, 2020","April 24, 2020","April 27, 2020",,"April 28, 2020","Lazarski Univeristy, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT04363788"
1626,"NCT04387799","Negative-PCR for Covid- 19 Pneumonia (NPC-19)","NPC-19","Recruiting","No Results Available","Pneumonia, Viral|Pneumonia, Bacterial|Coronavirus Infection|Obstructive Lung Disease","Diagnostic Test: Serology for Covid-19","Serology|Efficacy of CT scan and Serology|Efficacy of different pharmaceutical treatments","Catholic University of the Sacred Heart","All","18 Years to 100 Years   (Adult, Older Adult)",,"260","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20200505","May 13, 2020","June 12, 2020","July 10, 2020","May 14, 2020",,"May 14, 2020","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04387799"
1627,"NCT04280913","Clinical Outcomes of Patients With COVID19",,"Withdrawn","No Results Available","Coronavirus Disease 2019","Other: retrospective analysis","Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation","Guangzhou Institute of Respiratory Disease|Huizhou Municipal Central Hospital","All","Child, Adult, Older Adult",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GZHZ-COVID19","February 22, 2020","March 31, 2020","March 31, 2020","February 21, 2020",,"March 19, 2020","HuiZhou Municipal Central Hospital, Huizhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04280913"
1628,"NCT04392219","COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers",,"Recruiting","No Results Available","Coronavirus","Drug: EIDD-2801|Drug: Placebo","Safety and Tolerability of Single Ascending Dose (SAD) of EIDD-2801 (Part 1): Adverse Events|Safety and Tolerability of Multiple Ascending Dose (MAD) of EIDD-2801 (Part 3): Adverse Events|Pharmacokinetics (PK) of EIDD-2801 when given as Single Doses (Part 2): Maximum observed concentration Cmax|Pharmacokinetics (PK) of EIDD-2801 when given as Single Ascending Dose (SAD) (Part 1): Maximum observed concentration Cmax|Pharmacokinetics (PK) of EIDD-2801 when given as Multiple Ascending Dose (MAD) (Part 3): Maximum observed concentration Cmax|Safety and Tolerability of Single Doses of EIDD-2801 (Part 2): Adverse Events","Ridgeback Biotherapeutics, LP","All","18 Years to 60 Years   (Adult)","Phase 1","122","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EIDD-2801-1001|2020-001407-17","April 10, 2020","June 16, 2020","June 16, 2020","May 18, 2020",,"May 21, 2020","Covance Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States|Covance Dallas Clinical Research Unit, Dallas, Texas, United States|Covance Madison Clinical Research Unit, Madison, Wisconsin, United States|Covance Leeds Clinical Research Unit, Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04392219"
1629,"NCT04353245","Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System","PostCOVID19","Not yet recruiting","No Results Available","COVID19|Corona Virus Infection|Myocardial Injury|Pneumonia","Other: BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM","Fibrosis|Ergospirometers","University of Sao Paulo General Hospital","All","18 Years and older   (Adult, Older Adult)",,"130","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","UAP107","June 1, 2020","September 30, 2021","September 30, 2021","April 20, 2020",,"April 20, 2020","Instituto do Coração - Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT04353245"
1630,"NCT04370678","Changes in Preference for Surgery of Patients Signed up for Arthroscopic Procedures",,"Completed","No Results Available","Arthroscopy","Behavioral: Change in preference to surgery under COVID-19 pandemic.","Change in preference|Change in preference between groups","Region Zealand","All","18 Years and older   (Adult, Older Adult)",,"79","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","ArthrocancellationSUH2020","April 17, 2020","April 24, 2020","April 24, 2020","May 1, 2020",,"May 7, 2020","Zealand University Hospital, Køge, Zealand Region, Denmark","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04370678/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04370678"
1631,"NCT04394039","Post-Pandemic Perception of Public Space in Singapore",,"Not yet recruiting","No Results Available","Stress|Anxiety","Other: Public space exposure","EEG power in alpha band|EEG power in beta band|fNIRS haemodynamics|Profile of mood states|landscape preference measured with self-assessment manikin scale","National University, Singapore|National University Hospital, Singapore","All","21 Years to 75 Years   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","NUS-IRB_S-20-12","June 1, 2020","August 1, 2020","December 31, 2020","May 19, 2020",,"May 19, 2020","Institute for Health Innovation & Technology (iHealthtech), Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04394039"
1632,"NCT04394403","Pilot Internet-based Self-Help Program for Managing Corona (COVID-19) Stress","CoronaStress","Recruiting","No Results Available","Stress|Stress, Psychological","Behavioral: Internet-based guided self-help based on CBT principles","The CoRonavIruS Health Impact Survey (CRISIS)|Depression, Anxiety, and Stress Scale- 21 item version: DASS-21","Hebrew University of Jerusalem","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","coronastress","May 14, 2020","July 15, 2020","July 15, 2021","May 19, 2020",,"May 19, 2020","Hebrew University of Jerusalem, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT04394403"
1633,"NCT04363047","Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19",,"Not yet recruiting","No Results Available","SARS Virus","Other: 40ml blood sample","Prevalence and abundance of CD4+ T lymphocytes","University of Manchester","All","18 Years and older   (Adult, Older Adult)",,"125","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","282566","May 1, 2020","May 1, 2021","May 1, 2021","April 27, 2020",,"April 28, 2020","Universit of Manchester, Manchester, Greater Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04363047"
1634,"NCT04382560","Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic",,"Recruiting","No Results Available","Behavior, Social|Autonomic Imbalance","Other: Deep Breathing training|Other: Compassion focused intervention","Dispositional questionnaire 1|Dispositional questionnaire 2|Dispositional questionnaire 3|Dispositional questionnaire 4|Heart rate|Cardiac vagal modulation","University of Parma|University of Roma La Sapienza|King's College London","All","20 Years to 40 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other","ESPCOV1","May 2, 2020","May 31, 2020","May 31, 2020","May 11, 2020",,"May 11, 2020","Sapienza University of Rome, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT04382560"
1635,"NCT04388644","Survey of Satisfaction on Traditional Chinese Medicine Jing-Guan-Fang (JGF) for COVID-19 Prevention",,"Recruiting","No Results Available","Corona Virus Infection",,"the number confirmed COVID-19 cases|The person with COVID-19 like symptoms|The improving rate of COVID-19 like symptoms|The satisfaction% to taking JGF","Taipei City Hospital|National Yang Ming University","All","20 Years to 65 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","TCHIRB-10904015-E","February 20, 2020","May 20, 2020","May 30, 2020","May 14, 2020",,"May 14, 2020","Branch of Chinese Medicine, Taipei City Hospital, Taipei, Taiwan|Branch of Linsen Chinese Medicine and Kunming, Taipei City Hospital, Taipei, Taiwan|Taipei City Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04388644"
1636,"NCT04357886","Comparison of New Coronavirus (COVID-19) Awareness in Individuals of Different Age Groups: Analysis of Turkey",,"Not yet recruiting","No Results Available","Healthy",,"COVID-19 Awareness Survey","Istanbul University-Cerrahpasa","All","15 Years and older   (Child, Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","60350273-605.99-","May 2020","May 2020","June 2020","April 22, 2020",,"April 24, 2020","Istanbul University-Cerrahpasa, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04357886"
1637,"NCT04396600","The Professional Peer Resilience Initiative","PPRI","Recruiting","No Results Available","Stress|Stress Disorder|Stress, Psychological|Trauma, Psychological|Anxiety|Anxiety State|Post Traumatic Stress Disorder|Secondary Traumatic Stress|Professional Quality of Life|Stress Related Disorder|Stress Reaction|Stress Risk|Mental Resilience|Emotional Resilience","Behavioral: MinnRAP Peer Support Program","Change in professional quality of life|Change in mental health symptoms and resilience markers","University of Minnesota","All","18 Years and older   (Adult, Older Adult)",,"1200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STUDY00009564","May 25, 2020","May 25, 2022","May 25, 2022","May 20, 2020",,"May 20, 2020","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04396600"
1638,"NCT04368676","Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness","BREATH","Not yet recruiting","No Results Available","Job Stress|Workplace Stress|Compassion Fatigue|Psychological Trauma|Healthcare Workers|Healthcare Providers","Other: Sudarshan Kriya Yoga (SKY)|Other: Health Enhancement Program","Rate of participant recruitment|Rate of retention|Completeness of data entry|Cost of interventions|Unexpected costs|Change in Athens Insomnia Scale|Change in Generalized Anxiety Disorder 7-item scale|Change in Patient Health Questionnaire 9|Change in Connor-Davidson Resilience Scale","Lawson Health Research Institute|Art of Living Foundation","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","115855","May 10, 2020","June 30, 2021","June 30, 2021","April 30, 2020",,"April 30, 2020","London Health Sciences Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04368676"
1639,"NCT03648372","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)",,"Recruiting","No Results Available","Neoplasms|Lymphoma|Hematologic Neoplasms|Coronavirus Disease","Drug: TAK-981|Drug: Standard of care","Dose Escalation and Cancer Treatment Expansions: Number of Participants Reporting one or More Treatment Emergent Adverse Events (TEAEs)|Dose Escalation and Cancer Treatment Expansions: Number of Participants With Dose Limiting Toxicities (DLTs)|Dose Escalation and Cancer Treatment Expansions: Number of Participants With one or More Serious Adverse Events (SAEs)|Dose Escalation and Cancer Treatment Expansions: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations|Dose Escalation and Cancer Treatment Expansions: Number of Participants With Greater Than or Equal to (>=) Grade 3 TEAEs|Dose Escalation and Cancer Treatment Expansions: Number of Participants With Clinically Significant Laboratory Values|Dose Escalation and Cancer Treatment Expansions: Number of Participants With Clinically Significant Vital Sign Measurements|Dose Escalation and Cancer Treatment Expansions: Number of Participants who Experience Cytokine Release Syndrome CRS)|COVID-19 Expansion: Number of Participants With >=2 log Reduction From Baseline in Viral Load or Below Level of Detection (Negative) in Nasopharyngeal or Oropharyngeal Samples|Dose Escalation and Cancer Treatment Expansions, Cmax: Maximum Observed Plasma Concentration for TAK-981|Dose Escalation and Cancer Treatment Expansions, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-981|Dose Escalation and Cancer Treatment Expansions, AUCt: Area Under the Plasma Concentration-time Curve from Time 0 to Time t Over the Dosing Interval for TAK-981|Dose Escalation and Cancer Treatment Expansions, AUC∞: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-981|Dose Escalation and Cancer Treatment Expansions, Terminal Disposition Phase Half-life (t1/2z) for TAK-981|Dose Escalation and Cancer Treatment Expansions, Total Clearance After Intravenous Administration (CL) for TAK-981|Dose Escalation and Cancer Treatment Expansions, Volume of Distribution at Steady State After Intravenous Administration (Vss) for TAK-981|Dose Escalation and Cancer Treatment Expansions: Overall Response Rate (ORR)|Dose Escalation and Cancer Treatment Expansions: Duration of Response (DOR)|Dose Escalation and Cancer Treatment Expansions: Disease Control Rate (DCR)|Dose Escalation and Cancer Treatment Expansions: Progression-free Survival (PFS)|Dose Escalation and Cancer Treatment Expansions: Time to Response (TTR)|Dose Escalation and Cancer Treatment Expansions: Percentage of Participants at Each Dose Level Demonstrating Adduct Formation in Post-dose Skin or Tumor Biopsies|Dose Escalation and Cancer Treatment Expansions: Percent Change in Small Ubiquitin-like Modifier (SUMO) 2/3 Signal With Pre and Post-dose Skin or Tumor Biopsies at Each Dose Level|COVID-19 Expansion: Number of Participants Reporting one or More TEAEs|COVID-19 Expansion: Number of Participants Based on Severity of TEAEs|COVID-19 Expansion: Number of Participants Based on Duration of TEAEs|COVID-19 Expansion: Number of Participants who Experience CRS|COVID-19 Expansion: Change from Baseline in National Early Warning Score (NEWS)|COVID-19 Expansion: Percentage of Participants Reporting Each Hospitalization Severity Rating|COVID-19 Expansion: Change From Baseline in SARS-CoV-2 Viral Load in Nasopharyngeal or Oropharyngeal Samples|COVID-19 Expansion: Percentage of Participants Requiring Oxygen Supplementation; Assisted or Positive Pressure Non-invasive Ventilation; and Invasive Ventilation, on Days 3, 5, 8, 11, 15, and 30|COVID-19 Expansion: Percentage of Participants That met Intensive Care Unit (ICU) Criteria|COVID-19 Expansion: Duration of Hospitalization|COVID-19 Expansion: Time to Viral Ribonucleic Acid (RNA) Negativity in Nasopharyngeal or Oropharyngeal Samples|COVID-19 Expansion: Time to Discharge or to a NEWS of Less Than or Equal to (<=) 3 and Maintained for 24 Hours|COVID-19 Expansion: Number of Deaths in Hospital due to any Cause in First 30 Days and in 90 Days","Millennium Pharmaceuticals, Inc.|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-981-1002|U1111-1214-4537","October 1, 2018","February 16, 2021","October 6, 2021","August 27, 2018",,"May 25, 2020","University of California San Diego Moores Cancer Center, La Jolla, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|HealthPartners Cancer Care Center - Regions Hospital, Saint Paul, Minnesota, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03648372"
1640,"NCT04378803","Mindfulness Training for Seniors",,"Recruiting","No Results Available","Well Aging","Behavioral: Mindfulness training (MT) Connect","Change in mindfulness skills as measured by Five-Facet Mindfulness Questionnaire (5FMQ)|Change in mindfulness skills as measured by decentering - Experiences Questionnaire (EQ).|Change in psychological health as measured by Patient Health Questionnaire 4 items (PHQ4).|Change in positive affect on psychological health as measured by the short variant of the Positive and Negative Affect Scale (PANAS).|Change in negative affect on psychological health as measured by the short variant of the Positive and Negative Affect Scale (PANAS).|Change in loneliness measured by the loneliness questions from the social isolation battery.|Change in loneliness measured by a loneliness question.|Change in attention|Change in well-being as measured by the Perseverative Thought Questionnaire (PTQ)|Change in well-being as measured by the Experience of Intrusions Scale (EIS)|Change in well-being as measured by the short version of the perceived stress scale (PSS).|Change in well-being as measured by the PERMA-Profiler","University of Miami","All","60 Years to 95 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20200443","June 15, 2020","October 1, 2020","October 1, 2020","May 7, 2020",,"May 14, 2020","University of Miami, Coral Gables, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04378803"
1641,"NCT04335851","Video-Based Exercises and Well-Being During Social Isolation",,"Not yet recruiting","No Results Available","Social Isolation|Physical Inactivity|Well-Being","Other: Video based aerobic exercise","World Health Organization Quality of Life Questionnaire Bref|Rapid Assessment of Physical Activity|Global Rating of Change Scale","Biruni University|Istanbul University-Cerrahpasa","All","18 Years to 35 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Physical Activity Project","April 6, 2020","May 13, 2020","June 30, 2020","April 6, 2020",,"April 6, 2020","Biruni University, Istanbul, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04335851"
1642,"NCT04399005","The Efficacy Comparing Daily and After-each-case Room Disinfection.",,"Recruiting","No Results Available","Daily Room Disinfection|After-each-case Room Disinfection","Other: after-each-case room disinfection|Other: daily room disinfection","Qualified rate of room disinfection|The number of colony-forming units (CFU)","The First Affiliated Hospital of Zhejiang Chinese Medical University","All","Child, Adult, Older Adult","Not Applicable","240","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","DACD-HuY-2005","May 25, 2020","June 5, 2020","June 10, 2020","May 25, 2020",,"May 25, 2020","First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04399005"
1643,"NCT04383899","Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019","RISC","Not yet recruiting","No Results Available","Coronavirus Infection","Other: Questionnaire","Describe medications used prior to admission associated with worse infection in COVID-19 patients in France.|Quantify medications used prior to admission associated with worse infection in COVID-19 patients in France.|Describe other patient characteristics with worse infection in COVID-19 patients in France.|Quantify other patient characteristics with worse infection in COVID-19 patients in France.","University Hospital, Bordeaux|Bordeaux PharmacoEpi","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CHUBX 2020/13","May 11, 2020","June 30, 2020","July 31, 2020","May 12, 2020",,"May 13, 2020","HOPITAL PELLEGRIN, Service des maladies infectieuses et tropicales, Bordeaux, France|HOPITAL PELLEGRIN, service des maladies intensives et réanimation, Bordeaux, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Limoges, Limoges, France|Hôpital St Louis, Paris, France|HEGP, Paris, France|Hôpital Robert Debré, Paris, France|CHU de Rouen, Rouen, France",,"https://ClinicalTrials.gov/show/NCT04383899"
1644,"NCT04346927","Telerehabilitation for Patients Diagnosed With Coronavirus","COVID-19","Not yet recruiting","No Results Available","Telerehabilitation|Coronavirus","Other: Telerehabilitation|Other: exercise brochure","Visual Analogue Scale|Modified Borg Scale|Leicester Cough Questionnaire|Timed Up and Go|30 Second Chair Stand Test|The Beck Depression Inventory|The Beck Anxiety Inventory","Yasemin Çırak|Istinye University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","009","April 10, 2020","June 10, 2020","July 31, 2020","April 15, 2020",,"April 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04346927"
1645,"NCT04368299","Telemedicine for Follow-up of Systemic Lupus Erythematosus",,"Not yet recruiting","No Results Available","SLE","Other: Telemedicine|Other: Standard care","The percentage of patients in remission or LLDAS at one year.|Direct and indirect costs after one year.|The change of Lupus Quality of Life (LupusQoL) at one year.|Patient confidence and satisfaction score at one year.|Rates of adverse reaction and severe adverse reaction, including contracting COVID-19 infection, after one year.|Numbers of clinic visits, hospitalization, overall in-person hospital visits in one year.|The change of (Health Assessment Questionnaire Disability Index HAQ-DI) at one year.|The change of (Hospital Anxiety and Depression Scale) HADS at one year.","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","TeleSLE","May 1, 2020","October 31, 2021","December 31, 2021","April 29, 2020",,"April 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04368299"
1646,"NCT04393636","Digital Cardiac Counseling Trial: DCC Trial","DCC","Not yet recruiting","No Results Available","Cardiovascular Diseases|Cardiovascular Risk Factor","Other: Digital cardiac Counseling","MACEs|Mortality|Cardiovascular-related mortality|Covid-19 related mortality|Health-related quality of life|NYHA Functional classification|CCS grading of angina pectoris","Academisch Ziekenhuis Maastricht","All","18 Years and older   (Adult, Older Adult)","Not Applicable","394","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","NL72754.068.20","May 15, 2020","December 31, 2022","December 31, 2022","May 19, 2020",,"May 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04393636"
1647,"NCT04389372","Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients With Chronic Migraine and Medication Overuse","ChroMig-Smart","Recruiting","No Results Available","Migraine Headache","Behavioral: Mindfulness","Efficacy of Mindfullness by Smartphone|Change of Disability Score|Change in Quality of life","Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Chro-Mig-Smart","March 15, 2020","March 2021","December 2021","May 15, 2020",,"May 18, 2020","UOC Neurologia 3, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04389372"
1648,"NCT04319211","Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress","COVID-19","Not yet recruiting","No Results Available","Healthy People","Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.","International Physical Activity Questionnaire (IPAQ)|Health-Related Quality of Life SF-12 Scale|Beck Depression Scale","Istanbul University-Cerrahpasa","All","18 Years to 55 Years   (Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","EAvcil|İpek Yeldan","March 25, 2020","May 15, 2020","July 20, 2020","March 24, 2020",,"March 24, 2020","Istanbul University Cerrahpasa, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04319211"
1649,"NCT04369274","Repeated Measures Trial of Temporary Automated Manual Ventilation Versus Noninvasive Oxygenation or Conventional Vent",,"Not yet recruiting","No Results Available","Respiratory Failure","Device: Mechanical ventilation with the automated BVM compressor","Arterial oxygenation|Expired pressure of carbon dioxide.|Airway pressure|Heart rate|Blood pressure|Airway flow","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020P001051","May 2020","November 2020","November 2020","April 30, 2020",,"April 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04369274"
1650,"NCT04393649","First Level Socio-geriatric Evaluation: ESOGER Databank",,"Recruiting","No Results Available","COVID|Social Isolation|Anxiety|Frailty","Other: ESOGER","COVID-19 symptoms|issues related to medication and food delivery and access to home care|physical frailty|psychological frailty|Caregiver burden","Jewish General Hospital","All","70 Years and older   (Older Adult)",,"20000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MP-05-2021-2308","April 20, 2020","April 19, 2021","April 19, 2021","May 19, 2020",,"May 20, 2020","Jewish General Hospital, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04393649"
1651,"NCT04372693","Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement","(COVID-19)","Enrolling by invitation","No Results Available","Distance Learning-Online Learning|Traditional Classroom-Based Learning|Coronavirus Disease Social Distancing Measures|Nursing Students' Perception and Achievement","Other: impliminting Online Distance Learning","Students' Learning Perception Questionnaire (SLPQ),|students' scholar achievement.","Kasr El Aini Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","FON170133","February 1, 2020","May 30, 2020","June 30, 2020","May 4, 2020",,"May 5, 2020","Cairo University Hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04372693"
1652,"NCT04331808","CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)","CORIMUNO-TOC","Active, not recruiting","No Results Available","Corona Virus Infection","Drug: Tocilizumab","Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","228","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-1","March 30, 2020","March 31, 2021","December 31, 2021","April 2, 2020",,"April 28, 2020","APHP- Hopital Tenon, Paris, France|APHP - Beaujon, Paris, France|APHP - Bichat, Paris, France|APHP - Hopital Necker, Paris, France|APHP - Pitié Salpêtrière, Paris, France|APHP - Saint Louis, Paris, France|CHU Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT04331808"
1653,"NCT04394455","Cognitve Behavariol Brief Therapy on Perceived Stress Level and Anxiety, Depression and Post Traumatic Stress Symptoms",,"Not yet recruiting","No Results Available","Anxiety|Depressive Symptoms|Post Traumatic Stress Symptoms","Behavioral: Brief cognitive behavioural therapy|Behavioral: Crisis intervention therapy","Change in Depressive symptoms|Change in Anxiety symptoms|Change in Post traumatic Stress symptoms|Change in Perceived stress level","Universidad Nacional Autonoma de Honduras","All","21 Years and older   (Adult, Older Adult)","Not Applicable","236","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1503202018052020242912","May 25, 2020","July 30, 2020","July 30, 2020","May 19, 2020",,"May 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04394455"
1654,"NCT04386980","Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed",,"Not yet recruiting","No Results Available","Osteoarthritis, Knee|Osteo Arthritis Knee|Knee Pain Chronic","Drug: Resiniferatoxin|Drug: Placebo","Change in pain and function: WOMAC|Safety of RTX: Incidence and severity of adverse events|Change in analgesic usage|Change in pain and function: Change in the WOMAC Pain and Function combined score|Patient Global Impression of Change (PGIC) in index knee pain","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","152","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","STI-RTX-3004","June 2020","April 2021","April 2021","May 13, 2020",,"May 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04386980"
1655,"NCT04328467","Pre-exposure Prophylaxis for SARS-Coronavirus-2",,"Recruiting","No Results Available","COVID-19|Corona Virus Infection|ARDS|Acute Respiratory Distress Syndrome","Drug: Hydroxychloroquine|Other: Placebo","COVID-19-free survival|Incidence of confirmed SARS-CoV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related side effects","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 3","3500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STUDY00009414","April 6, 2020","August 2020","August 2020","March 31, 2020",,"April 10, 2020","Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04328467"
1656,"NCT04333251","Study Testing Convalescent Plasma vs Best Supportive Care",,"Not yet recruiting","No Results Available","Pneumonia, Interstitial","Biological: high-titer anti-Sars-CoV-2 plasma|Other: oxygen therapy","reduction in oxygen and ventilation support","Baylor Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","115","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","020-123","April 1, 2020","December 31, 2022","December 31, 2022","April 3, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04333251"
1657,"NCT04333875","Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis","AS DEFER","Active, not recruiting","No Results Available","Aortic Valve Stenosis","Device: TAVR or SAVR","Composite of all-cause mortality, disabling and non-disabling stroke, and hospitalization for heart failure","University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Older Adult)",,"71","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00672","March 20, 2020","December 2020","December 2020","April 3, 2020",,"May 4, 2020","Department of Cardiology, Bern University Hospital, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04333875"
1658,"NCT04316377","Norwegian Coronavirus Disease 2019 Study","NO COVID-19","Recruiting","No Results Available","Corona Virus Infection","Drug: Hydroxychloroquine Sulfate","Rate of decline in SARS-CoV-2 viral load|Change in National Early Warning Score score|Admission to intensive care unit|In-hospital mortality|Duration of hospital admission|Mortality at 30 and 90 days|Clinical status","University Hospital, Akershus","All","18 Years and older   (Adult, Older Adult)","Phase 4","202","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REC 121446","March 25, 2020","April 1, 2021","March 3, 2025","March 20, 2020",,"April 3, 2020","Akershus University Hospital, Lørenskog, Norway",,"https://ClinicalTrials.gov/show/NCT04316377"
1659,"NCT04276688","Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",,"Completed","No Results Available","Novel Coronavirus Infection","Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B","Time to negative NPS|Time to negative saliva|Time to clinical improvement|Hospitalisation|Mortality|Immune reaction|Adverse events|Time to negative all clinical specimens","The University of Hong Kong|Hospital Authority, Hong Kong","All","18 Years and older   (Adult, Older Adult)","Phase 2","127","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UW-20-074","February 10, 2020","March 30, 2020","March 31, 2020","February 19, 2020",,"April 15, 2020","University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04276688"
1660,"NCT04356144","Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections",,"Recruiting","No Results Available","Disseminated Intravascular Coagulation|Critical Illness|Sars-CoV2|Viral Infection|Coagulation Disorder, Blood|Covid19","Diagnostic Test: Thrombin Generation Assay (TGA)|Diagnostic Test: Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)","ETP (AUC) without rhThrombomodulin (rhTM)|ETP (AUC) with rhThrombomodulin (rhTM)|ETP-ratio|ETP-Normalisation","Medical University of Vienna|Medical Scientific Fund of the Mayor of Vienna","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TGA-TM-Critical-2019","April 15, 2020","October 1, 2020","December 1, 2020","April 22, 2020",,"May 5, 2020","Medical University Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04356144"
1661,"NCT04382508","Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.","ImmunoCOVID","Enrolling by invitation","No Results Available","Immune Suppression|Immune Deficiency|Infection|COVID|Children, Adult","Other: Questionnaire","To describe COVID19 infection in children/adults who are vulnerable for infection in an outpatients setting|Number of children/adults tested positive for COVID19|Number of children/adults admitted in hospital because of COVID19|To assess the impact of COVID19 infection on the daily activities of immunosuppressed adults and children","University Hospital Southampton NHS Foundation Trust|Cambridge University Hospitals NHS Foundation Trust|Alder Hey Children's Hospital|Birmingham Children’s Hospital|Bradford Royal Infirmary|Bristol Royal Hospital for Children|Cardiff and Vale University Health Board|Great North Children's Hospital|Great Ormond Street Hospital for Children NHS Foundation Trust|Oxford University Hospitals NHS Trust|Leeds Teaching Hospitals NHS Trust|Norfolk and Norwich University Hospitals NHS Foundation Trust|Nottingham Children's Hospital|Royal Alexandra Children's Hospital|Royal Hospital for Sick Children, Glasgow|Royal Manchester Children's Hospital|Royal Marsden NHS Foundation Trust|Northern Care Alliance NHS Group|Royal Sussex County Hospital|Sheffield Children's NHS Foundation Trust|St George's University Hospital National Health Service Foundation Trust|Swansae Bay University Health Board|University College London Hospitals|University Hospitals Coventry and Warwickshire National Health Service Trust|East Lancashire Hospitals National Health Service Trust|Imperial College Healthcare National Health Service Trust|National Heatlh Service Ayrshire and Arran",,"Child, Adult, Older Adult",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RHM CHI1061","March 22, 2020","March 21, 2021","March 21, 2021","May 11, 2020",,"May 20, 2020","University Hospital Southampton NHS FT, Southampton, Hampshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04382508"
1662,"NCT04363177","Global Mental Health of Urban Mothers","MUM","Not yet recruiting","No Results Available","Perinatal Depression|COVID19|Anxiety|PTSD|Pregnancy Related","Behavioral: Web-based psychosocial peer-to-peer support","Edinburgh Postnatal Depression Scale (EPDS)|Mental health status and COVID-19|Socio-economic status|Elective CS","Karolinska Institutet|Swiss National Science Foundation","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","P2SKP3_187728","June 2020","June 2021","June 2023","April 27, 2020",,"April 27, 2020","Shanghai Women's and Children's Health Center, Shanghai, Shanghai, China|Chinese University Hong Kong, Hong Kong, Hong Kong|Mamma till Mamma, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04363177"
1663,"NCT03852537","Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia",,"Recruiting","No Results Available","Pneumonia","Drug: Methylprednisolone|Other: Usual Care","Feasibility of the timely initiation of corticosteroids and implementation of biomarker-titrated corticosteroid dosing: percentage of eligible patients adhered to the timely initiation|Mortality|Progression of disease|Evolution of respiratory failure|Evolution of kidney failure|Evolution of shock|Length of stay|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Hyperglycemia|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Delirium|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Secondary Infection","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","18-010925","December 2, 2019","July 2021","July 2022","February 25, 2019",,"April 22, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03852537"
1664,"NCT04348552","Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study","PSI RECORd-XP","Not yet recruiting","No Results Available","Patient Safety","Other: Primary care professionals reports of potential patient safety incidents, non-COVID-19 related","Describe patient safety incidents (types, severity, contributing and correcting factors)","Nantes University Hospital","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC20_0183","April 15, 2020","June 15, 2020","June 15, 2020","April 16, 2020",,"April 16, 2020","University Hospital, Nantes, France",,"https://ClinicalTrials.gov/show/NCT04348552"
1665,"NCT04346121","Non-COVID Patient-safety Incidents Reported by General Practitioners in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study.cRisis","PSI RECORd-GP","Not yet recruiting","No Results Available","Patient Safety","Other: GPs reports of potential patient safety incidents, non-COVID-19 related","Describe patient safety incidents (types, severity, contributing and correcting factors)","Nantes University Hospital","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC20_0182","April 15, 2020","June 15, 2020","June 15, 2020","April 15, 2020",,"April 15, 2020","University Hospital, Nantes, France",,"https://ClinicalTrials.gov/show/NCT04346121"
1666,"NCT04393077","Emotional Freedom Technique (EFT) Effect on Nurses",,"Recruiting","No Results Available","Stress|Anxiety|Burnout, Caregiver","Behavioral: Emotional Freedom Technique","The subjective units of distress scale|The State Anxiety|Burnout","Istanbul Saglik Bilimleri University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","2020\0192","May 10, 2020","May 15, 2020","May 20, 2020","May 19, 2020",,"May 19, 2020","Medeniyet University, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04393077"
1667,"NCT04346940","The Effectiveness of Telerehabilitation-Based Exercises in Elderly People",,"Not yet recruiting","No Results Available","Telerehabilitation|Elderly People|Social Isolation","Other: Telerehabilitation|Other: Exercise brochure","Standardized Mini Mental Test|Mini Nutritional Assesment|Short Physical Performance Test|Single Leg Stance Test|Charlson Comorbidity Index|Clinic Fragility Scale|Pittsburgh Sleep Quality Index|Social Isolation Survey|Quality of life scale in the elderly|The Physical Activity Scale for the Elderly|Timed Up and Go Test|30 Second Chair Stand Test|The Beck Depression Inventory|The Beck Anxiety Inventory","Istinye University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","007","April 10, 2020","June 10, 2020","July 31, 2020","April 15, 2020",,"April 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04346940"
1668,"NCT03680274","Lessening Organ Dysfunction With VITamin C","LOVIT","Recruiting","No Results Available","Sepsis|Vitamin C|Intensive Care Unit|COVID-19|Pandemic|Coronavirus","Drug: Vitamin C|Other: Control","Number of deceased participants or with persistent organ dysfunction|Number of participants with persistent organ dysfunction-free days in intensive care unit|Number of participants deceased at 6 months|Score of health related quality of life in 6-month survivors|Global tissue dysoxia|Organ function (including renal function)|Rate of inflammation|Rate of infection|Rate of endothelial injury|Occurrence of stage 3 acute kidney injury|Acute hemolysis|Hypoglycemia|Vitamin C volume of distribution|Vitamin C clearance|Vitamin C plasma concentration","Université de Sherbrooke|Lotte & John Hecht Memorial Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP-31-2019-2945","November 8, 2018","December 31, 2021","December 31, 2022","September 21, 2018",,"April 10, 2020","Research Center of the CHUS, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03680274"
1669,"NCT04326309","Audio Data Collection for Identification and Classification of Coughing",,"Recruiting","No Results Available","COVID-19|Coronavirus Infections|Hay Fever|Asthma|Chronic Obstructive Pulmonary Disease|Influenza|Common Cold|Respiratory Tract Infections|Healthy",,"Dataset size|Cough sound identification|Improvement of the existing model|Evaluate the usability of the application","HealthMode Inc.","All","18 Years and older   (Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HM070102","March 25, 2020","September 25, 2022","September 25, 2022","March 30, 2020",,"March 30, 2020","Virtual Facility, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT04326309"
1670,"NCT04346966","The Effectiveness of Video-Based Exercises in Young Adults",,"Not yet recruiting","No Results Available","Social Isolation|Exercise|Healthy","Other: Study Group","International Physical Activity Questionnaire (Short Form)|Short Form-36 (SF-36)|The Pittsburgh Sleep Quality Index|Distress Tolerance Scale|Beck Anxiety Inventory|Nottingham Health Profile|Sit And Reach Test|Shoulder Flexibility Test|Curl-Up Test|Repetitive Squat Test|Side Plank Test|Timed Up and Go Test|Single Leg Stance Test","Istinye University","All","18 Years to 40 Years   (Adult)","Not Applicable","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","001","April 20, 2020","June 20, 2020","October 20, 2020","April 15, 2020",,"April 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04346966"
1671,"NCT03452774","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry",,"Recruiting","No Results Available","Cancer, Metastatic|Cancer|Cancer of Pancreas|Cancer of Liver|Cancer of Stomach|Cancer Liver|Cancer of Rectum|Cancer of Kidney|Cancer of Esophagus|Cancer of Cervix|Cancer of Colon|Cancer of Larynx|Cancer, Lung|Cancer, Breast|Cancer, Advanced|Cancer Prostate|Cancer of Neck|Cancer of Skin|Neuroendocrine Tumors|Carcinoma|Mismatch Repair Deficiency|BRCA Gene Rearrangement|Non Hodgkin Lymphoma|Leukemia|Non Small Cell Lung Cancer|Cholangiocarcinoma|Glioblastoma|Central Nervous System Tumor|Melanoma|Urothelial Carcinoma|Bladder Cancer|Ovarian Cancer|Endometrial Cancer|Testicular Cancer|Breast Cancer|COVID","Other: Clinical Trial Matching","Proportion of patients Eligible for CTE versus Actual CTE|Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis|Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis|Identification of Barriers to CTE|Real World Data Analytics|Virtual Tumor Board Utilization|Time from Intervention to Actual CTE (months)","Massive Bio, Inc.","All","Child, Adult, Older Adult",,"1500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","SYNERGY-AI","January 1, 2018","December 2021","December 2022","March 2, 2018",,"April 28, 2020","Massive Bio, Inc, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03452774"
1672,"NCT04379986","Remote Blood Pressure Monitoring With the Wearable SENBIOSYS Photoplethysmographic Device",,"Not yet recruiting","No Results Available","Blood Pressure","Device: Sensbiosys","Feasibility of non-invasive BP monitors: blood pressure|Percentage of signal with artefact,","Stéphane Cook, Prof|University of Freiburg","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","SENBIOSYS trial","May 1, 2020","May 31, 2020","June 1, 2020","May 8, 2020",,"May 8, 2020","University and hospital Fribourg, Fribourg, Switzerland",,"https://ClinicalTrials.gov/show/NCT04379986"
1673,"NCT04351880","Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge",,"Recruiting","No Results Available","Heart Failure|Copd|Liver Failure|Covid19|Diabetes Mellitus|Cancer|End Stage Renal Disease","Other: Medically Tailored Meals","Anxiety and Depression measured through the Hospital Anxiety and Depression Scale|Functional Status measured through the Katz Activities of Daily Living Scale|Re-hospitalization and Emergency Department Visits","Kaiser Permanente","All","18 Years and older   (Adult, Older Adult)","Not Applicable","640","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","IRB-1556587","April 16, 2020","February 2021","July 2021","April 17, 2020",,"May 4, 2020","St Joseph's Hospital, Denver, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04351880"
1674,"NCT04308668","Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","COVID-19 PEP","Recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections","Drug: Hydroxychloroquine|Other: Placebo","Incidence of COVID19 Disease among those who are asymptomatic at baseline|Overall change in disease severity over 14 days among those who are symptomatic at baseline|Incidence of Hospitalization|Incidence of Death|Incidence of Confirmed SARS-CoV-2 Detection|Incidence of Symptoms Compatible with COVID19 (possible disease)|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 days|Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry","University of Minnesota|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta","All","18 Years and older   (Adult, Older Adult)","Phase 3","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STUDY00009267","March 17, 2020","May 1, 2020","May 14, 2020","March 16, 2020",,"May 1, 2020","Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Internet, New York, New York, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04308668"
1675,"NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","POPS or POP02","Recruiting","No Results Available","Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:","Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling","Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 20 Years   (Child, Adult)",,"5000","Other|Industry|NIH","Observational","Observational Model: Other|Time Perspective: Prospective","Pro00103838","March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",,"May 14, 2020","Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|Colorado University Denver, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Childrens Mercy Hospital, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, United States|Kravis Children's Hospital at Mt. Sinai, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|University Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04278404"
1676,"NCT04329897","Acceptance and Commitment Therapy Delivered by Automated Software Messaging",,"Enrolling by invitation","No Results Available","Hip Osteoarthritis|Knee Osteoarthritis|Mental Stress|Coronavirus","Behavioral: Software Messaging","Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects.|Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects.|Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects.|Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects.","University of Iowa","All","18 Years and older   (Adult, Older Adult)","Not Applicable","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","201412701-1","April 5, 2020","May 30, 2020","June 30, 2020","April 1, 2020",,"April 8, 2020","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT04329897"
1677,"NCT04387708","Care in Patients Hospitalized for Anorexia Nervosa at the Time of the Coronavirus-19 Epidemic (QUALICOVID)","QUALICOVID","Not yet recruiting","No Results Available","Anorexia Nervosa",,"Content analysis concerning the reorganization of care for children or adolescent and thier parents","Centre Psychothérapique de Nancy","All","Child, Adult, Older Adult",,"18","Other","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","RIPH 2020-01","May 14, 2020","June 8, 2020","June 8, 2020","May 14, 2020",,"May 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04387708"
1678,"NCT04363775","Comparison of VieScope vs. Macintosh Laryngoscope for Intubation in Level Cpersonal Protective Equipment Conditions",,"Completed","No Results Available","Tracheal Intubation|Infection|Projection","Device: The standard Macintosh laryngoscope|Device: The Vie Scope laryngoscope","time to intubation|success of intubation|Number of optimalization maneuvers|Procedure Ease of use|the degree of visibility of the glottis|Cormack - Lehane grade","Lazarski University|Poznan University of Medical Sciences|Wroclaw Medical University|Medical University of Bialystok","All","18 Years and older   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","INT_PPE_2020_1","January 20, 2020","February 23, 2020","February 25, 2020","April 27, 2020",,"April 28, 2020","Lazarski Univeristy, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT04363775"
1679,"NCT04346979","Telerehabilitation-based Yoga and Mindfulness Home Program in Postmenopausal Women Having Social Isolation",,"Not yet recruiting","No Results Available","Telerehabilitation","Other: Telerehabilitation-Based|Other: Video-Based","The Brief Resilience Scale|Nottingham Health Profile|Mindful Attention Awareness Scale|The Body Awareness Questionnaire|Richard-Campbell Sleep Questionnaire|Lateral bridge test|Functional reach test|Beck Depression Scale","Istinye University","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","0001","May 1, 2020","July 1, 2020","August 1, 2020","April 15, 2020",,"April 15, 2020",,,"https://ClinicalTrials.gov/show/NCT04346979"
1680,"NCT04400682","Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions","Favipiravir","Not yet recruiting","No Results Available","Bioequivalence","Drug: Test Drug 200 mg favipiravir|Drug: Reference Drug 200 mg favipiravir","Primary PK End Points|Secondary PK End Points","Novelfarma Ilaç San. ve Tic. Ltd. Sti.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti","Male","20 Years to 40 Years   (Adult)","Phase 1","30","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","NOV2020/1923","May 28, 2020","June 5, 2020","July 17, 2020","May 25, 2020",,"May 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04400682"
1681,"NCT04276987","A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia",,"Not yet recruiting","No Results Available","Coronavirus","Biological: MSCs-derived exosomes","Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality","Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEXCOVID","February 15, 2020","May 31, 2020","July 31, 2020","February 19, 2020",,"February 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04276987"
1682,"NCT04339842","Eating Habits of Adults During the Quarantine",,"Recruiting","No Results Available","Health Behavior|Eating Behavior","Other: Assessment of Dietary Changes in Adults in the Quarantine","Changes in the Eating Habits of Adults during the Quarantine","Eliz Arter|Cyprus Science University|Eastern Mediterranean University","All","18 Years to 80 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Nutr2020","April 10, 2020","May 31, 2020","May 31, 2020","April 9, 2020",,"April 15, 2020","Online, Nicosia, Cyprus","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04339842/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04339842"
1683,"NCT04386876","Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions","Orvical","Active, not recruiting","No Results Available","Bioequivalence","Drug: Lopinavir 200Mg/Ritonavir 50Mg FT Test|Drug: Lopinavir 200Mg/Ritonavir 50Mg FT Reference","Primary PK End Points","World Medicine ILAC SAN. ve TIC. A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti","Male","20 Years to 40 Years   (Adult)","Phase 1","30","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","NOV2020/01911|FARGE365","April 30, 2020","May 22, 2020","June 20, 2020","May 13, 2020",,"May 15, 2020","Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey",,"https://ClinicalTrials.gov/show/NCT04386876"
1684,"NCT01306084","Viral Infections in Healthy and Immunocompromised Hosts",,"Enrolling by invitation","No Results Available","Herpes Viruses|Herpes Simplex Virus Infection|Epstein Barr Virus Infection|Cytomegalovirus Infection|Varicella-Zoster Virus Infection|Human Herpes Virus 6 Infection|Norovirus Infection|Adenovirus Infection|Respiratory Virus Infection",,"Sample collection, analysis of immune function, or review of tissue bx or clinical rpts from outside labs in designated pop. w/ viral, suspected, or recovered from a viral infection or a close contact of people w/or suspected to have a viral inf...","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"164","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","110109|11-I-0109","March 5, 2011",,,"March 1, 2011",,"May 20, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01306084"
